1	The	O	
2	main	O	
3	aim	O	
4	of	O	
5	the	O	
6	contribution	O	
7	,	O	
8	which	O	
9	opens	O	
10	an	O	
11	arena	O	
12	for	O	
13	discussion	O	
14	on	O	
15	the	O	
16	Rivista	O	
17	dell	O	
18	'	O	
19	Infermiere	O	
20	is	O	
21	to	O	
22	critically	O	
23	appraise	O	
24	published	O	
25	research	O	
26	works	O	
27	focusing	O	
28	both	O	
29	on	O	
30	strengths	O	
31	and	O	
32	novelty	O	
33	and	O	
34	weaknesses	O	
35	in	O	
36	the	O	
37	hypothesis	O	
38	formulation	O	
39	,	O	
40	methods	O	
41	and	O	
42	instruments	O	
43	used	O	
44	,	O	
45	discussion	O	
46	of	O	
47	results	O	
48	.	O	

1	Examination	O	
2	of	O	
3	DNA	O	
4	:	O	
5	protein	O	
6	binding	O	
7	complexes	O	
8	by	O	
9	gel	O	
10	-	O	
11	shift	O	
12	analysis	O	
13	indicated	O	
14	that	O	
15	nuclear	O	
16	factors	O	
17	from	O	
18	both	O	
19	proliferative	O	
20	and	O	
21	growth	O	
22	-	O	
23	arrested	O	
24	cells	O	
25	bound	O	
26	to	O	
27	the	O	
28	DNA	O	
29	fragment	O	
30	spanning	O	
31	-	O	
32	949	O	
33	-	O	
34	-	O	
35	722	O	
36	bp	O	
37	.	O	

1	Demonstration	O	
2	of	O	
3	fine	O	
4	structure	O	
5	of	O	
6	the	O	
7	guinea	O	
8	pig	O	
9	organ	O	
10	of	O	
11	Corti	O	
12	after	O	
13	electron	O	
14	microscopic	O	
15	silver	O	
16	staining	O	

1	Eukaryotic	B	
2	translation	I	
3	initiation	I	
4	factor	I	
5	4GI	I	
6	is	O	
7	a	O	
8	cellular	O	
9	target	O	
10	for	O	
11	NS1	B	
12	protein	I	
13	,	O	
14	a	O	
15	translational	O	
16	activator	O	
17	of	O	
18	influenza	O	
19	virus	O	
20	.	O	

1	Insert2	O	
2	contains	O	
3	repetitive	O	
4	non	O	
5	-	O	
6	Ig	B	
7	-	O	
8	related	O	
9	sequences	O	
10	and	O	
11	a	O	
12	small	B	
13	Ig	I	
14	-	I	
15	related	I	
16	sequence	I	
17	.	O	

1	In	O	
2	the	O	
3	Oct	B	
4	-	I	
5	1	I	
6	crystal	O	
7	,	O	
8	the	O	
9	POU	B	
10	-	I	
11	specific	I	
12	domain	I	
13	recognizes	O	
14	a	O	
15	GCAT	O	
16	half	O	
17	-	O	
18	site	O	
19	,	O	
20	while	O	
21	the	O	
22	corresponding	O	
23	sequence	O	
24	recognized	O	
25	by	O	
26	the	O	
27	Pit	B	
28	-	I	
29	1	I	
30	POU	I	
31	-	O	
32	specific	O	
33	domain	O	
34	,	O	
35	GTAT	O	
36	,	O	
37	is	O	
38	on	O	
39	the	O	
40	opposing	O	
41	strand	O	
42	.	O	

1	Consistent	O	
2	with	O	
3	ErbB	B	
4	-	I	
5	2	I	
6	being	O	
7	a	O	
8	shared	O	
9	receptor	O	
10	subunit	O	
11	,	O	
12	its	O	
13	tyrosine	O	
14	phosphorylation	O	
15	was	O	
16	increased	O	
17	by	O	
18	both	O	
19	heterologous	O	
20	ligands	O	
21	and	O	
22	it	O	
23	mediated	O	
24	a	O	
25	trans	O	
26	-	O	
27	inhibitory	O	
28	effect	O	
29	of	O	
30	NDF	B	
31	on	O	
32	EGF	B	
33	binding	O	
34	.	O	

1	A	O	
2	decamer	O	
3	sequence	O	
4	,	O	
5	5	O	
6	'-	O	
7	CGA	O	
8	-	O	
9	CCCCUCC	O	
10	-	O	
11	3	O	
12	',	O	
13	complementary	O	
14	to	O	
15	a	O	
16	conserved	O	
17	sequence	O	
18	adjacent	O	
19	to	O	
20	the	O	
21	enzymatic	O	
22	cleavage	O	
23	site	O	
24	on	O	
25	the	O	
26	mitochondrial	O	
27	RNA	O	
28	substrate	O	
29	,	O	
30	is	O	
31	present	O	
32	in	O	
33	the	O	
34	RNAase	B	
35	MRP	I	
36	RNA	I	
37	.	O	

1	These	O	
2	differences	O	
3	involve	O	
4	specific	O	
5	hydrogen	O	
6	-	O	
7	bonding	O	
8	interactions	O	
9	between	O	
10	the	O	
11	protein	O	
12	and	O	
13	DNA	O	
14	,	O	
15	including	O	
16	guanine	O	
17	N7	O	
18	sites	O	
19	in	O	
20	the	O	
21	major	O	
22	groove	O	
23	of	O	
24	DNA	O	
25	,	O	
26	and	O	
27	alterations	O	
28	in	O	
29	DNA	O	
30	phosphodiester	O	
31	conformation	O	
32	induced	O	
33	by	O	
34	protein	O	
35	binding	O	
36	.	O	

1	Anti	B	
2	-	I	
3	CRK	I	
4	antibodies	I	
5	detect	O	
6	a	O	
7	53kDa	O	
8	protein	O	
9	in	O	
10	extracts	O	
11	of	O	
12	C	O	
13	.	O	
14	fasciculata	O	
15	in	O	
16	agreement	O	
17	with	O	
18	the	O	
19	size	O	
20	predicted	O	
21	from	O	
22	the	O	
23	nucleotide	O	
24	sequence	O	
25	of	O	
26	the	O	
27	cloned	O	
28	gene	O	
29	.	O	

1	In	O	
2	an	O	
3	effort	O	
4	to	O	
5	separate	O	
6	domains	O	
7	of	O	
8	FadR	B	
9	required	O	
10	for	O	
11	DNA	O	
12	binding	O	
13	,	O	
14	dimerization	O	
15	,	O	
16	and	O	
17	ligand	O	
18	binding	O	
19	,	O	
20	chimeric	O	
21	protein	O	
22	fusions	O	
23	between	O	
24	the	O	
25	DNA	O	
26	binding	O	
27	domain	O	
28	of	O	
29	LexA	B	
30	and	O	
31	different	O	
32	regions	O	
33	of	O	
34	FadR	B	
35	were	O	
36	constructed	O	
37	.	O	

1	Neither	O	
2	model	O	
3	,	O	
4	as	O	
5	applied	O	
6	,	O	
7	provided	O	
8	a	O	
9	satisfactory	O	
10	account	O	
11	of	O	
12	the	O	
13	effects	O	
14	of	O	
15	the	O	
16	main	O	
17	variables	O	
18	of	O	
19	number	O	
20	of	O	
21	tones	O	
22	and	O	
23	amount	O	
24	of	O	
25	perturbation	O	
26	.(	O	
27	ABSTRACT	O	
28	TRUNCATED	O	
29	AT	O	
30	400	O	
31	WORDS	O	
32	)	O	

1	A	O	
2	herpesvirus	O	
3	proteinase	O	
4	activity	O	
5	has	O	
6	been	O	
7	identified	O	
8	and	O	
9	partially	O	
10	characterized	O	
11	by	O	
12	using	O	
13	the	O	
14	cloned	O	
15	enzyme	O	
16	and	O	
17	substrate	O	
18	genes	O	
19	in	O	
20	transient	O	
21	transfection	O	
22	assays	O	
23	.	O	

1	During	O	
2	the	O	
3	aftermath	O	
4	of	O	
5	excitation	O	
6	of	O	
7	the	O	
8	skin	O	
9	sympathetic	O	
10	nerve	O	
11	by	O	
12	mental	O	
13	arithmetics	O	
14	,	O	
15	3	O	
16	/	O	
17	12	O	
18	A	O	
19	delta	O	
20	units	O	
21	were	O	
22	turned	O	
23	to	O	
24	the	O	
25	active	O	
26	state	O	
27	with	O	
28	decreased	O	
29	mechanical	O	
30	threshold	O	
31	.	O	

1	When	O	
2	transfected	O	
3	into	O	
4	Drosophila	O	
5	SL	O	
6	-	O	
7	2	O	
8	cells	O	
9	,	O	
10	pCAT	O	
11	plasmid	O	
12	containing	O	
13	2	O	
14	,	O	
15	090	O	
16	bp	O	
17	of	O	
18	5	O	
19	'-	O	
20	flanking	O	
21	region	O	
22	shows	O	
23	a	O	
24	3	O	
25	.	O	
26	0	O	
27	-	O	
28	to	O	
29	3	O	
30	.	O	
31	5	O	
32	-	O	
33	fold	O	
34	increase	O	
35	in	O	
36	chloramphenicol	B	
37	acetyltransferase	I	
38	activity	O	
39	after	O	
40	induction	O	
41	with	O	
42	retinoic	O	
43	acid	O	
44	and	O	
45	/	O	
46	or	O	
47	8	O	
48	-	O	
49	bromo	O	
50	-	O	
51	cAMP	O	
52	.	O	

1	G	O	
2	.	O	

1	The	O	
2	effect	O	
3	of	O	
4	the	O	
5	thromboxane	B	
6	A2	I	
7	(	I	
8	TXA2	I	
9	)/	I	
10	prostaglandin	I	
11	endoperoxide	I	
12	receptor	I	
13	antagonist	O	
14	,	O	
15	SQ	O	
16	29	O	
17	,	O	
18	548	O	
19	on	O	
20	pacing	O	
21	-	O	
22	induced	O	
23	ischemia	O	
24	was	O	
25	determined	O	
26	in	O	
27	anesthetized	O	
28	open	O	
29	-	O	
30	chest	O	
31	dogs	O	
32	.	O	

1	The	O	
2	bHLH	B	
3	proteins	I	
4	function	O	
5	as	O	
6	potent	O	
7	transcriptional	O	
8	activators	O	
9	of	O	
10	tissue	O	
11	-	O	
12	specific	O	
13	genes	O	
14	by	O	
15	forming	O	
16	heterodimers	O	
17	between	O	
18	ubiquitous	O	
19	and	O	
20	cell	O	
21	-	O	
22	restricted	O	
23	family	O	
24	members	O	
25	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	the	O	
5	distribution	O	
6	of	O	
7	endocytic	O	
8	markers	O	
9	is	O	
10	not	O	
11	affected	O	
12	.	O	

1	Two	O	
2	patients	O	
3	had	O	
4	immediate	O	
5	adverse	O	
6	effects	O	
7	from	O	
8	NMF	O	
9	;	O	
10	one	O	
11	had	O	
12	a	O	
13	grand	O	
14	mal	O	
15	seizure	O	
16	and	O	
17	the	O	
18	other	O	
19	developed	O	
20	severe	O	
21	abdominal	O	
22	pain	O	
23	.	O	

1	Two	O	
2	polyadenylation	O	
3	sites	O	
4	were	O	
5	used	O	
6	,	O	
7	one	O	
8	at	O	
9	the	O	
10	end	O	
11	of	O	
12	the	O	
13	early	B	
14	(	I	
15	E	I	
16	)	I	
17	region	I	
18	of	O	
19	the	O	
20	viral	O	
21	DNA	O	
22	,	O	
23	the	O	
24	other	O	
25	at	O	
26	the	O	
27	end	O	
28	of	O	
29	the	O	
30	late	B	
31	(	I	
32	L	I	
33	)	I	
34	region	I	
35	.	O	

1	To	O	
2	evaluate	O	
3	the	O	
4	gas	O	
5	chromatographic	O	
6	electron	O	
7	capture	O	
8	detection	O	
9	method	O	
10	described	O	
11	earlier	O	
12	,	O	
13	23	O	
14	plasma	O	
15	samples	O	
16	have	O	
17	been	O	
18	analysed	O	
19	by	O	
20	both	O	
21	techniques	O	
22	.	O	

1	Production	O	
2	costs	O	
3	included	O	
4	feed	O	
5	,	O	
6	non	O	
7	-	O	
8	feed	O	
9	operating	O	
10	,	O	
11	fixed	O	
12	,	O	
13	and	O	
14	replacement	O	
15	stock	O	
16	costs	O	
17	.	O	

1	Gastric	O	
2	CO2	O	
3	/	O	
4	HCO3	O	
5	was	O	
6	determined	O	
7	in	O	
8	absence	O	
9	of	O	
10	simultaneous	O	
11	inhibition	O	
12	of	O	
13	acid	O	
14	secretion	O	
15	by	O	
16	intra	O	
17	-	O	
18	and	O	
19	extragastric	O	
20	pCO2	O	
21	/	O	
22	pH	O	
23	measurements	O	
24	in	O	
25	23	O	
26	persons	O	
27	and	O	
28	calculated	O	
29	using	O	
30	the	O	
31	equation	O	
32	of	O	
33	Henderson	O	
34	-	O	
35	Hasselbalch	O	
36	.	O	
37	pCO2	O	
38	was	O	
39	measured	O	
40	with	O	
41	use	O	
42	of	O	
43	a	O	
44	new	O	
45	electrode	O	
46	.	O	

1	Since	O	
2	proteins	O	
3	containing	O	
4	TPR	O	
5	elements	O	
6	are	O	
7	typically	O	
8	involved	O	
9	in	O	
10	multiple	O	
11	protein	O	
12	-	O	
13	protein	O	
14	interactions	O	
15	,	O	
16	we	O	
17	suggest	O	
18	that	O	
19	the	O	
20	102kD	O	
21	protein	O	
22	interacts	O	
23	within	O	
24	the	O	
25	tri	O	
26	-	O	
27	snRNP	O	
28	with	O	
29	both	O	
30	the	O	
31	U5	B	
32	and	O	
33	U4	B	
34	/	O	
35	U6	B	
36	snRNPs	O	
37	,	O	
38	thus	O	
39	bridging	O	
40	the	O	
41	two	O	
42	particles	O	
43	.	O	

1	The	O	
2	region	O	
3	that	O	
4	imparts	O	
5	inducibility	O	
6	by	O	
7	IL	B	
8	-	I	
9	1	I	
10	or	O	
11	TNF	B	
12	(	O	
13	positions	O	
14	-	O	
15	165	O	
16	to	O	
17	-	O	
18	58	O	
19	)	O	
20	contains	O	
21	potential	O	
22	binding	O	
23	sites	O	
24	for	O	
25	IRF	B	
26	-	I	
27	1	I	
28	and	I	
29	-	I	
30	2	I	
31	,	O	
32	AP	B	
33	-	I	
34	1	I	
35	,	O	
36	and	O	
37	NF	B	
38	-	I	
39	IL	I	
40	-	I	
41	6	I	
42	.	O	

1	One	O	
2	of	O	
3	these	O	
4	is	O	
5	surrounded	O	
6	by	O	
7	an	O	
8	adenine	O	
9	-	O	
10	uridine	O	
11	rich	O	
12	region	O	
13	that	O	
14	can	O	
15	form	O	
16	an	O	
17	11	O	
18	-	O	
19	base	O	
20	pair	O	
21	stem	O	
22	structure	O	
23	.	O	

1	The	O	
2	Saccharomyces	B	
3	cerevisiae	I	
4	RAD30	I	
5	gene	I	
6	,	O	
7	a	O	
8	homologue	B	
9	of	I	
10	Escherichia	I	
11	coli	I	
12	dinB	I	
13	and	O	
14	umuC	B	
15	,	O	
16	is	O	
17	DNA	O	
18	damage	O	
19	inducible	O	
20	and	O	
21	functions	O	
22	in	O	
23	a	O	
24	novel	O	
25	error	O	
26	-	O	
27	free	O	
28	postreplication	O	
29	repair	O	
30	mechanism	O	
31	.	O	

1	These	O	
2	data	O	
3	support	O	
4	a	O	
5	possible	O	
6	biological	O	
7	significance	O	
8	of	O	
9	the	O	
10	frameshift	O	
11	to	O	
12	occur	O	
13	at	O	
14	this	O	
15	position	O	
16	of	O	
17	the	O	
18	large	O	
19	overlap	O	
20	by	O	
21	including	O	
22	the	O	
23	putative	O	
24	RNA	O	
25	template	O	
26	-	O	
27	binding	O	
28	site	O	
29	of	O	
30	the	O	
31	PLRV	B	
32	replicase	I	
33	in	O	
34	the	O	
35	ORF2a	B	
36	/	I	
37	ORF2b	I	
38	transframe	I	
39	protein	I	
40	.	O	

1	Inhibition	O	
2	of	O	
3	RNA2	B	
4	translation	O	
5	was	O	
6	selective	O	
7	,	O	
8	with	O	
9	no	O	
10	effect	O	
11	on	O	
12	general	O	
13	cellular	O	
14	translation	O	
15	or	O	
16	translation	O	
17	of	O	
18	BMV	O	
19	RNA1	B	
20	-	O	
21	encoded	O	
22	replication	B	
23	factor	I	
24	1a	I	
25	,	O	
26	and	O	
27	was	O	
28	independent	O	
29	of	O	
30	p20	B	
31	,	O	
32	a	O	
33	cellular	O	
34	antagonist	O	
35	of	O	
36	DED1	B	
37	function	O	
38	in	O	
39	translation	O	
40	.	O	

1	We	O	
2	could	O	
3	demonstrate	O	
4	the	O	
5	involvement	O	
6	of	O	
7	cAMP	B	
8	-	I	
9	dependent	I	
10	protein	I	
11	kinase	I	
12	(	O	
13	PKA	B	
14	)	O	
15	in	O	
16	the	O	
17	phosphorylation	O	
18	of	O	
19	CDC25Mm	B	
20	in	O	
21	fibroblasts	O	
22	overexpressing	O	
23	this	O	
24	RasGEF	B	
25	as	O	
26	well	O	
27	as	O	
28	in	O	
29	mouse	O	
30	brain	O	
31	synaptosomal	O	
32	membranes	O	
33	.	O	

1	The	O	
2	effect	O	
3	of	O	
4	water	O	
5	deprivation	O	
6	for	O	
7	19	O	
8	h	O	
9	on	O	
10	renal	O	
11	Na	O	
12	excretion	O	
13	of	O	
14	conscious	O	
15	adrenalectomized	O	
16	(	O	
17	ADX	O	
18	)	O	
19	sheep	O	
20	maintained	O	
21	on	O	
22	a	O	
23	constant	O	
24	intravenous	O	
25	infusion	O	
26	of	O	
27	aldosterone	O	
28	and	O	
29	cortisol	O	
30	(	O	
31	ADX	O	
32	-	O	
33	constant	O	
34	steroid	O	
35	sheep	O	
36	)	O	
37	was	O	
38	investigated	O	
39	.	O	

1	Mothers	O	
2	with	O	
3	severe	O	
4	anatomical	O	
5	abnormalities	O	
6	,	O	
7	who	O	
8	are	O	
9	HIV	O	
10	positive	O	
11	,	O	
12	have	O	
13	active	O	
14	TB	O	
15	or	O	
16	whose	O	
17	children	O	
18	have	O	
19	inherited	O	
20	mono	O	
21	-	O	
22	or	O	
23	disaccharide	O	
24	intolerances	O	
25	should	O	
26	not	O	
27	breastfeed	O	
28	.	O	

1	The	O	
2	sequence	O	
3	of	O	
4	the	O	
5	HIR1	B	
6	gene	I	
7	predicts	O	
8	an	O	
9	88	O	
10	-	O	
11	kDa	O	
12	protein	O	
13	with	O	
14	three	O	
15	repeats	O	
16	of	O	
17	a	O	
18	motif	O	
19	found	O	
20	in	O	
21	the	O	
22	G	B	
23	beta	I	
24	subunit	I	
25	of	O	
26	retinal	B	
27	transducin	I	
28	and	O	
29	in	O	
30	a	O	
31	yeast	O	
32	transcriptional	O	
33	repressor	O	
34	,	O	
35	Tup1	B	
36	.	O	

1	This	O	
2	gene	O	
3	joins	O	
4	the	O	
5	group	O	
6	of	O	
7	genes	O	
8	whose	O	
9	members	O	
10	are	O	
11	rapidly	O	
12	transcribed	O	
13	in	O	
14	response	O	
15	to	O	
16	insulin	B	
17	and	O	
18	other	O	
19	mitogens	O	
20	.	O	

1	C	B	
2	/	I	
3	EBP	I	
4	alpha	I	
5	also	O	
6	activates	O	
7	the	O	
8	promoter	O	
9	of	O	
10	the	O	
11	rat	B	
12	class	I	
13	-	I	
14	I	I	
15	ADH	I	
16	gene	I	
17	in	O	
18	a	O	
19	sequence	O	
20	-	O	
21	specific	O	
22	manner	O	
23	[	O	
24	Potter	O	
25	et	O	
26	al	O	
27	.,	O	
28	Arch	O	
29	.	O	

1	Expression	O	
2	of	O	
3	the	O	
4	human	B	
5	papillomavirus	I	
6	type	I	
7	11	I	
8	E5A	I	
9	protein	I	
10	from	O	
11	the	O	
12	E1E4	B	
13	,	I	
14	E5	I	
15	transcript	I	
16	.	O	

1	The	O	
2	concentration	O	
3	of	O	
4	PGI2	O	
5	on	O	
6	the	O	
7	newly	O	
8	-	O	
9	formed	O	
10	luminal	O	
11	surface	O	
12	remained	O	
13	low	O	
14	.	O	

1	The	O	
2	mammalian	B	
3	phosphoinositide	I	
4	3	I	
5	-	I	
6	kinases	I	
7	(	O	
8	PI3Ks	B	
9	)	O	
10	p110alpha	B	
11	,	I	
12	beta	I	
13	,	I	
14	and	I	
15	delta	I	
16	form	O	
17	heterodimers	O	
18	with	O	
19	Src	B	
20	homology	I	
21	2	I	
22	(	O	
23	SH2	B	
24	)	O	
25	domain	O	
26	-	O	
27	containing	O	
28	adaptors	O	
29	such	O	
30	as	O	
31	p85alpha	B	
32	or	O	
33	p55	B	
34	(	O	
35	PIK	B	
36	).	O	

1	In	O	
2	vitro	O	
3	expression	O	
4	of	O	
5	four	O	
6	different	O	
7	naturally	O	
8	occurring	O	
9	nonsense	O	
10	and	O	
11	missense	O	
12	mutations	O	
13	revealed	O	
14	a	O	
15	dramatically	O	
16	altered	O	
17	subcellular	O	
18	location	O	
19	of	O	
20	the	O	
21	protein	O	
22	in	O	
23	cultured	O	
24	cells	O	
25	.	O	

1	Adjuvant	O	
2	therapy	O	
3	for	O	
4	colon	O	
5	cancer	O	
6	]	O	
7	Surgery	O	
8	alone	O	
9	may	O	
10	fail	O	
11	to	O	
12	cure	O	
13	a	O	
14	considerable	O	
15	number	O	
16	of	O	
17	locally	O	
18	advanced	O	
19	colon	O	
20	cancers	O	
21	.	O	

1	Subjects	O	
2	with	O	
3	a	O	
4	short	O	
5	postexposure	O	
6	time	O	
7	and	O	
8	a	O	
9	dioxin	O	
10	burden	O	
11	>	O	
12	0	O	
13	.	O	
14	6	O	
15	pg	O	
16	/	O	
17	m3	O	
18	had	O	
19	a	O	
20	significantly	O	
21	higher	O	
22	risk	O	
23	of	O	
24	hypoergy	O	
25	than	O	
26	unexposed	O	
27	subjects	O	
28	(	O	
29	hypoergy	O	
30	I	O	
31	:	O	
32	OR	O	
33	=	O	
34	9	O	
35	.	O	
36	51	O	
37	,	O	
38	95	O	
39	%	O	
40	CI	O	
41	=	O	
42	1	O	
43	.	O	
44	96	O	
45	-	O	
46	42	O	
47	.	O	
48	02	O	
49	;	O	
50	hypoergy	O	
51	II	O	
52	:	O	
53	OR	O	
54	=	O	
55	2	O	
56	.	O	
57	92	O	
58	,	O	
59	95	O	
60	%	O	
61	CI	O	
62	=	O	
63	1	O	
64	.	O	
65	14	O	
66	-	O	
67	7	O	
68	.	O	
69	5	O	
70	).	O	

1	We	O	
2	have	O	
3	demonstrated	O	
4	previously	O	
5	that	O	
6	two	O	
7	binding	O	
8	sites	O	
9	in	O	
10	the	O	
11	-	B	
12	184	I	
13	HNF	I	
14	-	I	
15	3	I	
16	beta	I	
17	promoter	I	
18	are	O	
19	recognized	O	
20	by	O	
21	widely	O	
22	distributed	O	
23	factors	O	
24	and	O	
25	that	O	
26	there	O	
27	is	O	
28	also	O	
29	a	O	
30	critical	O	
31	autoregulatory	O	
32	site	O	
33	,	O	
34	we	O	
35	identified	O	
36	a	O	
37	binding	O	
38	site	O	
39	for	O	
40	a	O	
41	cell	O	
42	-	O	
43	specific	O	
44	factor	O	
45	,	O	
46	LF	B	
47	-	I	
48	H3	I	
49	beta	I	
50	,	O	
51	that	O	
52	may	O	
53	function	O	
54	in	O	
55	restricting	O	
56	HNF	B	
57	-	I	
58	3	I	
59	beta	I	
60	gene	I	
61	expression	O	
62	to	O	
63	hepatocytes	O	
64	.	O	

1	The	O	
2	emerging	O	
3	complexity	O	
4	of	O	
5	the	O	
6	5	O	
7	'	O	
8	regulatory	O	
9	region	O	
10	of	O	
11	the	O	
12	GH	B	
13	receptor	I	
14	gene	I	
15	was	O	
16	emphasised	O	
17	by	O	
18	the	O	
19	observation	O	
20	that	O	
21	probes	O	
22	derived	O	
23	from	O	
24	exon	O	
25	1B	O	
26	and	O	
27	the	O	
28	distal	O	
29	3	O	
30	'	O	
31	intron	O	
32	boundary	O	
33	do	O	
34	not	O	
35	hybridise	O	
36	with	O	
37	previously	O	
38	cloned	O	
39	genomic	O	
40	sequences	O	
41	that	O	
42	span	O	
43	the	O	
44	liver	O	
45	-	O	
46	specific	O	
47	P1	O	
48	promoter	O	
49	and	O	
50	exon	O	
51	2	O	
52	.	O	

1	For	O	
2	this	O	
3	,	O	
4	cDNAs	O	
5	containing	O	
6	the	O	
7	60K	O	
8	,	O	
9	87K	O	
10	,	O	
11	110K	O	
12	and	O	
13	170K	O	
14	protein	O	
15	coding	O	
16	sequences	O	
17	were	O	
18	each	O	
19	provided	O	
20	with	O	
21	an	O	
22	ATG	O	
23	start	O	
24	codon	O	
25	and	O	
26	the	O	
27	cDNA	O	
28	containing	O	
29	the	O	
30	60K	O	
31	coding	O	
32	sequence	O	
33	with	O	
34	a	O	
35	TAA	O	
36	stop	O	
37	codon	O	
38	immediately	O	
39	downstream	O	
40	of	O	
41	the	O	
42	coding	O	
43	sequence	O	
44	.	O	

1	Apart	O	
2	from	O	
3	iron	O	
4	regulation	O	
5	,	O	
6	sodA	B	
7	expression	O	
8	was	O	
9	affected	O	
10	by	O	
11	changes	O	
12	in	O	
13	DNA	O	
14	topology	O	
15	induced	O	
16	by	O	
17	coumermycin	O	
18	A	O	
19	but	O	
20	not	O	
21	by	O	
22	the	O	
23	global	O	
24	virulence	O	
25	regulatory	O	
26	Bvg	B	
27	system	I	
28	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	our	O	
5	results	O	
6	show	O	
7	that	O	
8	ERKs	B	
9	and	O	
10	PI3Ks	B	
11	can	O	
12	synergise	O	
13	to	O	
14	convert	O	
15	ectoderm	O	
16	into	O	
17	mesoderm	O	
18	.	O	

1	We	O	
2	have	O	
3	now	O	
4	identified	O	
5	,	O	
6	after	O	
7	21	O	
8	serial	O	
9	undiluted	O	
10	passages	O	
11	of	O	
12	MHV	O	
13	,	O	
14	a	O	
15	small	B	
16	DI	I	
17	RNA	I	
18	,	O	
19	DIssF	B	
20	,	O	
21	which	O	
22	is	O	
23	efficiently	O	
24	packaged	O	
25	into	O	
26	virions	O	
27	.	O	

1	All	O	
2	radiologists	O	
3	using	O	
4	the	O	
5	machine	O	
6	found	O	
7	that	O	
8	the	O	
9	reporting	O	
10	terminal	O	
11	was	O	
12	simple	O	
13	to	O	
14	operate	O	
15	,	O	
16	but	O	
17	found	O	
18	that	O	
19	reporting	O	
20	abnormalities	O	
21	caused	O	
22	an	O	
23	increased	O	
24	effort	O	
25	and	O	
26	took	O	
27	a	O	
28	longer	O	
29	time	O	
30	.	O	

1	Both	O	
2	4	O	
3	,	O	
4	8	O	
5	-	O	
6	DiMeIQx	O	
7	and	O	
8	A	O	
9	alpha	O	
10	C	O	
11	were	O	
12	found	O	
13	at	O	
14	<	O	
15	1	O	
16	p	O	
17	.	O	
18	p	O	
19	.	O	
20	b	O	
21	.	O	

1	In	O	
2	addition	O	
3	to	O	
4	its	O	
5	elongation	O	
6	activity	O	
7	,	O	
8	ELL	B	
9	contains	O	
10	a	O	
11	novel	O	
12	type	O	
13	of	O	
14	RNA	B	
15	polymerase	I	
16	II	I	
17	interaction	I	
18	domain	I	
19	that	O	
20	is	O	
21	capable	O	
22	of	O	
23	repressing	O	
24	polymerase	O	
25	activity	O	
26	in	O	
27	promoter	O	
28	-	O	
29	specific	O	
30	transcription	O	
31	.	O	

1	Almost	O	
2	complete	O	
3	sequence	O	
4	identity	O	
5	was	O	
6	found	O	
7	between	O	
8	the	O	
9	3	O	
10	'	O	
11	end	O	
12	of	O	
13	the	O	
14	DXS6673E	B	
15	gene	I	
16	and	O	
17	two	O	
18	expressed	O	
19	sequence	O	
20	tags	O	
21	(	O	
22	ESTs	O	
23	)	O	
24	and	O	
25	between	O	
26	the	O	
27	5	O	
28	'	O	
29	end	O	
30	of	O	
31	the	O	
32	DXS6673E	B	
33	gene	I	
34	and	O	
35	a	O	
36	third	O	
37	EST	O	
38	.	O	

1	Molecular	O	
2	cloning	O	
3	of	O	
4	the	O	
5	cDNA	O	
6	for	O	
7	the	O	
8	human	B	
9	U2	I	
10	snRNA	I	
11	-	I	
12	specific	I	
13	A	I	
14	'	I	
15	protein	I	
16	.	O	

1	86	O	
2	:	O	
3	3199	O	
4	-	O	
5	3203	O	
6	)	O	
7	or	O	
8	G1	O	
9	to	O	
10	S	O	
11	phase	O	
12	(	O	
13	Reilly	O	
14	,	O	
15	C	O	
16	.	O	

1	Static	O	
2	and	O	
3	dynamic	O	
4	compliance	O	
5	was	O	
6	measured	O	
7	after	O	
8	induction	O	
9	of	O	
10	anesthesia	O	
11	,	O	
12	before	O	
13	and	O	
14	immediately	O	
15	after	O	
16	filtration	O	
17	in	O	
18	the	O	
19	operating	O	
20	theater	O	
21	,	O	
22	1	O	
23	hour	O	
24	after	O	
25	return	O	
26	to	O	
27	the	O	
28	pediatric	O	
29	intensive	O	
30	care	O	
31	unit	O	
32	,	O	
33	and	O	
34	24	O	
35	hours	O	
36	after	O	
37	the	O	
38	operation	O	
39	.	O	

1	Problems	O	
2	remain	O	
3	to	O	
4	be	O	
5	resolved	O	
6	in	O	
7	the	O	
8	area	O	
9	of	O	
10	quantitative	O	
11	risk	O	
12	assessment	O	
13	.	O	

1	A	O	
2	triple	B	
3	-	I	
4	mutant	I	
5	TBP	I	
6	(	O	
7	R231E	O	
8	+	O	
9	R235E	O	
10	+	O	
11	R239S	O	
12	)	O	
13	had	O	
14	greatly	O	
15	reduced	O	
16	activity	O	
17	for	O	
18	yeast	B	
19	U6	I	
20	snRNA	I	
21	gene	I	
22	transcription	O	
23	while	O	
24	remaining	O	
25	active	O	
26	for	O	
27	Pol	B	
28	II	I	
29	basal	O	
30	transcription	O	
31	.	O	

1	In	O	
2	all	O	
3	trials	O	
4	,	O	
5	antigen	O	
6	challenge	O	
7	followed	O	
8	1	O	
9	h	O	
10	after	O	
11	the	O	
12	last	O	
13	treatment	O	
14	.	O	

1	All	O	
2	four	O	
3	of	O	
4	the	O	
5	genes	O	
6	have	O	
7	a	O	
8	similar	O	
9	structure	O	
10	,	O	
11	with	O	
12	the	O	
13	receptor	O	
14	protein	O	
15	encoded	O	
16	in	O	
17	a	O	
18	single	O	
19	exon	O	
20	.	O	

1	The	O	
2	development	O	
3	and	O	
4	distribution	O	
5	of	O	
6	Trypanosoma	O	
7	congolense	O	
8	,	O	
9	T	O	
10	vivax	O	
11	and	O	
12	T	O	
13	brucei	O	
14	in	O	
15	the	O	
16	skin	O	
17	of	O	
18	goats	O	
19	was	O	
20	examined	O	
21	after	O	
22	the	O	
23	animals	O	
24	were	O	
25	bitten	O	
26	by	O	
27	infected	O	
28	Glossina	O	
29	morsitans	O	
30	centralis	O	
31	.	O	

1	There	O	
2	was	O	
3	also	O	
4	a	O	
5	highly	O	
6	significant	O	
7	correlation	O	
8	between	O	
9	total	O	
10	selenium	O	
11	intake	O	
12	and	O	
13	liver	O	
14	selenium	O	
15	concentration	O	
16	(	O	
17	r	O	
18	=	O	
19	0	O	
20	.	O	
21	99	O	
22	,	O	
23	p	O	
24	<	O	
25	0	O	
26	.	O	
27	01	O	
28	)	O	
29	after	O	
30	1	O	
31	mo	O	
32	of	O	
33	treatment	O	
34	,	O	
35	but	O	
36	this	O	
37	time	O	
38	liver	O	
39	selenium	O	
40	did	O	
41	not	O	
42	change	O	
43	with	O	
44	time	O	
45	,	O	
46	and	O	
47	the	O	
48	correlation	O	
49	remained	O	
50	highly	O	
51	significant	O	
52	throughout	O	
53	the	O	
54	investigation	O	
55	.	O	

1	When	O	
2	two	O	
3	determinations	O	
4	were	O	
5	performed	O	
6	on	O	
7	12	O	
8	samples	O	
9	of	O	
10	plasma	O	
11	taken	O	
12	from	O	
13	normal	O	
14	adults	O	
15	in	O	
16	October	O	
17	,	O	
18	the	O	
19	values	O	
20	were	O	
21	22	O	
22	.	O	
23	6	O	
24	+/-	O	
25	4	O	
26	.	O	
27	8	O	
28	and	O	
29	21	O	
30	.	O	
31	0	O	
32	+/-	O	
33	3	O	
34	.	O	
35	6	O	
36	(	O	
37	mean	O	
38	+/-	O	
39	SD	O	
40	)	O	
41	ng	O	
42	/	O	
43	ml	O	
44	,	O	
45	respectively	O	
46	.	O	

1	RESULTS	O	
2	:	O	
3	Prevalence	O	
4	of	O	
5	obesity	O	
6	(	O	
7	BMI	O	
8	SDS	O	
9	>	O	
10	2	O	
11	.	O	
12	0	O	
13	)	O	
14	was	O	
15	<	O	
16	2	O	
17	%	O	
18	at	O	
19	diagnosis	O	
20	,	O	
21	but	O	
22	increased	O	
23	to	O	
24	16	O	
25	%	O	
26	at	O	
27	3y	O	
28	.	O	

1	To	O	
2	investigate	O	
3	the	O	
4	potential	O	
5	role	O	
6	of	O	
7	SP1	B	
8	,	O	
9	we	O	
10	examined	O	
11	nuclear	O	
12	extracts	O	
13	from	O	
14	HCMV	O	
15	-	O	
16	infected	O	
17	cells	O	
18	.	O	

1	Allagille	O	
2	'	O	
3	s	O	
4	syndrome	O	
5	associated	O	
6	with	O	
7	antenatal	O	
8	ascites	O	

1	We	O	
2	found	O	
3	that	O	
4	T3	O	
5	(	O	
6	10	O	
7	(-	O	
8	8	O	
9	)	O	
10	M	O	
11	)	O	
12	selectively	O	
13	stimulates	O	
14	transcription	O	
15	from	O	
16	rGH	B	
17	-	O	
18	TRE	O	
19	-	O	
20	and	O	
21	TREpal	O	
22	-,	O	
23	but	O	
24	not	O	
25	ME	O	
26	-	O	
27	TRE	O	
28	-	O	
29	and	O	
30	F2	O	
31	-	O	
32	TRE	O	
33	-,	O	
34	containing	O	
35	templates	O	
36	in	O	
37	which	O	
38	these	O	
39	TREs	O	
40	are	O	
41	linked	O	
42	in	O	
43	front	O	
44	of	O	
45	the	O	
46	rGH	B	
47	minimal	I	
48	promoter	I	
49	containing	O	
50	only	O	
51	the	O	
52	TATA	B	
53	box	I	
54	binding	I	
55	protein	I	
56	,	O	
57	but	O	
58	not	O	
59	any	O	
60	other	O	
61	proximal	O	
62	binding	O	
63	protein	O	
64	,	O	
65	sequence	O	
66	.	O	

1	The	O	
2	deduced	O	
3	96	O	
4	-	O	
5	residue	O	
6	amino	O	
7	acid	O	
8	coding	O	
9	sequence	O	
10	of	O	
11	the	O	
12	murine	O	
13	HMG	B	
14	-	I	
15	I	I	
16	(	I	
17	Y	I	
18	)	I	
19	cDNA	O	
20	is	O	
21	very	O	
22	similar	O	
23	to	O	
24	the	O	
25	reported	O	
26	amino	O	
27	acid	O	
28	sequence	O	
29	of	O	
30	human	O	
31	HMG	B	
32	-	I	
33	I	I	
34	,	O	
35	except	O	
36	that	O	
37	it	O	
38	lacks	O	
39	11	O	
40	internal	O	
41	amino	O	
42	acids	O	
43	reported	O	
44	in	O	
45	the	O	
46	human	O	
47	protein	O	
48	.	O	

1	SETTING	O	
2	:	O	
3	A	O	
4	division	O	
5	of	O	
6	a	O	
7	large	O	
8	tea	O	
9	plantation	O	
10	in	O	
11	Kandy	O	
12	.	O	

1	ZK7	B	
2	and	O	
3	HZF16	B	
4	genes	I	
5	appear	O	
6	to	O	
7	be	O	
8	the	O	
9	splice	O	
10	variants	O	
11	transcribed	O	
12	from	O	
13	the	O	
14	same	O	
15	gene	O	
16	.	O	

1	The	O	
2	results	O	
3	confirm	O	
4	and	O	
5	extend	O	
6	previous	O	
7	work	O	
8	by	O	
9	other	O	
10	researchers	O	
11	.	O	

1	11	O	
2	-	O	
3	Aminoundecanoyl	O	
4	-	O	
5	SK	O	
6	-	O	
7	NH2	O	
8	and	O	
9	11	O	
10	-	O	
11	aminoundecanoyl	O	
12	-	O	
13	SH	O	
14	-	O	
15	NH2	O	
16	establish	O	
17	that	O	
18	a	O	
19	simple	O	
20	alkyl	O	
21	backbone	O	
22	can	O	
23	maintain	O	
24	an	O	
25	appropriate	O	
26	distance	O	
27	between	O	
28	three	O	
29	elements	O	
30	critical	O	
31	for	O	
32	recognition	O	
33	by	O	
34	the	O	
35	fungal	O	
36	enzyme	O	
37	'	O	
38	s	O	
39	peptide	O	
40	-	O	
41	binding	O	
42	site	O	
43	:	O	
44	a	O	
45	simple	O	
46	omega	O	
47	-	O	
48	terminal	O	
49	amino	O	
50	group	O	
51	,	O	
52	a	O	
53	beta	O	
54	-	O	
55	hydroxyl	O	
56	,	O	
57	and	O	
58	an	O	
59	epsilon	O	
60	-	O	
61	amino	O	
62	group	O	
63	or	O	
64	an	O	
65	imidazole	O	
66	.	O	

1	We	O	
2	characterized	O	
3	three	O	
4	Arabidopsis	O	
5	thaliana	O	
6	cDNA	O	
7	clones	O	
8	that	O	
9	could	O	
10	rescue	O	
11	the	O	
12	sterile	O	
13	phenotype	O	
14	of	O	
15	the	O	
16	Schizosaccharomyces	B	
17	pombe	I	
18	pde1	I	
19	mutant	I	
20	,	O	
21	which	O	
22	is	O	
23	defective	O	
24	in	O	
25	cAMP	B	
26	phosphodiesterase	I	
27	.	O	

1	The	O	
2	opioid	O	
3	antagonist	O	
4	naltrexone	O	
5	(	O	
6	0	O	
7	.	O	
8	01	O	
9	-	O	
10	1	O	
11	.	O	
12	0	O	
13	mg	O	
14	/	O	
15	kg	O	
16	)	O	
17	antagonized	O	
18	the	O	
19	discriminative	O	
20	stimulus	O	
21	effects	O	
22	of	O	
23	heroin	O	
24	,	O	
25	but	O	
26	naltrexone	O	
27	at	O	
28	doses	O	
29	up	O	
30	to	O	
31	10	O	
32	mg	O	
33	/	O	
34	kg	O	
35	had	O	
36	no	O	
37	effect	O	
38	on	O	
39	the	O	
40	discriminative	O	
41	stimulus	O	
42	effects	O	
43	of	O	
44	cocaine	O	
45	.	O	

1	The	O	
2	inhibitory	O	
3	response	O	
4	to	O	
5	taps	O	
6	is	O	
7	essentially	O	
8	a	O	
9	protective	O	
10	reflex	O	
11	which	O	
12	probably	O	
13	serves	O	
14	to	O	
15	reduce	O	
16	the	O	
17	activity	O	
18	of	O	
19	the	O	
20	jaw	O	
21	-	O	
22	closing	O	
23	muscles	O	
24	when	O	
25	one	O	
26	bites	O	
27	unexpectedly	O	
28	on	O	
29	hard	O	
30	objects	O	
31	.	O	

1	This	O	
2	would	O	
3	have	O	
4	had	O	
5	the	O	
6	effect	O	
7	of	O	
8	positioning	O	
9	the	O	
10	genes	O	
11	currently	O	
12	on	O	
13	the	O	
14	long	O	
15	arm	O	
16	adjacent	O	
17	to	O	
18	the	O	
19	centromeric	O	
20	heterochromatin	O	
21	,	O	
22	perhaps	O	
23	resulting	O	
24	in	O	
25	a	O	
26	"	O	
27	position	O	
28	effect	O	
29	"	O	
30	on	O	
31	transcription	O	
32	of	O	
33	these	O	
34	genes	O	
35	.	O	

1	The	O	
2	encoded	O	
3	protein	O	
4	has	O	
5	a	O	
6	leader	O	
7	sequence	O	
8	of	O	
9	27	O	
10	amino	O	
11	acids	O	
12	.	O	

1	The	O	
2	initial	O	
3	inpatient	O	
4	experience	O	
5	for	O	
6	individuals	O	
7	with	O	
8	HIV	O	
9	-	O	
10	related	O	
11	TB	O	
12	may	O	
13	be	O	
14	pivotal	O	
15	to	O	
16	the	O	
17	acceptance	O	
18	of	O	
19	and	O	
20	participation	O	
21	in	O	
22	ongoing	O	
23	TB	O	
24	care	O	
25	.	O	

1	Pathogenetic	O	
2	relationships	O	
3	between	O	
4	renal	O	
5	tubular	O	
6	acidosis	O	
7	and	O	
8	sodium	O	
9	metabolism	O	
10	alterations	O	
11	in	O	
12	liver	O	
13	cirrhosis	O	
14	.	O	

1	Our	O	
2	laboratory	O	
3	and	O	
4	others	O	
5	have	O	
6	shown	O	
7	alternative	O	
8	splicing	O	
9	of	O	
10	up	O	
11	to	O	
12	ten	O	
13	exons	O	
14	at	O	
15	a	O	
16	discrete	O	
17	extracellular	O	
18	site	O	
19	to	O	
20	be	O	
21	primarily	O	
22	responsible	O	
23	for	O	
24	the	O	
25	generation	O	
26	of	O	
27	CD44	B	
28	variant	I	
29	(	O	
30	CD44v	B	
31	)	O	
32	isoforms	O	
33	.	O	

1	Risk	O	
2	of	O	
3	infection	O	
4	in	O	
5	the	O	
6	treatment	O	
7	of	O	
8	fractures	O	

1	Icterus	O	
2	and	O	
3	beta	O	
4	-	O	
5	thalassemia	O	
6	in	O	
7	Congolese	O	
8	children	O	
9	in	O	
10	Brazzaville	O	

1	Proteasomes	O	
2	are	O	
3	the	O	
4	multisubunit	O	
5	protease	O	
6	involved	O	
7	in	O	
8	the	O	
9	generation	O	
10	of	O	
11	peptides	O	
12	presented	O	
13	by	O	
14	MHC	B	
15	class	I	
16	I	I	
17	molecules	I	
18	.	O	

1	This	O	
2	regulation	O	
3	could	O	
4	not	O	
5	be	O	
6	appreciably	O	
7	modified	O	
8	by	O	
9	enhanced	O	
10	expression	O	
11	of	O	
12	STAT	B	
13	proteins	I	
14	.	O	

1	To	O	
2	define	O	
3	the	O	
4	minimal	O	
5	VDRE	O	
6	binding	O	
7	domain	O	
8	for	O	
9	human	B	
10	VDR	I	
11	(	O	
12	hVDR	B	
13	),	O	
14	a	O	
15	series	O	
16	of	O	
17	C	O	
18	-	O	
19	terminally	O	
20	truncated	O	
21	hVDR	B	
22	mutants	I	
23	(	O	
24	Delta134	O	
25	,	O	
26	Delta113	O	
27	,	O	
28	Delta102	O	
29	,	O	
30	Delta90	O	
31	,	O	
32	Delta84	O	
33	,	O	
34	Delta80	O	
35	,	O	
36	and	O	
37	Delta60	O	
38	)	O	
39	was	O	
40	generated	O	
41	and	O	
42	expressed	O	
43	in	O	
44	bacteria	O	
45	.	O	

1	The	O	
2	rCBF	O	
3	and	O	
4	vasomotion	O	
5	were	O	
6	recorded	O	
7	by	O	
8	laser	O	
9	-	O	
10	doppler	O	
11	fluxmetry	O	
12	.	O	

1	CO2	O	
2	assimilation	O	
3	by	O	
4	chloroplasts	O	
5	illuminated	O	
6	on	O	
7	filter	O	
8	paper	O	
9	.	O	

1	UGA	O	
2	codon	O	
3	position	O	
4	affects	O	
5	the	O	
6	efficiency	O	
7	of	O	
8	selenocysteine	O	
9	incorporation	O	
10	into	O	
11	glutathione	B	
12	peroxidase	I	
13	-	I	
14	1	I	
15	.	O	

1	We	O	
2	analysed	O	
3	two	O	
4	regions	O	
5	involved	O	
6	in	O	
7	preS2	B	
8	/	O	
9	S	B	
10	gene	I	
11	transcription	O	
12	of	O	
13	the	O	
14	HBV	O	
15	adw	O	
16	subtype	O	
17	:	O	
18	the	O	
19	diverged	O	
20	TATA	O	
21	box	O	
22	and	O	
23	a	O	
24	putative	O	
25	initiator	O	
26	element	O	
27	.	O	

1	In	O	
2	most	O	
3	subjects	O	
4	,	O	
5	markers	O	
6	of	O	
7	bone	O	
8	formation	O	
9	and	O	
10	resorption	O	
11	were	O	
12	normal	O	
13	.	O	

1	Possible	O	
2	roles	O	
3	of	O	
4	RAD5	B	
5	putative	O	
6	ATPase	B	
7	/	O	
8	DNA	B	
9	helicase	I	
10	activity	O	
11	in	O	
12	DNA	O	
13	repair	O	
14	and	O	
15	in	O	
16	the	O	
17	maintenance	O	
18	of	O	
19	wild	O	
20	-	O	
21	type	O	
22	rates	O	
23	of	O	
24	instability	O	
25	of	O	
26	simple	O	
27	repetitive	O	
28	sequences	O	
29	are	O	
30	discussed	O	
31	.	O	

1	Oligonucleotide	O	
2	-	O	
3	directed	O	
4	mutagenesis	O	
5	was	O	
6	used	O	
7	to	O	
8	create	O	
9	an	O	
10	NdeI	B	
11	restriction	I	
12	site	I	
13	at	O	
14	the	O	
15	natural	O	
16	ATG	O	
17	of	O	
18	the	O	
19	yeast	O	
20	R	O	
21	.	O	

1	Lens	B	
2	aldose	I	
3	reductase	I	
4	in	O	
5	diabetic	O	
6	and	O	
7	galactosemic	O	
8	cataracts	O	
9	.	O	

1	Nipponbare	O	
2	as	O	
3	well	O	
4	as	O	
5	O	O	
6	.	O	
7	australiensis	O	
8	.	O	

1	In	O	
2	infected	O	
3	mammalian	O	
4	cells	O	
5	,	O	
6	the	O	
7	ARV	B	
8	G	I	
9	and	O	
10	GNS	B	
11	genes	I	
12	are	O	
13	transcribed	O	
14	primarily	O	
15	as	O	
16	a	O	
17	polycistronic	O	
18	mRNA	O	
19	which	O	
20	appears	O	
21	to	O	
22	extend	O	
23	from	O	
24	the	O	
25	consensus	O	
26	sequence	O	
27	(	O	
28	AACAG	O	
29	)	O	
30	at	O	
31	the	O	
32	start	O	
33	of	O	
34	the	O	
35	G	B	
36	gene	I	
37	to	O	
38	the	O	
39	next	O	
40	recognized	O	
41	polyadenylation	O	
42	signal	O	
43	(	O	
44	CATG	O	
45	[	O	
46	A	O	
47	]	O	
48	7	O	
49	)	O	
50	located	O	
51	697	O	
52	nucleotides	O	
53	downstream	O	
54	of	O	
55	the	O	
56	GNS	B	
57	protein	I	
58	termination	O	
59	codon	O	
60	.	O	

1	The	O	
2	novel	O	
3	protein	O	
4	kinases	O	
5	,	O	
6	c	B	
7	-	I	
8	Jun	I	
9	NH2	I	
10	-	I	
11	terminal	I	
12	kinases	I	
13	(	O	
14	JNKs	B	
15	)/	O	
16	stress	B	
17	-	I	
18	activated	I	
19	protein	I	
20	kinases	I	
21	,	O	
22	are	O	
23	also	O	
24	activated	O	
25	by	O	
26	TNF	B	
27	-	I	
28	alpha	I	
29	,	O	
30	IL	B	
31	-	I	
32	1	I	
33	,	O	
34	and	O	
35	CD28	B	
36	costimulation	O	
37	.	O	

1	Multivariate	O	
2	logistic	O	
3	regression	O	
4	analysis	O	
5	indicated	O	
6	that	O	
7	seropositivity	O	
8	was	O	
9	strongly	O	
10	associated	O	
11	with	O	
12	the	O	
13	prevalence	O	
14	of	O	
15	hepatitis	O	
16	B	O	
17	in	O	
18	an	O	
19	employee	O	
20	'	O	
21	s	O	
22	country	O	
23	of	O	
24	birth	O	
25	and	O	
26	with	O	
27	age	O	
28	.	O	

1	As	O	
2	predicted	O	
3	by	O	
4	the	O	
5	Wing	O	
6	and	O	
7	Kristofferson	O	
8	model	O	
9	,	O	
10	the	O	
11	durations	O	
12	of	O	
13	successive	O	
14	ISIs	O	
15	tended	O	
16	to	O	
17	be	O	
18	negatively	O	
19	correlated	O	
20	.	O	

1	Tristetraprolin	B	
2	(	O	
3	TTP	B	
4	)	O	
5	is	O	
6	the	O	
7	prototype	O	
8	of	O	
9	a	O	
10	group	O	
11	of	O	
12	potential	O	
13	transcription	O	
14	factors	O	
15	that	O	
16	contain	O	
17	two	O	
18	or	O	
19	more	O	
20	unusual	O	
21	CCCH	O	
22	zinc	O	
23	fingers	O	
24	.	O	

1	Interestingly	O	
2	,	O	
3	the	O	
4	RNA	O	
5	sequences	O	
6	selected	O	
7	by	O	
8	the	O	
9	mutated	O	
10	zinc	B	
11	knuckle	I	
12	9G8	I	
13	variant	I	
14	are	O	
15	efficiently	O	
16	recognized	O	
17	by	O	
18	SRp20	B	
19	,	O	
20	in	O	
21	agreement	O	
22	with	O	
23	the	O	
24	fact	O	
25	that	O	
26	the	O	
27	RBD	O	
28	of	O	
29	9G8	B	
30	and	O	
31	SRp20	B	
32	are	O	
33	similar	O	
34	.	O	

1	These	O	
2	modifications	O	
3	may	O	
4	improve	O	
5	the	O	
6	interlaboratory	O	
7	reproducibility	O	
8	of	O	
9	CD34	B	
10	determinations	O	
11	due	O	
12	to	O	
13	the	O	
14	reduction	O	
15	in	O	
16	sample	O	
17	handling	O	
18	and	O	
19	calculation	O	
20	of	O	
21	results	O	
22	.	O	

1	In	O	
2	support	O	
3	of	O	
4	a	O	
5	role	O	
6	at	O	
7	the	O	
8	spindle	O	
9	,	O	
10	two	O	
11	-	O	
12	hybrid	O	
13	library	O	
14	screening	O	
15	with	O	
16	HEF1	B	
17	identifies	O	
18	the	O	
19	human	O	
20	homolog	O	
21	of	O	
22	the	O	
23	G2	B	
24	/	I	
25	M	I	
26	spindle	I	
27	-	I	
28	regulatory	I	
29	protein	I	
30	Dim1p	I	
31	as	O	
32	a	O	
33	specific	O	
34	interactor	O	
35	with	O	
36	a	O	
37	region	O	
38	of	O	
39	HEF1	B	
40	encompassed	O	
41	in	O	
42	p55	B	
43	(	O	
44	HEF1	B	
45	).	O	

1	A	O	
2	-	O	
3	tracts	O	
4	functioned	O	
5	best	O	
6	when	O	
7	positioned	O	
8	close	O	
9	to	O	
10	the	O	
11	-	O	
12	35	O	
13	hexamer	O	
14	rather	O	
15	than	O	
16	one	O	
17	helical	O	
18	turn	O	
19	farther	O	
20	upstream	O	
21	,	O	
22	similar	O	
23	to	O	
24	the	O	
25	positioning	O	
26	optimal	O	
27	for	O	
28	UP	O	
29	element	O	
30	function	O	
31	.	O	

1	Nucleoprotein	O	
2	(	O	
3	N	O	
4	)	O	
5	expressed	O	
6	by	O	
7	both	O	
8	recombinant	O	
9	vaccinia	O	
10	virus	O	
11	and	O	
12	TGEV	O	
13	had	O	
14	a	O	
15	relative	O	
16	molecular	O	
17	mass	O	
18	(	O	
19	Mr	O	
20	)	O	
21	of	O	
22	47	O	
23	,	O	
24	000	O	
25	and	O	
26	was	O	
27	susceptible	O	
28	to	O	
29	degradation	O	
30	at	O	
31	the	O	
32	C	O	
33	-	O	
34	terminus	O	
35	yielding	O	
36	discrete	O	
37	breakdown	O	
38	products	O	
39	.	O	

1	A	O	
2	similar	O	
3	phenomenon	O	
4	has	O	
5	been	O	
6	reported	O	
7	in	O	
8	a	O	
9	few	O	
10	humans	O	
11	.	O	

1	The	O	
2	5	O	
3	'	O	
4	untranslated	O	
5	and	O	
6	coding	O	
7	regions	O	
8	are	O	
9	contained	O	
10	within	O	
11	12	O	
12	exons	O	
13	,	O	
14	with	O	
15	the	O	
16	translation	O	
17	start	O	
18	site	O	
19	located	O	
20	within	O	
21	the	O	
22	first	O	
23	exon	O	
24	.	O	

1	This	O	
2	element	O	
3	was	O	
4	used	O	
5	to	O	
6	screen	O	
7	an	O	
8	EMBL3	O	
9	mouse	O	
10	genomic	O	
11	library	O	
12	.	O	

1	Sequential	O	
2	cleavage	O	
3	by	O	
4	metallopeptidases	B	
5	and	O	
6	proteasomes	O	
7	is	O	
8	involved	O	
9	in	O	
10	processing	O	
11	HIV	B	
12	-	I	
13	1	I	
14	ENV	I	
15	epitope	I	
16	for	O	
17	endogenous	O	
18	MHC	B	
19	class	I	
20	I	I	
21	antigen	I	
22	presentation	O	
23	.	O	

1	In	O	
2	this	O	
3	study	O	
4	,	O	
5	to	O	
6	characterize	O	
7	the	O	
8	gene	O	
9	for	O	
10	protein	B	
11	Z	I	
12	,	O	
13	its	O	
14	organization	O	
15	and	O	
16	structure	O	
17	were	O	
18	determined	O	
19	by	O	
20	a	O	
21	combination	O	
22	of	O	
23	PCR	O	
24	amplification	O	
25	of	O	
26	leukocyte	O	
27	DNA	O	
28	and	O	
29	isolation	O	
30	of	O	
31	phage	O	
32	clones	O	
33	from	O	
34	a	O	
35	human	O	
36	genomic	O	
37	library	O	
38	.	O	

1	Furthermore	O	
2	,	O	
3	freezing	O	
4	in	O	
5	the	O	
6	presence	O	
7	of	O	
8	bovine	B	
9	lactalbumin	I	
10	resulted	O	
11	in	O	
12	a	O	
13	good	O	
14	maintenance	O	
15	of	O	
16	the	O	
17	cellular	O	
18	viability	O	
19	and	O	
20	of	O	
21	the	O	
22	CCCD	O	
23	heterogeneity	O	
24	in	O	
25	respect	O	
26	to	O	
27	fresh	O	
28	cells	O	
29	.	O	

1	Prognostic	O	
2	value	O	
3	of	O	
4	a	O	
5	treadmill	O	
6	exercise	O	
7	score	O	
8	in	O	
9	symptomatic	O	
10	patients	O	
11	with	O	
12	nonspecific	O	
13	ST	O	
14	-	O	
15	T	O	
16	abnormalities	O	
17	on	O	
18	resting	O	
19	ECG	O	
20	.	O	

1	Structure	O	
2	and	O	
3	regulation	O	
4	of	O	
5	the	O	
6	gene	O	
7	encoding	O	
8	the	O	
9	neuron	O	
10	-	O	
11	specific	O	
12	protein	B	
13	kinase	I	
14	C	I	
15	substrate	O	
16	neurogranin	B	
17	(	O	
18	RC3	B	
19	protein	I	
20	).	O	

1	Using	O	
2	autoantibodies	O	
3	from	O	
4	a	O	
5	Sjogren	O	
6	'	O	
7	s	O	
8	syndrome	O	
9	patient	O	
10	,	O	
11	we	O	
12	have	O	
13	previously	O	
14	identified	O	
15	a	O	
16	230	O	
17	-	O	
18	kDa	O	
19	peripheral	O	
20	membrane	O	
21	protein	O	
22	associated	O	
23	with	O	
24	the	O	
25	cytosolic	O	
26	face	O	
27	of	O	
28	the	O	
29	trans	O	
30	-	O	
31	Golgi	O	
32	(	O	
33	Kooy	O	
34	,	O	
35	J	O	
36	.,	O	
37	Toh	O	
38	,	O	
39	B	O	
40	.	O	

1	A	O	
2	complementary	O	
3	DNA	O	
4	was	O	
5	isolated	O	
6	from	O	
7	Caenorhabditis	O	
8	elegans	O	
9	that	O	
10	encoded	O	
11	a	O	
12	polypeptide	O	
13	of	O	
14	1438	O	
15	amino	O	
16	acid	O	
17	residues	O	
18	,	O	
19	CeGAP	B	
20	,	O	
21	which	O	
22	contains	O	
23	a	O	
24	domain	O	
25	with	O	
26	sequence	O	
27	similarity	O	
28	to	O	
29	the	O	
30	COOH	B	
31	-	I	
32	terminal	I	
33	segment	I	
34	(	I	
35	GTPase	I	
36	-	I	
37	activating	I	
38	protein	I	
39	region	I	
40	)	I	
41	of	O	
42	Bcr	B	
43	and	O	
44	other	O	
45	known	O	
46	GTPase	B	
47	-	I	
48	activating	I	
49	proteins	I	
50	of	O	
51	the	O	
52	Rho	B	
53	subfamily	I	
54	.	O	

1	Plasma	O	
2	concentrations	O	
3	of	O	
4	atracurium	O	
5	and	O	
6	laudanosine	O	
7	were	O	
8	0	O	
9	.	O	
10	73	O	
11	-	O	
12	3	O	
13	.	O	
14	11	O	
15	micrograms	O	
16	ml	O	
17	-	O	
18	1	O	
19	and	O	
20	0	O	
21	.	O	
22	48	O	
23	-	O	
24	8	O	
25	.	O	
26	65	O	
27	micrograms	O	
28	ml	O	
29	-	O	
30	1	O	
31	,	O	
32	respectively	O	
33	;	O	
34	CSF	O	
35	concentration	O	
36	of	O	
37	laudanosine	O	
38	was	O	
39	70	O	
40	-	O	
41	440	O	
42	ng	O	
43	ml	O	
44	-	O	
45	1	O	
46	.	O	

1	These	O	
2	results	O	
3	suggest	O	
4	that	O	
5	gluconeogenic	O	
6	genes	O	
7	are	O	
8	derepressed	O	
9	upon	O	
10	binding	O	
11	of	O	
12	Cat8p	B	
13	,	O	
14	whose	O	
15	synthesis	O	
16	depends	O	
17	on	O	
18	the	O	
19	release	O	
20	of	O	
21	Cat4p	B	
22	(	O	
23	Mig1p	B	
24	)	O	
25	from	O	
26	the	O	
27	CAT8	B	
28	promoter	I	
29	.	O	

1	Examples	O	
2	are	O	
3	using	O	
4	more	O	
5	subjects	O	
6	or	O	
7	an	O	
8	improved	O	
9	research	O	
10	design	O	
11	,	O	
12	developing	O	
13	consensus	O	
14	statements	O	
15	or	O	
16	using	O	
17	meta	O	
18	-	O	
19	analysis	O	
20	.	O	

1	Therefore	O	
2	,	O	
3	mechanisms	O	
4	that	O	
5	control	O	
6	activation	O	
7	of	O	
8	the	O	
9	MAP	B	
10	kinase	I	
11	cascade	O	
12	temporally	O	
13	and	O	
14	spatially	O	
15	may	O	
16	be	O	
17	important	O	
18	for	O	
19	specification	O	
20	of	O	
21	cellular	O	
22	responses	O	
23	.	O	

1	The	O	
2	mean	O	
3	transfer	O	
4	ratios	O	
5	of	O	
6	the	O	
7	drug	O	
8	into	O	
9	the	O	
10	genital	O	
11	tissues	O	
12	to	O	
13	the	O	
14	concentration	O	
15	in	O	
16	the	O	
17	uterine	O	
18	arterial	O	
19	blood	O	
20	were	O	
21	such	O	
22	that	O	
23	the	O	
24	transfer	O	
25	ratio	O	
26	into	O	
27	the	O	
28	portio	O	
29	vaginalis	O	
30	was	O	
31	the	O	
32	highest	O	
33	,	O	
34	followed	O	
35	by	O	
36	the	O	
37	uterine	O	
38	cervix	O	
39	and	O	
40	the	O	
41	myometrium	O	
42	,	O	
43	and	O	
44	that	O	
45	into	O	
46	the	O	
47	oviduct	O	
48	was	O	
49	the	O	
50	lowest	O	
51	with	O	
52	about	O	
53	1	O	
54	/	O	
55	2	O	
56	that	O	
57	into	O	
58	the	O	
59	portio	O	
60	vaginalis	O	
61	.	O	

1	Workers	O	
2	with	O	
3	"	O	
4	sensitivity	O	
5	"	O	
6	to	O	
7	toluene	O	
8	diisocyanate	O	
9	(	O	
10	TDI	O	
11	)	O	
12	studied	O	
13	in	O	
14	depth	O	
15	in	O	
16	an	O	
17	attempt	O	
18	to	O	
19	determine	O	
20	mechanisms	O	
21	of	O	
22	bronchial	O	
23	hyperreactivity	O	
24	.	O	

1	We	O	
2	examined	O	
3	behavioral	O	
4	alterations	O	
5	in	O	
6	the	O	
7	brown	O	
8	cockroach	O	
9	,	O	
10	Periplaneta	O	
11	brunnea	O	
12	,	O	
13	infected	O	
14	with	O	
15	the	O	
16	acanthocephalan	O	
17	,	O	
18	Moniliformis	O	
19	moniliformis	O	
20	.	O	

1	The	O	
2	subunit	O	
3	protein	O	
4	of	O	
5	curli	B	
6	was	O	
7	highly	O	
8	homologous	O	
9	at	O	
10	its	O	
11	amino	O	
12	terminus	O	
13	to	O	
14	SEF	B	
15	-	I	
16	17	I	
17	,	O	
18	the	O	
19	subunit	O	
20	protein	O	
21	of	O	
22	thin	O	
23	,	O	
24	aggregative	O	
25	fimbriae	O	
26	of	O	
27	Salmonella	O	
28	enteritidis	O	
29	27655	O	
30	strain	O	
31	3b	O	
32	,	O	
33	suggesting	O	
34	that	O	
35	these	O	
36	fibres	O	
37	form	O	
38	a	O	
39	novel	O	
40	class	O	
41	of	O	
42	surface	O	
43	organelles	O	
44	on	O	
45	enterobacteria	O	
46	.	O	

1	Furthermore	O	
2	,	O	
3	expression	O	
4	of	O	
5	the	O	
6	promoter	O	
7	in	O	
8	embryonic	O	
9	Drosophila	O	
10	melanogaster	O	
11	cells	O	
12	that	O	
13	lack	O	
14	MyoD1	B	
15	and	O	
16	Sp1	B	
17	is	O	
18	strictly	O	
19	dependent	O	
20	on	O	
21	all	O	
22	three	O	
23	sites	O	
24	remaining	O	
25	intact	O	
26	and	O	
27	on	O	
28	the	O	
29	presence	O	
30	of	O	
31	exogenously	O	
32	supplied	O	
33	Sp1	B	
34	and	O	
35	MyoD1	B	
36	.	O	

1	LY290181	O	
2	appears	O	
3	to	O	
4	inhibit	O	
5	uPA	B	
6	promoter	I	
7	activation	O	
8	by	O	
9	blocking	O	
10	phorbol	O	
11	ester	O	
12	-	O	
13	stimulated	O	
14	binding	O	
15	of	O	
16	nuclear	O	
17	proteins	O	
18	to	O	
19	the	O	
20	uPA	B	
21	PEA3	I	
22	/	O	
23	12	O	
24	-	O	
25	0	O	
26	-	O	
27	tetradecanoylphorbol	O	
28	13	O	
29	-	O	
30	acetate	O	
31	responsive	O	
32	element	O	
33	(	O	
34	TRE	O	
35	).	O	

1	Thalamotomy	O	
2	aiming	O	
3	at	O	
4	the	O	
5	CM	O	
6	-	O	
7	Pf	O	
8	complex	O	
9	and	O	
10	using	O	
11	stereotactic	O	
12	gamma	O	
13	irradiation	O	
14	has	O	
15	been	O	
16	performed	O	
17	in	O	
18	a	O	
19	series	O	
20	of	O	
21	52	O	
22	patients	O	
23	with	O	
24	severe	O	
25	pain	O	
26	due	O	
27	to	O	
28	malignancy	O	
29	.	O	

1	The	O	
2	IE13	O	
3	.	O	
4	1	O	
5	cell	O	
6	line	O	
7	was	O	
8	able	O	
9	to	O	
10	complement	O	
11	a	O	
12	recombinant	O	
13	virus	O	
14	in	O	
15	which	O	
16	both	O	
17	copies	O	
18	of	O	
19	the	O	
20	IE	B	
21	gene	I	
22	were	O	
23	replaced	O	
24	by	O	
25	insertion	O	
26	of	O	
27	the	O	
28	Escherichia	B	
29	coli	I	
30	lacZ	I	
31	gene	I	
32	.	O	

1	Effects	O	
2	of	O	
3	prostaglandin	O	
4	inhibitors	O	
5	on	O	
6	the	O	
7	onset	O	
8	of	O	
9	proteinuria	O	
10	and	O	
11	stroke	O	
12	in	O	
13	stroke	O	
14	-	O	
15	prone	O	
16	spontaneously	O	
17	hypertensive	O	
18	rats	O	
19	.	O	

1	Collectively	O	
2	,	O	
3	these	O	
4	data	O	
5	indicate	O	
6	that	O	
7	HIP	B	
8	is	O	
9	a	O	
10	membrane	O	
11	-	O	
12	associated	O	
13	HP	B	
14	-	I	
15	binding	I	
16	protein	I	
17	expressed	O	
18	on	O	
19	the	O	
20	surface	O	
21	of	O	
22	normal	O	
23	human	O	
24	uterine	O	
25	epithelia	O	
26	and	O	
27	uterine	O	
28	epithelial	O	
29	cell	O	
30	lines	O	
31	.	O	

1	In	O	
2	Schizosaccharomyces	O	
3	pombe	O	
4	,	O	
5	the	O	
6	activity	O	
7	of	O	
8	the	O	
9	M	O	
10	-	O	
11	phase	O	
12	-	O	
13	inducing	O	
14	Cdc2	B	
15	/	O	
16	Cdc13	B	
17	cyclin	O	
18	-	O	
19	dependent	O	
20	kinase	O	
21	is	O	
22	inhibited	O	
23	by	O	
24	Wee1	B	
25	and	O	
26	Mik1	B	
27	tyrosine	I	
28	kinases	I	
29	,	O	
30	and	O	
31	activated	O	
32	by	O	
33	Cdc25	B	
34	and	O	
35	Pyp3	B	
36	tyrosine	I	
37	phosphatases	I	
38	.	O	

1	However	O	
2	,	O	
3	parallax	O	
4	measurements	O	
5	showed	O	
6	that	O	
7	at	O	
8	150K	O	
9	,	O	
10	collapse	O	
11	of	O	
12	Epon	O	
13	sections	O	
14	does	O	
15	not	O	
16	take	O	
17	place	O	
18	.	O	

1	Three	O	
2	group	O	
3	1	O	
4	patients	O	
5	developed	O	
6	CMV	O	
7	disease	O	
8	;	O	
9	1	O	
10	group	O	
11	2	O	
12	patient	O	
13	developed	O	
14	CMV	O	
15	hepatitis	O	
16	.	O	

1	It	O	
2	applies	O	
3	Udry	O	
4	'	O	
5	s	O	
6	biosocial	O	
7	perspective	O	
8	,	O	
9	which	O	
10	attempts	O	
11	to	O	
12	reconcile	O	
13	the	O	
14	biological	O	
15	and	O	
16	sociological	O	
17	models	O	
18	of	O	
19	premarital	O	
20	sexual	O	
21	and	O	
22	reproductive	O	
23	behaviour	O	
24	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	carp	B	
5	JAK1	I	
6	shows	O	
7	higher	O	
8	sequence	O	
9	homology	O	
10	to	O	
11	mammalian	B	
12	JAK1	I	
13	in	O	
14	both	O	
15	the	O	
16	kinase	O	
17	-	O	
18	like	O	
19	(	O	
20	JH2	B	
21	)	O	
22	and	O	
23	kinase	O	
24	(	O	
25	JH1	B	
26	)	O	
27	domains	O	
28	(	O	
29	approximately	O	
30	70	O	
31	%	O	
32	identity	O	
33	).	O	

1	Following	O	
2	the	O	
3	patients	O	
4	during	O	
5	a	O	
6	course	O	
7	of	O	
8	therapy	O	
9	with	O	
10	a	O	
11	selective	O	
12	vasodilator	O	
13	calcium	O	
14	antagonist	O	
15	,	O	
16	the	O	
17	beta	O	
18	-	O	
19	adrenergic	O	
20	reflex	O	
21	vasodilation	O	
22	became	O	
23	substantially	O	
24	attenuated	O	
25	but	O	
26	was	O	
27	preserved	O	
28	during	O	
29	a	O	
30	placebo	O	
31	course	O	
32	of	O	
33	therapy	O	
34	.	O	

1	On	O	
2	the	O	
3	basis	O	
4	of	O	
5	this	O	
6	anatomic	O	
7	concept	O	
8	,	O	
9	the	O	
10	brachioplasty	O	
11	procedure	O	
12	was	O	
13	modified	O	
14	to	O	
15	provide	O	
16	secure	O	
17	anchoring	O	
18	of	O	
19	the	O	
20	arm	O	
21	flap	O	
22	to	O	
23	the	O	
24	axillary	O	
25	fascia	O	
26	along	O	
27	with	O	
28	strong	O	
29	superficial	O	
30	fascial	O	
31	system	O	
32	repair	O	
33	of	O	
34	incisions	O	
35	,	O	
36	reducing	O	
37	the	O	
38	risk	O	
39	of	O	
40	widening	O	
41	or	O	
42	migration	O	
43	of	O	
44	scars	O	
45	and	O	
46	unnatural	O	
47	contours	O	
48	.	O	

1	GH	B	
2	failed	O	
3	to	O	
4	stimulate	O	
5	phosphorylation	O	
6	or	O	
7	activation	O	
8	of	O	
9	Jun	B	
10	N	I	
11	-	I	
12	terminal	I	
13	kinase	I	
14	under	O	
15	the	O	
16	conditions	O	
17	used	O	
18	.	O	

1	Accumulated	O	
2	evidence	O	
3	indicates	O	
4	that	O	
5	,	O	
6	upon	O	
7	stimulation	O	
8	with	O	
9	interferon	B	
10	-	I	
11	gamma	I	
12	(	O	
13	IFN	B	
14	-	I	
15	gamma	I	
16	),	O	
17	three	O	
18	beta	O	
19	-	O	
20	type	O	
21	subunits	O	
22	,	O	
23	designated	O	
24	LMP2	B	
25	,	O	
26	LMP7	B	
27	,	O	
28	and	O	
29	PSMB10	B	
30	,	O	
31	are	O	
32	incorporated	O	
33	into	O	
34	the	O	
35	20S	B	
36	proteasome	I	
37	by	O	
38	displacing	O	
39	the	O	
40	housekeeping	O	
41	beta	O	
42	-	O	
43	type	O	
44	subunits	O	
45	designated	O	
46	PSMB6	B	
47	,	O	
48	PSMB5	B	
49	,	O	
50	and	O	
51	PSMB7	B	
52	,	O	
53	respectively	O	
54	.	O	

1	The	O	
2	nerve	B	
3	growth	I	
4	factor	I	
5	beta	I	
6	gene	I	
7	(	O	
8	NGFB	B	
9	)	O	
10	belongs	O	
11	to	O	
12	a	O	
13	conserved	O	
14	syntenic	O	
15	group	O	
16	on	O	
17	human	O	
18	chromosome	O	
19	1	O	
20	and	O	
21	mouse	O	
22	Chromosome	O	
23	3	O	
24	.	O	

1	Antibodies	O	
2	specific	O	
3	to	O	
4	rE12	B	
5	and	O	
6	rNFIL	B	
7	-	I	
8	6	I	
9	disrupt	O	
10	nucleoprotein	O	
11	complexes	O	
12	with	O	
13	these	O	
14	DNA	O	
15	-	O	
16	binding	O	
17	sites	O	
18	,	O	
19	confirming	O	
20	the	O	
21	interaction	O	
22	of	O	
23	native	O	
24	in	O	
25	vivo	O	
26	factors	O	
27	.	O	

1	These	O	
2	results	O	
3	indicate	O	
4	that	O	
5	during	O	
6	pregnancy	O	
7	there	O	
8	are	O	
9	increases	O	
10	in	O	
11	bone	O	
12	formation	O	
13	rates	O	
14	contributing	O	
15	to	O	
16	the	O	
17	increases	O	
18	in	O	
19	skeletal	O	
20	mass	O	
21	.	O	

1	In	O	
2	one	O	
3	mechanism	O	
4	,	O	
5	a	O	
6	specialized	O	
7	ubiquitin	B	
8	-	O	
9	dependent	O	
10	proteolytic	O	
11	system	O	
12	(	O	
13	called	O	
14	the	O	
15	APC	O	
16	-	O	
17	dependent	O	
18	proteolysis	O	
19	machinery	O	
20	)	O	
21	degrades	O	
22	the	O	
23	mitotic	O	
24	(	O	
25	Clb	B	
26	)	O	
27	cyclin	B	
28	subunit	I	
29	.	O	

1	Serum	B	
2	creatine	I	
3	kinase	I	
4	(	O	
5	SCK	B	
6	)	O	
7	was	O	
8	measured	O	
9	in	O	
10	ten	O	
11	subjects	O	
12	in	O	
13	the	O	
14	laboratory	O	
15	before	O	
16	and	O	
17	after	O	
18	the	O	
19	performance	O	
20	of	O	
21	bicycle	O	
22	ergometry	O	
23	and	O	
24	a	O	
25	lifting	O	
26	task	O	
27	.	O	

1	This	O	
2	sequence	O	
3	is	O	
4	almost	O	
5	identical	O	
6	with	O	
7	that	O	
8	of	O	
9	human	B	
10	luteinizing	I	
11	hormone	I	
12	(	O	
13	Sairam	O	
14	,	O	
15	M	O	
16	.	O	

1	A	O	
2	clinical	O	
3	,	O	
4	serological	O	
5	and	O	
6	prognostic	O	
7	study	O	

1	In	O	
2	similar	O	
3	transient	O	
4	transfection	O	
5	experiments	O	
6	in	O	
7	HeLa	O	
8	cells	O	
9	,	O	
10	overexpression	O	
11	of	O	
12	the	O	
13	wt	B	
14	human	I	
15	retinoblastoma	I	
16	susceptibility	I	
17	gene	I	
18	product	I	
19	,	O	
20	RB	B	
21	,	O	
22	was	O	
23	found	O	
24	to	O	
25	repress	O	
26	the	O	
27	serum	O	
28	-	O	
29	induced	O	
30	IL	B	
31	-	I	
32	6	I	
33	(-	O	
34	225	O	
35	to	O	
36	+	O	
37	13	O	
38	),	O	
39	c	B	
40	-	I	
41	fos	I	
42	(-	O	
43	711	O	
44	to	O	
45	+	O	
46	42	O	
47	),	O	
48	and	O	
49	beta	B	
50	-	I	
51	actin	I	
52	(-	O	
53	3400	O	
54	to	O	
55	+	O	
56	912	O	
57	)	O	
58	promoters	O	
59	but	O	
60	not	O	
61	the	O	
62	PRV	O	
63	-	O	
64	induced	O	
65	IL	B	
66	-	I	
67	6	I	
68	(-	O	
69	110	O	
70	to	O	
71	+	O	
72	13	O	
73	)	O	
74	or	O	
75	the	O	
76	serum	O	
77	-	O	
78	induced	O	
79	MHC	B	
80	(-	O	
81	528	O	
82	to	O	
83	-	O	
84	38	O	
85	)	O	
86	promoters	O	
87	.	O	

1	Cotransfection	O	
2	analyses	O	
3	of	O	
4	the	O	
5	T	B	
6	/	I	
7	EBP	I	
8	promoter	I	
9	-	I	
10	reporter	I	
11	constructs	I	
12	with	O	
13	a	O	
14	T	B	
15	/	I	
16	EBP	I	
17	expression	O	
18	vector	O	
19	into	O	
20	human	O	
21	HepG2	O	
22	cells	O	
23	,	O	
24	which	O	
25	do	O	
26	not	O	
27	express	O	
28	T	B	
29	/	I	
30	EBP	I	
31	,	O	
32	suggested	O	
33	that	O	
34	autoregulation	O	
35	may	O	
36	be	O	
37	involved	O	
38	in	O	
39	controlling	O	
40	both	O	
41	rat	O	
42	and	O	
43	human	B	
44	T	I	
45	/	I	
46	EBP	I	
47	gene	I	
48	expression	O	
49	.	O	

1	In	O	
2	Malmo	O	
3	,	O	
4	Sweden	O	
5	,	O	
6	17	O	
7	,	O	
8	181	O	
9	school	O	
10	children	O	
11	born	O	
12	in	O	
13	the	O	
14	years	O	
15	1961	O	
16	-	O	
17	1965	O	
18	were	O	
19	screened	O	
20	for	O	
21	scoliosis	O	
22	once	O	
23	a	O	
24	year	O	
25	between	O	
26	the	O	
27	ages	O	
28	of	O	
29	7	O	
30	and	O	
31	16	O	
32	years	O	
33	,	O	
34	during	O	
35	1971	O	
36	-	O	
37	1980	O	
38	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	the	O	
5	neu	B	
6	proto	I	
7	-	I	
8	oncogene	I	
9	did	O	
10	not	O	
11	show	O	
12	kinase	O	
13	activity	O	
14	or	O	
15	transforming	O	
16	properties	O	
17	when	O	
18	expressed	O	
19	at	O	
20	similar	O	
21	levels	O	
22	in	O	
23	NIH	O	
24	3T3	O	
25	cells	O	
26	.(	O	
27	ABSTRACT	O	
28	TRUNCATED	O	
29	AT	O	
30	250	O	
31	WORDS	O	
32	)	O	

1	One	O	
2	of	O	
3	these	O	
4	factors	O	
5	,	O	
6	HRF	B	
7	-	I	
8	1	I	
9	,	O	
10	recognizes	O	
11	a	O	
12	cis	O	
13	element	O	
14	consisting	O	
15	of	O	
16	an	O	
17	inverted	O	
18	palindromic	O	
19	motif	O	
20	.	O	

1	Since	O	
2	1968	O	
3	,	O	
4	a	O	
5	steep	O	
6	decrease	O	
7	in	O	
8	the	O	
9	number	O	
10	of	O	
11	strains	O	
12	resistant	O	
13	to	O	
14	three	O	
15	or	O	
16	more	O	
17	antibiotics	O	
18	(	O	
19	multiple	O	
20	-	O	
21	resistant	O	
22	)	O	
23	and	O	
24	in	O	
25	strains	O	
26	of	O	
27	the	O	
28	83A	O	
29	complex	O	
30	was	O	
31	noticed	O	
32	.	O	

1	The	O	
2	ubiquitously	O	
3	expressed	O	
4	hypoxia	B	
5	-	I	
6	inducible	I	
7	factor	I	
8	-	I	
9	1	I	
10	(	O	
11	HIF	B	
12	-	I	
13	1	I	
14	)	O	
15	is	O	
16	involved	O	
17	in	O	
18	expression	O	
19	of	O	
20	a	O	
21	large	O	
22	number	O	
23	of	O	
24	oxygen	O	
25	-	O	
26	regulated	O	
27	genes	O	
28	.	O	

1	Characterization	O	
2	of	O	
3	the	O	
4	promoter	O	
5	for	O	
6	the	O	
7	human	B	
8	85	I	
9	kDa	I	
10	cytosolic	I	
11	phospholipase	I	
12	A2	I	
13	gene	I	
14	.	O	

1	Hematocrit	O	
2	and	O	
3	PaO2	O	
4	did	O	
5	not	O	
6	change	O	
7	.	O	

1	A	O	
2	pharmacokinetic	O	
3	study	O	
4	of	O	
5	apalcillin	O	
6	was	O	
7	performed	O	
8	in	O	
9	12	O	
10	patients	O	
11	in	O	
12	an	O	
13	intensive	O	
14	-	O	
15	care	O	
16	unit	O	
17	.	O	

1	This	O	
2	study	O	
3	allows	O	
4	us	O	
5	to	O	
6	draw	O	
7	conclusions	O	
8	about	O	
9	the	O	
10	identity	O	
11	of	O	
12	proteins	O	
13	required	O	
14	for	O	
15	the	O	
16	development	O	
17	of	O	
18	the	O	
19	nervous	O	
20	system	O	
21	in	O	
22	Drosophila	O	
23	and	O	
24	provides	O	
25	an	O	
26	example	O	
27	of	O	
28	a	O	
29	molecular	O	
30	approach	O	
31	to	O	
32	characterize	O	
33	en	O	
34	masse	O	
35	transposon	O	
36	-	O	
37	tagged	O	
38	mutations	O	
39	identified	O	
40	in	O	
41	genetic	O	
42	screens	O	
43	.	O	

1	DESIGN	O	
2	AND	O	
3	METHODS	O	
4	:	O	
5	Case	O	
6	study	O	
7	.	O	

1	Effect	O	
2	of	O	
3	Azadirachta	O	
4	indica	O	
5	hydroalcoholic	O	
6	leaf	O	
7	extract	O	
8	on	O	
9	the	O	
10	cardiovascular	O	
11	system	O	
12	.	O	

1	Three	O	
2	mog	B	
3	-	I	
4	1	I	
5	alleles	I	
6	possess	O	
7	premature	O	
8	stop	O	
9	codons	O	
10	and	O	
11	are	O	
12	likely	O	
13	to	O	
14	be	O	
15	null	O	
16	alleles	O	
17	,	O	
18	and	O	
19	one	O	
20	is	O	
21	a	O	
22	missense	O	
23	mutation	O	
24	and	O	
25	is	O	
26	likely	O	
27	to	O	
28	retain	O	
29	residual	O	
30	activity	O	
31	.	O	
32	mog	B	
33	-	I	
34	1	I	
35	mRNA	I	
36	is	O	
37	expressed	O	
38	in	O	
39	both	O	
40	germ	O	
41	line	O	
42	and	O	
43	somatic	O	
44	tissues	O	
45	and	O	
46	appears	O	
47	to	O	
48	be	O	
49	ubiquitous	O	
50	.	O	

1	Anti	O	
2	-	O	
3	anxiety	O	
4	action	O	
5	of	O	
6	diazepam	O	
7	after	O	
8	intra	O	
9	-	O	
10	amygdaloid	O	
11	application	O	
12	in	O	
13	the	O	
14	rat	O	
15	.	O	

1	202	O	
2	-	O	
3	8	O	
4	.	O	

1	Magnetic	O	
2	trapping	O	
3	of	O	
4	spin	O	
5	-	O	
6	polarized	O	
7	atomic	O	
8	hydrogen	O	
9	.	O	

1	We	O	
2	have	O	
3	improved	O	
4	our	O	
5	system	O	
6	for	O	
7	nuclear	O	
8	contour	O	
9	digitization	O	
10	and	O	
11	determined	O	
12	its	O	
13	theoretical	O	
14	limitations	O	
15	by	O	
16	digitizing	O	
17	standardized	O	
18	objects	O	
19	.	O	

1	CREB	B	
2	was	O	
3	identified	O	
4	as	O	
5	one	O	
6	of	O	
7	the	O	
8	protein	O	
9	components	O	
10	in	O	
11	several	O	
12	of	O	
13	the	O	
14	gel	O	
15	shift	O	
16	complexes	O	
17	formed	O	
18	with	O	
19	the	O	
20	variant	O	
21	CRE	O	
22	.	O	

1	Similar	O	
2	waves	O	
3	were	O	
4	seen	O	
5	on	O	
6	cross	O	
7	-	O	
8	correlating	O	
9	a	O	
10	motor	O	
11	unit	O	
12	with	O	
13	an	O	
14	electronic	O	
15	oscillator	O	
16	,	O	
17	confirming	O	
18	that	O	
19	their	O	
20	occurrence	O	
21	does	O	
22	not	O	
23	necessarily	O	
24	demonstrate	O	
25	the	O	
26	existence	O	
27	of	O	
28	active	O	
29	neural	O	
30	interactions	O	
31	.	O	

1	Initial	O	
2	experience	O	
3	with	O	
4	a	O	
5	serotonin	O	
6	agonist	O	
7	.	O	

1	Reward	O	
2	value	O	
3	of	O	
4	prosodic	O	
5	features	O	
6	of	O	
7	language	O	
8	for	O	
9	autistic	O	
10	,	O	
11	mentally	O	
12	retarded	O	
13	,	O	
14	and	O	
15	normal	O	
16	children	O	
17	.	O	

1	In	O	
2	the	O	
3	case	O	
4	of	O	
5	the	O	
6	unspliceable	O	
7	intron	O	
8	,	O	
9	repression	O	
10	of	O	
11	luciferase	B	
12	expression	O	
13	likely	O	
14	involved	O	
15	two	O	
16	AUF1	B	
17	-	I	
18	binding	I	
19	sequences	I	
20	,	O	
21	since	O	
22	luciferase	B	
23	expression	O	
24	was	O	
25	increased	O	
26	by	O	
27	deletion	O	
28	of	O	
29	these	O	
30	sites	O	
31	.	O	

1	At	O	
2	all	O	
3	time	O	
4	-	O	
5	points	O	
6	,	O	
7	most	O	
8	patients	O	
9	(>/=	O	
10	87	O	
11	%)	O	
12	were	O	
13	receiving	O	
14	irbesartan	O	
15	/	O	
16	HCTZ	O	
17	alone	O	
18	.	O	

1	KFC	B	
2	,	O	
3	a	O	
4	Ste20	B	
5	-	I	
6	like	I	
7	kinase	I	
8	with	O	
9	mitogenic	O	
10	potential	O	
11	and	O	
12	capability	O	
13	to	O	
14	activate	O	
15	the	O	
16	SAPK	B	
17	/	O	
18	JNK	B	
19	pathway	O	
20	.	O	

1	The	O	
2	highest	O	
3	doses	O	
4	were	O	
5	found	O	
6	for	O	
7	drivers	O	
8	who	O	
9	transported	O	
10	large	O	
11	numbers	O	
12	of	O	
13	99Mo	O	
14	generators	O	
15	.	O	

1	However	O	
2	,	O	
3	a	O	
4	10	O	
5	--	O	
6	15	O	
7	%	O	
8	lengthening	O	
9	of	O	
10	the	O	
11	partial	O	
12	thromboplastin	B	
13	time	O	
14	is	O	
15	evident	O	
16	after	O	
17	24	O	
18	hours	O	
19	of	O	
20	storage	O	
21	.	O	

1	Cytogenetic	O	
2	studies	O	
3	were	O	
4	performed	O	
5	in	O	
6	lymphocytes	O	
7	from	O	
8	hospital	O	
9	workers	O	
10	exposed	O	
11	to	O	
12	low	O	
13	doses	O	
14	of	O	
15	radiation	O	
16	(	O	
17	1	O	
18	.	O	
19	6	O	
20	-	O	
21	42	O	
22	.	O	
23	71	O	
24	mSv	O	
25	).	O	

1	In	O	
2	contrast	O	
3	,	O	
4	both	O	
5	C	O	
6	-	O	
7	Lys	O	
8	and	O	
9	C	O	
10	-	O	
11	Thr	O	
12	retained	O	
13	high	O	
14	levels	O	
15	of	O	
16	kinase	O	
17	activity	O	
18	and	O	
19	were	O	
20	capable	O	
21	of	O	
22	responding	O	
23	to	O	
24	stimulation	O	
25	.	O	

1	Identification	O	
2	of	O	
3	a	O	
4	spliced	O	
5	gene	O	
6	from	O	
7	Kaposi	O	
8	'	O	
9	s	O	
10	sarcoma	O	
11	-	O	
12	associated	O	
13	herpesvirus	O	
14	encoding	O	
15	a	O	
16	protein	O	
17	with	O	
18	similarities	O	
19	to	O	
20	latent	B	
21	membrane	I	
22	proteins	I	
23	1	I	
24	and	I	
25	2A	I	
26	of	I	
27	Epstein	I	
28	-	I	
29	Barr	I	
30	virus	I	
31	.	O	

1	XYL1	B	
2	was	O	
3	isolated	O	
4	as	O	
5	a	O	
6	highly	O	
7	expressed	O	
8	fusion	O	
9	clone	O	
10	from	O	
11	a	O	
12	'	B	
13	lacZ	I	
14	translational	O	
15	fusion	O	
16	library	O	
17	.	O	

1	Western	O	
2	blot	O	
3	analysis	O	
4	of	O	
5	various	O	
6	bovine	O	
7	tissues	O	
8	with	O	
9	human	O	
10	NMT	B	
11	peptide	I	
12	antibody	I	
13	indicated	O	
14	a	O	
15	common	O	
16	prominent	O	
17	immunoreactive	O	
18	band	O	
19	with	O	
20	an	O	
21	apparent	O	
22	molecular	O	
23	mass	O	
24	of	O	
25	48	O	
26	.	O	
27	5	O	
28	-	O	
29	50	O	
30	kDa	O	
31	in	O	
32	all	O	
33	tissues	O	
34	.	O	

1	The	O	
2	frequency	O	
3	of	O	
4	PPNG	O	
5	strains	O	
6	increased	O	
7	from	O	
8	1	O	
9	.	O	
10	7	O	
11	%	O	
12	in	O	
13	1981	O	
14	to	O	
15	6	O	
16	.	O	
17	7	O	
18	%	O	
19	in	O	
20	1985	O	
21	.	O	

1	Secondary	O	
2	cleavage	O	
3	of	O	
4	RT	B	
5	at	O	
6	Trp	O	
7	-	O	
8	595	O	
9	-	O	
10	Tyr	O	
11	-	O	
12	596	O	
13	of	O	
14	Pol	B	
15	yields	O	
16	a	O	
17	truncated	O	
18	form	O	
19	lacking	O	
20	the	O	
21	C	B	
22	-	I	
23	terminal	I	
24	RNase	I	
25	H	I	
26	domain	I	
27	.	O	

1	The	O	
2	bZP2	O	
3	cDNA	O	
4	(	O	
5	115	O	
6	-	O	
7	1914	O	
8	nt	O	
9	,	O	
10	1	O	
11	.	O	
12	8	O	
13	kb	O	
14	),	O	
15	excluding	O	
16	sequences	O	
17	coding	O	
18	for	O	
19	N	O	
20	-	O	
21	terminal	O	
22	signal	O	
23	sequence	O	
24	and	O	
25	C	O	
26	-	O	
27	terminal	O	
28	transmembranelike	O	
29	domain	O	
30	,	O	
31	was	O	
32	PCR	O	
33	amplified	O	
34	and	O	
35	Sac1	B	
36	-	O	
37	Sal1	B	
38	restricted	O	
39	fragment	O	
40	cloned	O	
41	in	O	
42	frame	O	
43	downstream	O	
44	of	O	
45	the	O	
46	T5	O	
47	promoter	O	
48	under	O	
49	the	O	
50	lac	B	
51	operator	I	
52	control	O	
53	in	O	
54	a	O	
55	pQE	O	
56	-	O	
57	30	O	
58	vector	O	
59	.	O	

1	Termination	O	
2	of	O	
3	induced	O	
4	VT	O	
5	on	O	
6	the	O	
7	first	O	
8	attempt	O	
9	was	O	
10	comparable	O	
11	with	O	
12	BV	O	
13	pacing	O	
14	(	O	
15	87	O	
16	.	O	
17	4	O	
18	%)	O	
19	versus	O	
20	RV	O	
21	pacing	O	
22	(	O	
23	89	O	
24	.	O	
25	6	O	
26	%).	O	

1	Both	O	
2	receptors	O	
3	utilize	O	
4	protein	B	
5	tyrosine	I	
6	kinases	I	
7	(	O	
8	PTKs	B	
9	)	O	
10	for	O	
11	the	O	
12	phosphorylation	O	
13	of	O	
14	various	O	
15	signaling	O	
16	molecules	O	
17	,	O	
18	a	O	
19	process	O	
20	that	O	
21	is	O	
22	critical	O	
23	for	O	
24	the	O	
25	function	O	
26	of	O	
27	both	O	
28	receptors	O	
29	.	O	

1	Protein	B	
2	C	I	
3	deficiency	O	
4	or	O	
5	protein	B	
6	S	I	
7	deficiency	O	
8	was	O	
9	the	O	
10	only	O	
11	identified	O	
12	risk	O	
13	factor	O	
14	for	O	
15	5	O	
16	.	O	
17	4	O	
18	%	O	
19	(	O	
20	2	O	
21	patients	O	
22	)	O	
23	and	O	
24	13	O	
25	.	O	
26	5	O	
27	%	O	
28	(	O	
29	5	O	
30	patients	O	
31	),	O	
32	respectively	O	
33	,	O	
34	of	O	
35	these	O	
36	37	O	
37	children	O	
38	.	O	

1	It	O	
2	contains	O	
3	three	O	
4	putative	O	
5	TATA	O	
6	boxes	O	
7	far	O	
8	upstream	O	
9	of	O	
10	the	O	
11	main	O	
12	start	O	
13	sites	O	
14	region	O	
15	,	O	
16	one	O	
17	AP	B	
18	-	I	
19	1	I	
20	box	I	
21	,	O	
22	one	O	
23	AP	B	
24	-	I	
25	2	I	
26	box	I	
27	,	O	
28	one	O	
29	Malt	B	
30	box	I	
31	,	O	
32	one	O	
33	GAGA	O	
34	box	O	
35	,	O	
36	one	O	
37	half	O	
38	serum	O	
39	-	O	
40	responsive	O	
41	element	O	
42	,	O	
43	and	O	
44	putative	O	
45	binding	O	
46	sites	O	
47	for	O	
48	Sp1	B	
49	(	O	
50	five	O	
51	),	O	
52	GC	B	
53	-	I	
54	rich	I	
55	binding	I	
56	factor	I	
57	(	O	
58	five	O	
59	),	O	
60	CTF	B	
61	-	I	
62	NF1	I	
63	(	O	
64	one	O	
65	),	O	
66	Myb	B	
67	(	O	
68	one	O	
69	),	O	
70	p53	B	
71	(	O	
72	two	O	
73	),	O	
74	Ets	B	
75	-	I	
76	1	I	
77	(	O	
78	one	O	
79	),	O	
80	NF	B	
81	-	I	
82	IL6	I	
83	(	O	
84	two	O	
85	),	O	
86	MyoD	B	
87	(	O	
88	two	O	
89	),	O	
90	Zeste	B	
91	(	O	
92	one	O	
93	),	O	
94	and	O	
95	hepatocyte	B	
96	nuclear	I	
97	factor	I	
98	-	I	
99	5	I	
100	(	O	
101	one	O	
102	).	O	

1	No	O	
2	patient	O	
3	with	O	
4	bradyarrhythmia	O	
5	-	O	
6	related	O	
7	SCD	O	
8	had	O	
9	manifest	O	
10	atrioventricular	O	
11	block	O	
12	or	O	
13	bundle	O	
14	branch	O	
15	block	O	
16	.	O	

1	Genoa	O	
2	,	O	
3	Italy	O	
4	,	O	
5	24	O	
6	-	O	
7	28	O	
8	August	O	
9	1997	O	
10	.	O	

1	Increased	O	
2	p53	B	
3	activity	O	
4	induced	O	
5	by	O	
6	OP	O	
7	is	O	
8	not	O	
9	due	O	
10	to	O	
11	elevated	O	
12	p53	B	
13	mRNA	I	
14	nor	O	
15	to	O	
16	protein	O	
17	levels	O	
18	.	O	

1	Copyright	O	
2	1998	O	
3	Academic	O	
4	Press	O	
5	.	O	

1	Here	O	
2	the	O	
3	conventional	O	
4	tests	O	
5	clearly	O	
6	pointed	O	
7	to	O	
8	the	O	
9	presence	O	
10	of	O	
11	retrocochlear	O	
12	disease	O	
13	.	O	

1	The	O	
2	difficulties	O	
3	to	O	
4	analyse	O	
5	prostaglandins	O	
6	(	O	
7	PG	O	
8	)	O	
9	by	O	
10	gas	O	
11	-	O	
12	liquid	O	
13	chromatography	O	
14	are	O	
15	mainly	O	
16	due	O	
17	to	O	
18	the	O	
19	lack	O	
20	of	O	
21	sensitivity	O	
22	of	O	
23	the	O	
24	gas	O	
25	-	O	
26	chromatograph	O	
27	itself	O	
28	(	O	
29	higher	O	
30	than	O	
31	200	O	
32	ng	O	
33	)	O	
34	and	O	
35	to	O	
36	the	O	
37	poor	O	
38	resolution	O	
39	of	O	
40	the	O	
41	packed	O	
42	columns	O	
43	.	O	

1	Echinococcus	O	
2	granulosus	O	
3	was	O	
4	diagnosed	O	
5	by	O	
6	fine	O	
7	-	O	
8	needle	O	
9	aspiration	O	
10	cytology	O	
11	of	O	
12	a	O	
13	lung	O	
14	cyst	O	
15	in	O	
16	a	O	
17	6	O	
18	-	O	
19	yr	O	
20	-	O	
21	old	O	
22	white	O	
23	female	O	
24	in	O	
25	central	O	
26	Missouri	O	
27	.	O	

1	Replacement	O	
2	of	O	
3	the	O	
4	wild	O	
5	-	O	
6	type	O	
7	5	O	
8	'-	O	
9	regulatory	O	
10	region	O	
11	with	O	
12	either	O	
13	of	O	
14	the	O	
15	mutants	O	
16	'	O	
17	cis	O	
18	-	O	
19	acting	O	
20	regulatory	O	
21	element	O	
22	resulted	O	
23	in	O	
24	the	O	
25	anaerobic	O	
26	expression	O	
27	of	O	
28	active	B	
29	Mn	I	
30	-	I	
31	superoxide	I	
32	dismutase	I	
33	.	O	

1	Anoxia	O	
2	was	O	
3	introduced	O	
4	by	O	
5	perfusing	O	
6	the	O	
7	gill	O	
8	with	O	
9	water	O	
10	deprived	O	
11	of	O	
12	oxygen	O	
13	or	O	
14	by	O	
15	halting	O	
16	the	O	
17	water	O	
18	flow	O	
19	to	O	
20	the	O	
21	gill	O	
22	.	O	

1	Eight	O	
2	hours	O	
3	after	O	
4	the	O	
5	administration	O	
6	of	O	
7	colchicine	O	
8	,	O	
9	the	O	
10	serum	B	
11	ceruloplasmin	I	
12	level	O	
13	began	O	
14	to	O	
15	rise	O	
16	again	O	
17	in	O	
18	female	O	
19	rats	O	
20	,	O	
21	but	O	
22	not	O	
23	in	O	
24	male	O	
25	rats	O	
26	.	O	

1	Pseudomonas	O	
2	aeruginosa	O	
3	strains	O	
4	infecting	O	
5	patients	O	
6	with	O	
7	cystic	O	
8	fibrosis	O	
9	(	O	
10	CF	O	
11	)	O	
12	acquire	O	
13	a	O	
14	mucoid	O	
15	phenotype	O	
16	due	O	
17	to	O	
18	overproduction	O	
19	of	O	
20	alginate	O	
21	.	O	

1	Serodiagnosis	O	
2	of	O	
3	trypanosomiasis	O	
4	in	O	
5	dromedary	O	
6	camels	O	
7	using	O	
8	a	O	
9	card	O	
10	agglutination	O	
11	test	O	
12	set	O	
13	(	O	
14	Testryp	O	
15	CATT	O	
16	).	O	

1	In	O	
2	addition	O	
3	,	O	
4	the	O	
5	mouse	O	
6	ortholog	O	
7	(	O	
8	Mharp	B	
9	/	O	
10	Smarcal1	B	
11	)	O	
12	was	O	
13	cloned	O	
14	,	O	
15	and	O	
16	the	O	
17	Caenorhabditis	O	
18	elegans	O	
19	ortholog	O	
20	(	O	
21	CEHARP	B	
22	)	O	
23	was	O	
24	identified	O	
25	in	O	
26	the	O	
27	GenBank	O	
28	database	O	
29	.	O	

1	The	O	
2	emerging	O	
3	view	O	
4	based	O	
5	on	O	
6	studies	O	
7	in	O	
8	yeast	O	
9	is	O	
10	that	O	
11	each	O	
12	class	O	
13	of	O	
14	snoRNPs	O	
15	is	O	
16	composed	O	
17	of	O	
18	a	O	
19	unique	O	
20	set	O	
21	of	O	
22	proteins	O	
23	.	O	

1	Cowpox	O	
2	virus	O	
3	contains	O	
4	two	O	
5	copies	O	
6	of	O	
7	an	O	
8	early	B	
9	gene	I	
10	encoding	O	
11	a	O	
12	soluble	O	
13	secreted	O	
14	form	O	
15	of	O	
16	the	O	
17	type	B	
18	II	I	
19	TNF	I	
20	receptor	I	
21	.	O	

1	However	O	
2	,	O	
3	Cbf5p	B	
4	was	O	
5	found	O	
6	to	O	
7	be	O	
8	nucleolar	O	
9	and	O	
10	is	O	
11	highly	O	
12	homologous	O	
13	to	O	
14	the	O	
15	rat	B	
16	nucleolar	I	
17	protein	I	
18	NAP57	I	
19	,	O	
20	which	O	
21	coimmunoprecipitates	O	
22	with	O	
23	Nopp140	B	
24	and	O	
25	which	O	
26	is	O	
27	postulated	O	
28	to	O	
29	be	O	
30	involved	O	
31	in	O	
32	nucleolar	O	
33	-	O	
34	cytoplasmic	O	
35	shuttling	O	
36	(	O	
37	U	O	
38	.	O	

1	Synthetic	O	
2	ligands	O	
3	have	O	
4	been	O	
5	identified	O	
6	that	O	
7	reset	O	
8	and	O	
9	amplify	O	
10	the	O	
11	cycle	O	
12	of	O	
13	pulsatile	O	
14	GH	B	
15	secretion	O	
16	by	O	
17	interacting	O	
18	with	O	
19	the	O	
20	orphan	B	
21	GH	I	
22	-	I	
23	secretagogue	I	
24	receptor	I	
25	(	O	
26	GHS	B	
27	-	I	
28	R	I	
29	).	O	

1	In	O	
2	untransformed	O	
3	cells	O	
4	,	O	
5	three	O	
6	major	O	
7	proteins	O	
8	coprecipitated	O	
9	with	O	
10	CRKL	B	
11	,	O	
12	identified	O	
13	as	O	
14	C3G	B	
15	,	O	
16	SOS	B	
17	and	O	
18	c	B	
19	-	I	
20	ABL	I	
21	.	O	

1	The	O	
2	modalities	O	
3	for	O	
4	using	O	
5	reference	O	
6	values	O	
7	for	O	
8	individual	O	
9	subjects	O	
10	as	O	
11	well	O	
12	as	O	
13	for	O	
14	groups	O	
15	are	O	
16	then	O	
17	discussed	O	
18	and	O	
19	the	O	
20	main	O	
21	points	O	
22	of	O	
23	research	O	
24	which	O	
25	must	O	
26	be	O	
27	faced	O	
28	in	O	
29	the	O	
30	near	O	
31	future	O	
32	regarding	O	
33	reference	O	
34	values	O	
35	are	O	
36	highlighted	O	
37	.	O	

1	Two	O	
2	additional	O	
3	cis	O	
4	-	O	
5	acting	O	
6	sequences	O	
7	,	O	
8	conserved	O	
9	in	O	
10	both	O	
11	the	O	
12	region	O	
13	1	O	
14	and	O	
15	3	O	
16	promoters	O	
17	,	O	
18	were	O	
19	identified	O	
20	,	O	
21	suggesting	O	
22	a	O	
23	role	O	
24	for	O	
25	these	O	
26	sequences	O	
27	in	O	
28	the	O	
29	coordinate	O	
30	regulation	O	
31	of	O	
32	transcription	O	
33	from	O	
34	these	O	
35	promoters	O	
36	.	O	

1	Normocapnic	O	
2	(	O	
3	PACO2	O	
4	=	O	
5	40	O	
6	mm	O	
7	Hg	O	
8	)	O	
9	ventilatory	O	
10	drive	O	
11	increased	O	
12	significantly	O	
13	(	O	
14	p	O	
15	less	O	
16	than	O	
17	0	O	
18	.	O	
19	05	O	
20	)	O	
21	in	O	
22	six	O	
23	subjects	O	
24	(	O	
25	Type	O	
26	1	O	
27	response	O	
28	)	O	
29	and	O	
30	decreased	O	
31	substantially	O	
32	in	O	
33	the	O	
34	others	O	
35	(	O	
36	Type	O	
37	2	O	
38	response	O	
39	);	O	
40	with	O	
41	hypercapnia	O	
42	,	O	
43	the	O	
44	changes	O	
45	in	O	
46	drive	O	
47	were	O	
48	attenuated	O	
49	in	O	
50	both	O	
51	groups	O	
52	.	O	

1	This	O	
2	report	O	
3	describes	O	
4	the	O	
5	identification	O	
6	of	O	
7	a	O	
8	gene	O	
9	of	O	
10	related	O	
11	function	O	
12	,	O	
13	SMD1	B	
14	,	O	
15	located	O	
16	immediately	O	
17	3	O	
18	'	O	
19	to	O	
20	PRP38	B	
21	.	O	

1	The	O	
2	finding	O	
3	that	O	
4	the	O	
5	chimeric	B	
6	TdT	I	
7	::	O	
8	Pol	B	
9	beta	I	
10	protein	I	
11	possessed	O	
12	significant	O	
13	template	O	
14	-	O	
15	dependent	O	
16	polymerase	O	
17	activity	O	
18	suggests	O	
19	that	O	
20	aa	O	
21	1	O	
22	-	O	
23	60	O	
24	of	O	
25	Pol	B	
26	beta	I	
27	are	O	
28	involved	O	
29	in	O	
30	template	O	
31	utilization	O	
32	during	O	
33	the	O	
34	polymerization	O	
35	reaction	O	
36	,	O	
37	as	O	
38	suggested	O	
39	by	O	
40	the	O	
41	previous	O	
42	finding	O	
43	that	O	
44	the	O	
45	8	O	
46	-	O	
47	kDa	O	
48	N	O	
49	-	O	
50	terminal	O	
51	domain	O	
52	of	O	
53	Pol	B	
54	beta	I	
55	possesses	O	
56	ssDNA	O	
57	-	O	
58	binding	O	
59	activity	O	
60	[	O	
61	Kumar	O	
62	et	O	
63	al	O	
64	.,	O	
65	J	O	
66	.	O	

1	An	O	
2	InlC	B	
3	deletion	I	
4	mutant	I	
5	shows	O	
6	reduced	O	
7	virulence	O	
8	when	O	
9	tested	O	
10	in	O	
11	an	O	
12	intravenous	O	
13	mouse	O	
14	model	O	
15	,	O	
16	but	O	
17	intracellular	O	
18	replication	O	
19	of	O	
20	the	O	
21	mutant	O	
22	in	O	
23	Caco	O	
24	-	O	
25	2	O	
26	and	O	
27	J774	O	
28	cells	O	
29	appears	O	
30	to	O	
31	be	O	
32	comparable	O	
33	with	O	
34	that	O	
35	of	O	
36	the	O	
37	wild	O	
38	-	O	
39	type	O	
40	strain	O	
41	.	O	

1	Anesthesia	O	
2	with	O	
3	M	O	
4	/	O	
5	K	O	
6	was	O	
7	reversed	O	
8	after	O	
9	41	O	
10	.	O	
11	6	O	
12	min	O	
13	of	O	
14	immobilization	O	
15	with	O	
16	atipamezole	O	
17	.	O	

1	Clinical	O	
2	aspects	O	
3	of	O	
4	early	O	
5	increase	O	
6	in	O	
7	serum	O	
8	gamma	B	
9	-	I	
10	glutamyl	I	
11	transferase	I	
12	in	O	
13	cerebral	O	
14	infarction	O	
15	.	O	

1	Monotherapy	O	
2	with	O	
3	ceftazidime	O	
4	was	O	
5	clinically	O	
6	and	O	
7	bacteriologically	O	
8	as	O	
9	effective	O	
10	as	O	
11	a	O	
12	combination	O	
13	therapy	O	
14	with	O	
15	cefazolin	O	
16	and	O	
17	tobramycin	O	
18	.	O	

1	PMEK1	B	
2	displays	O	
3	96	O	
4	and	O	
5	80	O	
6	%	O	
7	identity	O	
8	respectively	O	
9	with	O	
10	the	O	
11	tobacco	B	
12	NTF3	I	
13	and	O	
14	Arabidopsis	B	
15	ATMPK1	I	
16	kinases	I	
17	,	O	
18	and	O	
19	only	O	
20	50	O	
21	%	O	
22	to	O	
23	the	O	
24	more	O	
25	distantly	O	
26	related	O	
27	plant	O	
28	MAP	O	
29	kinase	O	
30	MsERK1	B	
31	from	O	
32	alfalfa	O	
33	.	O	

1	The	O	
2	five	O	
3	-	O	
4	drug	O	
5	combination	O	
6	of	O	
7	fluorouracil	O	
8	imidazole	O	
9	carboxamide	O	
10	dimethyl	O	
11	triazeno	O	
12	,	O	
13	vincristine	O	
14	,	O	
15	bis	O	
16	-	O	
17	chloroethyl	O	
18	nitrosourea	O	
19	,	O	
20	and	O	
21	prednisone	O	
22	(	O	
23	FIVB	O	
24	+	O	
25	P	O	
26	)	O	
27	was	O	
28	given	O	
29	to	O	
30	120	O	
31	women	O	
32	with	O	
33	metastatic	O	
34	breast	O	
35	cancer	O	
36	.	O	

1	We	O	
2	show	O	
3	that	O	
4	the	O	
5	surfaces	O	
6	of	O	
7	tracheal	O	
8	cartilage	O	
9	matrix	O	
10	are	O	
11	collagen	B	
12	-	O	
13	rich	O	
14	and	O	
15	surround	O	
16	a	O	
17	proteoglycan	O	
18	-	O	
19	rich	O	
20	core	O	
21	.	O	

1	OBJECTIVES	O	
2	:	O	
3	The	O	
4	aim	O	
5	of	O	
6	the	O	
7	study	O	
8	was	O	
9	to	O	
10	analyze	O	
11	the	O	
12	clinical	O	
13	characteristics	O	
14	,	O	
15	treatment	O	
16	and	O	
17	outcome	O	
18	of	O	
19	310	O	
20	patients	O	
21	with	O	
22	hydatidiform	O	
23	mole	O	
24	.	O	

1	W	O	
2	.	O	

1	Furthermore	O	
2	,	O	
3	the	O	
4	initial	O	
5	plasma	O	
6	retinol	O	
7	level	O	
8	in	O	
9	conjunction	O	
10	with	O	
11	RBP	B	
12	was	O	
13	found	O	
14	to	O	
15	be	O	
16	even	O	
17	lower	O	
18	in	O	
19	12	O	
20	patients	O	
21	(	O	
22	35	O	
23	.	O	
24	1	O	
25	micrograms	O	
26	dl	O	
27	-	O	
28	1	O	
29	,	O	
30	3	O	
31	.	O	
32	7	O	
33	mg	O	
34	dl	O	
35	-	O	
36	1	O	
37	)	O	
38	who	O	
39	subsequently	O	
40	had	O	
41	cancer	O	
42	recurrence	O	
43	than	O	
44	in	O	
45	those	O	
46	who	O	
47	remained	O	
48	free	O	
49	of	O	
50	apparent	O	
51	cancer	O	
52	(	O	
53	44	O	
54	.	O	
55	5	O	
56	micrograms	O	
57	dl	O	
58	-	O	
59	1	O	
60	,	O	
61	4	O	
62	.	O	
63	6	O	
64	mg	O	
65	dl	O	
66	-	O	
67	1	O	
68	).	O	

1	HER2	B	
2	overexpressing	O	
3	cells	O	
4	showed	O	
5	a	O	
6	single	O	
7	prominent	O	
8	DNase	B	
9	I	I	
10	hypersensitive	O	
11	site	O	
12	near	O	
13	a	O	
14	conserved	O	
15	and	O	
16	hitherto	O	
17	unrecognized	O	
18	ets	B	
19	response	O	
20	element	O	
21	(	O	
22	GAGGAA	O	
23	),	O	
24	located	O	
25	38	O	
26	bases	O	
27	down	O	
28	-	O	
29	stream	O	
30	from	O	
31	the	O	
32	CAAT	O	
33	box	O	
34	and	O	
35	directly	O	
36	5	O	
37	'	O	
38	of	O	
39	the	O	
40	TATA	O	
41	box	O	
42	in	O	
43	the	O	
44	human	B	
45	HER2	I	
46	promoter	I	
47	.	O	

1	The	O	
2	UAS	O	
3	of	O	
4	the	O	
5	AAC2	B	
6	gene	I	
7	contains	O	
8	at	O	
9	least	O	
10	two	O	
11	distinct	O	
12	motifs	O	
13	for	O	
14	DNA	O	
15	-	O	
16	binding	O	
17	transcriptional	O	
18	activators	O	
19	,	O	
20	including	O	
21	one	O	
22	which	O	
23	is	O	
24	identical	O	
25	with	O	
26	the	O	
27	core	O	
28	HAP2	B	
29	/	I	
30	3	I	
31	/	I	
32	4	I	
33	binding	I	
34	motif	I	
35	,	O	
36	and	O	
37	a	O	
38	second	O	
39	one	O	
40	with	O	
41	the	O	
42	ABF1	B	
43	consensus	I	
44	binding	I	
45	sequence	I	
46	.	O	

1	The	O	
2	temporal	O	
3	component	O	
4	lacked	O	
5	a	O	
6	mandibular	O	
7	fossa	O	
8	as	O	
9	well	O	
10	as	O	
11	articular	O	
12	eminence	O	
13	.	O	

1	As	O	
2	the	O	
3	rate	O	
4	of	O	
5	protein	O	
6	synthesis	O	
7	decreases	O	
8	during	O	
9	late	O	
10	embryogenesis	O	
11	,	O	
12	levels	O	
13	of	O	
14	SEC	B	
15	-	I	
16	1	I	
17	and	O	
18	its	O	
19	cognate	O	
20	mRNA	O	
21	decline	O	
22	precipitously	O	
23	.	O	

1	This	O	
2	dominant	O	
3	-	O	
4	negative	O	
5	effect	O	
6	of	O	
7	FRNK	B	
8	was	O	
9	reversed	O	
10	by	O	
11	a	O	
12	point	O	
13	mutation	O	
14	(	O	
15	Leu	O	
16	-	O	
17	1034	O	
18	to	O	
19	Ser	O	
20	)	O	
21	which	O	
22	prevented	O	
23	FRNK	B	
24	localization	O	
25	to	O	
26	focal	O	
27	contact	O	
28	sites	O	
29	.	O	

1	The	O	
2	drug	O	
3	-	O	
4	resistant	O	
5	cell	O	
6	lines	O	
7	P388	O	
8	/	O	
9	ADR	O	
10	/	O	
11	3	O	
12	and	O	
13	P388	O	
14	/	O	
15	ADR	O	
16	/	O	
17	7	O	
18	express	O	
19	a	O	
20	shortened	O	
21	topo	B	
22	II	I	
23	alpha	I	
24	mRNA	I	
25	transcript	I	
26	in	O	
27	addition	O	
28	to	O	
29	the	O	
30	native	O	
31	transcript	O	
32	present	O	
33	in	O	
34	the	O	
35	drug	O	
36	-	O	
37	sensitive	O	
38	P388	O	
39	/	O	
40	4	O	
41	cell	O	
42	line	O	
43	.	O	

1	Buflomedil	O	
2	(	O	
3	i	O	
4	.	O	
5	v	O	
6	.)	O	
7	induced	O	
8	a	O	
9	dose	O	
10	-	O	
11	dependent	O	
12	increase	O	
13	of	O	
14	cardiac	O	
15	output	O	
16	at	O	
17	0	O	
18	.	O	
19	16	O	
20	-	O	
21	0	O	
22	.	O	
23	64	O	
24	mg	O	
25	/	O	
26	kg	O	
27	,	O	
28	biphasic	O	
29	changes	O	
30	at	O	
31	1	O	
32	.	O	
33	28	O	
34	and	O	
35	2	O	
36	.	O	
37	56	O	
38	mg	O	
39	/	O	
40	kg	O	
41	and	O	
42	a	O	
43	marked	O	
44	decrease	O	
45	and	O	
46	subsequent	O	
47	slight	O	
48	increase	O	
49	at	O	
50	a	O	
51	large	O	
52	dose	O	
53	of	O	
54	5	O	
55	.	O	
56	12	O	
57	mg	O	
58	/	O	
59	kg	O	
60	.	O	

1	Muscle	O	
2	action	O	
3	potential	O	
4	and	O	
5	masticatory	O	
6	rhythm	O	
7	of	O	
8	anterior	O	
9	temporal	O	
10	and	O	
11	masseter	O	
12	muscles	O	
13	in	O	
14	children	O	
15	and	O	
16	adults	O	

1	Preface	O	
2	.	O	

1	This	O	
2	concept	O	
3	is	O	
4	supported	O	
5	by	O	
6	the	O	
7	identification	O	
8	of	O	
9	RH	B	
10	-	I	
11	like	I	
12	genes	I	
13	in	O	
14	non	O	
15	human	O	
16	primates	O	
17	.	O	

1	Lastly	O	
2	,	O	
3	there	O	
4	are	O	
5	multiple	O	
6	instances	O	
7	in	O	
8	which	O	
9	short	O	
10	oligonucleotide	O	
11	direct	O	
12	repeats	O	
13	flank	O	
14	a	O	
15	region	O	
16	absent	O	
17	from	O	
18	either	O	
19	variola	O	
20	or	O	
21	vaccinia	O	
22	virus	O	
23	.	O	

1	XXI	O	
2	.	O	

1	The	O	
2	prevalence	O	
3	of	O	
4	hepatitis	B	
5	B	I	
6	surface	I	
7	antigen	I	
8	(	O	
9	HBsAg	B	
10	)	O	
11	and	O	
12	anti	B	
13	-	I	
14	HBs	I	
15	was	O	
16	determined	O	
17	by	O	
18	a	O	
19	sensitive	O	
20	double	O	
21	-	O	
22	antibody	O	
23	radio	O	
24	-	O	
25	immunoassay	O	
26	technique	O	
27	in	O	
28	a	O	
29	series	O	
30	of	O	
31	patients	O	
32	with	O	
33	chronic	O	
34	liver	O	
35	diseases	O	
36	.	O	

1	Immunofluorescence	O	
2	microscopy	O	
3	revealed	O	
4	extensive	O	
5	deposition	O	
6	of	O	
7	such	O	
8	extracellular	O	
9	matrices	O	
10	as	O	
11	type	B	
12	IV	I	
13	collagen	I	
14	and	O	
15	laminin	B	
16	in	O	
17	the	O	
18	vascular	O	
19	wall	O	
20	.	O	

1	Here	O	
2	we	O	
3	review	O	
4	progress	O	
5	to	O	
6	date	O	
7	in	O	
8	this	O	
9	area	O	
10	.	O	

1	Detection	O	
2	of	O	
3	congenital	O	
4	hypothyroidism	O	
5	in	O	
6	26	O	
7	,	O	
8	282	O	
9	newborn	O	
10	infants	O	

1	The	O	
2	up	O	
3	-	O	
4	regulation	O	
5	of	O	
6	E	B	
7	-	I	
8	selectin	I	
9	,	O	
10	one	O	
11	of	O	
12	the	O	
13	adhesion	O	
14	molecules	O	
15	on	O	
16	the	O	
17	endothelium	O	
18	,	O	
19	is	O	
20	an	O	
21	important	O	
22	event	O	
23	in	O	
24	the	O	
25	mediation	O	
26	of	O	
27	the	O	
28	inflammatory	O	
29	response	O	
30	.	O	

1	RNase	B	
2	protection	O	
3	assays	O	
4	reveal	O	
5	that	O	
6	this	O	
7	gene	O	
8	,	O	
9	unr	B	
10	,	O	
11	is	O	
12	transcribed	O	
13	in	O	
14	the	O	
15	same	O	
16	direction	O	
17	as	O	
18	N	B	
19	-	I	
20	ras	I	
21	and	O	
22	that	O	
23	its	O	
24	3	O	
25	'	O	
26	end	O	
27	is	O	
28	located	O	
29	just	O	
30	130	O	
31	base	O	
32	pairs	O	
33	away	O	
34	from	O	
35	the	O	
36	point	O	
37	at	O	
38	which	O	
39	N	B	
40	-	I	
41	ras	I	
42	transcription	O	
43	begins	O	
44	.	O	

1	One	O	
2	such	O	
3	mutant	O	
4	also	O	
5	affects	O	
6	the	O	
7	overlapping	O	
8	-	O	
9	10	O	
10	hexamer	O	
11	of	O	
12	PR	O	
13	and	O	
14	results	O	
15	in	O	
16	reduced	O	
17	occupancy	O	
18	by	O	
19	both	O	
20	MerR	B	
21	and	O	
22	RNA	B	
23	polymerase	I	
24	,	O	
25	likely	O	
26	as	O	
27	a	O	
28	result	O	
29	of	O	
30	inefficient	O	
31	transcriptional	O	
32	initiation	O	
33	of	O	
34	merR	B	
35	mRNA	I	
36	.	O	

1	Pseudosubstrate	O	
2	(	O	
3	19	O	
4	-	O	
5	36	O	
6	),	O	
7	derived	O	
8	from	O	
9	the	O	
10	C	O	
11	-	O	
12	terminus	O	
13	of	O	
14	Ca	B	
15	-	I	
16	dependent	I	
17	PKC	I	
18	isotypes	I	
19	,	O	
20	inhibited	O	
21	beta	B	
22	-	I	
23	PKC	I	
24	but	O	
25	not	O	
26	nPKC	B	
27	activity	O	
28	using	O	
29	either	O	
30	Histone	B	
31	IIIS	I	
32	or	O	
33	peptide	O	
34	(	O	
35	19	O	
36	-	O	
37	31	O	
38	)	O	
39	as	O	
40	substrate	O	
41	.	O	

1	SBF	B	
2	binds	O	
3	to	O	
4	the	O	
5	promoter	O	
6	prior	O	
7	to	O	
8	the	O	
9	activation	O	
10	of	O	
11	transcription	O	
12	in	O	
13	late	O	
14	G1	O	
15	,	O	
16	suggesting	O	
17	that	O	
18	Cln	B	
19	/	O	
20	Cdc28	B	
21	kinase	O	
22	regulates	O	
23	the	O	
24	ability	O	
25	of	O	
26	previously	O	
27	bound	O	
28	SBF	B	
29	to	O	
30	activate	O	
31	transcription	O	
32	.	O	

1	N	O	
2	.	O	
3	van	O	
4	Hoek	O	
5	,	O	
6	and	O	
7	M	O	
8	.	O	

1	The	O	
2	patients	O	
3	who	O	
4	presented	O	
5	with	O	
6	mucocutaneous	O	
7	disease	O	
8	also	O	
9	had	O	
10	low	O	
11	CD4	B	
12	+	I	
13	T	O	
14	lymphocyte	O	
15	counts	O	
16	,	O	
17	and	O	
18	most	O	
19	of	O	
20	them	O	
21	had	O	
22	AIDS	O	
23	defining	O	
24	illnesses	O	
25	.	O	

1	AIMS	O	
2	/	O	
3	METHODS	O	
4	:	O	
5	Reticuloendothelial	O	
6	system	O	
7	function	O	
8	,	O	
9	as	O	
10	assessed	O	
11	by	O	
12	clearance	O	
13	of	O	
14	radiolabelled	O	
15	bacteria	O	
16	,	O	
17	was	O	
18	evaluated	O	
19	in	O	
20	acute	O	
21	liver	O	
22	injury	O	
23	induced	O	
24	by	O	
25	D	O	
26	-	O	
27	galactosamine	O	
28	in	O	
29	rats	O	
30	,	O	
31	and	O	
32	compared	O	
33	with	O	
34	that	O	
35	after	O	
36	70	O	
37	%	O	
38	liver	O	
39	resection	O	
40	model	O	
41	.	O	

1	Targeted	O	
2	disruption	O	
3	of	O	
4	the	O	
5	OGG1	B	
6	gene	I	
7	in	O	
8	yeast	O	
9	revealed	O	
10	a	O	
11	second	O	
12	OG	B	
13	glycosylase	I	
14	/	I	
15	lyase	I	
16	protein	I	
17	,	O	
18	tentatively	O	
19	named	O	
20	Ogg2	B	
21	,	O	
22	which	O	
23	differs	O	
24	from	O	
25	Ogg1	B	
26	in	O	
27	that	O	
28	it	O	
29	preferentially	O	
30	acts	O	
31	on	O	
32	OG	O	
33	:	O	
34	G	O	
35	.	O	

1	Total	O	
2	cholesterol	O	
3	was	O	
4	measured	O	
5	in	O	
6	amniotic	O	
7	fluids	O	
8	collected	O	
9	at	O	
10	different	O	
11	stages	O	
12	of	O	
13	gestation	O	
14	.	O	

1	Structural	O	
2	organization	O	
3	and	O	
4	expression	O	
5	of	O	
6	the	O	
7	mouse	B	
8	estrogen	I	
9	receptor	I	
10	.	O	

1	The	O	
2	two	O	
3	main	O	
4	experimental	O	
5	variables	O	
6	were	O	
7	the	O	
8	attended	O	
9	hemifield	O	
10	(	O	
11	left	O	
12	or	O	
13	right	O	
14	)	O	
15	and	O	
16	the	O	
17	proportion	O	
18	of	O	
19	trials	O	
20	requiring	O	
21	a	O	
22	shift	O	
23	within	O	
24	that	O	
25	hemifield	O	
26	(	O	
27	20	O	
28	%	O	
29	or	O	
30	80	O	
31	%).	O	

1	Constructs	O	
2	designed	O	
3	and	O	
4	expressed	O	
5	were	O	
6	E2L1	O	
7	(	O	
8	1	O	
9	-	O	
10	98	O	
11	),	O	
12	E2L1	O	
13	.	O	
14	H1	O	
15	(	O	
16	1	O	
17	-	O	
18	128	O	
19	),	O	
20	E2L2	O	
21	(	O	
22	120	O	
23	-	O	
24	233	O	
25	),	O	
26	E2H1	O	
27	.	O	
28	L2	O	
29	(	O	
30	98	O	
31	-	O	
32	233	O	
33	),	O	
34	and	O	
35	E2L1	O	
36	.	O	
37	H1	O	
38	.	O	
39	L2	O	
40	(	O	
41	1	O	
42	-	O	
43	233	O	
44	),	O	
45	where	O	
46	numbers	O	
47	in	O	
48	parentheses	O	
49	give	O	
50	the	O	
51	amino	O	
52	acid	O	
53	sequence	O	
54	for	O	
55	the	O	
56	portions	O	
57	of	O	
58	the	O	
59	E2	B	
60	component	O	
61	incorporated	O	
62	into	O	
63	a	O	
64	construct	O	
65	.	O	

1	Keeping	O	
2	in	O	
3	mind	O	
4	the	O	
5	limited	O	
6	range	O	
7	of	O	
8	age	O	
9	and	O	
10	dosages	O	
11	,	O	
12	advantages	O	
13	and	O	
14	disadvantages	O	
15	of	O	
16	the	O	
17	drug	O	
18	are	O	
19	discussed	O	
20	,	O	
21	comparing	O	
22	the	O	
23	experimental	O	
24	results	O	
25	with	O	
26	those	O	
27	derived	O	
28	from	O	
29	the	O	
30	literature	O	
31	.	O	

1	This	O	
2	core	O	
3	sequence	O	
4	,	O	
5	along	O	
6	with	O	
7	additional	O	
8	nonspecific	O	
9	downstream	O	
10	nucleotides	O	
11	,	O	
12	is	O	
13	sufficient	O	
14	for	O	
15	partial	O	
16	suppression	O	
17	of	O	
18	spliceosome	O	
19	assembly	O	
20	and	O	
21	splicing	O	
22	of	O	
23	BPV	O	
24	-	O	
25	1	O	
26	pre	O	
27	-	O	
28	mRNAs	O	
29	.	O	

1	In	O	
2	30	O	
3	dogs	O	
4	the	O	
5	left	O	
6	limb	O	
7	(	O	
8	tail	O	
9	)	O	
10	of	O	
11	the	O	
12	pancreas	O	
13	was	O	
14	removed	O	
15	but	O	
16	left	O	
17	in	O	
18	the	O	
19	abdominal	O	
20	cavity	O	
21	after	O	
22	cessation	O	
23	of	O	
24	blood	O	
25	flow	O	
26	to	O	
27	produce	O	
28	warm	O	
29	ischemia	O	
30	for	O	
31	30	O	
32	,	O	
33	60	O	
34	,	O	
35	and	O	
36	120	O	
37	min	O	
38	(	O	
39	10	O	
40	dogs	O	
41	at	O	
42	each	O	
43	time	O	
44	point	O	
45	),	O	
46	and	O	
47	then	O	
48	was	O	
49	flushed	O	
50	with	O	
51	cold	O	
52	Ringers	O	
53	'	O	
54	lactate	O	
55	and	O	
56	transplanted	O	
57	to	O	
58	the	O	
59	iliac	O	
60	vessels	O	
61	.	O	

1	Localization	O	
2	of	O	
3	67	O	
4	exons	O	
5	on	O	
6	a	O	
7	YAC	O	
8	contig	O	
9	spanning	O	
10	1	O	
11	.	O	
12	5	O	
13	Mb	O	
14	around	O	
15	the	O	
16	multidrug	B	
17	resistance	I	
18	gene	I	
19	region	I	
20	of	O	
21	human	O	
22	chromosome	O	
23	7q21	O	
24	.	O	
25	1	O	
26	.	O	

1	The	O	
2	65	O	
3	-	O	
4	bp	O	
5	sequence	O	
6	contains	O	
7	the	O	
8	octameric	O	
9	cAMP	O	
10	-	O	
11	responsive	O	
12	enhancer	O	
13	(	O	
14	CRE	O	
15	)	O	
16	TGACGTCA	O	
17	(	O	
18	nucleotides	O	
19	-	O	
20	48	O	
21	to	O	
22	-	O	
23	41	O	
24	).	O	

1	The	O	
2	mutant	O	
3	protein	O	
4	is	O	
5	present	O	
6	at	O	
7	levels	O	
8	slightly	O	
9	greater	O	
10	than	O	
11	wild	O	
12	-	O	
13	type	O	
14	,	O	
15	but	O	
16	exhibits	O	
17	the	O	
18	same	O	
19	tissue	O	
20	distribution	O	
21	as	O	
22	wild	O	
23	-	O	
24	type	O	
25	protein	O	
26	,	O	
27	and	O	
28	has	O	
29	approximately	O	
30	normal	O	
31	affinity	O	
32	for	O	
33	known	O	
34	target	O	
35	sequences	O	
36	(	O	
37	though	O	
38	no	O	
39	DNA	O	
40	targets	O	
41	identified	O	
42	to	O	
43	date	O	
44	require	O	
45	the	O	
46	first	O	
47	cut	O	
48	repeat	O	
49	for	O	
50	binding	O	
51	).	O	

1	As	O	
2	regards	O	
3	lipid	O	
4	metabolism	O	
5	,	O	
6	the	O	
7	mean	O	
8	values	O	
9	for	O	
10	total	O	
11	triglycerides	O	
12	,	O	
13	cholesterol	O	
14	,	O	
15	LDL	B	
16	-	I	
17	cholesterol	I	
18	and	O	
19	HDL	B	
20	-	I	
21	cholesterol	I	
22	seen	O	
23	at	O	
24	the	O	
25	end	O	
26	of	O	
27	five	O	
28	years	O	
29	of	O	
30	Norplant	O	
31	-	O	
32	2	O	
33	rod	O	
34	use	O	
35	and	O	
36	six	O	
37	months	O	
38	postremoval	O	
39	were	O	
40	similar	O	
41	to	O	
42	the	O	
43	preinsertion	O	
44	mean	O	
45	.	O	

1	The	O	
2	T	O	
3	-	O	
4	box	O	
5	motif	O	
6	is	O	
7	present	O	
8	in	O	
9	a	O	
10	family	O	
11	of	O	
12	genes	O	
13	whose	O	
14	structural	O	
15	features	O	
16	and	O	
17	expression	O	
18	patterns	O	
19	support	O	
20	their	O	
21	involvement	O	
22	in	O	
23	developmental	O	
24	gene	O	
25	regulation	O	
26	.	O	

1	As	O	
2	for	O	
3	31	O	
4	stage	O	
5	I	O	
6	-	O	
7	II	O	
8	lung	O	
9	cancer	O	
10	patients	O	
11	,	O	
12	CR	O	
13	has	O	
14	been	O	
15	observed	O	
16	in	O	
17	82	O	
18	.	O	
19	8	O	
20	%	O	
21	of	O	
22	them	O	
23	and	O	
24	PR	O	
25	in	O	
26	13	O	
27	.	O	
28	8	O	
29	%;	O	
30	the	O	
31	response	O	
32	was	O	
33	always	O	
34	assessed	O	
35	with	O	
36	chest	O	
37	radiography	O	
38	,	O	
39	CT	O	
40	,	O	
41	FBS	O	
42	,	O	
43	cytology	O	
44	and	O	
45	/	O	
46	or	O	
47	histology	O	
48	.	O	

1	Here	O	
2	we	O	
3	show	O	
4	in	O	
5	mouse	O	
6	fibroblasts	O	
7	stably	O	
8	transformed	O	
9	by	O	
10	v	B	
11	-	I	
12	Src	I	
13	that	O	
14	mRNA	O	
15	and	O	
16	protein	O	
17	levels	O	
18	of	O	
19	p21	B	
20	(	O	
21	WAF1	B	
22	/	O	
23	CIP1	B	
24	),	O	
25	cyclin	B	
26	D1	I	
27	,	O	
28	and	O	
29	cyclin	B	
30	E	I	
31	are	O	
32	elevated	O	
33	.	O	

1	Alternative	O	
2	splicing	O	
3	of	O	
4	CDC25B	B	
5	may	O	
6	therefore	O	
7	contribute	O	
8	to	O	
9	the	O	
10	control	O	
11	of	O	
12	cell	O	
13	proliferation	O	
14	.	O	

1	Activated	O	
2	PKR	B	
3	may	O	
4	exist	O	
5	as	O	
6	a	O	
7	dimer	O	
8	and	O	
9	phosphorylates	O	
10	the	O	
11	eukaryotic	B	
12	translation	I	
13	initiation	I	
14	factor	I	
15	2	I	
16	alpha	I	
17	subunit	I	
18	(	O	
19	cIF	B	
20	-	I	
21	2	I	
22	alpha	I	
23	)	O	
24	to	O	
25	inhibit	O	
26	polypeptide	O	
27	chain	O	
28	initiation	O	
29	.	O	

1	New	O	
2	technologies	O	
3	in	O	
4	diagnosis	O	
5	and	O	
6	classification	O	
7	of	O	
8	malignancy	O	
9	.	O	

1	Serum	B	
2	IgM	I	
3	and	O	
4	IgE	B	
5	concentrations	O	
6	,	O	
7	allergen	B	
8	-	I	
9	specific	I	
10	IgE	I	
11	scores	O	
12	,	O	
13	and	O	
14	the	O	
15	tumor	O	
16	E2R	B	
17	status	O	
18	were	O	
19	combined	O	
20	to	O	
21	construct	O	
22	a	O	
23	three	O	
24	-	O	
25	level	O	
26	risk	O	
27	classification	O	
28	that	O	
29	was	O	
30	more	O	
31	prognostic	O	
32	than	O	
33	any	O	
34	of	O	
35	the	O	
36	individual	O	
37	components	O	
38	.	O	

1	Pharmacological	O	
2	action	O	
3	of	O	
4	eptazocine	O	
5	(	O	
6	l	O	
7	-	O	
8	1	O	
9	,	O	
10	4	O	
11	-	O	
12	dimethyl	O	
13	-	O	
14	10	O	
15	-	O	
16	hydroxy	O	
17	-	O	
18	2	O	
19	,	O	
20	3	O	
21	,	O	
22	4	O	
23	,	O	
24	5	O	
25	,	O	
26	6	O	
27	,	O	
28	7	O	
29	-	O	
30	hexahydro	O	
31	-	O	
32	1	O	
33	,	O	
34	6	O	
35	-	O	
36	methano	O	
37	-	O	
38	1H	O	
39	-	O	
40	4	O	
41	-	O	
42	benz	O	
43	azonine	O	
44	).	O	

1	Six	O	
2	patients	O	
3	with	O	
4	human	O	
5	T	O	
6	-	O	
7	cell	O	
8	lymphotropic	O	
9	virus	O	
10	type	O	
11	I	O	
12	(	O	
13	HTLV	O	
14	-	O	
15	I	O	
16	)-	O	
17	associated	O	
18	myelopathy	O	
19	(	O	
20	HAM	O	
21	)	O	
22	were	O	
23	studied	O	
24	by	O	
25	electrophysiologic	O	
26	methods	O	
27	.	O	

1	These	O	
2	activities	O	
3	are	O	
4	all	O	
5	required	O	
6	for	O	
7	stimulation	O	
8	of	O	
9	cell	O	
10	growth	O	
11	by	O	
12	middle	B	
13	-	I	
14	T	I	
15	and	O	
16	activate	O	
17	members	O	
18	of	O	
19	the	O	
20	MAP	B	
21	kinase	I	
22	family	I	
23	.	O	

1	3	O	
2	.	O	

1	The	O	
2	multidomain	O	
3	structure	O	
4	includes	O	
5	a	O	
6	cysteine	O	
7	-	O	
8	rich	O	
9	motif	O	
10	resembling	O	
11	those	O	
12	of	O	
13	protein	B	
14	kinase	I	
15	C	I	
16	and	O	
17	n	B	
18	-	I	
19	chimaerin	I	
20	and	O	
21	a	O	
22	putative	O	
23	pleckstrin	B	
24	homology	I	
25	domain	I	
26	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	COUP	B	
5	-	I	
6	TF	I	
7	alone	O	
8	had	O	
9	no	O	
10	effect	O	
11	on	O	
12	repCRS2	O	
13	-	O	
14	dependent	O	
15	reporter	O	
16	gene	O	
17	activity	O	
18	.	O	

1	The	O	
2	mean	O	
3	(+/-	O	
4	SD	O	
5	)	O	
6	PaO2	O	
7	increased	O	
8	from	O	
9	80	O	
10	.	O	
11	8	O	
12	+/-	O	
13	26	O	
14	.	O	
15	9	O	
16	mmHg	O	
17	before	O	
18	to	O	
19	89	O	
20	.	O	
21	8	O	
22	+/-	O	
23	27	O	
24	.	O	
25	3	O	
26	mmHg	O	
27	after	O	
28	the	O	
29	infusion	O	
30	(	O	
31	P	O	
32	<	O	
33	0	O	
34	.	O	
35	05	O	
36	)	O	
37	and	O	
38	the	O	
39	PaCO2	O	
40	decreased	O	
41	from	O	
42	42	O	
43	.	O	
44	4	O	
45	+/-	O	
46	8	O	
47	.	O	
48	3	O	
49	to	O	
50	39	O	
51	.	O	
52	6	O	
53	+/-	O	
54	7	O	
55	.	O	
56	9	O	
57	mmHg	O	
58	(	O	
59	P	O	
60	<	O	
61	0	O	
62	.	O	
63	05	O	
64	).	O	

1	We	O	
2	propose	O	
3	that	O	
4	refeeding	O	
5	may	O	
6	be	O	
7	an	O	
8	important	O	
9	mechanism	O	
10	for	O	
11	activation	O	
12	of	O	
13	certain	O	
14	viral	O	
15	infections	O	
16	previously	O	
17	suppressed	O	
18	by	O	
19	famine	O	
20	.	O	

1	IFN	B	
2	-	I	
3	stimulated	I	
4	gene	I	
5	factor	I	
6	-	I	
7	3	I	
8	and	O	
9	STAT1	B	
10	homodimers	I	
11	formed	O	
12	and	O	
13	bound	O	
14	an	O	
15	IFN	B	
16	-	I	
17	stimulated	I	
18	response	I	
19	element	I	
20	(	O	
21	ISRE	B	
22	)	O	
23	and	O	
24	gamma	B	
25	-	I	
26	activated	I	
27	sequence	I	
28	(	O	
29	GAS	B	
30	)	O	
31	element	O	
32	,	O	
33	respectively	O	
34	.	O	

1	We	O	
2	have	O	
3	examined	O	
4	by	O	
5	in	O	
6	vitro	O	
7	footprinting	O	
8	a	O	
9	region	O	
10	located	O	
11	downstream	O	
12	of	O	
13	the	O	
14	human	O	
15	immunodeficiency	O	
16	virus	O	
17	,	O	
18	type	O	
19	1	O	
20	(	O	
21	HIV	O	
22	-	O	
23	1	O	
24	)	O	
25	promoter	O	
26	found	O	
27	to	O	
28	be	O	
29	hypersensitive	O	
30	to	O	
31	DNase	B	
32	I	I	
33	digestion	O	
34	in	O	
35	vivo	O	
36	.	O	

1	Interestingly	O	
2	,	O	
3	a	O	
4	portion	O	
5	of	O	
6	the	O	
7	tail	O	
8	domain	O	
9	(	O	
10	aa	O	
11	,	O	
12	1	O	
13	,	O	
14	094	O	
15	-	O	
16	1	O	
17	,	O	
18	830	O	
19	)	O	
20	shares	O	
21	58	O	
22	%	O	
23	amino	O	
24	acid	O	
25	sequence	O	
26	identity	O	
27	with	O	
28	a	O	
29	723	O	
30	-	O	
31	aa	O	
32	protein	O	
33	from	O	
34	mouse	O	
35	brain	O	
36	reported	O	
37	to	O	
38	be	O	
39	a	O	
40	glutamic	B	
41	acid	I	
42	decarboxylase	I	
43	.	O	

1	The	O	
2	major	O	
3	pathological	O	
4	findings	O	
5	of	O	
6	the	O	
7	placenta	O	
8	were	O	
9	prematuration	O	
10	and	O	
11	hypoplasia	O	
12	.	O	

1	G	O	
2	.,	O	
3	and	O	
4	Hyde	O	
5	,	O	
6	C	O	
7	.	O	

1	The	O	
2	sequence	O	
3	was	O	
4	determined	O	
5	of	O	
6	6493	O	
7	nucleotides	O	
8	encompassing	O	
9	the	O	
10	bet	B	
11	genes	I	
12	of	I	
13	Escherichia	I	
14	coli	I	
15	which	O	
16	encode	O	
17	the	O	
18	osmoregulatory	O	
19	choline	O	
20	-	O	
21	glycine	O	
22	betaine	O	
23	pathway	O	
24	.	O	

1	The	O	
2	human	O	
3	T	O	
4	cell	O	
5	lymphotropic	O	
6	retrovirus	O	
7	type	O	
8	I	O	
9	(	O	
10	HTLV	O	
11	-	O	
12	I	O	
13	)	O	
14	trans	O	
15	-	O	
16	activator	O	
17	,	O	
18	Tax	B	
19	,	O	
20	interacts	O	
21	specifically	O	
22	with	O	
23	the	O	
24	basic	B	
25	-	I	
26	domain	I	
27	/	I	
28	leucine	I	
29	-	I	
30	zipper	I	
31	(	I	
32	bZip	I	
33	)	I	
34	protein	I	
35	,	O	
36	cAMP	B	
37	response	I	
38	element	I	
39	binding	I	
40	protein	I	
41	(	O	
42	CREB	B	
43	),	O	
44	bound	O	
45	to	O	
46	the	O	
47	viral	B	
48	Tax	I	
49	-	I	
50	responsive	I	
51	element	I	
52	consisting	O	
53	of	O	
54	three	O	
55	imperfect	O	
56	21	O	
57	-	O	
58	base	O	
59	pair	O	
60	repeats	O	
61	,	O	
62	each	O	
63	with	O	
64	a	O	
65	cAMP	O	
66	response	O	
67	element	O	
68	core	O	
69	flanked	O	
70	by	O	
71	G	O	
72	/	O	
73	C	O	
74	-	O	
75	rich	O	
76	sequences	O	
77	.	O	

1	CONCLUSION	O	
2	:	O	
3	The	O	
4	probability	O	
5	of	O	
6	cardiopulmonary	O	
7	complications	O	
8	increases	O	
9	significantly	O	
10	when	O	
11	patients	O	
12	develop	O	
13	class	O	
14	1	O	
15	HELLP	O	
16	syndrome	O	
17	.	O	

1	Selective	O	
2	bronchial	O	
3	intubation	O	
4	in	O	
5	the	O	
6	management	O	
7	of	O	
8	unilateral	O	
9	pulmonary	O	
10	interstitial	O	
11	emphysema	O	
12	.	O	

1	Incidence	O	
2	rate	O	
3	ranging	O	
4	between	O	
5	122	O	
6	/	O	
7	100	O	
8	,	O	
9	000	O	
10	/	O	
11	year	O	
12	and	O	
13	190	O	
14	/	O	
15	100	O	
16	,	O	
17	000	O	
18	/	O	
19	year	O	
20	were	O	
21	found	O	
22	(	O	
23	minimum	O	
24	,	O	
25	estimated	O	
26	and	O	
27	raw	O	
28	datasets	O	
29	).	O	

1	A	O	
2	favourable	O	
3	response	O	
4	was	O	
5	achieved	O	
6	with	O	
7	a	O	
8	combination	O	
9	of	O	
10	amphotericin	O	
11	B	O	
12	and	O	
13	cotrimoxazole	O	
14	.	O	

1	LDL	B	
2	cholesterol	I	
3	decreased	O	
4	from	O	
5	4	O	
6	.	O	
7	74	O	
8	+/-	O	
9	0	O	
10	.	O	
11	87	O	
12	to	O	
13	3	O	
14	.	O	
15	78	O	
16	+/-	O	
17	0	O	
18	.	O	
19	78	O	
20	mmol	O	
21	/	O	
22	l	O	
23	after	O	
24	8	O	
25	weeks	O	
26	on	O	
27	simvastatin	O	
28	(	O	
29	P	O	
30	<	O	
31	0	O	
32	.	O	
33	001	O	
34	),	O	
35	and	O	
36	apo	B	
37	B	I	
38	fell	O	
39	from	O	
40	142	O	
41	+/-	O	
42	31	O	
43	to	O	
44	112	O	
45	+/-	O	
46	22	O	
47	mg	O	
48	/	O	
49	dl	O	
50	(	O	
51	P	O	
52	<	O	
53	0	O	
54	.	O	
55	001	O	
56	).	O	

1	The	O	
2	human	B	
3	eps15	I	
4	gene	I	
5	,	O	
6	encoding	O	
7	a	O	
8	tyrosine	B	
9	kinase	I	
10	substrate	O	
11	,	O	
12	is	O	
13	conserved	O	
14	in	O	
15	evolution	O	
16	and	O	
17	maps	O	
18	to	O	
19	1p31	O	
20	-	O	
21	p32	O	
22	.	O	

1	No	O	
2	patient	O	
3	had	O	
4	a	O	
5	history	O	
6	of	O	
7	excess	O	
8	alcohol	O	
9	intake	O	
10	,	O	
11	or	O	
12	prolonged	O	
13	intake	O	
14	of	O	
15	hepatotoxic	O	
16	drugs	O	
17	and	O	
18	steroids	O	
19	,	O	
20	and	O	
21	were	O	
22	not	O	
23	obese	O	
24	or	O	
25	malnourished	O	
26	.	O	

1	RESULTS	O	
2	:	O	
3	In	O	
4	the	O	
5	pregnant	O	
6	group	O	
7	,	O	
8	serum	O	
9	PP14	B	
10	concentrations	O	
11	were	O	
12	markedly	O	
13	increased	O	
14	after	O	
15	ET	O	
16	,	O	
17	and	O	
18	a	O	
19	significant	O	
20	difference	O	
21	between	O	
22	the	O	
23	pregnant	O	
24	group	O	
25	and	O	
26	the	O	
27	nonpregnant	O	
28	group	O	
29	was	O	
30	observed	O	
31	8	O	
32	days	O	
33	following	O	
34	ET	O	
35	(	O	
36	p	O	
37	<	O	
38	0	O	
39	.	O	
40	01	O	
41	).	O	

1	In	O	
2	the	O	
3	absence	O	
4	of	O	
5	histological	O	
6	criteria	O	
7	,	O	
8	which	O	
9	it	O	
10	is	O	
11	difficult	O	
12	to	O	
13	demand	O	
14	in	O	
15	view	O	
16	of	O	
17	the	O	
18	variability	O	
19	of	O	
20	results	O	
21	and	O	
22	potential	O	
23	dangers	O	
24	of	O	
25	endomyocardial	O	
26	biopsy	O	
27	involving	O	
28	such	O	
29	thin	O	
30	and	O	
31	fragile	O	
32	ventricular	O	
33	walls	O	
34	,	O	
35	the	O	
36	diagnosis	O	
37	of	O	
38	ACRV	O	
39	is	O	
40	based	O	
41	upon	O	
42	the	O	
43	concomitant	O	
44	existence	O	
45	of	O	
46	:	O	
47	(	O	
48	1	O	
49	)	O	
50	electrophysiological	O	
51	criteria	O	
52	:	O	
53	ventricular	O	
54	arrhythmias	O	
55	,	O	
56	in	O	
57	particular	O	
58	sustained	O	
59	monomorphous	O	
60	VT	O	
61	,	O	
62	with	O	
63	the	O	
64	particular	O	
65	feature	O	
66	of	O	
67	a	O	
68	very	O	
69	high	O	
70	degree	O	
71	of	O	
72	sensitivity	O	
73	to	O	
74	adrenergic	O	
75	stimulation	O	
76	(	O	
77	exercise	O	
78	),	O	
79	the	O	
80	existence	O	
81	of	O	
82	late	O	
83	potentials	O	
84	on	O	
85	the	O	
86	high	O	
87	amplification	O	
88	ECG	O	
89	,	O	
90	a	O	
91	highly	O	
92	specific	O	
93	sign	O	
94	,	O	
95	though	O	
96	unfortunately	O	
97	of	O	
98	poor	O	
99	sensitivity	O	
100	in	O	
101	localized	O	
102	froms	O	
103	,	O	
104	those	O	
105	which	O	
106	are	O	
107	most	O	
108	difficult	O	
109	to	O	
110	identify	O	
111	(	O	
112	2	O	
113	);	O	
114	segmentary	O	
115	morphological	O	
116	and	O	
117	kinetic	O	
118	RV	O	
119	abnormalities	O	
120	,	O	
121	most	O	
122	often	O	
123	resulting	O	
124	in	O	
125	localized	O	
126	akinetic	O	
127	or	O	
128	dyskinetic	O	
129	parietal	O	
130	vaulting	O	
131	,	O	
132	with	O	
133	stasis	O	
134	"	O	
135	in	O	
136	situ	O	
137	".	O	

1	Emergency	O	
2	treatment	O	
3	of	O	
4	facial	O	
5	and	O	
6	maxillary	O	
7	/	O	
8	mandibular	O	
9	injuries	O	

1	A	O	
2	novel	O	
3	,	O	
4	testis	B	
5	-	I	
6	specific	I	
7	mRNA	I	
8	transcript	I	
9	encoding	O	
10	an	O	
11	NH2	B	
12	-	I	
13	terminal	I	
14	truncated	I	
15	nitric	I	
16	-	I	
17	oxide	I	
18	synthase	I	
19	.	O	
20	mRNA	O	
21	diversity	O	
22	represents	O	
23	a	O	
24	major	O	
25	theme	O	
26	of	O	
27	neuronal	B	
28	nitric	I	
29	-	I	
30	oxide	I	
31	synthase	I	
32	(	O	
33	nNOS	B	
34	)	O	
35	gene	O	
36	expression	O	
37	in	O	
38	somatic	O	
39	cells	O	
40	/	O	
41	tissues	O	
42	.	O	

1	Second	O	
2	,	O	
3	plasmid	O	
4	-	O	
5	derived	O	
6	transgenes	O	
7	and	O	
8	gene	O	
9	targeting	O	
10	of	O	
11	the	O	
12	endogenous	B	
13	Hnf3g	I	
14	gene	I	
15	locus	I	
16	were	O	
17	used	O	
18	to	O	
19	demonstrate	O	
20	that	O	
21	the	O	
22	3	O	
23	'-	O	
24	flanking	O	
25	region	O	
26	of	O	
27	the	O	
28	gene	O	
29	is	O	
30	necessary	O	
31	and	O	
32	sufficient	O	
33	to	O	
34	direct	O	
35	reporter	O	
36	gene	O	
37	expression	O	
38	in	O	
39	liver	O	
40	,	O	
41	pancreas	O	
42	,	O	
43	stomach	O	
44	and	O	
45	small	O	
46	intestine	O	
47	.	O	

1	Computer	O	
2	analysis	O	
3	included	O	
4	digital	O	
5	averaging	O	
6	,	O	
7	followed	O	
8	by	O	
9	digital	O	
10	filtering	O	
11	in	O	
12	different	O	
13	frequency	O	
14	bands	O	
15	in	O	
16	order	O	
17	to	O	
18	determine	O	
19	the	O	
20	frequency	O	
21	range	O	
22	corresponding	O	
23	to	O	
24	notches	O	
25	and	O	
26	slurs	O	
27	.	O	

1	Analysis	O	
2	of	O	
3	the	O	
4	upstream	O	
5	untranslated	O	
6	region	O	
7	of	O	
8	CHL15	B	
9	revealed	O	
10	the	O	
11	presence	O	
12	of	O	
13	the	O	
14	hexamer	O	
15	element	O	
16	,	O	
17	ACGCGT	O	
18	(	O	
19	an	O	
20	MluI	B	
21	restriction	I	
22	site	I	
23	)	O	
24	controlling	O	
25	both	O	
26	the	O	
27	periodic	O	
28	expression	O	
29	and	O	
30	coordinate	O	
31	regulation	O	
32	of	O	
33	the	O	
34	DNA	O	
35	synthesis	O	
36	genes	O	
37	in	O	
38	budding	O	
39	yeast	O	
40	.	O	

1	The	O	
2	amino	O	
3	acid	O	
4	sequence	O	
5	alignment	O	
6	of	O	
7	TC	B	
8	II	I	
9	with	O	
10	that	O	
11	of	O	
12	other	O	
13	Cbl	B	
14	binding	I	
15	proteins	I	
16	(	O	
17	rat	B	
18	intrinsic	I	
19	factor	I	
20	,	O	
21	human	B	
22	transcobalamin	I	
23	I	I	
24	and	O	
25	porcine	B	
26	haptocorrin	I	
27	)	O	
28	revealed	O	
29	only	O	
30	33	O	
31	%	O	
32	overall	O	
33	homology	O	
34	.	O	

1	Sample	O	
2	treatment	O	
3	was	O	
4	optimized	O	
5	in	O	
6	order	O	
7	to	O	
8	achieve	O	
9	a	O	
10	complete	O	
11	extraction	O	
12	of	O	
13	labetalol	O	
14	diastereoisomers	O	
15	and	O	
16	to	O	
17	avoid	O	
18	racemization	O	
19	during	O	
20	extraction	O	
21	.	O	

1	IV	O	
2	.	O	

1	These	O	
2	results	O	
3	indicate	O	
4	that	O	
5	virulence	O	
6	-	O	
7	associated	O	
8	genes	O	
9	and	O	
10	their	O	
11	overall	O	
12	chromosomal	O	
13	arrangement	O	
14	are	O	
15	relatively	O	
16	well	O	
17	conserved	O	
18	between	O	
19	B	O	
20	.	O	
21	henselae	O	
22	and	O	
23	other	O	
24	gram	O	
25	-	O	
26	negative	O	
27	bacteria	O	
28	such	O	
29	as	O	
30	A	O	
31	.	O	
32	tumefaciens	O	
33	.	O	

1	The	O	
2	high	O	
3	density	O	
4	of	O	
5	tegumental	O	
6	spines	O	
7	on	O	
8	posterior	O	
9	half	O	
10	of	O	
11	the	O	
12	body	O	
13	and	O	
14	the	O	
15	distribution	O	
16	of	O	
17	type	O	
18	II	O	
19	papillae	O	
20	on	O	
21	dorsal	O	
22	surface	O	
23	are	O	
24	considered	O	
25	to	O	
26	be	O	
27	characteristic	O	
28	of	O	
29	C	O	
30	.	O	
31	armatus	O	
32	.	O	

1	Using	O	
2	the	O	
3	polymerase	O	
4	chain	O	
5	reaction	O	
6	,	O	
7	Whipple	O	
8	-	O	
9	specific	O	
10	DNA	O	
11	fragments	O	
12	of	O	
13	284	O	
14	base	O	
15	pairs	O	
16	from	O	
17	the	O	
18	genome	O	
19	of	O	
20	the	O	
21	Whipple	O	
22	bacterium	O	
23	(	O	
24	Tropheryma	O	
25	whippelii	O	
26	)	O	
27	were	O	
28	demonstrated	O	
29	.	O	

1	Similarly	O	
2	,	O	
3	in	O	
4	mammalian	O	
5	cells	O	
6	PBP74	B	
7	is	O	
8	synthesized	O	
9	as	O	
10	a	O	
11	pre	O	
12	-	O	
13	protein	O	
14	that	O	
15	requires	O	
16	membrane	O	
17	potential	O	
18	-	O	
19	dependent	O	
20	import	O	
21	into	O	
22	mitochondria	O	
23	for	O	
24	its	O	
25	maturation	O	
26	.	O	

1	Paroxysmal	O	
2	fluctuations	O	
3	in	O	
4	observed	O	
5	parasitemia	O	
6	in	O	
7	Plasmodium	O	
8	falciparum	O	
9	malaria	O	
10	.	O	

1	Despite	O	
2	the	O	
3	activation	O	
4	of	O	
5	these	O	
6	intracellular	O	
7	signaling	O	
8	molecules	O	
9	,	O	
10	PDGF	B	
11	beta	I	
12	receptor	I	
13	activation	O	
14	elicited	O	
15	no	O	
16	detectable	O	
17	effect	O	
18	on	O	
19	cell	O	
20	proliferation	O	
21	or	O	
22	differentiation	O	
23	.	O	

1	This	O	
2	resulted	O	
3	in	O	
4	a	O	
5	complete	O	
6	inhibition	O	
7	of	O	
8	Site	O	
9	-	O	
10	1	O	
11	cleavage	O	
12	that	O	
13	was	O	
14	restored	O	
15	by	O	
16	concomitant	O	
17	overexpression	O	
18	of	O	
19	full	O	
20	-	O	
21	length	O	
22	SCAP	B	
23	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	there	O	
5	was	O	
6	a	O	
7	significant	O	
8	increase	O	
9	in	O	
10	postdexamethasone	O	
11	cortical	O	
12	concentrations	O	
13	with	O	
14	age	O	
15	(	O	
16	p	O	
17	less	O	
18	than	O	
19	0	O	
20	.	O	
21	01	O	
22	;	O	
23	r	O	
24	=	O	
25	0	O	
26	.	O	
27	31	O	
28	).	O	

1	Pediatric	O	
2	medical	O	
3	emergencies	O	
4	in	O	
5	a	O	
6	regional	O	
7	hospital	O	
8	:	O	
9	appropriate	O	
10	locale	O	
11	?	O	

1	Northern	O	
2	analysis	O	
3	of	O	
4	the	O	
5	3	B	
6	.	I	
7	1	I	
8	-	I	
9	kb	I	
10	PWP2H	I	
11	cDNA	I	
12	revealed	O	
13	that	O	
14	a	O	
15	3	O	
16	.	O	
17	3	O	
18	-	O	
19	kb	O	
20	major	O	
21	transcript	O	
22	is	O	
23	ubiquitously	O	
24	expressed	O	
25	in	O	
26	human	O	
27	adult	O	
28	tissues	O	
29	.	O	

1	These	O	
2	results	O	
3	indicate	O	
4	that	O	
5	HIV	O	
6	-	O	
7	1	O	
8	Gag	B	
9	sequences	I	
10	can	O	
11	influence	O	
12	the	O	
13	viral	B	
14	PR	I	
15	-	O	
16	mediated	O	
17	processing	O	
18	of	O	
19	the	O	
20	MuLV	O	
21	TM	B	
22	Env	I	
23	protein	I	
24	p15	O	
25	(	O	
26	E	O	
27	).	O	

1	SCL	O	
2	prolonged	O	
3	promptly	O	
4	after	O	
5	verapamil	O	
6	,	O	
7	and	O	
8	sinus	O	
9	arrest	O	
10	developed	O	
11	in	O	
12	two	O	
13	of	O	
14	10	O	
15	group	O	
16	2	O	
17	and	O	
18	two	O	
19	of	O	
20	five	O	
21	group	O	
22	3	O	
23	animals	O	
24	.	O	

1	Deletion	O	
2	mapping	O	
3	experiments	O	
4	determined	O	
5	that	O	
6	the	O	
7	sequences	O	
8	required	O	
9	for	O	
10	full	O	
11	activity	O	
12	in	O	
13	MSC	O	
14	-	O	
15	1	O	
16	cells	O	
17	were	O	
18	included	O	
19	within	O	
20	619	O	
21	bp	O	
22	of	O	
23	the	O	
24	start	O	
25	site	O	
26	and	O	
27	identified	O	
28	several	O	
29	regions	O	
30	that	O	
31	demonstrated	O	
32	increased	O	
33	luciferase	B	
34	activity	O	
35	:	O	
36	the	O	
37	-	O	
38	583	O	
39	bp	O	
40	to	O	
41	-	O	
42	564	O	
43	bp	O	
44	,	O	
45	-	O	
46	503	O	
47	bp	O	
48	to	O	
49	-	O	
50	484	O	
51	bp	O	
52	,	O	
53	and	O	
54	-	O	
55	114	O	
56	bp	O	
57	to	O	
58	-	O	
59	65	O	
60	regions	O	
61	.	O	

1	Ten	O	
2	patients	O	
3	with	O	
4	advanced	O	
5	,	O	
6	diffuse	O	
7	Hodgkin	O	
8	'	O	
9	s	O	
10	and	O	
11	non	O	
12	-	O	
13	Hodgkin	O	
14	'	O	
15	s	O	
16	lymphomas	O	
17	responding	O	
18	poorly	O	
19	to	O	
20	the	O	
21	most	O	
22	widely	O	
23	employed	O	
24	primary	O	
25	chemotherapy	O	
26	regimens	O	
27	were	O	
28	treated	O	
29	with	O	
30	a	O	
31	high	O	
32	-	O	
33	dose	O	
34	chemotherapy	O	
35	(	O	
36	HDC	O	
37	)	O	
38	followed	O	
39	by	O	
40	rescue	O	
41	with	O	
42	non	O	
43	-	O	
44	frozen	O	
45	autologous	O	
46	bone	O	
47	marrow	O	
48	infusion	O	
49	(	O	
50	ABMT	O	
51	).	O	

1	Overall	O	
2	prevalences	O	
3	of	O	
4	antibody	O	
5	were	O	
6	70	O	
7	per	O	
8	cent	O	
9	in	O	
10	cattle	O	
11	,	O	
12	67	O	
13	per	O	
14	cent	O	
15	in	O	
16	sheep	O	
17	and	O	
18	76	O	
19	per	O	
20	cent	O	
21	in	O	
22	goats	O	
23	as	O	
24	assessed	O	
25	by	O	
26	an	O	
27	immunodiffusion	O	
28	test	O	
29	.	O	

1	Of	O	
2	7	O	
3	patients	O	
4	treated	O	
5	with	O	
6	cyclophosphamide	O	
7	,	O	
8	hexamethylmelamine	O	
9	,	O	
10	adriamycin	O	
11	and	O	
12	cisplatin	O	
13	(	O	
14	CHAP	O	
15	-	O	
16	5	O	
17	),	O	
18	6	O	
19	had	O	
20	measurable	O	
21	disease	O	
22	,	O	
23	of	O	
24	whom	O	
25	5	O	
26	yielded	O	
27	a	O	
28	response	O	
29	(	O	
30	2	O	
31	complete	O	
32	responses	O	
33	for	O	
34	19	O	
35	+	O	
36	and	O	
37	40	O	
38	months	O	
39	and	O	
40	3	O	
41	partial	O	
42	responses	O	
43	for	O	
44	4	O	
45	,	O	
46	7	O	
47	and	O	
48	8	O	
49	months	O	
50	).	O	

1	M	B	
2	-	I	
3	66	I	
4	identified	O	
5	the	O	
6	14	O	
7	-	O	
8	kDa	O	
9	protein	O	
10	in	O	
11	another	O	
12	MMTV	O	
13	bearing	O	
14	T	O	
15	-	O	
16	cell	O	
17	lymphoma	O	
18	,	O	
19	EL	O	
20	-	O	
21	4	O	
22	.	O	

1	Two	O	
2	of	O	
3	seven	O	
4	initiation	O	
5	sites	O	
6	were	O	
7	flanked	O	
8	by	O	
9	a	O	
10	sequence	O	
11	homologous	O	
12	to	O	
13	the	O	
14	consensus	O	
15	promoter	O	
16	motif	O	
17	that	O	
18	includes	O	
19	the	O	
20	CRTA	O	
21	motif	O	
22	(	O	
23	where	O	
24	R	O	
25	is	O	
26	A	O	
27	or	O	
28	G	O	
29	)	O	
30	of	O	
31	the	O	
32	rice	O	
33	mitochondrion	O	
34	.	O	

1	There	O	
2	were	O	
3	15	O	
4	deaths	O	
5	,	O	
6	seven	O	
7	of	O	
8	which	O	
9	were	O	
10	felt	O	
11	to	O	
12	be	O	
13	avoidable	O	
14	.	O	

1	Nonvascular	O	
2	ophthalmic	O	
3	and	O	
4	neurologic	O	
5	disorders	O	
6	that	O	
7	can	O	
8	be	O	
9	confused	O	
10	with	O	
11	amaurosis	O	
12	fugax	O	
13	are	O	
14	listed	O	
15	,	O	
16	and	O	
17	an	O	
18	algorithm	O	
19	for	O	
20	evaluation	O	
21	(	O	
22	which	O	
23	includes	O	
24	ophthalmic	O	
25	examination	O	
26	,	O	
27	laboratory	O	
28	studies	O	
29	,	O	
30	and	O	
31	noninvasive	O	
32	carotid	O	
33	artery	O	
34	studies	O	
35	)	O	
36	is	O	
37	given	O	
38	.	O	

1	In	O	
2	all	O	
3	cells	O	
4	,	O	
5	the	O	
6	accumulation	O	
7	of	O	
8	high	O	
9	Dsg	B	
10	protein	I	
11	levels	O	
12	required	O	
13	calcium	O	
14	and	O	
15	was	O	
16	not	O	
17	observed	O	
18	in	O	
19	low	O	
20	calcium	O	
21	(	O	
22	0	O	
23	.	O	
24	05	O	
25	-	O	
26	0	O	
27	.	O	
28	07	O	
29	mM	O	
30	)	O	
31	media	O	
32	.	O	

1	The	O	
2	Drosophila	O	
3	clathrin	B	
4	heavy	I	
5	chain	I	
6	gene	O	
7	:	O	
8	clathrin	B	
9	function	O	
10	is	O	
11	essential	O	
12	in	O	
13	a	O	
14	multicellular	O	
15	organism	O	
16	.	O	

1	One	O	
2	chimpanzee	O	
3	reliably	O	
4	selected	O	
5	the	O	
6	larger	O	
7	numeral	O	
8	4	O	
9	during	O	
10	testing	O	
11	with	O	
12	a	O	
13	nonadjacent	O	
14	pair	O	
15	(	O	
16	2	O	
17	-	O	
18	4	O	
19	),	O	
20	and	O	
21	2	O	
22	chimps	O	
23	showed	O	
24	no	O	
25	preference	O	
26	.	O	

1	When	O	
2	the	O	
3	blood	O	
4	pressure	O	
5	increase	O	
6	in	O	
7	response	O	
8	to	O	
9	smoking	O	
10	was	O	
11	blunted	O	
12	by	O	
13	nitroprusside	O	
14	infusion	O	
15	,	O	
16	there	O	
17	was	O	
18	a	O	
19	striking	O	
20	increase	O	
21	in	O	
22	muscle	O	
23	SNA	O	
24	.	O	

1	All	O	
2	mutant	B	
3	JCV	I	
4	T	I	
5	antigens	I	
6	bound	O	
7	to	O	
8	JCV	O	
9	and	O	
10	SV40	O	
11	origins	O	
12	of	O	
13	DNA	O	
14	replication	O	
15	.	O	

1	Children	O	
2	born	O	
3	from	O	
4	chronic	O	
5	alcoholic	O	
6	mothers	O	
7	have	O	
8	shown	O	
9	behavioral	O	
10	teratogenic	O	
11	effects	O	
12	more	O	
13	frequently	O	
14	than	O	
15	morphological	O	
16	malformations	O	
17	.	O	

1	Does	O	
2	afferent	O	
3	loop	O	
4	syndrome	O	
5	exist	O	
6	?]	O	
7	It	O	
8	is	O	
9	the	O	
10	author	O	
11	'	O	
12	s	O	
13	opinion	O	
14	that	O	
15	diagnosis	O	
16	of	O	
17	the	O	
18	"	O	
19	adducent	O	
20	loop	O	
21	syndrome	O	
22	"	O	
23	is	O	
24	unlikely	O	
25	to	O	
26	be	O	
27	correct	O	
28	in	O	
29	patients	O	
30	subjected	O	
31	to	O	
32	Billroth	O	
33	-	O	
34	II	O	
35	gastrectomy	O	
36	.	O	

1	Diary	O	
2	.	O	

1	Patients	O	
2	enrolled	O	
3	in	O	
4	the	O	
5	Integrilin	O	
6	to	O	
7	Minimize	O	
8	Platelet	O	
9	Aggregation	O	
10	and	O	
11	Coronary	O	
12	Thrombosis	O	
13	-	O	
14	II	O	
15	(	O	
16	IMPACT	O	
17	-	O	
18	II	O	
19	)	O	
20	trial	O	
21	were	O	
22	analyzed	O	
23	.	O	

1	The	O	
2	present	O	
3	study	O	
4	shows	O	
5	that	O	
6	phosphatidylinositol	B	
7	3	I	
8	-	I	
9	kinase	I	
10	-	O	
11	dependent	O	
12	p38	B	
13	kinase	I	
14	activation	O	
15	regulates	O	
16	Akt	B	
17	phosphorylation	O	
18	and	O	
19	activity	O	
20	in	O	
21	human	O	
22	neutrophils	O	
23	.	O	

1	Furthermore	O	
2	,	O	
3	the	O	
4	deletion	O	
5	of	O	
6	bcp	B	
7	from	O	
8	the	O	
9	chromosome	O	
10	had	O	
11	no	O	
12	effect	O	
13	on	O	
14	gcv	B	
15	-	O	
16	lacZ	B	
17	expression	O	
18	.	O	

1	Null	O	
2	alleles	O	
3	of	O	
4	SAS4	B	
5	and	O	
6	SAS5	B	
7	bypassed	O	
8	the	O	
9	role	O	
10	of	O	
11	the	O	
12	Abf1p	B	
13	binding	I	
14	site	I	
15	of	O	
16	the	O	
17	HMR	B	
18	-	I	
19	E	I	
20	silencer	I	
21	but	O	
22	not	O	
23	the	O	
24	role	O	
25	of	O	
26	the	O	
27	ACS	B	
28	or	O	
29	Rap1p	B	
30	binding	I	
31	site	I	
32	.	O	

1	The	O	
2	function	O	
3	of	O	
4	the	O	
5	C	O	
6	-	O	
7	terminal	O	
8	tail	O	
9	in	O	
10	telomere	O	
11	maintenance	O	
12	is	O	
13	not	O	
14	mediated	O	
15	through	O	
16	the	O	
17	RAP1	B	
18	interacting	I	
19	factor	I	
20	RIF1	I	
21	:	O	
22	rap1	B	
23	alleles	I	
24	defective	O	
25	in	O	
26	both	O	
27	the	O	
28	C	O	
29	-	O	
30	terminal	O	
31	tail	O	
32	and	O	
33	RIF1	B	
34	interaction	I	
35	domains	I	
36	have	O	
37	additive	O	
38	effects	O	
39	on	O	
40	telomere	O	
41	length	O	
42	.	O	

1	The	O	
2	coding	O	
3	region	O	
4	of	O	
5	mkh1	B	
6	is	O	
7	contained	O	
8	within	O	
9	a	O	
10	single	O	
11	exon	O	
12	encoding	O	
13	a	O	
14	1	O	
15	,	O	
16	116	O	
17	-	O	
18	amino	O	
19	-	O	
20	acid	O	
21	protein	O	
22	.	O	

1	Tolerance	O	
2	test	O	
3	of	O	
4	HB	O	
5	419	O	
6	in	O	
7	animal	O	
8	experiments	O	

1	Although	O	
2	there	O	
3	are	O	
4	no	O	
5	octamer	O	
6	elements	O	
7	in	O	
8	the	O	
9	adenovirus	O	
10	genome	O	
11	that	O	
12	are	O	
13	known	O	
14	to	O	
15	be	O	
16	important	O	
17	for	O	
18	transcription	O	
19	,	O	
20	there	O	
21	are	O	
22	octamer	O	
23	elements	O	
24	in	O	
25	the	O	
26	viral	O	
27	terminal	O	
28	repeat	O	
29	sequences	O	
30	.	O	

1	Therapeutic	O	
2	effects	O	
3	of	O	
4	cefpirome	O	
5	(	O	
6	HR	O	
7	810	O	
8	)	O	
9	on	O	
10	experimental	O	
11	mixed	O	
12	infections	O	
13	with	O	
14	Enterococcus	O	
15	faecalis	O	
16	and	O	
17	Escherichia	O	
18	coli	O	
19	in	O	
20	mice	O	
21	.	O	

1	A	O	
2	recombinant	O	
3	vector	O	
4	,	O	
5	p410	O	
6	+,	O	
7	was	O	
8	constructed	O	
9	which	O	
10	carried	O	
11	the	O	
12	BamHI	B	
13	-	I	
14	K	I	
15	fragment	I	
16	(	O	
17	nucleotides	O	
18	107565	O	
19	to	O	
20	112625	O	
21	of	O	
22	the	O	
23	B95	O	
24	-	O	
25	8	O	
26	strain	O	
27	,	O	
28	encoding	O	
29	the	O	
30	EBV	O	
31	-	O	
32	associated	O	
33	nuclear	O	
34	antigen	O	
35	EBNA	B	
36	-	I	
37	1	I	
38	),	O	
39	the	O	
40	cis	O	
41	-	O	
42	acting	O	
43	sequence	O	
44	from	O	
45	the	O	
46	BamHI	B	
47	-	I	
48	C	I	
49	fragment	I	
50	,	O	
51	and	O	
52	a	O	
53	dominant	O	
54	selectable	O	
55	marker	O	
56	gene	O	
57	encoding	O	
58	G	O	
59	-	O	
60	418	O	
61	resistance	O	
62	in	O	
63	animal	O	
64	cells	O	
65	.	O	

1	In	O	
2	this	O	
3	report	O	
4	,	O	
5	we	O	
6	investigate	O	
7	the	O	
8	mechanism	O	
9	underlying	O	
10	Ras	B	
11	activation	O	
12	upon	O	
13	stimulation	O	
14	of	O	
15	these	O	
16	two	O	
17	types	O	
18	of	O	
19	receptors	O	
20	in	O	
21	hematopoietic	O	
22	cells	O	
23	.	O	

1	This	O	
2	gave	O	
3	rise	O	
4	to	O	
5	RNA	O	
6	molecules	O	
7	with	O	
8	3	O	
9	'-	O	
10	untranslated	O	
11	regions	O	
12	of	O	
13	roughly	O	
14	375	O	
15	,	O	
16	655	O	
17	,	O	
18	and	O	
19	945	O	
20	base	O	
21	pairs	O	
22	.	O	

1	During	O	
2	sub	O	
3	-	O	
4	maximal	O	
5	exercise	O	
6	,	O	
7	DCR	O	
8	in	O	
9	the	O	
10	UT	O	
11	dogs	O	
12	decreased	O	
13	from	O	
14	a	O	
15	resting	O	
16	value	O	
17	of	O	
18	4	O	
19	.	O	
20	08	O	
21	+/-	O	
22	0	O	
23	.	O	
24	18	O	
25	mm	O	
26	Hg	O	
27	X	O	
28	ml	O	
29	-	O	
30	1	O	
31	X	O	
32	min	O	
33	-	O	
34	1	O	
35	to	O	
36	1	O	
37	.	O	
38	91	O	
39	+/-	O	
40	0	O	
41	.	O	
42	17	O	
43	mm	O	
44	Hg	O	
45	X	O	
46	ml	O	
47	-	O	
48	1	O	
49	X	O	
50	min	O	
51	-	O	
52	1	O	
53	at	O	
54	a	O	
55	workload	O	
56	of	O	
57	6	O	
58	.	O	
59	4	O	
60	kph	O	
61	(	O	
62	speed	O	
63	)/	O	
64	16	O	
65	%	O	
66	(	O	
67	grade	O	
68	).	O	

1	We	O	
2	describe	O	
3	a	O	
4	case	O	
5	of	O	
6	a	O	
7	perinephric	O	
8	abscess	O	
9	treated	O	
10	with	O	
11	amphotericin	O	
12	B	O	
13	and	O	
14	nephrectomy	O	
15	.	O	

1	Osteosarcoma	O	
2	caused	O	
3	by	O	
4	3	O	
5	,	O	
6	4	O	
7	-	O	
8	benzopyrene	O	

1	Polyadenylation	O	
2	of	O	
3	B4	B	
4	RNA	I	
5	,	O	
6	which	O	
7	occurs	O	
8	very	O	
9	early	O	
10	during	O	
11	maturation	O	
12	,	O	
13	is	O	
14	limited	O	
15	to	O	
16	150	O	
17	residues	O	
18	,	O	
19	and	O	
20	it	O	
21	is	O	
22	this	O	
23	number	O	
24	that	O	
25	is	O	
26	required	O	
27	for	O	
28	polysomal	O	
29	recruitment	O	
30	.	O	

1	The	O	
2	results	O	
3	indicate	O	
4	that	O	
5	rep	B	
6	strongly	O	
7	enhances	O	
8	the	O	
9	function	O	
10	of	O	
11	negative	O	
12	regulatory	O	
13	elements	O	
14	of	O	
15	the	O	
16	LTR	O	
17	.	O	

1	Microcomputer	O	
2	management	O	
3	of	O	
4	chronic	O	
5	hepatitis	O	
6	B	O	
7	virus	O	
8	asymptomatic	O	
9	patients	O	

1	Substitution	O	
2	of	O	
3	bulky	O	
4	hydrophobic	O	
5	residues	O	
6	with	O	
7	charged	O	
8	residues	O	
9	within	O	
10	PEP1	B	
11	affects	O	
12	the	O	
13	fusion	O	
14	activity	O	
15	of	O	
16	the	O	
17	S	B	
18	protein	I	
19	without	O	
20	affecting	O	
21	processing	O	
22	and	O	
23	surface	O	
24	expression	O	
25	.	O	

1	Modification	O	
2	by	O	
3	this	O	
4	latter	O	
5	compound	O	
6	was	O	
7	so	O	
8	extensive	O	
9	that	O	
10	the	O	
11	amount	O	
12	of	O	
13	membrane	O	
14	-	O	
15	associated	O	
16	N	O	
17	-	O	
18	myristoylated	O	
19	protein	O	
20	was	O	
21	decreased	O	
22	.	O	

1	None	O	
2	of	O	
3	the	O	
4	patients	O	
5	was	O	
6	obese	O	
7	.	O	

1	Computer	O	
2	software	O	
3	assisted	O	
4	ordering	O	
5	(	O	
6	CSAO	O	
7	)	O	
8	was	O	
9	developed	O	
10	to	O	
11	integrate	O	
12	PN	O	
13	Ca	O	
14	:	O	
15	P	O	
16	solubility	O	
17	with	O	
18	clinical	O	
19	data	O	
20	to	O	
21	improve	O	
22	parenteral	O	
23	Ca	O	
24	and	O	
25	P	O	
26	administration	O	
27	.	O	

1	Unrecognized	O	
2	amnionitis	O	
3	and	O	
4	prematurity	O	
5	:	O	
6	a	O	
7	preliminary	O	
8	report	O	
9	.	O	

1	In	O	
2	view	O	
3	of	O	
4	the	O	
5	presence	O	
6	of	O	
7	SECIS	O	
8	elements	O	
9	in	O	
10	the	O	
11	open	O	
12	reading	O	
13	frames	O	
14	(	O	
15	ORFs	O	
16	)	O	
17	of	O	
18	bacterial	B	
19	selenoproteins	I	
20	,	O	
21	we	O	
22	examine	O	
23	the	O	
24	effects	O	
25	in	O	
26	the	O	
27	type	B	
28	1	I	
29	deiodinase	I	
30	of	O	
31	extending	O	
32	the	O	
33	ORF	O	
34	into	O	
35	the	O	
36	SECIS	O	
37	element	O	
38	,	O	
39	and	O	
40	find	O	
41	that	O	
42	this	O	
43	dramatically	O	
44	inhibits	O	
45	SECIS	O	
46	function	O	
47	.	O	

1	Ten	O	
2	volunteers	O	
3	were	O	
4	tested	O	
5	at	O	
6	18	O	
7	,	O	
8	000	O	
9	ft	O	
10	(	O	
11	5	O	
12	,	O	
13	486	O	
14	m	O	
15	),	O	
16	and	O	
17	through	O	
18	12	O	
19	,	O	
20	000	O	
21	,	O	
22	8	O	
23	,	O	
24	000	O	
25	,	O	
26	and	O	
27	5	O	
28	,	O	
29	000	O	
30	ft	O	
31	(	O	
32	3	O	
33	,	O	
34	657	O	
35	,	O	
36	2	O	
37	,	O	
38	438	O	
39	,	O	
40	and	O	
41	1	O	
42	,	O	
43	524	O	
44	m	O	
45	)	O	
46	with	O	
47	directional	O	
48	sounds	O	
49	recorded	O	
50	via	O	
51	a	O	
52	dummy	O	
53	head	O	
54	microphone	O	
55	and	O	
56	presented	O	
57	binaurally	O	
58	.	O	

1	In	O	
2	the	O	
3	whole	O	
4	group	O	
5	,	O	
6	basal	O	
7	GH	B	
8	and	O	
9	somatomedin	B	
10	-	I	
11	C	I	
12	levels	O	
13	decreased	O	
14	from	O	
15	a	O	
16	mean	O	
17	(+/-	O	
18	standard	O	
19	error	O	
20	of	O	
21	the	O	
22	mean	O	
23	)	O	
24	of	O	
25	52	O	
26	.	O	
27	3	O	
28	+/-	O	
29	12	O	
30	.	O	
31	7	O	
32	to	O	
33	11	O	
34	.	O	
35	1	O	
36	+/-	O	
37	6	O	
38	.	O	
39	3	O	
40	ng	O	
41	/	O	
42	ml	O	
43	and	O	
44	from	O	
45	7	O	
46	.	O	
47	6	O	
48	+/-	O	
49	0	O	
50	.	O	
51	7	O	
52	to	O	
53	2	O	
54	.	O	
55	5	O	
56	+/-	O	
57	0	O	
58	.	O	
59	5	O	
60	U	O	
61	/	O	
62	ml	O	
63	,	O	
64	respectively	O	
65	.	O	

1	To	O	
2	identify	O	
3	critical	O	
4	regions	O	
5	mediating	O	
6	growth	O	
7	signal	O	
8	transduction	O	
9	by	O	
10	hG	B	
11	-	I	
12	CSFR	I	
13	,	O	
14	deletions	O	
15	or	O	
16	site	O	
17	-	O	
18	directed	O	
19	amino	O	
20	acid	O	
21	substitutions	O	
22	were	O	
23	introduced	O	
24	into	O	
25	the	O	
26	cytoplasmic	O	
27	domain	O	
28	of	O	
29	hG	B	
30	-	I	
31	CSFR	I	
32	,	O	
33	and	O	
34	the	O	
35	mutant	O	
36	cDNAs	O	
37	were	O	
38	transfected	O	
39	into	O	
40	the	O	
41	murine	B	
42	interleukin	I	
43	-	I	
44	3	I	
45	(	O	
46	IL	B	
47	-	I	
48	3	I	
49	)-	O	
50	dependent	O	
51	Ba	O	
52	/	O	
53	F3	O	
54	and	O	
55	FDCP	O	
56	cell	O	
57	lines	O	
58	.	O	

1	Because	O	
2	decreases	O	
3	in	O	
4	the	O	
5	disfluency	O	
6	rates	O	
7	of	O	
8	stutterers	O	
9	were	O	
10	observed	O	
11	during	O	
12	the	O	
13	presentation	O	
14	of	O	
15	all	O	
16	three	O	
17	stimulus	O	
18	words	O	
19	,	O	
20	the	O	
21	data	O	
22	failed	O	
23	to	O	
24	support	O	
25	the	O	
26	operant	O	
27	model	O	
28	.	O	

1	Measurement	O	
2	of	O	
3	anti	B	
4	-	I	
5	HCV	I	
6	IgM	I	
7	antibodies	I	
8	with	O	
9	an	O	
10	experimental	O	
11	kit	O	

1	Erythrocyte	O	
2	AA	O	
3	in	O	
4	FO	O	
5	+	O	
6	EPO	B	
7	-	O	
8	supplemented	O	
9	infants	O	
10	remained	O	
11	low	O	
12	and	O	
13	below	O	
14	breast	O	
15	-	O	
16	and	O	
17	placebo	O	
18	formula	O	
19	-	O	
20	fed	O	
21	levels	O	
22	.	O	

1	These	O	
2	data	O	
3	are	O	
4	consistent	O	
5	with	O	
6	the	O	
7	idea	O	
8	that	O	
9	the	O	
10	neuron	B	
11	-	I	
12	specific	I	
13	SCG10	I	
14	gene	I	
15	evolved	O	
16	by	O	
17	duplication	O	
18	and	O	
19	modification	O	
20	of	O	
21	the	O	
22	more	O	
23	broadly	O	
24	expressed	O	
25	stathmin	B	
26	/	O	
27	Lap18	B	
28	gene	O	
29	.	O	

1	Paf1p	B	
2	may	O	
3	therefore	O	
4	be	O	
5	required	O	
6	for	O	
7	both	O	
8	positive	O	
9	and	O	
10	negative	O	
11	regulation	O	
12	of	O	
13	subsets	O	
14	of	O	
15	yeast	O	
16	genes	O	
17	.	O	

1	To	O	
2	determine	O	
3	whether	O	
4	food	O	
5	and	O	
6	/	O	
7	or	O	
8	water	O	
9	in	O	
10	the	O	
11	gastrointestinal	O	
12	tract	O	
13	affects	O	
14	restitution	O	
15	of	O	
16	blood	O	
17	volume	O	
18	and	O	
19	plasma	O	
20	protein	O	
21	after	O	
22	hemorrhage	O	
23	,	O	
24	fed	O	
25	and	O	
26	24	O	
27	-	O	
28	h	O	
29	-	O	
30	fasted	O	
31	awake	O	
32	rats	O	
33	received	O	
34	a	O	
35	20	O	
36	ml	O	
37	.	O	
38	kg	O	
39	-	O	
40	1	O	
41	x	O	
42	3	O	
43	min	O	
44	-	O	
45	1	O	
46	hemorrhage	O	
47	,	O	
48	and	O	
49	restitution	O	
50	of	O	
51	blood	O	
52	volume	O	
53	was	O	
54	measured	O	
55	by	O	
56	Evans	O	
57	blue	O	
58	dye	O	
59	and	O	
60	dilution	O	
61	of	O	
62	hematocrit	O	
63	.	O	

1	The	O	
2	Cut9	B	
3	subunit	I	
4	is	O	
5	likely	O	
6	to	O	
7	be	O	
8	a	O	
9	target	O	
10	for	O	
11	regulating	O	
12	APC	B	
13	/	I	
14	cyclosome	I	
15	function	O	
16	through	O	
17	protein	O	
18	-	O	
19	protein	O	
20	interactions	O	
21	and	O	
22	phosphorylation	O	
23	.	O	

1	Polyglactin	O	
2	910	O	
3	suture	O	
4	absorption	O	
5	and	O	
6	the	O	
7	role	O	
8	of	O	
9	cellular	O	
10	enzymes	O	
11	.	O	

1	The	O	
2	N	O	
3	-	O	
4	terminal	O	
5	115	O	
6	amino	O	
7	acids	O	
8	correspond	O	
9	to	O	
10	a	O	
11	putative	O	
12	DNA	O	
13	-	O	
14	binding	O	
15	domain	O	
16	and	O	
17	show	O	
18	significant	O	
19	sequence	O	
20	similarity	O	
21	with	O	
22	other	O	
23	cloned	O	
24	IFN	B	
25	response	I	
26	factors	I	
27	(	O	
28	IRF	B	
29	-	I	
30	1	I	
31	and	O	
32	IRF	B	
33	-	I	
34	2	I	
35	).	O	

1	Active	O	
2	lambda	B	
3	and	I	
4	kappa	I	
5	antibody	I	
6	gene	I	
7	rearrangement	O	
8	in	O	
9	Abelson	O	
10	murine	O	
11	leukemia	O	
12	virus	O	
13	-	O	
14	transformed	O	
15	pre	O	
16	-	O	
17	B	O	
18	cell	O	
19	lines	O	
20	.	O	

1	In	O	
2	another	O	
3	study	O	
4	,	O	
5	intravenous	O	
6	administration	O	
7	of	O	
8	devazepide	O	
9	,	O	
10	a	O	
11	specific	O	
12	cholecystokinin	B	
13	-	I	
14	A	I	
15	receptor	I	
16	antagonist	O	
17	,	O	
18	at	O	
19	a	O	
20	dose	O	
21	of	O	
22	0	O	
23	.	O	
24	1	O	
25	mg	O	
26	/	O	
27	kg	O	
28	/	O	
29	hr	O	
30	was	O	
31	begun	O	
32	15	O	
33	min	O	
34	before	O	
35	postprandial	O	
36	saline	O	
37	intake	O	
38	and	O	
39	continued	O	
40	for	O	
41	1	O	
42	hr	O	
43	.	O	

1	With	O	
2	a	O	
3	view	O	
4	to	O	
5	identifying	O	
6	other	O	
7	important	O	
8	U14	B	
9	interactions	O	
10	,	O	
11	a	O	
12	stem	O	
13	-	O	
14	loop	O	
15	domain	O	
16	required	O	
17	for	O	
18	activity	O	
19	of	O	
20	Saccharomyces	B	
21	cerevisiae	I	
22	U14	I	
23	RNAs	I	
24	(	O	
25	the	O	
26	Y	O	
27	domain	O	
28	)	O	
29	was	O	
30	first	O	
31	subjected	O	
32	to	O	
33	detailed	O	
34	mutational	O	
35	analysis	O	
36	.	O	

1	Taken	O	
2	together	O	
3	,	O	
4	our	O	
5	data	O	
6	suggest	O	
7	that	O	
8	prostate	O	
9	carcinomas	O	
10	with	O	
11	the	O	
12	Ras	B	
13	/	O	
14	MAPK	B	
15	pathway	O	
16	activation	O	
17	might	O	
18	have	O	
19	a	O	
20	selective	O	
21	growth	O	
22	advantage	O	
23	by	O	
24	autocrine	O	
25	TGF	B	
26	-	I	
27	beta1	I	
28	production	O	
29	.	O	

1	We	O	
2	have	O	
3	tested	O	
4	the	O	
5	function	O	
6	of	O	
7	two	O	
8	potential	O	
9	NF	B	
10	-	I	
11	kappaB	I	
12	-	I	
13	like	I	
14	sites	I	
15	present	O	
16	in	O	
17	the	O	
18	PAI	B	
19	-	I	
20	2	I	
21	proximal	I	
22	promoter	I	
23	for	O	
24	responsiveness	O	
25	to	O	
26	TNFalpha	B	
27	using	O	
28	chloramphenicol	B	
29	acetyl	I	
30	transferase	I	
31	reporter	I	
32	gene	I	
33	deletion	O	
34	and	O	
35	mutation	O	
36	analyses	O	
37	.	O	

1	No	O	
2	post	O	
3	-	O	
4	operative	O	
5	haemorrhages	O	
6	from	O	
7	the	O	
8	prostheses	O	
9	were	O	
10	observed	O	
11	.	O	

1	A	O	
2	.	O	

1	Between	O	
2	acoR	B	
3	and	O	
4	acoXABC	B	
5	,	O	
6	two	O	
7	different	O	
8	types	O	
9	of	O	
10	sequences	O	
11	with	O	
12	dual	O	
13	rotational	O	
14	symmetry	O	
15	[	O	
16	CAC	O	
17	-(	O	
18	N11	O	
19	to	O	
20	N18	O	
21	)-	O	
22	GTG	O	
23	and	O	
24	TGT	O	
25	-(	O	
26	N10	O	
27	to	O	
28	N14	O	
29	)-	O	
30	ACA	O	
31	]	O	
32	were	O	
33	found	O	
34	;	O	
35	these	O	
36	sequences	O	
37	are	O	
38	similar	O	
39	to	O	
40	NtrC	B	
41	and	O	
42	NifA	B	
43	upstream	I	
44	activator	I	
45	sequences	I	
46	,	O	
47	respectively	O	
48	.	O	

1	A	O	
2	genetic	O	
3	screen	O	
4	applied	O	
5	to	O	
6	mutants	O	
7	in	O	
8	the	O	
9	branch	O	
10	site	O	
11	region	O	
12	shows	O	
13	that	O	
14	all	O	
15	positions	O	
16	in	O	
17	the	O	
18	conserved	O	
19	TACTAAC	O	
20	sequence	O	
21	are	O	
22	important	O	
23	for	O	
24	intron	O	
25	recognition	O	
26	.	O	

1	Determination	O	
2	of	O	
3	lead	O	
4	in	O	
5	blood	O	
6	.	O	

1	The	O	
2	differential	O	
3	investigation	O	
4	of	O	
5	lipoproteins	O	
6	,	O	
7	however	O	
8	,	O	
9	showed	O	
10	that	O	
11	the	O	
12	high	B	
13	-	I	
14	density	I	
15	lipoprotein	I	
16	(	O	
17	HDL	B	
18	)	O	
19	fractions	O	
20	are	O	
21	absolutely	O	
22	or	O	
23	relatively	O	
24	decreased	O	
25	with	O	
26	respect	O	
27	to	O	
28	low	B	
29	-	I	
30	density	I	
31	lipoproteins	I	
32	(	O	
33	LDL	B	
34	)	O	
35	in	O	
36	cerebral	O	
37	infarcts	O	
38	and	O	
39	in	O	
40	transient	O	
41	ischaemic	O	
42	attacks	O	
43	.	O	

1	RESULTS	O	
2	:	O	
3	No	O	
4	significant	O	
5	deformation	O	
6	in	O	
7	vertebral	O	
8	artery	O	
9	flow	O	
10	was	O	
11	noted	O	
12	in	O	
13	the	O	
14	flexion	O	
15	-	O	
16	distraction	O	
17	Stage	O	
18	I	O	
19	injuries	O	
20	within	O	
21	the	O	
22	physiologic	O	
23	range	O	
24	of	O	
25	cervical	O	
26	flexion	O	
27	.	O	

1	COGLAB	O	
2	includes	O	
3	measures	O	
4	of	O	
5	preattentional	O	
6	,	O	
7	attentional	O	
8	,	O	
9	conceptual	O	
10	,	O	
11	and	O	
12	psychomotor	O	
13	performance	O	
14	.	O	

1	Assays	O	
2	of	O	
3	total	O	
4	cholesterol	O	
5	as	O	
6	well	O	
7	as	O	
8	the	O	
9	HDL	B	
10	,	O	
11	HDL2	B	
12	,	O	
13	LDL	B	
14	,	O	
15	triglycerides	O	
16	,	O	
17	endothelin	B	
18	-	I	
19	1	I	
20	,	O	
21	lipoprotein	O	
22	(	O	
23	a	O	
24	),	O	
25	estradiol	O	
26	and	O	
27	FSH	B	
28	were	O	
29	also	O	
30	obtained	O	
31	at	O	
32	baseline	O	
33	before	O	
34	receiving	O	
35	ERT	O	
36	and	O	
37	after	O	
38	3	O	
39	months	O	
40	of	O	
41	ERT	O	
42	.	O	

1	The	O	
2	Myc	B	
3	LZ	I	
4	was	O	
5	found	O	
6	to	O	
7	prevent	O	
8	homodimeric	O	
9	interactions	O	
10	,	O	
11	thus	O	
12	explaining	O	
13	Myc	B	
14	inability	O	
15	to	O	
16	homodimerize	O	
17	efficiently	O	
18	.	O	

1	To	O	
2	study	O	
3	the	O	
4	origin	O	
5	of	O	
6	different	O	
7	fMLF	B	
8	-	I	
9	R	I	
10	transcripts	I	
11	,	O	
12	the	O	
13	genetic	O	
14	linkage	O	
15	of	O	
16	chemotactic	O	
17	receptor	O	
18	genes	O	
19	,	O	
20	and	O	
21	the	O	
22	regulation	O	
23	of	O	
24	fMLF	B	
25	-	I	
26	R	I	
27	gene	I	
28	expression	O	
29	,	O	
30	we	O	
31	determined	O	
32	the	O	
33	copy	O	
34	number	O	
35	,	O	
36	chromosomal	O	
37	location	O	
38	,	O	
39	structural	O	
40	organization	O	
41	,	O	
42	and	O	
43	5	O	
44	'-	O	
45	flanking	O	
46	sequence	O	
47	of	O	
48	the	O	
49	human	B	
50	fMLF	I	
51	-	I	
52	R	I	
53	gene	I	
54	.	O	

1	The	O	
2	expression	O	
3	of	O	
4	the	O	
5	putative	O	
6	operon	O	
7	bglPH	B	
8	of	O	
9	Bacillus	O	
10	subtilis	O	
11	was	O	
12	studied	O	
13	by	O	
14	using	O	
15	bglP	O	
16	'-	O	
17	lacZ	B	
18	transcriptional	O	
19	fusions	O	
20	.	O	

1	Fifty	O	
2	-	O	
3	seven	O	
4	patients	O	
5	aged	O	
6	<	O	
7	55	O	
8	years	O	
9	with	O	
10	acute	O	
11	lymphoblastic	O	
12	leukemia	O	
13	(	O	
14	ALL	O	
15	)	O	
16	in	O	
17	second	O	
18	or	O	
19	third	O	
20	bone	O	
21	marrow	O	
22	(	O	
23	BM	O	
24	)	O	
25	relapse	O	
26	or	O	
27	refractory	O	
28	to	O	
29	first	O	
30	-	O	
31	line	O	
32	therapy	O	
33	were	O	
34	enrolled	O	
35	in	O	
36	an	O	
37	Italian	O	
38	cooperative	O	
39	study	O	
40	.	O	

1	This	O	
2	complex	O	
3	interacts	O	
4	at	O	
5	the	O	
6	GTPase	B	
7	domain	I	
8	in	O	
9	the	O	
10	large	O	
11	subunit	O	
12	rRNA	O	
13	,	O	
14	overlapping	O	
15	the	O	
16	binding	O	
17	site	O	
18	of	O	
19	the	O	
20	protein	B	
21	L11	I	
22	-	I	
23	like	I	
24	eukaryotic	I	
25	counterpart	I	
26	(	O	
27	Saccharomyces	B	
28	cerevisiae	I	
29	protein	I	
30	L15	I	
31	and	O	
32	mammalian	B	
33	protein	I	
34	L12	I	
35	).	O	

1	The	O	
2	seco	O	
3	-	O	
4	steroid	O	
5	hormone	O	
6	1	O	
7	,	O	
8	25	O	
9	-	O	
10	dihydroxyvitamin	O	
11	D3	O	
12	is	O	
13	known	O	
14	to	O	
15	induce	O	
16	the	O	
17	expression	O	
18	of	O	
19	a	O	
20	calcium	O	
21	binding	O	
22	protein	O	
23	termed	O	
24	calbindin	B	
25	-	I	
26	D28K	I	
27	in	O	
28	a	O	
29	variety	O	
30	of	O	
31	target	O	
32	tissues	O	
33	.	O	

1	TOR2	B	
2	is	O	
3	part	O	
4	of	O	
5	two	O	
6	related	O	
7	signaling	O	
8	pathways	O	
9	coordinating	O	
10	cell	O	
11	growth	O	
12	in	O	
13	Saccharomyces	O	
14	cerevisiae	O	
15	.	O	

1	Multiple	O	
2	SWI6	B	
3	-	O	
4	dependent	O	
5	cis	O	
6	-	O	
7	acting	O	
8	elements	O	
9	control	O	
10	SWI4	B	
11	transcription	O	
12	through	O	
13	the	O	
14	cell	O	
15	cycle	O	
16	.	O	

1	Although	O	
2	olfactory	O	
3	associative	O	
4	conditioning	O	
5	in	O	
6	newborn	O	
7	rats	O	
8	produces	O	
9	marked	O	
10	structural	O	
11	and	O	
12	functional	O	
13	changes	O	
14	in	O	
15	the	O	
16	olfactory	O	
17	bulb	O	
18	,	O	
19	recent	O	
20	evidence	O	
21	suggests	O	
22	that	O	
23	extrabulbar	O	
24	circuits	O	
25	must	O	
26	be	O	
27	involved	O	
28	in	O	
29	storing	O	
30	these	O	
31	early	O	
32	memories	O	
33	.	O	

1	The	O	
2	murine	B	
3	mutation	I	
4	dominant	I	
5	white	I	
6	spotting	I	
7	(	O	
8	W	B	
9	)	O	
10	is	O	
11	in	O	
12	the	O	
13	proto	O	
14	-	O	
15	oncogene	O	
16	,	O	
17	c	B	
18	-	I	
19	kit	I	
20	.	O	

1	Kindling	O	
2	of	O	
3	the	O	
4	primary	O	
5	visual	O	
6	cortex	O	
7	(	O	
8	VC	O	
9	)	O	
10	was	O	
11	compared	O	
12	with	O	
13	that	O	
14	of	O	
15	the	O	
16	amygdala	O	
17	in	O	
18	cats	O	
19	.	O	

1	Effect	O	
2	of	O	
3	biliary	O	
4	obstruction	O	
5	and	O	
6	cholangitis	O	
7	on	O	
8	serum	B	
9	SPan	I	
10	-	I	
11	1	I	
12	level	O	

1	Pharmacokinetic	O	
2	parameters	O	
3	were	O	
4	similar	O	
5	to	O	
6	values	O	
7	given	O	
8	in	O	
9	the	O	
10	literature	O	
11	for	O	
12	intravenous	O	
13	(	O	
14	IV	O	
15	)	O	
16	or	O	
17	intraarterial	O	
18	(	O	
19	IA	O	
20	)	O	
21	bolus	O	
22	MMC	O	
23	injections	O	
24	(	O	
25	Tmax	O	
26	=	O	
27	7	O	
28	.	O	
29	0	O	
30	min	O	
31	following	O	
32	the	O	
33	beginning	O	
34	of	O	
35	MMC	O	
36	infusion	O	
37	,	O	
38	Vss	O	
39	=	O	
40	0	O	
41	.	O	
42	57	O	
43	1	O	
44	/	O	
45	kg	O	
46	,	O	
47	C1	O	
48	=	O	
49	8	O	
50	.	O	
51	9	O	
52	ml	O	
53	/	O	
54	min	O	
55	.	O	
56	kg	O	
57	,	O	
58	T1	O	
59	/	O	
60	2	O	
61	alpha	O	
62	=	O	
63	8	O	
64	.	O	
65	3	O	
66	min	O	
67	,	O	
68	T1	O	
69	/	O	
70	2	O	
71	beta	O	
72	=	O	
73	58	O	
74	.	O	
75	6	O	
76	min	O	
77	).	O	

1	The	O	
2	RNA	B	
3	polymerase	I	
4	III	I	
5	-	I	
6	recruiting	I	
7	factor	I	
8	TFIIIB	I	
9	induces	O	
10	a	O	
11	DNA	O	
12	bend	O	
13	between	O	
14	the	O	
15	TATA	O	
16	box	O	
17	and	O	
18	the	O	
19	transcriptional	O	
20	start	O	
21	site	O	
22	.	O	

1	Melatonin	O	
2	and	O	
3	seasonality	O	
4	:	O	
5	filling	O	
6	the	O	
7	gap	O	
8	.	O	

1	A	O	
2	case	O	
3	of	O	
4	a	O	
5	dense	O	
6	epidermoid	O	
7	cyst	O	
8	of	O	
9	the	O	
10	suprasellar	O	
11	cistern	O	
12	is	O	
13	presented	O	
14	.	O	

1	One	O	
2	hundred	O	
3	twenty	O	
4	units	O	
5	of	O	
6	deglycerolized	O	
7	red	O	
8	blood	O	
9	cells	O	
10	,	O	
11	some	O	
12	with	O	
13	glycerol	O	
14	added	O	
15	so	O	
16	as	O	
17	to	O	
18	exceed	O	
19	an	O	
20	acceptable	O	
21	1	O	
22	%	O	
23	glycerol	O	
24	content	O	
25	,	O	
26	had	O	
27	measurements	O	
28	made	O	
29	of	O	
30	the	O	
31	post	O	
32	-	O	
33	wash	O	
34	supernatant	O	
35	fluid	O	
36	by	O	
37	refractive	O	
38	index	O	
39	and	O	
40	osmometry	O	
41	.	O	

1	A	O	
2	data	O	
3	base	O	
4	homology	O	
5	search	O	
6	revealed	O	
7	that	O	
8	the	O	
9	predicted	O	
10	ER1	B	
11	amino	O	
12	acid	O	
13	sequence	O	
14	contains	O	
15	three	O	
16	regions	O	
17	of	O	
18	similarity	O	
19	to	O	
20	the	O	
21	rat	O	
22	and	O	
23	human	O	
24	proteins	O	
25	encoded	O	
26	by	O	
27	the	O	
28	metastasis	O	
29	-	O	
30	associated	O	
31	gene	O	
32	,	O	
33	mta1	B	
34	,	O	
35	and	O	
36	two	O	
37	regions	O	
38	of	O	
39	similarity	O	
40	to	O	
41	the	O	
42	Caenorhabditis	O	
43	elegans	O	
44	sequence	O	
45	that	O	
46	is	O	
47	similar	O	
48	to	O	
49	mta1	B	
50	.	O	

1	UVA	O	
2	-	O	
3	induced	O	
4	melanocytic	O	
5	lesions	O	
6	.	O	

1	Effect	O	
2	of	O	
3	indomethacin	O	
4	and	O	
5	prostaglandin	O	
6	F2	O	
7	alpha	O	
8	on	O	
9	parturition	O	
10	in	O	
11	swine	O	
12	.	O	

1	Reduction	O	
2	in	O	
3	dosage	O	
4	restored	O	
5	normal	O	
6	taste	O	
7	sense	O	
8	in	O	
9	all	O	
10	three	O	
11	,	O	
12	but	O	
13	in	O	
14	two	O	
15	the	O	
16	drug	O	
17	had	O	
18	to	O	
19	be	O	
20	discontinued	O	
21	because	O	
22	of	O	
23	persisting	O	
24	high	O	
25	transaminase	O	
26	levels	O	
27	.	O	

1	RXR	B	
2	-	I	
3	gamma	I	
4	expression	O	
5	produced	O	
6	significant	O	
7	reduction	O	
8	in	O	
9	levels	O	
10	of	O	
11	RA	O	
12	-	O	
13	responsive	O	
14	genes	O	
15	including	O	
16	the	O	
17	cyclin	B	
18	-	I	
19	dependent	I	
20	kinase	I	
21	inhibitors	O	
22	p21Cip1	B	
23	/	O	
24	WAF1	B	
25	and	O	
26	p27Kip1	B	
27	,	O	
28	resulting	O	
29	in	O	
30	increased	O	
31	cdc2	B	
32	and	O	
33	cdk2	B	
34	kinase	I	
35	activity	O	
36	and	O	
37	RB	B	
38	phosphorylation	O	
39	.	O	

1	To	O	
2	lower	O	
3	the	O	
4	current	O	
5	high	O	
6	incidence	O	
7	of	O	
8	NANB	O	
9	-	O	
10	induced	O	
11	PTH	O	
12	,	O	
13	in	O	
14	1986	O	
15	,	O	
16	the	O	
17	American	O	
18	Association	O	
19	of	O	
20	Blood	O	
21	Banks	O	
22	(	O	
23	AABB	O	
24	)	O	
25	recommended	O	
26	testing	O	
27	for	O	
28	these	O	
29	PTH	O	
30	-	O	
31	associated	O	
32	"	O	
33	surrogate	O	
34	"	O	
35	markers	O	
36	on	O	
37	all	O	
38	donated	O	
39	units	O	
40	of	O	
41	blood	O	
42	.	O	

1	As	O	
2	with	O	
3	the	O	
4	heterologous	O	
5	DNA	O	
6	binding	O	
7	domain	O	
8	,	O	
9	MZF	B	
10	-	I	
11	1	I	
12	represses	O	
13	reporter	O	
14	gene	O	
15	expression	O	
16	in	O	
17	nonhematopoietic	O	
18	cell	O	
19	lines	O	
20	and	O	
21	activates	O	
22	expression	O	
23	in	O	
24	hematopoietic	O	
25	cell	O	
26	lines	O	
27	.	O	

1	The	O	
2	lymph	O	
3	nodes	O	
4	from	O	
5	two	O	
6	of	O	
7	the	O	
8	patients	O	
9	with	O	
10	rheumatoid	O	
11	arthritis	O	
12	contained	O	
13	numerous	O	
14	sarcoid	O	
15	like	O	
16	granulomata	O	
17	,	O	
18	further	O	
19	indicating	O	
20	a	O	
21	possible	O	
22	association	O	
23	between	O	
24	sarcoidosis	O	
25	and	O	
26	rheumatoid	O	
27	arthritis	O	
28	.	O	

1	Furthermore	O	
2	,	O	
3	overexpression	O	
4	of	O	
5	AML3	B	
6	/	O	
7	CBFalpha1	B	
8	could	O	
9	rescue	O	
10	the	O	
11	AML1	B	
12	-	O	
13	ETO	B	
14	repression	O	
15	.	O	

1	The	O	
2	core	O	
3	of	O	
4	this	O	
5	enhancer	O	
6	contains	O	
7	two	O	
8	evolutionarily	O	
9	conserved	O	
10	binding	O	
11	sites	O	
12	for	O	
13	the	O	
14	homeodomain	B	
15	protein	I	
16	Tinman	I	
17	(	O	
18	Tin	B	
19	),	O	
20	expressed	O	
21	in	O	
22	developing	O	
23	cardiac	O	
24	,	O	
25	somatic	O	
26	,	O	
27	and	O	
28	visceral	O	
29	muscle	O	
30	lineages	O	
31	.	O	

1	Thus	O	
2	,	O	
3	SPECT	O	
4	was	O	
5	not	O	
6	as	O	
7	sensitive	O	
8	as	O	
9	PET	O	
10	in	O	
11	this	O	
12	activation	O	
13	task	O	
14	.	O	

1	Flurazepam	O	
2	thus	O	
3	appears	O	
4	to	O	
5	be	O	
6	an	O	
7	effective	O	
8	hypnotic	O	
9	drug	O	
10	with	O	
11	the	O	
12	optimum	O	
13	dose	O	
14	for	O	
15	use	O	
16	in	O	
17	general	O	
18	practice	O	
19	being	O	
20	15	O	
21	mg	O	
22	at	O	
23	night	O	
24	.	O	

1	Down	O	
2	-	O	
3	regulation	O	
4	of	O	
5	IRS	B	
6	-	I	
7	1	I	
8	is	O	
9	linked	O	
10	to	O	
11	its	O	
12	serine	O	
13	phosphorylation	O	
14	dependent	O	
15	on	O	
16	PI	B	
17	3	I	
18	-	I	
19	kinase	I	
20	activity	O	
21	and	O	
22	appears	O	
23	required	O	
24	for	O	
25	differentiation	O	
26	to	O	
27	occur	O	
28	,	O	
29	as	O	
30	IRS	B	
31	-	I	
32	1	I	
33	is	O	
34	not	O	
35	modified	O	
36	and	O	
37	continues	O	
38	to	O	
39	accumulate	O	
40	in	O	
41	a	O	
42	nondifferentiating	O	
43	myoblast	O	
44	cell	O	
45	line	O	
46	.	O	

1	Determination	O	
2	of	O	
3	aortic	O	
4	distensibility	O	
5	and	O	
6	its	O	
7	variations	O	
8	in	O	
9	arterial	O	
10	hypertension	O	
11	.	O	

1	The	O	
2	degree	O	
3	of	O	
4	hypoperfusion	O	
5	was	O	
6	slightly	O	
7	related	O	
8	to	O	
9	decrease	O	
10	in	O	
11	FEV1	O	
12	.	O	
13	0	O	
14	%,	O	
15	V25	O	
16	and	O	
17	PaO2	O	
18	and	O	
19	increase	O	
20	in	O	
21	circulating	O	
22	blood	O	
23	volume	O	
24	and	O	
25	peripheral	O	
26	red	O	
27	blood	O	
28	cell	O	
29	counts	O	
30	.	O	

1	A	O	
2	developmentally	O	
3	regulated	O	
4	4	O	
5	.	O	
6	6	O	
7	kb	O	
8	mRNA	O	
9	is	O	
10	recognized	O	
11	on	O	
12	Northern	O	
13	blots	O	
14	of	O	
15	oocyte	O	
16	RNA	O	
17	using	O	
18	the	O	
19	X	O	
20	.	O	
21	laevis	O	
22	cDNA	O	
23	.	O	

1	The	O	
2	nucleosomal	O	
3	response	O	
4	associated	O	
5	with	O	
6	immediate	B	
7	-	I	
8	early	I	
9	gene	I	
10	induction	O	
11	is	O	
12	mediated	O	
13	via	O	
14	alternative	O	
15	MAP	B	
16	kinase	I	
17	cascades	I	
18	:	O	
19	MSK1	B	
20	as	O	
21	a	O	
22	potential	O	
23	histone	B	
24	H3	I	
25	/	O	
26	HMG	B	
27	-	I	
28	14	I	
29	kinase	O	
30	.	O	

1	Lymphatics	O	
2	in	O	
3	the	O	
4	aorta	O	
5	of	O	
6	rats	O	
7	treated	O	
8	with	O	
9	a	O	
10	soy	O	
11	-	O	
12	bean	O	
13	oil	O	
14	extract	O	
15	(	O	
16	lipofundin	O	
17	).	O	

1	BACKGROUND	O	
2	:	O	
3	It	O	
4	is	O	
5	generally	O	
6	accepted	O	
7	that	O	
8	smoking	O	
9	increases	O	
10	blood	O	
11	pressure	O	
12	and	O	
13	inhibits	O	
14	muscle	O	
15	sympathetic	O	
16	nerve	O	
17	activity	O	
18	(	O	
19	SNA	O	
20	).	O	

1	In	O	
2	order	O	
3	to	O	
4	study	O	
5	the	O	
6	influence	O	
7	of	O	
8	iron	O	
9	overload	O	
10	on	O	
11	the	O	
12	polymorphonuclear	O	
13	leucocyte	O	
14	(	O	
15	PMN	O	
16	)	O	
17	metabolism	O	
18	of	O	
19	patients	O	
20	on	O	
21	chronic	O	
22	hemodialysis	O	
23	,	O	
24	generation	O	
25	of	O	
26	superoxide	O	
27	anion	O	
28	(	O	
29	O2	O	
30	-)	O	
31	by	O	
32	PMN	O	
33	in	O	
34	whole	O	
35	blood	O	
36	was	O	
37	compared	O	
38	in	O	
39	two	O	
40	groups	O	
41	of	O	
42	hemodialyzed	O	
43	patients	O	
44	:	O	
45	group	O	
46	A	O	
47	consisted	O	
48	of	O	
49	twenty	O	
50	-	O	
51	one	O	
52	individuals	O	
53	with	O	
54	serum	O	
55	ferritin	B	
56	levels	O	
57	above	O	
58	1000	O	
59	ng	O	
60	/	O	
61	ml	O	
62	and	O	
63	group	O	
64	B	O	
65	of	O	
66	nineteen	O	
67	individuals	O	
68	with	O	
69	serum	O	
70	ferritin	B	
71	levels	O	
72	below	O	
73	1000	O	
74	ng	O	
75	/	O	
76	ml	O	
77	.	O	

1	A	O	
2	prospective	O	
3	observational	O	
4	study	O	
5	was	O	
6	conducted	O	
7	to	O	
8	identify	O	
9	early	O	
10	indicators	O	
11	of	O	
12	acute	O	
13	dengue	O	
14	virus	O	
15	infection	O	
16	.	O	

1	A	O	
2	cDNA	O	
3	cloning	O	
4	vector	O	
5	that	O	
6	permits	O	
7	expression	O	
8	of	O	
9	cDNA	O	
10	inserts	O	
11	in	O	
12	mammalian	O	
13	cells	O	
14	.	O	

1	A	O	
2	database	O	
3	search	O	
4	has	O	
5	revealed	O	
6	as	O	
7	the	O	
8	most	O	
9	significative	O	
10	homology	O	
11	a	O	
12	match	O	
13	with	O	
14	the	O	
15	human	B	
16	mitochondrial	I	
17	transcription	I	
18	termination	I	
19	factor	I	
20	(	O	
21	mTERF	B	
22	),	O	
23	a	O	
24	protein	O	
25	that	O	
26	also	O	
27	binds	O	
28	DNA	O	
29	as	O	
30	a	O	
31	monomer	O	
32	and	O	
33	contains	O	
34	three	O	
35	leucine	O	
36	zippers	O	
37	forming	O	
38	intramolecular	O	
39	interactions	O	
40	.	O	

1	The	O	
2	more	O	
3	traditional	O	
4	SERMS	O	
5	,	O	
6	clomiphene	O	
7	citrate	O	
8	and	O	
9	tamoxifen	O	
10	,	O	
11	will	O	
12	be	O	
13	reviewed	O	
14	along	O	
15	with	O	
16	such	O	
17	modern	O	
18	drugs	O	
19	as	O	
20	raloxifene	O	
21	and	O	
22	faslodex	O	
23	,	O	
24	with	O	
25	emphasis	O	
26	upon	O	
27	their	O	
28	actions	O	
29	on	O	
30	breast	O	
31	,	O	
32	uterus	O	
33	,	O	
34	bone	O	
35	and	O	
36	lipids	O	
37	.	O	

1	Among	O	
2	these	O	
3	,	O	
4	ACT1	B	
5	was	O	
6	isolated	O	
7	four	O	
8	times	O	
9	,	O	
10	and	O	
11	NSR1	B	
12	three	O	
13	times	O	
14	.	O	

1	Three	O	
2	ORFs	O	
3	(	O	
4	9765orfR002	O	
5	,	O	
6	9765orfR011	O	
7	and	O	
8	9765orfR013	O	
9	)	O	
10	were	O	
11	found	O	
12	to	O	
13	be	O	
14	homologous	O	
15	with	O	
16	Schizosaccharomyces	O	
17	pombe	O	
18	polyadenylate	B	
19	binding	I	
20	protein	I	
21	,	O	
22	Escherichia	O	
23	coli	O	
24	hypothetical	O	
25	38	O	
26	.	O	
27	1	O	
28	-	O	
29	kDa	O	
30	protein	O	
31	in	O	
32	the	O	
33	BCR	B	
34	5	O	
35	'	O	
36	region	O	
37	,	O	
38	and	O	
39	transcription	O	
40	regulatory	O	
41	protein	O	
42	Swi3	B	
43	,	O	
44	respectively	O	
45	.	O	

1	Expansins	B	
2	are	O	
3	a	O	
4	family	O	
5	of	O	
6	proteins	O	
7	that	O	
8	catalyse	O	
9	long	O	
10	-	O	
11	term	O	
12	extension	O	
13	of	O	
14	isolated	O	
15	plant	O	
16	cell	O	
17	walls	O	
18	due	O	
19	to	O	
20	an	O	
21	as	O	
22	yet	O	
23	unknown	O	
24	biochemical	O	
25	mechanism	O	
26	.	O	

1	Moreover	O	
2	,	O	
3	when	O	
4	added	O	
5	to	O	
6	the	O	
7	osteoclast	O	
8	cultures	O	
9	,	O	
10	mrIhh	B	
11	-	I	
12	N	I	
13	markedly	O	
14	stimulated	O	
15	the	O	
16	formation	O	
17	of	O	
18	resorption	O	
19	pits	O	
20	on	O	
21	dentine	O	
22	slices	O	
23	.	O	

1	Reproductive	O	
2	period	O	
3	affects	O	
4	water	O	
5	intake	O	
6	in	O	
7	heat	O	
8	-	O	
9	stressed	O	
10	dehydrated	O	
11	goats	O	
12	.	O	

1	Previous	O	
2	experience	O	
3	and	O	
4	contextual	O	
5	cues	O	
6	are	O	
7	essential	O	
8	elements	O	
9	in	O	
10	the	O	
11	generation	O	
12	of	O	
13	a	O	
14	subjective	O	
15	prediction	O	
16	.	O	

1	National	O	
2	certification	O	
3	:	O	
4	a	O	
5	vital	O	
6	component	O	
7	of	O	
8	quality	O	
9	assurance	O	
10	.	O	

1	Plasma	B	
2	renin	I	
3	activity	O	
4	rose	O	
5	and	O	
6	the	O	
7	plasma	O	
8	aldosterone	O	
9	level	O	
10	fell	O	
11	after	O	
12	taking	O	
13	lisinopril	O	
14	.	O	

1	The	O	
2	distribution	O	
3	of	O	
4	the	O	
5	various	O	
6	repeats	O	
7	suggests	O	
8	its	O	
9	organization	O	
10	is	O	
11	similar	O	
12	to	O	
13	the	O	
14	beta	O	
15	-	O	
16	heterochromatic	O	
17	regions	O	
18	near	O	
19	the	O	
20	base	O	
21	of	O	
22	the	O	
23	major	O	
24	chromosome	O	
25	arms	O	
26	.	O	

1	For	O	
2	this	O	
3	purpose	O	
4	,	O	
5	the	O	
6	writhing	O	
7	test	O	
8	,	O	
9	capsaicin	O	
10	and	O	
11	formalin	O	
12	induced	O	
13	-	O	
14	pain	O	
15	in	O	
16	mice	O	
17	were	O	
18	used	O	
19	.	O	

1	Five	O	
2	families	O	
3	of	O	
4	Ashkenazi	O	
5	Jewish	O	
6	descent	O	
7	carried	O	
8	the	O	
9	185delAG	O	
10	mutation	O	
11	and	O	
12	shared	O	
13	the	O	
14	same	O	
15	haplotype	O	
16	at	O	
17	eight	O	
18	polymorphic	O	
19	markers	O	
20	spanning	O	
21	approximately	O	
22	850	O	
23	kb	O	
24	at	O	
25	BRCA1	B	
26	.	O	

1	CDNA	O	
2	cloning	O	
3	of	O	
4	chick	B	
5	brain	I	
6	alpha	I	
7	-	I	
8	amino	I	
9	-	I	
10	3	I	
11	-	I	
12	hydroxy	I	
13	-	I	
14	5	I	
15	-	I	
16	methyl	I	
17	-	I	
18	4	I	
19	-	I	
20	isoxazolepropionic	I	
21	acid	I	
22	receptors	I	
23	reveals	O	
24	conservation	O	
25	of	O	
26	structure	O	
27	,	O	
28	function	O	
29	and	O	
30	post	O	
31	-	O	
32	transcriptional	O	
33	processes	O	
34	with	O	
35	mammalian	O	
36	receptors	O	
37	.	O	

1	An	O	
2	RME1	B	
3	-	O	
4	independent	O	
5	pathway	O	
6	for	O	
7	sporulation	O	
8	control	O	
9	in	O	
10	Saccharomyces	O	
11	cerevisiae	O	
12	acts	O	
13	through	O	
14	IME1	B	
15	transcript	I	
16	accumulation	O	
17	.	O	

1	Immunofluorescence	O	
2	microscopy	O	
3	and	O	
4	cell	O	
5	fractionation	O	
6	analyses	O	
7	showed	O	
8	that	O	
9	the	O	
10	110	O	
11	-	O	
12	kDa	O	
13	protein	O	
14	was	O	
15	exclusively	O	
16	nuclear	O	
17	,	O	
18	whereas	O	
19	the	O	
20	150	O	
21	-	O	
22	kDa	O	
23	protein	O	
24	was	O	
25	present	O	
26	in	O	
27	both	O	
28	the	O	
29	cytoplasm	O	
30	and	O	
31	nucleus	O	
32	of	O	
33	human	O	
34	cells	O	
35	.	O	

1	With	O	
2	the	O	
3	increasing	O	
4	use	O	
5	of	O	
6	ACE	B	
7	inhibitors	O	
8	,	O	
9	the	O	
10	incidence	O	
11	of	O	
12	rare	O	
13	adverse	O	
14	effects	O	
15	such	O	
16	as	O	
17	potentially	O	
18	lethal	O	
19	pancreatitis	O	
20	is	O	
21	likely	O	
22	to	O	
23	increase	O	
24	.	O	

1	Deletion	O	
2	mutagenesis	O	
3	demonstrated	O	
4	that	O	
5	these	O	
6	two	O	
7	elements	O	
8	are	O	
9	involved	O	
10	in	O	
11	the	O	
12	positive	O	
13	regulation	O	
14	of	O	
15	MLC	B	
16	-	I	
17	2	I	
18	gene	I	
19	transcription	O	
20	.	O	

1	Evidence	O	
2	for	O	
3	the	O	
4	promoting	O	
5	role	O	
6	of	O	
7	the	O	
8	intra	B	
9	-	I	
10	uterine	I	
11	kinin	I	
12	release	O	
13	in	O	
14	the	O	
15	development	O	
16	of	O	
17	late	O	
18	hypertonic	O	
19	saline	O	
20	-	O	
21	induced	O	
22	abortion	O	
23	.	O	

1	Recently	O	
2	,	O	
3	an	O	
4	alternatively	O	
5	spliced	O	
6	form	O	
7	of	O	
8	c	B	
9	-	I	
10	myb	I	
11	-	I	
12	encoded	I	
13	mRNA	I	
14	has	O	
15	been	O	
16	identified	O	
17	in	O	
18	murine	O	
19	cells	O	
20	containing	O	
21	either	O	
22	normal	O	
23	or	O	
24	rearranged	O	
25	c	B	
26	-	I	
27	myb	I	
28	genes	I	
29	.	O	

1	PATIENTS	O	
2	and	O	
3	METHODS	O	
4	:	O	
5	Thallium	O	
6	-	O	
7	201	O	
8	myocardial	O	
9	scintigraphy	O	
10	was	O	
11	performed	O	
12	at	O	
13	rest	O	
14	and	O	
15	after	O	
16	0	O	
17	.	O	
18	56	O	
19	mg	O	
20	/	O	
21	kg	O	
22	intravenous	O	
23	dipyridamole	O	
24	during	O	
25	four	O	
26	minutes	O	
27	in	O	
28	16	O	
29	patients	O	
30	with	O	
31	sarcoidosis	O	
32	.	O	

1	Comparative	O	
2	analysis	O	
3	with	O	
4	an	O	
5	antiandrogen	O	
6	niftolid	O	
7	and	O	
8	synthetic	B	
9	GnRH	I	
10	was	O	
11	carried	O	
12	out	O	
13	in	O	
14	22	O	
15	normal	O	
16	subjects	O	
17	,	O	
18	14	O	
19	patients	O	
20	with	O	
21	primary	O	
22	and	O	
23	20	O	
24	ones	O	
25	with	O	
26	secondary	O	
27	hypogonadism	O	
28	,	O	
29	and	O	
30	in	O	
31	5	O	
32	patients	O	
33	with	O	
34	clinical	O	
35	signs	O	
36	of	O	
37	gonadal	O	
38	insufficiency	O	
39	and	O	
40	obscure	O	
41	diagnosis	O	
42	in	O	
43	order	O	
44	to	O	
45	elucidate	O	
46	the	O	
47	pituitary	B	
48	gonadotropin	I	
49	reserves	O	
50	.	O	

1	Each	O	
2	of	O	
3	these	O	
4	genes	O	
5	contains	O	
6	a	O	
7	putative	O	
8	upstream	O	
9	ORF	O	
10	,	O	
11	while	O	
12	STA2	B	
13	has	O	
14	two	O	
15	additional	O	
16	in	O	
17	-	O	
18	frame	O	
19	AUG	O	
20	codons	O	
21	5	O	
22	'	O	
23	to	O	
24	the	O	
25	major	O	
26	cistron	O	
27	.	O	

1	In	O	
2	the	O	
3	course	O	
4	of	O	
5	a	O	
6	study	O	
7	of	O	
8	low	O	
9	dose	O	
10	X	O	
11	-	O	
12	rays	O	
13	effects	O	
14	,	O	
15	we	O	
16	found	O	
17	that	O	
18	male	O	
19	ICR	O	
20	white	O	
21	Swiss	O	
22	mice	O	
23	showed	O	
24	remarkable	O	
25	suppression	O	
26	of	O	
27	mounting	O	
28	behavior	O	
29	after	O	
30	whole	O	
31	body	O	
32	irradiation	O	
33	by	O	
34	5	O	
35	to	O	
36	15	O	
37	cGy	O	
38	X	O	
39	-	O	
40	rays	O	
41	.	O	

1	Effect	O	
2	of	O	
3	triftazin	O	
4	and	O	
5	aminazin	O	
6	on	O	
7	hippocampal	O	
8	bioelectric	O	
9	activity	O	

1	Physical	O	
2	analysis	O	
3	maps	O	
4	SAL6	B	
5	to	O	
6	chromosome	O	
7	XVI	O	
8	between	O	
9	TPK2	B	
10	and	O	
11	spt14	B	
12	.	O	

1	LMP	B	
2	-	I	
3	1	I	
4	is	O	
5	targeted	O	
6	to	O	
7	the	O	
8	plasma	O	
9	membrane	O	
10	,	O	
11	where	O	
12	it	O	
13	binds	O	
14	TRAF	B	
15	,	O	
16	TRADD	B	
17	,	O	
18	and	O	
19	JAK	B	
20	molecules	I	
21	to	O	
22	activate	O	
23	NF	B	
24	-	I	
25	kappaB	I	
26	-,	O	
27	AP	B	
28	-	I	
29	1	I	
30	-,	O	
31	and	O	
32	STAT	B	
33	-	O	
34	dependent	O	
35	pathways	O	
36	as	O	
37	does	O	
38	CD40	B	
39	.	O	

1	Acute	O	
2	feasibility	O	
3	and	O	
4	safety	O	
5	of	O	
6	a	O	
7	smoking	O	
8	reduction	O	
9	strategy	O	
10	for	O	
11	smokers	O	
12	with	O	
13	schizophrenia	O	
14	.	O	

1	Variations	O	
2	of	O	
3	the	O	
4	timing	O	
5	of	O	
6	deflections	O	
7	in	O	
8	the	O	
9	His	O	
10	bundle	O	
11	recordings	O	
12	.	O	

1	The	O	
2	effect	O	
3	of	O	
4	a	O	
5	beta	B	
6	-	I	
7	adrenoceptor	I	
8	antagonist	O	
9	,	O	
10	pindolol	O	
11	,	O	
12	on	O	
13	uterine	O	
14	smooth	O	
15	muscle	O	
16	in	O	
17	term	O	
18	pregnant	O	
19	women	O	
20	was	O	
21	studied	O	
22	in	O	
23	vitro	O	
24	and	O	
25	in	O	
26	vivo	O	
27	(	O	
28	in	O	
29	hypertensive	O	
30	women	O	
31	).	O	

1	Experimental	O	
2	reproduction	O	
3	of	O	
4	malignant	O	
5	catarrhal	O	
6	fever	O	
7	in	O	
8	Bali	O	
9	cattle	O	

1	Purification	O	
2	and	O	
3	cloning	O	
4	of	O	
5	a	O	
6	novel	O	
7	serine	B	
8	protease	I	
9	,	O	
10	RNK	B	
11	-	I	
12	Met	I	
13	-	I	
14	1	I	
15	,	O	
16	from	O	
17	the	O	
18	granules	O	
19	of	O	
20	a	O	
21	rat	O	
22	natural	O	
23	killer	O	
24	cell	O	
25	leukemia	O	
26	.	O	

1	The	O	
2	gene	B	
3	encoding	I	
4	human	I	
5	tissue	I	
6	-	I	
7	type	I	
8	plasminogen	I	
9	activator	I	
10	(	O	
11	t	B	
12	-	I	
13	PA	I	
14	)	O	
15	is	O	
16	regulated	O	
17	in	O	
18	a	O	
19	cell	O	
20	-	O	
21	type	O	
22	-	O	
23	specific	O	
24	manner	O	
25	.	O	

1	Using	O	
2	sequence	O	
3	information	O	
4	from	O	
5	human	B	
6	BMAL1	I	
7	(	O	
8	hBMAL1	B	
9	)	O	
10	cDNAs	O	
11	previously	O	
12	reported	O	
13	by	O	
14	our	O	
15	laboratory	O	
16	,	O	
17	we	O	
18	have	O	
19	isolated	O	
20	and	O	
21	characterized	O	
22	cDNAs	O	
23	encoding	O	
24	three	O	
25	splice	O	
26	variants	O	
27	of	O	
28	the	O	
29	mouse	B	
30	BMAL1	I	
31	(	O	
32	mBMAL1	B	
33	)	O	
34	gene	O	
35	.	O	

1	74	O	
2	,	O	
3	193	O	
4	-	O	
5	197	O	
6	).	O	

1	These	O	
2	thyroid	O	
3	hormone	O	
4	changes	O	
5	may	O	
6	be	O	
7	mediated	O	
8	in	O	
9	part	O	
10	by	O	
11	cytokines	O	
12	or	O	
13	other	O	
14	inflammatory	O	
15	mediators	O	
16	,	O	
17	acting	O	
18	at	O	
19	the	O	
20	level	O	
21	of	O	
22	the	O	
23	hypothalamus	O	
24	and	O	
25	pituitary	O	
26	gland	O	
27	,	O	
28	the	O	
29	thyroid	O	
30	gland	O	
31	,	O	
32	and	O	
33	the	O	
34	hepatic	B	
35	deiodinase	I	
36	system	O	
37	.	O	

1	DIBA	O	
2	was	O	
3	more	O	
4	sensitive	O	
5	and	O	
6	had	O	
7	a	O	
8	better	O	
9	negative	O	
10	predictive	O	
11	value	O	
12	and	O	
13	a	O	
14	lower	O	
15	false	O	
16	negative	O	
17	percentage	O	
18	than	O	
19	DFAT	O	
20	.	O	

1	Results	O	
2	of	O	
3	the	O	
4	official	O	
5	inspection	O	
6	of	O	
7	the	O	
8	commercial	O	
9	anti	O	
10	-	O	
11	inflammatory	O	
12	enzyme	O	
13	preparations	O	
14	containing	O	
15	chymotrypsin	B	
16	and	O	
17	trypsin	B	
18	by	O	
19	means	O	
20	of	O	
21	modified	O	
22	NF	O	
23	13	O	
24	methods	O	

1	Prostacyclin	O	
2	formation	O	
3	,	O	
4	reflected	O	
5	by	O	
6	the	O	
7	excretion	O	
8	rate	O	
9	of	O	
10	its	O	
11	stable	O	
12	metabolite	O	
13	6	O	
14	-	O	
15	keto	O	
16	-	O	
17	prostaglandin	O	
18	F1	O	
19	alpha	O	
20	,	O	
21	was	O	
22	measured	O	
23	by	O	
24	means	O	
25	of	O	
26	radioimmunoassay	O	
27	in	O	
28	4	O	
29	-	O	
30	hour	O	
31	urine	O	
32	specimens	O	
33	obtained	O	
34	during	O	
35	a	O	
36	smoking	O	
37	-	O	
38	free	O	
39	period	O	
40	and	O	
41	after	O	
42	participants	O	
43	had	O	
44	inhaled	O	
45	smoke	O	
46	from	O	
47	four	O	
48	high	O	
49	-	O	
50	nicotine	O	
51	cigarettes	O	
52	.	O	

1	Effects	O	
2	of	O	
3	verapamil	O	
4	and	O	
5	propranolol	O	
6	on	O	
7	early	O	
8	afterdepolarizations	O	
9	and	O	
10	ventricular	O	
11	arrhythmias	O	
12	induced	O	
13	by	O	
14	epinephrine	O	
15	in	O	
16	congenital	O	
17	long	O	
18	QT	O	
19	syndrome	O	
20	.	O	

1	As	O	
2	expected	O	
3	,	O	
4	the	O	
5	heparin	O	
6	did	O	
7	produce	O	
8	increased	O	
9	recalcification	O	
10	times	O	
11	and	O	
12	the	O	
13	development	O	
14	of	O	
15	occasional	O	
16	subcutaneous	O	
17	hematomas	O	
18	.	O	

1	Persistent	O	
2	activation	O	
3	of	O	
4	mitogen	B	
5	-	I	
6	activated	I	
7	protein	I	
8	kinases	I	
9	p42	I	
10	and	O	
11	p44	B	
12	and	O	
13	ets	B	
14	-	I	
15	2	I	
16	phosphorylation	O	
17	in	O	
18	response	O	
19	to	O	
20	colony	B	
21	-	I	
22	stimulating	I	
23	factor	I	
24	1	I	
25	/	O	
26	c	B	
27	-	I	
28	fms	I	
29	signaling	O	
30	.	O	

1	These	O	
2	data	O	
3	support	O	
4	the	O	
5	idea	O	
6	that	O	
7	the	O	
8	repression	O	
9	activity	O	
10	of	O	
11	NRSF	B	
12	/	O	
13	REST	B	
14	depends	O	
15	upon	O	
16	the	O	
17	species	O	
18	of	O	
19	promoter	O	
20	to	O	
21	which	O	
22	it	O	
23	is	O	
24	linked	O	
25	and	O	
26	upon	O	
27	the	O	
28	proteins	O	
29	that	O	
30	bind	O	
31	to	O	
32	those	O	
33	promoters	O	
34	.	O	

1	BYV	O	
2	,	O	
3	citrus	O	
4	tristeza	O	
5	virus	O	
6	(	O	
7	CTV	O	
8	),	O	
9	beet	O	
10	yellow	O	
11	stunt	O	
12	virus	O	
13	(	O	
14	BYSV	O	
15	)	O	
16	and	O	
17	carnation	O	
18	necrotic	O	
19	fleck	O	
20	virus	O	
21	templates	O	
22	produced	O	
23	1	O	
24	kb	O	
25	amplification	O	
26	products	O	
27	,	O	
28	which	O	
29	were	O	
30	shown	O	
31	by	O	
32	sequencing	O	
33	to	O	
34	represent	O	
35	fragments	O	
36	of	O	
37	the	O	
38	respective	O	
39	HSP70	B	
40	genes	I	
41	.	O	

1	Is	O	
2	desensitization	O	
3	'	O	
4	for	O	
5	ragweed	O	
6	hay	O	
7	fever	O	
8	immunologically	O	
9	specific	O	
10	?	O	

1	Long	O	
2	-	O	
3	latency	O	
4	:	O	
5	locked	O	
6	units	O	
7	responded	O	
8	to	O	
9	shocks	O	
10	with	O	
11	little	O	
12	jitter	O	
13	and	O	
14	long	O	
15	latency	O	
16	(	O	
17	4	O	
18	-	O	
19	11	O	
20	ms	O	
21	).	O	

1	Within	O	
2	the	O	
3	3	O	
4	'	O	
5	terminal	O	
6	50	O	
7	nucleotides	O	
8	,	O	
9	the	O	
10	mouse	B	
11	mt	I	
12	12S	I	
13	rRNA	I	
14	contains	O	
15	a	O	
16	potential	O	
17	10	O	
18	bp	O	
19	hairpin	O	
20	structure	O	
21	and	O	
22	a	O	
23	sequence	O	
24	of	O	
25	15	O	
26	consecutive	O	
27	nucleotides	O	
28	common	O	
29	to	O	
30	the	O	
31	RNA	O	
32	of	O	
33	the	O	
34	small	O	
35	ribosomal	O	
36	subunit	O	
37	in	O	
38	all	O	
39	systems	O	
40	,	O	
41	but	O	
42	does	O	
43	not	O	
44	contain	O	
45	the	O	
46	mRNA	O	
47	binding	O	
48	site	O	
49	(	O	
50	ACCUCC	O	
51	)	O	
52	found	O	
53	in	O	
54	E	O	
55	.	O	
56	coli	O	
57	and	O	
58	corn	O	
59	chloroplast	O	
60	rRNAs	O	
61	.	O	

1	OBJECTIVE	O	
2	:	O	
3	Our	O	
4	goal	O	
5	was	O	
6	to	O	
7	determine	O	
8	whether	O	
9	chlamydia	O	
10	-	O	
11	infected	O	
12	women	O	
13	have	O	
14	a	O	
15	higher	O	
16	rate	O	
17	of	O	
18	febrile	O	
19	complications	O	
20	after	O	
21	postpartum	O	
22	tubal	O	
23	ligation	O	
24	.	O	

1	Based	O	
2	on	O	
3	sequence	O	
4	homology	O	
5	,	O	
6	the	O	
7	genes	O	
8	were	O	
9	identified	O	
10	as	O	
11	TEF	B	
12	,	O	
13	encoding	O	
14	translation	B	
15	elongation	I	
16	factor	I	
17	-	I	
18	1	I	
19	alpha	I	
20	and	O	
21	RPS7	B	
22	,	O	
23	encoding	O	
24	ribosomal	O	
25	protein	O	
26	S7	B	
27	.	O	

1	Inspired	O	
2	CO2	O	
3	causing	O	
4	changes	O	
5	from	O	
6	hypo	O	
7	-	O	
8	to	O	
9	normocapnia	O	
10	has	O	
11	previously	O	
12	been	O	
13	shown	O	
14	to	O	
15	improve	O	
16	arterial	O	
17	O2	O	
18	tension	O	
19	(	O	
20	PaO2	O	
21	)	O	
22	and	O	
23	to	O	
24	reduce	O	
25	alveolar	O	
26	-	O	
27	arterial	O	
28	O2	O	
29	difference	O	
30	.	O	

1	This	O	
2	is	O	
3	the	O	
4	first	O	
5	description	O	
6	,	O	
7	to	O	
8	our	O	
9	knowledge	O	
10	,	O	
11	of	O	
12	regulatory	O	
13	elements	O	
14	that	O	
15	control	O	
16	expression	O	
17	of	O	
18	a	O	
19	gene	O	
20	encoding	O	
21	a	O	
22	B7	B	
23	costimulatory	I	
24	molecule	I	
25	.	O	

1	BACKGROUND	O	
2	:	O	
3	Measurement	O	
4	of	O	
5	stereoacuity	O	
6	at	O	
7	varying	O	
8	distances	O	
9	,	O	
10	by	O	
11	real	O	
12	or	O	
13	simulated	O	
14	depth	O	
15	stereoacuity	O	
16	tests	O	
17	,	O	
18	is	O	
19	helpful	O	
20	in	O	
21	the	O	
22	evaluation	O	
23	of	O	
24	patients	O	
25	with	O	
26	binocular	O	
27	imbalance	O	
28	or	O	
29	strabismus	O	
30	.	O	

1	The	O	
2	in	O	
3	vitro	O	
4	activity	O	
5	of	O	
6	mecillinam	O	
7	and	O	
8	amoxicillin	O	
9	/	O	
10	clavulanic	O	
11	acid	O	
12	against	O	
13	Escherichia	O	
14	coli	O	
15	strains	O	
16	producing	O	
17	beta	B	
18	-	I	
19	lactamases	I	
20	of	O	
21	the	O	
22	TEM	B	
23	-	I	
24	1	I	
25	,	O	
26	Oxa	B	
27	-	I	
28	1	I	
29	and	O	
30	chromosomal	O	
31	type	O	
32	were	O	
33	studied	O	
34	using	O	
35	the	O	
36	broth	O	
37	and	O	
38	agar	O	
39	dilution	O	
40	technique	O	
41	.	O	

1	DNA	O	
2	binding	O	
3	and	O	
4	glutathione	B	
5	S	I	
6	-	I	
7	transferase	I	
8	pull	O	
9	-	O	
10	down	O	
11	assays	O	
12	demonstrate	O	
13	that	O	
14	binding	O	
15	requires	O	
16	Elk	B	
17	-	I	
18	1	I	
19	(	I	
20	1	I	
21	-	I	
22	212	I	
23	)	I	
24	but	O	
25	not	O	
26	the	O	
27	C	O	
28	-	O	
29	terminal	O	
30	transactivation	O	
31	domain	O	
32	.	O	

1	Comparison	O	
2	of	O	
3	the	O	
4	proportion	O	
5	of	O	
6	nonsynonymous	O	
7	(	O	
8	pN	O	
9	)	O	
10	and	O	
11	synonymous	O	
12	(	O	
13	pS	O	
14	)	O	
15	substitutions	O	
16	occurring	O	
17	per	O	
18	site	O	
19	within	O	
20	tamarin	B	
21	variable	I	
22	region	I	
23	genes	I	
24	demonstrated	O	
25	a	O	
26	reduction	O	
27	in	O	
28	pN	O	
29	in	O	
30	the	O	
31	framework	O	
32	regions	O	
33	compared	O	
34	with	O	
35	pN	O	
36	in	O	
37	the	O	
38	presumed	O	
39	MHC	B	
40	contact	I	
41	regions	I	
42	(	O	
43	CDR1	B	
44	and	O	
45	CDR2	B	
46	).	O	

1	Patterns	O	
2	defined	O	
3	by	O	
4	combinations	O	
5	of	O	
6	normal	O	
7	and	O	
8	abnormal	O	
9	laboratory	O	
10	results	O	
11	had	O	
12	decreased	O	
13	the	O	
14	likelihood	O	
15	of	O	
16	PEM	O	
17	from	O	
18	an	O	
19	all	O	
20	-	O	
21	2	O	
22	to	O	
23	all	O	
24	-	O	
25	0	O	
26	pattern	O	
27	.	O	

1	Isolation	O	
2	of	O	
3	tha	O	
4	avian	O	
5	reticuloendothelial	O	
6	virus	O	
7	(	O	
8	strain	O	
9	T	O	
10	).	O	

1	The	O	
2	regional	O	
3	blockade	O	
4	of	O	
5	H1R	B	
6	was	O	
7	observed	O	
8	mainly	O	
9	in	O	
10	the	O	
11	frontal	O	
12	,	O	
13	temporal	O	
14	and	O	
15	anterior	O	
16	cingulate	O	
17	cortices	O	
18	,	O	
19	and	O	
20	the	O	
21	intravenous	O	
22	administration	O	
23	of	O	
24	d	O	
25	-	O	
26	chlorpheniramine	O	
27	as	O	
28	a	O	
29	therapeutic	O	
30	dose	O	
31	(	O	
32	2	O	
33	mg	O	
34	)	O	
35	blocked	O	
36	over	O	
37	60	O	
38	%	O	
39	of	O	
40	H1R	B	
41	in	O	
42	the	O	
43	frontal	O	
44	cortices	O	
45	.	O	

1	Preliminary	O	
2	use	O	
3	of	O	
4	the	O	
5	Nottingham	O	
6	Eczema	O	
7	Severity	O	
8	Score	O	
9	would	O	
10	support	O	
11	further	O	
12	development	O	
13	as	O	
14	a	O	
15	research	O	
16	tool	O	
17	for	O	
18	a	O	
19	simple	O	
20	assessment	O	
21	of	O	
22	disease	O	
23	severity	O	
24	that	O	
25	could	O	
26	be	O	
27	used	O	
28	in	O	
29	epidemiological	O	
30	studies	O	
31	.	O	

1	The	O	
2	Jem	B	
3	peptide	O	
4	sequence	O	
5	shows	O	
6	a	O	
7	'	O	
8	leucine	O	
9	-	O	
10	zipper	O	
11	'	O	
12	dimerisation	O	
13	motif	O	
14	with	O	
15	limited	O	
16	homology	O	
17	to	O	
18	Fos	B	
19	/	O	
20	Jun	B	
21	and	O	
22	ATF	B	
23	/	O	
24	CREB	B	
25	proteins	O	
26	and	O	
27	several	O	
28	putative	O	
29	phosphorylation	O	
30	sites	O	
31	.	O	

1	A	O	
2	poor	O	
3	correlation	O	
4	was	O	
5	found	O	
6	between	O	
7	a	O	
8	mildly	O	
9	-	O	
10	atypical	O	
11	(	O	
12	inflammatory	O	
13	)	O	
14	cytological	O	
15	result	O	
16	(	O	
17	class	O	
18	2	O	
19	)	O	
20	and	O	
21	a	O	
22	benign	O	
23	histological	O	
24	diagnosis	O	
25	:	O	
26	48	O	
27	%	O	
28	of	O	
29	class	O	
30	-	O	
31	2	O	
32	smears	O	
33	were	O	
34	diagnosed	O	
35	histologically	O	
36	as	O	
37	dysplasia	O	
38	or	O	
39	worse	O	
40	.	O	

1	An	O	
2	anatomical	O	
3	and	O	
4	histochemical	O	
5	study	O	
6	has	O	
7	been	O	
8	undertaken	O	
9	and	O	
10	as	O	
11	a	O	
12	result	O	
13	emphasis	O	
14	is	O	
15	given	O	
16	to	O	
17	recent	O	
18	hypotheses	O	
19	that	O	
20	suggest	O	
21	there	O	
22	are	O	
23	similarities	O	
24	with	O	
25	Type	O	
26	IV	O	
27	glycogen	O	
28	storage	O	
29	disease	O	
30	(	O	
31	Andersen	O	
32	'	O	
33	s	O	
34	disease	O	
35	)	O	
36	which	O	
37	,	O	
38	although	O	
39	clinically	O	
40	distinct	O	
41	,	O	
42	has	O	
43	the	O	
44	same	O	
45	enzyme	O	
46	defect	O	
47	.	O	

1	French	O	
2	bean	O	
3	contains	O	
4	a	O	
5	small	O	
6	family	O	
7	of	O	
8	genes	B	
9	encoding	I	
10	PAL	I	
11	and	O	
12	two	O	
13	of	O	
14	these	O	
15	genes	O	
16	,	O	
17	PAL2	B	
18	and	O	
19	PAL3	B	
20	,	O	
21	have	O	
22	been	O	
23	shown	O	
24	to	O	
25	be	O	
26	differentially	O	
27	expressed	O	
28	at	O	
29	the	O	
30	mRNA	O	
31	level	O	
32	in	O	
33	bean	O	
34	tissues	O	
35	.	O	

1	Gel	O	
2	electrophoresis	O	
3	and	O	
4	Western	O	
5	immunoblot	O	
6	analyses	O	
7	of	O	
8	intracellular	O	
9	fractions	O	
10	derived	O	
11	from	O	
12	infected	O	
13	cells	O	
14	revealed	O	
15	that	O	
16	large	O	
17	amounts	O	
18	of	O	
19	NS53	B	
20	were	O	
21	present	O	
22	in	O	
23	the	O	
24	cytosol	O	
25	and	O	
26	in	O	
27	association	O	
28	with	O	
29	the	O	
30	cytoskeletal	O	
31	matrix	O	
32	.	O	

1	The	O	
2	reduction	O	
3	in	O	
4	saturated	O	
5	fatty	O	
6	acids	O	
7	intake	O	
8	led	O	
9	to	O	
10	modest	O	
11	(	O	
12	but	O	
13	in	O	
14	group	O	
15	1	O	
16	significant	O	
17	)	O	
18	0	O	
19	.	O	
20	15	O	
21	mmol	O	
22	/	O	
23	l	O	
24	(	O	
25	2	O	
26	.	O	
27	5	O	
28	%)	O	
29	reduction	O	
30	in	O	
31	total	O	
32	serum	O	
33	cholesterol	O	
34	level	O	
35	.	O	

1	Thus	O	
2	,	O	
3	Sir	B	
4	proteins	I	
5	from	O	
6	K	O	
7	.	O	
8	lactis	O	
9	have	O	
10	roles	O	
11	in	O	
12	both	O	
13	silencing	O	
14	and	O	
15	telomere	O	
16	length	O	
17	maintenance	O	
18	,	O	
19	reflecting	O	
20	conserved	O	
21	functional	O	
22	themes	O	
23	.	O	

1	The	O	
2	stability	O	
3	of	O	
4	isoniazid	O	
5	solutions	O	
6	increases	O	
7	markedly	O	
8	with	O	
9	increasing	O	
10	NTA	O	
11	or	O	
12	EDTA	O	
13	concentration	O	
14	up	O	
15	to	O	
16	1	O	
17	mmol	O	
18	/	O	
19	l	O	
20	.	O	

1	IgG	B	
2	and	O	
3	IgM	B	
4	antibody	O	
5	activity	O	
6	was	O	
7	determined	O	
8	by	O	
9	adding	O	
10	a	O	
11	1	O	
12	:	O	
13	100	O	
14	dilution	O	
15	of	O	
16	serum	O	
17	to	O	
18	plates	O	
19	coated	O	
20	with	O	
21	A60	B	
22	antigen	I	
23	.	O	

1	In	O	
2	one	O	
3	patient	O	
4	with	O	
5	severe	O	
6	diarrhea	O	
7	the	O	
8	estriol	O	
9	concentration	O	
10	in	O	
11	serum	O	
12	was	O	
13	low	O	
14	until	O	
15	the	O	
16	intestinal	O	
17	function	O	
18	normalised	O	
19	and	O	
20	the	O	
21	estriol	O	
22	concentration	O	
23	went	O	
24	up	O	
25	exactly	O	
26	when	O	
27	the	O	
28	diarrhea	O	
29	stopped	O	
30	.	O	

1	Thus	O	
2	,	O	
3	the	O	
4	N	B	
5	-	O	
6	Nus	B	
7	complex	O	
8	may	O	
9	be	O	
10	affected	O	
11	through	O	
12	contacts	O	
13	with	O	
14	the	O	
15	CTD	O	
16	of	O	
17	the	O	
18	alpha	O	
19	subunit	O	
20	of	O	
21	RNA	B	
22	polymerase	I	
23	,	O	
24	as	O	
25	is	O	
26	a	O	
27	group	O	
28	of	O	
29	regulatory	O	
30	proteins	O	
31	that	O	
32	influences	O	
33	initiation	O	
34	of	O	
35	transcription	O	
36	.	O	

1	The	O	
2	PSD2	B	
3	gene	I	
4	was	O	
5	heterologously	O	
6	expressed	O	
7	by	O	
8	infection	O	
9	of	O	
10	Sf	O	
11	-	O	
12	9	O	
13	insect	O	
14	cells	O	
15	with	O	
16	recombinant	O	
17	baculovirus	O	
18	,	O	
19	resulting	O	
20	in	O	
21	a	O	
22	10	O	
23	-	O	
24	fold	O	
25	increase	O	
26	in	O	
27	PSD	B	
28	activity	O	
29	.	O	

1	An	O	
2	egg	O	
3	protein	O	
4	,	O	
5	lysozyme	B	
6	,	O	
7	is	O	
8	a	O	
9	still	O	
10	unlabeled	O	
11	additive	O	
12	currently	O	
13	used	O	
14	in	O	
15	cheese	O	
16	preparation	O	
17	.	O	

1	Different	O	
2	doses	O	
3	of	O	
4	15	O	
5	-	O	
6	methyl	O	
7	-	O	
8	PGF2	O	
9	alpha	O	
10	(	O	
11	0	O	
12	.	O	
13	125	O	
14	-	O	
15	10	O	
16	mg	O	
17	)	O	
18	were	O	
19	used	O	
20	to	O	
21	induce	O	
22	luteolysis	O	
23	and	O	
24	oestrus	O	
25	in	O	
26	7	O	
27	heifers	O	
28	with	O	
29	28	O	
30	treatments	O	
31	on	O	
32	day	O	
33	8	O	
34	-	O	
35	12	O	
36	of	O	
37	the	O	
38	oestrous	O	
39	cycle	O	
40	.	O	

1	Previously	O	
2	,	O	
3	we	O	
4	reported	O	
5	that	O	
6	scanthrough	O	
7	translation	O	
8	,	O	
9	where	O	
10	the	O	
11	initiating	O	
12	AUG	O	
13	of	O	
14	a	O	
15	primary	O	
16	open	O	
17	reading	O	
18	frame	O	
19	is	O	
20	bypassed	O	
21	,	O	
22	is	O	
23	most	O	
24	likely	O	
25	to	O	
26	account	O	
27	for	O	
28	the	O	
29	presentation	O	
30	of	O	
31	cryptic	O	
32	epitopes	O	
33	from	O	
34	alternative	O	
35	reading	O	
36	frames	O	
37	within	O	
38	the	O	
39	influenza	B	
40	A	I	
41	PR	I	
42	/	I	
43	8	I	
44	/	I	
45	34	I	
46	nucleoprotein	I	
47	gene	I	
48	.	O	

1	Nip7p	B	
2	-	O	
3	depleted	O	
4	cells	O	
5	exhibited	O	
6	the	O	
7	same	O	
8	defects	O	
9	as	O	
10	Nop8p	B	
11	-	O	
12	depleted	O	
13	cells	O	
14	,	O	
15	except	O	
16	that	O	
17	they	O	
18	accumulated	O	
19	27S	B	
20	precursors	I	
21	.	O	

1	In	O	
2	yeast	O	
3	,	O	
4	the	O	
5	products	O	
6	of	O	
7	the	O	
8	UPF1	B	
9	and	O	
10	UPF3	B	
11	genes	I	
12	are	O	
13	required	O	
14	for	O	
15	this	O	
16	decay	O	
17	pathway	O	
18	,	O	
19	and	O	
20	in	O	
21	this	O	
22	report	O	
23	we	O	
24	focus	O	
25	on	O	
26	the	O	
27	identification	O	
28	and	O	
29	characterization	O	
30	of	O	
31	additional	O	
32	factors	O	
33	required	O	
34	for	O	
35	rapid	O	
36	decay	O	
37	of	O	
38	nonsense	O	
39	-	O	
40	containing	O	
41	mRNAs	O	
42	.	O	

1	Failure	O	
2	of	O	
3	stapedius	O	
4	reflexometry	O	
5	in	O	
6	the	O	
7	diagnosis	O	
8	of	O	
9	myasthenia	O	
10	gravis	O	
11	.	O	

1	These	O	
2	results	O	
3	suggest	O	
4	that	O	
5	,	O	
6	in	O	
7	this	O	
8	experimental	O	
9	model	O	
10	,	O	
11	ACE	B	
12	inhibitors	O	
13	limit	O	
14	the	O	
15	arrhythmias	O	
16	following	O	
17	ischemia	O	
18	-	O	
19	reperfusion	O	
20	and	O	
21	free	O	
22	radical	O	
23	scavenging	O	
24	action	O	
25	of	O	
26	these	O	
27	drugs	O	
28	does	O	
29	not	O	
30	have	O	
31	a	O	
32	major	O	
33	contributory	O	
34	role	O	
35	in	O	
36	their	O	
37	protective	O	
38	effect	O	
39	.	O	

1	Site	O	
2	-	O	
3	directed	O	
4	mutagenesis	O	
5	of	O	
6	the	O	
7	R2	B	
8	protein	I	
9	was	O	
10	used	O	
11	to	O	
12	provide	O	
13	evidence	O	
14	that	O	
15	this	O	
16	motif	O	
17	is	O	
18	also	O	
19	part	O	
20	of	O	
21	the	O	
22	active	O	
23	site	O	
24	of	O	
25	the	O	
26	endonuclease	O	
27	encoded	O	
28	by	O	
29	this	O	
30	element	O	
31	.	O	

1	Landsberg	O	
2	(	O	
3	La	O	
4	-	O	
5	O	O	
6	)	O	
7	and	O	
8	cv	O	
9	.	O	

1	FK	O	
2	33	O	
3	-	O	
4	824	O	
5	,	O	
6	a	O	
7	methionine	O	
8	-	O	
9	enkephalin	B	
10	analogue	O	
11	,	O	
12	suppressed	O	
13	plasma	O	
14	ACTH	B	
15	to	O	
16	85	O	
17	%	O	
18	of	O	
19	basal	O	
20	level	O	
21	,	O	
22	while	O	
23	bromocriptine	O	
24	(	O	
25	CB	O	
26	-	O	
27	154	O	
28	)	O	
29	caused	O	
30	no	O	
31	significant	O	
32	change	O	
33	.	O	

1	Both	O	
2	PPC	O	
3	-	O	
4	1	O	
5	and	O	
6	ALVA	O	
7	-	O	
8	31	O	
9	cells	O	
10	display	O	
11	tumorigenesis	O	
12	and	O	
13	invasiveness	O	
14	in	O	
15	nude	O	
16	mice	O	
17	,	O	
18	whereas	O	
19	LNCap	O	
20	cells	O	
21	exhibit	O	
22	a	O	
23	less	O	
24	malignant	O	
25	phenotype	O	
26	,	O	
27	suggesting	O	
28	a	O	
29	correlation	O	
30	between	O	
31	CD44	B	
32	variant	I	
33	(	O	
34	CD44v	B	
35	)	O	
36	expression	O	
37	and	O	
38	aggressive	O	
39	prostate	O	
40	tumor	O	
41	behavior	O	
42	.	O	

1	A	O	
2	receptor	B	
3	-	I	
4	like	I	
5	protein	I	
6	kinase	I	
7	,	O	
8	OsPK10	B	
9	,	O	
10	has	O	
11	been	O	
12	cloned	O	
13	from	O	
14	rice	O	
15	(	O	
16	Oryza	O	
17	sativa	O	
18	).	O	

1	Relationship	O	
2	between	O	
3	mitochondrial	B	
4	NADH	I	
5	-	I	
6	ubiquinone	I	
7	reductase	I	
8	and	O	
9	a	O	
10	bacterial	B	
11	NAD	I	
12	-	I	
13	reducing	I	
14	hydrogenase	I	
15	.	O	

1	In	O	
2	several	O	
3	studies	O	
4	the	O	
5	RDFS	O	
6	has	O	
7	shown	O	
8	evidence	O	
9	of	O	
10	reliability	O	
11	and	O	
12	validity	O	
13	.	O	

1	Against	O	
2	200	O	
3	strains	O	
4	of	O	
5	methicillin	O	
6	-	O	
7	resistant	O	
8	Staphylococcus	O	
9	aureus	O	
10	(	O	
11	MRSA	O	
12	)	O	
13	isolated	O	
14	from	O	
15	1990	O	
16	to	O	
17	1991	O	
18	,	O	
19	minimum	O	
20	inhibitory	O	
21	concentrations	O	
22	(	O	
23	MICs	O	
24	)	O	
25	of	O	
26	a	O	
27	total	O	
28	of	O	
29	15	O	
30	antibacterial	O	
31	agents	O	
32	including	O	
33	arbekacin	O	
34	(	O	
35	ABK	O	
36	)	O	
37	were	O	
38	determined	O	
39	.	O	

1	Is	O	
2	nisoldipine	O	
3	capable	O	
4	of	O	
5	reducing	O	
6	left	O	
7	ventricular	O	
8	preload	O	
9	?	O	
10	In	O	
11	ten	O	
12	anesthetized	O	
13	pigs	O	
14	,	O	
15	nisoldipine	O	
16	(	O	
17	2	O	
18	-	O	
19	4	O	
20	micrograms	O	
21	X	O	
22	kg	O	
23	-	O	
24	1	O	
25	X	O	
26	min	O	
27	-	O	
28	1	O	
29	),	O	
30	a	O	
31	calcium	O	
32	channel	O	
33	blocker	O	
34	structurally	O	
35	related	O	
36	to	O	
37	nifedipine	O	
38	,	O	
39	reduced	O	
40	left	O	
41	ventricular	O	
42	systolic	O	
43	pressure	O	
44	(	O	
45	40	O	
46	%)	O	
47	and	O	
48	systemic	O	
49	vascular	O	
50	resistance	O	
51	(	O	
52	35	O	
53	%),	O	
54	whereas	O	
55	maxLVdP	O	
56	/	O	
57	dt	O	
58	decreased	O	
59	by	O	
60	20	O	
61	%	O	
62	and	O	
63	cardiac	O	
64	output	O	
65	was	O	
66	unchanged	O	
67	.	O	

1	Insulin	B	
2	stimulation	O	
3	promoted	O	
4	the	O	
5	association	O	
6	of	O	
7	mIRS3	B	
8	with	O	
9	p85	B	
10	,	O	
11	SHP2	B	
12	,	O	
13	Nck	B	
14	,	O	
15	and	O	
16	Shc	B	
17	.	O	

1	All	O	
2	other	O	
3	changes	O	
4	at	O	
5	the	O	
6	3	O	
7	-,	O	
8	5	O	
9	-,	O	
10	and	O	
11	6	O	
12	-	O	
13	positions	O	
14	,	O	
15	as	O	
16	well	O	
17	as	O	
18	the	O	
19	replacement	O	
20	of	O	
21	the	O	
22	phenyl	O	
23	group	O	
24	at	O	
25	position	O	
26	2	O	
27	,	O	
28	caused	O	
29	a	O	
30	marked	O	
31	decrease	O	
32	of	O	
33	activity	O	
34	.	O	

1	Transcription	O	
2	readthrough	O	
3	into	O	
4	the	O	
5	inverted	O	
6	repeats	O	
7	has	O	
8	little	O	
9	effect	O	
10	on	O	
11	this	O	
12	event	O	
13	.	O	

1	Therefore	O	
2	,	O	
3	the	O	
4	results	O	
5	indicate	O	
6	that	O	
7	repeated	O	
8	exposure	O	
9	to	O	
10	amphetamine	O	
11	or	O	
12	apomorphine	O	
13	overcomes	O	
14	the	O	
15	context	O	
16	-	O	
17	dependent	O	
18	component	O	
19	of	O	
20	sensitization	O	
21	of	O	
22	amphetamine	O	
23	-	O	
24	or	O	
25	apomorphine	O	
26	-	O	
27	induced	O	
28	stereotyped	O	
29	behavior	O	
30	.	O	

1	The	O	
2	response	O	
3	of	O	
4	the	O	
5	plasma	B	
6	fibrinogen	I	
7	level	O	
8	to	O	
9	the	O	
10	subucutaneous	O	
11	injection	O	
12	of	O	
13	turpentine	O	
14	and	O	
15	to	O	
16	the	O	
17	intravenous	O	
18	injection	O	
19	of	O	
20	endotoxin	O	
21	was	O	
22	measured	O	
23	in	O	
24	normal	O	
25	rabbits	O	
26	and	O	
27	in	O	
28	rabbits	O	
29	made	O	
30	granulocytopenic	O	
31	and	O	
32	thrombocytopenic	O	
33	with	O	
34	busulfan	O	
35	.	O	

1	High	O	
2	-	O	
3	pressure	O	
4	effects	O	
5	on	O	
6	ultrafast	O	
7	-	O	
8	relaxation	O	
9	kinetics	O	
10	of	O	
11	excitons	O	
12	in	O	
13	polydiacetylene	O	
14	4BCMU	O	
15	.	O	

1	Mutagenesis	O	
2	of	O	
3	IM1	B	
4	enhances	O	
5	the	O	
6	ability	O	
7	of	O	
8	c	B	
9	-	I	
10	Fos	I	
11	to	O	
12	activate	O	
13	an	O	
14	AP1	B	
15	bearing	I	
16	promoter	I	
17	.	O	

1	Both	O	
2	increasing	O	
3	basal	O	
4	FSH	B	
5	and	O	
6	age	O	
7	were	O	
8	associated	O	
9	significantly	O	
10	with	O	
11	increased	O	
12	total	O	
13	gonadotrophin	B	
14	dose	O	
15	,	O	
16	and	O	
17	reduced	O	
18	number	O	
19	of	O	
20	oocytes	O	
21	collected	O	
22	and	O	
23	pregnancy	O	
24	rate	O	
25	.	O	

1	During	O	
2	the	O	
3	following	O	
4	pregnancy	O	
5	ultrasonographic	O	
6	studies	O	
7	of	O	
8	the	O	
9	male	O	
10	fetus	O	
11	in	O	
12	the	O	
13	16th	O	
14	week	O	
15	of	O	
16	gestation	O	
17	revealed	O	
18	severe	O	
19	micrognathia	O	
20	,	O	
21	short	O	
22	and	O	
23	wide	O	
24	thumbs	O	
25	,	O	
26	and	O	
27	big	O	
28	toes	O	
29	,	O	
30	and	O	
31	bowed	O	
32	tibiae	O	
33	.	O	

1	Only	O	
2	transcripts	O	
3	specific	O	
4	for	O	
5	TSGF	B	
6	-	I	
7	2	I	
8	are	O	
9	detected	O	
10	in	O	
11	ovary	O	
12	and	O	
13	testes	O	
14	tissues	O	
15	of	O	
16	adults	O	
17	as	O	
18	well	O	
19	as	O	
20	in	O	
21	puparia	O	
22	,	O	
23	while	O	
24	neither	O	
25	gene	O	
26	is	O	
27	expressed	O	
28	during	O	
29	the	O	
30	larval	O	
31	developmental	O	
32	stages	O	
33	.	O	

1	Ligand	O	
2	-	O	
3	independent	O	
4	activation	O	
5	of	O	
6	platelet	B	
7	-	I	
8	derived	I	
9	growth	I	
10	factor	I	
11	receptor	I	
12	is	O	
13	a	O	
14	necessary	O	
15	intermediate	O	
16	in	O	
17	lysophosphatidic	O	
18	,	O	
19	acid	O	
20	-	O	
21	stimulated	O	
22	mitogenic	O	
23	activity	O	
24	in	O	
25	L	O	
26	cells	O	
27	.	O	

1	We	O	
2	have	O	
3	synthesized	O	
4	[	O	
5	7	O	
6	,	O	
7	7	O	
8	-	O	
9	2H2	O	
10	]-	O	
11	19	O	
12	-	O	
13	OHA	O	
14	with	O	
15	high	O	
16	deuterium	O	
17	content	O	
18	and	O	
19	,	O	
20	together	O	
21	with	O	
22	[	O	
23	7	O	
24	,	O	
25	7	O	
26	-	O	
27	2H2	O	
28	]	O	
29	A	O	
30	and	O	
31	[	O	
32	9	O	
33	,	O	
34	11	O	
35	-	O	
36	2H2	O	
37	]	O	
38	estrone	O	
39	(	O	
40	E1	O	
41	),	O	
42	have	O	
43	developed	O	
44	a	O	
45	quantitative	O	
46	assay	O	
47	of	O	
48	serum	O	
49	level	O	
50	19	O	
51	-	O	
52	OHA	O	
53	,	O	
54	A	O	
55	,	O	
56	and	O	
57	E1	O	
58	using	O	
59	the	O	
60	gas	O	
61	chromatography	O	
62	/	O	
63	mass	O	
64	spectrometry	O	
65	-	O	
66	mass	O	
67	fragmentography	O	
68	method	O	
69	to	O	
70	monitor	O	
71	individual	O	
72	subjects	O	
73	throughout	O	
74	pregnancy	O	
75	.	O	

1	The	O	
2	COOH	O	
3	-	O	
4	terminal	O	
5	46	O	
6	codons	O	
7	of	O	
8	slyD	B	
9	encode	O	
10	a	O	
11	remarkable	O	
12	histidine	O	
13	-	O	
14	rich	O	
15	peptide	O	
16	sequence	O	
17	which	O	
18	is	O	
19	at	O	
20	least	O	
21	partly	O	
22	dispensable	O	
23	for	O	
24	slyD	B	
25	function	O	
26	in	O	
27	E	B	
28	-	O	
29	mediated	O	
30	lysis	O	
31	.	O	

1	After	O	
2	hemodynamic	O	
3	stabilization	O	
4	,	O	
5	the	O	
6	goal	O	
7	of	O	
8	therapy	O	
9	is	O	
10	to	O	
11	diminish	O	
12	the	O	
13	chance	O	
14	that	O	
15	an	O	
16	ulcer	O	
17	will	O	
18	continue	O	
19	to	O	
20	bleed	O	
21	or	O	
22	will	O	
23	rebleed	O	
24	.	O	

1	The	O	
2	disturbance	O	
3	of	O	
4	pulmonary	O	
5	gas	O	
6	exchange	O	
7	,	O	
8	as	O	
9	revealed	O	
10	by	O	
11	the	O	
12	high	O	
13	value	O	
14	of	O	
15	AaDO2	O	
16	,	O	
17	existed	O	
18	without	O	
19	left	O	
20	ventricular	O	
21	dysfunction	O	
22	,	O	
23	and	O	
24	AaDO2	O	
25	had	O	
26	no	O	
27	significant	O	
28	relationship	O	
29	with	O	
30	any	O	
31	of	O	
32	the	O	
33	hemodynamic	O	
34	parameters	O	
35	including	O	
36	the	O	
37	difference	O	
38	between	O	
39	plasma	O	
40	colloid	O	
41	osmotic	O	
42	pressure	O	
43	and	O	
44	PCW	O	
45	.	O	

1	Resultant	O	
2	activation	O	
3	of	O	
4	c	B	
5	-	I	
6	Jun	I	
7	N	I	
8	-	I	
9	terminal	I	
10	kinase	I	
11	/	O	
12	stress	B	
13	-	I	
14	activated	I	
15	protein	I	
16	kinase	I	
17	(	O	
18	JNK	B	
19	/	O	
20	SAPK	B	
21	).	O	

1	Deletion	O	
2	analysis	O	
3	indicates	O	
4	that	O	
5	TBP	B	
6	and	O	
7	hTAFII18	B	
8	bind	O	
9	to	O	
10	distinct	O	
11	domains	O	
12	of	O	
13	hTAFII28	B	
14	.	O	
15	hTAFII18	B	
16	also	O	
17	interacts	O	
18	with	O	
19	TBP	B	
20	,	O	
21	but	O	
22	it	O	
23	interacts	O	
24	more	O	
25	strongly	O	
26	with	O	
27	hTAFII28	B	
28	and	O	
29	hTAFII30	B	
30	.	O	

1	With	O	
2	a	O	
3	cutoff	O	
4	level	O	
5	for	O	
6	TSST	B	
7	-	I	
8	1	I	
9	of	O	
10	less	O	
11	than	O	
12	100	O	
13	pg	O	
14	/	O	
15	ml	O	
16	,	O	
17	28	O	
18	samples	O	
19	obtained	O	
20	from	O	
21	12	O	
22	patients	O	
23	were	O	
24	positive	O	
25	for	O	
26	TSST	B	
27	-	I	
28	1	I	
29	.	O	

1	A	O	
2	three	O	
3	-	O	
4	phased	O	
5	analysis	O	
6	of	O	
7	treatment	O	
8	plans	O	
9	for	O	
10	45	O	
11	patients	O	
12	was	O	
13	undertaken	O	
14	.	O	

1	A	O	
2	contiguous	O	
3	and	O	
4	sequentially	O	
5	occupied	O	
6	secondary	O	
7	Fur	B	
8	-	I	
9	binding	I	
10	site	I	
11	in	O	
12	entC	B	
13	was	O	
14	protected	O	
15	at	O	
16	higher	O	
17	Fur	B	
18	concentrations	O	
19	,	O	
20	extending	O	
21	the	O	
22	protected	O	
23	region	O	
24	to	O	
25	+	O	
26	49	O	
27	,	O	
28	and	O	
29	sequestering	O	
30	the	O	
31	putative	O	
32	Shine	O	
33	-	O	
34	Dalgarno	O	
35	sequence	O	
36	.	O	

1	The	O	
2	high	O	
3	degree	O	
4	of	O	
5	sequence	O	
6	identity	O	
7	(	O	
8	96	O	
9	%)	O	
10	between	O	
11	hydrolase	B	
12	B	I	
13	and	I	
14	C	I	
15	,	O	
16	particularly	O	
17	in	O	
18	the	O	
19	3	O	
20	'	O	
21	untranslated	O	
22	region	O	
23	,	O	
24	suggests	O	
25	that	O	
26	the	O	
27	genes	O	
28	encoding	O	
29	these	O	
30	two	O	
31	carboxylesterases	B	
32	evolved	O	
33	by	O	
34	duplication	O	
35	and	O	
36	divergence	O	
37	of	O	
38	a	O	
39	common	O	
40	ancestral	O	
41	gene	O	
42	.	O	

1	By	O	
2	contrast	O	
3	,	O	
4	all	O	
5	proteins	O	
6	initiated	O	
7	with	O	
8	a	O	
9	methionine	O	
10	placed	O	
11	one	O	
12	residue	O	
13	upstream	O	
14	of	O	
15	the	O	
16	natural	O	
17	N	O	
18	terminus	O	
19	of	O	
20	PR	B	
21	failed	O	
22	to	O	
23	show	O	
24	specific	O	
25	proteolysis	O	
26	.	O	

1	Previous	O	
2	transactivation	O	
3	experiments	O	
4	indicated	O	
5	that	O	
6	three	O	
7	amino	O	
8	acids	O	
9	residing	O	
10	in	O	
11	this	O	
12	region	O	
13	,	O	
14	Gly	O	
15	,	O	
16	Ser	O	
17	and	O	
18	Val	O	
19	,	O	
20	appear	O	
21	to	O	
22	be	O	
23	critical	O	
24	for	O	
25	target	O	
26	-	O	
27	site	O	
28	discrimination	O	
29	.	O	

1	Thus	O	
2	,	O	
3	NART	O	
4	-	O	
5	R	O	
6	performance	O	
7	may	O	
8	not	O	
9	be	O	
10	a	O	
11	valid	O	
12	estimate	O	
13	of	O	
14	baseline	O	
15	IQ	O	
16	for	O	
17	patients	O	
18	with	O	
19	neurologic	O	
20	disorders	O	
21	with	O	
22	suspected	O	
23	language	O	
24	impairment	O	
25	.	O	

1	In	O	
2	the	O	
3	diabetics	O	
4	,	O	
5	Ca2	O	
6	+	O	
7	infusions	O	
8	induced	O	
9	a	O	
10	rise	O	
11	of	O	
12	plasma	O	
13	Ca2	O	
14	+	O	
15	up	O	
16	to	O	
17	3	O	
18	.	O	
19	2	O	
20	+/-	O	
21	0	O	
22	.	O	
23	1	O	
24	mmol	O	
25	/	O	
26	1	O	
27	and	O	
28	a	O	
29	fall	O	
30	of	O	
31	circulating	O	
32	glucagon	B	
33	(-	O	
34	26	O	
35	.	O	
36	4	O	
37	+/-	O	
38	5	O	
39	.	O	
40	7	O	
41	%;	O	
42	p	O	
43	less	O	
44	than	O	
45	0	O	
46	.	O	
47	001	O	
48	)	O	
49	and	O	
50	glucose	O	
51	(-	O	
52	23	O	
53	.	O	
54	3	O	
55	+/-	O	
56	3	O	
57	.	O	
58	6	O	
59	%;	O	
60	p	O	
61	less	O	
62	than	O	
63	0	O	
64	.	O	
65	05	O	
66	).	O	

1	Haploid	O	
2	cells	O	
3	of	O	
4	mating	O	
5	type	O	
6	A	O	
7	of	O	
8	the	O	
9	basidiomycetous	O	
10	yeast	O	
11	Rhodosporidium	O	
12	toruloides	O	
13	secrete	O	
14	a	O	
15	mating	O	
16	pheromone	O	
17	,	O	
18	rhodotorucine	B	
19	A	I	
20	,	O	
21	which	O	
22	is	O	
23	an	O	
24	undecapeptide	O	
25	containing	O	
26	S	O	
27	-	O	
28	farnesyl	O	
29	cysteine	O	
30	at	O	
31	its	O	
32	carboxy	O	
33	terminus	O	
34	.	O	

1	y	O	
2	.	O	

1	After	O	
2	screening	O	
3	the	O	
4	Berkeley	O	
5	Drosophila	O	
6	Genome	O	
7	Project	O	
8	database	O	
9	with	O	
10	sequences	O	
11	from	O	
12	a	O	
13	recently	O	
14	characterized	O	
15	Leu	B	
16	-	I	
17	rich	I	
18	repeats	I	
19	-	I	
20	containing	I	
21	G	I	
22	protein	I	
23	-	I	
24	coupled	I	
25	receptor	I	
26	(	O	
27	LGR	B	
28	)	O	
29	from	O	
30	Drosophila	O	
31	(	O	
32	DLGR	B	
33	-	I	
34	1	I	
35	),	O	
36	we	O	
37	identified	O	
38	a	O	
39	second	O	
40	gene	O	
41	for	O	
42	a	O	
43	different	O	
44	LGR	B	
45	(	O	
46	DLGR	B	
47	-	I	
48	2	I	
49	)	O	
50	and	O	
51	cloned	O	
52	its	O	
53	cDNA	O	
54	.	O	

1	The	O	
2	7	O	
3	-	O	
4	day	O	
5	treatment	O	
6	resulted	O	
7	in	O	
8	a	O	
9	decrease	O	
10	in	O	
11	mitochondrial	O	
12	uptake	O	
13	of	O	
14	Rh123	O	
15	and	O	
16	an	O	
17	increase	O	
18	in	O	
19	NAO	O	
20	uptake	O	
21	.	O	

1	Initial	O	
2	experience	O	
3	with	O	
4	a	O	
5	microprocessor	O	
6	controlled	O	
7	current	O	
8	based	O	
9	defibrillator	O	
10	.	O	

1	Biol	O	
2	.	O	

1	The	O	
2	activity	O	
3	of	O	
4	serum	B	
5	lipase	I	
6	and	O	
7	amylase	B	
8	distinctly	O	
9	increased	O	
10	at	O	
11	3	O	
12	h	O	
13	and	O	
14	went	O	
15	up	O	
16	to	O	
17	the	O	
18	maximum	O	
19	at	O	
20	12	O	
21	h	O	
22	after	O	
23	injection	O	
24	of	O	
25	Na	O	
26	-	O	
27	Tc	O	
28	.	O	

1	E2	B	
2	point	O	
3	mutants	O	
4	unable	O	
5	to	O	
6	inhibit	O	
7	cell	O	
8	growth	O	
9	did	O	
10	not	O	
11	repress	O	
12	cdc25A	B	
13	and	O	
14	cdc25B	B	
15	expression	O	
16	,	O	
17	nor	O	
18	did	O	
19	the	O	
20	cell	O	
21	cycle	O	
22	inhibitors	O	
23	hydroxyurea	O	
24	and	O	
25	mimosine	O	
26	.	O	

1	Furthermore	O	
2	,	O	
3	the	O	
4	over	O	
5	-	O	
6	replication	O	
7	phenotype	O	
8	produced	O	
9	by	O	
10	this	O	
11	mutant	B	
12	p65cdc18	I	
13	is	O	
14	resistant	O	
15	to	O	
16	increased	O	
17	mitotic	O	
18	cyclin	B	
19	/	O	
20	CDK	B	
21	activity	O	
22	,	O	
23	a	O	
24	known	O	
25	inhibitor	O	
26	of	O	
27	over	O	
28	-	O	
29	replication	O	
30	.	O	

1	Taken	O	
2	together	O	
3	,	O	
4	our	O	
5	data	O	
6	suggest	O	
7	that	O	
8	PecS	B	
9	attenuates	O	
10	pelD	B	
11	and	O	
12	pelE	B	
13	expression	O	
14	rather	O	
15	than	O	
16	acting	O	
17	as	O	
18	a	O	
19	true	O	
20	repressor	O	
21	like	O	
22	KdgR	B	
23	.	O	

1	Acad	O	
2	.	O	

1	The	O	
2	purpose	O	
3	of	O	
4	this	O	
5	study	O	
6	is	O	
7	twofold	O	
8	:	O	
9	(	O	
10	1	O	
11	)	O	
12	to	O	
13	present	O	
14	a	O	
15	parallel	O	
16	form	O	
17	of	O	
18	the	O	
19	Gudjonsson	O	
20	Suggestibility	O	
21	Scale	O	
22	(	O	
23	GSS	O	
24	,	O	
25	Form	O	
26	1	O	
27	);	O	
28	(	O	
29	2	O	
30	)	O	
31	to	O	
32	study	O	
33	test	O	
34	-	O	
35	retest	O	
36	reliabilities	O	
37	of	O	
38	interrogative	O	
39	suggestibility	O	
40	.	O	

1	The	O	
2	conditions	O	
3	for	O	
4	obtaining	O	
5	titanium	O	
6	dioxide	O	
7	from	O	
8	the	O	
9	substrates	O	
10	titanium	O	
11	tetrachloride	O	
12	and	O	
13	oxygen	O	
14	and	O	
15	applying	O	
16	this	O	
17	to	O	
18	a	O	
19	surgical	O	
20	stainless	O	
21	steel	O	
22	of	O	
23	the	O	
24	type	O	
25	316L	O	
26	by	O	
27	the	O	
28	plasma	O	
29	assisted	O	
30	chemical	O	
31	vapour	O	
32	deposition	O	
33	method	O	
34	have	O	
35	been	O	
36	determined	O	
37	.	O	

1	DR1	B	
2	molecules	I	
3	purified	O	
4	from	O	
5	human	O	
6	lymphoblastoid	O	
7	cell	O	
8	lines	O	
9	could	O	
10	specifically	O	
11	bind	O	
12	to	O	
13	these	O	
14	peptide	O	
15	sequences	O	
16	expressed	O	
17	on	O	
18	the	O	
19	phage	O	
20	surface	O	
21	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	we	O	
5	identified	O	
6	two	O	
7	mutations	O	
8	,	O	
9	Delta	O	
10	M1281	O	
11	and	O	
12	IVS51	O	
13	+	O	
14	5G	O	
15	-->	O	
16	A	O	
17	,	O	
18	in	O	
19	a	O	
20	German	O	
21	USH1	B	
22	patient	O	
23	.	O	

1	Although	O	
2	a	O	
3	great	O	
4	deal	O	
5	is	O	
6	understood	O	
7	about	O	
8	how	O	
9	bHLH	B	
10	factors	I	
11	activate	O	
12	gene	O	
13	transcription	O	
14	via	O	
15	E	O	
16	-	O	
17	box	O	
18	DNA	O	
19	consensus	O	
20	sequences	O	
21	,	O	
22	studies	O	
23	of	O	
24	bHLH	B	
25	factor	I	
26	function	O	
27	in	O	
28	higher	O	
29	eukaryotes	O	
30	often	O	
31	have	O	
32	been	O	
33	hindered	O	
34	by	O	
35	the	O	
36	presence	O	
37	of	O	
38	multiple	O	
39	family	O	
40	members	O	
41	.	O	

1	A	O	
2	system	O	
3	is	O	
4	described	O	
5	in	O	
6	which	O	
7	the	O	
8	volume	O	
9	flow	O	
10	rate	O	
11	of	O	
12	blood	O	
13	in	O	
14	a	O	
15	vessel	O	
16	is	O	
17	determined	O	
18	using	O	
19	transverse	O	
20	colour	O	
21	Doppler	O	
22	ultrasound	O	
23	imaging	O	
24	.	O	

1	Escherichia	O	
2	coli	O	
3	BL21	O	
4	(	O	
5	DE3	O	
6	)	O	
7	plysS	O	
8	,	O	
9	harbouring	O	
10	a	O	
11	recombinant	O	
12	plasmid	O	
13	containing	O	
14	the	O	
15	catalase	B	
16	-	O	
17	peroxidase	B	
18	gene	O	
19	,	O	
20	produced	O	
21	a	O	
22	large	O	
23	amount	O	
24	of	O	
25	proteins	O	
26	that	O	
27	co	O	
28	-	O	
29	migrated	O	
30	on	O	
31	SDS	O	
32	/	O	
33	PAGE	O	
34	with	O	
35	the	O	
36	native	O	
37	enzyme	O	
38	.	O	

1	Using	O	
2	the	O	
3	rap1t	B	
4	alleles	I	
5	to	O	
6	generate	O	
7	wild	O	
8	-	O	
9	type	O	
10	cells	O	
11	differing	O	
12	only	O	
13	in	O	
14	telomere	O	
15	tract	O	
16	lengths	O	
17	,	O	
18	we	O	
19	also	O	
20	show	O	
21	that	O	
22	telomere	O	
23	position	O	
24	effects	O	
25	are	O	
26	highly	O	
27	sensitive	O	
28	to	O	
29	changes	O	
30	in	O	
31	the	O	
32	size	O	
33	(	O	
34	or	O	
35	structure	O	
36	)	O	
37	of	O	
38	the	O	
39	telomeric	O	
40	tract	O	
41	.	O	

1	A	O	
2	prospectively	O	
3	gated	O	
4	2D	O	
5	axial	O	
6	sequence	O	
7	with	O	
8	velocity	O	
9	encoding	O	
10	in	O	
11	the	O	
12	craniocaudal	O	
13	direction	O	
14	in	O	
15	the	O	
16	cervical	O	
17	region	O	
18	was	O	
19	set	O	
20	at	O	
21	a	O	
22	velocity	O	
23	of	O	
24	+/-	O	
25	10	O	
26	cm	O	
27	/	O	
28	s	O	
29	.	O	

1	The	O	
2	phosphorylation	O	
3	efficiency	O	
4	is	O	
5	improved	O	
6	by	O	
7	increasing	O	
8	the	O	
9	number	O	
10	of	O	
11	N	O	
12	-	O	
13	terminal	O	
14	arginine	O	
15	residues	O	
16	and	O	
17	by	O	
18	moving	O	
19	the	O	
20	arginyl	O	
21	cluster	O	
22	one	O	
23	residue	O	
24	further	O	
25	away	O	
26	from	O	
27	the	O	
28	serine	O	
29	,	O	
30	the	O	
31	nonapeptide	O	
32	(	O	
33	Arg	O	
34	)	O	
35	4	O	
36	-	O	
37	Ala	O	
38	-	O	
39	Ala	O	
40	-	O	
41	Ser	O	
42	-	O	
43	Val	O	
44	-	O	
45	Ala	O	
46	being	O	
47	the	O	
48	best	O	
49	substrate	O	
50	among	O	
51	all	O	
52	the	O	
53	short	O	
54	peptides	O	
55	tested	O	
56	(	O	
57	Km	O	
58	=	O	
59	15	O	
60	microM	O	
61	).	O	

1	Replacing	O	
2	residues	O	
3	405	O	
4	-	O	
5	419	O	
6	on	O	
7	delta419	O	
8	with	O	
9	the	O	
10	conserved	O	
11	AF	O	
12	-	O	
13	2	O	
14	domain	O	
15	from	O	
16	the	O	
17	vitamin	B	
18	D3	I	
19	receptor	I	
20	or	O	
21	the	O	
22	estrogen	B	
23	receptor	I	
24	results	O	
25	in	O	
26	a	O	
27	receptor	O	
28	with	O	
29	wild	O	
30	-	O	
31	type	O	
32	or	O	
33	low	O	
34	transcriptional	O	
35	activity	O	
36	,	O	
37	respectively	O	
38	.	O	

1	This	O	
2	is	O	
3	based	O	
4	on	O	
5	partitioning	O	
6	an	O	
7	underlying	O	
8	multivariate	O	
9	normal	O	
10	distribution	O	
11	.	O	

1	It	O	
2	was	O	
3	concluded	O	
4	,	O	
5	that	O	
6	on	O	
7	a	O	
8	given	O	
9	section	O	
10	,	O	
11	75	O	
12	,	O	
13	7	O	
14	per	O	
15	cent	O	
16	of	O	
17	the	O	
18	trabeculae	O	
19	were	O	
20	in	O	
21	contact	O	
22	with	O	
23	vascular	O	
24	cavities	O	
25	.	O	

1	Various	O	
2	treatment	O	
3	modalities	O	
4	are	O	
5	reviewed	O	
6	in	O	
7	the	O	
8	context	O	
9	of	O	
10	the	O	
11	psychology	O	
12	as	O	
13	well	O	
14	as	O	
15	the	O	
16	physiology	O	
17	of	O	
18	severe	O	
19	intractable	O	
20	pain	O	
21	.	O	

1	DNase	B	
2	I	I	
3	footprinting	O	
4	with	O	
5	rat	O	
6	liver	O	
7	nuclear	O	
8	extracts	O	
9	identified	O	
10	7	O	
11	major	O	
12	protein	O	
13	-	O	
14	binding	O	
15	domains	O	
16	termed	O	
17	P1	O	
18	through	O	
19	P7	O	
20	in	O	
21	a	O	
22	796	O	
23	base	O	
24	pair	O	
25	DNA	O	
26	fragment	O	
27	(	O	
28	base	O	
29	pairs	O	
30	-	O	
31	763	O	
32	to	O	
33	+	O	
34	33	O	
35	).	O	

1	Two	O	
2	of	O	
3	these	O	
4	resulted	O	
5	in	O	
6	increased	O	
7	levels	O	
8	of	O	
9	the	O	
10	alpha	O	
11	subunit	O	
12	,	O	
13	and	O	
14	one	O	
15	caused	O	
16	a	O	
17	substitution	O	
18	of	O	
19	glycine	O	
20	for	O	
21	the	O	
22	aspartic	O	
23	acid	O	
24	residue	O	
25	at	O	
26	position	O	
27	171	O	
28	,	O	
29	in	O	
30	the	O	
31	N	O	
32	-	O	
33	terminal	O	
34	domain	O	
35	.	O	

1	LH	B	
2	/	I	
3	CG	I	
4	receptor	I	
5	activation	O	
6	of	O	
7	ARNO	B	
8	is	O	
9	not	O	
10	mediated	O	
11	by	O	
12	activation	O	
13	of	O	
14	phosphatidylinositol	B	
15	3	I	
16	-	I	
17	kinase	I	
18	(	O	
19	PI	B	
20	3	I	
21	-	I	
22	kinase	I	
23	)	O	
24	or	O	
25	by	O	
26	G	B	
27	protein	I	
28	beta	I	
29	gamma	I	
30	subunits	I	
31	.	O	

1	Expression	O	
2	of	O	
3	a	O	
4	dominant	B	
5	negative	I	
6	Smad2	I	
7	significantly	O	
8	reduces	O	
9	the	O	
10	level	O	
11	of	O	
12	luciferase	B	
13	reporter	I	
14	activity	O	
15	induced	O	
16	by	O	
17	nodal	O	
18	treatment	O	
19	.	O	

1	Studied	O	
2	groups	O	
3	were	O	
4	(	O	
5	1	O	
6	)	O	
7	untreated	O	
8	control	O	
9	,	O	
10	n	O	
11	=	O	
12	12	O	
13	;	O	
14	(	O	
15	2	O	
16	)	O	
17	FK	O	
18	-	O	
19	1	O	
20	,	O	
21	n	O	
22	=	O	
23	8	O	
24	;	O	
25	(	O	
26	3	O	
27	)	O	
28	FK	O	
29	-	O	
30	3	O	
31	,	O	
32	n	O	
33	=	O	
34	8	O	
35	.	O	

1	Study	O	
2	on	O	
3	re	O	
4	-	O	
5	establishment	O	
6	of	O	
7	ovulation	O	
8	after	O	
9	termination	O	
10	of	O	
11	sex	O	
12	-	O	
13	steroidal	O	
14	treatment	O	
15	--	O	
16	compared	O	
17	with	O	
18	re	O	
19	-	O	
20	appearance	O	
21	of	O	
22	ovulation	O	
23	after	O	
24	abortion	O	
25	and	O	
26	premature	O	
27	delivery	O	
28	.	O	

1	Schwab	O	
2	and	O	
3	England	O	
4	ADL	O	
5	scores	O	
6	in	O	
7	the	O	
8	"	O	
9	off	O	
10	"	O	
11	state	O	
12	were	O	
13	improved	O	
14	by	O	
15	18	O	
16	%	O	
17	and	O	
18	in	O	
19	the	O	
20	"	O	
21	on	O	
22	"	O	
23	state	O	
24	the	O	
25	scores	O	
26	declined	O	
27	by	O	
28	2	O	
29	%.	O	

1	The	O	
2	B	B	
3	cell	I	
4	antigen	I	
5	receptor	I	
6	activates	O	
7	the	O	
8	Akt	B	
9	(	O	
10	protein	B	
11	kinase	I	
12	B	I	
13	)/	O	
14	glycogen	B	
15	synthase	I	
16	kinase	I	
17	-	I	
18	3	I	
19	signaling	O	
20	pathway	O	
21	via	O	
22	phosphatidylinositol	B	
23	3	I	
24	-	I	
25	kinase	I	
26	.	O	

1	The	O	
2	determination	O	
3	of	O	
4	physical	O	
5	performance	O	
6	capacity	O	
7	was	O	
8	based	O	
9	on	O	
10	W170	O	
11	,	O	
12	W85	O	
13	%	O	
14	and	O	
15	on	O	
16	predicted	O	
17	VO2	O	
18	max	O	
19	measured	O	
20	with	O	
21	continuously	O	
22	increasing	O	
23	work	O	
24	load	O	
25	on	O	
26	a	O	
27	bicycle	O	
28	ergometer	O	
29	.	O	

1	Penicillinase	B	
2	production	O	
3	in	O	
4	Staphylococcus	O	
5	aureus	O	
6	strains	O	
7	of	O	
8	clinical	O	
9	importance	O	
10	.	O	

1	Nuclease	O	
2	footprinting	O	
3	revealed	O	
4	that	O	
5	purified	O	
6	glucocorticoid	B	
7	receptor	I	
8	bound	O	
9	at	O	
10	multiple	O	
11	discrete	O	
12	sites	O	
13	within	O	
14	and	O	
15	at	O	
16	the	O	
17	borders	O	
18	of	O	
19	the	O	
20	tandemly	O	
21	repeated	O	
22	sequence	O	
23	motif	O	
24	that	O	
25	defines	O	
26	Sa	B	
27	.	O	

1	The	O	
2	GPI	O	
3	anchor	O	
4	moiety	O	
5	is	O	
6	either	O	
7	absent	O	
8	or	O	
9	present	O	
10	at	O	
11	a	O	
12	very	O	
13	low	O	
14	level	O	
15	in	O	
16	the	O	
17	polypeptide	O	
18	expressed	O	
19	from	O	
20	the	O	
21	cDNA	O	
22	that	O	
23	contained	O	
24	both	O	
25	the	O	
26	signal	O	
27	peptide	O	
28	and	O	
29	GPI	O	
30	signal	O	
31	sequences	O	
32	.	O	

1	We	O	
2	show	O	
3	that	O	
4	these	O	
5	three	O	
6	gain	O	
7	-	O	
8	of	O	
9	-	O	
10	function	O	
11	mutants	O	
12	differ	O	
13	considerably	O	
14	in	O	
15	their	O	
16	ability	O	
17	to	O	
18	bypass	O	
19	the	O	
20	sex	O	
21	determination	O	
22	signal	O	
23	,	O	
24	with	O	
25	SxlM4	B	
26	being	O	
27	the	O	
28	strongest	O	
29	and	O	
30	SxlM1	B	
31	the	O	
32	weakest	O	
33	.	O	

1	Treatment	O	
2	with	O	
3	amphotericin	O	
4	B	O	
5	and	O	
6	flucytosine	O	
7	led	O	
8	to	O	
9	improvement	O	
10	of	O	
11	the	O	
12	symptoms	O	
13	but	O	
14	did	O	
15	not	O	
16	eradicate	O	
17	the	O	
18	micro	O	
19	-	O	
20	organisms	O	
21	from	O	
22	the	O	
23	cerebrospinal	O	
24	fluid	O	
25	(	O	
26	CSF	O	
27	).	O	

1	CMV	O	
2	hyperimmunoglobulin	B	
3	treatment	O	
4	(	O	
5	Cytotect	O	
6	,	O	
7	Biotest	O	
8	)	O	
9	was	O	
10	started	O	
11	(	O	
12	2	O	
13	ml	O	
14	/	O	
15	kg	O	
16	bw	O	
17	on	O	
18	day	O	
19	1	O	
20	and	O	
21	3	O	
22	,	O	
23	and	O	
24	1	O	
25	ml	O	
26	/	O	
27	kg	O	
28	on	O	
29	days	O	
30	5	O	
31	,	O	
32	7	O	
33	and	O	
34	9	O	
35	),	O	
36	which	O	
37	led	O	
38	to	O	
39	the	O	
40	eradication	O	
41	of	O	
42	the	O	
43	residual	O	
44	infiltrate	O	
45	and	O	
46	CMV	O	
47	-	O	
48	DNA	O	
49	in	O	
50	the	O	
51	myocardium	O	
52	.	O	

1	We	O	
2	suggest	O	
3	that	O	
4	apart	O	
5	from	O	
6	the	O	
7	World	O	
8	Summit	O	
9	for	O	
10	Children	O	
11	'	O	
12	s	O	
13	under	O	
14	-	O	
15	five	O	
16	mortality	O	
17	target	O	
18	for	O	
19	the	O	
20	year	O	
21	2000	O	
22	,	O	
23	intraregional	O	
24	targets	O	
25	to	O	
26	reduce	O	
27	geographical	O	
28	inequalities	O	
29	in	O	
30	under	O	
31	-	O	
32	five	O	
33	mortality	O	
34	should	O	
35	be	O	
36	specified	O	
37	.	O	

1	These	O	
2	findings	O	
3	suggest	O	
4	that	O	
5	there	O	
6	may	O	
7	be	O	
8	a	O	
9	relationship	O	
10	between	O	
11	the	O	
12	pathogenesis	O	
13	of	O	
14	MAL	O	
15	,	O	
16	narcolepsy	O	
17	,	O	
18	and	O	
19	OSA	O	
20	.	O	

1	RNA	B	
2	polymerase	I	
3	IIA	I	
4	was	O	
5	recovered	O	
6	in	O	
7	transcriptionally	O	
8	active	O	
9	complexes	O	
10	in	O	
11	reactions	O	
12	in	O	
13	which	O	
14	the	O	
15	input	O	
16	enzyme	O	
17	was	O	
18	RNA	B	
19	polymerase	I	
20	IIA	I	
21	.	O	

1	327	O	
2	and	O	
3	736	O	
4	protocols	O	
5	of	O	
6	postmortem	O	
7	examinations	O	
8	from	O	
9	Moscow	O	
10	hospitals	O	
11	N	O	
12	31	O	
13	and	O	
14	57	O	
15	,	O	
16	respectively	O	
17	,	O	
18	were	O	
19	evaluated	O	
20	statistically	O	
21	.	O	

1	The	O	
2	structure	O	
3	of	O	
4	the	O	
5	calcineurin	B	
6	A	I	
7	gene	I	
8	was	O	
9	determined	O	
10	by	O	
11	comparison	O	
12	of	O	
13	the	O	
14	genomic	O	
15	and	O	
16	cDNA	O	
17	sequences	O	
18	.	O	

1	In	O	
2	some	O	
3	cases	O	
4	,	O	
5	the	O	
6	aberrant	O	
7	methylation	O	
8	of	O	
9	CpGs	O	
10	within	O	
11	5	O	
12	'	O	
13	regulatory	O	
14	regions	O	
15	has	O	
16	led	O	
17	to	O	
18	suppression	O	
19	of	O	
20	gene	O	
21	activity	O	
22	.	O	

1	In	O	
2	addition	O	
3	to	O	
4	the	O	
5	nine	O	
6	and	O	
7	51	O	
8	terminal	O	
9	amino	O	
10	acid	O	
11	forms	O	
12	already	O	
13	known	O	
14	,	O	
15	we	O	
16	identified	O	
17	a	O	
18	third	O	
19	with	O	
20	43	O	
21	terminal	O	
22	amino	O	
23	acids	O	
24	predicted	O	
25	to	O	
26	encode	O	
27	a	O	
28	novel	O	
29	RET	B	
30	protein	I	
31	isoform	I	
32	.	O	

1	cDNA	O	
2	encoding	O	
3	a	O	
4	functional	O	
5	feline	B	
6	liver	I	
7	/	I	
8	bone	I	
9	/	I	
10	kidney	I	
11	-	I	
12	type	I	
13	alkaline	I	
14	phosphatase	I	
15	.	O	

1	The	O	
2	influence	O	
3	of	O	
4	patient	O	
5	-	O	
6	related	O	
7	factors	O	
8	on	O	
9	inter	O	
10	-	O	
11	observer	O	
12	variability	O	
13	in	O	
14	the	O	
15	evaluation	O	
16	of	O	
17	neurological	O	
18	signs	O	
19	was	O	
20	investigated	O	
21	.	O	

1	When	O	
2	expressed	O	
3	alone	O	
4	in	O	
5	test	O	
6	cells	O	
7	,	O	
8	Atr	B	
9	-	I	
10	I	I	
11	is	O	
12	unable	O	
13	to	O	
14	bind	O	
15	TGF	B	
16	-	I	
17	beta	I	
18	,	O	
19	activin	B	
20	,	O	
21	or	O	
22	bone	B	
23	morphogenetic	I	
24	protein	I	
25	2	I	
26	.	O	

1	In	O	
2	4	O	
3	spinalized	O	
4	cats	O	
5	,	O	
6	the	O	
7	effects	O	
8	of	O	
9	afferent	O	
10	inputs	O	
11	from	O	
12	hindlimb	O	
13	cutaneous	O	
14	nerves	O	
15	(	O	
16	sural	O	
17	cutaneous	O	
18	nerve	O	
19	:	O	
20	Sur	O	
21	)	O	
22	on	O	
23	mono	O	
24	-	O	
25	and	O	
26	poly	O	
27	-	O	
28	synaptic	O	
29	reflex	O	
30	recorded	O	
31	from	O	
32	tail	O	
33	muscle	O	
34	motoneurons	O	
35	were	O	
36	studied	O	
37	before	O	
38	and	O	
39	after	O	
40	spinal	O	
41	lesioning	O	
42	at	O	
43	S2	O	
44	-	O	
45	3	O	
46	level	O	
47	.	O	

1	A	O	
2	decrease	O	
3	of	O	
4	the	O	
5	lysozyme	B	
6	activity	O	
7	coincided	O	
8	with	O	
9	the	O	
10	clinical	O	
11	improvement	O	
12	of	O	
13	the	O	
14	bacterial	O	
15	meningitis	O	
16	.	O	

1	Raf	B	
2	is	O	
3	a	O	
4	key	O	
5	serine	B	
6	-	I	
7	threonine	I	
8	protein	I	
9	kinase	I	
10	which	O	
11	participates	O	
12	in	O	
13	the	O	
14	transmission	O	
15	of	O	
16	growth	O	
17	,	O	
18	anti	O	
19	-	O	
20	apoptotic	O	
21	and	O	
22	differentiation	O	
23	messages	O	
24	.	O	

1	We	O	
2	have	O	
3	mutated	O	
4	to	O	
5	cysteine	O	
6	,	O	
7	one	O	
8	at	O	
9	a	O	
10	time	O	
11	,	O	
12	21	O	
13	consecutive	O	
14	residues	O	
15	in	O	
16	the	O	
17	fourth	O	
18	TMS	O	
19	(	O	
20	TM4	O	
21	).	O	

1	In	O	
2	vitro	O	
3	affinity	O	
4	analyses	O	
5	demonstrated	O	
6	that	O	
7	recombinant	O	
8	130	O	
9	-	O	
10	kD	O	
11	protein	O	
12	directly	O	
13	interacts	O	
14	with	O	
15	ZO	B	
16	-	I	
17	1	I	
18	and	O	
19	the	O	
20	cytoplasmic	O	
21	domain	O	
22	of	O	
23	occludin	B	
24	,	O	
25	but	O	
26	not	O	
27	with	O	
28	ZO	B	
29	-	I	
30	2	I	
31	.	O	

1	Hypersplenism	O	

1	The	O	
2	serum	O	
3	levels	O	
4	of	O	
5	IgE	B	
6	,	O	
7	and	O	
8	asIgE	B	
9	and	O	
10	IgG	B	
11	-	I	
12	4	I	
13	against	O	
14	14	O	
15	common	O	
16	food	O	
17	allergens	O	
18	were	O	
19	determined	O	
20	.	O	

1	No	O	
2	difference	O	
3	in	O	
4	elastin	B	
5	peptide	I	
6	concentration	O	
7	was	O	
8	observed	O	
9	between	O	
10	emphysematous	O	
11	patients	O	
12	and	O	
13	control	O	
14	subjects	O	
15	(	O	
16	mean	O	
17	+/-	O	
18	SD	O	
19	=	O	
20	2	O	
21	.	O	
22	39	O	
23	+/-	O	
24	1	O	
25	.	O	
26	18	O	
27	micrograms	O	
28	/	O	
29	ml	O	
30	in	O	
31	patients	O	
32	versus	O	
33	2	O	
34	.	O	
35	55	O	
36	+/-	O	
37	1	O	
38	.	O	
39	34	O	
40	micrograms	O	
41	/	O	
42	ml	O	
43	in	O	
44	policemen	O	
45	and	O	
46	2	O	
47	.	O	
48	59	O	
49	+/-	O	
50	1	O	
51	.	O	
52	20	O	
53	micrograms	O	
54	/	O	
55	ml	O	
56	in	O	
57	coal	O	
58	miners	O	
59	).	O	

1	BIAcore	O	
2	analysis	O	
3	gave	O	
4	a	O	
5	Kaff	O	
6	of	O	
7	4	O	
8	.	O	
9	4	O	
10	x	O	
11	10	O	
12	(	O	
13	10	O	
14	)	O	
15	M	O	
16	-	O	
17	1	O	
18	for	O	
19	the	O	
20	binding	O	
21	of	O	
22	N	B	
23	-	I	
24	A3	I	
25	to	O	
26	T84	B	
27	.	I	
28	1	I	
29	and	O	
30	2	O	
31	.	O	
32	2	O	
33	x	O	
34	10	O	
35	(	O	
36	10	O	
37	)	O	
38	M	O	
39	-	O	
40	1	O	
41	for	O	
42	the	O	
43	binding	O	
44	of	O	
45	N	B	
46	-	I	
47	A3	I	
48	to	O	
49	T84	B	
50	.	I	
51	66	I	
52	.	O	

1	The	O	
2	used	O	
3	expression	O	
4	system	O	
5	could	O	
6	allow	O	
7	to	O	
8	produce	O	
9	mutated	O	
10	forms	O	
11	of	O	
12	SsEF	B	
13	-	I	
14	2	I	
15	obtained	O	
16	by	O	
17	mutagenesis	O	
18	of	O	
19	the	O	
20	corresponding	O	
21	gene	O	
22	.	O	

1	Complete	O	
2	sequences	O	
3	were	O	
4	obtained	O	
5	for	O	
6	the	O	
7	three	O	
8	large	O	
9	thrombic	O	
10	peptides	O	
11	,	O	
12	and	O	
13	these	O	
14	were	O	
15	aligned	O	
16	by	O	
17	using	O	
18	peptides	O	
19	from	O	
20	the	O	
21	V8	B	
22	protease	I	
23	digest	O	
24	.	O	

1	Circulating	O	
2	thrombomodulin	B	
3	:	O	
4	current	O	
5	knowledge	O	
6	and	O	
7	future	O	
8	prospects	O	

1	Confirming	O	
2	measures	O	
3	made	O	
4	by	O	
5	nurses	O	
6	and	O	
7	additionally	O	
8	,	O	
9	ABPM	O	
10	for	O	
11	women	O	
12	,	O	
13	seem	O	
14	to	O	
15	lessen	O	
16	this	O	
17	effect	O	
18	.	O	

1	Using	O	
2	a	O	
3	battery	O	
4	of	O	
5	I	B	
6	kappa	I	
7	B	I	
8	alpha	I	
9	mutants	I	
10	,	O	
11	we	O	
12	show	O	
13	that	O	
14	(	O	
15	i	O	
16	)	O	
17	a	O	
18	dimer	O	
19	binds	O	
20	a	O	
21	single	O	
22	I	B	
23	kappa	I	
24	B	I	
25	alpha	I	
26	molecule	I	
27	,	O	
28	(	O	
29	ii	O	
30	)	O	
31	the	O	
32	acidic	O	
33	C	O	
34	-	O	
35	terminal	O	
36	region	O	
37	of	O	
38	I	B	
39	kappa	I	
40	B	I	
41	alpha	I	
42	is	O	
43	not	O	
44	required	O	
45	for	O	
46	protein	O	
47	-	O	
48	protein	O	
49	binding	O	
50	and	O	
51	does	O	
52	not	O	
53	mask	O	
54	the	O	
55	nuclear	O	
56	localization	O	
57	signal	O	
58	of	O	
59	the	O	
60	dimer	O	
61	,	O	
62	(	O	
63	iii	O	
64	)	O	
65	the	O	
66	same	O	
67	C	O	
68	-	O	
69	terminal	O	
70	region	O	
71	is	O	
72	required	O	
73	for	O	
74	inhibition	O	
75	of	O	
76	DNA	O	
77	binding	O	
78	,	O	
79	and	O	
80	(	O	
81	iv	O	
82	)	O	
83	this	O	
84	inhibition	O	
85	may	O	
86	be	O	
87	accomplished	O	
88	by	O	
89	direct	O	
90	interaction	O	
91	between	O	
92	the	O	
93	PEST	O	
94	-	O	
95	like	O	
96	region	O	
97	and	O	
98	the	O	
99	DNA	O	
100	-	O	
101	binding	O	
102	region	O	
103	of	O	
104	one	O	
105	of	O	
106	the	O	
107	subunits	O	
108	of	O	
109	the	O	
110	dimer	O	
111	.	O	

1	However	O	
2	,	O	
3	a	O	
4	strongly	O	
5	increased	O	
6	frequency	O	
7	of	O	
8	CpG	O	
9	dinucleotides	O	
10	was	O	
11	found	O	
12	.	O	

1	Most	O	
2	kinases	O	
3	are	O	
4	not	O	
5	significantly	O	
6	inhibited	O	
7	by	O	
8	roscovitine	O	
9	.	O	
10	cdc2	B	
11	/	O	
12	cyclin	B	
13	B	I	
14	,	O	
15	cdk2	B	
16	/	O	
17	cyclin	B	
18	A	I	
19	,	O	
20	cdk2	B	
21	/	O	
22	cyclin	B	
23	E	I	
24	and	O	
25	cdk5	B	
26	/	O	
27	p35	B	
28	only	O	
29	are	O	
30	substantially	O	
31	inhibited	O	
32	(	O	
33	IC50	O	
34	values	O	
35	of	O	
36	0	O	
37	.	O	
38	65	O	
39	,	O	
40	0	O	
41	.	O	
42	7	O	
43	,	O	
44	0	O	
45	.	O	
46	7	O	
47	and	O	
48	0	O	
49	.	O	
50	2	O	
51	microM	O	
52	,	O	
53	respectively	O	
54	).	O	
55	cdk4	B	
56	/	O	
57	cyclin	B	
58	D1	I	
59	and	O	
60	cdk6	B	
61	/	O	
62	cyclin	B	
63	D2	I	
64	are	O	
65	very	O	
66	poorly	O	
67	inhibited	O	
68	by	O	
69	roscovitine	O	
70	(	O	
71	IC50	O	
72	>	O	
73	100	O	
74	microM	O	
75	).	O	

1	These	O	
2	results	O	
3	indicate	O	
4	that	O	
5	Rb	B	
6	protein	I	
7	is	O	
8	interacting	O	
9	with	O	
10	some	O	
11	component	O	
12	(	O	
13	s	O	
14	)	O	
15	of	O	
16	the	O	
17	cell	O	
18	cycle	O	
19	-	O	
20	regulatory	O	
21	machinery	O	
22	during	O	
23	G2	O	
24	phase	O	
25	.	O	

1	In	O	
2	the	O	
3	second	O	
4	experiment	O	
5	,	O	
6	a	O	
7	stable	O	
8	nickel	O	
9	isotope	O	
10	,	O	
11	61Ni	O	
12	,	O	
13	was	O	
14	given	O	
15	in	O	
16	drinking	O	
17	water	O	
18	to	O	
19	20	O	
20	nickel	O	
21	-	O	
22	sensitized	O	
23	women	O	
24	and	O	
25	20	O	
26	age	O	
27	-	O	
28	matched	O	
29	controls	O	
30	,	O	
31	both	O	
32	groups	O	
33	having	O	
34	vesicular	O	
35	hand	O	
36	eczema	O	
37	of	O	
38	the	O	
39	pompholyx	O	
40	type	O	
41	.	O	

1	These	O	
2	genes	O	
3	are	O	
4	expressed	O	
5	within	O	
6	a	O	
7	few	O	
8	hours	O	
9	of	O	
10	the	O	
11	initiation	O	
12	of	O	
13	development	O	
14	;	O	
15	their	O	
16	mRNAs	O	
17	accumulate	O	
18	to	O	
19	a	O	
20	peak	O	
21	at	O	
22	12	O	
23	hr	O	
24	and	O	
25	persist	O	
26	until	O	
27	culmination	O	
28	.	O	

1	Fluorometric	O	
2	methods	O	
3	can	O	
4	also	O	
5	provide	O	
6	information	O	
7	about	O	
8	porphyrin	O	
9	binding	O	
10	sites	O	
11	that	O	
12	is	O	
13	useful	O	
14	in	O	
15	understanding	O	
16	porphyrin	O	
17	transport	O	
18	and	O	
19	clearance	O	
20	.	O	

1	Although	O	
2	it	O	
3	has	O	
4	been	O	
5	shown	O	
6	that	O	
7	it	O	
8	is	O	
9	possible	O	
10	to	O	
11	use	O	
12	orally	O	
13	administered	O	
14	testosterone	O	
15	to	O	
16	maintain	O	
17	se	O	
18	-	O	
19	T	O	
20	levels	O	
21	in	O	
22	the	O	
23	normal	O	
24	male	O	
25	range	O	
26	,	O	
27	the	O	
28	convenience	O	
29	to	O	
30	the	O	
31	patient	O	
32	must	O	
33	be	O	
34	balanced	O	
35	against	O	
36	the	O	
37	cost	O	
38	and	O	
39	possible	O	
40	side	O	
41	effects	O	
42	of	O	
43	the	O	
44	large	O	
45	doses	O	
46	required	O	
47	.	O	

1	The	O	
2	binding	O	
3	site	O	
4	for	O	
5	OxyR	B	
6	overlapped	O	
7	P1oxyR	B	
8	,	O	
9	reminiscent	O	
10	of	O	
11	the	O	
12	autoregulatory	O	
13	loops	O	
14	controlling	O	
15	expression	O	
16	of	O	
17	oxyR	B	
18	in	O	
19	enteric	O	
20	bacteria	O	
21	and	O	
22	characteristic	O	
23	of	O	
24	the	O	
25	LysR	B	
26	superfamily	I	
27	in	O	
28	general	O	
29	.	O	

1	Viral	O	
2	genomic	O	
3	RNA	O	
4	for	O	
5	these	O	
6	reactions	O	
7	was	O	
8	obtained	O	
9	directly	O	
10	from	O	
11	fecal	O	
12	specimens	O	
13	of	O	
14	infected	O	
15	infant	O	
16	rats	O	
17	.	O	

1	Private	O	
2	hospital	O	
3	accreditation	O	
4	.	O	

1	Pituitary	O	
2	adenylate	B	
3	cyclase	I	
4	-	I	
5	activating	I	
6	polypeptide	I	
7	regulates	O	
8	prolactin	B	
9	promoter	I	
10	activity	O	
11	via	O	
12	a	O	
13	protein	B	
14	kinase	I	
15	A	I	
16	-	O	
17	mediated	O	
18	pathway	O	
19	that	O	
20	is	O	
21	independent	O	
22	of	O	
23	the	O	
24	transcriptional	O	
25	pathway	O	
26	employed	O	
27	by	O	
28	thyrotropin	B	
29	-	I	
30	releasing	I	
31	hormone	I	
32	.	O	

1	Bilateral	O	
2	basal	O	
3	arteries	O	
4	were	O	
5	measured	O	
6	by	O	
7	the	O	
8	transtemporal	O	
9	approach	O	
10	with	O	
11	a	O	
12	2	O	
13	MHz	O	
14	pulsed	O	
15	Doppler	O	
16	instrument	O	
17	(	O	
18	TC	O	
19	-	O	
20	2	O	
21	64B	O	
22	EME	O	
23	).	O	

1	Its	O	
2	role	O	
3	in	O	
4	these	O	
5	processes	O	
6	suggests	O	
7	that	O	
8	the	O	
9	function	O	
10	of	O	
11	c	B	
12	-	I	
13	Myb	I	
14	may	O	
15	be	O	
16	important	O	
17	early	O	
18	in	O	
19	the	O	
20	establishment	O	
21	of	O	
22	the	O	
23	hematopoietic	O	
24	lineage	O	
25	.	O	

1	The	O	
2	selenium	O	
3	level	O	
4	and	O	
5	glutathione	B	
6	peroxidase	I	
7	activity	O	
8	in	O	
9	the	O	
10	blood	O	
11	,	O	
12	liver	O	
13	,	O	
14	and	O	
15	stomach	O	
16	mucosa	O	
17	were	O	
18	significantly	O	
19	higher	O	
20	in	O	
21	the	O	
22	high	O	
23	-	O	
24	selenium	O	
25	diet	O	
26	group	O	
27	than	O	
28	in	O	
29	the	O	
30	low	O	
31	-	O	
32	selenium	O	
33	diet	O	
34	group	O	
35	.	O	

1	The	O	
2	decrease	O	
3	in	O	
4	HDL	B	
5	-	I	
6	cholesterol	I	
7	with	O	
8	increasing	O	
9	VLDL	B	
10	-	I	
11	triglycerides	I	
12	was	O	
13	relatively	O	
14	much	O	
15	larger	O	
16	than	O	
17	the	O	
18	concomitant	O	
19	decrease	O	
20	in	O	
21	apo	B	
22	A	I	
23	-	I	
24	I	I	
25	.	O	

1	After	O	
2	two	O	
3	successive	O	
4	rounds	O	
5	of	O	
6	selection	O	
7	by	O	
8	focus	O	
9	formation	O	
10	assay	O	
11	,	O	
12	a	O	
13	transforming	O	
14	ribozyme	O	
15	(	O	
16	Rz007	B	
17	)	O	
18	was	O	
19	identified	O	
20	.	O	

1	Histochemistry	O	
2	and	O	
3	electron	O	
4	microscopy	O	
5	of	O	
6	acute	O	
7	liver	O	
8	lesions	O	
9	induced	O	
10	by	O	
11	Aflatoxin	O	
12	B1	O	
13	in	O	
14	ducklings	O	
15	.	O	

1	The	O	
2	level	O	
3	of	O	
4	subclinical	O	
5	infection	O	
6	was	O	
7	75	O	
8	%	O	
9	among	O	
10	seropositive	O	
11	dogs	O	
12	.	O	

1	Enhancer	O	
2	activity	O	
3	requires	O	
4	both	O	
5	the	O	
6	AP	B	
7	-	I	
8	1	I	
9	site	I	
10	and	O	
11	these	O	
12	adjacent	O	
13	sequences	O	
14	.	O	

1	Young	O	
2	fish	O	
3	(	O	
4	Oreochromis	O	
5	mossambicus	O	
6	)	O	
7	were	O	
8	exposed	O	
9	to	O	
10	microgravity	O	
11	(	O	
12	micro	O	
13	g	O	
14	)	O	
15	for	O	
16	9	O	
17	to	O	
18	10	O	
19	days	O	
20	during	O	
21	space	O	
22	missions	O	
23	STS	O	
24	-	O	
25	55	O	
26	and	O	
27	STS	O	
28	-	O	
29	84	O	
30	,	O	
31	or	O	
32	to	O	
33	hypergravity	O	
34	(	O	
35	hg	O	
36	)	O	
37	for	O	
38	9	O	
39	days	O	
40	.	O	

1	Paper	O	
2	alert	O	
3	.	O	

1	Although	O	
2	a	O	
3	wide	O	
4	range	O	
5	of	O	
6	cognitive	O	
7	functions	O	
8	had	O	
9	been	O	
10	tested	O	
11	,	O	
12	all	O	
13	but	O	
14	one	O	
15	seizure	O	
16	occurred	O	
17	during	O	
18	assessment	O	
19	of	O	
20	memory	O	
21	performance	O	
22	.	O	

1	Bipolarity	O	
2	in	O	
3	Jungian	O	
4	type	O	
5	theory	O	
6	and	O	
7	the	O	
8	Myers	O	
9	-	O	
10	Briggs	O	
11	Type	O	
12	Indicator	O	
13	.	O	

1	Army	O	
2	veterans	O	
3	given	O	
4	yellow	O	
5	fever	O	
6	vaccine	O	
7	contaminated	O	
8	with	O	
9	hepatitis	O	
10	B	O	
11	virus	O	
12	in	O	
13	1942	O	
14	and	O	
15	controls	O	
16	and	O	
17	(	O	
18	b	O	
19	)	O	
20	a	O	
21	case	O	
22	-	O	
23	control	O	
24	study	O	
25	comparing	O	
26	veterans	O	
27	with	O	
28	hepatocellular	O	
29	carcinoma	O	
30	in	O	
31	Veterans	O	
32	Affairs	O	
33	hospitals	O	
34	with	O	
35	matched	O	
36	controls	O	
37	with	O	
38	respect	O	
39	to	O	
40	receipt	O	
41	of	O	
42	contaminated	O	
43	vaccine	O	
44	in	O	
45	1942	O	
46	.	O	

1	In	O	
2	the	O	
3	presence	O	
4	of	O	
5	the	O	
6	in	O	
7	vivo	O	
8	reducing	O	
9	system	O	
10	(	O	
11	thioredoxin	B	
12	,	O	
13	thioredoxin	B	
14	reductase	I	
15	,	O	
16	and	O	
17	NADPH	O	
18	),	O	
19	however	O	
20	,	O	
21	each	O	
22	of	O	
23	these	O	
24	mutants	O	
25	catalyzed	O	
26	the	O	
27	formation	O	
28	of	O	
29	only	O	
30	0	O	
31	.	O	
32	6	O	
33	-	O	
34	0	O	
35	.	O	
36	8	O	
37	dCTPs	O	
38	per	O	
39	mole	O	
40	of	O	
41	enzyme	O	
42	.	O	

1	This	O	
2	region	O	
3	does	O	
4	not	O	
5	contain	O	
6	an	O	
7	identifiable	O	
8	TATA	O	
9	element	O	
10	,	O	
11	indicating	O	
12	that	O	
13	transcription	O	
14	of	O	
15	the	O	
16	glutaminase	B	
17	gene	I	
18	is	O	
19	driven	O	
20	by	O	
21	a	O	
22	TATA	O	
23	-	O	
24	less	O	
25	promoter	O	
26	.	O	

1	However	O	
2	,	O	
3	overexpression	O	
4	of	O	
5	both	O	
6	the	O	
7	STE4	B	
8	and	O	
9	STE18	B	
10	proteins	I	
11	did	O	
12	not	O	
13	generate	O	
14	a	O	
15	stronger	O	
16	pheromone	O	
17	response	O	
18	than	O	
19	overexpression	O	
20	of	O	
21	STE4	B	
22	in	O	
23	the	O	
24	presence	O	
25	of	O	
26	wild	O	
27	-	O	
28	type	O	
29	levels	O	
30	of	O	
31	STE18	B	
32	.	O	

1	Dynamic	O	
2	decision	O	
3	making	O	
4	:	O	
5	human	O	
6	control	O	
7	of	O	
8	complex	O	
9	systems	O	
10	.	O	

1	Carnitine	B	
2	palmitoyltransferase	I	
3	(	I	
4	CPT	I	
5	)	I	
6	II	I	
7	deficiency	O	
8	is	O	
9	the	O	
10	most	O	
11	common	O	
12	inherited	O	
13	disorder	O	
14	of	O	
15	lipid	O	
16	metabolism	O	
17	affecting	O	
18	skeletal	O	
19	muscle	O	
20	.	O	

1	The	O	
2	results	O	
3	of	O	
4	this	O	
5	study	O	
6	suggest	O	
7	that	O	
8	NF	B	
9	-	I	
10	kappaB	I	
11	activity	O	
12	may	O	
13	be	O	
14	regulated	O	
15	by	O	
16	its	O	
17	interaction	O	
18	with	O	
19	the	O	
20	cell	O	
21	cycle	O	
22	regulatory	O	
23	protein	O	
24	,	O	
25	E2F	B	
26	-	I	
27	1	I	
28	.	O	

1	Another	O	
2	putative	O	
3	HNF3	B	
4	site	I	
5	in	O	
6	close	O	
7	apposition	O	
8	to	O	
9	a	O	
10	NF1	B	
11	/	O	
12	CTF	B	
13	site	O	
14	was	O	
15	localized	O	
16	upstream	O	
17	of	O	
18	the	O	
19	silencer	O	
20	-	O	
21	like	O	
22	element	O	
23	.	O	

1	FK506	O	
2	is	O	
3	10	O	
4	-	O	
5	to	O	
6	100	O	
7	-	O	
8	fold	O	
9	more	O	
10	potent	O	
11	than	O	
12	cyclosporin	O	
13	A	O	
14	in	O	
15	preventing	O	
16	organ	O	
17	rejection	O	
18	and	O	
19	in	O	
20	toxicity	O	
21	.	O	

1	In	O	
2	a	O	
3	second	O	
4	series	O	
5	of	O	
6	experiments	O	
7	,	O	
8	the	O	
9	efficacy	O	
10	of	O	
11	PDC	O	
12	/	O	
13	HDC	O	
14	Ac	O	
15	was	O	
16	evaluated	O	
17	in	O	
18	both	O	
19	single	O	
20	and	O	
21	multiple	O	
22	dose	O	
23	regiments	O	
24	.	O	

1	Administration	O	
2	of	O	
3	a	O	
4	second	O	
5	dose	O	
6	of	O	
7	vaccine	O	
8	during	O	
9	the	O	
10	outbreak	O	
11	was	O	
12	not	O	
13	protective	O	
14	.	O	

1	Carbonic	B	
2	anhydrase	I	
3	V	I	
4	(	O	
5	CA	B	
6	V	I	
7	)	O	
8	is	O	
9	expressed	O	
10	in	O	
11	mitochondrial	O	
12	matrix	O	
13	in	O	
14	liver	O	
15	and	O	
16	several	O	
17	other	O	
18	tissues	O	
19	.	O	

1	Endothelial	O	
2	cell	O	
3	seeding	O	
4	.	O	

1	It	O	
2	may	O	
3	be	O	
4	time	O	
5	to	O	
6	reevaluate	O	
7	the	O	
8	dichotomy	O	
9	between	O	
10	AD	O	
11	and	O	
12	VaD	O	
13	.	O	

1	The	O	
2	findings	O	
3	are	O	
4	compatible	O	
5	with	O	
6	the	O	
7	idea	O	
8	that	O	
9	the	O	
10	genes	O	
11	encoding	O	
12	PDGF	B	
13	receptors	I	
14	in	O	
15	glioma	O	
16	cells	O	
17	are	O	
18	regulated	O	
19	in	O	
20	concert	O	
21	with	O	
22	other	O	
23	genes	O	
24	,	O	
25	the	O	
26	expression	O	
27	of	O	
28	which	O	
29	may	O	
30	reflect	O	
31	the	O	
32	developmental	O	
33	program	O	
34	of	O	
35	normal	O	
36	glia	O	
37	cell	O	
38	lineages	O	
39	.	O	

1	Mycoplasma	O	
2	hominis	O	
3	infections	O	
4	are	O	
5	easily	O	
6	missed	O	
7	because	O	
8	conventional	O	
9	methods	O	
10	for	O	
11	bacterial	O	
12	detection	O	
13	may	O	
14	fail	O	
15	.	O	

1	Analysis	O	
2	of	O	
3	lacZ	B	
4	transcriptional	I	
5	fusions	I	
6	shows	O	
7	that	O	
8	the	O	
9	KdgR	B	
10	-	I	
11	binding	I	
12	sites	I	
13	negatively	O	
14	affect	O	
15	the	O	
16	expression	O	
17	of	O	
18	rsmB	B	
19	.	O	

1	Disruption	O	
2	demonstrates	O	
3	that	O	
4	CDC14	B	
5	is	O	
6	an	O	
7	essential	O	
8	gene	O	
9	.	O	

1	The	O	
2	predicted	O	
3	DNA	O	
4	-	O	
5	binding	O	
6	,	O	
7	zinc	B	
8	finger	I	
9	domain	I	
10	protein	I	
11	sequence	O	
12	was	O	
13	strictly	O	
14	conserved	O	
15	.	O	

1	Saccharomyces	O	
2	cerevisiae	O	
3	contains	O	
4	four	O	
5	known	O	
6	acyl	B	
7	-	I	
8	CoA	I	
9	synthetases	I	
10	(	O	
11	fatty	B	
12	acid	I	
13	activation	I	
14	proteins	I	
15	,	O	
16	Faaps	B	
17	).	O	

1	Whereas	O	
2	a	O	
3	PR55	B	
4	beta	I	
5	transcript	I	
6	of	O	
7	about	O	
8	2	O	
9	.	O	
10	3	O	
11	kb	O	
12	was	O	
13	detected	O	
14	at	O	
15	high	O	
16	levels	O	
17	in	O	
18	the	O	
19	neuroblastoma	O	
20	derived	O	
21	cell	O	
22	line	O	
23	LA	O	
24	-	O	
25	N	O	
26	-	O	
27	1	O	
28	,	O	
29	the	O	
30	level	O	
31	of	O	
32	the	O	
33	mRNA	O	
34	was	O	
35	very	O	
36	low	O	
37	in	O	
38	the	O	
39	other	O	
40	human	O	
41	cell	O	
42	lines	O	
43	analyzed	O	
44	.	O	

1	OBJECTIVE	O	
2	:	O	
3	This	O	
4	study	O	
5	was	O	
6	designed	O	
7	to	O	
8	analyze	O	
9	the	O	
10	common	O	
11	cause	O	
12	of	O	
13	asthenopia	O	
14	,	O	
15	mixed	O	
16	astigmatism	O	
17	.	O	

1	Transcription	O	
2	of	O	
3	the	O	
4	first	O	
5	operon	O	
6	coding	O	
7	for	O	
8	m	O	
9	-	O	
10	xylene	O	
11	-	O	
12	degrading	O	
13	enzymes	O	
14	on	O	
15	the	O	
16	TOL	O	
17	plasmid	O	
18	of	O	
19	Pseudomonas	O	
20	putida	O	
21	is	O	
22	activated	O	
23	by	O	
24	the	O	
25	xylR	B	
26	gene	I	
27	product	I	
28	in	O	
29	the	O	
30	presence	O	
31	of	O	
32	m	O	
33	-	O	
34	xylene	O	
35	.	O	

1	The	O	
2	Drosophila	B	
3	suppressor	I	
4	of	I	
5	sable	I	
6	gene	I	
7	encodes	O	
8	a	O	
9	polypeptide	O	
10	with	O	
11	regions	O	
12	similar	O	
13	to	O	
14	those	O	
15	of	O	
16	RNA	O	
17	-	O	
18	binding	O	
19	proteins	O	
20	.	O	

1	Combination	O	
2	of	O	
3	a	O	
4	Shwachman	O	
5	syndrome	O	
6	and	O	
7	a	O	
8	complex	O	
9	granulocyte	O	
10	function	O	
11	disorder	O	
12	in	O	
13	a	O	
14	girl	O	

1	Polypeptide	O	
2	growth	O	
3	factors	O	
4	and	O	
5	cytokines	O	
6	mediate	O	
7	their	O	
8	biochemical	O	
9	functions	O	
10	through	O	
11	their	O	
12	responsive	O	
13	receptors	O	
14	.	O	

1	However	O	
2	,	O	
3	further	O	
4	analyses	O	
5	of	O	
6	the	O	
7	data	O	
8	indicate	O	
9	that	O	
10	increasing	O	
11	VO2	O	
12	AT	O	
13	(	O	
14	r	O	
15	=	O	
16	-	O	
17	0	O	
18	.	O	
19	63	O	
20	,	O	
21	P	O	
22	less	O	
23	than	O	
24	0	O	
25	.	O	
26	05	O	
27	)	O	
28	rather	O	
29	than	O	
30	VO2max	O	
31	(	O	
32	r	O	
33	=	O	
34	-	O	
35	0	O	
36	.	O	
37	15	O	
38	)	O	
39	could	O	
40	result	O	
41	in	O	
42	improving	O	
43	the	O	
44	10	O	
45	,	O	
46	000	O	
47	m	O	
48	race	O	
49	performance	O	
50	to	O	
51	a	O	
52	larger	O	
53	extent	O	
54	,	O	
55	and	O	
56	that	O	
57	the	O	
58	absolute	O	
59	amount	O	
60	of	O	
61	change	O	
62	(	O	
63	delta	O	
64	)	O	
65	in	O	
66	the	O	
67	10	O	
68	,	O	
69	000	O	
70	m	O	
71	run	O	
72	time	O	
73	is	O	
74	best	O	
75	accounted	O	
76	for	O	
77	by	O	
78	a	O	
79	combination	O	
80	of	O	
81	delta	O	
82	VO2	O	
83	AT	O	
84	and	O	
85	delta	O	
86	5	O	
87	,	O	
88	000	O	
89	m	O	
90	run	O	
91	time	O	
92	.	O	

1	Thus	O	
2	,	O	
3	we	O	
4	have	O	
5	identified	O	
6	a	O	
7	GRE	O	
8	sufficient	O	
9	to	O	
10	account	O	
11	for	O	
12	full	O	
13	glucocorticoid	O	
14	inducibility	O	
15	and	O	
16	an	O	
17	HNF	B	
18	-	I	
19	1	I	
20	site	I	
21	close	O	
22	to	O	
23	the	O	
24	promoter	O	
25	that	O	
26	are	O	
27	major	O	
28	determinants	O	
29	of	O	
30	transcriptional	O	
31	control	O	
32	of	O	
33	the	O	
34	Xenopus	B	
35	fibrinogen	I	
36	B	I	
37	beta	I	
38	subunit	I	
39	gene	I	
40	in	O	
41	cells	O	
42	from	O	
43	normal	O	
44	liver	O	
45	tissue	O	
46	.	O	

1	HA	O	
2	resulted	O	
3	in	O	
4	decreased	O	
5	(	O	
6	p	O	
7	less	O	
8	than	O	
9	0	O	
10	.	O	
11	05	O	
12	)	O	
13	Tre	O	
14	(	O	
15	0	O	
16	.	O	
17	4	O	
18	degrees	O	
19	C	O	
20	)	O	
21	and	O	
22	HR	O	
23	(	O	
24	17	O	
25	b	O	
26	X	O	
27	min	O	
28	-	O	
29	1	O	
30	),	O	
31	and	O	
32	increased	O	
33	(	O	
34	p	O	
35	less	O	
36	than	O	
37	0	O	
38	.	O	
39	05	O	
40	)	O	
41	Msw	O	
42	(	O	
43	16	O	
44	g	O	
45	X	O	
46	m	O	
47	-	O	
48	2	O	
49	X	O	
50	h	O	
51	-	O	
52	1	O	
53	)	O	
54	during	O	
55	the	O	
56	saline	O	
57	experiments	O	
58	.	O	

1	This	O	
2	region	O	
3	contains	O	
4	a	O	
5	motif	O	
6	with	O	
7	partial	O	
8	identity	O	
9	with	O	
10	the	O	
11	binding	O	
12	site	O	
13	for	O	
14	the	O	
15	ubiquitous	O	
16	transcription	O	
17	factor	O	
18	upstream	B	
19	stimulatory	I	
20	factor	I	
21	(	O	
22	USF	B	
23	),	O	
24	which	O	
25	binds	O	
26	to	O	
27	the	O	
28	human	B	
29	insulin	I	
30	promoter	I	
31	.	O	

1	In	O	
2	contrast	O	
3	to	O	
4	the	O	
5	signaling	O	
6	triggered	O	
7	by	O	
8	surface	O	
9	Ig	B	
10	engagement	O	
11	in	O	
12	B	O	
13	lymphocytes	O	
14	,	O	
15	CD38	B	
16	ligation	O	
17	did	O	
18	not	O	
19	appear	O	
20	to	O	
21	induce	O	
22	tyrosine	O	
23	phosphorylation	O	
24	of	O	
25	the	O	
26	src	B	
27	-	I	
28	like	I	
29	protein	I	
30	tyrosine	I	
31	kinases	I	
32	lyn	I	
33	,	O	
34	fyn	B	
35	,	O	
36	and	O	
37	btk	B	
38	,	O	
39	or	O	
40	of	O	
41	vav	B	
42	-	I	
43	and	I	
44	ras	I	
45	-	I	
46	GTPase	I	
47	-	I	
48	activating	I	
49	protein	I	
50	,	O	
51	nor	O	
52	did	O	
53	it	O	
54	induce	O	
55	detectable	O	
56	changes	O	
57	in	O	
58	cytosolic	O	
59	CA2	O	
60	+	O	
61	concentrations	O	
62	.	O	

1	Epithelial	O	
2	damage	O	
3	was	O	
4	not	O	
5	observed	O	
6	in	O	
7	any	O	
8	controls	O	
9	but	O	
10	was	O	
11	in	O	
12	all	O	
13	tissues	O	
14	exposed	O	
15	to	O	
16	SO2	O	
17	.	O	

1	The	O	
2	analysis	O	
3	of	O	
4	the	O	
5	structure	O	
6	of	O	
7	the	O	
8	sleep	O	
9	period	O	
10	as	O	
11	a	O	
12	whole	O	
13	reveals	O	
14	that	O	
15	with	O	
16	increasing	O	
17	of	O	
18	the	O	
19	age	O	
20	the	O	
21	delta	O	
22	-	O	
23	wave	O	
24	stage	O	
25	(	O	
26	DS	O	
27	)	O	
28	of	O	
29	the	O	
30	QS	O	
31	(	O	
32	determined	O	
33	by	O	
34	defined	O	
35	polygraphic	O	
36	parameters	O	
37	)	O	
38	increases	O	
39	,	O	
40	while	O	
41	the	O	
42	paradoxical	O	
43	phase	O	
44	of	O	
45	sleep	O	
46	(	O	
47	PS	O	
48	)	O	
49	decreases	O	
50	,	O	
51	this	O	
52	change	O	
53	being	O	
54	more	O	
55	pronounced	O	
56	during	O	
57	the	O	
58	first	O	
59	six	O	
60	months	O	
61	than	O	
62	during	O	
63	the	O	
64	second	O	
65	ones	O	
66	of	O	
67	the	O	
68	first	O	
69	year	O	
70	of	O	
71	the	O	
72	life	O	
73	.	O	

1	Identity	O	
2	of	O	
3	GABP	B	
4	with	O	
5	NRF	B	
6	-	I	
7	2	I	
8	,	O	
9	a	O	
10	multisubunit	O	
11	activator	O	
12	of	O	
13	cytochrome	B	
14	oxidase	I	
15	expression	O	
16	,	O	
17	reveals	O	
18	a	O	
19	cellular	O	
20	role	O	
21	for	O	
22	an	O	
23	ETS	B	
24	domain	I	
25	activator	O	
26	of	O	
27	viral	O	
28	promoters	O	
29	.	O	

1	Here	O	
2	we	O	
3	show	O	
4	that	O	
5	for	O	
6	expression	O	
7	of	O	
8	snRNA	O	
9	genes	O	
10	in	O	
11	maize	O	
12	,	O	
13	a	O	
14	monocotyledonous	O	
15	plant	O	
16	,	O	
17	the	O	
18	USE	O	
19	and	O	
20	TATA	O	
21	elements	O	
22	are	O	
23	essential	O	
24	,	O	
25	but	O	
26	not	O	
27	sufficient	O	
28	,	O	
29	for	O	
30	transcription	O	
31	.	O	

1	The	O	
2	protein	B	
3	-	I	
4	tyrosine	I	
5	kinase	I	
6	fer	I	
7	associates	O	
8	with	O	
9	signaling	O	
10	complexes	O	
11	containing	O	
12	insulin	B	
13	receptor	I	
14	substrate	I	
15	-	I	
16	1	I	
17	and	O	
18	phosphatidylinositol	B	
19	3	I	
20	-	I	
21	kinase	I	
22	.	O	

1	35	O	
2	patients	O	
3	with	O	
4	acute	O	
5	arterial	O	
6	occlusions	O	
7	[	O	
8	27	O	
9	]	O	
10	and	O	
11	graft	O	
12	thromboses	O	
13	[	O	
14	8	O	
15	],	O	
16	responsible	O	
17	for	O	
18	severe	O	
19	and	O	
20	recent	O	
21	ischemia	O	
22	,	O	
23	were	O	
24	treated	O	
25	by	O	
26	fibrinolytic	O	
27	therapy	O	
28	(	O	
29	Urokinase	B	
30	:	O	
31	1	O	
32	000	O	
33	units	O	
34	/	O	
35	kg	O	
36	/	O	
37	hour	O	
38	,	O	
39	and	O	
40	Lys	O	
41	Plasminogen	B	
42	).	O	

1	Ivermectin	O	
2	uptake	O	
3	and	O	
4	distribution	O	
5	in	O	
6	the	O	
7	plasma	O	
8	and	O	
9	tissue	O	
10	of	O	
11	Sudanese	O	
12	and	O	
13	Mexican	O	
14	patients	O	
15	infected	O	
16	with	O	
17	Onchocerca	O	
18	volvulus	O	
19	.	O	

1	Rev	B	
2	-	O	
3	erbAalpha	B	
4	/	I	
5	beta	I	
6	),	O	
7	Mxi	B	
8	-	I	
9	1	I	
10	and	O	
11	Mad	B	
12	bHLH	O	
13	-	O	
14	zip	O	
15	proteins	O	
16	and	O	
17	the	O	
18	oncoproteins	O	
19	PLZF	B	
20	and	O	
21	LAZ3	B	
22	/	O	
23	BCL6	B	
24	is	O	
25	mediated	O	
26	by	O	
27	the	O	
28	corepressors	O	
29	N	B	
30	-	I	
31	CoR	I	
32	and	O	
33	SMRT	B	
34	.	O	

1	Depending	O	
2	on	O	
3	treatment	O	
4	exposures	O	
5	,	O	
6	this	O	
7	at	O	
8	-	O	
9	risk	O	
10	population	O	
11	may	O	
12	experience	O	
13	life	O	
14	-	O	
15	threatening	O	
16	late	O	
17	effects	O	
18	,	O	
19	such	O	
20	as	O	
21	cirrhosis	O	
22	secondary	O	
23	to	O	
24	hepatitis	O	
25	C	O	
26	or	O	
27	late	O	
28	-	O	
29	onset	O	
30	anthracycline	O	
31	-	O	
32	induced	O	
33	cardiomyopathy	O	
34	,	O	
35	or	O	
36	life	O	
37	-	O	
38	changing	O	
39	late	O	
40	effects	O	
41	,	O	
42	such	O	
43	as	O	
44	cognitive	O	
45	dysfunction	O	
46	.	O	

1	Update	O	
2	:	O	
3	diphtheria	O	
4	epidemic	O	
5	in	O	
6	the	O	
7	newly	O	
8	independent	O	
9	states	O	
10	of	O	
11	the	O	
12	former	O	
13	USSR	O	
14	,	O	
15	January	O	
16	1995	O	
17	-	O	
18	March	O	
19	1996	O	
20	.	O	

1	When	O	
2	combined	O	
3	with	O	
4	independent	O	
5	activating	O	
6	mutations	O	
7	in	O	
8	the	O	
9	c	B	
10	-	I	
11	abl	I	
12	kinase	I	
13	domain	I	
14	or	O	
15	NH2	O	
16	-	O	
17	terminus	O	
18	,	O	
19	the	O	
20	G128R	B	
21	mutation	O	
22	blocked	O	
23	transformation	O	
24	by	O	
25	the	O	
26	double	O	
27	mutant	O	
28	,	O	
29	suggesting	O	
30	that	O	
31	the	O	
32	G128R	B	
33	mutant	I	
34	was	O	
35	unable	O	
36	to	O	
37	transform	O	
38	cells	O	
39	for	O	
40	trivial	O	
41	reasons	O	
42	.	O	

1	Mutually	O	
2	exclusive	O	
3	interaction	O	
4	of	O	
5	the	O	
6	adenovirus	B	
7	E4	I	
8	-	I	
9	6	I	
10	/	I	
11	7	I	
12	protein	I	
13	and	O	
14	the	O	
15	retinoblastoma	B	
16	gene	I	
17	product	I	
18	with	O	
19	internal	O	
20	domains	O	
21	of	O	
22	E2F	B	
23	-	I	
24	1	I	
25	and	O	
26	DP	B	
27	-	I	
28	1	I	
29	.	O	

1	Abnormal	O	
2	urinary	O	
3	coproporphyrin	O	
4	levels	O	
5	in	O	
6	patients	O	
7	infected	O	
8	by	O	
9	hepatitis	O	
10	C	O	
11	virus	O	
12	with	O	
13	or	O	
14	without	O	
15	human	O	
16	immunodeficiency	O	
17	virus	O	
18	.	O	

1	Scientific	O	
2	cooperation	O	
3	of	O	
4	CMEA	O	
5	member	O	
6	countries	O	
7	has	O	
8	been	O	
9	carried	O	
10	out	O	
11	since	O	
12	1974	O	
13	under	O	
14	the	O	
15	sponsorship	O	
16	of	O	
17	the	O	
18	Cancer	O	
19	Research	O	
20	Institute	O	
21	,	O	
22	Slovak	O	
23	Academy	O	
24	of	O	
25	Sciences	O	
26	(	O	
27	Czechoslovakia	O	
28	)	O	
29	within	O	
30	the	O	
31	framework	O	
32	of	O	
33	CMEA	O	
34	.	O	

1	The	O	
2	dnaK	B	
3	operon	I	
4	of	I	
5	Bacillus	I	
6	subtilis	I	
7	is	O	
8	heptacistronic	O	
9	.	O	

1	The	O	
2	dopamine	B	
3	D4	I	
4	receptor	I	
5	as	O	
6	well	O	
7	as	O	
8	many	O	
9	other	O	
10	catecholaminergic	B	
11	receptors	I	
12	contain	O	
13	several	O	
14	putative	O	
15	SH3	B	
16	binding	I	
17	domains	I	
18	.	O	

1	Together	O	
2	,	O	
3	these	O	
4	results	O	
5	indicate	O	
6	that	O	
7	IL	B	
8	-	I	
9	1	I	
10	beta	I	
11	induces	O	
12	VEGF	B	
13	gene	I	
14	expression	O	
15	at	O	
16	both	O	
17	transcriptional	O	
18	and	O	
19	post	O	
20	-	O	
21	transcriptional	O	
22	levels	O	
23	,	O	
24	and	O	
25	IL	B	
26	-	I	
27	1	I	
28	beta	I	
29	evokes	O	
30	p38	B	
31	MAPK	O	
32	and	O	
33	JNK	B	
34	signalings	O	
35	,	O	
36	which	O	
37	in	O	
38	turn	O	
39	stimulate	O	
40	the	O	
41	transcription	O	
42	of	O	
43	the	O	
44	VEGF	B	
45	gene	I	
46	through	O	
47	Sp1	B	
48	-	I	
49	binding	I	
50	sites	I	
51	.	O	

1	Inactivation	O	
2	of	O	
3	the	O	
4	Neurospora	B	
5	crassa	I	
6	mitochondrial	I	
7	outer	I	
8	membrane	I	
9	protein	I	
10	TOM70	I	
11	by	O	
12	repeat	O	
13	-	O	
14	induced	O	
15	point	O	
16	mutation	O	
17	(	O	
18	RIP	O	
19	)	O	
20	causes	O	
21	defects	O	
22	in	O	
23	mitochondrial	O	
24	protein	O	
25	import	O	
26	and	O	
27	morphology	O	
28	.	O	

1	In	O	
2	order	O	
3	to	O	
4	define	O	
5	potential	O	
6	candidate	O	
7	genes	O	
8	for	O	
9	inherited	O	
10	disorders	O	
11	characterized	O	
12	by	O	
13	aberrant	O	
14	gene	O	
15	expression	O	
16	,	O	
17	we	O	
18	utilized	O	
19	Kruppel	B	
20	-	I	
21	related	I	
22	sequences	I	
23	to	O	
24	isolate	O	
25	zinc	O	
26	finger	O	
27	-	O	
28	containing	O	
29	cDNAs	O	
30	.	O	

1	The	O	
2	effect	O	
3	of	O	
4	the	O	
5	opiate	O	
6	antagonist	O	
7	naloxone	O	
8	was	O	
9	evaluated	O	
10	in	O	
11	11	O	
12	unselected	O	
13	patients	O	
14	with	O	
15	cerebral	O	
16	ischemia	O	
17	.	O	

1	The	O	
2	murine	B	
3	int	I	
4	-	I	
5	6	I	
6	locus	I	
7	,	O	
8	identified	O	
9	as	O	
10	a	O	
11	frequent	O	
12	integration	O	
13	site	O	
14	of	O	
15	mouse	O	
16	mammary	O	
17	tumor	O	
18	viruses	O	
19	,	O	
20	encodes	O	
21	the	O	
22	48	B	
23	-	I	
24	kDa	I	
25	eIF3e	I	
26	subunit	I	
27	of	I	
28	translation	I	
29	initiation	I	
30	factor	I	
31	eIF3	I	
32	.	O	

1	As	O	
2	in	O	
3	Tb	O	
4	,	O	
5	U6	B	
6	is	O	
7	a	O	
8	single	O	
9	-	O	
10	copy	O	
11	gene	O	
12	and	O	
13	two	O	
14	tRNA	O	
15	genes	O	
16	,	O	
17	tRNAGln	B	
18	and	O	
19	tRNAIle	B	
20	,	O	
21	are	O	
22	found	O	
23	upstream	O	
24	to	O	
25	the	O	
26	gene	O	
27	.	O	

1	In	O	
2	order	O	
3	to	O	
4	investigate	O	
5	the	O	
6	blood	O	
7	compatibility	O	
8	of	O	
9	autogenous	O	
10	vein	O	
11	graft	O	
12	(	O	
13	AVG	O	
14	),	O	
15	changes	O	
16	in	O	
17	prostacyclin	O	
18	(	O	
19	PGI2	O	
20	)	O	
21	production	O	
22	following	O	
23	harvesting	O	
24	and	O	
25	arterial	O	
26	implantation	O	
27	were	O	
28	studied	O	
29	experimentally	O	
30	.	O	

1	Transcervical	O	
2	amnioinfusion	O	
3	.	O	

1	Fasting	O	
2	plasma	O	
3	and	O	
4	lipoprotein	O	
5	lipid	O	
6	concentrations	O	
7	,	O	
8	adipose	B	
9	tissue	I	
10	lipoprotein	I	
11	lipase	I	
12	activity	O	
13	,	O	
14	anthropometric	O	
15	data	O	
16	,	O	
17	alcohol	O	
18	consumption	O	
19	,	O	
20	smoking	O	
21	habits	O	
22	,	O	
23	weekly	O	
24	mileage	O	
25	run	O	
26	and	O	
27	performance	O	
28	on	O	
29	a	O	
30	bicycle	O	
31	ergometer	O	
32	were	O	
33	recorded	O	
34	before	O	
35	and	O	
36	after	O	
37	the	O	
38	training	O	
39	period	O	
40	.	O	

1	Ten	O	
2	-	O	
3	year	O	
4	experience	O	
5	with	O	
6	one	O	
7	-	O	
8	stage	O	
9	proctocolectomy	O	
10	and	O	
11	anal	O	
12	ileostomy	O	
13	.	O	

1	Precipitation	O	
2	using	O	
3	GST	B	
4	fusion	I	
5	proteins	I	
6	containing	O	
7	Fyn	B	
8	SH2	I	
9	,	O	
10	SH3	B	
11	,	O	
12	and	O	
13	SH2	B	
14	/	O	
15	SH3	B	
16	domains	O	
17	revealed	O	
18	that	O	
19	PI	B	
20	3	I	
21	-	I	
22	kinase	I	
23	bound	O	
24	principally	O	
25	to	O	
26	the	O	
27	SH3	B	
28	domain	I	
29	of	O	
30	Fyn	B	
31	.	O	

1	This	O	
2	repression	O	
3	does	O	
4	not	O	
5	require	O	
6	the	O	
7	PU	B	
8	.	I	
9	1	I	
10	transactivation	O	
11	or	O	
12	PEST	O	
13	domains	O	
14	and	O	
15	cannot	O	
16	be	O	
17	reversed	O	
18	by	O	
19	p300	B	
20	expression	O	
21	.	O	

1	Selenium	O	
2	status	O	
3	of	O	
4	thoroughbreds	O	
5	in	O	
6	the	O	
7	United	O	
8	Kingdom	O	
9	.	O	

1	To	O	
2	evaluate	O	
3	the	O	
4	hepatic	O	
5	regenerative	O	
6	response	O	
7	in	O	
8	patients	O	
9	with	O	
10	alcoholic	O	
11	liver	O	
12	disease	O	
13	,	O	
14	sera	O	
15	from	O	
16	263	O	
17	patients	O	
18	with	O	
19	severe	O	
20	alcoholic	O	
21	hepatitis	O	
22	and	O	
23	/	O	
24	or	O	
25	cirrhosis	O	
26	were	O	
27	analyzed	O	
28	for	O	
29	hepatocyte	B	
30	growth	I	
31	factor	I	
32	(	O	
33	HGF	B	
34	)	O	
35	and	O	
36	alpha	B	
37	-	I	
38	fetoprotein	I	
39	(	O	
40	AFP	B	
41	).	O	

1	We	O	
2	have	O	
3	investigated	O	
4	the	O	
5	role	O	
6	of	O	
7	cellular	B	
8	p21ras	I	
9	protein	I	
10	in	O	
11	insulin	B	
12	and	O	
13	insulin	B	
14	-	I	
15	like	I	
16	growth	I	
17	factor	I	
18	-	I	
19	I	I	
20	(	O	
21	IGF	B	
22	-	I	
23	I	I	
24	)	O	
25	signaling	O	
26	pathways	O	
27	.	O	

1	SSF	O	
2	experiments	O	
3	were	O	
4	carried	O	
5	out	O	
6	in	O	
7	bench	O	
8	-	O	
9	scale	O	
10	bioreactors	O	
11	(	O	
12	equipped	O	
13	with	O	
14	CO2	O	
15	and	O	
16	volatile	O	
17	organic	O	
18	traps	O	
19	)	O	
20	containing	O	
21	a	O	
22	mixture	O	
23	of	O	
24	lignocellulosic	O	
25	materials	O	
26	and	O	
27	a	O	
28	radiolabeled	O	
29	pesticide	O	
30	.	O	

1	Transcription	O	
2	from	O	
3	the	O	
4	promoter	O	
5	containing	O	
6	the	O	
7	mutated	O	
8	direct	O	
9	repeats	O	
10	was	O	
11	increased	O	
12	greatly	O	
13	,	O	
14	consistent	O	
15	with	O	
16	the	O	
17	conclusion	O	
18	that	O	
19	these	O	
20	motifs	O	
21	functions	O	
22	in	O	
23	vivo	O	
24	to	O	
25	repress	O	
26	GPT	B	
27	gene	I	
28	expression	O	
29	.	O	

1	Gel	O	
2	-	O	
3	shift	O	
4	assays	O	
5	identified	O	
6	two	O	
7	Sp1	B	
8	binding	I	
9	sites	I	
10	within	O	
11	this	O	
12	element	O	
13	.	O	

1	Recent	O	
2	studies	O	
3	have	O	
4	suggested	O	
5	that	O	
6	SHP	B	
7	-	I	
8	1	I	
9	regulates	O	
10	the	O	
11	function	O	
12	of	O	
13	Jak	B	
14	family	O	
15	tyrosine	B	
16	kinases	I	
17	,	O	
18	as	O	
19	shown	O	
20	by	O	
21	its	O	
22	constitutive	O	
23	association	O	
24	with	O	
25	the	O	
26	Tyk2	B	
27	kinase	I	
28	and	O	
29	the	O	
30	hyperphosphorylation	O	
31	of	O	
32	Jak	B	
33	kinases	I	
34	in	O	
35	the	O	
36	motheaten	O	
37	cells	O	
38	that	O	
39	lack	O	
40	functional	O	
41	SHP	B	
42	-	I	
43	1	I	
44	.	O	

1	In	O	
2	the	O	
3	unclipped	O	
4	group	O	
5	arterial	O	
6	pressure	O	
7	decreased	O	
8	50	O	
9	mmHg	O	
10	to	O	
11	normal	O	
12	by	O	
13	24	O	
14	h	O	
15	and	O	
16	was	O	
17	associated	O	
18	with	O	
19	increased	O	
20	diuresis	O	
21	and	O	
22	a	O	
23	small	O	
24	decrease	O	
25	in	O	
26	blood	O	
27	volume	O	
28	(	O	
29	9	O	
30	.	O	
31	8	O	
32	%).	O	

1	To	O	
2	confirm	O	
3	the	O	
4	GapIII	B	
5	protein	I	
6	activity	O	
7	,	O	
8	constructs	O	
9	containing	O	
10	different	O	
11	GapIII	B	
12	-	O	
13	GRD	B	
14	domains	O	
15	were	O	
16	transformed	O	
17	into	O	
18	iral	B	
19	mutant	O	
20	yeast	O	
21	to	O	
22	determine	O	
23	their	O	
24	relative	O	
25	ability	O	
26	to	O	
27	replace	O	
28	IRA1	B	
29	functionally	O	
30	.	O	

1	Cross	O	
2	-	O	
3	linking	O	
4	the	O	
5	B	B	
6	cell	I	
7	Ag	I	
8	receptor	I	
9	(	O	
10	BCR	B	
11	)	O	
12	to	O	
13	surface	B	
14	Fc	I	
15	receptors	I	
16	for	O	
17	IgG	B	
18	(	O	
19	Fc	B	
20	gamma	I	
21	R	I	
22	)	O	
23	inhibits	O	
24	G1	O	
25	-	O	
26	to	O	
27	-	O	
28	S	O	
29	progression	O	
30	;	O	
31	the	O	
32	mechanism	O	
33	by	O	
34	which	O	
35	this	O	
36	occurs	O	
37	is	O	
38	not	O	
39	completely	O	
40	known	O	
41	.	O	

1	DNA	O	
2	sequencing	O	
3	of	O	
4	a	O	
5	17	O	
6	-	O	
7	kb	O	
8	segment	O	
9	encompassing	O	
10	a	O	
11	gammaherpesvirus	O	
12	divergent	O	
13	locus	O	
14	(	O	
15	DL	O	
16	-	O	
17	B	O	
18	)	O	
19	between	O	
20	ORF11	O	
21	and	O	
22	ORF17	O	
23	revealed	O	
24	the	O	
25	presence	O	
26	of	O	
27	nine	O	
28	viral	O	
29	ORFs	O	
30	with	O	
31	predicted	O	
32	gene	O	
33	products	O	
34	related	O	
35	to	O	
36	cellular	O	
37	proteins	O	
38	.	O	

1	Neither	O	
2	mutant	O	
3	exhibited	O	
4	derepression	O	
5	of	O	
6	the	O	
7	silent	B	
8	mating	I	
9	type	I	
10	loci	I	
11	.	O	

1	Using	O	
2	Scheffe	O	
3	'	O	
4	s	O	
5	procedure	O	
6	as	O	
7	an	O	
8	illustration	O	
9	,	O	
10	comparisons	O	
11	are	O	
12	made	O	
13	to	O	
14	usual	O	
15	sample	O	
16	size	O	
17	methods	O	
18	that	O	
19	incorrectly	O	
20	ignore	O	
21	the	O	
22	stochastic	O	
23	nature	O	
24	of	O	
25	S2p	O	
26	.	O	

1	Enzyme	O	
2	histochemical	O	
3	findings	O	
4	in	O	
5	the	O	
6	ultimobranchial	O	
7	body	O	
8	of	O	
9	the	O	
10	horse	O	

1	From	O	
2	the	O	
3	Icelandic	O	
4	Red	O	
5	Cross	O	
6	activities	O	

1	These	O	
2	results	O	
3	indicate	O	
4	that	O	
5	both	O	
6	naturally	O	
7	acquired	O	
8	and	O	
9	passive	O	
10	(	O	
11	modified	O	
12	immune	B	
13	serum	I	
14	globulin	I	
15	)	O	
16	antibodies	O	
17	to	O	
18	type	B	
19	III	I	
20	group	I	
21	B	I	
22	Streptococcus	I	
23	antigen	I	
24	are	O	
25	partially	O	
26	protective	O	
27	against	O	
28	intra	O	
29	-	O	
30	amniotic	O	
31	infection	O	
32	.	O	

1	On	O	
2	the	O	
3	diagnosis	O	
4	of	O	
5	bovine	O	
6	leucosis	O	
7	and	O	
8	its	O	
9	control	O	
10	in	O	
11	southern	O	
12	Lower	O	
13	Saxony	O	

1	Thus	O	
2	,	O	
3	VDR	B	
4	acts	O	
5	selectively	O	
6	on	O	
7	the	O	
8	two	O	
9	components	O	
10	required	O	
11	for	O	
12	activation	O	
13	of	O	
14	this	O	
15	promoter	O	
16	/	O	
17	enhancer	O	
18	:	O	
19	it	O	
20	competes	O	
21	with	O	
22	NFAT1	B	
23	for	O	
24	binding	O	
25	to	O	
26	the	O	
27	composite	O	
28	site	O	
29	,	O	
30	positioning	O	
31	itself	O	
32	adjacent	O	
33	to	O	
34	Jun	B	
35	-	O	
36	Fos	B	
37	on	O	
38	the	O	
39	DNA	O	
40	.	O	

1	Manganese	O	
2	ions	O	
3	were	O	
4	found	O	
5	to	O	
6	be	O	
7	essential	O	
8	for	O	
9	autophosphorylation	O	
10	of	O	
11	BGLF4	B	
12	,	O	
13	and	O	
14	magnesium	O	
15	can	O	
16	stimulate	O	
17	the	O	
18	activity	O	
19	.	O	

1	When	O	
2	data	O	
3	were	O	
4	expressed	O	
5	in	O	
6	a	O	
7	cumulative	O	
8	manner	O	
9	,	O	
10	the	O	
11	response	O	
12	to	O	
13	intravenous	O	
14	adenosine	O	
15	3	O	
16	mg	O	
17	,	O	
18	6	O	
19	mg	O	
20	,	O	
21	9	O	
22	mg	O	
23	and	O	
24	12	O	
25	mg	O	
26	in	O	
27	the	O	
28	24	O	
29	episodes	O	
30	of	O	
31	PSVT	O	
32	were	O	
33	5	O	
34	episodes	O	
35	(	O	
36	21	O	
37	%),	O	
38	16	O	
39	episodes	O	
40	(	O	
41	67	O	
42	%),	O	
43	20	O	
44	episodes	O	
45	(	O	
46	83	O	
47	%)	O	
48	and	O	
49	20	O	
50	episodes	O	
51	(	O	
52	83	O	
53	%)	O	
54	respectively	O	
55	.	O	

1	This	O	
2	dependence	O	
3	,	O	
4	however	O	
5	,	O	
6	can	O	
7	be	O	
8	overcome	O	
9	to	O	
10	a	O	
11	large	O	
12	extent	O	
13	by	O	
14	dividing	O	
15	min	O	
16	LVdP	O	
17	/	O	
18	dt	O	
19	by	O	
20	mean	O	
21	aortic	O	
22	pressure	O	
23	.	O	

1	Ask	O	
2	AONE	O	
3	'	O	
4	s	O	
5	experts	O	
6	...	O	
7	about	O	
8	productivity	O	
9	indicators	O	
10	.	O	

1	The	O	
2	Arabidopsis	B	
3	FAD7	I	
4	gene	I	
5	encodes	O	
6	a	O	
7	chloroplast	B	
8	omega	I	
9	-	I	
10	3	I	
11	fatty	I	
12	acid	I	
13	desaturase	I	
14	that	O	
15	catalyzes	O	
16	the	O	
17	desaturation	O	
18	of	O	
19	lipid	O	
20	-	O	
21	linked	O	
22	dienoic	O	
23	fatty	O	
24	acids	O	
25	(	O	
26	18	O	
27	:	O	
28	2	O	
29	and	O	
30	16	O	
31	:	O	
32	2	O	
33	).	O	

1	Leukemia	O	
2	in	O	
3	twins	O	
4	:	O	
5	world	O	
6	-	O	
7	wide	O	
8	review	O	
9	of	O	
10	clinical	O	
11	cases	O	
12	.	O	

1	Survival	O	
2	was	O	
3	calculated	O	
4	both	O	
5	from	O	
6	the	O	
7	date	O	
8	of	O	
9	onset	O	
10	and	O	
11	from	O	
12	the	O	
13	date	O	
14	of	O	
15	diagnosis	O	
16	.	O	

1	Pure	O	
2	T1	O	
3	and	O	
4	dual	O	
5	-	O	
6	T1	O	
7	images	O	
8	were	O	
9	visually	O	
10	evaluated	O	
11	for	O	
12	image	O	
13	quality	O	
14	(	O	
15	IQ	O	
16	)	O	
17	on	O	
18	a	O	
19	five	O	
20	-	O	
21	point	O	
22	scale	O	
23	(	O	
24	0	O	
25	=	O	
26	unacceptable	O	
27	to	O	
28	4	O	
29	=	O	
30	excellent	O	
31	).	O	

1	Intra	O	
2	-	O	
3	operative	O	
4	ultrasound	O	
5	(	O	
6	IOUS	O	
7	)	O	
8	has	O	
9	been	O	
10	widely	O	
11	used	O	
12	in	O	
13	an	O	
14	attempt	O	
15	to	O	
16	overcome	O	
17	these	O	
18	difficulties	O	
19	,	O	
20	but	O	
21	is	O	
22	limited	O	
23	by	O	
24	its	O	
25	two	O	
26	-	O	
27	dimensional	O	
28	nature	O	
29	,	O	
30	inter	O	
31	-	O	
32	user	O	
33	variability	O	
34	,	O	
35	and	O	
36	image	O	
37	obliteration	O	
38	with	O	
39	ablative	O	
40	or	O	
41	resectional	O	
42	techniques	O	
43	.	O	

1	The	O	
2	human	B	
3	MSH	I	
4	-	I	
5	2	I	
6	gene	I	
7	product	I	
8	is	O	
9	a	O	
10	member	O	
11	of	O	
12	a	O	
13	highly	O	
14	conserved	O	
15	family	O	
16	of	O	
17	proteins	O	
18	which	O	
19	are	O	
20	involved	O	
21	in	O	
22	post	O	
23	-	O	
24	replication	O	
25	mismatch	O	
26	repair	O	
27	.	O	
28	hMSH	B	
29	-	I	
30	2	I	
31	is	O	
32	homologous	O	
33	to	O	
34	Escherichia	O	
35	coli	O	
36	(	O	
37	E	O	
38	.	O	
39	coli	O	
40	)	O	
41	MutS	B	
42	and	O	
43	Sacchromyces	B	
44	cerevisiae	I	
45	MSH	I	
46	-	I	
47	1	I	
48	and	O	
49	MSH	B	
50	-	I	
51	2	I	
52	proteins	I	
53	,	O	
54	which	O	
55	recognise	O	
56	heteroduplex	O	
57	DNA	O	
58	at	O	
59	the	O	
60	sites	O	
61	of	O	
62	all	O	
63	single	O	
64	base	O	
65	mismatches	O	
66	and	O	
67	deletions	O	
68	or	O	
69	insertions	O	
70	up	O	
71	to	O	
72	4	O	
73	base	O	
74	pairs	O	
75	.	O	
76	hMSH	B	
77	-	I	
78	2	I	
79	is	O	
80	one	O	
81	of	O	
82	the	O	
83	hereditary	B	
84	non	I	
85	-	I	
86	polyposis	I	
87	colorectal	I	
88	cancer	I	
89	(	I	
90	HNPCC	I	
91	)	I	
92	tumor	I	
93	suppressor	I	
94	genes	I	
95	,	O	
96	and	O	
97	maps	O	
98	to	O	
99	human	O	
100	chromosome	O	
101	2p16	O	
102	.	O	

1	Initial	O	
2	control	O	
3	of	O	
4	bleeding	O	
5	is	O	
6	similar	O	
7	,	O	
8	but	O	
9	eradication	O	
10	is	O	
11	achieved	O	
12	in	O	
13	fewer	O	
14	sessions	O	
15	with	O	
16	EVL	O	
17	.	O	

1	In	O	
2	part	O	
3	as	O	
4	a	O	
5	result	O	
6	of	O	
7	its	O	
8	inability	O	
9	to	O	
10	sustain	O	
11	radiative	O	
12	loses	O	
13	,	O	
14	the	O	
15	BB	O	
16	resonator	O	
17	has	O	
18	extremely	O	
19	low	O	
20	RF	O	
21	power	O	
22	requirements	O	
23	.	O	

1	This	O	
2	study	O	
3	underlines	O	
4	the	O	
5	importance	O	
6	of	O	
7	terminal	O	
8	SC5b	B	
9	-	I	
10	9	I	
11	complement	I	
12	complex	I	
13	as	O	
14	a	O	
15	suitable	O	
16	marker	O	
17	in	O	
18	the	O	
19	evaluation	O	
20	of	O	
21	complement	O	
22	activation	O	
23	during	O	
24	cardiopulmonary	O	
25	bypass	O	
26	.	O	

1	Cell	O	
2	adhesion	O	
3	and	O	
4	migration	O	
5	assays	O	
6	demonstrate	O	
7	that	O	
8	alpha	B	
9	6	I	
10	beta	I	
11	1	I	
12	is	O	
13	the	O	
14	major	O	
15	laminin	B	
16	receptor	I	
17	in	O	
18	undifferentiated	O	
19	F9	O	
20	cells	O	
21	as	O	
22	well	O	
23	as	O	
24	F9	O	
25	-	O	
26	derived	O	
27	PE	O	
28	cells	O	
29	.	O	

1	Effects	O	
2	of	O	
3	moderate	O	
4	hypercapnia	O	
5	on	O	
6	hypothermia	O	
7	induced	O	
8	by	O	
9	cold	O	
10	He	O	
11	-	O	
12	O2	O	
13	in	O	
14	rats	O	
15	.	O	

1	X2	O	
2	test	O	
3	,	O	
4	with	O	
5	Yates	O	
6	correction	O	
7	if	O	
8	need	O	
9	,	O	
10	was	O	
11	used	O	
12	as	O	
13	statistical	O	
14	.	O	
15	method	O	
16	.	O	

1	The	O	
2	DNase	B	
3	I	I	
4	footprint	O	
5	extended	O	
6	5	O	
7	'	O	
8	in	O	
9	the	O	
10	silencer	O	
11	region	O	
12	to	O	
13	include	O	
14	an	O	
15	inverted	O	
16	repeat	O	
17	of	O	
18	a	O	
19	six	O	
20	-	O	
21	nucleotide	O	
22	motif	O	
23	(	O	
24	epsilon	O	
25	-	O	
26	267	O	
27	to	O	
28	-	O	
29	278	O	
30	bp	O	
31	)	O	
32	which	O	
33	shares	O	
34	5	O	
35	of	O	
36	6	O	
37	bases	O	
38	with	O	
39	the	O	
40	GATA	B	
41	-	I	
42	1	I	
43	consensus	I	
44	sequence	I	
45	.	O	

1	Radiation	O	
2	therapy	O	
3	was	O	
4	effective	O	
5	in	O	
6	controlling	O	
7	symptomatic	O	
8	metastasis	O	
9	in	O	
10	all	O	
11	three	O	
12	patients	O	
13	.	O	

1	Biohydrogenation	O	
2	of	O	
3	linoleic	O	
4	acid	O	
5	into	O	
6	octadecenoic	O	
7	acid	O	
8	was	O	
9	observed	O	
10	.	O	

1	Mechanism	O	
2	of	O	
3	enhancement	O	
4	of	O	
5	DNA	O	
6	expression	O	
7	consequent	O	
8	to	O	
9	cointernalization	O	
10	of	O	
11	a	O	
12	replication	O	
13	-	O	
14	deficient	O	
15	adenovirus	O	
16	and	O	
17	unmodified	O	
18	plasmid	O	
19	DNA	O	
20	.	O	

1	They	O	
2	were	O	
3	checked	O	
4	for	O	
5	anti	B	
6	-	I	
7	HCV	I	
8	(	O	
9	anti	B	
10	-	I	
11	C100	I	
12	-	I	
13	3	I	
14	)	O	
15	with	O	
16	HCV	O	
17	EIA	O	
18	kit	O	
19	(	O	
20	Abbott	O	
21	Lab	O	
22	.,	O	
23	North	O	
24	Chicago	O	
25	,	O	
26	IL	O	
27	).	O	

1	This	O	
2	is	O	
3	the	O	
4	first	O	
5	report	O	
6	of	O	
7	the	O	
8	successful	O	
9	resection	O	
10	of	O	
11	a	O	
12	MFH	O	
13	originating	O	
14	in	O	
15	the	O	
16	renal	O	
17	capsular	O	
18	tissue	O	
19	and	O	
20	extending	O	
21	into	O	
22	the	O	
23	inferior	O	
24	vena	O	
25	cava	O	
26	.	O	

1	Antithrombin	B	
2	III	I	
3	in	O	
4	hip	O	
5	surgery	O	

1	There	O	
2	were	O	
3	differences	O	
4	between	O	
5	males	O	
6	(	O	
7	p	O	
8	<	O	
9	0	O	
10	.	O	
11	05	O	
12	)	O	
13	for	O	
14	most	O	
15	of	O	
16	the	O	
17	characteristics	O	
18	studied	O	
19	.	O	

1	Sip1	B	
2	was	O	
3	initially	O	
4	identified	O	
5	by	O	
6	virtue	O	
7	of	O	
8	its	O	
9	interaction	O	
10	with	O	
11	SC35	B	
12	,	O	
13	a	O	
14	splicing	O	
15	factor	O	
16	of	O	
17	the	O	
18	SR	B	
19	family	I	
20	.	O	

1	The	O	
2	study	O	
3	of	O	
4	calcium	O	
5	metabolism	O	
6	in	O	
7	ten	O	
8	thalassaemic	O	
9	children	O	
10	comperatively	O	
11	with	O	
12	controls	O	
13	after	O	
14	oral	O	
15	administration	O	
16	of	O	
17	47Ca	O	
18	has	O	
19	shown	O	
20	diminished	O	
21	intestinal	O	
22	absorption	O	
23	.	O	

1	Ab	O	
2	-	O	
3	MLV	O	
4	strains	O	
5	expressing	O	
6	P70	B	
7	/	O	
8	S2	B	
9	failed	O	
10	to	O	
11	transform	O	
12	NIH	O	
13	3T3	O	
14	cells	O	
15	and	O	
16	demonstrated	O	
17	a	O	
18	greatly	O	
19	reduced	O	
20	capacity	O	
21	to	O	
22	mediate	O	
23	signaling	O	
24	events	O	
25	associated	O	
26	with	O	
27	the	O	
28	Ras	B	
29	-	O	
30	dependent	O	
31	mitogen	B	
32	-	I	
33	activated	I	
34	protein	I	
35	(	I	
36	MAP	I	
37	)	I	
38	kinase	I	
39	pathway	O	
40	.	O	

1	In	O	
2	this	O	
3	study	O	
4	,	O	
5	we	O	
6	investigated	O	
7	the	O	
8	signal	O	
9	transduction	O	
10	pathways	O	
11	that	O	
12	are	O	
13	involved	O	
14	in	O	
15	OM	B	
16	-	O	
17	induced	O	
18	LDLR	B	
19	transcription	O	
20	.	O	

1	Although	O	
2	IL	B	
3	-	I	
4	2	I	
5	and	O	
6	IFN	B	
7	-	I	
8	alpha	I	
9	activated	O	
10	STAT1	B	
11	alpha	I	
12	and	O	
13	STAT5	B	
14	,	O	
15	IL	B	
16	-	I	
17	2	I	
18	predominantly	O	
19	activated	O	
20	STAT5	B	
21	,	O	
22	while	O	
23	IFN	B	
24	-	I	
25	alpha	I	
26	predominantly	O	
27	activated	O	
28	STAT1	B	
29	alpha	I	
30	.	O	

1	Interferon	B	
2	-	I	
3	alpha	I	
4	treatment	O	
5	of	O	
6	posttransplant	O	
7	lymphoproliferative	O	
8	disorder	O	
9	in	O	
10	recipients	O	
11	of	O	
12	solid	O	
13	organ	O	
14	transplants	O	
15	.	O	

1	Galphaq	B	
2	,	O	
3	Galpha12	B	
4	,	O	
5	and	O	
6	Galpha13	B	
7	,	O	
8	but	O	
9	not	O	
10	Galphai	B	
11	,	O	
12	activate	O	
13	SRF	B	
14	through	O	
15	RhoA	B	
16	.	O	

1	Retinoid	O	
2	-	O	
3	dependent	O	
4	activation	O	
5	of	O	
6	the	O	
7	tissue	B	
8	transglutaminase	I	
9	promoter	I	
10	depends	O	
11	on	O	
12	both	O	
13	a	O	
14	proximal	O	
15	regulatory	O	
16	region	O	
17	containing	O	
18	sequences	O	
19	highly	O	
20	conserved	O	
21	between	O	
22	the	O	
23	human	O	
24	and	O	
25	the	O	
26	mouse	B	
27	tissue	I	
28	transglutaminase	I	
29	promoters	I	
30	and	O	
31	a	O	
32	distal	O	
33	region	O	
34	that	O	
35	includes	O	
36	a	O	
37	30	O	
38	-	O	
39	base	O	
40	pair	O	
41	retinoid	O	
42	response	O	
43	element	O	
44	(	O	
45	mTGRRE1	O	
46	).	O	
47	mTGRRE1	O	
48	contains	O	
49	three	O	
50	hexanucleotide	O	
51	half	O	
52	-	O	
53	sites	O	
54	(	O	
55	two	O	
56	canonical	O	
57	and	O	
58	one	O	
59	non	O	
60	-	O	
61	canonical	O	
62	)	O	
63	in	O	
64	a	O	
65	DR7	B	
66	/	O	
67	DR5	B	
68	motif	O	
69	that	O	
70	bind	O	
71	both	O	
72	RAR	B	
73	*	O	
74	RXR	B	
75	heterodimers	O	
76	and	O	
77	RXR	B	
78	homodimers	I	
79	.	O	

1	These	O	
2	results	O	
3	suggest	O	
4	that	O	
5	HAC1	B	
6	may	O	
7	also	O	
8	be	O	
9	one	O	
10	of	O	
11	the	O	
12	meiotic	O	
13	genes	O	
14	.	O	

1	We	O	
2	suggest	O	
3	that	O	
4	this	O	
5	gene	O	
6	cluster	O	
7	codes	O	
8	for	O	
9	(	O	
10	parts	O	
11	of	O	
12	)	O	
13	a	O	
14	multisubunit	B	
15	cytochrome	I	
16	c	I	
17	haem	I	
18	lyase	I	
19	.	O	

1	One	O	
2	antibody	O	
3	,	O	
4	mAb1C2	B	
5	,	O	
6	and	O	
7	a	O	
8	synthetic	O	
9	peptide	O	
10	comprising	O	
11	its	O	
12	epitope	O	
13	selectively	O	
14	inhibited	O	
15	in	O	
16	vitro	O	
17	transcription	O	
18	from	O	
19	TATA	O	
20	-	O	
21	containing	O	
22	,	O	
23	but	O	
24	not	O	
25	from	O	
26	TATA	O	
27	-	O	
28	less	O	
29	promoters	O	
30	,	O	
31	irrespective	O	
32	of	O	
33	whether	O	
34	they	O	
35	were	O	
36	transcribed	O	
37	by	O	
38	Pol	B	
39	II	I	
40	or	O	
41	Pol	B	
42	III	I	
43	.	O	

1	The	O	
2	rationale	O	
3	for	O	
4	continuous	O	
5	dopaminergic	O	
6	stimulation	O	
7	in	O	
8	patients	O	
9	with	O	
10	Parkinson	O	
11	'	O	
12	s	O	
13	disease	O	
14	.	O	

1	The	O	
2	expression	O	
3	of	O	
4	this	O	
5	clone	O	
6	in	O	
7	a	O	
8	wee1	B	
9	/	O	
10	mik1	B	
11	-	O	
12	deficient	O	
13	mutant	O	
14	causes	O	
15	an	O	
16	elongated	O	
17	cell	O	
18	phenotype	O	
19	under	O	
20	non	O	
21	-	O	
22	permissive	O	
23	growth	O	
24	conditions	O	
25	.	O	

1	This	O	
2	conclusion	O	
3	was	O	
4	confirmed	O	
5	by	O	
6	Northern	O	
7	blotting	O	
8	analysis	O	
9	of	O	
10	the	O	
11	5	O	
12	'-	O	
13	flanking	O	
14	region	O	
15	of	O	
16	CAD	B	
17	gene	I	
18	.	O	

1	Time	O	
2	delay	O	
3	effects	O	
4	on	O	
5	the	O	
6	tensile	O	
7	bond	O	
8	strength	O	
9	developed	O	
10	by	O	
11	the	O	
12	Silicoater	O	
13	.	O	

1	Tctex	B	
2	-	I	
3	1	I	
4	binding	O	
5	required	O	
6	the	O	
7	first	O	
8	19	O	
9	amino	O	
10	acids	O	
11	of	O	
12	Fyn	B	
13	and	O	
14	integrity	O	
15	of	O	
16	two	O	
17	lysine	O	
18	residues	O	
19	within	O	
20	this	O	
21	sequence	O	
22	that	O	
23	were	O	
24	previously	O	
25	shown	O	
26	to	O	
27	be	O	
28	important	O	
29	for	O	
30	Fyn	B	
31	interactions	O	
32	with	O	
33	the	O	
34	immunoreceptor	O	
35	tyrosine	O	
36	-	O	
37	based	O	
38	activation	O	
39	motifs	O	
40	(	O	
41	ITAMs	O	
42	)	O	
43	of	O	
44	lymphocyte	B	
45	Ag	I	
46	receptors	I	
47	.	O	

1	Supraventricular	O	
2	arrhythmias	O	
3	--	O	
4	digoxin	O	
5	and	O	
6	quinidine	O	
7	revisited	O	
8	.	O	

1	Amikacin	O	
2	was	O	
3	the	O	
4	most	O	
5	stable	O	
6	and	O	
7	tobramycin	O	
8	was	O	
9	the	O	
10	least	O	
11	stable	O	
12	aminoglycoside	O	
13	under	O	
14	the	O	
15	conditions	O	
16	tested	O	
17	.	O	

1	No	O	
2	difference	O	
3	in	O	
4	telomere	O	
5	length	O	
6	was	O	
7	seen	O	
8	in	O	
9	mutants	O	
10	affected	O	
11	in	O	
12	the	O	
13	regulation	O	
14	of	O	
15	Cdc2	B	
16	,	O	
17	whereas	O	
18	some	O	
19	of	O	
20	the	O	
21	DNA	O	
22	repair	O	
23	mutants	O	
24	examined	O	
25	had	O	
26	slightly	O	
27	longer	O	
28	telomeres	O	
29	than	O	
30	did	O	
31	the	O	
32	wild	O	
33	type	O	
34	.	O	

1	State	O	
2	-	O	
3	approved	O	
4	schools	O	
5	of	O	
6	nursing	O	
7	R	O	
8	.	O	
9	N	O	
10	.	O	

1	We	O	
2	now	O	
3	describe	O	
4	the	O	
5	identification	O	
6	of	O	
7	DEK	B	
8	as	O	
9	this	O	
10	43	B	
11	-	I	
12	kDa	I	
13	pets	I	
14	factor	I	
15	.	O	

1	Treatment	O	
2	of	O	
3	Graves	O	
4	'	O	
5	disease	O	
6	.	O	

1	Trial	O	
2	treatment	O	
3	of	O	
4	schizophrenia	O	
5	with	O	
6	des	B	
7	-	I	
8	Tyr	I	
9	-	I	
10	gamma	I	
11	-	I	
12	endorphin	I	

1	IFN	B	
2	alpha	I	
3	and	O	
4	IFN	B	
5	gamma	I	
6	inducibility	O	
7	is	O	
8	mediated	O	
9	by	O	
10	a	O	
11	single	O	
12	element	O	
13	:	O	
14	a	O	
15	high	O	
16	affinity	O	
17	,	O	
18	nearly	O	
19	palindromic	O	
20	version	O	
21	of	O	
22	the	O	
23	IFN	B	
24	gamma	I	
25	activation	I	
26	site	I	
27	(	O	
28	GAS	B	
29	).	O	

1	GnRH	B	
2	treatment	O	
3	was	O	
4	found	O	
5	to	O	
6	increase	O	
7	the	O	
8	phosphorylation	O	
9	of	O	
10	tyrosine	O	
11	residues	O	
12	of	O	
13	MAPK	B	
14	and	O	
15	to	O	
16	increase	O	
17	MAPK	B	
18	activity	O	
19	,	O	
20	as	O	
21	determined	O	
22	by	O	
23	an	O	
24	immune	O	
25	complex	O	
26	kinase	O	
27	assay	O	
28	.	O	

1	Previous	O	
2	studies	O	
3	have	O	
4	shown	O	
5	[	O	
6	Hisanaga	O	
7	,	O	
8	S	O	
9	.,	O	
10	Kusubata	O	
11	,	O	
12	M	O	
13	.,	O	
14	Okumura	O	
15	,	O	
16	E	O	
17	.	O	
18	&	O	
19	Kishimoto	O	
20	,	O	
21	T	O	
22	.	O	

1	PM	O	
2	12	O	
3	or	O	
4	18	O	
5	mg	O	
6	/	O	
7	kg	O	
8	daily	O	
9	plus	O	
10	a	O	
11	standard	O	
12	dose	O	
13	of	O	
14	SB	O	
15	for	O	
16	21	O	
17	days	O	
18	was	O	
19	statistically	O	
20	more	O	
21	effective	O	
22	than	O	
23	SB	O	
24	in	O	
25	producing	O	
26	a	O	
27	final	O	
28	cure	O	
29	for	O	
30	patients	O	
31	with	O	
32	VL	O	
33	in	O	
34	Bihar	O	
35	,	O	
36	India	O	
37	.	O	

1	The	O	
2	early	O	
3	lethality	O	
4	of	O	
5	the	O	
6	left	O	
7	-	O	
8	sided	O	
9	resectio	O	
10	was	O	
11	0	O	
12	%	O	
13	and	O	
14	the	O	
15	postoperative	O	
16	survival	O	
17	--	O	
18	5	O	
19	-	O	
20	10	O	
21	months	O	
22	.	O	

1	In	O	
2	the	O	
3	present	O	
4	report	O	
5	,	O	
6	66	O	
7	hemochromatosis	O	
8	families	O	
9	yielding	O	
10	151	O	
11	hemochromatosis	O	
12	chromosomes	O	
13	and	O	
14	182	O	
15	normal	O	
16	chromosomes	O	
17	were	O	
18	RFLP	O	
19	-	O	
20	typed	O	
21	with	O	
22	a	O	
23	battery	O	
24	of	O	
25	probes	O	
26	,	O	
27	including	O	
28	two	O	
29	newly	O	
30	derived	O	
31	polymorphic	O	
32	markers	O	
33	from	O	
34	the	O	
35	6	O	
36	.	O	
37	7	O	
38	and	O	
39	HLA	B	
40	-	I	
41	F	I	
42	loci	I	
43	located	O	
44	150	O	
45	and	O	
46	250	O	
47	kb	O	
48	telomeric	O	
49	to	O	
50	HLA	B	
51	-	I	
52	A	I	
53	,	O	
54	respectively	O	
55	.	O	

1	Mutagenesis	O	
2	of	O	
3	the	O	
4	pecT	B	
5	regulatory	O	
6	region	O	
7	revealed	O	
8	the	O	
9	presence	O	
10	of	O	
11	two	O	
12	sites	O	
13	in	O	
14	which	O	
15	insertions	O	
16	reproduced	O	
17	the	O	
18	pec	B	
19	-	I	
20	1	I	
21	phenotype	O	
22	.	O	

1	The	O	
2	manifestations	O	
3	often	O	
4	include	O	
5	a	O	
6	moderate	O	
7	thrombocytopenia	O	
8	and	O	
9	,	O	
10	less	O	
11	commonly	O	
12	,	O	
13	hemolysis	O	
14	.	O	

1	The	O	
2	P13	O	
3	and	O	
4	N22	O	
5	of	O	
6	ppSEPs	O	
7	had	O	
8	phase	O	
9	reversal	O	
10	relationship	O	
11	with	O	
12	the	O	
13	P2	O	
14	and	O	
15	N2	O	
16	recorded	O	
17	from	O	
18	the	O	
19	PES	O	
20	,	O	
21	respectively	O	
22	.	O	

1	The	O	
2	CANNTG	O	
3	motifs	O	
4	were	O	
5	found	O	
6	to	O	
7	bind	O	
8	MyoD	B	
9	and	O	
10	myogenin	B	
11	fusion	I	
12	proteins	I	
13	and	O	
14	to	O	
15	interact	O	
16	with	O	
17	proteins	O	
18	in	O	
19	nuclear	O	
20	extracts	O	
21	from	O	
22	cultured	O	
23	myotubes	O	
24	.	O	

1	We	O	
2	also	O	
3	review	O	
4	the	O	
5	role	O	
6	of	O	
7	grains	O	
8	in	O	
9	the	O	
10	formation	O	
11	of	O	
12	complex	O	
13	molecules	O	
14	in	O	
15	interstellar	O	
16	molecular	O	
17	clouds	O	
18	.	O	

1	Osteogenesis	O	
2	imperfecta	O	

1	We	O	
2	examined	O	
3	Akt	B	
4	activation	O	
5	in	O	
6	Lyn	B	
7	-,	O	
8	Syk	B	
9	-	O	
10	and	O	
11	Btk	B	
12	-	O	
13	deficient	O	
14	DT40	O	
15	cells	O	
16	and	O	
17	B	O	
18	cells	O	
19	from	O	
20	Lyn	B	
21	(-/-)	I	
22	mice	O	
23	.	O	

1	A	O	
2	transcript	O	
3	of	O	
4	about	O	
5	2	O	
6	kb	O	
7	is	O	
8	expected	O	
9	for	O	
10	each	O	
11	PPO	B	
12	.	O	

1	Degradation	O	
2	of	O	
3	the	O	
4	soybean	B	
5	ribulose	I	
6	-	I	
7	1	I	
8	,	I	
9	5	I	
10	-	I	
11	bisphosphate	I	
12	carboxylase	I	
13	small	I	
14	-	I	
15	subunit	I	
16	mRNA	I	
17	,	O	
18	SRS4	B	
19	,	O	
20	initiates	O	
21	with	O	
22	endonucleolytic	O	
23	cleavage	O	
24	.	O	

1	We	O	
2	mapped	O	
3	two	O	
4	overlapping	O	
5	expressed	O	
6	sequence	O	
7	tag	O	
8	clones	O	
9	within	O	
10	a	O	
11	genomic	O	
12	contig	O	
13	on	O	
14	human	O	
15	chromosome	O	
16	5	O	
17	,	O	
18	band	O	
19	q31	O	
20	.	O	

1	High	B	
2	-	I	
3	mobility	I	
4	-	I	
5	group	I	
6	protein	I	
7	I	I	
8	can	O	
9	modulate	O	
10	binding	O	
11	of	O	
12	transcription	O	
13	factors	O	
14	to	O	
15	the	O	
16	U5	B	
17	region	I	
18	of	O	
19	the	O	
20	human	B	
21	immunodeficiency	I	
22	virus	I	
23	type	I	
24	1	I	
25	proviral	I	
26	promoter	I	
27	.	O	

1	Possibility	O	
2	of	O	
3	a	O	
4	TSH	B	
5	-	O	
6	Screening	O	
7	method	O	
8	for	O	
9	detection	O	
10	of	O	
11	hypothyroidism	O	
12	in	O	
13	the	O	
14	newborn	O	

1	Using	O	
2	an	O	
3	RNase	B	
4	H	I	
5	protection	O	
6	assay	O	
7	and	O	
8	specific	O	
9	blocking	O	
10	oligonucleotides	O	
11	,	O	
12	we	O	
13	find	O	
14	that	O	
15	recognition	O	
16	of	O	
17	the	O	
18	5	O	
19	'	O	
20	splice	O	
21	-	O	
22	site	O	
23	(	O	
24	5	O	
25	'	O	
26	ss	O	
27	)	O	
28	and	O	
29	branchpoint	O	
30	sequence	O	
31	(	O	
32	BPS	O	
33	)	O	
34	elements	O	
35	by	O	
36	U11	B	
37	and	O	
38	U12	B	
39	snRNPs	I	
40	,	O	
41	respectively	O	
42	,	O	
43	displays	O	
44	strong	O	
45	cooperativity	O	
46	,	O	
47	requiring	O	
48	both	O	
49	sites	O	
50	in	O	
51	the	O	
52	pre	O	
53	-	O	
54	mRNA	O	
55	substrate	O	
56	for	O	
57	efficient	O	
58	complex	O	
59	formation	O	
60	.	O	

1	nos	B	
2	-	I	
3	1	I	
4	and	O	
5	nos	B	
6	-	I	
7	2	I	
8	,	O	
9	two	O	
10	genes	O	
11	related	O	
12	to	O	
13	Drosophila	B	
14	nanos	I	
15	,	O	
16	regulate	O	
17	primordial	O	
18	germ	O	
19	cell	O	
20	development	O	
21	and	O	
22	survival	O	
23	in	O	
24	Caenorhabditis	O	
25	elegans	O	
26	.	O	

1	The	O	
2	interaction	O	
3	of	O	
4	zf4	B	
5	-	I	
6	6	I	
7	with	O	
8	full	B	
9	-	I	
10	length	I	
11	5	I	
12	S	I	
13	RNA	I	
14	was	O	
15	far	O	
16	more	O	
17	sensitive	O	
18	to	O	
19	non	O	
20	-	O	
21	specific	O	
22	competitor	O	
23	concentration	O	
24	than	O	
25	was	O	
26	the	O	
27	zf4	B	
28	-	I	
29	7	I	
30	:	O	
31	5	B	
32	S	I	
33	RNA	I	
34	interaction	O	
35	,	O	
36	suggesting	O	
37	that	O	
38	finger	O	
39	seven	O	
40	contributes	O	
41	to	O	
42	both	O	
43	affinity	O	
44	and	O	
45	specificity	O	
46	in	O	
47	this	O	
48	protein	O	
49	:	O	
50	RNA	O	
51	interaction	O	
52	.	O	

1	For	O	
2	patients	O	
3	with	O	
4	recurrent	O	
5	or	O	
6	metastatic	O	
7	disease	O	
8	,	O	
9	the	O	
10	data	O	
11	suggest	O	
12	that	O	
13	I	O	
14	-	O	
15	131	O	
16	MIBG	O	
17	scintigraphy	O	
18	is	O	
19	the	O	
20	examination	O	
21	of	O	
22	choice	O	
23	.	O	

1	The	O	
2	dynamic	O	
3	properties	O	
4	of	O	
5	this	O	
6	protein	O	
7	fragment	O	
8	were	O	
9	measured	O	
10	and	O	
11	analyzed	O	
12	using	O	
13	both	O	
14	isotropic	O	
15	and	O	
16	anisotropic	O	
17	models	O	
18	of	O	
19	molecular	O	
20	motion	O	
21	.	O	

1	Possibilities	O	
2	of	O	
3	needleless	O	
4	administration	O	
5	of	O	
6	various	O	
7	substances	O	
8	to	O	
9	animals	O	

1	Identification	O	
2	and	O	
3	characterization	O	
4	of	O	
5	IS2404	B	
6	and	O	
7	IS2606	B	
8	:	O	
9	two	O	
10	distinct	O	
11	repeated	O	
12	sequences	O	
13	for	O	
14	detection	O	
15	of	O	
16	Mycobacterium	O	
17	ulcerans	O	
18	by	O	
19	PCR	O	
20	.	O	

1	The	O	
2	carboxyl	O	
3	-	O	
4	terminal	O	
5	proline	O	
6	-	O	
7	rich	O	
8	domain	O	
9	of	O	
10	SOS1	B	
11	is	O	
12	involved	O	
13	in	O	
14	the	O	
15	interaction	O	
16	with	O	
17	the	O	
18	PLC	B	
19	-	I	
20	gamma1	I	
21	SH3	I	
22	domain	I	
23	.	O	

1	Only	O	
2	one	O	
3	ADR	O	
4	was	O	
5	related	O	
6	definitely	O	
7	to	O	
8	ciprofloxacin	O	
9	therapy	O	
10	.	O	

1	In	O	
2	gel	O	
3	mobility	O	
4	shift	O	
5	assays	O	
6	,	O	
7	we	O	
8	found	O	
9	no	O	
10	evidence	O	
11	for	O	
12	VDR	B	
13	-	O	
14	TR	B	
15	heterodimer	O	
16	interaction	O	
17	with	O	
18	any	O	
19	tested	O	
20	element	O	
21	.	O	

1	Medicare	O	
2	SNF	O	
3	benefits	O	
4	revised	O	
5	--	O	
6	again	O	
7	.	O	

1	2	O	
2	new	O	
3	Algerian	O	
4	cases	O	

1	Cost	O	
2	-	O	
3	effectiveness	O	
4	of	O	
5	interferon	B	
6	beta	I	
7	-	I	
8	1b	I	
9	in	O	
10	slowing	O	
11	multiple	O	
12	sclerosis	O	
13	disability	O	
14	progression	O	
15	.	O	

1	There	O	
2	were	O	
3	no	O	
4	instances	O	
5	of	O	
6	major	O	
7	flap	O	
8	necrosis	O	
9	although	O	
10	two	O	
11	flaps	O	
12	showed	O	
13	tip	O	
14	ischaemia	O	
15	.	O	

1	CD3	B	
2	cross	O	
3	-	O	
4	linking	O	
5	induced	O	
6	tyrosine	O	
7	phosphorylation	O	
8	of	O	
9	Sam68	B	
10	in	O	
11	uninfected	O	
12	T	O	
13	cells	O	
14	.	O	

1	The	O	
2	14	B	
3	.	I	
4	1	I	
5	(	I	
6	IGLL1	I	
7	)	I	
8	gene	I	
9	is	O	
10	expressed	O	
11	in	O	
12	a	O	
13	lineage	O	
14	-	O	
15	and	O	
16	stage	O	
17	-	O	
18	restricted	O	
19	manner	O	
20	.	O	

1	100	O	
2	and	O	
3	14	O	
4	p	O	
5	.	O	

1	The	O	
2	partial	O	
3	categories	O	
4	of	O	
5	the	O	
6	SIP	O	
7	that	O	
8	were	O	
9	more	O	
10	affected	O	
11	were	O	
12	work	O	
13	,	O	
14	recreation	O	
15	and	O	
16	pastimes	O	
17	,	O	
18	home	O	
19	management	O	
20	,	O	
21	and	O	
22	sleep	O	
23	and	O	
24	rest	O	
25	.	O	

1	STK	B	
2	/	O	
3	RON	B	
4	-	O	
5	expressing	O	
6	Ba	O	
7	/	O	
8	F3	O	
9	pro	O	
10	-	O	
11	B	O	
12	cells	O	
13	(	O	
14	BaF	O	
15	/	O	
16	STK	B	
17	)	O	
18	exhibited	O	
19	MSP	B	
20	-	O	
21	dependent	O	
22	growth	O	
23	,	O	
24	whereas	O	
25	STK	B	
26	/	O	
27	RON	B	
28	-	O	
29	expressing	O	
30	mouse	O	
31	erythroleukaemia	O	
32	cells	O	
33	(	O	
34	MEL	O	
35	/	O	
36	STK	B	
37	)	O	
38	displayed	O	
39	MSP	B	
40	-	O	
41	induced	O	
42	apoptosis	O	
43	.	O	

1	Since	O	
2	September	O	
3	1980	O	
4	to	O	
5	June	O	
6	1983	O	
7	we	O	
8	have	O	
9	treated	O	
10	32	O	
11	patients	O	
12	with	O	
13	ovarian	O	
14	cancer	O	
15	.	O	

1	Because	O	
2	GH	B	
3	-	O	
4	induced	O	
5	Akt	B	
6	activation	O	
7	was	O	
8	completely	O	
9	inhibited	O	
10	in	O	
11	both	O	
12	cells	O	
13	by	O	
14	the	O	
15	same	O	
16	concentration	O	
17	of	O	
18	LY294002	O	
19	,	O	
20	these	O	
21	findings	O	
22	indicate	O	
23	that	O	
24	the	O	
25	wortmannin	O	
26	sensitivity	O	
27	of	O	
28	both	O	
29	the	O	
30	IRS	B	
31	-	I	
32	1	I	
33	-	O	
34	independent	O	
35	and	O	
36	-	O	
37	dependent	O	
38	GH	B	
39	-	O	
40	induced	O	
41	MAP	B	
42	kinase	I	
43	activation	O	
44	may	O	
45	reflect	O	
46	the	O	
47	activity	O	
48	of	O	
49	another	O	
50	wortmannin	O	
51	-	O	
52	sensitive	O	
53	target	O	
54	(	O	
55	s	O	
56	)	O	
57	in	O	
58	addition	O	
59	to	O	
60	PI3K	B	
61	in	O	
62	mediation	O	
63	of	O	
64	GH	B	
65	-	O	
66	induced	O	
67	MAP	B	
68	kinase	I	
69	activation	O	
70	in	O	
71	these	O	
72	cells	O	
73	.	O	

1	Like	O	
2	humans	O	
3	,	O	
4	the	O	
5	PITSLRE	B	
6	PK	I	
7	genes	I	
8	in	I	
9	chickens	I	
10	must	O	
11	be	O	
12	closely	O	
13	linked	O	
14	,	O	
15	based	O	
16	on	O	
17	fluorescent	O	
18	in	O	
19	situ	O	
20	hybridization	O	
21	(	O	
22	FISH	O	
23	)	O	
24	localization	O	
25	of	O	
26	these	O	
27	genes	O	
28	to	O	
29	a	O	
30	single	O	
31	chicken	O	
32	microchromosome	O	
33	.	O	

1	We	O	
2	have	O	
3	shown	O	
4	previously	O	
5	that	O	
6	in	O	
7	contrast	O	
8	to	O	
9	other	O	
10	extracellular	O	
11	matrix	O	
12	molecules	O	
13	pepsin	B	
14	-	O	
15	solubilized	O	
16	collagen	B	
17	VI	I	
18	(	O	
19	CVI	B	
20	)	O	
21	can	O	
22	stimulate	O	
23	DNA	O	
24	synthesis	O	
25	of	O	
26	various	O	
27	mesenchymal	O	
28	cell	O	
29	types	O	
30	,	O	
31	apparently	O	
32	independent	O	
33	of	O	
34	integrin	B	
35	-	O	
36	mediated	O	
37	signal	O	
38	transduction	O	
39	.	O	

1	An	O	
2	epidemic	O	
3	of	O	
4	hepatitis	O	
5	B	O	
6	virus	O	
7	infection	O	
8	among	O	
9	intravenous	O	
10	drug	O	
11	users	O	
12	in	O	
13	Iceland	O	
14	.	O	

1	Deletion	O	
2	of	O	
3	a	O	
4	53	O	
5	-	O	
6	bp	O	
7	early	O	
8	promoter	O	
9	region	O	
10	containing	O	
11	the	O	
12	transcription	O	
13	start	O	
14	site	O	
15	and	O	
16	a	O	
17	putative	O	
18	TATA	O	
19	box	O	
20	completely	O	
21	abolishes	O	
22	the	O	
23	ability	O	
24	of	O	
25	upstream	O	
26	elements	O	
27	to	O	
28	drive	O	
29	transcription	O	
30	of	O	
31	the	O	
32	luciferase	B	
33	cDNA	I	
34	.	O	

1	Our	O	
2	data	O	
3	complement	O	
4	other	O	
5	studies	O	
6	of	O	
7	circumpolar	O	
8	populations	O	
9	and	O	
10	reinforce	O	
11	the	O	
12	reported	O	
13	high	O	
14	prevalences	O	
15	of	O	
16	SPA	O	
17	and	O	
18	HLA	B	
19	-	I	
20	B27	I	
21	among	O	
22	those	O	
23	populations	O	
24	.	O	

1	Pressure	O	
2	ulcers	O	
3	.	O	

1	After	O	
2	treatment	O	
3	with	O	
4	tunicamycin	O	
5	,	O	
6	the	O	
7	transfectants	O	
8	secreted	O	
9	unglycosylated	O	
10	18	O	
11	-	O	
12	kDa	O	
13	polypeptides	O	
14	which	O	
15	could	O	
16	also	O	
17	bind	O	
18	IgE	B	
19	.	O	

1	Hovenitin	O	
2	I	O	
3	and	O	
4	(+)-	O	
5	ampelopsin	O	
6	,	O	
7	both	O	
8	of	O	
9	which	O	
10	were	O	
11	principal	O	
12	ingredients	O	
13	of	O	
14	the	O	
15	active	O	
16	fractions	O	
17	from	O	
18	this	O	
19	natural	O	
20	medicine	O	
21	,	O	
22	were	O	
23	found	O	
24	to	O	
25	show	O	
26	an	O	
27	inhibitory	O	
28	activity	O	
29	on	O	
30	the	O	
31	ethanol	O	
32	-	O	
33	induced	O	
34	muscle	O	
35	relaxation	O	
36	in	O	
37	rats	O	
38	.	O	

1	The	O	
2	study	O	
3	included	O	
4	139	O	
5	eyes	O	
6	with	O	
7	presumed	O	
8	ocular	O	
9	histoplasmosis	O	
10	syndrome	O	
11	(	O	
12	POHS	O	
13	)	O	
14	and	O	
15	age	O	
16	-	O	
17	related	O	
18	macular	O	
19	degeneration	O	
20	(	O	
21	AMD	O	
22	).	O	

1	These	O	
2	results	O	
3	would	O	
4	suggest	O	
5	that	O	
6	a	O	
7	high	O	
8	UV	O	
9	sensitivity	O	
10	is	O	
11	associated	O	
12	with	O	
13	high	O	
14	phaeomelanin	O	
15	and	O	
16	low	O	
17	eumelanin	O	
18	levels	O	
19	,	O	
20	and	O	
21	point	O	
22	to	O	
23	the	O	
24	eumelanin	O	
25	/	O	
26	phaeomelanin	O	
27	ratio	O	
28	as	O	
29	a	O	
30	novel	O	
31	chemical	O	
32	parameter	O	
33	that	O	
34	could	O	
35	be	O	
36	used	O	
37	for	O	
38	predicting	O	
39	individuals	O	
40	at	O	
41	high	O	
42	risk	O	
43	for	O	
44	skin	O	
45	cancer	O	
46	and	O	
47	melanoma	O	
48	.	O	

1	Sestamibi	O	
2	scintigraphy	O	
3	,	O	
4	performed	O	
5	in	O	
6	70	O	
7	patients	O	
8	,	O	
9	was	O	
10	less	O	
11	sensitive	O	
12	than	O	
13	ultrasonography	O	
14	(	O	
15	80	O	
16	%).	O	

1	This	O	
2	approach	O	
3	was	O	
4	examined	O	
5	utilizing	O	
6	the	O	
7	fetal	O	
8	protein	O	
9	,	O	
10	HGB	B	
11	F	I	
12	.	O	

1	Interplane	O	
2	coupling	O	
3	in	O	
4	the	O	
5	superconductor	O	
6	Y2Ba4Cu7O15	O	
7	as	O	
8	revealed	O	
9	by	O	
10	NQR	O	
11	spin	O	
12	-	O	
13	echo	O	
14	double	O	
15	resonance	O	
16	.	O	

1	No	O	
2	difference	O	
3	in	O	
4	the	O	
5	clinical	O	
6	acceptability	O	
7	could	O	
8	be	O	
9	ascertained	O	
10	between	O	
11	the	O	
12	two	O	
13	groups	O	
14	.	O	

1	On	O	
2	line	O	
3	calculation	O	
4	of	O	
5	steroid	O	
6	concentrations	O	
7	by	O	
8	radioimmunoassay	O	

1	Movement	O	
2	programming	O	
3	depends	O	
4	on	O	
5	understanding	O	
6	of	O	
7	behavioral	O	
8	requirements	O	
9	.	O	

1	We	O	
2	studied	O	
3	the	O	
4	human	O	
5	vestibulo	O	
6	-	O	
7	ocular	O	
8	reflex	O	
9	(	O	
10	VOR	O	
11	)	O	
12	in	O	
13	response	O	
14	to	O	
15	head	O	
16	'	O	
17	impulses	O	
18	':	O	
19	brief	O	
20	,	O	
21	unpredictable	O	
22	,	O	
23	passive	O	
24	,	O	
25	high	O	
26	-	O	
27	acceleration	O	
28	(	O	
29	up	O	
30	to	O	
31	4000	O	
32	degrees	O	
33	/	O	
34	s2	O	
35	),	O	
36	low	O	
37	-	O	
38	amplitude	O	
39	(	O	
40	20	O	
41	-	O	
42	30	O	
43	degrees	O	
44	)	O	
45	head	O	
46	rotations	O	
47	.	O	

1	The	O	
2	mean	O	
3	total	O	
4	white	O	
5	cell	O	
6	count	O	
7	increased	O	
8	from	O	
9	a	O	
10	baseline	O	
11	of	O	
12	11	O	
13	.	O	
14	3	O	
15	x	O	
16	10	O	
17	(	O	
18	9	O	
19	)/	O	
20	L	O	
21	(	O	
22	SD	O	
23	2	O	
24	.	O	
25	3	O	
26	)	O	
27	to	O	
28	16	O	
29	.	O	
30	2	O	
31	x	O	
32	10	O	
33	(	O	
34	9	O	
35	)/	O	
36	L	O	
37	(	O	
38	SD	O	
39	4	O	
40	.	O	
41	6	O	
42	)	O	
43	on	O	
44	day	O	
45	1	O	
46	,	O	
47	normalising	O	
48	thereafter	O	
49	.	O	

1	Reporter	O	
2	constructs	O	
3	function	O	
4	in	O	
5	a	O	
6	parallel	O	
7	manner	O	
8	,	O	
9	demonstrating	O	
10	the	O	
11	key	O	
12	role	O	
13	of	O	
14	the	O	
15	AhR	B	
16	in	O	
17	constitutive	O	
18	as	O	
19	well	O	
20	as	O	
21	TCDD	O	
22	-	O	
23	induced	O	
24	expression	O	
25	of	O	
26	Cyp1B1	B	
27	in	O	
28	mouse	O	
29	embryo	O	
30	fibroblasts	O	
31	.	O	

1	The	O	
2	most	O	
3	frequent	O	
4	risk	O	
5	factor	O	
6	for	O	
7	ischaemic	O	
8	was	O	
9	hypertension	O	
10	.	O	

1	Paleoceanographic	O	
2	data	O	
3	from	O	
4	the	O	
5	Laurentian	O	
6	Fan	O	
7	,	O	
8	used	O	
9	as	O	
10	a	O	
11	proxy	O	
12	for	O	
13	sea	O	
14	surface	O	
15	temperature	O	
16	,	O	
17	reveal	O	
18	that	O	
19	surface	O	
20	slope	O	
21	waters	O	
22	north	O	
23	of	O	
24	the	O	
25	Gulf	O	
26	Stream	O	
27	experienced	O	
28	warming	O	
29	during	O	
30	the	O	
31	Little	O	
32	Ice	O	
33	Age	O	
34	of	O	
35	the	O	
36	16th	O	
37	to	O	
38	19th	O	
39	centuries	O	
40	and	O	
41	support	O	
42	the	O	
43	notion	O	
44	of	O	
45	an	O	
46	NAO	O	
47	-	O	
48	driven	O	
49	coupled	O	
50	system	O	
51	.	O	

1	Furthermore	O	
2	,	O	
3	we	O	
4	notice	O	
5	two	O	
6	potential	O	
7	consensus	O	
8	motifs	O	
9	which	O	
10	are	O	
11	also	O	
12	found	O	
13	in	O	
14	corresponding	O	
15	positions	O	
16	in	O	
17	the	O	
18	genes	O	
19	for	O	
20	the	O	
21	nerve	B	
22	growth	I	
23	factor	I	
24	receptor	I	
25	and	O	
26	the	O	
27	68	B	
28	-	I	
29	kDa	I	
30	neurofilament	I	
31	protein	I	
32	.	O	

1	Acute	O	
2	pancreatitis	O	
3	is	O	
4	a	O	
5	rather	O	
6	common	O	
7	abdominal	O	
8	disorder	O	
9	.	O	

1	Cranio	O	
2	-	O	
3	caudal	O	
4	differences	O	
5	in	O	
6	granulation	O	
7	tissue	O	
8	formation	O	
9	:	O	
10	an	O	
11	experimental	O	
12	study	O	
13	in	O	
14	the	O	
15	rat	O	
16	.	O	

1	Cloning	O	
2	,	O	
3	sequencing	O	
4	and	O	
5	expression	O	
6	of	O	
7	the	O	
8	3	B	
9	-	I	
10	phosphoglycerate	I	
11	kinase	I	
12	gene	I	
13	of	O	
14	Pyrococcus	O	
15	woesei	O	
16	in	O	
17	Escherichia	O	
18	coli	O	
19	and	O	
20	characterization	O	
21	of	O	
22	the	O	
23	protein	O	
24	.	O	

1	The	O	
2	persistence	O	
3	of	O	
4	members	O	
5	of	O	
6	the	O	
7	prostigmatid	O	
8	families	O	
9	Tydeidae	O	
10	,	O	
11	Nanorchestidae	O	
12	and	O	
13	Tarsonemidae	O	
14	in	O	
15	the	O	
16	moisture	O	
17	-	O	
18	deficient	O	
19	90	O	
20	%-	O	
21	concentration	O	
22	treatments	O	
23	supports	O	
24	previous	O	
25	evidence	O	
26	of	O	
27	adaptations	O	
28	to	O	
29	low	O	
30	-	O	
31	water	O	
32	-	O	
33	content	O	
34	habitats	O	
35	.	O	

1	Immunocytochemical	O	
2	analysis	O	
3	demonstrated	O	
4	the	O	
5	presence	O	
6	of	O	
7	DREF	B	
8	polypeptide	I	
9	in	O	
10	nuclei	O	
11	after	O	
12	the	O	
13	eighth	O	
14	nuclear	O	
15	division	O	
16	cycle	O	
17	,	O	
18	suggesting	O	
19	that	O	
20	nuclear	O	
21	accumulation	O	
22	of	O	
23	DREF	B	
24	is	O	
25	important	O	
26	for	O	
27	the	O	
28	coordinate	O	
29	zygotic	O	
30	expression	O	
31	of	O	
32	DNA	O	
33	replication	O	
34	-	O	
35	related	O	
36	genes	O	
37	carrying	O	
38	DRE	O	
39	sequences	O	
40	.	O	

1	Conversely	O	
2	,	O	
3	when	O	
4	VDR	B	
5	is	O	
6	overexpressed	O	
7	,	O	
8	vitamin	O	
9	D3	O	
10	attenuates	O	
11	9	O	
12	-	O	
13	cis	O	
14	RA	O	
15	induction	O	
16	from	O	
17	an	O	
18	RXR	B	
19	-	O	
20	responsive	O	
21	element	O	
22	.	O	

1	A	O	
2	panel	O	
3	of	O	
4	pharmacologic	O	
5	inhibitors	O	
6	was	O	
7	used	O	
8	to	O	
9	investigate	O	
10	the	O	
11	signal	O	
12	transduction	O	
13	pathways	O	
14	involved	O	
15	in	O	
16	TRAIL	B	
17	gene	I	
18	induction	O	
19	following	O	
20	T	O	
21	lymphocyte	O	
22	activation	O	
23	.	O	

1	Taken	O	
2	together	O	
3	,	O	
4	our	O	
5	data	O	
6	suggest	O	
7	that	O	
8	the	O	
9	antagonistic	O	
10	effects	O	
11	of	O	
12	CRP	B	
13	and	O	
14	KdgR	B	
15	on	O	
16	the	O	
17	expression	O	
18	of	O	
19	the	O	
20	pectinolysis	B	
21	genes	I	
22	occur	O	
23	by	O	
24	different	O	
25	mechanisms	O	
26	,	O	
27	including	O	
28	direct	O	
29	competition	O	
30	between	O	
31	the	O	
32	two	O	
33	regulators	O	
34	or	O	
35	between	O	
36	the	O	
37	repressor	O	
38	and	O	
39	RNA	B	
40	polymerase	I	
41	for	O	
42	the	O	
43	occupation	O	
44	of	O	
45	a	O	
46	common	O	
47	DNA	O	
48	region	O	
49	on	O	
50	the	O	
51	target	O	
52	genes	O	
53	.	O	

1	Peptide	O	
2	sequences	O	
3	of	O	
4	the	O	
5	zinc	B	
6	finger	I	
7	protein	I	
8	Ttk	I	
9	and	O	
10	the	O	
11	transcription	B	
12	factor	I	
13	Adf	I	
14	-	I	
15	1	I	
16	were	O	
17	obtained	O	
18	.	O	

1	Although	O	
2	we	O	
3	predicted	O	
4	that	O	
5	overexpression	O	
6	of	O	
7	the	O	
8	COOH	O	
9	-	O	
10	terminal	O	
11	domains	O	
12	,	O	
13	which	O	
14	were	O	
15	thought	O	
16	to	O	
17	be	O	
18	involved	O	
19	in	O	
20	the	O	
21	regulation	O	
22	of	O	
23	SREBP	B	
24	processing	O	
25	,	O	
26	would	O	
27	result	O	
28	in	O	
29	disruption	O	
30	of	O	
31	the	O	
32	SREBP	B	
33	-	O	
34	dependent	O	
35	transcriptional	O	
36	regulation	O	
37	of	O	
38	several	O	
39	genes	O	
40	,	O	
41	the	O	
42	mRNA	O	
43	levels	O	
44	for	O	
45	3	B	
46	-	I	
47	hydroxy	I	
48	-	I	
49	3	I	
50	-	I	
51	methylglutaryl	I	
52	coenzyme	I	
53	A	I	
54	(	I	
55	HMG	I	
56	CoA	I	
57	)	I	
58	synthase	I	
59	in	O	
60	these	O	
61	two	O	
62	cell	O	
63	lines	O	
64	were	O	
65	regulated	O	
66	in	O	
67	a	O	
68	sterol	O	
69	-	O	
70	dependent	O	
71	manner	O	
72	.	O	

1	We	O	
2	show	O	
3	here	O	
4	that	O	
5	the	O	
6	protein	O	
7	kinase	O	
8	MEKK1	B	
9	can	O	
10	induce	O	
11	reporter	O	
12	gene	O	
13	expression	O	
14	from	O	
15	the	O	
16	atrial	B	
17	natriuretic	I	
18	factor	I	
19	(	O	
20	ANF	B	
21	)	O	
22	promoter	O	
23	,	O	
24	a	O	
25	genetic	O	
26	marker	O	
27	that	O	
28	is	O	
29	activated	O	
30	during	O	
31	in	O	
32	vivo	O	
33	hypertrophy	O	
34	.	O	

1	This	O	
2	is	O	
3	the	O	
4	first	O	
5	example	O	
6	of	O	
7	a	O	
8	eukaryotic	O	
9	transcription	O	
10	factor	O	
11	complex	O	
12	containing	O	
13	both	O	
14	a	O	
15	MADS	B	
16	-	I	
17	box	I	
18	and	O	
19	a	O	
20	forkhead	B	
21	protein	I	
22	,	O	
23	and	O	
24	it	O	
25	has	O	
26	important	O	
27	implications	O	
28	for	O	
29	the	O	
30	regulation	O	
31	of	O	
32	mammalian	O	
33	gene	O	
34	expression	O	
35	.	O	

1	Microcirculatory	O	
2	oxygenation	O	
3	and	O	
4	shunting	O	
5	in	O	
6	sepsis	O	
7	and	O	
8	shock	O	
9	.	O	

1	Mn2	O	
2	+	O	
3	increased	O	
4	both	O	
5	the	O	
6	junction	O	
7	binding	O	
8	and	O	
9	cleaving	O	
10	activities	O	
11	of	O	
12	the	O	
13	mutant	O	
14	proteins	O	
15	.	O	

1	Molecular	O	
2	cloning	O	
3	of	O	
4	human	O	
5	cDNA	O	
6	encoding	O	
7	a	O	
8	novel	O	
9	beta1	B	
10	,	I	
11	6	I	
12	-	I	
13	N	I	
14	-	I	
15	acetylglucosaminyltransferase	I	
16	forming	O	
17	core	O	
18	2	O	
19	and	O	
20	core	O	
21	4	O	
22	.	O	

1	Serotonin	B	
2	receptors	I	
3	in	O	
4	suicide	O	
5	victims	O	
6	with	O	
7	major	O	
8	depression	O	
9	.	O	

1	We	O	
2	previously	O	
3	showed	O	
4	that	O	
5	v	B	
6	-	I	
7	Rel	I	
8	,	O	
9	the	O	
10	oncoprotein	O	
11	of	O	
12	the	O	
13	avian	O	
14	retrovirus	O	
15	Rev	O	
16	-	O	
17	T	O	
18	,	O	
19	can	O	
20	increase	O	
21	expression	O	
22	from	O	
23	promoters	O	
24	containing	O	
25	binding	O	
26	sites	O	
27	for	O	
28	the	O	
29	cellular	O	
30	transcription	O	
31	factor	O	
32	Sp1	B	
33	in	O	
34	chicken	O	
35	embryo	O	
36	fibroblasts	O	
37	(	O	
38	S	O	
39	.	O	

1	In	O	
2	HCMV	O	
3	(	O	
4	Towne	O	
5	)-	O	
6	infected	O	
7	HF	O	
8	cells	O	
9	at	O	
10	24	O	
11	to	O	
12	48	O	
13	h	O	
14	,	O	
15	IE2	B	
16	also	O	
17	accumulated	O	
18	in	O	
19	newly	O	
20	formed	O	
21	viral	O	
22	DNA	O	
23	replication	O	
24	compartments	O	
25	containing	O	
26	the	O	
27	polymerase	B	
28	processivity	I	
29	factor	I	
30	(	O	
31	UL44	B	
32	),	O	
33	the	O	
34	single	B	
35	-	I	
36	stranded	I	
37	DNA	I	
38	binding	I	
39	protein	I	
40	(	O	
41	SSB	B	
42	;	O	
43	UL57	B	
44	),	O	
45	the	O	
46	UL112	B	
47	-	I	
48	113	I	
49	accessory	I	
50	protein	I	
51	,	O	
52	and	O	
53	newly	O	
54	incorporated	O	
55	bromodeoxyuridine	O	
56	(	O	
57	BrdU	O	
58	).	O	

1	The	O	
2	present	O	
3	data	O	
4	also	O	
5	indicate	O	
6	that	O	
7	patients	O	
8	with	O	
9	TGBM	O	
10	nephropathy	O	
11	often	O	
12	have	O	
13	concomitant	O	
14	IgA	B	
15	nephropathy	O	
16	and	O	
17	mesangial	O	
18	proliferative	O	
19	glomerulonephritis	O	
20	.	O	

1	The	O	
2	possibility	O	
3	of	O	
4	a	O	
5	hereditary	O	
6	disorder	O	
7	leading	O	
8	to	O	
9	a	O	
10	minor	O	
11	defect	O	
12	in	O	
13	elastic	O	
14	fibre	O	
15	structure	O	
16	which	O	
17	could	O	
18	be	O	
19	responsible	O	
20	for	O	
21	the	O	
22	spontaneous	O	
23	lesions	O	
24	is	O	
25	discussed	O	
26	.	O	

1	These	O	
2	REPs	O	
3	,	O	
4	or	O	
5	clusters	O	
6	of	O	
7	paralogous	O	
8	loci	O	
9	,	O	
10	are	O	
11	15	O	
12	-	O	
13	100	O	
14	kb	O	
15	and	O	
16	harbor	O	
17	at	O	
18	least	O	
19	four	O	
20	ESTs	O	
21	and	O	
22	an	O	
23	expressed	O	
24	SH3GL	B	
25	pseudogene	I	
26	.	O	

1	In	O	
2	10	O	
3	pentobarbitalized	O	
4	dogs	O	
5	,	O	
6	plasma	O	
7	viscosity	O	
8	(	O	
9	Ep	O	
10	)	O	
11	was	O	
12	raised	O	
13	fourfold	O	
14	while	O	
15	apparent	O	
16	blood	O	
17	viscosity	O	
18	(	O	
19	Ea	O	
20	)	O	
21	increased	O	
22	about	O	
23	twofold	O	
24	by	O	
25	two	O	
26	steps	O	
27	of	O	
28	exchange	O	
29	transfusion	O	
30	of	O	
31	200	O	
32	ml	O	
33	of	O	
34	plasma	O	
35	with	O	
36	plasma	O	
37	containing	O	
38	high	O	
39	molecular	O	
40	weight	O	
41	dextran	O	
42	(	O	
43	mol	O	
44	wt	O	
45	500	O	
46	,	O	
47	000	O	
48	,	O	
49	20	O	
50	%	O	
51	wt	O	
52	/	O	
53	vol	O	
54	).	O	

1	A	O	
2	new	O	
3	method	O	
4	for	O	
5	the	O	
6	quantitative	O	
7	analysis	O	
8	of	O	
9	sleep	O	
10	spindles	O	
11	during	O	
12	continuous	O	
13	overnight	O	
14	EEG	O	
15	recordings	O	
16	.	O	

1	The	O	
2	differences	O	
3	among	O	
4	subgenera	O	
5	of	O	
6	the	O	
7	genus	O	
8	Dermacentor	O	
9	are	O	
10	more	O	
11	significant	O	
12	.	O	

1	The	O	
2	protein	O	
3	is	O	
4	composed	O	
5	of	O	
6	a	O	
7	central	O	
8	alpha	O	
9	-	O	
10	helical	O	
11	portion	O	
12	with	O	
13	globular	O	
14	domains	O	
15	at	O	
16	both	O	
17	NH2	O	
18	and	O	
19	COOH	O	
20	termini	O	
21	,	O	
22	and	O	
23	the	O	
24	epitope	O	
25	to	O	
26	the	O	
27	monoclonal	O	
28	antibody	O	
29	resides	O	
30	in	O	
31	the	O	
32	central	O	
33	alpha	O	
34	-	O	
35	helical	O	
36	stalk	O	
37	.	O	

1	These	O	
2	data	O	
3	provide	O	
4	the	O	
5	molecular	O	
6	tools	O	
7	for	O	
8	the	O	
9	final	O	
10	identification	O	
11	of	O	
12	the	O	
13	MKS	B	
14	and	O	
15	the	O	
16	MUL	B	
17	genes	I	
18	.	O	

1	The	O	
2	PCr	O	
3	resynthesis	O	
4	rate	O	
5	(	O	
6	P	O	
7	<	O	
8	0	O	
9	.	O	
10	01	O	
11	)	O	
12	and	O	
13	the	O	
14	effective	O	
15	maximal	O	
16	rate	O	
17	of	O	
18	mitochondrial	O	
19	ATP	O	
20	synthesis	O	
21	(	O	
22	P	O	
23	<	O	
24	0	O	
25	.	O	
26	05	O	
27	)	O	
28	also	O	
29	improved	O	
30	.	O	

1	HEF1	B	
2	,	O	
3	p130	B	
4	(	O	
5	Cas	B	
6	),	O	
7	and	O	
8	Efs	B	
9	/	O	
10	Sin	B	
11	constitute	O	
12	a	O	
13	family	O	
14	of	O	
15	multidomain	O	
16	docking	O	
17	proteins	O	
18	that	O	
19	have	O	
20	been	O	
21	implicated	O	
22	in	O	
23	coordinating	O	
24	the	O	
25	regulation	O	
26	of	O	
27	cell	O	
28	adhesion	O	
29	.	O	

1	We	O	
2	have	O	
3	measured	O	
4	the	O	
5	kinetics	O	
6	of	O	
7	the	O	
8	recovery	O	
9	of	O	
10	mRNA	O	
11	synthesis	O	
12	in	O	
13	the	O	
14	inducible	O	
15	GAL10	B	
16	and	O	
17	RNR3	B	
18	genes	I	
19	after	O	
20	exposure	O	
21	of	O	
22	yeast	O	
23	cells	O	
24	to	O	
25	ultraviolet	O	
26	(	O	
27	UV	O	
28	)	O	
29	radiation	O	
30	.	O	

1	Letter	O	
2	:	O	
3	Aryl	B	
4	hydrocarbon	I	
5	hydroxylase	I	
6	and	O	
7	smoking	O	
8	.	O	

1	Standard	O	
2	curve	O	
3	correlation	O	
4	coefficients	O	
5	of	O	
6	0	O	
7	.	O	
8	995	O	
9	or	O	
10	greater	O	
11	were	O	
12	obtained	O	
13	during	O	
14	validation	O	
15	experiments	O	
16	and	O	
17	analysis	O	
18	of	O	
19	study	O	
20	samples	O	
21	.	O	

1	In	O	
2	the	O	
3	control	O	
4	group	O	
5	the	O	
6	histological	O	
7	picture	O	
8	resembled	O	
9	osteoarthritis	O	
10	.	O	

1	Surprisingly	O	
2	,	O	
3	TFIIIC	B	
4	alpha	I	
5	has	O	
6	no	O	
7	homology	O	
8	to	O	
9	any	O	
10	of	O	
11	the	O	
12	yeast	B	
13	TFIIIC	I	
14	subunits	I	
15	already	O	
16	cloned	O	
17	,	O	
18	suggesting	O	
19	a	O	
20	significant	O	
21	degree	O	
22	of	O	
23	evolutionary	O	
24	divergence	O	
25	for	O	
26	RNA	B	
27	polymerase	I	
28	III	I	
29	factors	I	
30	.	O	

1	An	O	
2	anchored	O	
3	AFLP	O	
4	-	O	
5	and	O	
6	retrotransposon	O	
7	-	O	
8	based	O	
9	map	O	
10	of	O	
11	diploid	O	
12	Avena	O	
13	.	O	

1	The	O	
2	gene	O	
3	(	O	
4	ApxII	B	
5	)	O	
6	encoding	O	
7	both	O	
8	chloroplastic	B	
9	ascorbate	I	
10	peroxidase	I	
11	isoenzymes	I	
12	was	O	
13	isolated	O	
14	and	O	
15	the	O	
16	organization	O	
17	of	O	
18	the	O	
19	gene	O	
20	was	O	
21	determined	O	
22	.	O	

1	Recombinant	B	
2	prenylcysteine	I	
3	lyase	I	
4	was	O	
5	produced	O	
6	in	O	
7	a	O	
8	baculovirus	O	
9	-	O	
10	Sf9	O	
11	expression	O	
12	system	O	
13	.	O	

1	We	O	
2	have	O	
3	also	O	
4	found	O	
5	that	O	
6	the	O	
7	in	O	
8	vitro	O	
9	interaction	O	
10	between	O	
11	the	O	
12	SV40	O	
13	octamer	O	
14	motif	O	
15	and	O	
16	the	O	
17	lymphoid	B	
18	cell	I	
19	-	I	
20	specific	I	
21	protein	I	
22	oct	I	
23	-	I	
24	B2	I	
25	was	O	
26	negatively	O	
27	modulated	O	
28	by	O	
29	a	O	
30	component	O	
31	present	O	
32	in	O	
33	the	O	
34	nuclear	O	
35	extracts	O	
36	from	O	
37	several	O	
38	lymphoid	O	
39	cell	O	
40	lines	O	
41	.	O	

1	Samples	O	
2	from	O	
3	1415	O	
4	neurological	O	
5	patients	O	
6	were	O	
7	used	O	
8	to	O	
9	study	O	
10	the	O	
11	diagnostic	O	
12	value	O	
13	of	O	
14	acid	B	
15	alpha	I	
16	1	I	
17	-	I	
18	glycoprotein	I	
19	in	O	
20	the	O	
21	lumbar	O	
22	cerebrospinal	O	
23	fluid	O	
24	.	O	

1	Closure	O	
2	of	O	
3	an	O	
4	open	O	
5	high	O	
6	below	O	
7	-	O	
8	knee	O	
9	guillotine	O	
10	amputation	O	
11	wound	O	
12	using	O	
13	a	O	
14	skin	O	
15	-	O	
16	stretching	O	
17	device	O	
18	.	O	

1	Genetic	O	
2	interactions	O	
3	between	O	
4	BCK2	B	
5	and	O	
6	other	O	
7	pathway	O	
8	components	O	
9	suggested	O	
10	that	O	
11	BCK2	B	
12	functions	O	
13	on	O	
14	a	O	
15	common	O	
16	pathway	O	
17	branch	O	
18	with	O	
19	PPZ1	B	
20	and	O	
21	PPZ2	B	
22	.	O	

1	The	O	
2	rate	O	
3	-	O	
4	decreasing	O	
5	effects	O	
6	of	O	
7	morphine	O	
8	and	O	
9	U50488	O	
10	were	O	
11	reversed	O	
12	completely	O	
13	by	O	
14	a	O	
15	0	O	
16	.	O	
17	01	O	
18	and	O	
19	1	O	
20	.	O	
21	0	O	
22	mg	O	
23	/	O	
24	kg	O	
25	dose	O	
26	of	O	
27	naloxone	O	
28	,	O	
29	respectively	O	
30	.	O	

1	Assessment	O	
2	of	O	
3	nutrient	O	
4	media	O	
5	in	O	
6	the	O	
7	diagnosis	O	
8	of	O	
9	diptheria	O	

1	Human	B	
2	LAF	I	
3	-	I	
4	4	I	
5	readily	O	
6	hybridized	O	
7	with	O	
8	genes	O	
9	in	O	
10	mouse	O	
11	and	O	
12	chicken	O	
13	,	O	
14	thus	O	
15	showing	O	
16	that	O	
17	this	O	
18	gene	O	
19	family	O	
20	has	O	
21	been	O	
22	highly	O	
23	conserved	O	
24	during	O	
25	vertebrate	O	
26	evolution	O	
27	.	O	

1	Adipocyte	O	
2	differentiation	O	
3	of	O	
4	nontransformed	O	
5	cells	O	
6	also	O	
7	markedly	O	
8	represses	O	
9	the	O	
10	ability	O	
11	of	O	
12	SRF	B	
13	to	O	
14	bind	O	
15	to	O	
16	the	O	
17	junB	B	
18	SRE	O	
19	,	O	
20	the	O	
21	c	B	
22	-	I	
23	fos	I	
24	SRE	O	
25	,	O	
26	and	O	
27	other	O	
28	SREs	O	
29	,	O	
30	as	O	
31	determined	O	
32	by	O	
33	mobility	O	
34	shift	O	
35	and	O	
36	gel	O	
37	supershift	O	
38	assays	O	
39	,	O	
40	without	O	
41	affecting	O	
42	the	O	
43	DNA	O	
44	binding	O	
45	characteristics	O	
46	of	O	
47	the	O	
48	nuclear	O	
49	protein	O	
50	SP	O	
51	-	O	
52	1	O	
53	.	O	

1	Oxygen	O	
2	delivery	O	
3	and	O	
4	base	O	
5	excess	O	
6	decreased	O	
7	significantly	O	
8	and	O	
9	four	O	
10	pigs	O	
11	died	O	
12	.	O	

1	No	O	
2	homologs	O	
3	of	O	
4	other	O	
5	members	O	
6	of	O	
7	the	O	
8	Surfeit	B	
9	gene	I	
10	cluster	I	
11	were	O	
12	detected	O	
13	in	O	
14	close	O	
15	proximity	O	
16	to	O	
17	the	O	
18	D	O	
19	.	O	
20	melanogaster	O	
21	Surf	B	
22	-	I	
23	3	I	
24	/	O	
25	rpL7a	B	
26	gene	O	
27	.	O	

1	A	O	
2	comparison	O	
3	of	O	
4	the	O	
5	nucleotide	O	
6	and	O	
7	deduced	O	
8	amino	O	
9	acid	O	
10	sequences	O	
11	of	O	
12	the	O	
13	core	O	
14	regions	O	
15	of	O	
16	the	O	
17	RNA	B	
18	-	I	
19	dependent	I	
20	RNA	I	
21	polymerase	I	
22	domains	I	
23	found	O	
24	in	O	
25	these	O	
26	three	O	
27	dsRNAs	O	
28	suggested	O	
29	that	O	
30	these	O	
31	dsRNAs	O	
32	probably	O	
33	evolved	O	
34	independently	O	
35	within	O	
36	each	O	
37	host	O	
38	plant	O	
39	from	O	
40	a	O	
41	common	O	
42	ancestor	O	
43	.	O	

1	These	O	
2	HPV16	O	
3	E6	B	
4	/	O	
5	E7	B	
6	cDNAs	O	
7	were	O	
8	cloned	O	
9	under	O	
10	the	O	
11	SV40	B	
12	enhancer	I	
13	/	I	
14	promoter	I	
15	and	O	
16	the	O	
17	MMTV	B	
18	LTR	I	
19	to	O	
20	examine	O	
21	the	O	
22	activities	O	
23	of	O	
24	ras	B	
25	-	O	
26	collaborative	O	
27	transformation	O	
28	and	O	
29	induction	O	
30	of	O	
31	cellular	O	
32	DNA	O	
33	synthesis	O	
34	,	O	
35	both	O	
36	of	O	
37	which	O	
38	depend	O	
39	on	O	
40	the	O	
41	E7	B	
42	gene	I	
43	product	O	
44	.	O	

1	To	O	
2	characterize	O	
3	the	O	
4	gene	O	
5	products	O	
6	,	O	
7	the	O	
8	cvaA	B	
9	gene	I	
10	was	O	
11	subcloned	O	
12	and	O	
13	expressed	O	
14	under	O	
15	the	O	
16	control	O	
17	of	O	
18	T7	B	
19	RNA	I	
20	polymerase	I	
21	promoter	I	
22	.	O	

1	The	O	
2	liver	O	
3	in	O	
4	the	O	
5	severely	O	
6	ill	O	

1	Measurement	O	
2	of	O	
3	SaO2	O	
4	at	O	
5	moderate	O	
6	altitude	O	
7	can	O	
8	be	O	
9	helpful	O	
10	in	O	
11	the	O	
12	care	O	
13	of	O	
14	both	O	
15	healthy	O	
16	and	O	
17	ill	O	
18	newborns	O	
19	or	O	
20	infants	O	
21	.	O	

1	Our	O	
2	findings	O	
3	also	O	
4	provide	O	
5	the	O	
6	basis	O	
7	for	O	
8	the	O	
9	development	O	
10	of	O	
11	assays	O	
12	to	O	
13	screen	O	
14	for	O	
15	the	O	
16	ligands	O	
17	to	O	
18	testis	B	
19	receptor	I	
20	2	I	
21	and	O	
22	hERR1	B	
23	.	O	

1	However	O	
2	,	O	
3	subcutaneously	O	
4	administered	O	
5	pneumococci	O	
6	gave	O	
7	a	O	
8	lower	O	
9	mortality	O	
10	than	O	
11	pneumococci	O	
12	given	O	
13	intravenously	O	
14	or	O	
15	intraperitoneally	O	
16	.	O	

1	DNA	O	
2	sequencing	O	
3	of	O	
4	the	O	
5	DPM1	B	
6	gene	I	
7	revealed	O	
8	an	O	
9	open	O	
10	reading	O	
11	frame	O	
12	of	O	
13	801	O	
14	bases	O	
15	.	O	

1	The	O	
2	overall	O	
3	prevalence	O	
4	of	O	
5	psoriasis	O	
6	was	O	
7	4	O	
8	.	O	
9	79	O	
10	%	O	
11	in	O	
12	men	O	
13	and	O	
14	4	O	
15	.	O	
16	85	O	
17	%	O	
18	in	O	
19	women	O	
20	.	O	

1	Chronic	O	
2	dose	O	
3	effects	O	
4	of	O	
5	methyl	O	
6	parathion	O	
7	on	O	
8	nuthatches	O	
9	:	O	
10	cholinesterase	B	
11	and	O	
12	ptilochronology	O	
13	.	O	

1	V	O	
2	.	O	

1	A	O	
2	preliminary	O	
3	study	O	
4	on	O	
5	pyogenic	O	
6	arthritis	O	
7	.	O	

1	These	O	
2	data	O	
3	indicate	O	
4	that	O	
5	activation	O	
6	of	O	
7	these	O	
8	enzymes	O	
9	is	O	
10	not	O	
11	sufficient	O	
12	for	O	
13	the	O	
14	acute	O	
15	stimulation	O	
16	of	O	
17	glucose	O	
18	transport	O	
19	.	O	

1	Novel	O	
2	multigene	O	
3	families	O	
4	encoding	O	
5	highly	O	
6	repetitive	O	
7	peptide	O	
8	sequences	O	
9	.	O	

1	Conservation	O	
2	of	O	
3	function	O	
4	of	O	
5	Drosophila	B	
6	melanogaster	I	
7	abl	I	
8	and	O	
9	murine	B	
10	v	I	
11	-	I	
12	abl	I	
13	proteins	I	
14	in	O	
15	transformation	O	
16	of	O	
17	mammalian	O	
18	cells	O	
19	.	O	

1	There	O	
2	is	O	
3	no	O	
4	correlation	O	
5	between	O	
6	C2	O	
7	-	O	
8	C3	O	
9	disk	O	
10	morphology	O	
11	and	O	
12	the	O	
13	diskographically	O	
14	provoked	O	
15	response	O	
16	.	O	

1	An	O	
2	overexpression	O	
3	of	O	
4	the	O	
5	betaAPP	B	
6	gene	I	
7	in	O	
8	certain	O	
9	areas	O	
10	of	O	
11	the	O	
12	AD	O	
13	brain	O	
14	has	O	
15	been	O	
16	suggested	O	
17	to	O	
18	be	O	
19	an	O	
20	important	O	
21	factor	O	
22	in	O	
23	the	O	
24	neuropathology	O	
25	of	O	
26	AD	O	
27	.	O	

1	The	O	
2	wavenumbers	O	
3	corresponding	O	
4	to	O	
5	the	O	
6	normal	O	
7	modes	O	
8	of	O	
9	vibration	O	
10	were	O	
11	calculated	O	
12	using	O	
13	the	O	
14	DFT	O	
15	(	O	
16	B3LYP	O	
17	/	O	
18	6	O	
19	-	O	
20	31G	O	
21	**)	O	
22	approximation	O	
23	and	O	
24	their	O	
25	agreement	O	
26	with	O	
27	the	O	
28	measured	O	
29	values	O	
30	improved	O	
31	after	O	
32	scaling	O	
33	of	O	
34	the	O	
35	associated	O	
36	force	O	
37	field	O	
38	.	O	

1	Genomic	O	
2	DNA	O	
3	clones	O	
4	containing	O	
5	the	O	
6	T	B	
7	-	I	
8	cell	I	
9	-	I	
10	specific	I	
11	human	I	
12	MAL	I	
13	gene	I	
14	were	O	
15	isolated	O	
16	.	O	

1	Gestational	O	
2	trophoblastic	O	
3	diseases	O	
4	:	O	
5	recent	O	
6	advances	O	
7	in	O	
8	the	O	
9	understanding	O	
10	of	O	
11	cytogenetics	O	
12	,	O	
13	histopathology	O	
14	,	O	
15	and	O	
16	natural	O	
17	history	O	
18	.	O	

1	SELECTION	O	
2	CRITERIA	O	
3	:	O	
4	Randomised	O	
5	trials	O	
6	comparing	O	
7	children	O	
8	undergoing	O	
9	systematic	O	
10	therapy	O	
11	focusing	O	
12	on	O	
13	the	O	
14	family	O	
15	in	O	
16	conjunction	O	
17	with	O	
18	asthma	O	
19	medication	O	
20	,	O	
21	with	O	
22	children	O	
23	taking	O	
24	asthma	O	
25	medication	O	
26	only	O	
27	.	O	

1	Using	O	
2	immunolocalization	O	
3	,	O	
4	we	O	
5	observe	O	
6	that	O	
7	ACE3	B	
8	,	O	
9	a	O	
10	440	O	
11	-	O	
12	bp	O	
13	chorion	O	
14	element	O	
15	that	O	
16	contains	O	
17	information	O	
18	sufficient	O	
19	to	O	
20	drive	O	
21	amplification	O	
22	,	O	
23	directs	O	
24	DmORC	B	
25	localization	O	
26	in	O	
27	follicle	O	
28	cells	O	
29	.	O	

1	A	O	
2	third	O	
3	prominent	O	
4	component	O	
5	of	O	
6	apparent	O	
7	molecular	O	
8	mass	O	
9	16	O	
10	kDa	O	
11	displayed	O	
12	several	O	
13	properties	O	
14	,	O	
15	including	O	
16	ability	O	
17	to	O	
18	bind	O	
19	45Ca2	O	
20	+,	O	
21	that	O	
22	are	O	
23	characteristic	O	
24	of	O	
25	the	O	
26	regulatory	O	
27	(	O	
28	B	O	
29	)	O	
30	subunit	O	
31	of	O	
32	mammalian	B	
33	calcineurin	I	
34	and	O	
35	was	O	
36	recognized	O	
37	by	O	
38	an	O	
39	antiserum	O	
40	raised	O	
41	against	O	
42	bovine	B	
43	calcineurin	I	
44	.	O	

1	Vaccinia	O	
2	virus	O	
3	-	O	
4	expressed	O	
5	,	O	
6	purified	O	
7	full	B	
8	-	I	
9	length	I	
10	HPV	I	
11	-	I	
12	16	I	
13	and	I	
14	BPV	I	
15	-	I	
16	1	I	
17	E2	I	
18	proteins	I	
19	bound	O	
20	a	O	
21	consensus	O	
22	E2	B	
23	site	I	
24	with	O	
25	high	O	
26	specific	O	
27	affinities	O	
28	(	O	
29	Kd	O	
30	=	O	
31	approximately	O	
32	10	O	
33	(-	O	
34	9	O	
35	)	O	
36	M	O	
37	)	O	
38	and	O	
39	stimulated	O	
40	in	O	
41	vitro	O	
42	transcription	O	
43	up	O	
44	to	O	
45	six	O	
46	-	O	
47	to	O	
48	eightfold	O	
49	.	O	

1	AB004534	B	
2	.	O	

1	Overlapping	O	
2	clones	O	
3	representing	O	
4	full	O	
5	-	O	
6	length	O	
7	cDNAs	O	
8	for	O	
9	MMI	B	
10	alpha	I	
11	were	O	
12	obtained	O	
13	from	O	
14	mouse	O	
15	brain	O	
16	.	O	

1	Moreover	O	
2	,	O	
3	glucan	B	
4	synthase	I	
5	activity	O	
6	,	O	
7	which	O	
8	is	O	
9	activated	O	
10	by	O	
11	Rho1p	B	
12	,	O	
13	was	O	
14	significantly	O	
15	reduced	O	
16	in	O	
17	the	O	
18	deltabem4	B	
19	mutant	I	
20	.	O	

1	Conversely	O	
2	,	O	
3	activated	O	
4	glucocorticoid	B	
5	receptors	I	
6	suppressed	O	
7	the	O	
8	transactivation	O	
9	function	O	
10	of	O	
11	p53	B	
12	,	O	
13	while	O	
14	transrepression	O	
15	by	O	
16	p53	B	
17	was	O	
18	largely	O	
19	unaffected	O	
20	.	O	

1	Improvement	O	
2	of	O	
3	the	O	
4	polypyrimidine	O	
5	tract	O	
6	also	O	
7	increased	O	
8	the	O	
9	splicing	O	
10	efficiency	O	
11	,	O	
12	but	O	
13	to	O	
14	a	O	
15	degree	O	
16	slightly	O	
17	less	O	
18	than	O	
19	that	O	
20	obtained	O	
21	with	O	
22	the	O	
23	branchpoint	O	
24	mutation	O	
25	.	O	

1	Mutating	O	
2	a	O	
3	potential	O	
4	cleavage	O	
5	site	O	
6	located	O	
7	N	O	
8	-	O	
9	terminal	O	
10	to	O	
11	the	O	
12	protease	O	
13	domain	O	
14	,	O	
15	Gln2526	O	
16	-	O	
17	Asp2527	O	
18	,	O	
19	diminished	O	
20	processing	O	
21	.	O	

1	Prediction	O	
2	of	O	
3	the	O	
4	times	O	
5	of	O	
6	sandfly	O	
7	development	O	

1	This	O	
2	paper	O	
3	brings	O	
4	together	O	
5	data	O	
6	,	O	
7	obtained	O	
8	from	O	
9	a	O	
10	variety	O	
11	of	O	
12	sources	O	
13	,	O	
14	on	O	
15	the	O	
16	extent	O	
17	of	O	
18	prescription	O	
19	and	O	
20	use	O	
21	of	O	
22	psychotropic	O	
23	drugs	O	
24	in	O	
25	the	O	
26	late	O	
27	1960s	O	
28	and	O	
29	early	O	
30	1970s	O	
31	.	O	

1	Its	O	
2	hydropathy	O	
3	profile	O	
4	predicts	O	
5	seven	O	
6	transmembrane	O	
7	spans	O	
8	and	O	
9	a	O	
10	hydrophilic	O	
11	amino	O	
12	terminus	O	
13	of	O	
14	approximately	O	
15	100	O	
16	residues	O	
17	,	O	
18	and	O	
19	it	O	
20	suggests	O	
21	the	O	
22	presence	O	
23	of	O	
24	an	O	
25	amphiphilic	O	
26	alpha	O	
27	-	O	
28	helix	O	
29	(	O	
30	L	O	
31	-	O	
32	61	O	
33	to	O	
34	F	O	
35	-	O	
36	97	O	
37	)	O	
38	in	O	
39	close	O	
40	proximity	O	
41	to	O	
42	the	O	
43	first	O	
44	strongly	O	
45	hydrophobic	O	
46	segment	O	
47	of	O	
48	ProW	B	
49	.	O	

1	However	O	
2	the	O	
3	sequence	O	
4	surrounding	O	
5	the	O	
6	transcription	O	
7	start	O	
8	site	O	
9	CTCA	O	
10	(+	O	
11	1	O	
12	)	O	
13	TTCC	O	
14	was	O	
15	similar	O	
16	to	O	
17	the	O	
18	consensus	O	
19	CTCA	O	
20	(+	O	
21	1	O	
22	)	O	
23	NTCT	O	
24	(	O	
25	N	O	
26	is	O	
27	any	O	
28	nucleoside	O	
29	)	O	
30	for	O	
31	an	O	
32	initiator	O	
33	element	O	
34	found	O	
35	in	O	
36	terminal	B	
37	deoxynucleotidyltransferase	I	
38	and	O	
39	a	O	
40	number	O	
41	of	O	
42	other	O	
43	highly	O	
44	regulated	O	
45	genes	O	
46	.	O	

1	Glomerular	O	
2	hemodynamics	O	
3	during	O	
4	abortion	O	
5	induced	O	
6	by	O	
7	RU	O	
8	486	O	
9	and	O	
10	sepsis	O	
11	in	O	
12	rats	O	
13	.	O	

1	Specific	O	
2	requirements	O	
3	for	O	
4	branched	O	
5	-	O	
6	chain	O	
7	amino	O	
8	acids	O	
9	,	O	
10	glutamine	O	
11	,	O	
12	and	O	
13	arginine	O	
14	are	O	
15	evaluated	O	
16	.	O	

1	The	O	
2	detectability	O	
3	of	O	
4	the	O	
5	defects	O	
6	in	O	
7	RCA	O	
8	or	O	
9	LAD	O	
10	region	O	
11	was	O	
12	80	O	
13	%	O	
14	in	O	
15	single	O	
16	-	O	
17	position	O	
18	scans	O	
19	in	O	
20	stress	O	
21	studies	O	
22	.	O	

1	Evidence	O	
2	for	O	
3	the	O	
4	involvement	O	
5	of	O	
6	the	O	
7	Glc7	B	
8	-	O	
9	Reg1	B	
10	phosphatase	O	
11	and	O	
12	the	O	
13	Snf1	B	
14	-	O	
15	Snf4	B	
16	kinase	O	
17	in	O	
18	the	O	
19	regulation	O	
20	of	O	
21	INO1	B	
22	transcription	O	
23	in	O	
24	Saccharomyces	O	
25	cerevisiae	O	
26	.	O	

1	ATP	O	
2	by	O	
3	itself	O	
4	also	O	
5	reduced	O	
6	polypeptide	O	
7	binding	O	
8	to	O	
9	Ssb1	B	
10	/	I	
11	2p	I	
12	to	O	
13	a	O	
14	level	O	
15	that	O	
16	was	O	
17	intermediate	O	
18	between	O	
19	that	O	
20	observed	O	
21	for	O	
22	the	O	
23	Ssa	B	
24	Hsp70	I	
25	proteins	I	
26	tested	O	
27	and	O	
28	BiP	B	
29	and	O	
30	DnaK	B	
31	.	O	

1	Familial	O	
2	glutathione	B	
3	reductase	I	
4	deficiency	O	
5	and	O	
6	disorder	O	
7	of	O	
8	glutathione	O	
9	synthesis	O	
10	in	O	
11	the	O	
12	erythrocyte	O	

1	Stable	O	
2	transfection	O	
3	of	O	
4	the	O	
5	BL	O	
6	cell	O	
7	line	O	
8	Raji	O	
9	with	O	
10	constructs	O	
11	containing	O	
12	core	O	
13	promoter	O	
14	mutations	O	
15	confirmed	O	
16	that	O	
17	the	O	
18	proximal	O	
19	Sp1	B	
20	site	I	
21	and	O	
22	the	O	
23	TATA	O	
24	box	O	
25	are	O	
26	essential	O	
27	for	O	
28	the	O	
29	activation	O	
30	of	O	
31	promoter	O	
32	P1	O	
33	by	O	
34	the	O	
35	Ig	B	
36	kappa	I	
37	enhancers	I	
38	.	O	

1	Differential	O	
2	expression	O	
3	of	O	
4	AP	B	
5	-	I	
6	2alpha	I	
7	and	O	
8	AP	B	
9	-	I	
10	2beta	I	
11	in	O	
12	the	O	
13	developing	O	
14	chick	O	
15	retina	O	
16	:	O	
17	repression	O	
18	of	O	
19	R	B	
20	-	I	
21	FABP	I	
22	promoter	I	
23	activity	O	
24	by	O	
25	AP	B	
26	-	I	
27	2	I	
28	.	O	

1	The	O	
2	recruitment	O	
3	of	O	
4	constitutively	O	
5	phosphorylated	O	
6	p185	B	
7	(	O	
8	neu	B	
9	)	O	
10	and	O	
11	the	O	
12	activated	O	
13	mitogenic	O	
14	pathway	O	
15	proteins	O	
16	to	O	
17	this	O	
18	membrane	O	
19	-	O	
20	microfilament	O	
21	interaction	O	
22	site	O	
23	provides	O	
24	a	O	
25	physical	O	
26	model	O	
27	for	O	
28	integrating	O	
29	the	O	
30	assembly	O	
31	of	O	
32	the	O	
33	mitogenic	O	
34	pathway	O	
35	with	O	
36	the	O	
37	transmission	O	
38	of	O	
39	growth	O	
40	factor	O	
41	signal	O	
42	to	O	
43	the	O	
44	cytoskeleton	O	
45	.	O	

1	Re	O	
2	-	O	
3	examination	O	
4	of	O	
5	the	O	
6	ED01	O	
7	study	O	
8	.	O	

1	The	O	
2	phi	B	
3	AP3	I	
4	factor	I	
5	is	O	
6	a	O	
7	nuclear	O	
8	phosphoprotein	O	
9	;	O	
10	the	O	
11	extent	O	
12	of	O	
13	its	O	
14	phosphorylation	O	
15	is	O	
16	regulated	O	
17	during	O	
18	the	O	
19	cell	O	
20	cycle	O	
21	.	O	

1	Cortisone	O	
2	induced	O	
3	bone	O	
4	changes	O	
5	and	O	
6	its	O	
7	response	O	
8	to	O	
9	lipid	O	
10	clearing	O	
11	agents	O	
12	.	O	

1	Comparative	O	
2	study	O	
3	on	O	
4	acute	O	
5	oral	O	
6	overload	O	
7	using	O	
8	tolbutamide	O	
9	and	O	
10	tolazamide	O	
11	in	O	
12	normal	O	
13	and	O	
14	diabetic	O	
15	subjects	O	
16	.	O	

1	Substantial	O	
2	amounts	O	
3	of	O	
4	liposomal	O	
5	ampicillin	O	
6	were	O	
7	recovered	O	
8	from	O	
9	isolated	O	
10	Kupffer	O	
11	cells	O	
12	,	O	
13	the	O	
14	target	O	
15	cells	O	
16	of	O	
17	L	O	
18	.	O	
19	monocytogenes	O	
20	after	O	
21	intravenous	O	
22	inoculation	O	
23	.	O	

1	There	O	
2	occurred	O	
3	a	O	
4	linear	O	
5	relationship	O	
6	between	O	
7	the	O	
8	drop	O	
9	in	O	
10	glucose	B	
11	-	I	
12	6	I	
13	-	I	
14	phosphatase	I	
15	dehydrogenase	I	
16	activity	O	
17	and	O	
18	in	O	
19	vitamin	O	
20	E	O	
21	level	O	
22	,	O	
23	on	O	
24	one	O	
25	hand	O	
26	,	O	
27	and	O	
28	the	O	
29	duration	O	
30	of	O	
31	poisoning	O	
32	with	O	
33	sodium	O	
34	nitrite	O	
35	.	O	

1	Our	O	
2	results	O	
3	favor	O	
4	the	O	
5	possibility	O	
6	that	O	
7	the	O	
8	Drosophila	B	
9	EGF	I	
10	receptor	I	
11	DER	I	
12	/	O	
13	Egfr	B	
14	expressed	O	
15	by	O	
16	the	O	
17	EMA	O	
18	cells	O	
19	functions	O	
20	as	O	
21	a	O	
22	receptor	O	
23	for	O	
24	Vein	B	
25	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	on	O	
5	the	O	
6	Cohler	O	
7	'	O	
8	s	O	
9	maternal	O	
10	scale	O	
11	,	O	
12	Korean	O	
13	mothers	O	
14	were	O	
15	found	O	
16	to	O	
17	view	O	
18	their	O	
19	infants	O	
20	as	O	
21	more	O	
22	passive	O	
23	and	O	
24	dependent	O	
25	than	O	
26	American	O	
27	mothers	O	
28	did	O	
29	(	O	
30	P	O	
31	less	O	
32	than	O	
33	0	O	
34	.	O	
35	00	O	
36	).	O	

1	From	O	
2	these	O	
3	results	O	
4	,	O	
5	it	O	
6	is	O	
7	concluded	O	
8	that	O	
9	EDLF	O	
10	has	O	
11	clear	O	
12	vasoconstrictor	O	
13	properties	O	
14	which	O	
15	are	O	
16	not	O	
17	due	O	
18	to	O	
19	adrenergic	O	
20	or	O	
21	calcium	O	
22	entry	O	
23	mechanisms	O	
24	and	O	
25	that	O	
26	there	O	
27	are	O	
28	differences	O	
29	in	O	
30	the	O	
31	vasoconstrictor	O	
32	effects	O	
33	of	O	
34	EDLFs	O	
35	with	O	
36	respect	O	
37	to	O	
38	different	O	
39	vascular	O	
40	beds	O	
41	.	O	

1	Human	B	
2	papillomavirus	I	
3	type	I	
4	31b	I	
5	late	I	
6	gene	I	
7	expression	O	
8	is	O	
9	regulated	O	
10	through	O	
11	protein	B	
12	kinase	I	
13	C	I	
14	-	O	
15	mediated	O	
16	changes	O	
17	in	O	
18	RNA	O	
19	processing	O	
20	.	O	

1	We	O	
2	have	O	
3	overexpressed	O	
4	,	O	
5	purified	O	
6	,	O	
7	characterized	O	
8	,	O	
9	and	O	
10	crystallized	O	
11	the	O	
12	BTB	B	
13	/	O	
14	POZ	O	
15	domain	O	
16	from	O	
17	PLZF	B	
18	(	O	
19	PLZF	B	
20	-	O	
21	BTB	B	
22	/	O	
23	POZ	O	
24	).	O	

1	The	O	
2	pulmonary	O	
3	effects	O	
4	observed	O	
5	,	O	
6	became	O	
7	more	O	
8	pronounced	O	
9	with	O	
10	increasing	O	
11	NO2	O	
12	concentrations	O	
13	(	O	
14	0	O	
15	,	O	
16	25	O	
17	,	O	
18	75	O	
19	,	O	
20	125	O	
21	,	O	
22	175	O	
23	or	O	
24	200	O	
25	ppm	O	
26	,	O	
27	1	O	
28	ppm	O	
29	NO2	O	
30	=	O	
31	1	O	
32	.	O	
33	88	O	
34	mg	O	
35	m	O	
36	-	O	
37	3	O	
38	NO2	O	
39	)	O	
40	and	O	
41	exposure	O	
42	times	O	
43	(	O	
44	5	O	
45	,	O	
46	10	O	
47	,	O	
48	20	O	
49	or	O	
50	30	O	
51	min	O	
52	).	O	

1	The	O	
2	effects	O	
3	of	O	
4	loading	O	
5	the	O	
6	respiratory	O	
7	pumps	O	
8	on	O	
9	the	O	
10	oxygen	O	
11	consumption	O	
12	of	O	
13	Callionymus	O	
14	lyra	O	
15	.	O	

1	Certain	O	
2	spt10	B	
3	spontaneous	O	
4	alleles	O	
5	are	O	
6	good	O	
7	suppressors	O	
8	but	O	
9	have	O	
10	a	O	
11	normal	O	
12	growth	O	
13	rate	O	
14	,	O	
15	suggesting	O	
16	that	O	
17	the	O	
18	SPT10	B	
19	protein	I	
20	may	O	
21	have	O	
22	two	O	
23	distinct	O	
24	functions	O	
25	.	O	

1	Abstracts	O	
2	.	O	

1	There	O	
2	was	O	
3	a	O	
4	trend	O	
5	in	O	
6	all	O	
7	studies	O	
8	favouring	O	
9	PVI	O	
10	.	O	

1	Both	O	
2	NUP98	B	
3	-	O	
4	HOXA9	B	
5	chimeras	O	
6	transformed	O	
7	NIH	O	
8	3T3	O	
9	fibroblasts	O	
10	,	O	
11	and	O	
12	this	O	
13	transformation	O	
14	required	O	
15	the	O	
16	HOXA9	B	
17	domains	I	
18	for	O	
19	DNA	O	
20	binding	O	
21	and	O	
22	PBX	B	
23	interaction	O	
24	.	O	

1	DAF16	B	
2	is	O	
3	known	O	
4	to	O	
5	be	O	
6	a	O	
7	component	O	
8	of	O	
9	a	O	
10	signaling	O	
11	pathway	O	
12	that	O	
13	has	O	
14	been	O	
15	partially	O	
16	dissected	O	
17	genetically	O	
18	and	O	
19	includes	O	
20	homologues	O	
21	of	O	
22	the	O	
23	insulin	B	
24	/	O	
25	IGF	B	
26	-	I	
27	1	I	
28	receptor	I	
29	,	O	
30	PtdIns	B	
31	3	I	
32	-	I	
33	kinase	I	
34	and	O	
35	PKB	B	
36	.	O	

1	Simple	O	
2	models	O	
3	of	O	
4	bimolecular	O	
5	interaction	O	
6	did	O	
7	not	O	
8	fully	O	
9	account	O	
10	for	O	
11	the	O	
12	kinetic	O	
13	profiles	O	
14	obtained	O	
15	with	O	
16	the	O	
17	parental	O	
18	antibodies	O	
19	and	O	
20	the	O	
21	hybrids	O	
22	,	O	
23	and	O	
24	this	O	
25	complexity	O	
26	suggested	O	
27	the	O	
28	existence	O	
29	of	O	
30	a	O	
31	conformational	O	
32	heterogeneity	O	
33	in	O	
34	these	O	
35	molecules	O	
36	.	O	

1	In	O	
2	the	O	
3	second	O	
4	case	O	
5	,	O	
6	an	O	
7	epidermal	O	
8	cyst	O	
9	was	O	
10	diagnosed	O	
11	.	O	

1	Wrist	O	
2	measurement	O	
3	of	O	
4	blood	O	
5	pressure	O	
6	:	O	
7	some	O	
8	critical	O	
9	remarks	O	
10	to	O	
11	oscillometry	O	
12	.	O	

1	Losartan	O	
2	Intervention	O	
3	For	O	
4	Endpoint	O	
5	.	O	

1	A	O	
2	rare	O	
3	chronic	O	
4	course	O	
5	of	O	
6	Budd	O	
7	-	O	
8	Chiari	O	
9	syndrome	O	
10	associated	O	
11	with	O	
12	thrombosis	O	
13	of	O	
14	the	O	
15	portal	O	
16	vein	O	
17	was	O	
18	observed	O	
19	in	O	
20	a	O	
21	30	O	
22	-	O	
23	year	O	
24	-	O	
25	old	O	
26	male	O	
27	patient	O	
28	suffering	O	
29	from	O	
30	postmyocarditic	O	
31	cardiosclerosis	O	
32	.	O	

1	Varicella	B	
2	-	I	
3	zoster	I	
4	virus	I	
5	(	I	
6	VZV	I	
7	)	I	
8	glycoprotein	I	
9	gI	I	
10	is	O	
11	a	O	
12	type	B	
13	1	I	
14	transmembrane	I	
15	glycoprotein	I	
16	which	O	
17	is	O	
18	one	O	
19	component	O	
20	of	O	
21	the	O	
22	heterodimeric	O	
23	gE	B	
24	:	O	
25	gI	B	
26	Fc	I	
27	receptor	I	
28	complex	O	
29	.	O	

1	Identification	O	
2	of	O	
3	an	O	
4	AfsA	B	
5	homologue	I	
6	(	O	
7	BarX	B	
8	)	O	
9	from	O	
10	Streptomyces	O	
11	virginiae	O	
12	as	O	
13	a	O	
14	pleiotropic	O	
15	regulator	O	
16	controlling	O	
17	autoregulator	O	
18	biosynthesis	O	
19	,	O	
20	virginiamycin	O	
21	biosynthesis	O	
22	and	O	
23	virginiamycin	O	
24	M1	O	
25	resistance	O	
26	.	O	

1	Lower	O	
2	limits	O	
3	(	O	
4	to	O	
5	10	O	
6	micrograms	O	
7	/	O	
8	kg	O	
9	)	O	
10	were	O	
11	detectable	O	
12	,	O	
13	but	O	
14	with	O	
15	lower	O	
16	reliability	O	
17	(	O	
18	60	O	
19	%).	O	

1	Induction	O	
2	of	O	
3	AtP5CS1	B	
4	mRNA	I	
5	accumulation	O	
6	in	O	
7	salt	O	
8	-	O	
9	treated	O	
10	seedlings	O	
11	involves	O	
12	an	O	
13	immediate	O	
14	early	O	
15	transcriptional	O	
16	response	O	
17	regulated	O	
18	by	O	
19	ABA	O	
20	signalling	O	
21	that	O	
22	is	O	
23	not	O	
24	inhibited	O	
25	by	O	
26	cycloheximide	O	
27	,	O	
28	but	O	
29	abolished	O	
30	by	O	
31	the	O	
32	deficiency	O	
33	of	O	
34	ABA	O	
35	biosynthesis	O	
36	in	O	
37	the	O	
38	aba1	B	
39	Arabidopsis	I	
40	mutant	I	
41	.	O	

1	Of	O	
2	49	O	
3	receptors	O	
4	which	O	
5	fired	O	
6	in	O	
7	phase	O	
8	with	O	
9	ventilation	O	
10	,	O	
11	13	O	
12	behaved	O	
13	like	O	
14	mammalian	O	
15	rapidly	O	
16	adapting	O	
17	pulmonary	O	
18	stretch	O	
19	receptors	O	
20	,	O	
21	19	O	
22	like	O	
23	mammalian	O	
24	slowly	O	
25	adapting	O	
26	pulmonary	O	
27	stretch	O	
28	receptors	O	
29	(	O	
30	PSR	O	
31	),	O	
32	and	O	
33	17	O	
34	like	O	
35	avian	O	
36	intrapulmonary	O	
37	CO2	O	
38	-	O	
39	sensitive	O	
40	chemoreceptors	O	
41	(	O	
42	IPC	O	
43	).	O	

1	This	O	
2	philosophy	O	
3	was	O	
4	instituted	O	
5	for	O	
6	the	O	
7	compound	O	
8	RP	O	
9	73401	O	
10	,	O	
11	a	O	
12	specific	O	
13	phosphodiesterase	B	
14	IV	I	
15	inhibitor	O	
16	,	O	
17	that	O	
18	was	O	
19	being	O	
20	developed	O	
21	simultaneously	O	
22	for	O	
23	delivery	O	
24	by	O	
25	both	O	
26	oral	O	
27	and	O	
28	pulmonary	O	
29	routes	O	
30	of	O	
31	administration	O	
32	.	O	

1	The	O	
2	Euglena	B	
3	ribosomal	I	
4	protein	I	
5	gene	I	
6	cluster	I	
7	resembles	O	
8	the	O	
9	S	B	
10	-	I	
11	10	I	
12	ribosomal	I	
13	protein	I	
14	operon	I	
15	of	I	
16	Escherichia	I	
17	coli	I	
18	in	O	
19	gene	O	
20	organization	O	
21	and	O	
22	follows	O	
23	the	O	
24	exact	O	
25	linear	O	
26	order	O	
27	of	O	
28	the	O	
29	analogous	O	
30	genes	O	
31	in	O	
32	the	O	
33	tobacco	O	
34	and	O	
35	liverwort	O	
36	chloroplast	O	
37	genomes	O	
38	.	O	

1	Cloning	O	
2	by	O	
3	complementation	O	
4	and	O	
5	subsequent	O	
6	physical	O	
7	and	O	
8	genetic	O	
9	analysis	O	
10	revealed	O	
11	that	O	
12	it	O	
13	maps	O	
14	to	O	
15	RAF1	B	
16	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	CaMig1	B	
5	formed	O	
6	specific	O	
7	complexes	O	
8	with	O	
9	the	O	
10	URS1	O	
11	region	O	
12	of	O	
13	the	O	
14	S	B	
15	.	I	
16	cerevisiae	I	
17	FBP1	I	
18	gene	I	
19	.	O	

1	These	O	
2	results	O	
3	indicate	O	
4	that	O	
5	the	O	
6	p33	B	
7	subunit	I	
8	of	O	
9	eIF3	B	
10	plays	O	
11	an	O	
12	important	O	
13	role	O	
14	in	O	
15	the	O	
16	initiation	O	
17	phase	O	
18	of	O	
19	protein	O	
20	synthesis	O	
21	and	O	
22	that	O	
23	its	O	
24	RNA	O	
25	-	O	
26	binding	O	
27	domain	O	
28	is	O	
29	required	O	
30	for	O	
31	optimal	O	
32	activity	O	
33	.	O	

1	In	O	
2	vitro	O	
3	transcription	O	
4	extracts	O	
5	from	O	
6	ret1	B	
7	-	I	
8	1	I	
9	cells	O	
10	terminate	O	
11	less	O	
12	efficiently	O	
13	at	O	
14	weak	O	
15	transcription	O	
16	termination	O	
17	signals	O	
18	than	O	
19	those	O	
20	from	O	
21	RET1	B	
22	cells	O	
23	,	O	
24	using	O	
25	a	O	
26	variety	O	
27	of	O	
28	tRNA	O	
29	templates	O	
30	.	O	

1	In	O	
2	the	O	
3	present	O	
4	study	O	
5	,	O	
6	we	O	
7	identified	O	
8	a	O	
9	strong	O	
10	positive	O	
11	cis	O	
12	-	O	
13	regulatory	O	
14	element	O	
15	at	O	
16	-	O	
17	70	O	
18	bp	O	
19	to	O	
20	-	O	
21	75	O	
22	bp	O	
23	in	O	
24	the	O	
25	LpS1	B	
26	beta	I	
27	promoter	I	
28	with	O	
29	the	O	
30	sequence	O	
31	(	O	
32	G	O	
33	)	O	
34	6	O	
35	and	O	
36	a	O	
37	similar	O	
38	,	O	
39	more	O	
40	distal	O	
41	cis	O	
42	-	O	
43	element	O	
44	at	O	
45	-	O	
46	721	O	
47	bp	O	
48	to	O	
49	-	O	
50	726	O	
51	bp	O	
52	.	O	

1	Molecular	O	
2	cloning	O	
3	and	O	
4	functional	O	
5	characterization	O	
6	of	O	
7	murine	B	
8	sphingosine	I	
9	kinase	I	
10	.	O	

1	Azygos	O	
2	vein	O	
3	abutting	O	
4	the	O	
5	posterior	O	
6	wall	O	
7	of	O	
8	the	O	
9	right	O	
10	main	O	
11	and	O	
12	upper	O	
13	lobe	O	
14	bronchi	O	
15	:	O	
16	a	O	
17	normal	O	
18	CT	O	
19	variant	O	
20	.	O	

1	Using	O	
2	the	O	
3	yeast	O	
4	one	O	
5	-	O	
6	hybrid	O	
7	screen	O	
8	with	O	
9	integrated	O	
10	NRE	O	
11	and	O	
12	flanking	O	
13	DNA	O	
14	as	O	
15	bait	O	
16	,	O	
17	the	O	
18	predominant	O	
19	clone	O	
20	obtained	O	
21	was	O	
22	bovine	B	
23	Nrl	I	
24	.	O	

1	OUTCOME	O	
2	:	O	
3	Acetylcholine	B	
4	receptor	I	
5	antibodies	I	
6	and	O	
7	single	O	
8	-	O	
9	fibre	O	
10	electromyogram	O	
11	were	O	
12	useful	O	
13	in	O	
14	the	O	
15	diagnosis	O	
16	of	O	
17	myasthenia	O	
18	gravis	O	
19	.	O	

1	We	O	
2	conclude	O	
3	that	O	
4	,	O	
5	with	O	
6	autonomic	O	
7	nervous	O	
8	system	O	
9	activity	O	
10	intact	O	
11	,	O	
12	carotid	O	
13	chemoreceptor	O	
14	reflex	O	
15	activation	O	
16	can	O	
17	elicit	O	
18	an	O	
19	absolute	O	
20	reflexly	O	
21	mediated	O	
22	reduction	O	
23	in	O	
24	coronary	O	
25	blood	O	
26	flow	O	
27	in	O	
28	the	O	
29	normal	O	
30	,	O	
31	conscious	O	
32	dog	O	
33	,	O	
34	despite	O	
35	an	O	
36	increase	O	
37	in	O	
38	arterial	O	
39	pressure	O	
40	.	O	

1	Comparison	O	
2	of	O	
3	the	O	
4	deduced	O	
5	amino	O	
6	acid	O	
7	sequences	O	
8	with	O	
9	protein	O	
10	sequences	O	
11	of	O	
12	T	O	
13	.	O	
14	pyriformis	O	
15	H2As	B	
16	showed	O	
17	only	O	
18	two	O	
19	and	O	
20	three	O	
21	differences	O	
22	respectively	O	
23	,	O	
24	in	O	
25	a	O	
26	total	O	
27	of	O	
28	137	O	
29	amino	O	
30	acids	O	
31	for	O	
32	H2A1	B	
33	,	O	
34	and	O	
35	132	O	
36	amino	O	
37	acids	O	
38	for	O	
39	H2A2	B	
40	,	O	
41	indicating	O	
42	the	O	
43	two	O	
44	genes	O	
45	arose	O	
46	before	O	
47	the	O	
48	divergence	O	
49	of	O	
50	these	O	
51	two	O	
52	species	O	
53	.	O	

1	We	O	
2	then	O	
3	demonstrated	O	
4	that	O	
5	1	O	
6	)	O	
7	GAL4	B	
8	-	O	
9	REV	B	
10	-	O	
11	erbA	B	
12	alpha	I	
13	chimeras	O	
14	that	O	
15	contain	O	
16	the	O	
17	'	O	
18	AB	O	
19	'	O	
20	region	O	
21	and	O	
22	lack	O	
23	the	O	
24	'	O	
25	E	O	
26	'	O	
27	region	O	
28	activated	O	
29	transcription	O	
30	of	O	
31	GAL4	B	
32	response	I	
33	elements	I	
34	in	O	
35	the	O	
36	presence	O	
37	of	O	
38	8	O	
39	-	O	
40	Br	O	
41	-	O	
42	cAMP	O	
43	and	O	
44	2	O	
45	)	O	
46	the	O	
47	ligand	O	
48	-	O	
49	binding	O	
50	domain	O	
51	(	O	
52	LBD	O	
53	)	O	
54	contains	O	
55	an	O	
56	active	O	
57	transcriptional	O	
58	silencer	O	
59	.	O	

1	A	O	
2	noncatalytic	O	
3	domain	O	
4	conserved	O	
5	among	O	
6	cytoplasmic	B	
7	protein	I	
8	-	I	
9	tyrosine	I	
10	kinases	I	
11	modifies	O	
12	the	O	
13	kinase	O	
14	function	O	
15	and	O	
16	transforming	O	
17	activity	O	
18	of	O	
19	Fujinami	B	
20	sarcoma	I	
21	virus	I	
22	P130gag	I	
23	-	O	
24	fps	B	
25	.	O	

1	Appl	O	
2	.	O	

1	D	O	
2	.	O	

1	An	O	
2	evolutionary	O	
3	conserved	O	
4	element	O	
5	is	O	
6	essential	O	
7	for	O	
8	somite	O	
9	and	O	
10	adjacent	O	
11	mesenchymal	O	
12	expression	O	
13	of	O	
14	the	O	
15	Hoxa1	B	
16	gene	I	
17	.	O	

1	Competitive	O	
2	reverse	O	
3	transcription	O	
4	-	O	
5	polymerase	O	
6	chain	O	
7	reaction	O	
8	and	O	
9	HPLC	O	
10	analysis	O	
11	showed	O	
12	that	O	
13	RUSH	B	
14	-	I	
15	1alpha	I	
16	is	O	
17	the	O	
18	progesterone	O	
19	-	O	
20	dependent	O	
21	splice	O	
22	variant	O	
23	.	O	

1	Diagnostic	O	
2	value	O	
3	of	O	
4	adenosine	B	
5	deaminase	I	
6	activity	O	
7	in	O	
8	tuberculous	O	
9	effusions	O	
10	.	O	

1	Here	O	
2	,	O	
3	we	O	
4	show	O	
5	that	O	
6	IRF	B	
7	-	I	
8	1	I	
9	is	O	
10	degraded	O	
11	via	O	
12	the	O	
13	ubiquitin	B	
14	-	O	
15	proteasome	O	
16	pathway	O	
17	.	O	

1	Finger	B	
2	associated	I	
3	box	I	
4	-	I	
5	zinc	I	
6	finger	I	
7	proteins	I	
8	(	O	
9	FAX	B	
10	-	I	
11	ZFPs	I	
12	)	O	
13	constitute	O	
14	a	O	
15	subfamily	O	
16	of	O	
17	the	O	
18	many	O	
19	C2H2	B	
20	type	I	
21	ZFPs	I	
22	in	O	
23	Xenopus	O	
24	laevis	O	
25	.	O	

1	Valuing	O	
2	families	O	
3	:	O	
4	social	O	
5	work	O	
6	practice	O	
7	with	O	
8	families	O	
9	from	O	
10	a	O	
11	strengths	O	
12	perspective	O	
13	.	O	

1	Initially	O	
2	,	O	
3	we	O	
4	observed	O	
5	that	O	
6	unmutated	O	
7	p53	B	
8	is	O	
9	strongly	O	
10	expressed	O	
11	in	O	
12	premalignant	O	
13	mammary	O	
14	glands	O	
15	and	O	
16	in	O	
17	mammary	O	
18	tumors	O	
19	derived	O	
20	from	O	
21	the	O	
22	MMTV	O	
23	-	O	
24	c	B	
25	-	I	
26	myc	I	
27	strain	O	
28	.	O	

1	The	O	
2	Stryker	O	
3	frame	O	
4	modification	O	
5	to	O	
6	the	O	
7	standard	O	
8	Dornier	O	
9	HM3	O	
10	lithotriptor	O	
11	allows	O	
12	for	O	
13	improved	O	
14	visualization	O	
15	and	O	
16	easier	O	
17	localization	O	
18	of	O	
19	distal	O	
20	ureteral	O	
21	calculi	O	
22	compared	O	
23	to	O	
24	the	O	
25	standard	O	
26	gantry	O	
27	.	O	

1	In	O	
2	a	O	
3	randomised	O	
4	double	O	
5	-	O	
6	blind	O	
7	study	O	
8	,	O	
9	46	O	
10	first	O	
11	episode	O	
12	schizophrenics	O	
13	were	O	
14	given	O	
15	pimozide	O	
16	or	O	
17	flupenthixol	O	
18	for	O	
19	up	O	
20	to	O	
21	5	O	
22	weeks	O	
23	;	O	
24	the	O	
25	mean	O	
26	daily	O	
27	dose	O	
28	at	O	
29	the	O	
30	end	O	
31	was	O	
32	18	O	
33	.	O	
34	8	O	
35	mg	O	
36	pimozide	O	
37	and	O	
38	20	O	
39	mg	O	
40	flupenthixol	O	
41	.	O	

1	Using	O	
2	an	O	
3	ELISA	O	
4	,	O	
5	we	O	
6	found	O	
7	that	O	
8	surfactant	B	
9	protein	I	
10	A	I	
11	(	O	
12	SP	B	
13	-	I	
14	A	I	
15	)	O	
16	was	O	
17	markedly	O	
18	elevated	O	
19	in	O	
20	the	O	
21	pneumonia	O	
22	patients	O	
23	.	O	

1	The	O	
2	fusion	O	
3	proteins	O	
4	were	O	
5	tested	O	
6	by	O	
7	ELISA	O	
8	for	O	
9	reactivity	O	
10	with	O	
11	a	O	
12	panel	O	
13	of	O	
14	human	B	
15	anti	I	
16	-	I	
17	La	I	
18	sera	I	
19	in	O	
20	order	O	
21	to	O	
22	define	O	
23	the	O	
24	nature	O	
25	of	O	
26	the	O	
27	epitopes	O	
28	.	O	

1	Alternative	O	
2	splicing	O	
3	of	O	
4	RNA	O	
5	transcripts	O	
6	encoded	O	
7	by	O	
8	the	O	
9	murine	O	
10	p105	B	
11	NF	I	
12	-	I	
13	kappa	I	
14	B	I	
15	gene	O	
16	generates	O	
17	I	B	
18	kappa	I	
19	B	I	
20	gamma	I	
21	isoforms	I	
22	with	O	
23	different	O	
24	inhibitory	O	
25	activities	O	
26	.	O	

1	Experiments	O	
2	with	O	
3	epitope	O	
4	-	O	
5	tagged	O	
6	proteins	O	
7	show	O	
8	that	O	
9	UEV1A	B	
10	is	O	
11	a	O	
12	nuclear	O	
13	protein	O	
14	,	O	
15	whereas	O	
16	both	O	
17	Kua	B	
18	and	O	
19	Kua	B	
20	-	O	
21	UEV	B	
22	localize	O	
23	to	O	
24	cytoplasmic	O	
25	structures	O	
26	,	O	
27	indicating	O	
28	that	O	
29	the	O	
30	Kua	B	
31	domain	I	
32	determines	O	
33	the	O	
34	cytoplasmic	O	
35	localization	O	
36	of	O	
37	Kua	B	
38	-	O	
39	UEV	B	
40	.	O	

1	Insertion	O	
2	of	O	
3	short	O	
4	oligonucleotides	O	
5	encoding	O	
6	the	O	
7	basic	O	
8	amino	O	
9	acid	O	
10	motifs	O	
11	726	O	
12	-	O	
13	GRKRKSP	O	
14	-	O	
15	732	O	
16	from	O	
17	IE175	B	
18	and	O	
19	500	O	
20	-	O	
21	VRPRKRR	O	
22	-	O	
23	506	O	
24	from	O	
25	IE110	B	
26	into	O	
27	deleted	O	
28	cytoplasmic	O	
29	forms	O	
30	of	O	
31	the	O	
32	two	O	
33	proteins	O	
34	restored	O	
35	the	O	
36	karyophilic	O	
37	phenotype	O	
38	and	O	
39	confirmed	O	
40	that	O	
41	these	O	
42	motifs	O	
43	are	O	
44	both	O	
45	necessary	O	
46	and	O	
47	sufficient	O	
48	for	O	
49	proper	O	
50	nuclear	O	
51	localization	O	
52	.	O	

1	The	O	
2	method	O	
3	described	O	
4	may	O	
5	prove	O	
6	useful	O	
7	in	O	
8	studying	O	
9	the	O	
10	physiology	O	
11	of	O	
12	the	O	
13	nasal	O	
14	cycle	O	
15	.	O	

1	The	O	
2	rational	O	
3	for	O	
4	the	O	
5	prophylactic	O	
6	treatment	O	
7	,	O	
8	the	O	
9	therapy	O	
10	of	O	
11	the	O	
12	meningopathy	O	
13	and	O	
14	AIL	O	
15	-	O	
16	AIEOP	O	
17	protocols	O	
18	are	O	
19	exposed	O	
20	.	O	

1	We	O	
2	now	O	
3	demonstrate	O	
4	that	O	
5	CCAAT	B	
6	/	I	
7	enhancer	I	
8	-	I	
9	binding	I	
10	protein	I	
11	(	I	
12	C	I	
13	/	I	
14	EBP	I	
15	)	I	
16	delta	I	
17	is	O	
18	a	O	
19	major	O	
20	component	O	
21	of	O	
22	a	O	
23	PGE2	O	
24	-	O	
25	stimulated	O	
26	DNA	O	
27	-	O	
28	protein	O	
29	complex	O	
30	involving	O	
31	HS3D	B	
32	and	O	
33	find	O	
34	that	O	
35	C	B	
36	/	I	
37	EBPdelta	I	
38	transactivates	O	
39	IGF	B	
40	-	I	
41	I	I	
42	promoter	I	
43	1	I	
44	through	O	
45	this	O	
46	site	O	
47	.	O	

1	A	O	
2	population	O	
3	pharmacokinetic	O	
4	study	O	
5	of	O	
6	cyclosporin	O	
7	in	O	
8	organ	O	
9	transplant	O	
10	patients	O	
11	,	O	
12	including	O	
13	elderly	O	
14	allograft	O	
15	recipients	O	
16	up	O	
17	to	O	
18	75	O	
19	years	O	
20	of	O	
21	age	O	
22	,	O	
23	did	O	
24	not	O	
25	identify	O	
26	age	O	
27	as	O	
28	a	O	
29	covariable	O	
30	influencing	O	
31	cyclosporin	O	
32	pharmacokinetics	O	
33	.	O	

1	Effect	O	
2	of	O	
3	variations	O	
4	in	O	
5	time	O	
6	interval	O	
7	between	O	
8	treatment	O	
9	with	O	
10	BCG	O	
11	and	O	
12	quartz	O	
13	dust	O	
14	on	O	
15	translocation	O	
16	of	O	
17	quartz	O	
18	dust	O	
19	from	O	
20	the	O	
21	lungs	O	
22	to	O	
23	their	O	
24	regional	O	
25	lymph	O	
26	nodes	O	
27	.	O	

1	In	O	
2	order	O	
3	to	O	
4	provide	O	
5	adequate	O	
6	local	O	
7	control	O	
8	without	O	
9	compromising	O	
10	cosmetic	O	
11	outcome	O	
12	,	O	
13	the	O	
14	amount	O	
15	of	O	
16	breast	O	
17	tissue	O	
18	that	O	
19	must	O	
20	be	O	
21	excised	O	
22	in	O	
23	BCT	O	
24	needs	O	
25	to	O	
26	be	O	
27	individualized	O	
28	.	O	

1	The	O	
2	missing	O	
3	5	O	
4	'	O	
5	sequences	O	
6	were	O	
7	obtained	O	
8	by	O	
9	5	O	
10	'-	O	
11	rapid	O	
12	amplification	O	
13	of	O	
14	cDNA	O	
15	ends	O	
16	and	O	
17	by	O	
18	analysis	O	
19	of	O	
20	an	O	
21	NHE5	B	
22	genomic	I	
23	clone	I	
24	,	O	
25	and	O	
26	the	O	
27	missing	O	
28	3	O	
29	'	O	
30	sequences	O	
31	were	O	
32	obtained	O	
33	by	O	
34	3	O	
35	'-	O	
36	rapid	O	
37	amplification	O	
38	of	O	
39	cDNA	O	
40	ends	O	
41	.	O	

1	Karger	O	
2	AG	O	
3	,	O	
4	Basel	O	

1	The	O	
2	kallistatin	B	
3	gene	I	
4	was	O	
5	localized	O	
6	by	O	
7	in	O	
8	situ	O	
9	hybridization	O	
10	to	O	
11	human	O	
12	chromosome	O	
13	14q31	O	
14	-	O	
15	q32	O	
16	.	O	
17	1	O	
18	,	O	
19	close	O	
20	to	O	
21	the	O	
22	serpin	B	
23	genes	I	
24	encoding	O	
25	alpha	B	
26	1	I	
27	-	I	
28	antichymotrypsin	I	
29	,	O	
30	protein	B	
31	C	I	
32	inhibitor	I	
33	,	O	
34	alpha	B	
35	1	I	
36	-	I	
37	antitrypsin	I	
38	,	O	
39	and	O	
40	corticosteroid	B	
41	-	I	
42	binding	I	
43	globulin	I	
44	.	O	

1	Six	O	
2	(	O	
3	four	O	
4	FAP	O	
5	;	O	
6	two	O	
7	primary	O	
8	amyloidosis	O	
9	)	O	
10	also	O	
11	had	O	
12	diffusely	O	
13	positive	O	
14	myocardial	O	
15	uptakes	O	
16	,	O	
17	but	O	
18	the	O	
19	intensity	O	
20	was	O	
21	less	O	
22	than	O	
23	that	O	
24	of	O	
25	the	O	
26	sternum	O	
27	.	O	

1	Recognition	O	
2	of	O	
3	emphysema	O	
4	was	O	
5	poor	O	
6	when	O	
7	radiographs	O	
8	of	O	
9	inadequate	O	
10	quality	O	
11	were	O	
12	included	O	
13	(	O	
14	anteroposterior	O	
15	films	O	
16	or	O	
17	films	O	
18	from	O	
19	patients	O	
20	with	O	
21	acute	O	
22	or	O	
23	chronic	O	
24	lung	O	
25	disease	O	
26	).	O	

1	The	O	
2	Stat5b	B	
3	mRNA	I	
4	has	O	
5	a	O	
6	size	O	
7	of	O	
8	5	O	
9	.	O	
10	6	O	
11	kb	O	
12	and	O	
13	encodes	O	
14	a	O	
15	protein	O	
16	of	O	
17	786	O	
18	amino	O	
19	acids	O	
20	.	O	

1	Gng3lg	B	
2	transcripts	I	
3	are	O	
4	expressed	O	
5	in	O	
6	a	O	
7	variety	O	
8	of	O	
9	tissues	O	
10	including	O	
11	both	O	
12	brain	O	
13	and	O	
14	testes	O	
15	.	O	

1	This	O	
2	shows	O	
3	that	O	
4	the	O	
5	characteristically	O	
6	diffuse	O	
7	banding	O	
8	pattern	O	
9	of	O	
10	plant	O	
11	nuclear	O	
12	proteins	O	
13	interacting	O	
14	with	O	
15	the	O	
16	G	O	
17	-	O	
18	box	O	
19	is	O	
20	also	O	
21	observed	O	
22	in	O	
23	a	O	
24	binding	O	
25	assay	O	
26	using	O	
27	only	O	
28	one	O	
29	recombinant	B	
30	GBF	I	
31	.	O	

1	No	O	
2	serious	O	
3	side	O	
4	effects	O	
5	were	O	
6	observed	O	
7	.	O	

1	One	O	
2	of	O	
3	its	O	
4	unique	O	
5	features	O	
6	appears	O	
7	to	O	
8	be	O	
9	the	O	
10	unusually	O	
11	short	O	
12	5	O	
13	'-	O	
14	untranslated	O	
15	regions	O	
16	(	O	
17	UTR	O	
18	)	O	
19	(	O	
20	1	O	
21	-	O	
22	6	O	
23	nucleotides	O	
24	(	O	
25	nts	O	
26	))	O	
27	and	O	
28	the	O	
29	apparent	O	
30	absence	O	
31	of	O	
32	5	O	
33	'-	O	
34	cap	O	
35	structures	O	
36	from	O	
37	its	O	
38	mRNAs	O	
39	.	O	

1	On	O	
2	long	O	
3	-	O	
4	term	O	
5	follow	O	
6	-	O	
7	up	O	
8	,	O	
9	there	O	
10	was	O	
11	no	O	
12	significant	O	
13	difference	O	
14	in	O	
15	the	O	
16	incidence	O	
17	of	O	
18	hospitalizations	O	
19	(	O	
20	1	O	
21	per	O	
22	2	O	
23	.	O	
24	1	O	
25	vs	O	
26	.	O	

1	Major	O	
2	clinical	O	
3	symptoms	O	
4	of	O	
5	the	O	
6	disease	O	
7	were	O	
8	defined	O	
9	in	O	
10	this	O	
11	group	O	
12	of	O	
13	patients	O	
14	.	O	

1	Nuclear	O	
2	localization	O	
3	and	O	
4	protein	O	
5	sequence	O	
6	similarities	O	
7	suggested	O	
8	that	O	
9	the	O	
10	SPT2	B	
11	/	O	
12	SIN1	B	
13	protein	O	
14	may	O	
15	be	O	
16	related	O	
17	to	O	
18	the	O	
19	nonhistone	B	
20	chromosomal	I	
21	protein	I	
22	HMG1	I	
23	.	O	

1	Tyrosine	O	
2	phosphorylation	O	
3	of	O	
4	cellular	O	
5	proteins	O	
6	is	O	
7	the	O	
8	earliest	O	
9	identifiable	O	
10	event	O	
11	following	O	
12	T	B	
13	-	I	
14	cell	I	
15	antigen	I	
16	receptor	I	
17	(	O	
18	TCR	B	
19	)	O	
20	stimulation	O	
21	and	O	
22	is	O	
23	essential	O	
24	for	O	
25	activating	O	
26	downstream	O	
27	signaling	O	
28	machinery	O	
29	.	O	

1	The	O	
2	p34	B	
3	.	I	
4	8	I	
5	gene	I	
6	has	O	
7	a	O	
8	strong	O	
9	codon	O	
10	usage	O	
11	bias	O	
12	which	O	
13	is	O	
14	strikingly	O	
15	different	O	
16	from	O	
17	that	O	
18	of	O	
19	the	O	
20	polyhedrin	B	
21	gene	I	
22	.	O	

1	Changes	O	
2	in	O	
3	dopamine	B	
4	receptor	I	
5	sensitivity	O	
6	in	O	
7	humans	O	
8	after	O	
9	heavy	O	
10	alcohol	O	
11	intake	O	
12	.	O	

1	Both	O	
2	inhaled	O	
3	and	O	
4	superfused	O	
5	isoflurane	O	
6	dilated	O	
7	the	O	
8	baseline	O	
9	vein	O	
10	diameter	O	
11	before	O	
12	stimulation	O	
13	.	O	

1	The	O	
2	mobility	O	
3	of	O	
4	the	O	
5	upper	O	
6	and	O	
7	lower	O	
8	premolars	O	
9	under	O	
10	load	O	
11	was	O	
12	investigated	O	
13	in	O	
14	relation	O	
15	to	O	
16	the	O	
17	interproximal	O	
18	contact	O	
19	and	O	
20	occlusal	O	
21	facets	O	
22	.	O	

1	The	O	
2	5	O	
3	'	O	
4	end	O	
5	of	O	
6	the	O	
7	genomic	O	
8	RNA	O	
9	of	O	
10	rubella	O	
11	virus	O	
12	(	O	
13	RUB	O	
14	)	O	
15	contains	O	
16	a	O	
17	14	O	
18	-	O	
19	nucleotide	O	
20	(	O	
21	nt	O	
22	)	O	
23	single	O	
24	-	O	
25	stranded	O	
26	leader	O	
27	(	O	
28	ss	O	
29	-	O	
30	leader	O	
31	)	O	
32	followed	O	
33	by	O	
34	a	O	
35	stem	O	
36	-	O	
37	and	O	
38	-	O	
39	loop	O	
40	structure	O	
41	[	O	
42	5	O	
43	'(+)	O	
44	SL	O	
45	]	O	
46	(	O	
47	nt	O	
48	15	O	
49	to	O	
50	65	O	
51	),	O	
52	the	O	
53	complement	O	
54	of	O	
55	which	O	
56	at	O	
57	the	O	
58	3	O	
59	'	O	
60	end	O	
61	of	O	
62	the	O	
63	minus	O	
64	-	O	
65	strand	O	
66	RNA	O	
67	[	O	
68	3	O	
69	'(-)	O	
70	SL	O	
71	]	O	
72	has	O	
73	been	O	
74	proposed	O	
75	to	O	
76	function	O	
77	as	O	
78	a	O	
79	promoter	O	
80	for	O	
81	synthesis	O	
82	of	O	
83	genomic	O	
84	plus	O	
85	strands	O	
86	.	O	

1	Evaluation	O	
2	of	O	
3	myocardial	O	
4	perfusion	O	
5	by	O	
6	99mTc	O	
7	-	O	
8	tetrofosmin	O	
9	SPECT	O	
10	before	O	
11	and	O	
12	after	O	
13	emergent	O	
14	percutaneous	O	
15	transluminal	O	
16	coronary	O	
17	angioplasty	O	
18	for	O	
19	acute	O	
20	myocardial	O	
21	infarction	O	

1	Aberrant	O	
2	protein	O	
3	phosphorylation	O	
4	at	O	
5	tyrosine	O	
6	is	O	
7	responsible	O	
8	for	O	
9	the	O	
10	growth	O	
11	-	O	
12	inhibitory	O	
13	action	O	
14	of	O	
15	pp60v	B	
16	-	I	
17	src	I	
18	expressed	O	
19	in	O	
20	the	O	
21	yeast	O	
22	Saccharomyces	O	
23	cerevisiae	O	
24	.	O	

1	The	O	
2	structural	O	
3	study	O	
4	of	O	
5	peptides	O	
6	belonging	O	
7	to	O	
8	the	O	
9	terminal	O	
10	domains	O	
11	of	O	
12	histone	B	
13	H1	I	
14	can	O	
15	be	O	
16	considered	O	
17	as	O	
18	a	O	
19	step	O	
20	toward	O	
21	the	O	
22	understanding	O	
23	of	O	
24	the	O	
25	function	O	
26	of	O	
27	H1	B	
28	in	O	
29	chromatin	O	
30	.	O	

1	The	O	
2	isolated	O	
3	plasmin	B	
4	fragments	O	
5	of	O	
6	VEGF	B	
7	were	O	
8	compared	O	
9	with	O	
10	respect	O	
11	to	O	
12	heparin	O	
13	binding	O	
14	,	O	
15	interaction	O	
16	with	O	
17	soluble	O	
18	VEGF	B	
19	receptors	I	
20	,	O	
21	and	O	
22	ability	O	
23	to	O	
24	promote	O	
25	endothelial	O	
26	cell	O	
27	mitogenesis	O	
28	.	O	

1	Because	O	
2	of	O	
3	its	O	
4	wide	O	
5	spectrum	O	
6	of	O	
7	activity	O	
8	particularly	O	
9	against	O	
10	ampicillin	O	
11	resistant	O	
12	strains	O	
13	of	O	
14	H	O	
15	.	O	
16	influenzae	O	
17	and	O	
18	because	O	
19	of	O	
20	its	O	
21	good	O	
22	tolerance	O	
23	Cefaclor	O	
24	is	O	
25	very	O	
26	useful	O	
27	in	O	
28	treatment	O	
29	of	O	
30	respiratory	O	
31	tract	O	
32	infections	O	
33	in	O	
34	children	O	
35	.	O	

1	These	O	
2	findings	O	
3	suggest	O	
4	that	O	
5	the	O	
6	F	O	
7	-	O	
8	wave	O	
9	may	O	
10	be	O	
11	elicited	O	
12	in	O	
13	motoneuron	O	
14	of	O	
15	different	O	
16	depolarization	O	
17	threshold	O	
18	but	O	
19	primarily	O	
20	in	O	
21	larger	O	
22	and	O	
23	faster	O	
24	nerve	O	
25	fibers	O	
26	,	O	
27	with	O	
28	a	O	
29	lower	O	
30	threshold	O	
31	of	O	
32	depolarization	O	
33	.	O	

1	55	O	
2	+/-	O	
3	11	O	
4	%),	O	
5	all	O	
6	other	O	
7	parameters	O	
8	showed	O	
9	a	O	
10	significant	O	
11	increase	O	
12	:	O	
13	RS	O	
14	index	O	
15	5	O	
16	.	O	
17	4	O	
18	+/-	O	
19	1	O	
20	.	O	
21	4	O	
22	mVolt	O	
23	to	O	
24	6	O	
25	.	O	
26	0	O	
27	+/-	O	
28	1	O	
29	.	O	
30	7	O	
31	mVolt	O	
32	(	O	
33	p	O	
34	less	O	
35	than	O	
36	0	O	
37	.	O	
38	01	O	
39	);	O	
40	EDD	O	
41	6	O	
42	.	O	
43	3	O	
44	+/-	O	
45	0	O	
46	.	O	
47	7	O	
48	to	O	
49	6	O	
50	.	O	
51	8	O	
52	+/-	O	
53	0	O	
54	.	O	
55	9	O	
56	cm	O	
57	(	O	
58	p	O	
59	less	O	
60	than	O	
61	0	O	
62	.	O	
63	001	O	
64	);	O	
65	HV	O	
66	1017	O	
67	+/-	O	
68	151	O	
69	ml	O	
70	to	O	
71	1099	O	
72	+/-	O	
73	261	O	
74	ml	O	
75	(	O	
76	p	O	
77	less	O	
78	than	O	
79	0	O	
80	.	O	
81	01	O	
82	);	O	
83	EDV	O	
84	371	O	
85	+/-	O	
86	131	O	
87	ml	O	
88	to	O	
89	441	O	
90	+/-	O	
91	175	O	
92	ml	O	
93	(	O	
94	p	O	
95	less	O	
96	than	O	
97	0	O	
98	.	O	
99	001	O	
100	);	O	
101	RBV	O	
102	117	O	
103	+/-	O	
104	57	O	
105	ml	O	
106	to	O	
107	151	O	
108	+/-	O	
109	77	O	
110	ml	O	
111	(	O	
112	p	O	
113	less	O	
114	than	O	
115	0	O	
116	.	O	
117	001	O	
118	).	O	

1	Moreover	O	
2	,	O	
3	unlike	O	
4	control	O	
5	rats	O	
6	operated	O	
7	animals	O	
8	did	O	
9	not	O	
10	show	O	
11	aversion	O	
12	to	O	
13	the	O	
14	highest	O	
15	concentrations	O	
16	of	O	
17	saccharin	O	
18	solutions	O	
19	.	O	

1	A	O	
2	single	O	
3	-	O	
4	case	O	
5	experimental	O	
6	ABAB	O	
7	multiple	O	
8	baseline	O	
9	design	O	
10	was	O	
11	employed	O	
12	to	O	
13	test	O	
14	for	O	
15	treatment	O	
16	effectiveness	O	
17	.	O	

1	Translation	O	
2	of	O	
3	specific	O	
4	cellular	O	
5	genes	O	
6	from	O	
7	the	O	
8	chimeric	O	
9	viral	O	
10	-	O	
11	cellular	O	
12	transcripts	O	
13	seems	O	
14	to	O	
15	be	O	
16	unlikely	O	
17	.	O	

1	These	O	
2	results	O	
3	suggested	O	
4	that	O	
5	BACH1t	B	
6	recruits	O	
7	BACH1	B	
8	to	O	
9	the	O	
10	nucleus	O	
11	through	O	
12	BTB	B	
13	domain	O	
14	-	O	
15	mediated	O	
16	interaction	O	
17	.	O	

1	The	O	
2	most	O	
3	striking	O	
4	difference	O	
5	in	O	
6	the	O	
7	birch	B	
8	NAD	I	
9	(	I	
10	P	I	
11	)	I	
12	H	I	
13	-	I	
14	NR	I	
15	sequence	I	
16	in	O	
17	comparison	O	
18	to	O	
19	NADH	B	
20	-	I	
21	NR	I	
22	sequences	I	
23	was	O	
24	found	O	
25	at	O	
26	the	O	
27	putative	O	
28	pyridine	O	
29	nucleotide	O	
30	binding	O	
31	site	O	
32	.	O	

1	One	O	
2	patients	O	
3	had	O	
4	plasma	B	
5	C	I	
6	-	I	
7	peptide	I	
8	greater	O	
9	than	O	
10	3	O	
11	pM	O	
12	and	O	
13	was	O	
14	therefore	O	
15	excluded	O	
16	from	O	
17	analysis	O	
18	.	O	

1	While	O	
2	daily	O	
3	food	O	
4	intake	O	
5	was	O	
6	almost	O	
7	constant	O	
8	regardless	O	
9	of	O	
10	the	O	
11	dietary	O	
12	protein	O	
13	level	O	
14	,	O	
15	water	O	
16	intake	O	
17	and	O	
18	urine	O	
19	volume	O	
20	increased	O	
21	with	O	
22	increasing	O	
23	the	O	
24	dietary	O	
25	protein	O	
26	.	O	

1	Tumor	B	
2	necrosis	I	
3	factor	I	
4	-	I	
5	alpha	I	
6	(	O	
7	TNF	B	
8	alpha	I	
9	)	O	
10	is	O	
11	one	O	
12	of	O	
13	several	O	
14	autocrine	O	
15	/	O	
16	paracrine	O	
17	factors	O	
18	known	O	
19	to	O	
20	exert	O	
21	potent	O	
22	inhibitory	O	
23	effects	O	
24	on	O	
25	bone	O	
26	.	O	

1	The	O	
2	structure	O	
3	of	O	
4	the	O	
5	free	O	
6	SH2	B	
7	domain	I	
8	has	O	
9	been	O	
10	compared	O	
11	to	O	
12	that	O	
13	of	O	
14	the	O	
15	SH2	B	
16	complexed	O	
17	with	O	
18	a	O	
19	doubly	O	
20	phosphorylated	O	
21	peptide	O	
22	derived	O	
23	from	O	
24	polyomavirus	B	
25	middle	I	
26	T	I	
27	antigen	I	
28	(	O	
29	MT	B	
30	).	O	

1	The	O	
2	smallest	O	
3	of	O	
4	the	O	
5	mini	O	
6	-	O	
7	Mu	O	
8	elements	O	
9	is	O	
10	only	O	
11	7	O	
12	.	O	
13	9	O	
14	kilobase	O	
15	pairs	O	
16	long	O	
17	,	O	
18	allowing	O	
19	the	O	
20	cloning	O	
21	of	O	
22	DNA	O	
23	fragments	O	
24	of	O	
25	up	O	
26	to	O	
27	31	O	
28	.	O	
29	1	O	
30	kilobase	O	
31	pairs	O	
32	,	O	
33	and	O	
34	the	O	
35	largest	O	
36	of	O	
37	them	O	
38	is	O	
39	21	O	
40	.	O	
41	7	O	
42	kilobase	O	
43	pairs	O	
44	,	O	
45	requiring	O	
46	that	O	
47	clones	O	
48	carry	O	
49	insertions	O	
50	of	O	
51	less	O	
52	than	O	
53	17	O	
54	.	O	
55	3	O	
56	kilobase	O	
57	pairs	O	
58	.	O	

1	A	O	
2	tyrosine	O	
3	-	O	
4	based	O	
5	sorting	O	
6	signal	O	
7	in	O	
8	the	O	
9	beta2	B	
10	integrin	I	
11	cytoplasmic	I	
12	domain	I	
13	mediates	O	
14	its	O	
15	recycling	O	
16	to	O	
17	the	O	
18	plasma	O	
19	membrane	O	
20	and	O	
21	is	O	
22	required	O	
23	for	O	
24	ligand	O	
25	-	O	
26	supported	O	
27	migration	O	
28	.	O	

1	We	O	
2	propose	O	
3	that	O	
4	the	O	
5	ambiguous	O	
6	discrimination	O	
7	required	O	
8	a	O	
9	greater	O	
10	time	O	
11	for	O	
12	simulus	O	
13	evaluation	O	
14	and	O	
15	that	O	
16	this	O	
17	was	O	
18	reflected	O	
19	in	O	
20	the	O	
21	delayed	O	
22	P3	O	
23	latencies	O	
24	.	O	

1	Another	O	
2	group	O	
3	of	O	
4	HIPP	O	
5	-	O	
6	and	O	
7	HCX	O	
8	-	O	
9	lesioned	O	
10	animals	O	
11	trained	O	
12	on	O	
13	the	O	
14	tasks	O	
15	after	O	
16	the	O	
17	lesion	O	
18	showed	O	
19	reduced	O	
20	impairments	O	
21	of	O	
22	the	O	
23	type	O	
24	described	O	
25	above	O	
26	,	O	
27	suggesting	O	
28	that	O	
29	extrahippocampal	O	
30	structures	O	
31	trained	O	
32	after	O	
33	the	O	
34	lesion	O	
35	can	O	
36	assume	O	
37	the	O	
38	role	O	
39	of	O	
40	the	O	
41	hippocampus	O	
42	to	O	
43	some	O	
44	degree	O	
45	.	O	

1	Circulating	O	
2	oxytocin	B	
3	in	O	
4	male	O	
5	guinea	O	
6	pigs	O	
7	affected	O	
8	by	O	
9	the	O	
10	female	O	
11	cohabitation	O	
12	and	O	
13	reproductive	O	
14	condition	O	
15	.	O	

1	While	O	
2	fusion	O	
3	to	O	
4	the	O	
5	N	O	
6	-	O	
7	terminus	O	
8	required	O	
9	a	O	
10	linker	O	
11	to	O	
12	become	O	
13	surface	O	
14	accessible	O	
15	,	O	
16	both	O	
17	fusion	O	
18	to	O	
19	the	O	
20	N	O	
21	-	O	
22	terminus	O	
23	and	O	
24	to	O	
25	the	O	
26	C	O	
27	-	O	
28	terminus	O	
29	was	O	
30	compatible	O	
31	with	O	
32	particle	O	
33	assembly	O	
34	and	O	
35	preserved	O	
36	the	O	
37	native	O	
38	antigenicity	O	
39	and	O	
40	immunogenicity	O	
41	of	O	
42	HBcAg	B	
43	.	O	

1	The	O	
2	evaluation	O	
3	of	O	
4	amniotic	O	
5	fluid	O	
6	delta	O	
7	OD450	O	
8	is	O	
9	considered	O	
10	to	O	
11	be	O	
12	the	O	
13	cornerstone	O	
14	of	O	
15	clinical	O	
16	management	O	
17	.	O	

1	However	O	
2	,	O	
3	five	O	
4	new	O	
5	mutation	O	
6	sites	O	
7	(	O	
8	S61	B	
9	,	O	
10	SL1	B	
11	,	O	
12	S29	B	
13	,	O	
14	SL11	B	
15	,	O	
16	SL196	B	
17	and	O	
18	SL126	B	
19	)	O	
20	are	O	
21	unique	O	
22	to	O	
23	the	O	
24	nrdB	B	
25	intron	O	
26	and	O	
27	disrupt	O	
28	self	O	
29	-	O	
30	splicing	O	
31	.	O	

1	The	O	
2	results	O	
3	obtained	O	
4	tend	O	
5	to	O	
6	prove	O	
7	that	O	
8	the	O	
9	reticuloendothelial	O	
10	system	O	
11	mainly	O	
12	participated	O	
13	in	O	
14	beryllium	O	
15	retention	O	
16	.	O	

1	3	O	
2	.	O	

1	Finally	O	
2	,	O	
3	we	O	
4	determined	O	
5	the	O	
6	genomic	O	
7	organization	O	
8	of	O	
9	the	O	
10	human	B	
11	TrxR2	I	
12	gene	I	
13	,	O	
14	which	O	
15	consists	O	
16	of	O	
17	18	O	
18	exons	O	
19	spanning	O	
20	about	O	
21	67	O	
22	kb	O	
23	,	O	
24	and	O	
25	its	O	
26	chromosomal	O	
27	localization	O	
28	at	O	
29	position	O	
30	22q11	O	
31	.	O	
32	2	O	
33	.	O	

1	Mean	O	
2	fluorosis	O	
3	scores	O	
4	,	O	
5	however	O	
6	,	O	
7	were	O	
8	similar	O	
9	.	O	

1	Natural	O	
2	Haemophilus	O	
3	influenzae	O	
4	type	O	
5	b	O	
6	capsular	O	
7	polysaccharide	O	
8	antibodies	O	
9	in	O	
10	412	O	
11	infants	O	
12	and	O	
13	children	O	
14	from	O	
15	West	O	
16	Africa	O	
17	(	O	
18	Burkina	O	
19	-	O	
20	Faso	O	
21	)	O	
22	and	O	
23	France	O	
24	:	O	
25	a	O	
26	cross	O	
27	-	O	
28	sectional	O	
29	serosurvey	O	
30	.	O	

1	Exon	O	
2	A	O	
3	is	O	
4	located	O	
5	approximately	O	
6	7	O	
7	kb	O	
8	5	O	
9	'	O	
10	to	O	
11	the	O	
12	HSL	B	
13	translation	I	
14	start	I	
15	site	I	
16	.	O	

1	After	O	
2	selection	O	
3	and	O	
4	conversion	O	
5	to	O	
6	adipocytes	O	
7	,	O	
8	the	O	
9	level	O	
10	of	O	
11	EGFR	B	
12	expression	O	
13	was	O	
14	retained	O	
15	in	O	
16	infectant	O	
17	adipocytes	O	
18	(	O	
19	150	O	
20	,	O	
21	000	O	
22	and	O	
23	250	O	
24	,	O	
25	000	O	
26	/	O	
27	cell	O	
28	,	O	
29	respectively	O	
30	),	O	
31	but	O	
32	not	O	
33	in	O	
34	the	O	
35	parental	O	
36	3T3	O	
37	-	O	
38	L1	O	
39	adipocytes	O	
40	(<	O	
41	5000	O	
42	/	O	
43	cell	O	
44	).	O	

1	Unlike	O	
2	the	O	
3	mammalian	O	
4	proteins	O	
5	,	O	
6	XFGF3	B	
7	is	O	
8	efficiently	O	
9	secreted	O	
10	as	O	
11	a	O	
12	Mr	O	
13	31	O	
14	,	O	
15	000	O	
16	glycoprotein	O	
17	,	O	
18	gp31	B	
19	,	O	
20	which	O	
21	undergoes	O	
22	proteolytic	O	
23	cleavage	O	
24	to	O	
25	produce	O	
26	an	O	
27	NH2	O	
28	-	O	
29	terminally	O	
30	truncated	O	
31	product	O	
32	,	O	
33	gp27	B	
34	.	O	

1	RVR	B	
2	'	O	
3	loss	O	
4	of	O	
5	function	O	
6	'	O	
7	studies	O	
8	by	O	
9	constitutive	O	
10	over	O	
11	-	O	
12	expression	O	
13	of	O	
14	a	O	
15	dominant	O	
16	negative	O	
17	RVR	B	
18	delta	I	
19	E	I	
20	resulted	O	
21	in	O	
22	increased	O	
23	levels	O	
24	of	O	
25	p21Cip1	B	
26	/	O	
27	Waf1	B	
28	and	O	
29	myogenin	B	
30	mRNAs	I	
31	after	O	
32	serum	O	
33	withdrawal	O	
34	.	O	

1	The	O	
2	complete	O	
3	cDNA	O	
4	sequence	O	
5	of	O	
6	human	B	
7	betaV	I	
8	spectrin	I	
9	is	O	
10	available	O	
11	from	O	
12	GenBank	O	
13	(	O	
14	TM	O	
15	)	O	
16	as	O	
17	accession	O	
18	number	O	
19	.	O	

1	A	O	
2	2	O	
3	years	O	
4	and	O	
5	9	O	
6	months	O	
7	old	O	
8	female	O	
9	patient	O	
10	,	O	
11	with	O	
12	the	O	
13	diagnosis	O	
14	of	O	
15	Weaver	O	
16	syndrome	O	
17	is	O	
18	reported	O	
19	.	O	

1	On	O	
2	an	O	
3	antithrombin	B	
4	unit	O	
5	basis	O	
6	,	O	
7	CY	O	
8	216	O	
9	and	O	
10	CY	O	
11	222	O	
12	were	O	
13	equivalent	O	
14	and	O	
15	more	O	
16	potent	O	
17	than	O	
18	UH	O	
19	.	O	

1	Whereas	O	
2	cDNA	O	
3	hybridization	O	
4	to	O	
5	genomic	O	
6	DNA	O	
7	blots	O	
8	indicated	O	
9	a	O	
10	small	O	
11	subfamily	O	
12	of	O	
13	G0S19	B	
14	genes	I	
15	,	O	
16	simple	O	
17	patterns	O	
18	of	O	
19	bands	O	
20	indicated	O	
21	that	O	
22	most	O	
23	cDNAs	O	
24	,	O	
25	including	O	
26	G0S30	B	
27	cDNA	I	
28	,	O	
29	corresponded	O	
30	to	O	
31	single	O	
32	-	O	
33	copy	O	
34	genes	O	
35	.	O	

1	The	O	
2	pel	B	
3	gene	I	
4	from	O	
5	an	O	
6	Amycolata	O	
7	sp	O	
8	.	O	
9	encoding	O	
10	a	O	
11	pectate	B	
12	lyase	I	
13	(	O	
14	EC	B	
15	4	I	
16	.	I	
17	2	I	
18	.	I	
19	2	I	
20	.	I	
21	2	I	
22	)	O	
23	was	O	
24	isolated	O	
25	by	O	
26	activity	O	
27	screening	O	
28	a	O	
29	genomic	O	
30	DNA	O	
31	library	O	
32	in	O	
33	Streptomyces	O	
34	lividans	O	
35	TK24	O	
36	.	O	

1	Future	O	
2	analysis	O	
3	of	O	
4	long	O	
5	-	O	
6	term	O	
7	outcome	O	
8	measures	O	
9	of	O	
10	performance	O	
11	with	O	
12	the	O	
13	implant	O	
14	will	O	
15	confirm	O	
16	or	O	
17	dispute	O	
18	the	O	
19	benefit	O	
20	of	O	
21	ear	O	
22	selection	O	
23	using	O	
24	the	O	
25	Prom	O	
26	-	O	
27	EABR	O	
28	.	O	

1	We	O	
2	describe	O	
3	here	O	
4	a	O	
5	Drosophila	B	
6	melanogaster	I	
7	FAK	I	
8	homologue	I	
9	,	O	
10	DFak56	B	
11	,	O	
12	which	O	
13	maps	O	
14	to	O	
15	band	O	
16	56D	O	
17	on	O	
18	the	O	
19	right	O	
20	arm	O	
21	of	O	
22	the	O	
23	second	O	
24	chromosome	O	
25	.	O	

1	Staining	O	
2	with	O	
3	IF	O	
4	MoAB	O	
5	alone	O	
6	of	O	
7	BAL	O	
8	fluid	O	
9	only	O	
10	seemed	O	
11	to	O	
12	be	O	
13	even	O	
14	more	O	
15	sensitive	O	
16	than	O	
17	silver	O	
18	methenamine	O	
19	staining	O	
20	of	O	
21	BAL	O	
22	,	O	
23	TBB	O	
24	and	O	
25	brushing	O	
26	material	O	
27	.	O	

1	A	O	
2	consensus	O	
3	binding	O	
4	site	O	
5	for	O	
6	the	O	
7	transcription	O	
8	factor	O	
9	SP1	B	
10	was	O	
11	identified	O	
12	in	O	
13	intron	O	
14	As	O	
15	downstream	O	
16	of	O	
17	the	O	
18	proenkephalin	B	
19	germ	I	
20	cell	I	
21	cap	I	
22	site	I	
23	region	I	
24	.	O	

1	Up	O	
2	to	O	
3	now	O	
4	the	O	
5	number	O	
6	of	O	
7	patients	O	
8	examined	O	
9	is	O	
10	about	O	
11	300	O	
12	,	O	
13	additionally	O	
14	6	O	
15	persons	O	
16	who	O	
17	underwent	O	
18	binephrectomy	O	
19	.	O	

1	Myosin	B	
2	light	I	
3	chain	I	
4	kinase	I	
5	functions	O	
6	downstream	O	
7	of	O	
8	Ras	B	
9	/	O	
10	ERK	B	
11	to	O	
12	promote	O	
13	migration	O	
14	of	O	
15	urokinase	B	
16	-	I	
17	type	I	
18	plasminogen	I	
19	activator	I	
20	-	O	
21	stimulated	O	
22	cells	O	
23	in	O	
24	an	O	
25	integrin	B	
26	-	O	
27	selective	O	
28	manner	O	
29	.	O	

1	The	O	
2	effects	O	
3	of	O	
4	procedural	O	
5	variations	O	
6	on	O	
7	lateralized	O	
8	Stroop	O	
9	effects	O	
10	.	O	

1	Apropos	O	
2	of	O	
3	a	O	
4	case	O	

1	Here	O	
2	we	O	
3	present	O	
4	evidence	O	
5	that	O	
6	major	B	
7	IE	I	
8	proteins	I	
9	IE86	I	
10	,	O	
11	IE72	B	
12	,	O	
13	and	O	
14	IE55	B	
15	are	O	
16	capable	O	
17	of	O	
18	trans	O	
19	-	O	
20	activating	O	
21	the	O	
22	HIV	B	
23	LTR	I	
24	in	O	
25	a	O	
26	T	O	
27	-	O	
28	cell	O	
29	line	O	
30	,	O	
31	HUT	O	
32	-	O	
33	78	O	
34	.	O	

1	Ovaries	O	
2	of	O	
3	10	O	
4	animals	O	
5	per	O	
6	group	O	
7	from	O	
8	16	O	
9	studies	O	
10	in	O	
11	CD	O	
12	-	O	
13	1	O	
14	mice	O	
15	and	O	
16	1	O	
17	study	O	
18	each	O	
19	in	O	
20	C3H	O	
21	and	O	
22	C57BL	O	
23	/	O	
24	6	O	
25	mice	O	
26	were	O	
27	sectioned	O	
28	serially	O	
29	at	O	
30	6	O	
31	microm	O	
32	.	O	

1	The	O	
2	morphological	O	
3	effects	O	
4	of	O	
5	two	O	
6	snake	O	
7	venoms	O	
8	,	O	
9	N	O	
10	.	O	
11	naja	O	
12	and	O	
13	A	O	
14	.	O	
15	piscivorus	O	
16	,	O	
17	and	O	
18	of	O	
19	the	O	
20	Direct	B	
21	Lytic	I	
22	Factor	I	
23	and	O	
24	Phospholipase	B	
25	-	I	
26	A	I	
27	,	O	
28	compounds	O	
29	purified	O	
30	from	O	
31	N	O	
32	.	O	
33	naja	O	
34	crude	O	
35	venom	O	
36	,	O	
37	were	O	
38	investigated	O	
39	on	O	
40	lung	O	
41	and	O	
42	cremaster	O	
43	vessels	O	
44	of	O	
45	rats	O	
46	.	O	

1	We	O	
2	also	O	
3	identify	O	
4	several	O	
5	regulatory	O	
6	domain	O	
7	mutants	O	
8	in	O	
9	which	O	
10	Cd	O	
11	(	O	
12	2	O	
13	+)	O	
14	tolerance	O	
15	of	O	
16	the	O	
17	mutant	O	
18	strain	O	
19	and	O	
20	transport	O	
21	activity	O	
22	of	O	
23	the	O	
24	protein	O	
25	are	O	
26	dissociated	O	
27	.	O	

1	Depletion	O	
2	of	O	
3	dopamine	O	
4	in	O	
5	the	O	
6	nucleus	O	
7	accumbens	O	
8	led	O	
9	to	O	
10	a	O	
11	dramatic	O	
12	shift	O	
13	in	O	
14	behavior	O	
15	in	O	
16	which	O	
17	there	O	
18	was	O	
19	a	O	
20	significant	O	
21	decrease	O	
22	in	O	
23	lever	O	
24	pressing	O	
25	but	O	
26	a	O	
27	significant	O	
28	increase	O	
29	in	O	
30	consumption	O	
31	of	O	
32	lab	O	
33	chow	O	
34	.	O	

1	Interaction	O	
2	of	O	
3	Ets	B	
4	-	I	
5	1	I	
6	and	O	
7	the	O	
8	POU	B	
9	-	I	
10	homeodomain	I	
11	protein	I	
12	GHF	I	
13	-	I	
14	1	I	
15	/	O	
16	Pit	B	
17	-	I	
18	1	I	
19	reconstitutes	O	
20	pituitary	O	
21	-	O	
22	specific	O	
23	gene	O	
24	expression	O	
25	.	O	

1	The	O	
2	DNA	O	
3	binding	O	
4	activities	O	
5	of	O	
6	the	O	
7	three	O	
8	repressor	O	
9	preparations	O	
10	were	O	
11	studied	O	
12	using	O	
13	fragments	O	
14	containing	O	
15	CIRs	O	
16	(	O	
17	CIR3	O	
18	-	O	
19	CIR6	O	
20	)	O	
21	from	O	
22	the	O	
23	essential	O	
24	early	O	
25	region	O	
26	as	O	
27	templates	O	
28	for	O	
29	DNase	B	
30	I	I	
31	footprinting	O	
32	.	O	

1	This	O	
2	in	O	
3	turn	O	
4	will	O	
5	further	O	
6	enhance	O	
7	the	O	
8	role	O	
9	of	O	
10	meta	O	
11	-	O	
12	analysis	O	
13	in	O	
14	helping	O	
15	clinicians	O	
16	and	O	
17	policy	O	
18	makers	O	
19	answer	O	
20	clinical	O	
21	questions	O	
22	.	O	

1	Mouse	B	
2	growth	I	
3	hormone	I	
4	transcription	I	
5	factor	I	
6	Zn	I	
7	-	I	
8	16	I	
9	:	O	
10	unique	O	
11	bipartite	O	
12	structure	O	
13	containing	O	
14	tandemly	O	
15	repeated	O	
16	zinc	O	
17	finger	O	
18	domains	O	
19	not	O	
20	reported	O	
21	in	O	
22	rat	B	
23	Zn	I	
24	-	I	
25	15	I	
26	.	O	

1	We	O	
2	have	O	
3	earlier	O	
4	evolved	O	
5	an	O	
6	experimental	O	
7	model	O	
8	by	O	
9	means	O	
10	of	O	
11	which	O	
12	changes	O	
13	identical	O	
14	to	O	
15	the	O	
16	microembolism	O	
17	syndrome	O	
18	can	O	
19	be	O	
20	induced	O	
21	from	O	
22	a	O	
23	reproducible	O	
24	musculo	O	
25	-	O	
26	skeletal	O	
27	trauma	O	
28	in	O	
29	pigs	O	
30	observed	O	
31	under	O	
32	long	O	
33	-	O	
34	term	O	
35	anesthesia	O	
36	under	O	
37	standardized	O	
38	conditions	O	
39	.	O	

1	Cross	O	
2	-	O	
3	reaction	O	
4	between	O	
5	a	O	
6	monoclonal	O	
7	antibody	O	
8	and	O	
9	two	O	
10	alpha	B	
11	beta	I	
12	T	I	
13	cell	I	
14	receptors	I	
15	.	O	

1	The	O	
2	hormonal	O	
3	response	O	
4	to	O	
5	a	O	
6	standardized	O	
7	bicycle	O	
8	exercise	O	
9	test	O	
10	was	O	
11	studied	O	
12	in	O	
13	11	O	
14	male	O	
15	cadets	O	
16	exposed	O	
17	to	O	
18	a	O	
19	course	O	
20	of	O	
21	107	O	
22	h	O	
23	of	O	
24	continuous	O	
25	activity	O	
26	with	O	
27	less	O	
28	than	O	
29	2	O	
30	h	O	
31	sleep	O	
32	.	O	

1	Investigations	O	
2	using	O	
3	hippocampal	O	
4	slices	O	
5	maintained	O	
6	in	O	
7	vitro	O	
8	have	O	
9	demonstrated	O	
10	that	O	
11	bursts	O	
12	of	O	
13	oscillatory	O	
14	field	O	
15	potentials	O	
16	in	O	
17	the	O	
18	gamma	O	
19	frequency	O	
20	range	O	
21	(	O	
22	30	O	
23	-	O	
24	80	O	
25	Hz	O	
26	)	O	
27	are	O	
28	followed	O	
29	by	O	
30	a	O	
31	slower	O	
32	oscillation	O	
33	in	O	
34	the	O	
35	beta	O	
36	1	O	
37	range	O	
38	(	O	
39	12	O	
40	-	O	
41	20	O	
42	Hz	O	
43	).	O	

1	Patients	O	
2	receiving	O	
3	VPA	O	
4	showed	O	
5	differences	O	
6	in	O	
7	attention	O	
8	,	O	
9	visuomotor	O	
10	performance	O	
11	,	O	
12	verbal	O	
13	span	O	
14	and	O	
15	sensory	O	
16	discrimination	O	
17	tasks	O	
18	at	O	
19	T1	O	
20	,	O	
21	in	O	
22	visuomotor	O	
23	performance	O	
24	at	O	
25	T2	O	
26	and	O	
27	in	O	
28	spatial	O	
29	span	O	
30	at	O	
31	T3	O	
32	,	O	
33	whereas	O	
34	no	O	
35	differences	O	
36	were	O	
37	detected	O	
38	at	O	
39	T4	O	
40	.	O	

1	SvO2	O	
2	can	O	
3	be	O	
4	determined	O	
5	in	O	
6	vitro	O	
7	and	O	
8	in	O	
9	vivo	O	
10	.	O	

1	The	O	
2	only	O	
3	isolate	O	
4	of	O	
5	Aeromonas	O	
6	hydrophila	O	
7	produced	O	
8	cytotoxic	O	
9	enterotoxin	O	
10	and	O	
11	was	O	
12	invasive	O	
13	.	O	

1	We	O	
2	conclude	O	
3	that	O	
4	(	O	
5	i	O	
6	)	O	
7	we	O	
8	have	O	
9	identified	O	
10	several	O	
11	candidate	O	
12	latency	O	
13	genes	O	
14	of	O	
15	murine	O	
16	gammaHV68	O	
17	,	O	
18	(	O	
19	ii	O	
20	)	O	
21	expression	O	
22	of	O	
23	genes	O	
24	during	O	
25	latency	O	
26	may	O	
27	be	O	
28	different	O	
29	in	O	
30	different	O	
31	organs	O	
32	,	O	
33	consistent	O	
34	with	O	
35	multiple	O	
36	latency	O	
37	programs	O	
38	and	O	
39	/	O	
40	or	O	
41	multiple	O	
42	cellular	O	
43	sites	O	
44	of	O	
45	latency	O	
46	,	O	
47	and	O	
48	(	O	
49	iii	O	
50	)	O	
51	regions	O	
52	of	O	
53	the	O	
54	viral	O	
55	genome	O	
56	(	O	
57	v	B	
58	-	I	
59	bcl	I	
60	-	I	
61	2	I	
62	gene	I	
63	,	O	
64	v	B	
65	-	I	
66	GCR	I	
67	gene	I	
68	,	O	
69	and	O	
70	gene	B	
71	73	I	
72	)	O	
73	are	O	
74	transcribed	O	
75	during	O	
76	latency	O	
77	with	O	
78	both	O	
79	gammaHV68	O	
80	and	O	
81	primate	O	
82	gammaherpesviruses	O	
83	.	O	

1	A	O	
2	deletion	O	
3	series	O	
4	of	O	
5	the	O	
6	5	O	
7	'	O	
8	flanking	O	
9	region	O	
10	was	O	
11	created	O	
12	from	O	
13	position	O	
14	-	O	
15	1329	O	
16	to	O	
17	-	O	
18	74	O	
19	relative	O	
20	to	O	
21	the	O	
22	transcriptional	O	
23	initiation	O	
24	site	O	
25	and	O	
26	similarly	O	
27	examined	O	
28	in	O	
29	transgenic	O	
30	tobacco	O	
31	.	O	

1	A	O	
2	comparison	O	
3	of	O	
4	the	O	
5	amino	O	
6	acid	O	
7	sequence	O	
8	of	O	
9	the	O	
10	T	O	
11	.	O	
12	thermophilus	O	
13	enzyme	O	
14	with	O	
15	that	O	
16	of	O	
17	the	O	
18	Escherichia	O	
19	coli	O	
20	enzyme	O	
21	showed	O	
22	(	O	
23	i	O	
24	)	O	
25	a	O	
26	37	O	
27	%	O	
28	overall	O	
29	similarity	O	
30	;	O	
31	(	O	
32	ii	O	
33	)	O	
34	the	O	
35	conservation	O	
36	of	O	
37	the	O	
38	Ser	O	
39	residue	O	
40	,	O	
41	which	O	
42	is	O	
43	known	O	
44	to	O	
45	be	O	
46	phosphorylated	O	
47	in	O	
48	the	O	
49	E	O	
50	.	O	
51	coli	O	
52	enzyme	O	
53	,	O	
54	and	O	
55	of	O	
56	the	O	
57	surrounding	O	
58	sequence	O	
59	;	O	
60	and	O	
61	(	O	
62	iii	O	
63	)	O	
64	the	O	
65	presence	O	
66	of	O	
67	141	O	
68	extra	O	
69	residues	O	
70	at	O	
71	the	O	
72	C	O	
73	terminus	O	
74	of	O	
75	the	O	
76	T	O	
77	.	O	
78	thermophilus	O	
79	enzyme	O	
80	.	O	

1	Following	O	
2	seven	O	
3	days	O	
4	'	O	
5	incubation	O	
6	both	O	
7	at	O	
8	20	O	
9	degrees	O	
10	C	O	
11	and	O	
12	28	O	
13	degrees	O	
14	C	O	
15	,	O	
16	Ae	O	
17	.	O	
18	vexans	O	
19	nip	O	
20	.	O	
21	was	O	
22	capable	O	
23	of	O	
24	transmitting	O	
25	the	O	
26	virus	O	
27	.	O	

1	Primers	O	
2	for	O	
3	subsequent	O	
4	rounds	O	
5	of	O	
6	RACE	O	
7	were	O	
8	designed	O	
9	from	O	
10	the	O	
11	5	O	
12	'-	O	
13	ends	O	
14	of	O	
15	amplified	O	
16	RACE	O	
17	products	O	
18	.	O	

1	Primary	O	
2	infection	O	
3	is	O	
4	usually	O	
5	managed	O	
6	conservatively	O	
7	.	O	

1	A	O	
2	sharp	O	
3	outbreak	O	
4	of	O	
5	influenza	O	
6	A	O	
7	occurred	O	
8	on	O	
9	the	O	
10	base	O	
11	during	O	
12	February	O	
13	that	O	
14	was	O	
15	due	O	
16	to	O	
17	an	O	
18	A	O	
19	/	O	
20	Texas	O	
21	/	O	
22	1	O	
23	/	O	
24	77	O	
25	-	O	
26	like	O	
27	virus	O	
28	,	O	
29	a	O	
30	variant	O	
31	of	O	
32	the	O	
33	A	O	
34	/	O	
35	Victoria	O	
36	/	O	
37	3	O	
38	/	O	
39	75	O	
40	prototpye	O	
41	.	O	

1	Using	O	
2	transgenic	O	
3	Xenopus	O	
4	embryos	O	
5	,	O	
6	we	O	
7	demonstrate	O	
8	that	O	
9	the	O	
10	integrity	O	
11	of	O	
12	these	O	
13	two	O	
14	sequences	O	
15	is	O	
16	necessary	O	
17	for	O	
18	correct	O	
19	spatial	O	
20	expression	O	
21	of	O	
22	a	O	
23	Xbra2	B	
24	promoter	I	
25	-	I	
26	driven	I	
27	reporter	I	
28	gene	I	
29	.	O	

1	Primary	O	
2	adrenal	O	
3	hypersensitivity	O	
4	to	O	
5	ACTH	B	
6	drive	O	
7	in	O	
8	obesity	O	
9	has	O	
10	also	O	
11	been	O	
12	suggested	O	
13	.	O	

1	Escherichia	O	
2	coli	O	
3	JRG582	O	
4	is	O	
5	an	O	
6	ampD	B	
7	ampE	I	
8	deletion	O	
9	derivative	O	
10	of	O	
11	strain	O	
12	HfrH	O	
13	and	O	
14	accordingly	O	
15	it	O	
16	is	O	
17	derepressed	O	
18	for	O	
19	expression	O	
20	of	O	
21	the	O	
22	cloned	O	
23	inducible	O	
24	beta	B	
25	-	I	
26	lactamase	I	
27	gene	I	
28	of	O	
29	Citrobacter	O	
30	freundii	O	
31	,	O	
32	carried	O	
33	on	O	
34	plasmid	O	
35	pNU305	O	
36	.	O	

1	We	O	
2	have	O	
3	examined	O	
4	the	O	
5	regulation	O	
6	of	O	
7	the	O	
8	FGFR	B	
9	-	I	
10	1	I	
11	gene	I	
12	(	O	
13	cek	B	
14	-	I	
15	1	I	
16	)	O	
17	in	O	
18	avian	O	
19	myogenic	O	
20	cultures	O	
21	by	O	
22	immunocytochemistry	O	
23	and	O	
24	Northern	O	
25	blot	O	
26	analysis	O	
27	.	O	

1	These	O	
2	results	O	
3	indicate	O	
4	a	O	
5	possible	O	
6	involvement	O	
7	of	O	
8	endogenous	O	
9	opioid	O	
10	peptides	O	
11	in	O	
12	the	O	
13	cardiac	O	
14	effects	O	
15	due	O	
16	to	O	
17	myocardial	O	
18	ischaemia	O	
19	and	O	
20	reperfusion	O	
21	,	O	
22	mediated	O	
23	by	O	
24	opiate	B	
25	receptors	I	
26	through	O	
27	opiate	O	
28	antagonism	O	
29	.	O	

1	Although	O	
2	the	O	
3	fertility	O	
4	decline	O	
5	in	O	
6	the	O	
7	black	O	
8	population	O	
9	in	O	
10	the	O	
11	Mississippi	O	
12	Delta	O	
13	between	O	
14	the	O	
15	late	O	
16	1870	O	
17	'	O	
18	s	O	
19	and	O	
20	early	O	
21	1930	O	
22	'	O	
23	s	O	
24	closely	O	
25	paralleled	O	
26	that	O	
27	of	O	
28	the	O	
29	national	O	
30	black	O	
31	population	O	
32	,	O	
33	it	O	
34	rose	O	
35	much	O	
36	more	O	
37	dramatically	O	
38	in	O	
39	the	O	
40	1940	O	
41	'	O	
42	s	O	
43	and	O	
44	1950	O	
45	'	O	
46	s	O	
47	to	O	
48	almost	O	
49	1880	O	
50	levels	O	
51	.	O	

1	Cloning	O	
2	of	O	
3	individual	O	
4	ZI	O	
5	domains	O	
6	upstream	O	
7	of	O	
8	a	O	
9	minimal	O	
10	promoter	O	
11	demonstrated	O	
12	that	O	
13	the	O	
14	ZIA	O	
15	,	O	
16	ZIC	O	
17	,	O	
18	and	O	
19	ZID	O	
20	domains	O	
21	,	O	
22	but	O	
23	not	O	
24	the	O	
25	ZIB	O	
26	domain	O	
27	,	O	
28	are	O	
29	TPA	O	
30	responsive	O	
31	.	O	

1	Demographic	O	
2	characteristics	O	
3	and	O	
4	risk	O	
5	factor	O	
6	data	O	
7	for	O	
8	76	O	
9	,	O	
10	672	O	
11	clients	O	
12	were	O	
13	studied	O	
14	to	O	
15	characterize	O	
16	the	O	
17	distribution	O	
18	of	O	
19	infection	O	
20	with	O	
21	human	O	
22	immunodeficiency	O	
23	virus	O	
24	(	O	
25	HIV	O	
26	)	O	
27	and	O	
28	the	O	
29	use	O	
30	of	O	
31	counseling	O	
32	and	O	
33	testing	O	
34	facilities	O	
35	in	O	
36	Houston	O	
37	,	O	
38	Tex	O	
39	.	O	

1	Interestingly	O	
2	,	O	
3	an	O	
4	increase	O	
5	of	O	
6	distance	O	
7	per	O	
8	se	O	
9	did	O	
10	not	O	
11	have	O	
12	a	O	
13	deleterious	O	
14	effect	O	
15	on	O	
16	translation	O	
17	efficiency	O	
18	.	O	

1	Effects	O	
2	of	O	
3	methylene	O	
4	chloride	O	
5	,	O	
6	trichloroethane	O	
7	,	O	
8	trichloroethylene	O	
9	,	O	
10	tetrachloroethylene	O	
11	and	O	
12	toluene	O	
13	on	O	
14	the	O	
15	development	O	
16	of	O	
17	chick	O	
18	embryos	O	
19	.	O	

1	CONCLUSION	O	
2	:	O	
3	These	O	
4	results	O	
5	suggest	O	
6	that	O	
7	vibration	O	
8	-	O	
9	induced	O	
10	neural	O	
11	involvement	O	
12	can	O	
13	be	O	
14	considered	O	
15	neither	O	
16	pure	O	
17	digital	O	
18	neuropathy	O	
19	,	O	
20	nor	O	
21	definite	O	
22	CTS	O	
23	,	O	
24	as	O	
25	previously	O	
26	described	O	
27	.	O	

1	Reversal	O	
2	of	O	
3	the	O	
4	increase	O	
5	in	O	
6	apomorphine	O	
7	-	O	
8	induced	O	
9	stereotypy	O	
10	and	O	
11	aggression	O	
12	in	O	
13	REM	O	
14	sleep	O	
15	deprived	O	
16	rats	O	
17	by	O	
18	dopamine	O	
19	agonist	O	
20	pretreatments	O	
21	.	O	

1	In	O	
2	the	O	
3	work	O	
4	reported	O	
5	here	O	
6	,	O	
7	we	O	
8	used	O	
9	peptide	O	
10	mapping	O	
11	,	O	
12	mass	O	
13	spectrometry	O	
14	,	O	
15	and	O	
16	site	O	
17	-	O	
18	directed	O	
19	mutagenesis	O	
20	to	O	
21	identify	O	
22	two	O	
23	sets	O	
24	of	O	
25	pAP	B	
26	phosphorylation	O	
27	sites	O	
28	.	O	

1	Data	O	
2	from	O	
3	119	O	
4	men	O	
5	and	O	
6	40	O	
7	women	O	
8	undergoing	O	
9	coronary	O	
10	angiography	O	
11	provide	O	
12	an	O	
13	opportunity	O	
14	to	O	
15	compare	O	
16	these	O	
17	associations	O	
18	in	O	
19	relation	O	
20	to	O	
21	a	O	
22	direct	O	
23	and	O	
24	continuous	O	
25	measure	O	
26	of	O	
27	atherosclerosis	O	
28	while	O	
29	controlling	O	
30	for	O	
31	age	O	
32	,	O	
33	sex	O	
34	,	O	
35	income	O	
36	,	O	
37	hypertension	O	
38	,	O	
39	serum	O	
40	cholesterol	O	
41	,	O	
42	smoking	O	
43	,	O	
44	angina	O	
45	,	O	
46	diabetes	O	
47	,	O	
48	family	O	
49	history	O	
50	of	O	
51	heart	O	
52	disease	O	
53	,	O	
54	Type	O	
55	A	O	
56	behavior	O	
57	pattern	O	
58	,	O	
59	and	O	
60	hostility	O	
61	.	O	

1	Optima	O	
2	)	O	
3	genomic	O	
4	library	O	
5	by	O	
6	hybridizing	O	
7	with	O	
8	elicitor	O	
9	-	O	
10	induced	O	
11	stilbene	B	
12	synthase	I	
13	cDNA	I	
14	as	O	
15	a	O	
16	probe	O	
17	.	O	

1	The	O	
2	resurgence	O	
3	of	O	
4	drug	O	
5	-	O	
6	resistant	O	
7	malaria	O	
8	makes	O	
9	urgent	O	
10	the	O	
11	evaluation	O	
12	of	O	
13	new	O	
14	antimalarial	O	
15	agents	O	
16	.	O	

1	Transient	O	
2	hyperammonaemia	O	
3	in	O	
4	an	O	
5	adult	O	
6	German	O	
7	shepherd	O	
8	dog	O	
9	.	O	

1	We	O	
2	established	O	
3	that	O	
4	the	O	
5	2	O	
6	.	O	
7	6	O	
8	kb	O	
9	mRNA	O	
10	V	O	
11	-	O	
12	1	O	
13	and	O	
14	the	O	
15	2	O	
16	.	O	
17	3	O	
18	kb	O	
19	GGT	B	
20	mRNA	O	
21	V	O	
22	-	O	
23	2	O	
24	derive	O	
25	,	O	
26	by	O	
27	alternate	O	
28	splicing	O	
29	,	O	
30	from	O	
31	a	O	
32	primary	O	
33	transcript	O	
34	initiated	O	
35	on	O	
36	a	O	
37	distal	O	
38	promoter	O	
39	on	O	
40	the	O	
41	rat	B	
42	GGT	I	
43	gene	I	
44	.	O	

1	The	O	
2	novel	O	
3	hematopoietic	B	
4	growth	I	
5	factor	I	
6	FLT3	I	
7	ligand	I	
8	(	O	
9	FL	B	
10	)	O	
11	is	O	
12	the	O	
13	cognate	O	
14	ligand	O	
15	for	O	
16	the	O	
17	FLT3	B	
18	,	O	
19	tyrosine	B	
20	kinase	I	
21	receptor	I	
22	(	O	
23	R	B	
24	),	O	
25	also	O	
26	referred	O	
27	to	O	
28	as	O	
29	FLK	B	
30	-	I	
31	2	I	
32	and	O	
33	STK	B	
34	-	I	
35	1	I	
36	.	O	

1	The	O	
2	N	O	
3	-	O	
4	terminal	O	
5	domain	O	
6	of	O	
7	approximately	O	
8	70	O	
9	kDa	O	
10	exhibits	O	
11	11	O	
12	imperfect	O	
13	amino	O	
14	acid	O	
15	repeats	O	
16	that	O	
17	show	O	
18	some	O	
19	homology	O	
20	to	O	
21	promastigote	O	
22	surface	O	
23	glycoproteins	O	
24	of	O	
25	the	O	
26	psa2	B	
27	/	O	
28	gp46	B	
29	complex	O	
30	.	O	

1	In	O	
2	fact	O	
3	,	O	
4	families	O	
5	of	O	
6	polypeptides	O	
7	were	O	
8	produced	O	
9	by	O	
10	initiation	O	
11	of	O	
12	translation	O	
13	at	O	
14	AUG	O	
15	codons	O	
16	within	O	
17	sequences	O	
18	coding	O	
19	for	O	
20	VP1	B	
21	and	O	
22	T	B	
23	,	O	
24	presumably	O	
25	as	O	
26	a	O	
27	result	O	
28	of	O	
29	transcription	O	
30	initiation	O	
31	events	O	
32	that	O	
33	generated	O	
34	5	O	
35	'	O	
36	ends	O	
37	immediately	O	
38	upstream	O	
39	from	O	
40	these	O	
41	AUGs	O	
42	.	O	

1	Regional	O	
2	CBF	O	
3	was	O	
4	determined	O	
5	by	O	
6	clearance	O	
7	of	O	
8	xenon	O	
9	133	O	
10	in	O	
11	67	O	
12	patients	O	
13	undergoing	O	
14	coronary	O	
15	bypass	O	
16	grafting	O	
17	procedures	O	
18	.	O	

1	Serodiagnosis	O	
2	of	O	
3	ectromelia	O	
4	in	O	
5	laboratory	O	
6	mice	O	

1	The	O	
2	results	O	
3	of	O	
4	these	O	
5	analyses	O	
6	indicate	O	
7	that	O	
8	the	O	
9	proteinase	O	
10	cleaves	O	
11	at	O	
12	amino	O	
13	acid	O	
14	residues	O	
15	E960	O	
16	-	O	
17	A961	O	
18	,	O	
19	E1071	O	
20	-	O	
21	S1072	O	
22	,	O	
23	E1345	O	
24	-	O	
25	T1346	O	
26	,	O	
27	and	O	
28	E1419	O	
29	-	O	
30	G1420	O	
31	;	O	
32	however	O	
33	,	O	
34	the	O	
35	cleavage	O	
36	efficiency	O	
37	is	O	
38	varied	O	
39	.	O	

1	This	O	
2	sequence	O	
3	also	O	
4	confers	O	
5	VDR	B	
6	and	O	
7	vitamin	O	
8	D	O	
9	responsiveness	O	
10	to	O	
11	a	O	
12	heterologous	O	
13	promoter	O	
14	.	O	

1	At	O	
2	4	O	
3	wk	O	
4	however	O	
5	,	O	
6	tumor	O	
7	relapse	O	
8	was	O	
9	noted	O	
10	in	O	
11	6	O	
12	of	O	
13	7	O	
14	group	O	
15	4	O	
16	responders	O	
17	,	O	
18	10	O	
19	of	O	
20	12	O	
21	in	O	
22	group	O	
23	5	O	
24	,	O	
25	13	O	
26	of	O	
27	16	O	
28	in	O	
29	group	O	
30	7	O	
31	,	O	
32	but	O	
33	only	O	
34	4	O	
35	of	O	
36	19	O	
37	group	O	
38	8	O	
39	responders	O	
40	(	O	
41	p	O	
42	less	O	
43	than	O	
44	.	O	
45	001	O	
46	group	O	
47	8	O	
48	versus	O	
49	4	O	
50	,	O	
51	5	O	
52	,	O	
53	7	O	
54	).	O	

1	A	O	
2	5	O	
3	.	O	
4	0	O	
5	-	O	
6	kb	O	
7	transcript	O	
8	detected	O	
9	by	O	
10	the	O	
11	differential	O	
12	display	O	
13	amplicon	O	
14	3G1	O	
15	was	O	
16	found	O	
17	to	O	
18	correlate	O	
19	strongly	O	
20	with	O	
21	RAG1	B	
22	mRNA	I	
23	expression	O	
24	in	O	
25	various	O	
26	human	O	
27	cell	O	
28	lines	O	
29	.	O	

1	They	O	
2	include	O	
3	genes	O	
4	encoding	O	
5	three	O	
6	subunits	O	
7	of	O	
8	the	O	
9	cytochrome	B	
10	oxidase	I	
11	(	O	
12	cox1	B	
13	to	I	
14	3	I	
15	),	O	
16	apocytochrome	B	
17	b	I	
18	(	O	
19	cob	B	
20	),	O	
21	seven	O	
22	subunits	O	
23	of	O	
24	the	O	
25	NADH	B	
26	dehydrogenase	I	
27	complex	I	
28	(	O	
29	nad1	B	
30	to	I	
31	6	I	
32	,	O	
33	nad4L	B	
34	),	O	
35	two	O	
36	ATPase	B	
37	subunits	O	
38	(	O	
39	atp6	B	
40	and	O	
41	atp9	B	
42	),	O	
43	three	O	
44	ribosomal	O	
45	RNAs	O	
46	(	O	
47	rrn5	B	
48	,	O	
49	srn	B	
50	and	O	
51	lrn	B	
52	),	O	
53	23	O	
54	tRNAs	O	
55	and	O	
56	four	O	
57	ribosomal	O	
58	proteins	O	
59	(	O	
60	rps3	B	
61	,	O	
62	rps11	B	
63	,	O	
64	rps12	B	
65	and	O	
66	rpl16	B	
67	).	O	

1	Northern	O	
2	blot	O	
3	analysis	O	
4	of	O	
5	total	O	
6	cellular	O	
7	RNA	O	
8	indicated	O	
9	that	O	
10	xylP	B	
11	encodes	O	
12	a	O	
13	1	O	
14	.	O	
15	3	O	
16	-	O	
17	kb	O	
18	transcript	O	
19	which	O	
20	is	O	
21	induced	O	
22	by	O	
23	xylan	O	
24	.	O	

1	One	O	
2	R	O	
3	-	O	
4	EST	O	
5	and	O	
6	one	O	
7	Pto	B	
8	-	I	
9	like	I	
10	sequence	I	
11	each	O	
12	mapped	O	
13	to	O	
14	two	O	
15	locations	O	
16	.	O	

1	These	O	
2	results	O	
3	suggest	O	
4	that	O	
5	VP1	B	
6	was	O	
7	efficiently	O	
8	transported	O	
9	to	O	
10	the	O	
11	nucleus	O	
12	and	O	
13	localized	O	
14	in	O	
15	the	O	
16	discrete	O	
17	subnuclear	O	
18	regions	O	
19	,	O	
20	possibly	O	
21	with	O	
22	VP2	B	
23	and	O	
24	VP3	B	
25	.	O	

1	NIK	O	
2	-	O	
3	244	O	
4	suppressed	O	
5	coronary	O	
6	ligation	O	
7	-	O	
8	and	O	
9	digitalis	O	
10	-	O	
11	induced	O	
12	arrhythmias	O	
13	,	O	
14	and	O	
15	the	O	
16	minimum	O	
17	effective	O	
18	plasma	O	
19	concentrations	O	
20	for	O	
21	arrhythmias	O	
22	induced	O	
23	by	O	
24	24	O	
25	-	O	
26	h	O	
27	and	O	
28	48	O	
29	-	O	
30	h	O	
31	coronary	O	
32	ligation	O	
33	and	O	
34	digitalis	O	
35	were	O	
36	0	O	
37	.	O	
38	41	O	
39	+/-	O	
40	0	O	
41	.	O	
42	10	O	
43	(	O	
44	by	O	
45	1	O	
46	mg	O	
47	/	O	
48	kg	O	
49	i	O	
50	.	O	
51	v	O	
52	.),	O	
53	0	O	
54	.	O	
55	70	O	
56	+/-	O	
57	0	O	
58	.	O	
59	13	O	
60	(	O	
61	by	O	
62	1	O	
63	mg	O	
64	/	O	
65	kg	O	
66	i	O	
67	.	O	
68	v	O	
69	.),	O	
70	and	O	
71	0	O	
72	.	O	
73	21	O	
74	+/-	O	
75	0	O	
76	.	O	
77	08	O	
78	(	O	
79	by	O	
80	0	O	
81	.	O	
82	5	O	
83	mg	O	
84	/	O	
85	kg	O	
86	i	O	
87	.	O	
88	v	O	
89	.)	O	
90	microgram	O	
91	/	O	
92	ml	O	
93	,	O	
94	respectively	O	
95	(	O	
96	mean	O	
97	+/-	O	
98	SD	O	
99	of	O	
100	the	O	
101	mean	O	
102	,	O	
103	n	O	
104	=	O	
105	6	O	
106	).	O	

1	The	O	
2	initial	O	
3	translation	O	
4	protein	O	
5	encoded	O	
6	by	O	
7	the	O	
8	cDNA	O	
9	is	O	
10	53	O	
11	,	O	
12	932	O	
13	kDa	O	
14	and	O	
15	possesses	O	
16	a	O	
17	hydrophilic	O	
18	amino	O	
19	acid	O	
20	composition	O	
21	with	O	
22	glutamic	O	
23	acid	O	
24	comprising	O	
25	22	O	
26	%	O	
27	of	O	
28	the	O	
29	total	O	
30	amino	O	
31	acid	O	
32	residues	O	
33	.	O	

1	The	O	
2	human	O	
3	coreceptor	O	
4	was	O	
5	as	O	
6	active	O	
7	as	O	
8	the	O	
9	simian	O	
10	for	O	
11	SIV	O	
12	entry	O	
13	.	O	

1	Gonadal	O	
2	dysfunction	O	
3	in	O	
4	patients	O	
5	with	O	
6	ataxia	O	
7	telangiectasia	O	
8	.	O	

1	These	O	
2	two	O	
3	contigs	O	
4	contain	O	
5	a	O	
6	total	O	
7	of	O	
8	163	O	
9	open	O	
10	reading	O	
11	frames	O	
12	(	O	
13	ORFs	O	
14	)	O	
15	in	O	
16	26	O	
17	-	O	
18	29	O	
19	putative	O	
20	operons	O	
21	;	O	
22	56	O	
23	ORFs	O	
24	could	O	
25	be	O	
26	identified	O	
27	with	O	
28	reasonable	O	
29	certainty	O	
30	.	O	

1	Ang	B	
2	II	I	
3	-	O	
4	induced	O	
5	fibronectin	B	
6	mRNA	O	
7	was	O	
8	not	O	
9	affected	O	
10	by	O	
11	PKC	B	
12	inhibitors	O	
13	or	O	
14	PKC	B	
15	depletion	O	
16	,	O	
17	whereas	O	
18	specific	O	
19	inhibition	O	
20	of	O	
21	EGF	B	
22	-	I	
23	R	I	
24	function	O	
25	by	O	
26	a	O	
27	dominant	B	
28	negative	I	
29	EGF	I	
30	-	I	
31	R	I	
32	mutant	I	
33	and	O	
34	tyrphostin	O	
35	AG1478	O	
36	abolished	O	
37	induction	O	
38	of	O	
39	fibronectin	B	
40	mRNA	I	
41	.	O	

1	Ovulation	O	
2	was	O	
3	induced	O	
4	in	O	
5	8	O	
6	(	O	
7	56	O	
8	.	O	
9	7	O	
10	%)	O	
11	patients	O	
12	who	O	
13	conceived	O	
14	.	O	

1	Based	O	
2	on	O	
3	these	O	
4	data	O	
5	,	O	
6	we	O	
7	conclude	O	
8	that	O	
9	transcription	O	
10	of	O	
11	prgX	B	
12	is	O	
13	initiated	O	
14	from	O	
15	the	O	
16	Qa	B	
17	promoter	I	
18	in	O	
19	prgQ	B	
20	,	O	
21	and	O	
22	PrgX	B	
23	autoregulates	O	
24	its	O	
25	transcription	O	
26	either	O	
27	by	O	
28	mediating	O	
29	transcriptional	O	
30	readthrough	O	
31	or	O	
32	increasing	O	
33	mRNA	O	
34	stability	O	
35	.	O	

1	National	O	
2	abortion	O	
3	laws	O	
4	usually	O	
5	do	O	
6	not	O	
7	allow	O	
8	abortion	O	
9	when	O	
10	a	O	
11	foetus	O	
12	is	O	
13	independently	O	
14	viable	O	
15	,	O	
16	i	O	
17	.	O	
18	e	O	
19	.	O	
20	from	O	
21	a	O	
22	gestational	O	
23	age	O	
24	of	O	
25	about	O	
26	24	O	
27	weeks	O	
28	.	O	

1	High	O	
2	-	O	
3	resolution	O	
4	structure	O	
5	of	O	
6	the	O	
7	diphtheria	B	
8	toxin	I	
9	repressor	I	
10	complexed	O	
11	with	O	
12	cobalt	O	
13	and	O	
14	manganese	O	
15	reveals	O	
16	an	O	
17	SH3	B	
18	-	I	
19	like	I	
20	third	O	
21	domain	O	
22	and	O	
23	suggests	O	
24	a	O	
25	possible	O	
26	role	O	
27	of	O	
28	phosphate	O	
29	as	O	
30	co	O	
31	-	O	
32	corepressor	O	
33	.	O	

1	A	O	
2	safe	O	
3	and	O	
4	simple	O	
5	system	O	
6	for	O	
7	the	O	
8	detection	O	
9	of	O	
10	sudden	O	
11	infant	O	
12	death	O	
13	syndrome	O	
14	(	O	
15	SIDS	O	
16	)	O	
17	is	O	
18	proposed	O	
19	.	O	

1	Nucleotide	O	
2	sequence	O	
3	of	O	
4	DNA	O	
5	controlling	O	
6	expression	O	
7	of	O	
8	genes	O	
9	for	O	
10	maltosaccharide	O	
11	utilization	O	
12	in	O	
13	Streptococcus	O	
14	pneumoniae	O	
15	.	O	

1	OBJECTIVE	O	
2	:	O	
3	To	O	
4	follow	O	
5	-	O	
6	up	O	
7	prospectively	O	
8	patients	O	
9	with	O	
10	arthritis	O	
11	after	O	
12	infection	O	
13	with	O	
14	beta	O	
15	-	O	
16	haemolytic	O	
17	streptococci	O	
18	of	O	
19	Lancefield	O	
20	group	O	
21	A	O	
22	(	O	
23	beta	O	
24	HSA	O	
25	),	O	
26	with	O	
27	emphasis	O	
28	on	O	
29	clinical	O	
30	characteristics	O	
31	and	O	
32	serological	O	
33	features	O	
34	.	O	

1	Felodipine	O	
2	did	O	
3	not	O	
4	alter	O	
5	the	O	
6	baseline	O	
7	FEV1	O	
8	,	O	
9	but	O	
10	showed	O	
11	a	O	
12	small	O	
13	significant	O	
14	inhibitory	O	
15	effect	O	
16	upon	O	
17	histamine	O	
18	and	O	
19	AMP	O	
20	induced	O	
21	bronchoconstriction	O	
22	.	O	

1	Blood	O	
2	eosinophils	O	
3	in	O	
4	patients	O	
5	with	O	
6	Taenia	O	
7	saginata	O	
8	taeniasis	O	
9	.	O	

1	The	O	
2	zona	O	
3	pellucida	O	
4	(	O	
5	ZP	O	
6	),	O	
7	the	O	
8	extracellular	O	
9	glycocalyx	O	
10	that	O	
11	surrounds	O	
12	the	O	
13	oocyte	O	
14	,	O	
15	is	O	
16	well	O	
17	known	O	
18	to	O	
19	mediate	O	
20	homologous	O	
21	gamete	O	
22	interaction	O	
23	.	O	

1	Sodium	O	
2	-	O	
3	taurocholate	O	
4	-	O	
5	induced	O	
6	acute	O	
7	necrotizing	O	
8	pancreatitis	O	
9	does	O	
10	not	O	
11	affect	O	
12	jejunal	O	
13	oxygenation	O	
14	in	O	
15	pigs	O	
16	.	O	

1	Isolation	O	
2	of	O	
3	a	O	
4	novel	O	
5	TP53	B	
6	target	I	
7	gene	I	
8	from	O	
9	a	O	
10	colon	O	
11	cancer	O	
12	cell	O	
13	line	O	
14	carrying	O	
15	a	O	
16	highly	O	
17	regulated	O	
18	wild	B	
19	-	I	
20	type	I	
21	TP53	I	
22	expression	O	
23	system	O	
24	.	O	

1	This	O	
2	sequence	O	
3	possessed	O	
4	homology	O	
5	with	O	
6	a	O	
7	methylation	O	
8	-	O	
9	sensitive	O	
10	promoter	O	
11	element	O	
12	,	O	
13	Enh2	O	
14	,	O	
15	present	O	
16	in	O	
17	the	O	
18	LTR	O	
19	of	O	
20	mouse	O	
21	intractisternal	O	
22	A	O	
23	-	O	
24	particles	O	
25	.	O	

1	The	O	
2	microdensitometric	O	
3	scores	O	
4	and	O	
5	their	O	
6	side	O	
7	-	O	
8	to	O	
9	-	O	
10	side	O	
11	differences	O	
12	in	O	
13	patients	O	
14	correlated	O	
15	negatively	O	
16	with	O	
17	the	O	
18	serum	O	
19	25	O	
20	-	O	
21	OHD	O	
22	concentration	O	
23	and	O	
24	positively	O	
25	with	O	
26	the	O	
27	degree	O	
28	of	O	
29	paralysis	O	
30	.	O	

1	In	O	
2	this	O	
3	respect	O	
4	C	B	
5	reactive	I	
6	protein	I	
7	concentrations	O	
8	are	O	
9	superior	O	
10	to	O	
11	white	O	
12	cell	O	
13	count	O	
14	,	O	
15	erythrocyte	O	
16	sedimentation	O	
17	rate	O	
18	,	O	
19	and	O	
20	temperature	O	
21	and	O	
22	the	O	
23	concentrations	O	
24	of	O	
25	antiproteases	O	
26	.	O	

1	The	O	
2	interleukin	B	
3	2	I	
4	receptor	I	
5	alpha	I	
6	-	I	
7	chain	I	
8	(	O	
9	IL	B	
10	-	I	
11	2R	I	
12	alpha	I	
13	)	O	
14	gene	O	
15	is	O	
16	rapidly	O	
17	and	O	
18	potently	O	
19	induced	O	
20	in	O	
21	T	O	
22	cells	O	
23	in	O	
24	response	O	
25	to	O	
26	mitogenic	O	
27	stimuli	O	
28	.	O	

1	From	O	
2	day	O	
3	30	O	
4	after	O	
5	turnout	O	
6	,	O	
7	the	O	
8	PFB	O	
9	-	O	
10	group	O	
11	had	O	
12	significantly	O	
13	lower	O	
14	serum	B	
15	pepsinogen	I	
16	levels	O	
17	,	O	
18	which	O	
19	reflects	O	
20	the	O	
21	low	O	
22	degree	O	
23	of	O	
24	abomasal	O	
25	damage	O	
26	in	O	
27	these	O	
28	animals	O	
29	.	O	

1	Poly	O	
2	(	O	
3	dT	O	
4	)	O	
5	and	O	
6	denatured	O	
7	calf	O	
8	thymus	O	
9	DNA	O	
10	were	O	
11	more	O	
12	effective	O	
13	than	O	
14	were	O	
15	other	O	
16	polynucleotides	O	
17	tested	O	
18	in	O	
19	promoting	O	
20	accumulation	O	
21	of	O	
22	19	O	
23	HDP	O	
24	*;	O	
25	(	O	
26	dT	O	
27	)	O	
28	8	O	
29	was	O	
30	as	O	
31	effective	O	
32	as	O	
33	were	O	
34	longer	O	
35	molecules	O	
36	of	O	
37	(	O	
38	dT	O	
39	)	O	
40	n	O	
41	,	O	
42	but	O	
43	(	O	
44	dT	O	
45	)	O	
46	4	O	
47	and	O	
48	(	O	
49	dT	O	
50	)	O	
51	6	O	
52	were	O	
53	much	O	
54	less	O	
55	effective	O	
56	,	O	
57	indicating	O	
58	that	O	
59	the	O	
60	binding	O	
61	site	O	
62	involved	O	
63	in	O	
64	19	O	
65	HDP	B	
66	*	I	
67	accumulation	O	
68	covered	O	
69	between	O	
70	6	O	
71	and	O	
72	8	O	
73	residues	O	
74	of	O	
75	(	O	
76	dT	O	
77	)	O	
78	n	O	
79	.	O	

1	Temperature	O	
2	dependence	O	
3	of	O	
4	the	O	
5	sublattice	O	
6	spontaneous	O	
7	magnetization	O	
8	of	O	
9	YBa2Cu3O6	O	
10	.	O	

1	Kodak	O	
2	XV	O	
3	-	O	
4	2	O	
5	film	O	
6	is	O	
7	wrapped	O	
8	around	O	
9	a	O	
10	cylindrical	O	
11	water	O	
12	-	O	
13	filled	O	
14	phantom	O	
15	and	O	
16	the	O	
17	dose	O	
18	distribution	O	
19	is	O	
20	recorded	O	
21	.	O	

1	The	O	
2	majority	O	
3	of	O	
4	MRF	O	
5	units	O	
6	were	O	
7	behaviorally	O	
8	incongruent	O	
9	;	O	
10	in	O	
11	the	O	
12	most	O	
13	frequently	O	
14	observed	O	
15	case	O	
16	,	O	
17	their	O	
18	activity	O	
19	failed	O	
20	to	O	
21	change	O	
22	reliably	O	
23	when	O	
24	behavior	O	
25	habituated	O	
26	.	O	

1	After	O	
2	1	O	
3	.	O	
4	5	O	
5	years	O	
6	of	O	
7	such	O	
8	photoperiodic	O	
9	control	O	
10	,	O	
11	all	O	
12	ewes	O	
13	were	O	
14	blinded	O	
15	by	O	
16	bilateral	O	
17	orbital	O	
18	enucleation	O	
19	.	O	

1	Antibodies	O	
2	directed	O	
3	against	O	
4	the	O	
5	SNM1	B	
6	protein	I	
7	immunoprecipitated	O	
8	RNase	B	
9	MRP	I	
10	RNA	I	
11	from	O	
12	whole	O	
13	-	O	
14	cell	O	
15	extracts	O	
16	without	O	
17	precipitating	O	
18	the	O	
19	structurally	O	
20	and	O	
21	functionally	O	
22	related	O	
23	RNase	B	
24	P	I	
25	RNA	I	
26	.	O	

1	Cardiac	B	
2	myosin	I	
3	-	I	
4	binding	I	
5	protein	I	
6	C	I	
7	(	O	
8	MyBP	B	
9	-	I	
10	C	I	
11	):	O	
12	identification	O	
13	of	O	
14	protein	B	
15	kinase	I	
16	A	I	
17	and	O	
18	protein	B	
19	kinase	I	
20	C	I	
21	phosphorylation	O	
22	sites	O	
23	.	O	

1	CCAAT	B	
2	/	I	
3	enhancer	I	
4	-	I	
5	binding	I	
6	protein	I	
7	isoforms	I	
8	beta	I	
9	and	I	
10	delta	I	
11	are	O	
12	expressed	O	
13	in	O	
14	mammary	O	
15	epithelial	O	
16	cells	O	
17	and	O	
18	bind	O	
19	to	O	
20	multiple	O	
21	sites	O	
22	in	O	
23	the	O	
24	beta	B	
25	-	I	
26	casein	I	
27	gene	I	
28	promoter	I	
29	.	O	

1	The	O	
2	foregoing	O	
3	results	O	
4	show	O	
5	that	O	
6	CXD	O	
7	has	O	
8	high	O	
9	efficacy	O	
10	and	O	
11	safety	O	
12	and	O	
13	it	O	
14	can	O	
15	be	O	
16	said	O	
17	that	O	
18	it	O	
19	is	O	
20	a	O	
21	drug	O	
22	required	O	
23	in	O	
24	the	O	
25	pediatric	O	
26	field	O	
27	.	O	

1	Based	O	
2	on	O	
3	these	O	
4	results	O	
5	,	O	
6	a	O	
7	new	O	
8	model	O	
9	for	O	
10	the	O	
11	regulation	O	
12	of	O	
13	nif	B	
14	/	O	
15	fix	B	
16	gene	O	
17	expression	O	
18	in	O	
19	A	O	
20	.	O	
21	caulinodans	O	
22	is	O	
23	proposed	O	
24	.	O	

1	METHOD	O	
2	:	O	
3	50	O	
4	consecutive	O	
5	children	O	
6	aged	O	
7	from	O	
8	6	O	
9	months	O	
10	to	O	
11	17	O	
12	years	O	
13	were	O	
14	included	O	
15	into	O	
16	the	O	
17	study	O	
18	which	O	
19	comprised	O	
20	questionnaires	O	
21	of	O	
22	patient	O	
23	and	O	
24	family	O	
25	histories	O	
26	,	O	
27	serological	O	
28	screening	O	
29	tests	O	
30	for	O	
31	common	O	
32	inhalational	O	
33	allergens	O	
34	(	O	
35	CAP	O	
36	SX1	O	
37	),	O	
38	and	O	
39	determination	O	
40	of	O	
41	total	O	
42	serum	B	
43	immunoglobulin	I	
44	E	I	
45	(	O	
46	IgE	B	
47	)	O	
48	and	O	
49	of	O	
50	latex	O	
51	-	O	
52	specific	O	
53	serum	B	
54	IgE	I	
55	by	O	
56	solid	O	
57	-	O	
58	phase	O	
59	immunoassays	O	
60	.	O	

1	Once	O	
2	the	O	
3	proliferation	O	
4	of	O	
5	fibroblasts	O	
6	and	O	
7	collagen	B	
8	synthesis	O	
9	had	O	
10	led	O	
11	to	O	
12	an	O	
13	increase	O	
14	of	O	
15	mechanical	O	
16	strength	O	
17	,	O	
18	no	O	
19	negative	O	
20	effect	O	
21	on	O	
22	wound	O	
23	healing	O	
24	could	O	
25	be	O	
26	detected	O	
27	applying	O	
28	the	O	
29	same	O	
30	chemotherapeutic	O	
31	agents	O	
32	.	O	

1	D	O	
2	.	O	

1	Successful	O	
2	treatment	O	
3	with	O	
4	nasal	O	
5	continuous	O	
6	positive	O	
7	airway	O	
8	pressure	O	
9	(	O	
10	8	O	
11	.	O	
12	3	O	
13	+/-	O	
14	1	O	
15	.	O	
16	5	O	
17	cmH2O	O	
18	)	O	
19	for	O	
20	3	O	
21	days	O	
22	caused	O	
23	a	O	
24	significant	O	
25	decrease	O	
26	in	O	
27	mean	O	
28	blood	O	
29	pressure	O	
30	in	O	
31	OSAS	O	
32	.	O	

1	However	O	
2	,	O	
3	F	B	
4	-	I	
5	SRC	I	
6	-	I	
7	1	I	
8	mutant	I	
9	lacking	O	
10	CBP	B	
11	-	I	
12	interacting	I	
13	domain	I	
14	still	O	
15	preserved	O	
16	enhancing	O	
17	activity	O	
18	.	O	

1	The	O	
2	priming	O	
3	activity	O	
4	of	O	
5	DNA	O	
6	incised	O	
7	by	O	
8	either	O	
9	of	O	
10	the	O	
11	Drosophila	O	
12	enzymes	O	
13	can	O	
14	be	O	
15	enhanced	O	
16	,	O	
17	however	O	
18	,	O	
19	by	O	
20	an	O	
21	additional	O	
22	incubation	O	
23	with	O	
24	E	B	
25	.	I	
26	coli	I	
27	endonuclease	I	
28	IV	I	
29	,	O	
30	which	O	
31	is	O	
32	known	O	
33	to	O	
34	cleave	O	
35	depurinated	O	
36	DNA	O	
37	on	O	
38	the	O	
39	5	O	
40	'-	O	
41	side	O	
42	of	O	
43	an	O	
44	apurinic	O	
45	site	O	
46	.	O	

1	There	O	
2	is	O	
3	growing	O	
4	evidence	O	
5	that	O	
6	mammalian	B	
7	AMP	I	
8	-	I	
9	activated	I	
10	protein	I	
11	kinase	I	
12	(	O	
13	AMPK	B	
14	)	O	
15	plays	O	
16	a	O	
17	role	O	
18	in	O	
19	protecting	O	
20	cells	O	
21	from	O	
22	stresses	O	
23	that	O	
24	cause	O	
25	ATP	O	
26	depletion	O	
27	by	O	
28	switching	O	
29	off	O	
30	ATP	O	
31	-	O	
32	consuming	O	
33	biosynthetic	O	
34	pathways	O	
35	.	O	

1	The	O	
2	syndrome	O	
3	of	O	
4	resistance	O	
5	to	O	
6	thyroid	O	
7	hormone	O	
8	is	O	
9	characterized	O	
10	by	O	
11	elevated	O	
12	serum	O	
13	free	O	
14	thyroid	O	
15	hormones	O	
16	,	O	
17	failure	O	
18	to	O	
19	suppress	O	
20	pituitary	B	
21	thyrotropin	I	
22	secretion	O	
23	,	O	
24	and	O	
25	variable	O	
26	peripheral	O	
27	refractoriness	O	
28	to	O	
29	hormone	O	
30	action	O	
31	.	O	

1	To	O	
2	quantify	O	
3	any	O	
4	mechanical	O	
5	inhibitory	O	
6	effect	O	
7	of	O	
8	nasal	O	
9	intermittent	O	
10	positive	O	
11	pressure	O	
12	ventilation	O	
13	(	O	
14	IPPV	O	
15	)	O	
16	on	O	
17	inspiratory	O	
18	activity	O	
19	of	O	
20	the	O	
21	diaphragm	O	
22	we	O	
23	ventilated	O	
24	five	O	
25	conscious	O	
26	relaxed	O	
27	subjects	O	
28	on	O	
29	two	O	
30	occasions	O	
31	at	O	
32	respiratory	O	
33	rates	O	
34	similar	O	
35	to	O	
36	quiet	O	
37	breathing	O	
38	(	O	
39	QB	O	
40	)	O	
41	and	O	
42	at	O	
43	three	O	
44	levels	O	
45	of	O	
46	applied	O	
47	pressure	O	
48	(	O	
49	Pappl	O	
50	)--	O	
51	6	O	
52	,	O	
53	9	O	
54	and	O	
55	12	O	
56	cmH2O	O	
57	,	O	
58	each	O	
59	during	O	
60	hypocapnia	O	
61	(	O	
62	P	O	
63	(	O	
64	CO2	O	
65	)	O	
66	allowed	O	
67	to	O	
68	decrease	O	
69	)	O	
70	and	O	
71	eucapnia	O	
72	(	O	
73	CO2	O	
74	added	O	
75	to	O	
76	inspired	O	
77	gas	O	
78	).	O	

1	ME1a1	B	
2	,	O	
3	a	O	
4	16	O	
5	-	O	
6	base	O	
7	-	O	
8	pair	O	
9	nuclear	O	
10	factor	O	
11	binding	O	
12	site	O	
13	residing	O	
14	between	O	
15	the	O	
16	c	B	
17	-	I	
18	MYC	I	
19	P1	I	
20	and	I	
21	P2	I	
22	transcription	I	
23	initiation	I	
24	sites	I	
25	,	O	
26	is	O	
27	required	O	
28	for	O	
29	P2	O	
30	activity	O	
31	.	O	

1	We	O	
2	also	O	
3	provide	O	
4	evidence	O	
5	that	O	
6	gar2	B	
7	is	O	
8	phosphorylated	O	
9	in	O	
10	vitro	O	
11	by	O	
12	a	O	
13	p13	B	
14	(	O	
15	suc1	B	
16	)-	O	
17	Sepharose	O	
18	-	O	
19	bound	O	
20	kinase	O	
21	from	O	
22	Schizosaccharomyces	O	
23	pombe	O	
24	extracts	O	
25	that	O	
26	displays	O	
27	cell	O	
28	cycle	O	
29	-	O	
30	regulated	O	
31	activity	O	
32	similar	O	
33	to	O	
34	that	O	
35	of	O	
36	the	O	
37	p34	B	
38	(	O	
39	cdc2	B	
40	(	O	
41	kinase	O	
42	.	O	

1	Two	O	
2	points	O	
3	are	O	
4	indicated	O	
5	:	O	
6	first	O	
7	,	O	
8	the	O	
9	photosensitized	O	
10	damage	O	
11	of	O	
12	YHPD	O	
13	is	O	
14	interrelated	O	
15	to	O	
16	not	O	
17	only	O	
18	1O2	O	
19	,	O	
20	but	O	
21	also	O	
22	free	O	
23	radicals	O	
24	(	O	
25	O2	O	
26	-.	O	
27	.	O	
28	OH	O	
29	and	O	
30	YHPD	O	
31	-.);	O	
32	second	O	
33	,	O	
34	although	O	
35	the	O	
36	photosensitized	O	
37	damage	O	
38	of	O	
39	YHPD	O	
40	is	O	
41	stronger	O	
42	than	O	
43	that	O	
44	of	O	
45	BHPD	O	
46	,	O	
47	yet	O	
48	the	O	
49	photosensitized	O	
50	damage	O	
51	is	O	
52	negatively	O	
53	correlated	O	
54	to	O	
55	the	O	
56	yield	O	
57	of	O	
58	1O2	O	
59	but	O	
60	positively	O	
61	correlated	O	
62	to	O	
63	those	O	
64	of	O	
65	O2	O	
66	-.	O	
67	and	O	
68	OH	O	
69	.	O	

1	In	O	
2	vivo	O	
3	,	O	
4	selective	O	
5	activation	O	
6	of	O	
7	SAPKs	B	
8	stimulates	O	
9	formation	O	
10	of	O	
11	the	O	
12	ternary	O	
13	complex	O	
14	containing	O	
15	Elk	B	
16	-	I	
17	1	I	
18	,	O	
19	serum	B	
20	response	I	
21	factor	I	
22	and	O	
23	the	O	
24	serum	O	
25	response	O	
26	element	O	
27	,	O	
28	and	O	
29	enhances	O	
30	Elk	B	
31	-	I	
32	1	I	
33	-	O	
34	dependent	O	
35	transcription	O	
36	.	O	

1	A	O	
2	Y	B	
3	.	I	
4	lipolytica	I	
5	Kar2p	I	
6	mutant	I	
7	was	O	
8	isolated	O	
9	that	O	
10	restored	O	
11	interaction	O	
12	with	O	
13	an	O	
14	Sls1p	B	
15	mutant	I	
16	,	O	
17	suggesting	O	
18	that	O	
19	the	O	
20	interaction	O	
21	with	O	
22	Sls1p	B	
23	could	O	
24	be	O	
25	nucleotide	O	
26	and	O	
27	/	O	
28	or	O	
29	conformation	O	
30	dependent	O	
31	.	O	

1	Transformation	O	
2	blocks	O	
3	differentiation	O	
4	-	O	
5	induced	O	
6	inhibition	O	
7	of	O	
8	serum	B	
9	response	I	
10	factor	I	
11	interactions	O	
12	with	O	
13	serum	O	
14	response	O	
15	elements	O	
16	.	O	

1	Drag	O	
2	reduction	O	
3	in	O	
4	turbulent	O	
5	flows	O	
6	by	O	
7	polymers	O	
8	.	O	

1	The	O	
2	various	O	
3	muscles	O	
4	of	O	
5	the	O	
6	pelvic	O	
7	floor	O	
8	region	O	
9	could	O	
10	be	O	
11	reflexly	O	
12	activated	O	
13	either	O	
14	individually	O	
15	or	O	
16	as	O	
17	a	O	
18	mass	O	
19	unit	O	
20	depending	O	
21	on	O	
22	the	O	
23	intensity	O	
24	of	O	
25	stimulation	O	
26	.	O	

1	Morphological	O	
2	features	O	
3	of	O	
4	Jat	O	
5	dentition	O	
6	.	O	

1	Here	O	
2	we	O	
3	report	O	
4	that	O	
5	in	O	
6	cultured	O	
7	cells	O	
8	from	O	
9	Drosophila	O	
10	melanogaster	O	
11	human	B	
12	Sp1	I	
13	efficiently	O	
14	activates	O	
15	transcription	O	
16	from	O	
17	synthetic	O	
18	promoters	O	
19	containing	O	
20	TATA	O	
21	boxes	O	
22	,	O	
23	but	O	
24	not	O	
25	from	O	
26	promoters	O	
27	that	O	
28	contain	O	
29	an	O	
30	initiator	O	
31	instead	O	
32	of	O	
33	a	O	
34	TATA	O	
35	box	O	
36	.	O	

1	In	O	
2	that	O	
3	case	O	
4	,	O	
5	the	O	
6	ratio	O	
7	of	O	
8	brush	O	
9	abrasion	O	
10	was	O	
11	0	O	
12	.	O	
13	268	O	
14	,	O	
15	compressive	O	
16	and	O	
17	transverse	O	
18	strength	O	
19	,	O	
20	124	O	
21	.	O	
22	3	O	
23	and	O	
24	86	O	
25	.	O	
26	3	O	
27	MPa	O	
28	respectively	O	
29	,	O	
30	hardness	O	
31	,	O	
32	43	O	
33	.	O	
34	2	O	
35	Hk	O	
36	,	O	
37	water	O	
38	absorption	O	
39	14	O	
40	.	O	
41	2	O	
42	micrograms	O	
43	/	O	
44	mm3	O	
45	and	O	
46	thermal	O	
47	expansion	O	
48	coefficient	O	
49	,	O	
50	47	O	
51	.	O	
52	4	O	
53	x	O	
54	10	O	
55	(-	O	
56	6	O	
57	)/	O	
58	degrees	O	
59	C	O	
60	.	O	

1	This	O	
2	rapid	O	
3	and	O	
4	extensive	O	
5	penetration	O	
6	of	O	
7	intrathecally	O	
8	administered	O	
9	chemotherapy	O	
10	may	O	
11	offer	O	
12	insight	O	
13	into	O	
14	the	O	
15	myelopathy	O	
16	observed	O	
17	with	O	
18	these	O	
19	treatments	O	
20	.	O	

1	Later	O	
2	in	O	
3	development	O	
4	,	O	
5	Tbx6	B	
6	expression	O	
7	is	O	
8	restricted	O	
9	to	O	
10	presomitic	O	
11	,	O	
12	paraxial	O	
13	mesoderm	O	
14	and	O	
15	to	O	
16	the	O	
17	tail	O	
18	bud	O	
19	,	O	
20	which	O	
21	replaces	O	
22	the	O	
23	streak	O	
24	as	O	
25	the	O	
26	source	O	
27	of	O	
28	mesoderm	O	
29	.	O	

1	The	O	
2	ICBF	O	
3	in	O	
4	the	O	
5	ischaemic	O	
6	cortex	O	
7	revealed	O	
8	a	O	
9	graded	O	
10	reduction	O	
11	from	O	
12	the	O	
13	ischaemic	O	
14	centre	O	
15	to	O	
16	the	O	
17	surrounding	O	
18	tissues	O	
19	.	O	

1	Protein	B	
2	kinase	I	
3	C	I	
4	(	O	
5	PKC	B	
6	),	O	
7	a	O	
8	widely	O	
9	-	O	
10	distributed	O	
11	enzyme	O	
12	implicated	O	
13	in	O	
14	the	O	
15	regulation	O	
16	of	O	
17	many	O	
18	physiological	O	
19	processes	O	
20	,	O	
21	consists	O	
22	of	O	
23	a	O	
24	family	O	
25	of	O	
26	at	O	
27	least	O	
28	twelve	O	
29	isoenzymes	O	
30	which	O	
31	differ	O	
32	in	O	
33	tissue	O	
34	distribution	O	
35	,	O	
36	subcellular	O	
37	localization	O	
38	,	O	
39	regulatory	O	
40	properties	O	
41	,	O	
42	etc	O	
43	.	O	

1	Association	O	
2	of	O	
3	stress	O	
4	during	O	
5	delivery	O	
6	with	O	
7	increased	O	
8	numbers	O	
9	of	O	
10	nucleated	O	
11	cells	O	
12	and	O	
13	hematopoietic	O	
14	progenitor	O	
15	cells	O	
16	in	O	
17	umbilical	O	
18	cord	O	
19	blood	O	
20	.	O	

1	Analysis	O	
2	of	O	
3	the	O	
4	gag	B	
5	and	O	
6	rev	B	
7	proteins	I	
8	in	O	
9	the	O	
10	transfected	O	
11	cells	O	
12	demonstrated	O	
13	that	O	
14	these	O	
15	proteins	O	
16	were	O	
17	not	O	
18	detectable	O	
19	in	O	
20	cells	O	
21	transfected	O	
22	with	O	
23	the	O	
24	tat	B	
25	mutants	I	
26	but	O	
27	could	O	
28	be	O	
29	readily	O	
30	detected	O	
31	when	O	
32	the	O	
33	mutations	O	
34	were	O	
35	complemented	O	
36	in	O	
37	trans	O	
38	with	O	
39	a	O	
40	tat	B	
41	expression	O	
42	vector	O	
43	.	O	

1	The	O	
2	mammalian	B	
3	homeodomain	I	
4	proteins	I	
5	encoded	O	
6	by	O	
7	Hox	B	
8	genes	I	
9	play	O	
10	an	O	
11	important	O	
12	role	O	
13	in	O	
14	embryonic	O	
15	development	O	
16	by	O	
17	providing	O	
18	positional	O	
19	queues	O	
20	which	O	
21	define	O	
22	developmental	O	
23	identities	O	
24	along	O	
25	the	O	
26	anteroposterior	O	
27	axis	O	
28	of	O	
29	developing	O	
30	organisms	O	
31	.	O	

1	One	O	
2	hundred	O	
3	units	O	
4	/	O	
5	kg	O	
6	of	O	
7	recombinant	B	
8	human	I	
9	erythropoietin	I	
10	(	O	
11	rhEPO	B	
12	)	O	
13	was	O	
14	given	O	
15	subcutaneously	O	
16	3	O	
17	times	O	
18	a	O	
19	week	O	
20	for	O	
21	3	O	
22	weeks	O	
23	.	O	

1	Although	O	
2	ANP	B	
3	induced	O	
4	systemic	O	
5	capillary	O	
6	filtration	O	
7	,	O	
8	in	O	
9	the	O	
10	calf	O	
11	,	O	
12	filtration	O	
13	was	O	
14	reduced	O	
15	with	O	
16	ANP	B	
17	.	O	

1	During	O	
2	a	O	
3	28	O	
4	-	O	
5	week	O	
6	promotion	O	
7	bioassay	O	
8	,	O	
9	groups	O	
10	of	O	
11	30	O	
12	male	O	
13	CD	O	
14	-	O	
15	1	O	
16	mice	O	
17	were	O	
18	treated	O	
19	once	O	
20	with	O	
21	50	O	
22	microliter	O	
23	of	O	
24	either	O	
25	DMBA	O	
26	(	O	
27	1	O	
28	.	O	
29	0	O	
30	mg	O	
31	/	O	
32	ml	O	
33	)	O	
34	or	O	
35	acetone	O	
36	,	O	
37	rested	O	
38	for	O	
39	2	O	
40	weeks	O	
41	,	O	
42	and	O	
43	then	O	
44	treated	O	
45	twice	O	
46	per	O	
47	week	O	
48	with	O	
49	test	O	
50	material	O	
51	for	O	
52	the	O	
53	remaining	O	
54	25	O	
55	weeks	O	
56	.	O	

1	Functional	O	
2	analysis	O	
3	of	O	
4	promoter	O	
5	activity	O	
6	of	O	
7	the	O	
8	5	O	
9	'-	O	
10	flanking	O	
11	region	O	
12	of	O	
13	cyclin	B	
14	D2	I	
15	suggested	O	
16	that	O	
17	the	O	
18	region	O	
19	-	O	
20	1	O	
21	,	O	
22	100	O	
23	to	O	
24	-	O	
25	805	O	
26	including	O	
27	C	B	
28	/	I	
29	EBP	I	
30	,	O	
31	PEA3	B	
32	,	O	
33	AP2	B	
34	,	O	
35	NF	B	
36	-	I	
37	Y	I	
38	,	O	
39	c	B	
40	-	I	
41	Myc	I	
42	,	O	
43	and	O	
44	Sp1	B	
45	may	O	
46	have	O	
47	a	O	
48	major	O	
49	positive	O	
50	regulatory	O	
51	activity	O	
52	for	O	
53	expression	O	
54	of	O	
55	cyclin	B	
56	D2	I	
57	.	O	

1	Changes	O	
2	in	O	
3	xanthine	B	
4	oxidase	I	
5	activity	O	
6	in	O	
7	patients	O	
8	with	O	
9	circulatory	O	
10	failure	O	

1	The	O	
2	detection	O	
3	ratio	O	
4	peaked	O	
5	at	O	
6	ages	O	
7	30	O	
8	to	O	
9	34	O	
10	and	O	
11	decreased	O	
12	heavily	O	
13	during	O	
14	the	O	
15	next	O	
16	15	O	
17	years	O	
18	of	O	
19	age	O	
20	.	O	

1	Influence	O	
2	of	O	
3	cigarette	O	
4	smoking	O	
5	on	O	
6	some	O	
7	blood	O	
8	coagulation	O	
9	tests	O	
10	.	O	

1	Similarly	O	
2	,	O	
3	supraventricular	O	
4	tachycaydia	O	
5	following	O	
6	resuscitative	O	
7	efforts	O	
8	appeared	O	
9	to	O	
10	be	O	
11	associated	O	
12	with	O	
13	a	O	
14	negative	O	
15	outcome	O	
16	.	O	

1	EGFR	B	
2	levels	O	
3	were	O	
4	found	O	
5	to	O	
6	be	O	
7	elevated	O	
8	5	O	
9	-,	O	
10	3	O	
11	.	O	

1	This	O	
2	study	O	
3	demonstrates	O	
4	secretion	O	
5	of	O	
6	bicarbonate	O	
7	by	O	
8	the	O	
9	human	O	
10	stomach	O	
11	in	O	
12	vivo	O	
13	at	O	
14	a	O	
15	rate	O	
16	equivalent	O	
17	to	O	
18	10	O	
19	--	O	
20	20	O	
21	%	O	
22	of	O	
23	basal	O	
24	acid	O	
25	secretion	O	
26	.	O	

1	With	O	
2	chemical	O	
3	shift	O	
4	imaging	O	
5	,	O	
6	the	O	
7	signal	O	
8	intensity	O	
9	decreased	O	
10	on	O	
11	the	O	
12	out	O	
13	-	O	
14	of	O	
15	-	O	
16	phase	O	
17	images	O	
18	in	O	
19	six	O	
20	of	O	
21	seven	O	
22	(	O	
23	86	O	
24	%)	O	
25	patients	O	
26	with	O	
27	APA	O	
28	and	O	
29	in	O	
30	eight	O	
31	of	O	
32	nine	O	
33	(	O	
34	89	O	
35	%)	O	
36	patients	O	
37	with	O	
38	BAH	O	
39	.	O	

1	The	O	
2	results	O	
3	of	O	
4	these	O	
5	studies	O	
6	demonstrate	O	
7	that	O	
8	the	O	
9	rat	O	
10	HDL	O	
11	receptor	O	
12	SR	B	
13	-	I	
14	BI	I	
15	promoter	O	
16	contains	O	
17	two	O	
18	sterol	O	
19	response	O	
20	elements	O	
21	(	O	
22	pSRE	O	
23	and	O	
24	dSRE	O	
25	)	O	
26	through	O	
27	which	O	
28	SREBP	B	
29	-	I	
30	1a	I	
31	can	O	
32	bind	O	
33	and	O	
34	activate	O	
35	transcription	O	
36	of	O	
37	this	O	
38	gene	O	
39	.	O	

1	The	O	
2	purified	O	
3	recombinant	O	
4	enzyme	O	
5	catalyzed	O	
6	specific	O	
7	phosphoryl	O	
8	transfer	O	
9	from	O	
10	ATP	O	
11	to	O	
12	UMP	O	
13	and	O	
14	CMP	O	
15	.	O	

1	The	O	
2	mRNAs	O	
3	of	O	
4	the	O	
5	GRF	B	
6	genes	I	
7	are	O	
8	encoded	O	
9	by	O	
10	six	O	
11	exons	O	
12	interrupted	O	
13	by	O	
14	five	O	
15	introns	O	
16	.	O	

1	In	O	
2	diethyl	O	
3	ether	O	
4	solution	O	
5	the	O	
6	main	O	
7	peak	O	
8	is	O	
9	that	O	
10	of	O	
11	2	O	
12	-	O	
13	benzylidenamio	O	
14	-	O	
15	1	O	
16	-	O	
17	phenylpropane	O	
18	,	O	
19	which	O	
20	has	O	
21	a	O	
22	retention	O	
23	time	O	
24	of	O	
25	23	O	
26	,	O	
27	2	O	
28	minutes	O	
29	under	O	
30	the	O	
31	condition	O	
32	delineated	O	
33	.	O	

1	Luteinizing	B	
2	hormone	I	
3	-	I	
4	releasing	I	
5	hormone	I	
6	analog	O	
7	therapy	O	
8	of	O	
9	uterine	O	
10	fibroid	O	
11	:	O	
12	analysis	O	
13	of	O	
14	results	O	
15	obtained	O	
16	with	O	
17	buserelin	O	
18	administered	O	
19	intranasally	O	
20	and	O	
21	goserelin	O	
22	administered	O	
23	subcutaneously	O	
24	as	O	
25	a	O	
26	monthly	O	
27	depot	O	
28	.	O	

1	Calmodulin	B	
2	-	I	
3	binding	I	
4	peptide	I	
5	(	O	
6	CBP	B	
7	),	O	
8	a	O	
9	peptide	O	
10	of	O	
11	26	O	
12	amino	O	
13	acids	O	
14	derived	O	
15	from	O	
16	muscle	B	
17	myosin	I	
18	light	I	
19	chain	I	
20	kinase	I	
21	(	O	
22	MLCK	B	
23	),	O	
24	binds	O	
25	to	O	
26	calmodulin	B	
27	with	O	
28	nanomolar	O	
29	affinity	O	
30	.	O	

1	Further	O	
2	studies	O	
3	on	O	
4	a	O	
5	"	O	
6	new	O	
7	"	O	
8	human	O	
9	isoprecipitin	B	
10	system	O	
11	(	O	
12	Australia	O	
13	antigen	O	
14	).	O	

1	With	O	
2	the	O	
3	help	O	
4	of	O	
5	a	O	
6	nomogram	O	
7	one	O	
8	can	O	
9	read	O	
10	off	O	
11	the	O	
12	refraction	O	
13	,	O	
14	when	O	
15	axis	O	
16	length	O	
17	and	O	
18	corneal	O	
19	curvature	O	
20	are	O	
21	known	O	
22	.	O	

1	Transient	O	
2	transfection	O	
3	assays	O	
4	using	O	
5	P19	O	
6	cells	O	
7	revealed	O	
8	that	O	
9	expression	O	
10	of	O	
11	NDRF	B	
12	/	O	
13	NeuroD2	B	
14	increased	O	
15	the	O	
16	transactivation	O	
17	of	O	
18	the	O	
19	rat	B	
20	insulin	I	
21	promoter	I	
22	element	I	
23	3	I	
24	(	O	
25	RIPE3	B	
26	)	O	
27	enhancer	O	
28	up	O	
29	to	O	
30	approximately	O	
31	12	O	
32	-	O	
33	fold	O	
34	and	O	
35	that	O	
36	co	O	
37	-	O	
38	expression	O	
39	of	O	
40	catalytically	O	
41	active	O	
42	form	O	
43	of	O	
44	PKN	B	
45	,	O	
46	but	O	
47	not	O	
48	kinase	O	
49	-	O	
50	deficient	O	
51	derivative	O	
52	,	O	
53	resulted	O	
54	in	O	
55	a	O	
56	further	O	
57	threefold	O	
58	increase	O	
59	of	O	
60	NDRF	B	
61	/	O	
62	NeuroD2	B	
63	-	O	
64	mediated	O	
65	transcription	O	
66	.	O	

1	It	O	
2	has	O	
3	been	O	
4	shown	O	
5	in	O	
6	experiments	O	
7	in	O	
8	vitro	O	
9	that	O	
10	the	O	
11	hepatotrophic	O	
12	organic	O	
13	anions	O	
14	,	O	
15	the	O	
16	radiographic	O	
17	contrast	O	
18	agent	O	
19	(	O	
20	RCA	O	
21	)	O	
22	bilignost	O	
23	used	O	
24	in	O	
25	cholecystography	O	
26	and	O	
27	Bengal	O	
28	pink	O	
29	,	O	
30	have	O	
31	an	O	
32	affinity	O	
33	,	O	
34	unlike	O	
35	the	O	
36	urographic	O	
37	RCA	O	
38	triombrin	O	
39	and	O	
40	renotrophic	O	
41	dye	O	
42	indigo	O	
43	-	O	
44	carmine	O	
45	,	O	
46	for	O	
47	the	O	
48	plasmatic	O	
49	membranes	O	
50	(	O	
51	PM	O	
52	)	O	
53	of	O	
54	liver	O	
55	cells	O	
56	.	O	

1	The	O	
2	gene	O	
3	encoding	O	
4	the	O	
5	105	B	
6	-	I	
7	kDa	I	
8	protein	I	
9	(	I	
10	p105	I	
11	)	I	
12	precursor	I	
13	of	O	
14	the	O	
15	p50	B	
16	subunit	I	
17	of	O	
18	transcription	O	
19	factor	O	
20	NF	B	
21	-	I	
22	kappa	I	
23	B	I	
24	also	O	
25	encodes	O	
26	a	O	
27	p70	B	
28	I	I	
29	kappa	I	
30	B	I	
31	protein	I	
32	,	O	
33	I	B	
34	kappa	I	
35	B	I	
36	gamma	I	
37	,	O	
38	which	O	
39	is	O	
40	identical	O	
41	to	O	
42	the	O	
43	C	O	
44	-	O	
45	terminal	O	
46	607	O	
47	amino	O	
48	acids	O	
49	of	O	
50	p105	B	
51	.	O	

1	Binding	O	
2	activity	O	
3	in	O	
4	rat	O	
5	liver	O	
6	nuclear	O	
7	extracts	O	
8	includes	O	
9	these	O	
10	orphan	O	
11	receptors	O	
12	as	O	
13	judged	O	
14	from	O	
15	electromobility	O	
16	supershift	O	
17	experiments	O	
18	and	O	
19	from	O	
20	results	O	
21	obtained	O	
22	with	O	
23	expressed	O	
24	receptors	O	
25	,	O	
26	although	O	
27	the	O	
28	element	O	
29	in	O	
30	CYP2C11	B	
31	did	O	
32	not	O	
33	bind	O	
34	HNF	B	
35	-	I	
36	4	I	
37	.	O	

1	Contrary	O	
2	to	O	
3	expectations	O	
4	,	O	
5	we	O	
6	find	O	
7	a	O	
8	relatively	O	
9	high	O	
10	level	O	
11	of	O	
12	variation	O	
13	in	O	
14	the	O	
15	stripe	B	
16	2	I	
17	enhancer	O	
18	region	O	
19	,	O	
20	including	O	
21	point	O	
22	substitutions	O	
23	and	O	
24	insertion	O	
25	/	O	
26	deletions	O	
27	in	O	
28	binding	O	
29	sites	O	
30	,	O	
31	and	O	
32	a	O	
33	comparable	O	
34	level	O	
35	of	O	
36	variation	O	
37	in	O	
38	the	O	
39	other	O	
40	noncoding	O	
41	regions	O	
42	.	O	

1	In	O	
2	this	O	
3	study	O	
4	,	O	
5	we	O	
6	purified	O	
7	and	O	
8	characterized	O	
9	the	O	
10	recombinant	B	
11	furin	I	
12	from	O	
13	the	O	
14	conditioned	O	
15	medium	O	
16	of	O	
17	these	O	
18	cells	O	
19	.	O	

1	M	O	
2	.,	O	
3	and	O	
4	D	O	
5	.	O	

1	Scintigraphic	O	
2	visualisation	O	
3	of	O	
4	Walker	O	
5	carcinoma	O	
6	-	O	
7	256	O	
8	in	O	
9	Sprague	O	
10	-	O	
11	Dawley	O	
12	rats	O	
13	by	O	
14	means	O	
15	of	O	
16	99mTc	O	
17	-	O	
18	labelled	O	
19	monocytes	O	
20	.	O	

1	Bound	O	
2	-	O	
3	exciton	O	
4	transfer	O	
5	and	O	
6	photoluminescence	O	
7	undulation	O	
8	spectra	O	
9	for	O	
10	acceptors	O	
11	in	O	
12	ZnTe	O	
13	.	O	

1	Investigation	O	
2	on	O	
3	the	O	
4	exchange	O	
5	of	O	
6	Ca45	O	
7	in	O	
8	intact	O	
9	and	O	
10	burned	O	
11	rats	O	
12	by	O	
13	the	O	
14	kinetic	O	
15	analysis	O	
16	method	O	

1	The	O	
2	normal	O	
3	cell	O	
4	cycle	O	
5	is	O	
6	regulated	O	
7	by	O	
8	several	O	
9	molecules	O	
10	,	O	
11	such	O	
12	as	O	
13	the	O	
14	tumor	B	
15	-	I	
16	suppressor	I	
17	protein	I	
18	pRb	I	
19	,	O	
20	the	O	
21	G1	B	
22	cyclins	I	
23	,	O	
24	the	O	
25	cyclin	B	
26	-	I	
27	dependent	I	
28	kinases	I	
29	,	O	
30	and	O	
31	their	O	
32	inhibitors	O	
33	.	O	

1	After	O	
2	4	O	
3	h	O	
4	,	O	
5	lesions	O	
6	in	O	
7	the	O	
8	secretory	O	
9	part	O	
10	of	O	
11	the	O	
12	stomach	O	
13	were	O	
14	scored	O	
15	and	O	
16	mucosal	O	
17	prostaglandin	O	
18	E2	O	
19	synthesis	O	
20	was	O	
21	determined	O	
22	by	O	
23	the	O	
24	ex	O	
25	vivo	O	
26	prostaglandin	O	
27	generation	O	
28	technique	O	
29	.	O	

1	Thus	O	
2	it	O	
3	appears	O	
4	that	O	
5	the	O	
6	management	O	
7	of	O	
8	blood	O	
9	,	O	
10	including	O	
11	washing	O	
12	is	O	
13	of	O	
14	great	O	
15	importance	O	
16	.	O	

1	In	O	
2	order	O	
3	to	O	
4	delineate	O	
5	structural	O	
6	motifs	O	
7	regulating	O	
8	substrate	O	
9	affinity	O	
10	and	O	
11	recognition	O	
12	for	O	
13	the	O	
14	human	B	
15	dopamine	I	
16	transporter	I	
17	(	O	
18	DAT	B	
19	),	O	
20	we	O	
21	assessed	O	
22	[	O	
23	3H	O	
24	]	O	
25	dopamine	O	
26	uptake	O	
27	kinetics	O	
28	and	O	
29	[	O	
30	3H	O	
31	]	O	
32	CFT	O	
33	binding	O	
34	characteristics	O	
35	of	O	
36	COS	O	
37	-	O	
38	7	O	
39	cells	O	
40	transiently	O	
41	expressing	O	
42	mutant	B	
43	DATs	I	
44	in	O	
45	which	O	
46	the	O	
47	COOH	O	
48	terminus	O	
49	was	O	
50	truncated	O	
51	or	O	
52	substituted	O	
53	.	O	

1	The	O	
2	Caenorhabditis	B	
3	elegans	I	
4	death	I	
5	susceptibility	I	
6	gene	I	
7	,	O	
8	ced	B	
9	-	I	
10	3	I	
11	,	O	
12	has	O	
13	a	O	
14	number	O	
15	of	O	
16	homologs	O	
17	in	O	
18	vertebrate	O	
19	species	O	
20	,	O	
21	including	O	
22	interleukin	B	
23	-	I	
24	1	I	
25	beta	I	
26	(	I	
27	IL	I	
28	-	I	
29	1	I	
30	beta	I	
31	)-	I	
32	converting	I	
33	enzyme	I	
34	(	O	
35	ICE	B	
36	),	O	
37	Ich	B	
38	-	I	
39	1long	I	
40	,	O	
41	and	O	
42	CPP32	B	
43	.	O	

1	Taurine	O	
2	deficiency	O	
3	significantly	O	
4	depressed	O	
5	the	O	
6	amplitude	O	
7	of	O	
8	OP1	O	
9	and	O	
10	OP4	O	
11	.	O	

1	Rip1p	B	
2	is	O	
3	inessential	O	
4	,	O	
5	associated	O	
6	with	O	
7	nuclear	O	
8	pore	O	
9	complexes	O	
10	,	O	
11	and	O	
12	structurally	O	
13	related	O	
14	to	O	
15	the	O	
16	FG	B	
17	-	I	
18	nucleoporin	I	
19	family	I	
20	of	O	
21	pore	O	
22	proteins	O	
23	.	O	

1	The	O	
2	systolic	O	
3	peak	O	
4	of	O	
5	pulmonary	O	
6	vein	O	
7	was	O	
8	higher	O	
9	than	O	
10	the	O	
11	diastolic	O	
12	peak	O	
13	in	O	
14	45	O	
15	out	O	
16	of	O	
17	56	O	
18	cases	O	
19	.	O	

1	In	O	
2	ferrets	O	
3	naturally	O	
4	infected	O	
5	with	O	
6	H	O	
7	.	O	
8	mustelae	O	
9	,	O	
10	a	O	
11	single	O	
12	dose	O	
13	(	O	
14	50	O	
15	mg	O	
16	/	O	
17	kg	O	
18	,	O	
19	per	O	
20	os	O	
21	)	O	
22	of	O	
23	fluorofamide	O	
24	completely	O	
25	inhibited	O	
26	bacterial	B	
27	urease	I	
28	.	O	

1	We	O	
2	report	O	
3	here	O	
4	the	O	
5	isolation	O	
6	of	O	
7	a	O	
8	full	O	
9	-	O	
10	length	O	
11	cDNA	O	
12	clone	O	
13	coding	O	
14	for	O	
15	a	O	
16	hitherto	O	
17	undiscovered	O	
18	isoform	O	
19	of	O	
20	the	O	
21	bovine	B	
22	C	I	
23	-	I	
24	subunit	I	
25	.	O	

1	Approximately	O	
2	50	O	
3	%	O	
4	of	O	
5	the	O	
6	ribosomal	O	
7	DNA	O	
8	(	O	
9	rDNA	O	
10	)	O	
11	units	O	
12	of	O	
13	Drosophila	O	
14	melanogaster	O	
15	are	O	
16	inactivated	O	
17	by	O	
18	two	O	
19	different	O	
20	28	B	
21	S	I	
22	RNA	I	
23	ribosomal	I	
24	gene	I	
25	insertions	O	
26	(	O	
27	type	O	
28	I	O	
29	and	O	
30	type	O	
31	II	O	
32	).	O	

1	METHODS	O	
2	:	O	
3	Rats	O	
4	received	O	
5	continuous	O	
6	intragastric	O	
7	infusion	O	
8	of	O	
9	elemental	O	
10	diet	O	
11	or	O	
12	with	O	
13	supplementation	O	
14	of	O	
15	oatbase	O	
16	,	O	
17	Lactobacillus	O	
18	reuteri	O	
19	R2LC	O	
20	,	O	
21	and	O	
22	Lactobacillus	O	
23	plantarum	O	
24	DSM	O	
25	9843	O	
26	,	O	
27	with	O	
28	and	O	
29	without	O	
30	fermentation	O	
31	,	O	
32	from	O	
33	the	O	
34	beginning	O	
35	of	O	
36	the	O	
37	study	O	
38	.	O	

1	ORF	O	
2	M1	O	
3	has	O	
4	striking	O	
5	homology	O	
6	to	O	
7	poxvirus	O	
8	serpins	B	
9	,	O	
10	while	O	
11	ORF	O	
12	M11	O	
13	encodes	O	
14	a	O	
15	potential	O	
16	homolog	O	
17	of	O	
18	Bcl	B	
19	-	I	
20	2	I	
21	-	I	
22	like	I	
23	molecules	I	
24	encoded	O	
25	by	O	
26	other	O	
27	gammaherpesviruses	O	
28	(	O	
29	gene	B	
30	16	I	
31	of	O	
32	HVS	O	
33	and	O	
34	KSHV	O	
35	and	O	
36	the	O	
37	BHRF1	B	
38	gene	I	
39	of	O	
40	EBV	O	
41	).	O	

1	The	O	
2	asymmetric	O	
3	methylation	O	
4	was	O	
5	associated	O	
6	with	O	
7	tissue	O	
8	-	O	
9	specific	O	
10	disruption	O	
11	of	O	
12	H19	B	
13	genomic	O	
14	imprinting	O	
15	in	O	
16	fetal	O	
17	brain	O	
18	.	O	

1	Analysis	O	
2	of	O	
3	the	O	
4	E2F1	B	
5	gene	I	
6	promoter	I	
7	showed	O	
8	that	O	
9	the	O	
10	-	O	
11	146	O	
12	to	O	
13	-	O	
14	54	O	
15	region	O	
16	was	O	
17	required	O	
18	for	O	
19	E2	B	
20	-	O	
21	responsiveness	O	
22	in	O	
23	transient	O	
24	transfection	O	
25	assays	O	
26	,	O	
27	and	O	
28	subsequent	O	
29	deletion	O	
30	/	O	
31	mutation	O	
32	analysis	O	
33	showed	O	
34	that	O	
35	a	O	
36	single	O	
37	upstream	O	
38	GC	O	
39	-	O	
40	rich	O	
41	and	O	
42	two	O	
43	downstream	O	
44	CCAAT	O	
45	-	O	
46	binding	O	
47	sites	O	
48	were	O	
49	required	O	
50	for	O	
51	transactivation	O	
52	by	O	
53	E2	B	
54	.	O	

1	Furthermore	O	
2	,	O	
3	the	O	
4	insertion	O	
5	of	O	
6	the	O	
7	ColE1	B	
8	cer	I	
9	site	I	
10	into	O	
11	the	O	
12	RK2	O	
13	plasmid	O	
14	deleted	O	
15	for	O	
16	the	O	
17	par	O	
18	region	O	
19	failed	O	
20	to	O	
21	stabilize	O	
22	the	O	
23	plasmid	O	
24	in	O	
25	the	O	
26	MC1061K	O	
27	strain	O	
28	,	O	
29	indicating	O	
30	that	O	
31	the	O	
32	multimer	O	
33	resolution	O	
34	activity	O	
35	encoded	O	
36	by	O	
37	parCBA	B	
38	is	O	
39	not	O	
40	by	O	
41	itself	O	
42	responsible	O	
43	for	O	
44	the	O	
45	stabilization	O	
46	activity	O	
47	observed	O	
48	for	O	
49	this	O	
50	operon	O	
51	.	O	

1	Mean	O	
2	longitudinal	O	
3	extension	O	
4	of	O	
5	the	O	
6	epidural	O	
7	lesion	O	
8	was	O	
9	2	O	
10	.	O	
11	6	O	
12	vertebral	O	
13	segments	O	
14	.	O	

1	RESULTS	O	
2	:	O	
3	The	O	
4	binding	O	
5	of	O	
6	99mTc	O	
7	d	O	
8	,	O	
9	1	O	
10	-	O	
11	HMPAO	O	
12	to	O	
13	human	O	
14	placenta	O	
15	ranged	O	
16	from	O	
17	2	O	
18	.	O	
19	95	O	
20	%	O	
21	+/-	O	
22	1	O	
23	.	O	
24	5	O	
25	%	O	
26	to	O	
27	5	O	
28	.	O	
29	82	O	
30	%	O	
31	+/-	O	
32	0	O	
33	.	O	
34	3	O	
35	%	O	
36	per	O	
37	1	O	
38	ml	O	
39	standard	O	
40	solution	O	
41	.	O	

1	(	O	
2	3	O	
3	).	O	

1	Consequently	O	
2	,	O	
3	it	O	
4	is	O	
5	not	O	
6	known	O	
7	how	O	
8	knee	O	
9	loading	O	
10	changes	O	
11	following	O	
12	ACL	O	
13	transection	O	
14	,	O	
15	and	O	
16	how	O	
17	it	O	
18	contributes	O	
19	to	O	
20	cartilage	O	
21	degeneration	O	
22	.	O	

1	The	O	
2	viral	B	
3	oncoprotein	I	
4	E1A	I	
5	inhibits	O	
6	NFAT	B	
7	-	O	
8	dependent	O	
9	transactivation	O	
10	in	O	
11	a	O	
12	p300	B	
13	-	O	
14	dependent	O	
15	manner	O	
16	.	O	

1	Data	O	
2	from	O	
3	the	O	
4	V	O	
5	-	O	
6	HeFT	O	
7	II	O	
8	show	O	
9	that	O	
10	at	O	
11	2	O	
12	-	O	
13	year	O	
14	follow	O	
15	-	O	
16	up	O	
17	,	O	
18	a	O	
19	progressive	O	
20	rise	O	
21	of	O	
22	plasma	O	
23	norepinephrine	O	
24	was	O	
25	observed	O	
26	in	O	
27	both	O	
28	treatment	O	
29	arms	O	
30	,	O	
31	suggesting	O	
32	that	O	
33	disease	O	
34	progresses	O	
35	despite	O	
36	treatment	O	
37	with	O	
38	either	O	
39	an	O	
40	angiotensin	B	
41	-	I	
42	converting	I	
43	enzyme	I	
44	inhibitor	O	
45	,	O	
46	enalapril	O	
47	,	O	
48	or	O	
49	vasodilator	O	
50	therapy	O	
51	with	O	
52	hydralazine	O	
53	/	O	
54	isosorbide	O	
55	dinitrate	O	
56	.	O	

1	Analysis	O	
2	by	O	
3	cell	O	
4	surface	O	
5	immunofluorescence	O	
6	showed	O	
7	that	O	
8	the	O	
9	UL28	B	
10	gene	I	
11	is	O	
12	not	O	
13	required	O	
14	for	O	
15	expression	O	
16	of	O	
17	viral	O	
18	glycoproteins	O	
19	on	O	
20	the	O	
21	surface	O	
22	of	O	
23	infected	O	
24	cells	O	
25	.	O	

1	A	O	
2	single	O	
3	protease	O	
4	-	O	
5	resistant	O	
6	structure	O	
7	formed	O	
8	by	O	
9	the	O	
10	entirety	O	
11	of	O	
12	both	O	
13	PDZ	B	
14	repeats	I	
15	1	I	
16	and	I	
17	2	I	
18	(	O	
19	PDZ1	B	
20	-	I	
21	2	I	
22	)	O	
23	contains	O	
24	the	O	
25	protein	B	
26	4	I	
27	.	I	
28	1	I	
29	-	I	
30	binding	I	
31	site	I	
32	.	O	

1	Whole	O	
2	bowel	O	
3	irrigation	O	
4	is	O	
5	a	O	
6	recently	O	
7	described	O	
8	technique	O	
9	to	O	
10	enhance	O	
11	the	O	
12	passage	O	
13	of	O	
14	drugs	O	
15	already	O	
16	beyond	O	
17	the	O	
18	pylorus	O	
19	.	O	

1	The	O	
2	effect	O	
3	of	O	
4	independent	O	
5	predictors	O	
6	on	O	
7	survival	O	
8	was	O	
9	examined	O	
10	in	O	
11	a	O	
12	Cox	O	
13	regression	O	
14	model	O	
15	with	O	
16	adjustment	O	
17	for	O	
18	existing	O	
19	illnesses	O	
20	.	O	

1	Collectively	O	
2	,	O	
3	these	O	
4	results	O	
5	suggest	O	
6	that	O	
7	components	O	
8	of	O	
9	the	O	
10	protein	B	
11	kinase	I	
12	A	I	
13	signaling	O	
14	pathway	O	
15	are	O	
16	recruited	O	
17	by	O	
18	mIg	B	
19	to	O	
20	induce	O	
21	junB	B	
22	transcription	O	
23	.	O	

1	When	O	
2	a	O	
3	tumour	O	
4	is	O	
5	present	O	
6	nipple	O	
7	discharge	O	
8	is	O	
9	of	O	
10	little	O	
11	importance	O	
12	for	O	
13	the	O	
14	diagnosis	O	
15	and	O	
16	treatment	O	
17	.	O	

1	Large	O	
2	-	O	
3	scale	O	
4	sequencing	O	
5	of	O	
6	two	O	
7	regions	O	
8	in	O	
9	human	O	
10	chromosome	O	
11	7q22	O	
12	:	O	
13	analysis	O	
14	of	O	
15	650	O	
16	kb	O	
17	of	O	
18	genomic	O	
19	sequence	O	
20	around	O	
21	the	O	
22	EPO	B	
23	and	O	
24	CUTL1	B	
25	loci	I	
26	reveals	O	
27	17	O	
28	genes	O	
29	.	O	

1	In	O	
2	conclusion	O	
3	,	O	
4	changes	O	
5	in	O	
6	carotid	O	
7	sinus	O	
8	stimulation	O	
9	alters	O	
10	blood	O	
11	flow	O	
12	to	O	
13	the	O	
14	hindlimb	O	
15	through	O	
16	changes	O	
17	in	O	
18	both	O	
19	Pcrit	O	
20	and	O	
21	Ra	O	
22	.	O	

1	The	O	
2	ZNF274	B	
3	gene	I	
4	is	O	
5	mapped	O	
6	distal	O	
7	to	O	
8	marker	O	
9	RP	O	
10	S28	O	
11	1	O	
12	in	O	
13	the	O	
14	human	O	
15	chromosome	O	
16	19qter	O	
17	region	O	
18	,	O	
19	by	O	
20	RH	O	
21	mapping	O	
22	.	O	

1	The	O	
2	recombinant	O	
3	enzymes	O	
4	exist	O	
5	as	O	
6	monomers	O	
7	.	O	

1	RNA	B	
2	polymerase	I	
3	II	I	
4	inhibition	O	
5	increased	O	
6	the	O	
7	binding	O	
8	of	O	
9	ARE	O	
10	(	O	
11	AUBP	O	
12	activity	O	
13	)	O	
14	and	O	
15	poly	O	
16	(	O	
17	U	O	
18	)-	O	
19	Sepharose	O	
20	by	O	
21	cytoplasmic	B	
22	hnRNP	I	
23	A1	I	
24	,	O	
25	while	O	
26	nuclear	B	
27	hnRNP	I	
28	A1	I	
29	binding	O	
30	was	O	
31	unaffected	O	
32	.	O	

1	Seventeen	O	
2	of	O	
3	the	O	
4	35	O	
5	patients	O	
6	were	O	
7	randomly	O	
8	chosen	O	
9	to	O	
10	receive	O	
11	a	O	
12	training	O	
13	program	O	
14	(	O	
15	lasting	O	
16	approximately	O	
17	1	O	
18	month	O	
19	)	O	
20	designed	O	
21	to	O	
22	establish	O	
23	a	O	
24	systematic	O	
25	strategy	O	
26	of	O	
27	organizing	O	
28	complex	O	
29	visual	O	
30	material	O	
31	.	O	

1	Gap	B	
2	b3	I	
3	consists	O	
4	of	O	
5	two	O	
6	polypeptide	O	
7	chains	O	
8	(	O	
9	Mr	O	
10	=	O	
11	110	O	
12	,	O	
13	000	O	
14	and	O	
15	30	O	
16	,	O	
17	000	O	
18	),	O	
19	which	O	
20	seem	O	
21	to	O	
22	be	O	
23	proteolytic	O	
24	cleavage	O	
25	products	O	
26	connected	O	
27	by	O	
28	disulfide	O	
29	bonds	O	
30	from	O	
31	a	O	
32	precursor	O	
33	protein	O	
34	.	O	

1	Expression	O	
2	of	O	
3	a	O	
4	dominant	B	
5	-	I	
6	negative	I	
7	ras	I	
8	gene	I	
9	also	O	
10	blocks	O	
11	TIS10	B	
12	/	O	
13	PGS2	B	
14	induction	O	
15	by	O	
16	v	B	
17	-	I	
18	src	I	
19	.	O	

1	CONCLUSIONS	O	
2	:	O	
3	Use	O	
4	of	O	
5	the	O	
6	first	O	
7	method	O	
8	was	O	
9	associated	O	
10	with	O	
11	a	O	
12	reduction	O	
13	in	O	
14	the	O	
15	time	O	
16	patients	O	
17	remained	O	
18	in	O	
19	the	O	
20	ICU	O	
21	before	O	
22	transfer	O	
23	to	O	
24	another	O	
25	unit	O	
26	and	O	
27	savings	O	
28	in	O	
29	nursing	O	
30	time	O	
31	,	O	
32	but	O	
33	the	O	
34	two	O	
35	methods	O	
36	did	O	
37	not	O	
38	differ	O	
39	according	O	
40	to	O	
41	clinical	O	
42	outcomes	O	
43	.	O	

1	Suppressors	O	
2	of	O	
3	defective	O	
4	silencing	O	
5	in	O	
6	yeast	O	
7	:	O	
8	effects	O	
9	on	O	
10	transcriptional	O	
11	repression	O	
12	at	O	
13	the	O	
14	HMR	B	
15	locus	I	
16	,	O	
17	cell	O	
18	growth	O	
19	and	O	
20	telomere	O	
21	structure	O	
22	.	O	

1	The	O	
2	use	O	
3	of	O	
4	the	O	
5	PLCgamma	B	
6	inhibitory	I	
7	peptide	I	
8	,	O	
9	neomycin	O	
10	and	O	
11	the	O	
12	calcium	O	
13	chelator	O	
14	BAPTA	O	
15	-	O	
16	AM	O	
17	on	O	
18	oocytes	O	
19	expressing	O	
20	FGFR1	B	
21	or	O	
22	the	O	
23	stimulation	O	
24	by	O	
25	PDGF	B	
26	-	I	
27	BB	I	
28	of	O	
29	oocytes	O	
30	expressing	O	
31	PDGFR	B	
32	-	O	
33	FGFR1	B	
34	mutated	O	
35	on	O	
36	the	O	
37	PLCgamma	B	
38	binding	I	
39	site	I	
40	,	O	
41	prevented	O	
42	GVBD	O	
43	and	O	
44	ERK2	B	
45	phosphorylation	O	
46	.	O	

1	Identification	O	
2	of	O	
3	mutations	O	
4	in	O	
5	the	O	
6	coding	O	
7	sequence	O	
8	of	O	
9	the	O	
10	proto	B	
11	-	I	
12	oncogene	I	
13	c	I	
14	-	I	
15	kit	I	
16	in	O	
17	a	O	
18	human	O	
19	mast	O	
20	cell	O	
21	leukemia	O	
22	cell	O	
23	line	O	
24	causing	O	
25	ligand	O	
26	-	O	
27	independent	O	
28	activation	O	
29	of	O	
30	c	B	
31	-	I	
32	kit	I	
33	product	I	
34	.	O	

1	The	O	
2	smaller	O	
3	uptake	O	
4	rate	O	
5	and	O	
6	faster	O	
7	clearance	O	
8	rate	O	
9	resulted	O	
10	in	O	
11	the	O	
12	lower	O	
13	BCF	O	
14	for	O	
15	SWA	O	
16	killifish	O	
17	.	O	

1	ROS	B	
2	x	O	
3	SRC	B	
4	(	O	
5	R	B	
6	)	O	
7	contains	O	
8	a	O	
9	16	O	
10	-	O	
11	amino	O	
12	-	O	
13	acid	O	
14	deletion	O	
15	that	O	
16	includes	O	
17	the	O	
18	3	O	
19	'	O	
20	half	O	
21	of	O	
22	the	O	
23	transmembrane	O	
24	domain	O	
25	of	O	
26	ros	B	
27	.	O	

1	The	O	
2	neuroleptic	O	
3	-	O	
4	induced	O	
5	increase	O	
6	in	O	
7	central	O	
8	DA	O	
9	turnover	O	
10	(	O	
11	an	O	
12	indicator	O	
13	for	O	
14	the	O	
15	degree	O	
16	of	O	
17	DA	B	
18	receptor	I	
19	blocking	O	
20	)	O	
21	was	O	
22	found	O	
23	to	O	
24	be	O	
25	positively	O	
26	correlated	O	
27	with	O	
28	the	O	
29	therapeutic	O	
30	effect	O	
31	of	O	
32	neuroleptics	O	
33	and	O	
34	the	O	
35	development	O	
36	of	O	
37	hypokinetic	O	
38	-	O	
39	rigid	O	
40	symptoms	O	
41	.	O	

1	Postglucose	O	
2	serum	B	
3	insulin	I	
4	levels	O	
5	showed	O	
6	no	O	
7	significant	O	
8	correlations	O	
9	with	O	
10	systolic	O	
11	or	O	
12	diastolic	O	
13	blood	O	
14	pressure	O	
15	levels	O	
16	in	O	
17	men	O	
18	,	O	
19	but	O	
20	in	O	
21	female	O	
22	diabetic	O	
23	and	O	
24	non	O	
25	-	O	
26	diabetic	O	
27	subjects	O	
28	significant	O	
29	correlations	O	
30	were	O	
31	found	O	
32	in	O	
33	particular	O	
34	with	O	
35	systolic	O	
36	blood	O	
37	pressure	O	
38	level	O	
39	.	O	

1	(	O	
2	1994	O	
3	,	O	
4	Hum	O	
5	.	O	

1	Menetrier	O	
2	disease	O	
3	in	O	
4	a	O	
5	child	O	
6	.	O	

1	The	O	
2	ability	O	
3	of	O	
4	spt2	B	
5	mutations	I	
6	to	O	
7	suppress	O	
8	the	O	
9	transcriptional	O	
10	interference	O	
11	caused	O	
12	by	O	
13	the	O	
14	delta	B	
15	promoter	I	
16	insertion	I	
17	his	I	
18	-	I	
19	4	I	
20	-	I	
21	912	I	
22	delta	I	
23	correlates	O	
24	with	O	
25	an	O	
26	increase	O	
27	in	O	
28	wild	B	
29	-	I	
30	type	I	
31	HIS4	I	
32	mRNA	I	
33	levels	O	
34	.	O	

1	Northern	O	
2	blotting	O	
3	with	O	
4	a	O	
5	unique	O	
6	17	O	
7	-	O	
8	mer	O	
9	oligonucleotide	O	
10	demonstrated	O	
11	the	O	
12	absence	O	
13	of	O	
14	the	O	
15	mutant	O	
16	sequence	O	
17	in	O	
18	the	O	
19	mRNA	O	
20	from	O	
21	which	O	
22	the	O	
23	cDNA	O	
24	library	O	
25	giving	O	
26	rise	O	
27	to	O	
28	the	O	
29	mutant	O	
30	cDNA	O	
31	was	O	
32	constructed	O	
33	.	O	

1	Positional	O	
2	cloning	O	
3	has	O	
4	already	O	
5	produced	O	
6	the	O	
7	sequences	O	
8	of	O	
9	more	O	
10	than	O	
11	70	O	
12	human	O	
13	genes	O	
14	associated	O	
15	with	O	
16	specific	O	
17	diseases	O	
18	.	O	

1	This	O	
2	proposed	O	
3	method	O	
4	is	O	
5	similar	O	
6	in	O	
7	principle	O	
8	to	O	
9	the	O	
10	sets	O	
11	technique	O	
12	but	O	
13	is	O	
14	shown	O	
15	to	O	
16	have	O	
17	much	O	
18	better	O	
19	expected	O	
20	time	O	
21	to	O	
22	alarm	O	
23	properties	O	
24	.	O	

1	A	O	
2	.	O	

1	However	O	
2	,	O	
3	the	O	
4	signaling	O	
5	cascade	O	
6	utilized	O	
7	by	O	
8	the	O	
9	urokinase	B	
10	receptor	I	
11	is	O	
12	only	O	
13	incompletely	O	
14	understood	O	
15	.	O	

1	IRF	B	
2	-	I	
3	1	I	
4	acts	O	
5	as	O	
6	a	O	
7	transcriptional	O	
8	activator	O	
9	,	O	
10	while	O	
11	IRF	B	
12	-	I	
13	2	I	
14	acts	O	
15	as	O	
16	a	O	
17	repressor	O	
18	.	O	

1	The	O	
2	84	B	
3	.	I	
4	1C	I	
5	mAb	I	
6	recognizes	O	
7	a	O	
8	site	O	
9	on	O	
10	IgE	B	
11	which	O	
12	is	O	
13	identical	O	
14	or	O	
15	very	O	
16	close	O	
17	to	O	
18	the	O	
19	Fc	B	
20	epsilon	I	
21	R	I	
22	binding	I	
23	site	I	
24	,	O	
25	and	O	
26	95	O	
27	.	O	
28	3	O	
29	recognizes	O	
30	a	O	
31	site	O	
32	on	O	
33	IgE	B	
34	which	O	
35	is	O	
36	related	O	
37	,	O	
38	but	O	
39	not	O	
40	identical	O	
41	to	O	
42	the	O	
43	Fc	B	
44	epsilon	I	
45	R	I	
46	binding	I	
47	site	I	
48	.	O	

1	Kinetics	O	
2	of	O	
3	the	O	
4	inhibition	O	
5	indicated	O	
6	that	O	
7	this	O	
8	polymerase	O	
9	domain	O	
10	can	O	
11	inhibit	O	
12	viral	O	
13	replication	O	
14	only	O	
15	during	O	
16	the	O	
17	preinitiation	O	
18	stage	O	
19	.	O	

1	Fas	B	
2	has	O	
3	been	O	
4	shown	O	
5	to	O	
6	require	O	
7	ICE	B	
8	(	O	
9	interleukin	B	
10	-	I	
11	1	I	
12	beta	I	
13	-	I	
14	converting	I	
15	enzyme	I	
16	)	O	
17	family	O	
18	proteases	O	
19	to	O	
20	induce	O	
21	apoptosis	O	
22	from	O	
23	studies	O	
24	utilizing	O	
25	the	O	
26	cowpox	O	
27	ICE	B	
28	inhibitor	I	
29	protein	I	
30	CrmA	I	
31	,	O	
32	the	O	
33	synthetic	O	
34	tetrapeptide	O	
35	ICE	B	
36	inhibitor	O	
37	YVAD	B	
38	-	I	
39	CMK	I	
40	,	O	
41	and	O	
42	the	O	
43	tripeptide	O	
44	pan	O	
45	-	O	
46	ICE	B	
47	inhibitor	O	
48	Z	B	
49	-	I	
50	VAD	I	
51	-	I	
52	FMK	I	
53	.	O	

1	Compensatory	O	
2	renal	O	
3	hypertrophy	O	
4	in	O	
5	parabiotic	O	
6	rats	O	
7	.	O	

1	RNase	B	
2	protection	O	
3	and	O	
4	primer	O	
5	extension	O	
6	assays	O	
7	confirmed	O	
8	that	O	
9	the	O	
10	5	O	
11	'	O	
12	non	O	
13	-	O	
14	coding	O	
15	exon	O	
16	is	O	
17	included	O	
18	in	O	
19	the	O	
20	DDT1	O	
21	aFGF	B	
22	mRNA	I	
23	and	O	
24	that	O	
25	a	O	
26	major	O	
27	transcription	O	
28	start	O	
29	site	O	
30	is	O	
31	approximately	O	
32	136	O	
33	bp	O	
34	upstream	O	
35	of	O	
36	the	O	
37	5	O	
38	'	O	
39	non	O	
40	-	O	
41	coding	O	
42	splice	O	
43	junction	O	
44	of	O	
45	this	O	
46	exon	O	
47	.	O	

1	During	O	
2	the	O	
3	2h	O	
4	resuscitation	O	
5	period	O	
6	,	O	
7	extracellular	O	
8	aspartate	O	
9	and	O	
10	glutamate	O	
11	concentrations	O	
12	in	O	
13	the	O	
14	cerebral	O	
15	striatum	O	
16	were	O	
17	higher	O	
18	during	O	
19	hypoxaemic	O	
20	resuscitation	O	
21	(	O	
22	p	O	
23	=	O	
24	0	O	
25	.	O	
26	044	O	
27	and	O	
28	p	O	
29	=	O	
30	0	O	
31	.	O	
32	055	O	
33	,	O	
34	respectively	O	
35	)	O	
36	than	O	
37	during	O	
38	resuscitation	O	
39	with	O	
40	21	O	
41	%	O	
42	O2	O	
43	or	O	
44	100	O	
45	%	O	
46	O2	O	
47	,	O	
48	suggesting	O	
49	an	O	
50	unfavourable	O	
51	accumulation	O	
52	of	O	
53	potent	O	
54	excitotoxins	O	
55	during	O	
56	hypoxaemic	O	
57	resuscitation	O	
58	.	O	

1	Deletion	O	
2	analyses	O	
3	of	O	
4	the	O	
5	construct	O	
6	revealed	O	
7	that	O	
8	the	O	
9	transcription	O	
10	of	O	
11	BOXF1	B	
12	gene	I	
13	is	O	
14	regulated	O	
15	by	O	
16	BOX	O	
17	DNA	O	
18	,	O	
19	preferentially	O	
20	in	O	
21	undifferentiated	O	
22	EC	O	
23	cells	O	
24	versus	O	
25	differentiated	O	
26	cells	O	
27	.	O	

1	L	O	
2	.,	O	
3	Stange	O	
4	,	O	
5	G	O	
6	.,	O	
7	Markovich	O	
8	,	O	
9	D	O	
10	.,	O	
11	Biber	O	
12	,	O	
13	J	O	
14	.,	O	
15	Testar	O	
16	,	O	
17	X	O	
18	.,	O	
19	Zorzano	O	
20	,	O	
21	A	O	
22	.,	O	
23	Palacin	O	
24	,	O	
25	M	O	
26	.,	O	
27	and	O	
28	Murer	O	
29	,	O	
30	H	O	
31	.	O	

1	The	O	
2	amino	O	
3	-	O	
4	terminal	O	
5	region	O	
6	of	O	
7	E1A	B	
8	binds	O	
9	several	O	
10	high	O	
11	molecular	O	
12	weight	O	
13	proteins	O	
14	and	O	
15	inhibits	O	
16	the	O	
17	transcriptional	O	
18	coactivator	O	
19	function	O	
20	of	O	
21	p300	B	
22	and	O	
23	the	O	
24	homologous	O	
25	cAMP	B	
26	response	I	
27	element	I	
28	(	I	
29	CRE	I	
30	)-	I	
31	binding	I	
32	protein	I	
33	.	O	

1	One	O	
2	complex	O	
3	most	O	
4	likely	O	
5	contained	O	
6	Sp1	B	
7	,	O	
8	and	O	
9	another	O	
10	complex	O	
11	showed	O	
12	S	O	
13	-	O	
14	phase	O	
15	-	O	
16	specific	O	
17	binding	O	
18	,	O	
19	suggesting	O	
20	a	O	
21	direct	O	
22	role	O	
23	in	O	
24	the	O	
25	cell	O	
26	-	O	
27	cycle	O	
28	-	O	
29	dependent	O	
30	R1	B	
31	gene	I	
32	expression	O	
33	.	O	

1	A	O	
2	randomised	O	
3	,	O	
4	controlled	O	
5	trial	O	
6	was	O	
7	undertaken	O	
8	in	O	
9	40	O	
10	patients	O	
11	with	O	
12	active	O	
13	Crohn	O	
14	'	O	
15	s	O	
16	disease	O	
17	to	O	
18	evaluate	O	
19	clinical	O	
20	and	O	
21	nutritional	O	
22	outcomes	O	
23	after	O	
24	an	O	
25	amino	O	
26	acid	O	
27	based	O	
28	diet	O	
29	containing	O	
30	3	O	
31	%	O	
32	fat	O	
33	was	O	
34	given	O	
35	by	O	
36	a	O	
37	feeding	O	
38	tube	O	
39	compared	O	
40	with	O	
41	a	O	
42	peptide	O	
43	based	O	
44	diet	O	
45	containing	O	
46	33	O	
47	%	O	
48	fat	O	
49	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	REP21	O	
5	plants	O	
6	were	O	
7	resistant	O	
8	to	O	
9	an	O	
10	unusually	O	
11	broad	O	
12	range	O	
13	of	O	
14	tobamoviruses	O	
15	including	O	
16	tomato	O	
17	mosaic	O	
18	virus	O	
19	,	O	
20	tobacco	O	
21	mild	O	
22	green	O	
23	mosaic	O	
24	virus	O	
25	,	O	
26	TMV	O	
27	-	O	
28	U5	O	
29	,	O	
30	green	O	
31	tomato	O	
32	atypical	O	
33	mosaic	O	
34	virus	O	
35	,	O	
36	and	O	
37	ribgrass	O	
38	mosaic	O	
39	virus	O	
40	.	O	

1	The	O	
2	second	O	
3	transcript	O	
4	,	O	
5	rhis4l	B	
6	,	O	
7	is	O	
8	bicistronic	O	
9	.	O	

1	During	O	
2	pentobarbital	O	
3	anesthesia	O	
4	,	O	
5	the	O	
6	basal	O	
7	VO2	O	
8	was	O	
9	5	O	
10	.	O	
11	26	O	
12	ml	O	
13	/	O	
14	kg	O	
15	/	O	
16	min	O	
17	and	O	
18	was	O	
19	increased	O	
20	by	O	
21	epinephrine	O	
22	in	O	
23	a	O	
24	dose	O	
25	dependent	O	
26	manner	O	
27	at	O	
28	plasma	O	
29	concentrations	O	
30	between	O	
31	3	O	
32	.	O	
33	9	O	
34	ng	O	
35	/	O	
36	ml	O	
37	(	O	
38	VO2	O	
39	=	O	
40	5	O	
41	.	O	
42	68	O	
43	ml	O	
44	/	O	
45	kg	O	
46	/	O	
47	min	O	
48	)	O	
49	and	O	
50	36	O	
51	.	O	
52	5	O	
53	ng	O	
54	/	O	
55	ml	O	
56	(	O	
57	VO2	O	
58	=	O	
59	6	O	
60	.	O	
61	47	O	
62	ml	O	
63	/	O	
64	kg	O	
65	/	O	
66	min	O	
67	).	O	

1	Finally	O	
2	,	O	
3	we	O	
4	determined	O	
5	that	O	
6	the	O	
7	P68	B	
8	amino	O	
9	terminus	O	
10	was	O	
11	both	O	
12	necessary	O	
13	and	O	
14	sufficient	O	
15	for	O	
16	binding	O	
17	dsRNA	O	
18	as	O	
19	we	O	
20	were	O	
21	able	O	
22	to	O	
23	transfer	O	
24	dsRNA	O	
25	-	O	
26	binding	O	
27	properties	O	
28	to	O	
29	a	O	
30	reporter	O	
31	gene	O	
32	product	O	
33	previously	O	
34	unable	O	
35	to	O	
36	bind	O	
37	RNA	O	
38	.	O	

1	Five	O	
2	of	O	
3	these	O	
4	have	O	
5	ocular	O	
6	or	O	
7	oculocutaneous	O	
8	albinism	O	
9	.	O	

1	Evaluation	O	
2	of	O	
3	thyroid	O	
4	function	O	
5	.	O	

1	About	O	
2	20	O	
3	%	O	
4	of	O	
5	single	O	
6	-	O	
7	stranded	O	
8	DNA	O	
9	binding	O	
10	was	O	
11	observed	O	
12	in	O	
13	the	O	
14	presence	O	
15	of	O	
16	MgdTDP	O	
17	,	O	
18	but	O	
19	none	O	
20	was	O	
21	detectable	O	
22	in	O	
23	the	O	
24	absence	O	
25	of	O	
26	nucleotides	O	
27	.	O	

1	To	O	
2	determine	O	
3	the	O	
4	effects	O	
5	on	O	
6	the	O	
7	pulmonary	O	
8	barrier	O	
9	of	O	
10	several	O	
11	surface	O	
12	active	O	
13	agents	O	
14	,	O	
15	a	O	
16	series	O	
17	of	O	
18	metered	O	
19	dose	O	
20	inhalers	O	
21	(	O	
22	MDIs	O	
23	)	O	
24	was	O	
25	prepared	O	
26	and	O	
27	used	O	
28	to	O	
29	dose	O	
30	aerosolized	O	
31	surfactant	O	
32	to	O	
33	the	O	
34	airways	O	
35	of	O	
36	isolated	O	
37	perfused	O	
38	rat	O	
39	lungs	O	
40	.	O	

1	The	O	
2	genetic	O	
3	basis	O	
4	for	O	
5	the	O	
6	expression	O	
7	of	O	
8	a	O	
9	latent	O	
10	VH	B	
11	allotype	I	
12	in	O	
13	the	O	
14	rabbit	O	
15	was	O	
16	investigated	O	
17	.	O	

1	Of	O	
2	those	O	
3	injuries	O	
4	,	O	
5	143	O	
6	cases	O	
7	were	O	
8	snowboard	O	
9	related	O	
10	and	O	
11	158	O	
12	cases	O	
13	were	O	
14	ski	O	
15	related	O	
16	.	O	

1	These	O	
2	results	O	
3	suggest	O	
4	that	O	
5	FK	O	
6	506	O	
7	is	O	
8	a	O	
9	useful	O	
10	immunosuppressive	O	
11	agent	O	
12	in	O	
13	kidney	O	
14	transplantation	O	
15	.	O	

1	Codon	O	
2	usage	O	
3	in	O	
4	C	O	
5	.	O	
6	reinhardtii	O	
7	mitochondria	O	
8	is	O	
9	highly	O	
10	biased	O	
11	,	O	
12	with	O	
13	eight	O	
14	codons	O	
15	entirely	O	
16	absent	O	
17	from	O	
18	all	O	
19	protein	O	
20	-	O	
21	coding	O	
22	genes	O	
23	;	O	
24	however	O	
25	,	O	
26	even	O	
27	though	O	
28	codon	O	
29	usage	O	
30	is	O	
31	restricted	O	
32	,	O	
33	it	O	
34	appears	O	
35	that	O	
36	C	O	
37	.	O	
38	reinhardtii	O	
39	mtDNA	O	
40	cannot	O	
41	encode	O	
42	the	O	
43	minimum	O	
44	number	O	
45	of	O	
46	tRNAs	O	
47	needed	O	
48	to	O	
49	support	O	
50	mitochondrial	O	
51	protein	O	
52	synthesis	O	
53	.	O	

1	Thus	O	
2	,	O	
3	the	O	
4	multidomained	O	
5	ROK	B	
6	alpha	I	
7	appears	O	
8	to	O	
9	be	O	
10	involved	O	
11	in	O	
12	reorganization	O	
13	of	O	
14	the	O	
15	cytoskeleton	O	
16	,	O	
17	with	O	
18	the	O	
19	N	O	
20	and	O	
21	C	O	
22	termini	O	
23	acting	O	
24	as	O	
25	positive	O	
26	and	O	
27	negative	O	
28	regulators	O	
29	,	O	
30	respectively	O	
31	,	O	
32	of	O	
33	the	O	
34	kinase	O	
35	domain	O	
36	whose	O	
37	activity	O	
38	is	O	
39	crucial	O	
40	for	O	
41	formation	O	
42	of	O	
43	stress	O	
44	fibers	O	
45	and	O	
46	focal	O	
47	adhesion	O	
48	complexes	O	
49	.	O	

1	The	O	
2	RanQ69L	B	
3	preincubation	O	
4	leads	O	
5	to	O	
6	accumulation	O	
7	of	O	
8	CRM1	B	
9	at	O	
10	the	O	
11	cytoplasmic	O	
12	periphery	O	
13	of	O	
14	the	O	
15	nuclear	O	
16	pore	O	
17	complex	O	
18	(	O	
19	NPC	O	
20	)	O	
21	in	O	
22	association	O	
23	with	O	
24	the	O	
25	p62	B	
26	complex	I	
27	and	O	
28	Can	B	
29	/	O	
30	Nup214	B	
31	.	O	

1	A	O	
2	method	O	
3	is	O	
4	described	O	
5	for	O	
6	detecting	O	
7	targeted	O	
8	events	O	
9	at	O	
10	the	O	
11	mu	B	
12	heavy	I	
13	chain	I	
14	gene	I	
15	which	O	
16	relies	O	
17	on	O	
18	co	O	
19	-	O	
20	conversion	O	
21	(	O	
22	or	O	
23	co	O	
24	-	O	
25	exchange	O	
26	)	O	
27	of	O	
28	a	O	
29	point	O	
30	mutation	O	
31	with	O	
32	a	O	
33	selectable	O	
34	marker	O	
35	contained	O	
36	on	O	
37	a	O	
38	replacement	O	
39	vector	O	
40	.	O	

1	1	O	
2	("	O	
3	long	O	
4	method	O	
5	")	O	
6	and	O	
7	the	O	
8	HML	O	
9	method	O	
10	.	O	

1	Moreover	O	
2	,	O	
3	we	O	
4	found	O	
5	that	O	
6	cyclin	B	
7	E	I	
8	,	O	
9	in	O	
10	contrast	O	
11	to	O	
12	cyclin	B	
13	D1	I	
14	,	O	
15	was	O	
16	required	O	
17	for	O	
18	the	O	
19	G1	O	
20	/	O	
21	S	O	
22	transition	O	
23	even	O	
24	in	O	
25	cells	O	
26	lacking	O	
27	retinoblastoma	B	
28	protein	I	
29	function	O	
30	.	O	

1	Point	O	
2	mutations	O	
3	in	O	
4	the	O	
5	third	O	
6	SH3	B	
7	domain	I	
8	abolished	O	
9	the	O	
10	vinexin	B	
11	-	O	
12	Sos	B	
13	interaction	O	
14	.	O	

1	Characterization	O	
2	of	O	
3	the	O	
4	3	O	
5	'	O	
6	ends	O	
7	of	O	
8	the	O	
9	plus	O	
10	-	O	
11	strand	O	
12	DNA	O	
13	fragments	O	
14	reveals	O	
15	(	O	
16	1	O	
17	)	O	
18	that	O	
19	the	O	
20	upstream	O	
21	fragment	O	
22	is	O	
23	elongated	O	
24	beyond	O	
25	PPT2	B	
26	creating	O	
27	a	O	
28	plus	O	
29	-	O	
30	strand	O	
31	overlap	O	
32	and	O	
33	(	O	
34	2	O	
35	)	O	
36	that	O	
37	the	O	
38	majority	O	
39	of	O	
40	plus	O	
41	-	O	
42	strand	O	
43	strong	O	
44	-	O	
45	stop	O	
46	DNA	O	
47	fragments	O	
48	bear	O	
49	a	O	
50	copy	O	
51	of	O	
52	the	O	
53	minus	O	
54	-	O	
55	strand	O	
56	primer	O	
57	binding	O	
58	site	O	
59	in	O	
60	agreement	O	
61	with	O	
62	the	O	
63	accepted	O	
64	model	O	
65	of	O	
66	retroviral	O	
67	genomic	O	
68	RNA	O	
69	reverse	O	
70	transcription	O	
71	.	O	

1	Our	O	
2	results	O	
3	showed	O	
4	that	O	
5	compared	O	
6	to	O	
7	the	O	
8	primary	O	
9	photon	O	
10	fluence	O	
11	,	O	
12	the	O	
13	extra	O	
14	-	O	
15	focal	O	
16	photon	O	
17	fluence	O	
18	from	O	
19	the	O	
20	primary	O	
21	collimator	O	
22	and	O	
23	the	O	
24	flattening	O	
25	filter	O	
26	was	O	
27	11	O	
28	%-	O	
29	16	O	
30	%	O	
31	at	O	
32	the	O	
33	isocenter	O	
34	,	O	
35	among	O	
36	which	O	
37	70	O	
38	%	O	
39	was	O	
40	contributed	O	
41	by	O	
42	the	O	
43	flattening	O	
44	filter	O	
45	.	O	

1	Here	O	
2	we	O	
3	report	O	
4	that	O	
5	the	O	
6	proline	O	
7	-	O	
8	rich	O	
9	region	O	
10	of	O	
11	CAP	B	
12	is	O	
13	recognized	O	
14	by	O	
15	the	O	
16	SH3	B	
17	domains	I	
18	of	O	
19	several	O	
20	proteins	O	
21	,	O	
22	including	O	
23	the	O	
24	yeast	B	
25	actin	I	
26	-	I	
27	associated	I	
28	protein	I	
29	Abp1p	I	
30	.	O	

1	All	O	
2	clinical	O	
3	isolates	O	
4	were	O	
5	concomitantly	O	
6	tested	O	
7	by	O	
8	disk	O	
9	diffusion	O	
10	and	O	
11	agar	O	
12	dilution	O	
13	procedures	O	
14	as	O	
15	outlined	O	
16	by	O	
17	the	O	
18	National	O	
19	Committee	O	
20	for	O	
21	Clinical	O	
22	Laboratory	O	
23	Standards	O	
24	.	O	

1	Regional	O	
2	insertional	O	
3	mutagenesis	O	
4	of	O	
5	specific	O	
6	genes	O	
7	on	O	
8	the	O	
9	CIC5F11	B	
10	/	O	
11	CIC2B9	B	
12	locus	O	
13	of	O	
14	Arabidopsis	O	
15	thaliana	O	
16	chromosome	O	
17	5	O	
18	using	O	
19	the	O	
20	Ac	B	
21	/	O	
22	Ds	B	
23	transposon	O	
24	in	O	
25	combination	O	
26	with	O	
27	the	O	
28	cDNA	O	
29	scanning	O	
30	method	O	
31	.	O	

1	Among	O	
2	them	O	
3	,	O	
4	26	O	
5	cases	O	
6	were	O	
7	benign	O	
8	and	O	
9	34	O	
10	malignant	O	
11	.	O	

1	Determination	O	
2	of	O	
3	20	O	
4	alpha	O	
5	-	O	
6	hydroxy	O	
7	-	O	
8	9	O	
9	beta	O	
10	,	O	
11	10	O	
12	alpha	O	
13	-	O	
14	pregna	O	
15	-	O	
16	4	O	
17	,	O	
18	6	O	
19	-	O	
20	dien	O	
21	-	O	
22	3	O	
23	-	O	
24	one	O	
25	in	O	
26	plasma	O	
27	by	O	
28	selected	O	
29	ion	O	
30	monitoring	O	
31	.	O	

1	The	O	
2	nucleotide	O	
3	sequence	O	
4	of	O	
5	22	O	
6	,	O	
7	846	O	
8	bp	O	
9	of	O	
10	the	O	
11	left	O	
12	arm	O	
13	of	O	
14	chromosome	O	
15	IV	O	
16	is	O	
17	described	O	
18	.	O	

1	Sequencing	O	
2	of	O	
3	the	O	
4	16p	O	
5	11	O	
6	.	O	
7	1	O	
8	/	O	
9	Xq28	O	
10	duplication	O	
11	breakpoints	O	
12	has	O	
13	revealed	O	
14	the	O	
15	presence	O	
16	of	O	
17	repetitive	O	
18	immunoglobulin	B	
19	-	I	
20	like	I	
21	CAGGG	I	
22	pentamer	I	
23	sequences	I	
24	at	O	
25	or	O	
26	near	O	
27	the	O	
28	paralogy	O	
29	boundaries	O	
30	.	O	

1	Zinc	O	
2	fingers	O	
3	(	O	
4	Zf	O	
5	)	O	
6	are	O	
7	a	O	
8	common	O	
9	structural	O	
10	motif	O	
11	found	O	
12	in	O	
13	many	O	
14	nucleic	O	
15	acid	O	
16	-	O	
17	binding	O	
18	proteins	O	
19	.	O	

1	Spores	O	
2	from	O	
3	Rhizopus	O	
4	stolonifer	O	
5	were	O	
6	suspended	O	
7	in	O	
8	distilled	O	
9	water	O	
10	(	O	
11	1	O	
12	x	O	
13	10	O	
14	(	O	
15	6	O	
16	)	O	
17	spores	O	
18	/	O	
19	mL	O	
20	)	O	
21	and	O	
22	used	O	
23	as	O	
24	starter	O	
25	.	O	

1	These	O	
2	results	O	
3	suggest	O	
4	that	O	
5	ULK2	B	
6	is	O	
7	involved	O	
8	in	O	
9	a	O	
10	previously	O	
11	uncharacterized	O	
12	signaling	O	
13	pathway	O	
14	in	O	
15	mammalian	O	
16	cells	O	
17	.	O	

1	The	O	
2	remaining	O	
3	RAD	B	
4	+	I	
5	cells	O	
6	progressed	O	
7	to	O	
8	form	O	
9	microcolonies	O	
10	(<	O	
11	30	O	
12	cells	O	
13	)	O	
14	containing	O	
15	aberrantly	O	
16	shaped	O	
17	inviable	O	
18	cells	O	
19	.	O	

1	There	O	
2	were	O	
3	27	O	
4	men	O	
5	and	O	
6	156	O	
7	women	O	
8	.	O	

1	Erythrocyte	B	
2	delta	I	
3	-	I	
4	aminolevulinic	I	
5	acid	I	
6	dehydratase	I	
7	(	O	
8	ALAD	B	
9	)	O	
10	activity	O	
11	,	O	
12	erythrocyte	O	
13	zinc	O	
14	protoporphyrin	O	
15	(	O	
16	ZPP	O	
17	)/	O	
18	heme	O	
19	ratio	O	
20	,	O	
21	and	O	
22	urinary	O	
23	coproporphyrin	O	
24	(	O	
25	UC	O	
26	)	O	
27	concentration	O	
28	have	O	
29	been	O	
30	employed	O	
31	as	O	
32	biological	O	
33	indicators	O	
34	of	O	
35	moderate	O	
36	-	O	
37	to	O	
38	high	O	
39	-	O	
40	level	O	
41	lead	O	
42	exposure	O	
43	,	O	
44	corresponding	O	
45	to	O	
46	blood	O	
47	levels	O	
48	in	O	
49	excess	O	
50	of	O	
51	50	O	
52	micrograms	O	
53	/	O	
54	dl	O	
55	,	O	
56	in	O	
57	human	O	
58	subjects	O	
59	.	O	

1	From	O	
2	February	O	
3	1991	O	
4	to	O	
5	August	O	
6	1997	O	
7	,	O	
8	124	O	
9	patients	O	
10	with	O	
11	endometrial	O	
12	carcinoma	O	
13	were	O	
14	treated	O	
15	postoperatively	O	
16	with	O	
17	high	O	
18	-	O	
19	dose	O	
20	-	O	
21	rate	O	
22	vaginal	O	
23	vault	O	
24	brachytherapy	O	
25	as	O	
26	the	O	
27	only	O	
28	adjuvant	O	
29	treatment	O	
30	.	O	

1	On	O	
2	the	O	
3	basis	O	
4	of	O	
5	S1	B	
6	nuclease	I	
7	protection	O	
8	analysis	O	
9	of	O	
10	RNA	O	
11	preparations	O	
12	from	O	
13	several	O	
14	mouse	O	
15	tissues	O	
16	,	O	
17	both	O	
18	dhfr	B	
19	and	O	
20	divergent	O	
21	genes	O	
22	showed	O	
23	similar	O	
24	levels	O	
25	of	O	
26	expression	O	
27	but	O	
28	did	O	
29	show	O	
30	some	O	
31	specificity	O	
32	in	O	
33	start	O	
34	site	O	
35	utilization	O	
36	.	O	

1	P	O	
2	.,	O	
3	Peyron	O	
4	,	O	
5	J	O	
6	.	O	

1	Pentobarbital	O	
2	(	O	
3	1	O	
4	,	O	
5	3	O	
6	,	O	
7	10	O	
8	,	O	
9	and	O	
10	17	O	
11	.	O	
12	5	O	
13	mg	O	
14	/	O	
15	kg	O	
16	)	O	
17	was	O	
18	also	O	
19	tested	O	
20	in	O	
21	combination	O	
22	with	O	
23	rate	O	
24	-	O	
25	decreasing	O	
26	doses	O	
27	of	O	
28	normeperidine	O	
29	(	O	
30	17	O	
31	.	O	
32	5	O	
33	mg	O	
34	/	O	
35	kg	O	
36	),	O	
37	anileridine	O	
38	(	O	
39	10	O	
40	mg	O	
41	/	O	
42	kg	O	
43	),	O	
44	alphaprodine	O	
45	(	O	
46	10	O	
47	mg	O	
48	/	O	
49	kg	O	
50	),	O	
51	and	O	
52	fentanyl	O	
53	(	O	
54	0	O	
55	.	O	
56	3	O	
57	mg	O	
58	/	O	
59	kg	O	
60	).	O	

1	The	O	
2	data	O	
3	indicate	O	
4	that	O	
5	the	O	
6	minimal	O	
7	catalytic	O	
8	domain	O	
9	of	O	
10	Nmt1p	B	
11	is	O	
12	located	O	
13	between	O	
14	Ile59	O	
15	-->	O	
16	Phe96	O	
17	and	O	
18	Gly451	O	
19	-->	O	
20	Leu455	O	
21	.	O	

1	Based	O	
2	on	O	
3	previous	O	
4	mapping	O	
5	of	O	
6	the	O	
7	G	B	
8	beta	I	
9	gamma	I	
10	binding	I	
11	region	I	
12	of	O	
13	beta	B	
14	ARK	I	
15	,	O	
16	and	O	
17	conserved	O	
18	residues	O	
19	within	O	
20	the	O	
21	PH	B	
22	domain	I	
23	,	O	
24	we	O	
25	have	O	
26	constructed	O	
27	a	O	
28	series	O	
29	of	O	
30	mutants	O	
31	in	O	
32	the	O	
33	carboxyl	O	
34	terminus	O	
35	of	O	
36	beta	B	
37	ARK	I	
38	in	O	
39	order	O	
40	to	O	
41	determine	O	
42	important	O	
43	residues	O	
44	involved	O	
45	in	O	
46	G	B	
47	beta	I	
48	gamma	I	
49	and	O	
50	PIP2	O	
51	binding	O	
52	.	O	

1	Both	O	
2	HERV	O	
3	-	O	
4	K	O	
5	type	O	
6	1	O	
7	and	O	
8	2	O	
9	clones	O	
10	were	O	
11	isolated	O	
12	.	O	

1	The	O	
2	central	O	
3	(	O	
4	R	O	
5	)	O	
6	domain	O	
7	is	O	
8	responsible	O	
9	for	O	
10	receptor	O	
11	-	O	
12	binding	O	
13	activity	O	
14	whereas	O	
15	the	O	
16	N	O	
17	-	O	
18	terminal	O	
19	(	O	
20	T	O	
21	)	O	
22	domain	O	
23	mediates	O	
24	translocation	O	
25	,	O	
26	the	O	
27	process	O	
28	by	O	
29	which	O	
30	the	O	
31	C	O	
32	-	O	
33	terminal	O	
34	cytotoxic	O	
35	domain	O	
36	is	O	
37	transported	O	
38	from	O	
39	the	O	
40	receptor	O	
41	to	O	
42	the	O	
43	site	O	
44	of	O	
45	its	O	
46	cytotoxicity	O	
47	.	O	

1	The	O	
2	Man9	B	
3	-	I	
4	mannosidase	I	
5	specificity	O	
6	of	O	
7	the	O	
8	cDNA	O	
9	construct	O	
10	was	O	
11	verified	O	
12	by	O	
13	the	O	
14	observation	O	
15	that	O	
16	all	O	
17	peptide	O	
18	sequences	O	
19	derived	O	
20	from	O	
21	a	O	
22	previously	O	
23	purified	O	
24	,	O	
25	catalytically	O	
26	active	O	
27	49	O	
28	-	O	
29	kDa	O	
30	fragment	O	
31	were	O	
32	found	O	
33	within	O	
34	the	O	
35	coding	O	
36	region	O	
37	.	O	

1	However	O	
2	,	O	
3	while	O	
4	the	O	
5	sequence	O	
6	similarity	O	
7	between	O	
8	the	O	
9	membrane	O	
10	exons	O	
11	of	O	
12	avian	B	
13	mIgY	I	
14	and	O	
15	mammalian	B	
16	mIgG	I	
17	and	I	
18	IgE	I	
19	is	O	
20	striking	O	
21	,	O	
22	the	O	
23	overall	O	
24	similarity	O	
25	with	O	
26	Xenopus	B	
27	mIgY	I	
28	is	O	
29	very	O	
30	low	O	
31	.	O	

1	The	O	
2	correlation	O	
3	between	O	
4	PaCO2	O	
5	and	O	
6	PtcO2	O	
7	in	O	
8	RDS	O	
9	was	O	
10	insufficient	O	
11	to	O	
12	make	O	
13	clinical	O	
14	judgement	O	
15	.	O	

1	Observations	O	
2	on	O	
3	the	O	
4	flight	O	
5	activities	O	
6	of	O	
7	Chrysops	O	
8	caecutiens	O	
9	L	O	
10	.	O	

1	Prenatal	O	
2	exposure	O	
3	to	O	
4	the	O	
5	fungicide	O	
6	dinocap	O	
7	causes	O	
8	behavioral	O	
9	torticollis	O	
10	,	O	
11	ballooning	O	
12	and	O	
13	cleft	O	
14	palate	O	
15	in	O	
16	mice	O	
17	,	O	
18	but	O	
19	not	O	
20	rats	O	
21	or	O	
22	hamsters	O	
23	.	O	

1	Translation	O	
2	of	O	
3	the	O	
4	coding	O	
5	segment	O	
6	,	O	
7	which	O	
8	was	O	
9	designated	O	
10	MsPRP2	B	
11	,	O	
12	suggested	O	
13	it	O	
14	encodes	O	
15	a	O	
16	chimeric	O	
17	40	O	
18	,	O	
19	569	O	
20	Da	O	
21	cell	O	
22	wall	O	
23	protein	O	
24	with	O	
25	an	O	
26	amino	O	
27	-	O	
28	terminal	O	
29	signal	O	
30	sequence	O	
31	,	O	
32	a	O	
33	repetitive	O	
34	proline	O	
35	-	O	
36	rich	O	
37	sequence	O	
38	,	O	
39	and	O	
40	a	O	
41	cysteine	O	
42	-	O	
43	rich	O	
44	carboxyl	O	
45	-	O	
46	terminal	O	
47	sequence	O	
48	homologous	O	
49	to	O	
50	nonspecific	O	
51	lipid	O	
52	transfer	O	
53	proteins	O	
54	.	O	

1	TPO	B	
2	by	O	
3	itself	O	
4	did	O	
5	not	O	
6	activate	O	
7	ERK1	B	
8	,	O	
9	ERK2	B	
10	and	O	
11	protein	B	
12	kinase	I	
13	C	I	
14	(	O	
15	PKC	B	
16	),	O	
17	whereas	O	
18	TPO	B	
19	directly	O	
20	enhanced	O	
21	the	O	
22	PKC	B	
23	-	O	
24	dependent	O	
25	activation	O	
26	of	O	
27	ERKs	B	
28	induced	O	
29	by	O	
30	other	O	
31	agonists	O	
32	including	O	
33	thrombin	B	
34	and	O	
35	phorbol	O	
36	esters	O	
37	,	O	
38	without	O	
39	affecting	O	
40	the	O	
41	PKC	B	
42	activation	O	
43	by	O	
44	those	O	
45	agonists	O	
46	.	O	

1	The	O	
2	HPLC	O	
3	method	O	
4	involves	O	
5	an	O	
6	octadecylsilane	O	
7	column	O	
8	at	O	
9	55	O	
10	degrees	O	
11	C	O	
12	,	O	
13	a	O	
14	mixture	O	
15	of	O	
16	water	O	
17	-	O	
18	acetonitrile	O	
19	-	O	
20	orthophosphoric	O	
21	acid	O	
22	(	O	
23	779	O	
24	:	O	
25	220	O	
26	:	O	
27	1	O	
28	,	O	
29	v	O	
30	/	O	
31	v	O	
32	)	O	
33	as	O	
34	mobile	O	
35	phase	O	
36	and	O	
37	detection	O	
38	at	O	
39	226	O	
40	nm	O	
41	.	O	

1	These	O	
2	results	O	
3	illustrate	O	
4	an	O	
5	important	O	
6	role	O	
7	for	O	
8	La	B	
9	in	O	
10	RNA	O	
11	production	O	
12	by	O	
13	demonstrating	O	
14	its	O	
15	ability	O	
16	to	O	
17	clear	O	
18	the	O	
19	termination	O	
20	sites	O	
21	of	O	
22	class	O	
23	III	O	
24	templates	O	
25	,	O	
26	thereby	O	
27	promoting	O	
28	efficient	O	
29	use	O	
30	of	O	
31	transcription	O	
32	complexes	O	
33	by	O	
34	pol	B	
35	III	I	
36	.	O	

1	Unlike	O	
2	wild	B	
3	-	I	
4	type	I	
5	p53	I	
6	,	O	
7	the	O	
8	delta	B	
9	proAE	I	
10	mutant	I	
11	cDNA	I	
12	can	O	
13	be	O	
14	stably	O	
15	expressed	O	
16	in	O	
17	tumor	O	
18	derived	O	
19	cell	O	
20	lines	O	
21	with	O	
22	few	O	
23	immediate	O	
24	detrimental	O	
25	effects	O	
26	.	O	

1	At	O	
2	pH	O	
3	6	O	
4	.	O	
5	9	O	
6	,	O	
7	the	O	
8	same	O	
9	lidocaine	O	
10	concentrations	O	
11	significantly	O	
12	reduced	O	
13	resting	O	
14	potential	O	
15	(	O	
16	3	O	
17	-	O	
18	10	O	
19	%),	O	
20	action	O	
21	potential	O	
22	amplitude	O	
23	(	O	
24	3	O	
25	-	O	
26	8	O	
27	%)	O	
28	and	O	
29	Vmax	O	
30	(	O	
31	14	O	
32	-	O	
33	22	O	
34	%).	O	

1	The	O	
2	experiment	O	
3	results	O	
4	showed	O	
5	:	O	
6	(	O	
7	i	O	
8	)	O	
9	not	O	
10	only	O	
11	1O2	O	
12	,	O	
13	but	O	
14	also	O	
15	free	O	
16	radicals	O	
17	(	O	
18	O2	O	
19	-.	O	
20	.	O	
21	OH	O	
22	and	O	
23	YHPD	O	
24	-.)	O	
25	can	O	
26	be	O	
27	formed	O	
28	by	O	
29	the	O	
30	aid	O	
31	of	O	
32	YHPD	O	
33	;	O	
34	and	O	
35	(	O	
36	ii	O	
37	)	O	
38	as	O	
39	to	O	
40	the	O	
41	ability	O	
42	of	O	
43	producing	O	
44	1O2	O	
45	,	O	
46	YHPD	O	
47	less	O	
48	than	O	
49	BHPD	O	
50	,	O	
51	while	O	
52	for	O	
53	generating	O	
54	O2	O	
55	-.	O	
56	and	O	
57	.	O	
58	OH	O	
59	,	O	
60	YHPD	O	
61	greater	O	
62	than	O	
63	BHPD	O	
64	.	O	

1	Therefore	O	
2	,	O	
3	PC	B	
4	-	I	
5	PLC	I	
6	is	O	
7	a	O	
8	component	O	
9	of	O	
10	a	O	
11	signal	O	
12	transduction	O	
13	pathway	O	
14	leading	O	
15	to	O	
16	transcription	O	
17	of	O	
18	c	B	
19	-	I	
20	fos	I	
21	and	O	
22	junB	B	
23	that	O	
24	collaborates	O	
25	with	O	
26	c	B	
27	-	I	
28	myc	I	
29	and	O	
30	is	O	
31	independent	O	
32	of	O	
33	PKC	B	
34	-	I	
35	delta	I	
36	and	O	
37	Ras	B	
38	activation	O	
39	.	O	

1	Superoxide	B	
2	dismutase	I	
3	(	O	
4	SOD	B	
5	)	O	
6	activity	O	
7	decreased	O	
8	significantly	O	
9	in	O	
10	sperm	O	
11	subjected	O	
12	to	O	
13	direct	O	
14	electric	O	
15	current	O	
16	in	O	
17	comparison	O	
18	to	O	
19	the	O	
20	control	O	
21	or	O	
22	the	O	
23	sample	O	
24	incubated	O	
25	with	O	
26	electrolyzed	O	
27	medium	O	
28	.	O	

1	Autorosette	O	
2	-	O	
3	forming	O	
4	cells	O	
5	are	O	
6	characterized	O	
7	by	O	
8	a	O	
9	high	O	
10	activity	O	
11	of	O	
12	alkaline	B	
13	and	I	
14	acid	I	
15	phosphatases	I	
16	and	O	
17	low	O	
18	NBT	O	
19	-	O	
20	test	O	
21	values	O	
22	.	O	

1	Selective	O	
2	stimulation	O	
3	of	O	
4	central	O	
5	alpha	B	
6	-	I	
7	autoreceptors	I	
8	following	O	
9	treatment	O	
10	with	O	
11	alpha	O	
12	-	O	
13	methyldopa	O	
14	and	O	
15	FLA	O	
16	136	O	
17	.	O	

1	Using	O	
2	a	O	
3	v	B	
4	-	I	
5	erbA	I	
6	probe	O	
7	,	O	
8	we	O	
9	obtained	O	
10	a	O	
11	cDNA	O	
12	which	O	
13	encodes	O	
14	a	O	
15	novel	O	
16	445	O	
17	-	O	
18	amino	O	
19	-	O	
20	acid	O	
21	protein	O	
22	,	O	
23	RLD	B	
24	-	I	
25	1	I	
26	,	O	
27	that	O	
28	contains	O	
29	the	O	
30	characteristic	O	
31	domains	O	
32	of	O	
33	nuclear	O	
34	receptors	O	
35	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	a	O	
5	potent	O	
6	splicing	O	
7	enhancer	O	
8	sequence	O	
9	isolated	O	
10	in	O	
11	the	O	
12	selection	O	
13	specifically	O	
14	binds	O	
15	a	O	
16	20	B	
17	-	I	
18	kDa	I	
19	SR	I	
20	protein	I	
21	.	O	

1	Three	O	
2	mutants	O	
3	(	O	
4	pms1	B	
5	,	O	
6	pms2	B	
7	and	O	
8	pms3	B	
9	)	O	
10	isolated	O	
11	earlier	O	
12	from	O	
13	MW104	O	
14	-	O	
15	1B	O	
16	were	O	
17	shown	O	
18	to	O	
19	correct	O	
20	in	O	
21	vitro	O	
22	constructed	O	
23	plasmids	O	
24	with	O	
25	defined	O	
26	DNA	O	
27	mismatches	O	
28	(	O	
29	G	O	
30	/	O	
31	T	O	
32	,	O	
33	A	O	
34	/	O	
35	C	O	
36	,	O	
37	G	O	
38	/	O	
39	G	O	
40	,	O	
41	etc	O	
42	.)	O	
43	poorly	O	
44	(	O	
45	Kramer	O	
46	et	O	
47	al	O	
48	.,	O	
49	1989a	O	
50	).	O	

1	Thus	O	
2	,	O	
3	IRF	B	
4	-	I	
5	7	I	
6	exhibits	O	
7	functional	O	
8	similarity	O	
9	to	O	
10	IRF	B	
11	-	I	
12	3	I	
13	;	O	
14	however	O	
15	,	O	
16	the	O	
17	preferential	O	
18	expression	O	
19	of	O	
20	IRF	B	
21	-	I	
22	7	I	
23	in	O	
24	lymphoid	O	
25	cells	O	
26	(	O	
27	the	O	
28	cell	O	
29	type	O	
30	that	O	
31	expresses	O	
32	IFNA	B	
33	)	O	
34	suggests	O	
35	that	O	
36	IRF	B	
37	-	I	
38	7	I	
39	may	O	
40	play	O	
41	a	O	
42	critical	O	
43	role	O	
44	in	O	
45	regulating	O	
46	the	O	
47	IFNA	B	
48	gene	I	
49	expression	O	
50	.	O	

1	The	O	
2	lines	O	
3	also	O	
4	differed	O	
5	in	O	
6	postsynaptic	O	
7	,	O	
8	but	O	
9	not	O	
10	presynaptic	O	
11	,	O	
12	5	B	
13	-	I	
14	HT1A	I	
15	receptors	I	
16	.	O	

1	A	O	
2	single	O	
3	i	O	
4	.	O	
5	p	O	
6	.	O	
7	injection	O	
8	of	O	
9	d	O	
10	,	O	
11	l	O	
12	-	O	
13	baclofen	O	
14	10	O	
15	mg	O	
16	/	O	
17	kg	O	
18	both	O	
19	reduced	O	
20	noradrenaline	O	
21	(	O	
22	NA	O	
23	)	O	
24	biosynthesis	O	
25	in	O	
26	vivo	O	
27	(	O	
28	31	O	
29	%)	O	
30	and	O	
31	the	O	
32	endogenous	O	
33	concentration	O	
34	of	O	
35	normetanephrine	O	
36	(	O	
37	NMN	O	
38	)	O	
39	(	O	
40	32	O	
41	%)	O	
42	and	O	
43	increased	O	
44	NA	O	
45	levels	O	
46	(	O	
47	28	O	
48	%).	O	

1	Polarised	O	
2	expression	O	
3	of	O	
4	human	O	
5	intestinal	O	
6	N	B	
7	-	I	
8	benzoyl	I	
9	-	I	
10	L	I	
11	-	I	
12	tyrosyl	I	
13	-	I	
14	p	I	
15	-	I	
16	aminobenzoic	I	
17	acid	I	
18	hydrolase	I	
19	(	O	
20	human	B	
21	meprin	I	
22	)	O	
23	alpha	O	
24	and	O	
25	beta	O	
26	subunits	O	
27	in	O	
28	Madin	O	
29	-	O	
30	Darby	O	
31	canine	O	
32	kidney	O	
33	cells	O	
34	.	O	

1	Delayed	O	
2	hypersensitivity	O	
3	in	O	
4	man	O	
5	:	O	
6	effects	O	
7	of	O	
8	systemic	O	
9	anticoagulation	O	
10	.	O	

1	An	O	
2	experiment	O	
3	was	O	
4	carried	O	
5	on	O	
6	133	O	
7	grown	O	
8	up	O	
9	fowls	O	
10	and	O	
11	broilers	O	
12	from	O	
13	4	O	
14	industrial	O	
15	farms	O	
16	,	O	
17	vaccinated	O	
18	with	O	
19	spray	O	
20	lento	O	
21	and	O	
22	mesogenic	O	
23	vaccines	O	
24	for	O	
25	straining	O	
26	the	O	
27	immunity	O	
28	against	O	
29	pseodopest	O	
30	through	O	
31	RIHA	O	
32	and	O	
33	provoking	O	
34	pseudoplague	O	
35	with	O	
36	a	O	
37	pathogenic	O	
38	virus	O	
39	.	O	

1	Interestingly	O	
2	,	O	
3	the	O	
4	activated	O	
5	PDGF	B	
6	beta	I	
7	-	I	
8	receptor	I	
9	was	O	
10	found	O	
11	not	O	
12	to	O	
13	bind	O	
14	Crk	B	
15	proteins	I	
16	.	O	

1	To	O	
2	begin	O	
3	to	O	
4	understand	O	
5	this	O	
6	role	O	
7	,	O	
8	we	O	
9	overexpressed	O	
10	ATF	B	
11	-	I	
12	2	I	
13	in	O	
14	a	O	
15	human	O	
16	cancer	O	
17	cell	O	
18	line	O	
19	.	O	

1	The	O	
2	mean	O	
3	power	O	
4	(	O	
5	in	O	
6	mu	O	
7	W	O	
8	)	O	
9	required	O	
10	to	O	
11	produce	O	
12	the	O	
13	observed	O	
14	flow	O	
15	rate	O	
16	was	O	
17	estimated	O	
18	at	O	
19	each	O	
20	outflow	O	
21	pressure	O	
22	as	O	
23	the	O	
24	product	O	
25	of	O	
26	the	O	
27	flow	O	
28	rate	O	
29	and	O	
30	the	O	
31	pressure	O	
32	across	O	
33	the	O	
34	lymphatic	O	
35	vessel	O	
36	.	O	

1	Structure	O	
2	and	O	
3	expression	O	
4	of	O	
5	the	O	
6	mouse	B	
7	growth	I	
8	hormone	I	
9	receptor	I	
10	/	O	
11	growth	B	
12	hormone	I	
13	binding	I	
14	protein	I	
15	gene	I	
16	.	O	

1	Mean	O	
2	corpuscular	B	
3	hemoglobin	I	
4	concentrations	O	
5	remained	O	
6	normal	O	
7	for	O	
8	48	O	
9	h	O	
10	and	O	
11	then	O	
12	decreased	O	
13	in	O	
14	both	O	
15	groups	O	
16	,	O	
17	the	O	
18	CO2	O	
19	group	O	
20	showing	O	
21	the	O	
22	larger	O	
23	decrease	O	
24	.	O	

1	However	O	
2	,	O	
3	the	O	
4	serum	B	
5	TNF	I	
6	-	I	
7	a	I	
8	concentration	O	
9	decreased	O	
10	significantly	O	
11	in	O	
12	patients	O	
13	receiving	O	
14	pentoxifylline	O	
15	(	O	
16	basal	O	
17	623	O	
18	+/-	O	
19	366	O	
20	pg	O	
21	/	O	
22	ml	O	
23	;	O	
24	6th	O	
25	month	O	
26	562	O	
27	+/-	O	
28	358	O	
29	pg	O	
30	/	O	
31	ml	O	
32	,	O	
33	p	O	
34	<	O	
35	0	O	
36	.	O	
37	01	O	
38	),	O	
39	but	O	
40	not	O	
41	in	O	
42	the	O	
43	control	O	
44	group	O	
45	.	O	

1	Glycemic	O	
2	response	O	
3	to	O	
4	malted	O	
5	,	O	
6	popped	O	
7	and	O	
8	roller	O	
9	dried	O	
10	wheat	O	
11	-	O	
12	legume	O	
13	based	O	
14	foods	O	
15	in	O	
16	normal	O	
17	subjects	O	
18	.	O	

1	The	O	
2	ZnF20	B	
3	cDNA	I	
4	hybridized	O	
5	to	O	
6	multiple	O	
7	transcripts	O	
8	in	O	
9	a	O	
10	thyroid	O	
11	cancer	O	
12	cell	O	
13	line	O	
14	(	O	
15	8	O	
16	.	O	
17	0	O	
18	,	O	
19	4	O	
20	.	O	
21	5	O	
22	and	O	
23	2	O	
24	kb	O	
25	)	O	
26	that	O	
27	increased	O	
28	after	O	
29	cycloheximide	O	
30	treatment	O	
31	and	O	
32	decayed	O	
33	<	O	
34	2	O	
35	h	O	
36	after	O	
37	addition	O	
38	of	O	
39	actinomycin	O	
40	D	O	
41	.	O	

1	The	O	
2	results	O	
3	indicate	O	
4	that	O	
5	DNA	O	
6	methylation	O	
7	,	O	
8	chromatin	O	
9	structure	O	
10	,	O	
11	and	O	
12	transactivation	O	
13	at	O	
14	an	O	
15	Sp1	B	
16	site	I	
17	contribute	O	
18	to	O	
19	the	O	
20	highly	O	
21	restricted	O	
22	expression	O	
23	of	O	
24	this	O	
25	myelomonocytic	O	
26	lineage	O	
27	specific	O	
28	gene	O	
29	.	O	

1	Differential	O	
2	activation	O	
3	of	O	
4	the	O	
5	extracellular	B	
6	signal	I	
7	-	I	
8	regulated	I	
9	kinase	I	
10	,	O	
11	Jun	B	
12	kinase	I	
13	and	O	
14	Janus	B	
15	kinase	I	
16	-	O	
17	Stat	B	
18	pathways	O	
19	by	O	
20	oncostatin	B	
21	M	I	
22	and	O	
23	basic	B	
24	fibroblast	I	
25	growth	I	
26	factor	I	
27	in	O	
28	AIDS	O	
29	-	O	
30	derived	O	
31	Kaposi	O	
32	'	O	
33	s	O	
34	sarcoma	O	
35	cells	O	
36	.	O	

1	During	O	
2	heat	O	
3	exposure	O	
4	,	O	
5	chicks	O	
6	that	O	
7	had	O	
8	been	O	
9	subjected	O	
10	to	O	
11	early	O	
12	60	O	
13	%	O	
14	restriction	O	
15	with	O	
16	non	O	
17	-	O	
18	metyrapone	O	
19	-	O	
20	treated	O	
21	food	O	
22	had	O	
23	lower	O	
24	H	O	
25	/	O	
26	L	O	
27	ratios	O	
28	and	O	
29	improved	O	
30	resistance	O	
31	to	O	
32	marble	O	
33	spleen	O	
34	disease	O	
35	infection	O	
36	.	O	

1	Stable	O	
2	transfection	O	
3	of	O	
4	the	O	
5	truncated	O	
6	reduced	B	
7	folate	I	
8	carrier	I	
9	cDNA	I	
10	into	O	
11	mouse	O	
12	L1210	O	
13	leukemia	O	
14	cells	O	
15	:	O	
16	increased	O	
17	folate	O	
18	accumulation	O	
19	,	O	
20	decreased	O	
21	their	O	
22	leucovorin	O	
23	and	O	
24	folic	O	
25	acid	O	
26	growth	O	
27	requirements	O	
28	,	O	
29	and	O	
30	increased	O	
31	their	O	
32	sensitivity	O	
33	to	O	
34	methotrexate	O	
35	.	O	

1	Although	O	
2	large	O	
3	epidemiologic	O	
4	studies	O	
5	are	O	
6	best	O	
7	able	O	
8	to	O	
9	identify	O	
10	the	O	
11	relative	O	
12	contributions	O	
13	of	O	
14	specific	O	
15	risk	O	
16	factors	O	
17	while	O	
18	controlling	O	
19	for	O	
20	other	O	
21	risk	O	
22	factors	O	
23	,	O	
24	new	O	
25	studies	O	
26	need	O	
27	to	O	
28	focus	O	
29	on	O	
30	important	O	
31	unresolved	O	
32	questions	O	
33	.	O	

1	The	O	
2	reason	O	
3	that	O	
4	nitrous	O	
5	oxide	O	
6	does	O	
7	not	O	
8	produce	O	
9	hydroxyl	O	
10	radicals	O	
11	readily	O	
12	might	O	
13	be	O	
14	that	O	
15	the	O	
16	one	O	
17	-	O	
18	electron	O	
19	reduction	O	
20	proceeds	O	
21	through	O	
22	an	O	
23	N2O	O	
24	-	O	
25	intermediate	O	
26	which	O	
27	is	O	
28	energetically	O	
29	very	O	
30	unfavourable	O	
31	:	O	
32	EO	O	
33	(	O	
34	N2O	O	
35	/	O	
36	N2O	O	
37	-)	O	
38	=	O	
39	-	O	
40	1	O	
41	.	O	
42	1	O	
43	V	O	
44	.	O	

1	Thus	O	
2	,	O	
3	methylation	O	
4	of	O	
5	Pph21p	B	
6	is	O	
7	important	O	
8	for	O	
9	formation	O	
10	of	O	
11	PP2A	B	
12	trimeric	I	
13	and	I	
14	dimeric	I	
15	complexes	I	
16	,	O	
17	and	O	
18	consequently	O	
19	,	O	
20	for	O	
21	PP2A	B	
22	function	O	
23	.	O	

1	The	O	
2	ratio	O	
3	of	O	
4	the	O	
5	activity	O	
6	of	O	
7	arogenate	B	
8	dehydrogenase	I	
9	to	O	
10	that	O	
11	of	O	
12	prephenate	B	
13	dehydrogenase	I	
14	(	O	
15	approximately	O	
16	3	O	
17	:	O	
18	1	O	
19	)	O	
20	remained	O	
21	constant	O	
22	throughout	O	
23	purification	O	
24	,	O	
25	and	O	
26	the	O	
27	two	O	
28	activities	O	
29	were	O	
30	therefore	O	
31	inseparable	O	
32	.	O	

1	Serum	B	
2	insulin	I	
3	-	I	
4	like	I	
5	growth	I	
6	factor	I	
7	I	I	
8	(	O	
9	IGF	B	
10	-	I	
11	I	I	
12	)	O	
13	SD	O	
14	score	O	
15	increased	O	
16	from	O	
17	-	O	
18	2	O	
19	.	O	
20	2	O	
21	and	O	
22	-	O	
23	4	O	
24	.	O	
25	2	O	
26	in	O	
27	men	O	
28	and	O	
29	women	O	
30	,	O	
31	respectively	O	
32	,	O	
33	to	O	
34	1	O	
35	.	O	
36	8	O	
37	and	O	
38	-	O	
39	0	O	
40	.	O	
41	9	O	
42	at	O	
43	6	O	
44	months	O	
45	and	O	
46	0	O	
47	.	O	
48	8	O	
49	and	O	
50	-	O	
51	0	O	
52	.	O	
53	7	O	
54	at	O	
55	12	O	
56	months	O	
57	.	O	

1	These	O	
2	results	O	
3	indicate	O	
4	that	O	
5	the	O	
6	cis	O	
7	-	O	
8	regulatory	O	
9	elements	O	
10	required	O	
11	for	O	
12	developmental	O	
13	control	O	
14	of	O	
15	the	O	
16	HaG3	B	
17	-	I	
18	A	I	
19	helianthinin	I	
20	gene	I	
21	are	O	
22	located	O	
23	in	O	
24	a	O	
25	2	O	
26	.	O	
27	4	O	
28	kb	O	
29	upstream	O	
30	region	O	
31	of	O	
32	this	O	
33	gene	O	
34	.	O	

1	Effects	O	
2	of	O	
3	repeated	O	
4	exposures	O	
5	of	O	
6	hydrogen	O	
7	sulphide	O	
8	on	O	
9	rat	O	
10	hippocampal	O	
11	EEG	O	
12	.	O	

1	Instead	O	
2	,	O	
3	mRNA	O	
4	of	O	
5	2	O	
6	.	O	
7	0	O	
8	and	O	
9	2	O	
10	.	O	
11	8	O	
12	kb	O	
13	are	O	
14	detected	O	
15	in	O	
16	varying	O	
17	abundance	O	
18	.	O	

1	The	O	
2	unexpected	O	
3	presence	O	
4	of	O	
5	the	O	
6	tRNA	B	
7	(	I	
8	trp	I	
9	)(	I	
10	CCA	I	
11	)-	I	
12	gene	I	
13	transcript	I	
14	in	I	
15	mitochondria	I	
16	is	O	
17	also	O	
18	reported	O	
19	.	O	

1	Sixty	O	
2	months	O	
3	after	O	
4	the	O	
5	initial	O	
6	vaccination	O	
7	,	O	
8	all	O	
9	vaccinees	O	
10	who	O	
11	received	O	
12	annual	O	
13	follow	O	
14	-	O	
15	up	O	
16	still	O	
17	had	O	
18	protective	O	
19	levels	O	
20	of	O	
21	anti	B	
22	-	I	
23	HAV	I	
24	.	O	

1	These	O	
2	results	O	
3	indicate	O	
4	that	O	
5	patients	O	
6	who	O	
7	undergo	O	
8	postoperative	O	
9	irradiation	O	
10	for	O	
11	low	O	
12	grade	O	
13	spinal	O	
14	astrocytomas	O	
15	and	O	
16	localized	O	
17	spinal	O	
18	ependymomas	O	
19	achieve	O	
20	excellent	O	
21	survival	O	
22	.	O	

1	Both	O	
2	functional	O	
3	analyses	O	
4	in	O	
5	undifferentiated	O	
6	and	O	
7	differentiated	O	
8	F9	O	
9	cells	O	
10	and	O	
11	characterization	O	
12	of	O	
13	DNA	O	
14	-	O	
15	protein	O	
16	complexes	O	
17	in	O	
18	vitro	O	
19	have	O	
20	identified	O	
21	the	O	
22	sequence	O	
23	motifs	O	
24	GTGACT	O	
25	(	O	
26	C	O	
27	),	O	
28	ATTGT	O	
29	,	O	
30	and	O	
31	GATA	O	
32	as	O	
33	the	O	
34	key	O	
35	transcription	O	
36	factor	O	
37	binding	O	
38	sites	O	
39	.	O	

1	The	O	
2	specific	O	
3	interaction	O	
4	between	O	
5	a	O	
6	defined	O	
7	structural	O	
8	element	O	
9	of	O	
10	the	O	
11	human	O	
12	immunodeficiency	O	
13	virus	O	
14	mRNA	O	
15	(	O	
16	RRE	B	
17	,	O	
18	the	O	
19	Rev	B	
20	response	I	
21	element	I	
22	)	O	
23	and	O	
24	the	O	
25	virus	B	
26	-	I	
27	encoded	I	
28	protein	I	
29	Rev	I	
30	has	O	
31	been	O	
32	implicated	O	
33	in	O	
34	the	O	
35	regulation	O	
36	of	O	
37	the	O	
38	export	O	
39	of	O	
40	unspliced	O	
41	or	O	
42	singly	O	
43	spliced	O	
44	mRNA	O	
45	from	O	
46	the	O	
47	nucleus	O	
48	to	O	
49	the	O	
50	cytoplasm	O	
51	.	O	

1	Endorphins	B	
2	and	O	
3	legal	O	
4	issues	O	
5	.	O	

1	Dermal	O	
2	toxicity	O	
3	and	O	
4	carcinogenicity	O	
5	of	O	
6	4	O	
7	-	O	
8	vinyl	O	
9	-	O	
10	1	O	
11	-	O	
12	cyclohexene	O	
13	diepoxide	O	
14	in	O	
15	Fischer	O	
16	rats	O	
17	and	O	
18	B6C3F1	O	
19	mice	O	
20	.	O	

1	Family	O	
2	visits	O	
3	and	O	
4	involvement	O	
5	in	O	
6	treatment	O	
7	of	O	
8	patients	O	
9	at	O	
10	a	O	
11	state	O	
12	hospital	O	
13	.	O	

1	A	O	
2	36	O	
3	year	O	
4	-	O	
5	old	O	
6	woman	O	
7	was	O	
8	given	O	
9	Ergotamine	O	
10	Tartrate	O	
11	4	O	
12	.	O	
13	5	O	
14	mg	O	
15	p	O	
16	.	O	
17	d	O	
18	.	O	
19	during	O	
20	seven	O	
21	days	O	
22	,	O	
23	after	O	
24	an	O	
25	abortion	O	
26	(	O	
27	a	O	
28	still	O	
29	birth	O	
30	).	O	

1	We	O	
2	provide	O	
3	community	O	
4	metabolic	O	
5	data	O	
6	that	O	
7	indicate	O	
8	that	O	
9	large	O	
10	changes	O	
11	in	O	
12	CO2	O	
13	concentration	O	
14	can	O	
15	occur	O	
16	in	O	
17	coral	O	
18	reef	O	
19	waters	O	
20	via	O	
21	biogeochemical	O	
22	processes	O	
23	not	O	
24	directly	O	
25	associated	O	
26	with	O	
27	photosynthesis	O	
28	,	O	
29	respiration	O	
30	,	O	
31	calcification	O	
32	,	O	
33	and	O	
34	CaCO3	O	
35	dissolution	O	
36	.	O	

1	Thus	O	
2	,	O	
3	in	O	
4	normal	O	
5	intestinal	O	
6	epithelial	O	
7	goblet	O	
8	cells	O	
9	,	O	
10	TbetaRI	B	
11	and	O	
12	TbetaRII	B	
13	can	O	
14	respond	O	
15	to	O	
16	autocrine	O	
17	but	O	
18	not	O	
19	exogenous	O	
20	TGF	B	
21	-	I	
22	beta	I	
23	without	O	
24	the	O	
25	participation	O	
26	of	O	
27	TbetaRIII	B	
28	.	O	

1	Thus	O	
2	our	O	
3	observations	O	
4	establish	O	
5	a	O	
6	functional	O	
7	link	O	
8	between	O	
9	the	O	
10	PKC	B	
11	and	O	
12	retinoid	O	
13	pathways	O	
14	,	O	
15	which	O	
16	are	O	
17	generally	O	
18	considered	O	
19	to	O	
20	have	O	
21	antagonistic	O	
22	activities	O	
23	on	O	
24	differentiation	O	
25	processes	O	
26	.	O	

1	Specific	O	
2	and	O	
3	heritable	O	
4	genetic	O	
5	interference	O	
6	by	O	
7	double	O	
8	-	O	
9	stranded	O	
10	RNA	O	
11	in	O	
12	Arabidopsis	O	
13	thaliana	O	
14	.	O	

1	Pargyline	O	
2	,	O	
3	a	O	
4	monoamine	B	
5	oxidase	I	
6	inhibitor	O	
7	,	O	
8	reduces	O	
9	peak	O	
10	3	O	
11	transiently	O	
12	(	O	
13	max	O	
14	.	O	

1	There	O	
2	was	O	
3	a	O	
4	weak	O	
5	significant	O	
6	correlation	O	
7	between	O	
8	TGF	B	
9	beta	I	
10	1	I	
11	levels	O	
12	and	O	
13	normal	O	
14	cell	O	
15	radiosensitivity	O	
16	(	O	
17	lymphocyte	O	
18	SF2	O	
19	).	O	

1	Functional	O	
2	studies	O	
3	which	O	
4	introduced	O	
5	a	O	
6	mutation	O	
7	in	O	
8	the	O	
9	AP2	B	
10	core	I	
11	binding	I	
12	region	I	
13	as	O	
14	well	O	
15	as	O	
16	cotransfection	O	
17	experiments	O	
18	using	O	
19	an	O	
20	AP2	B	
21	expression	O	
22	vector	O	
23	revealed	O	
24	that	O	
25	AP2	B	
26	exerts	O	
27	a	O	
28	repressive	O	
29	role	O	
30	on	O	
31	the	O	
32	HGF	B	
33	gene	I	
34	promoter	I	
35	activity	O	
36	.	O	

1	The	O	
2	osmotic	O	
3	diuretic	O	
4	mannitol	O	
5	was	O	
6	administered	O	
7	to	O	
8	21	O	
9	patients	O	
10	.	O	

1	Alternating	O	
2	proline	O	
3	/	O	
4	alanine	O	
5	sequence	O	
6	of	O	
7	beta	B	
8	B1	I	
9	subunit	I	
10	originates	O	
11	from	O	
12	a	O	
13	repetitive	O	
14	DNA	O	
15	sequence	O	
16	.	O	

1	CONCLUSIONS	O	
2	:	O	
3	Physiologic	O	
4	pacing	O	
5	provides	O	
6	little	O	
7	benefit	O	
8	over	O	
9	ventricular	O	
10	pacing	O	
11	for	O	
12	the	O	
13	prevention	O	
14	of	O	
15	stroke	O	
16	or	O	
17	death	O	
18	due	O	
19	to	O	
20	cardiovascular	O	
21	causes	O	
22	.	O	

1	Analysis	O	
2	of	O	
3	SRE	O	
4	oligonucleotide	O	
5	gel	O	
6	mobility	O	
7	shift	O	
8	assays	O	
9	with	O	
10	nuclear	O	
11	extracts	O	
12	from	O	
13	Sertoli	O	
14	cells	O	
15	demonstrated	O	
16	the	O	
17	presence	O	
18	of	O	
19	both	O	
20	the	O	
21	SRF	B	
22	and	O	
23	the	O	
24	ubiquitously	O	
25	expressed	O	
26	bHLH	O	
27	protein	O	
28	E12	B	
29	/	O	
30	E47	B	
31	.	O	

1	The	O	
2	multiple	O	
3	functions	O	
4	of	O	
5	Pmt3p	B	
6	described	O	
7	here	O	
8	suggest	O	
9	that	O	
10	several	O	
11	nuclear	O	
12	proteins	O	
13	are	O	
14	regulated	O	
15	by	O	
16	Pmt3p	B	
17	conjugation	O	
18	.	O	

1	A	O	
2	concentration	O	
3	of	O	
4	12	O	
5	.	O	
6	5	O	
7	ppm	O	
8	SO2	O	
9	induced	O	
10	a	O	
11	decrease	O	
12	from	O	
13	baseline	O	
14	values	O	
15	of	O	
16	approximately	O	
17	80	O	
18	%	O	
19	in	O	
20	mean	O	
21	MCA	O	
22	and	O	
23	of	O	
24	roughly	O	
25	70	O	
26	%	O	
27	in	O	
28	mean	O	
29	CBF	O	
30	.	O	

1	There	O	
2	was	O	
3	a	O	
4	trend	O	
5	toward	O	
6	an	O	
7	association	O	
8	between	O	
9	IENF	O	
10	and	O	
11	sural	O	
12	nerve	O	
13	unmyelinated	O	
14	fiber	O	
15	densities	O	
16	(	O	
17	r	O	
18	=	O	
19	0	O	
20	.	O	
21	32	O	
22	,	O	
23	p	O	
24	=	O	
25	0	O	
26	.	O	
27	054	O	
28	).	O	

1	The	O	
2	antibodies	O	
3	inhibited	O	
4	specifically	O	
5	the	O	
6	transcription	O	
7	of	O	
8	DNA	B	
9	polymerase	I	
10	alpha	I	
11	promoter	O	
12	in	O	
13	vitro	O	
14	.	O	

1	We	O	
2	have	O	
3	determined	O	
4	the	O	
5	nucleotide	O	
6	(	O	
7	nt	O	
8	)	O	
9	sequence	O	
10	of	O	
11	the	O	
12	7	B	
13	.	I	
14	5	I	
15	-	I	
16	kb	I	
17	COR	I	
18	segment	I	
19	that	O	
20	encompasses	O	
21	a	O	
22	cluster	O	
23	of	O	
24	six	O	
25	genes	O	
26	(	O	
27	CYC1	B	
28	,	O	
29	UTR1	B	
30	,	O	
31	UTR3	B	
32	,	O	
33	OSM1	B	
34	,	O	
35	tRNA	B	
36	(	I	
37	Gly	I	
38	)	I	
39	and	O	
40	RAD7	B	
41	)	O	
42	located	O	
43	on	O	
44	chromosome	O	
45	X	O	
46	of	O	
47	the	O	
48	yeast	O	
49	Saccharomyces	O	
50	cerevisiae	O	
51	.	O	

1	Confocal	O	
2	fluorescence	O	
3	microscopy	O	
4	in	O	
5	modern	O	
6	cell	O	
7	biology	O	
8	.	O	

1	Circularized	O	
2	Ac	B	
3	/	O	
4	Ds	B	
5	transposons	O	
6	:	O	
7	formation	O	
8	,	O	
9	structure	O	
10	and	O	
11	fate	O	
12	.	O	

1	Higher	O	
2	fasting	O	
3	serum	O	
4	gastrin	B	
5	concentration	O	
6	(	O	
7	102	O	
8	.	O	
9	0	O	
10	+/-	O	
11	21	O	
12	.	O	
13	1	O	
14	vs	O	
15	63	O	
16	.	O	
17	3	O	
18	+/-	O	
19	8	O	
20	.	O	
21	3	O	
22	ng	O	
23	.	O	
24	l	O	
25	-	O	
26	1	O	
27	),	O	
28	and	O	
29	greater	O	
30	postprandial	O	
31	gastrin	B	
32	release	O	
33	(	O	
34	AUC0	O	
35	-	O	
36	120	O	
37	:	O	
38	16690	O	
39	+/-	O	
40	2648	O	
41	vs	O	
42	10654	O	
43	+/-	O	
44	1283	O	
45	ng	O	
46	.	O	
47	l	O	
48	-	O	
49	1	O	
50	min	O	
51	)	O	
52	were	O	
53	observed	O	
54	after	O	
55	VTP	O	
56	-	O	
57	HM	O	
58	than	O	
59	after	O	
60	VTP	O	
61	-	O	
62	Cas	O	
63	.	O	

1	The	O	
2	transverse	O	
3	magnetization	O	
4	decays	O	
5	mentioned	O	
6	above	O	
7	exhibited	O	
8	two	O	
9	components	O	
10	,	O	
11	a	O	
12	T2	O	
13	fast	O	
14	(	O	
15	T2f	O	
16	)	O	
17	and	O	
18	a	O	
19	T2	O	
20	slow	O	
21	(	O	
22	T2s	O	
23	)	O	
24	component	O	
25	.	O	

1	A	O	
2	cDNA	O	
3	,	O	
4	cak1At	B	
5	,	O	
6	was	O	
7	isolated	O	
8	that	O	
9	suppressed	O	
10	the	O	
11	CAK	B	
12	mutation	I	
13	in	O	
14	budding	O	
15	yeast	O	
16	,	O	
17	and	O	
18	it	O	
19	also	O	
20	complemented	O	
21	a	O	
22	fission	B	
23	yeast	I	
24	CAK	I	
25	mutant	I	
26	.	O	
27	cak1At	B	
28	encodes	O	
29	a	O	
30	protein	O	
31	related	O	
32	to	O	
33	animal	B	
34	CAKs	I	
35	.	O	

1	Crisis	O	
2	of	O	
3	the	O	
4	therapeutic	O	
5	community	O	
6	in	O	
7	Great	O	
8	Britain	O	

1	Competition	O	
2	analysis	O	
3	by	O	
4	gel	O	
5	mobility	O	
6	shift	O	
7	electrophoresis	O	
8	indicates	O	
9	that	O	
10	this	O	
11	DNA	O	
12	-	O	
13	protein	O	
14	interaction	O	
15	is	O	
16	novel	O	
17	and	O	
18	not	O	
19	related	O	
20	to	O	
21	many	O	
22	transcription	O	
23	factors	O	
24	previously	O	
25	reported	O	
26	.	O	

1	Human	O	
2	adenovirus	O	
3	type	O	
4	41	O	
5	contains	O	
6	two	O	
7	fibers	O	
8	.	O	

1	Significant	O	
2	correlations	O	
3	existed	O	
4	between	O	
5	FEV1	O	
6	and	O	
7	the	O	
8	corresponding	O	
9	values	O	
10	of	O	
11	Raw	O	
12	,	O	
13	MEF50	O	
14	and	O	
15	MEF25	O	
16	,	O	
17	although	O	
18	there	O	
19	were	O	
20	considerable	O	
21	individual	O	
22	differences	O	
23	between	O	
24	test	O	
25	results	O	
26	.	O	

1	Personal	O	
2	satisfaction	O	
3	in	O	
4	nursing	O	
5	:	O	
6	an	O	
7	encounter	O	
8	with	O	
9	extremely	O	
10	hostile	O	
11	patients	O	

1	A	O	
2	total	O	
3	of	O	
4	57	O	
5	patients	O	
6	with	O	
7	Hodgkin	O	
8	'	O	
9	s	O	
10	disease	O	
11	limited	O	
12	to	O	
13	above	O	
14	the	O	
15	diaphragm	O	
16	(	O	
17	Stages	O	
18	I	O	
19	and	O	
20	II	O	
21	,	O	
22	A	O	
23	and	O	
24	B	O	
25	)	O	
26	were	O	
27	treated	O	
28	with	O	
29	radiation	O	
30	therapy	O	
31	alone	O	
32	at	O	
33	the	O	
34	University	O	
35	of	O	
36	Florida	O	
37	between	O	
38	1964	O	
39	and	O	
40	1974	O	
41	.	O	

1	Use	O	
2	of	O	
3	prostaglandin	O	
4	F2	O	
5	alpha	O	
6	(	O	
7	PGF2	O	
8	alpha	O	
9	)	O	
10	in	O	
11	cattle	O	
12	breeding	O	
13	.	O	

1	Recurrence	O	
2	of	O	
3	bladder	O	
4	tumors	O	
5	among	O	
6	the	O	
7	original	O	
8	9	O	
9	cases	O	
10	has	O	
11	occurred	O	
12	only	O	
13	among	O	
14	the	O	
15	5	O	
16	whose	O	
17	properdin	B	
18	levels	O	
19	remained	O	
20	below	O	
21	the	O	
22	median	O	
23	.	O	

1	The	O	
2	plateau	O	
3	MO2	O	
4	value	O	
5	was	O	
6	that	O	
7	predicted	O	
8	by	O	
9	allometric	O	
10	relation	O	
11	.	O	

1	The	O	
2	first	O	
3	gene	O	
4	,	O	
5	NSR1	B	
6	,	O	
7	a	O	
8	previously	O	
9	identified	O	
10	gene	O	
11	,	O	
12	encodes	O	
13	a	O	
14	protein	O	
15	involved	O	
16	in	O	
17	ribosomal	O	
18	RNA	O	
19	maturation	O	
20	and	O	
21	possibly	O	
22	in	O	
23	transport	O	
24	of	O	
25	proteins	O	
26	into	O	
27	the	O	
28	nucleus	O	
29	.	O	

1	Glomerular	O	
2	mesangial	O	
3	cells	O	
4	expressed	O	
5	an	O	
6	abundant	O	
7	1	O	
8	.	O	
9	1	O	
10	kb	O	
11	mRNA	O	
12	transcript	O	
13	for	O	
14	Id1	B	
15	,	O	
16	but	O	
17	in	O	
18	contrast	O	
19	to	O	
20	other	O	
21	cell	O	
22	types	O	
23	Id1	B	
24	mRNA	I	
25	was	O	
26	expressed	O	
27	in	O	
28	both	O	
29	randomly	O	
30	cycling	O	
31	cells	O	
32	and	O	
33	in	O	
34	serum	O	
35	-	O	
36	deprived	O	
37	,	O	
38	quiescent	O	
39	cultures	O	
40	.	O	

1	The	O	
2	result	O	
3	suggests	O	
4	that	O	
5	this	O	
6	non	O	
7	-	O	
8	invasive	O	
9	TTD	O	
10	method	O	
11	is	O	
12	easily	O	
13	available	O	
14	and	O	
15	useful	O	
16	in	O	
17	monitoring	O	
18	the	O	
19	intraoperative	O	
20	cardiac	O	
21	output	O	
22	.	O	

1	Calcitriol	O	
2	therapy	O	
3	was	O	
4	associated	O	
5	with	O	
6	a	O	
7	decrease	O	
8	in	O	
9	serum	O	
10	iPTH	B	
11	levels	O	
12	(	O	
13	701	O	
14	+/-	O	
15	103	O	
16	.	O	
17	9	O	
18	vs	O	
19	.	O	

1	Validity	O	
2	of	O	
3	NIR	O	
4	spectroscopy	O	
5	for	O	
6	quantitatively	O	
7	measuring	O	
8	muscle	O	
9	oxidative	O	
10	metabolic	O	
11	rate	O	
12	in	O	
13	exercise	O	
14	.	O	

1	This	O	
2	E	O	
3	box	O	
4	sequence	O	
5	(	O	
6	CACGTG	O	
7	)	O	
8	is	O	
9	identical	O	
10	to	O	
11	the	O	
12	binding	O	
13	element	O	
14	for	O	
15	USF	B	
16	(	O	
17	upstream	B	
18	stimulatory	I	
19	factor	I	
20	),	O	
21	a	O	
22	member	O	
23	of	O	
24	the	O	
25	helix	B	
26	-	I	
27	loop	I	
28	-	I	
29	helix	I	
30	family	I	
31	of	I	
32	transcription	I	
33	factors	I	
34	.	O	

1	Is	O	
2	more	O	
3	better	O	
4	?	O	
5	About	O	
6	dose	O	
7	levels	O	
8	of	O	
9	ACE	B	
10	inhibitors	O	
11	in	O	
12	chronic	O	
13	heart	O	
14	failure	O	
15	.	O	

1	Hemodynamic	O	
2	assessment	O	
3	was	O	
4	obtained	O	
5	before	O	
6	and	O	
7	following	O	
8	administration	O	
9	of	O	
10	digoxin	O	
11	10	O	
12	micrograms	O	
13	/	O	
14	kg	O	
15	IV	O	
16	or	O	
17	dopamine	O	
18	,	O	
19	5	O	
20	to	O	
21	12	O	
22	micrograms	O	
23	/	O	
24	kg	O	
25	/	O	
26	min	O	
27	IV	O	
28	.	O	

1	SETTING	O	
2	:	O	
3	University	O	
4	hospital	O	
5	-	O	
6	based	O	
7	,	O	
8	tertiary	O	
9	care	O	
10	infertility	O	
11	center	O	
12	.	O	

1	Electrophoretic	O	
2	mobility	O	
3	shift	O	
4	analysis	O	
5	indicates	O	
6	that	O	
7	NF	B	
8	-	I	
9	IL	I	
10	-	I	
11	6	I	
12	,	O	
13	as	O	
14	well	O	
15	as	O	
16	other	O	
17	related	O	
18	members	O	
19	of	O	
20	this	O	
21	family	O	
22	,	O	
23	bind	O	
24	specifically	O	
25	to	O	
26	the	O	
27	NF	B	
28	-	I	
29	IL	I	
30	-	I	
31	6	I	
32	site	O	
33	in	O	
34	the	O	
35	IL	B	
36	-	I	
37	8	I	
38	promoter	I	
39	.	O	

1	These	O	
2	results	O	
3	suggest	O	
4	that	O	
5	decreased	O	
6	class	O	
7	I	O	
8	enhancer	O	
9	activity	O	
10	in	O	
11	Ad12	O	
12	-	O	
13	transformed	O	
14	cells	O	
15	may	O	
16	,	O	
17	at	O	
18	least	O	
19	in	O	
20	part	O	
21	,	O	
22	be	O	
23	due	O	
24	to	O	
25	the	O	
26	higher	O	
27	levels	O	
28	of	O	
29	an	O	
30	enhancer	O	
31	-	O	
32	specific	O	
33	factor	O	
34	,	O	
35	possibly	O	
36	acting	O	
37	as	O	
38	a	O	
39	repressor	O	
40	.	O	

1	Furthermore	O	
2	,	O	
3	both	O	
4	rhHR23	B	
5	proteins	I	
6	function	O	
7	in	O	
8	a	O	
9	defined	O	
10	NER	O	
11	system	O	
12	reconstituted	O	
13	with	O	
14	purified	O	
15	proteins	O	
16	,	O	
17	indicating	O	
18	direct	O	
19	involvement	O	
20	of	O	
21	hHR23	B	
22	proteins	I	
23	in	O	
24	the	O	
25	DNA	O	
26	repair	O	
27	reaction	O	
28	via	O	
29	interaction	O	
30	with	O	
31	XPC	B	
32	.	O	

1	The	O	
2	possible	O	
3	benefits	O	
4	of	O	
5	LMW	O	
6	heparin	O	
7	(	O	
8	reduced	O	
9	frequency	O	
10	of	O	
11	bleeding	O	
12	,	O	
13	alleviation	O	
14	of	O	
15	hypertriglyceridemia	O	
16	)	O	
17	were	O	
18	not	O	
19	,	O	
20	however	O	
21	,	O	
22	apparent	O	
23	,	O	
24	possibly	O	
25	because	O	
26	of	O	
27	the	O	
28	short	O	
29	observation	O	
30	period	O	
31	and	O	
32	the	O	
33	low	O	
34	incidence	O	
35	of	O	
36	hemorrhagic	O	
37	complications	O	
38	in	O	
39	routine	O	
40	dialyses	O	
41	.	O	

1	The	O	
2	mechanism	O	
3	of	O	
4	peroxisome	O	
5	proliferation	O	
6	is	O	
7	poorly	O	
8	understood	O	
9	.	O	

1	Cimetidine	O	
2	800	O	
3	mg	O	
4	given	O	
5	at	O	
6	night	O	
7	is	O	
8	as	O	
9	effective	O	
10	as	O	
11	400	O	
12	mg	O	
13	twice	O	
14	daily	O	
15	;	O	
16	the	O	
17	single	O	
18	dose	O	
19	regimen	O	
20	may	O	
21	improve	O	
22	patient	O	
23	compliance	O	
24	,	O	
25	thus	O	
26	facilitating	O	
27	treatment	O	
28	.	O	

1	Until	O	
2	such	O	
3	investigations	O	
4	are	O	
5	performed	O	
6	,	O	
7	we	O	
8	conclude	O	
9	that	O	
10	the	O	
11	role	O	
12	for	O	
13	adjuvant	O	
14	treatment	O	
15	is	O	
16	questionable	O	
17	and	O	
18	that	O	
19	TME	O	
20	surgery	O	
21	is	O	
22	preferred	O	
23	as	O	
24	the	O	
25	treatment	O	
26	option	O	
27	for	O	
28	Stage	O	
29	T1	O	
30	-	O	
31	T3	O	
32	rectal	O	
33	cancers	O	
34	.	O	

1	The	O	
2	Nostoc	O	
3	petBD	B	
4	genes	I	
5	are	O	
6	not	O	
7	closely	O	
8	linked	O	
9	to	O	
10	the	O	
11	psbB	B	
12	gene	I	
13	(	O	
14	encoding	O	
15	the	O	
16	51	O	
17	-	O	
18	kDa	O	
19	photosystem	B	
20	II	I	
21	polypeptide	I	
22	)	O	
23	and	O	
24	do	O	
25	not	O	
26	contain	O	
27	introns	O	
28	as	O	
29	do	O	
30	the	O	
31	closely	O	
32	related	O	
33	chloroplast	O	
34	genes	O	
35	.	O	

1	Synchronous	O	
2	extracts	O	
3	showed	O	
4	no	O	
5	significant	O	
6	migration	O	
7	inhibition	O	
8	in	O	
9	allogeneic	O	
10	assays	O	
11	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	the	O	
5	Anabaena	O	
6	strain	O	
7	7120	O	
8	leuA	B	
9	gene	O	
10	did	O	
11	not	O	
12	complement	O	
13	the	O	
14	nifV	B	
15	mutation	I	
16	of	O	
17	R229I	O	
18	efficiently	O	
19	.	O	

1	Relationship	O	
2	between	O	
3	gross	O	
4	lesions	O	
5	and	O	
6	Escherichia	O	
7	coli	O	
8	serotypes	O	
9	in	O	
10	chronic	O	
11	respiratory	O	
12	disease	O	
13	(	O	
14	CRD	O	
15	)	O	
16	of	O	
17	poultry	O	
18	.	O	

1	Factors	O	
2	influencing	O	
3	the	O	
4	bond	O	
5	strength	O	
6	between	O	
7	glass	O	
8	polyalkenoate	O	
9	(	O	
10	ionomer	O	
11	)	O	
12	cements	O	
13	and	O	
14	dentine	O	
15	.	O	

1	In	O	
2	this	O	
3	paper	O	
4	,	O	
5	characterization	O	
6	is	O	
7	given	O	
8	of	O	
9	clinical	O	
10	and	O	
11	biochemical	O	
12	features	O	
13	of	O	
14	VH	O	
15	B	O	
16	course	O	
17	against	O	
18	the	O	
19	background	O	
20	of	O	
21	narcomania	O	
22	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	the	O	
5	lumenal	O	
6	domains	O	
7	of	O	
8	Sec12p	B	
9	,	O	
10	Stl1p	B	
11	and	O	
12	Stl2p	B	
13	are	O	
14	very	O	
15	different	O	
16	in	O	
17	size	O	
18	and	O	
19	do	O	
20	not	O	
21	show	O	
22	any	O	
23	appreciable	O	
24	homology	O	
25	.	O	

1	The	O	
2	models	O	
3	were	O	
4	tested	O	
5	by	O	
6	studying	O	
7	their	O	
8	response	O	
9	to	O	
10	disturbances	O	
11	of	O	
12	the	O	
13	afferent	O	
14	signal	O	
15	from	O	
16	the	O	
17	bladder	O	
18	.	O	

1	We	O	
2	propose	O	
3	that	O	
4	the	O	
5	technique	O	
6	of	O	
7	low	O	
8	-	O	
9	frequency	O	
10	kindling	O	
11	is	O	
12	a	O	
13	useful	O	
14	experimental	O	
15	model	O	
16	in	O	
17	assessing	O	
18	the	O	
19	effects	O	
20	of	O	
21	antipsychotic	O	
22	or	O	
23	antiepileptic	O	
24	drugs	O	
25	on	O	
26	the	O	
27	excitability	O	
28	of	O	
29	the	O	
30	limbic	O	
31	regions	O	
32	.	O	

1	Marrow	O	
2	dysplasia	O	
3	is	O	
4	a	O	
5	major	O	
6	characteristic	O	
7	of	O	
8	patients	O	
9	with	O	
10	myelodysplastic	O	
11	syndrome	O	
12	(	O	
13	MDS	O	
14	),	O	
15	along	O	
16	with	O	
17	marrow	O	
18	blastosis	O	
19	,	O	
20	cytopenia	O	
21	and	O	
22	cytogenetic	O	
23	anomalies	O	
24	.	O	

1	This	O	
2	new	O	
3	knowledge	O	
4	has	O	
5	contributed	O	
6	to	O	
7	the	O	
8	development	O	
9	of	O	
10	a	O	
11	successful	O	
12	immunoprophylactic	O	
13	strategy	O	
14	for	O	
15	eliminating	O	
16	Hib	O	
17	disease	O	
18	.	O	

1	It	O	
2	was	O	
3	proposed	O	
4	that	O	
5	the	O	
6	synthetase	O	
7	-	O	
8	related	O	
9	sequences	O	
10	of	O	
11	GCN2	B	
12	stimulate	O	
13	the	O	
14	activity	O	
15	of	O	
16	the	O	
17	kinase	O	
18	by	O	
19	interacting	O	
20	directly	O	
21	with	O	
22	uncharged	O	
23	tRNA	O	
24	that	O	
25	accumulates	O	
26	during	O	
27	amino	O	
28	acid	O	
29	limitation	O	
30	.	O	

1	Although	O	
2	it	O	
3	is	O	
4	well	O	
5	known	O	
6	that	O	
7	calcium	O	
8	channel	O	
9	blockers	O	
10	can	O	
11	influence	O	
12	contraction	O	
13	of	O	
14	vascular	O	
15	smooth	O	
16	muscle	O	
17	,	O	
18	there	O	
19	is	O	
20	less	O	
21	knowledge	O	
22	on	O	
23	its	O	
24	effect	O	
25	on	O	
26	excitation	O	
27	contraction	O	
28	coupling	O	
29	in	O	
30	the	O	
31	endocrine	O	
32	glands	O	
33	and	O	
34	more	O	
35	specifically	O	
36	on	O	
37	insulin	B	
38	and	O	
39	glucagon	B	
40	release	O	
41	.	O	

1	The	O	
2	uterine	O	
3	response	O	
4	to	O	
5	prostaglandin	O	
6	E2	O	
7	(	O	
8	PGE2	O	
9	)	O	
10	and	O	
11	prostaglandin	O	
12	F2alpha	O	
13	(	O	
14	administered	O	
15	by	O	
16	intravenous	O	
17	and	O	
18	intrauterine	O	
19	routes	O	
20	)	O	
21	was	O	
22	evaluated	O	
23	during	O	
24	different	O	
25	phases	O	
26	of	O	
27	the	O	
28	menstrual	O	
29	cycle	O	
30	in	O	
31	five	O	
32	functionally	O	
33	infertile	O	
34	women	O	
35	.	O	

1	Atherosclerosis	O	

1	Chronic	O	
2	endotoxemia	O	
3	appears	O	
4	to	O	
5	be	O	
6	associated	O	
7	with	O	
8	an	O	
9	elevated	O	
10	pulmonary	O	
11	microvascular	O	
12	permeability	O	
13	and	O	
14	a	O	
15	tendency	O	
16	toward	O	
17	a	O	
18	hyperdynamic	O	
19	circulation	O	
20	but	O	
21	with	O	
22	an	O	
23	appreciable	O	
24	degree	O	
25	of	O	
26	refractoriness	O	
27	associated	O	
28	with	O	
29	regional	O	
30	hemodynamics	O	
31	and	O	
32	eicosanoid	O	
33	biosynthesis	O	
34	.	O	

1	Thus	O	
2	,	O	
3	while	O	
4	the	O	
5	genomic	O	
6	organization	O	
7	of	O	
8	mHuA	B	
9	is	O	
10	similar	O	
11	to	O	
12	the	O	
13	neural	O	
14	-	O	
15	restricted	O	
16	members	O	
17	of	O	
18	the	O	
19	Elav	B	
20	family	I	
21	,	O	
22	the	O	
23	promoter	O	
24	element	O	
25	differs	O	
26	substantially	O	
27	both	O	
28	by	O	
29	sequence	O	
30	analysis	O	
31	and	O	
32	transcriptional	O	
33	activity	O	
34	in	O	
35	non	O	
36	-	O	
37	neural	O	
38	cell	O	
39	types	O	
40	.	O	

1	The	O	
2	qualitative	O	
3	concentrations	O	
4	of	O	
5	HCG	B	
6	had	O	
7	a	O	
8	sensitivity	O	
9	of	O	
10	37	O	
11	.	O	
12	5	O	
13	%	O	
14	and	O	
15	a	O	
16	specificity	O	
17	of	O	
18	100	O	
19	%.	O	

1	When	O	
2	desipramine	O	
3	was	O	
4	injected	O	
5	16	O	
6	hrs	O	
7	after	O	
8	fluoxetine	O	
9	injection	O	
10	,	O	
11	brain	O	
12	levels	O	
13	of	O	
14	desipramine	O	
15	were	O	
16	no	O	
17	longer	O	
18	elevated	O	
19	.	O	

1	We	O	
2	conclude	O	
3	that	O	
4	cAMP	O	
5	,	O	
6	acting	O	
7	through	O	
8	PKA	B	
9	,	O	
10	is	O	
11	an	O	
12	essential	O	
13	regulator	O	
14	of	O	
15	basal	O	
16	CFTR	B	
17	gene	I	
18	expression	O	
19	and	O	
20	may	O	
21	mediate	O	
22	an	O	
23	induction	O	
24	of	O	
25	CFTR	B	
26	in	O	
27	responsive	O	
28	cell	O	
29	types	O	
30	.	O	

1	A	O	
2	cDNA	O	
3	encoding	O	
4	a	O	
5	MYC	B	
6	-	I	
7	related	I	
8	DNA	I	
9	binding	I	
10	protein	I	
11	was	O	
12	isolated	O	
13	by	O	
14	DNA	O	
15	-	O	
16	ligand	O	
17	binding	O	
18	screening	O	
19	,	O	
20	using	O	
21	the	O	
22	67	O	
23	-	O	
24	bp	O	
25	region	O	
26	as	O	
27	a	O	
28	probe	O	
29	,	O	
30	and	O	
31	designated	O	
32	rd22BP1	B	
33	.	O	

1	Parasitological	O	
2	post	O	
3	-	O	
4	mortem	O	
5	examination	O	
6	of	O	
7	all	O	
8	seropositive	O	
9	animals	O	
10	showed	O	
11	five	O	
12	and	O	
13	seven	O	
14	false	O	
15	-	O	
16	positive	O	
17	animals	O	
18	when	O	
19	E	B	
20	/	I	
21	S	I	
22	and	I	
23	CWE	I	
24	antigens	I	
25	were	O	
26	used	O	
27	,	O	
28	respectively	O	
29	.	O	

1	To	O	
2	study	O	
3	the	O	
4	role	O	
5	of	O	
6	heavy	O	
7	chain	O	
8	motifs	O	
9	in	O	
10	substrate	O	
11	recognition	O	
12	,	O	
13	secreted	O	
14	variants	O	
15	of	O	
16	recombinant	B	
17	bovine	I	
18	proenteropeptidase	I	
19	were	O	
20	constructed	O	
21	by	O	
22	replacing	O	
23	the	O	
24	transmembrane	O	
25	domain	O	
26	with	O	
27	a	O	
28	signal	O	
29	peptide	O	
30	.	O	

1	Lung	O	
2	density	O	
3	increased	O	
4	in	O	
5	quartz	O	
6	-	O	
7	exposed	O	
8	,	O	
9	but	O	
10	not	O	
11	in	O	
12	volcanic	O	
13	-	O	
14	ash	O	
15	-	O	
16	exposed	O	
17	animals	O	
18	.	O	

1	The	O	
2	slower	O	
3	-	O	
4	electrophoretic	O	
5	-	O	
6	mobility	O	
7	form	O	
8	of	O	
9	p68	B	
10	was	O	
11	absent	O	
12	in	O	
13	human	O	
14	cells	O	
15	in	O	
16	G1	O	
17	/	O	
18	S	O	
19	and	O	
20	appeared	O	
21	as	O	
22	the	O	
23	cells	O	
24	entered	O	
25	G2	O	
26	/	O	
27	M	O	
28	.	O	

1	Teicoplanin	O	
2	was	O	
3	given	O	
4	most	O	
5	often	O	
6	because	O	
7	of	O	
8	persistent	O	
9	fever	O	
10	or	O	
11	initial	O	
12	Gram	O	
13	-	O	
14	positive	O	
15	bacteraemia	O	
16	and	O	
17	only	O	
18	one	O	
19	-	O	
20	third	O	
21	of	O	
22	these	O	
23	cases	O	
24	responded	O	
25	.	O	

1	The	O	
2	risk	O	
3	for	O	
4	these	O	
5	complications	O	
6	is	O	
7	increased	O	
8	by	O	
9	the	O	
10	following	O	
11	factors	O	
12	:	O	
13	multiple	O	
14	gestation	O	
15	,	O	
16	the	O	
17	combination	O	
18	of	O	
19	magnesium	O	
20	sulfate	O	
21	and	O	
22	beta	O	
23	-	O	
24	adrenergic	O	
25	agonist	O	
26	,	O	
27	and	O	
28	the	O	
29	use	O	
30	of	O	
31	adrenocortico	O	
32	-	O	
33	steroids	O	
34	to	O	
35	hasten	O	
36	fetal	O	
37	pulmonary	O	
38	maturity	O	
39	.	O	

1	Control	O	
2	of	O	
3	fatty	O	
4	liver	O	
5	syndrome	O	
6	in	O	
7	a	O	
8	Jersey	O	
9	herd	O	
10	by	O	
11	a	O	
12	change	O	
13	of	O	
14	diet	O	
15	and	O	
16	the	O	
17	use	O	
18	of	O	
19	recombinant	O	
20	bovine	O	
21	somatotrophin	B	
22	.	O	

1	In	O	
2	PC12	O	
3	cells	O	
4	,	O	
5	nerve	B	
6	growth	I	
7	factor	I	
8	induces	O	
9	neuronal	O	
10	differentiation	O	
11	and	O	
12	repressed	O	
13	expression	O	
14	of	O	
15	nrg	B	
16	-	I	
17	1	I	
18	.	O	

1	Patients	O	
2	at	O	
3	risk	O	
4	of	O	
5	hypothyroidism	O	
6	.	O	

1	(	O	
2	iv	O	
3	)	O	
4	The	O	
5	accumulation	O	
6	of	O	
7	cyclin	B	
8	D3	I	
9	protein	I	
10	in	O	
11	Vero	O	
12	cells	O	
13	infected	O	
14	with	O	
15	an	O	
16	alpha0	B	
17	deletion	I	
18	mutant	I	
19	was	O	
20	reduced	O	
21	relative	O	
22	to	O	
23	that	O	
24	of	O	
25	cells	O	
26	infected	O	
27	with	O	
28	wild	O	
29	-	O	
30	type	O	
31	virus	O	
32	or	O	
33	a	O	
34	recombinant	O	
35	virus	O	
36	in	O	
37	which	O	
38	the	O	
39	deleted	O	
40	alpha0	B	
41	sequences	I	
42	were	O	
43	restored	O	
44	.	O	

1	Polyvinyl	O	
2	alcohol	O	
3	as	O	
4	a	O	
5	solution	O	
6	mediator	O	

1	In	O	
2	vitro	O	
3	expression	O	
4	levels	O	
5	of	O	
6	the	O	
7	different	O	
8	plasmids	O	
9	differed	O	
10	by	O	
11	as	O	
12	much	O	
13	as	O	
14	tenfold	O	
15	.	O	

1	Our	O	
2	results	O	
3	implicate	O	
4	TGF	B	
5	-	I	
6	beta	I	
7	RII	I	
8	as	O	
9	a	O	
10	direct	O	
11	target	O	
12	of	O	
13	EWS	B	
14	-	O	
15	FLI1	B	
16	.	O	

1	Opposite	O	
2	effects	O	
3	of	O	
4	CYP1	B	
5	are	O	
6	observed	O	
7	in	O	
8	aerobic	O	
9	,	O	
10	heme	O	
11	-	O	
12	sufficient	O	
13	cells	O	
14	.	O	

1	Elevation	O	
2	of	O	
3	intracellular	O	
4	Ca	O	
5	(	O	
6	2	O	
7	+)	O	
8	levels	O	
9	are	O	
10	also	O	
11	involved	O	
12	because	O	
13	treatment	O	
14	with	O	
15	receptor	O	
16	-	O	
17	associated	O	
18	protein	O	
19	,	O	
20	nifedipine	O	
21	,	O	
22	MK801	O	
23	,	O	
24	removal	O	
25	of	O	
26	Ca	O	
27	(	O	
28	2	O	
29	+)	O	
30	from	O	
31	the	O	
32	medium	O	
33	and	O	
34	dantrolene	O	
35	all	O	
36	served	O	
37	to	O	
38	inhibit	O	
39	calcium	O	
40	elevation	O	
41	and	O	
42	attenuate	O	
43	the	O	
44	activation	O	
45	of	O	
46	CREB	B	
47	.	O	

1	Univariate	O	
2	statistical	O	
3	analysis	O	
4	based	O	
5	on	O	
6	Kaplan	O	
7	-	O	
8	Meier	O	
9	-	O	
10	estimates	O	
11	and	O	
12	Log	O	
13	-	O	
14	Rank	O	
15	-	O	
16	Test	O	
17	showed	O	
18	the	O	
19	following	O	
20	prognostically	O	
21	beneficial	O	
22	factors	O	
23	:	O	
24	Limited	O	
25	disease	O	
26	stage	O	
27	(	O	
28	p	O	
29	=	O	
30	0	O	
31	.	O	
32	009	O	
33	),	O	
34	NSE	B	
35	serum	O	
36	level	O	
37	less	O	
38	than	O	
39	25	O	
40	micrograms	O	
41	/	O	
42	l	O	
43	(	O	
44	p	O	
45	=	O	
46	0	O	
47	.	O	
48	016	O	
49	),	O	
50	serum	O	
51	alkaline	B	
52	phosphatase	I	
53	less	O	
54	than	O	
55	200	O	
56	U	O	
57	/	O	
58	l	O	
59	(	O	
60	p	O	
61	=	O	
62	0	O	
63	.	O	
64	035	O	
65	),	O	
66	normal	O	
67	serum	O	
68	albumin	B	
69	(	O	
70	p	O	
71	=	O	
72	0	O	
73	.	O	
74	003	O	
75	)	O	
76	and	O	
77	activity	O	
78	index	O	
79	of	O	
80	minimum	O	
81	of	O	
82	70	O	
83	(	O	
84	p	O	
85	<	O	
86	0	O	
87	.	O	
88	001	O	
89	).	O	

1	No	O	
2	significant	O	
3	differences	O	
4	between	O	
5	the	O	
6	two	O	
7	treatment	O	
8	groups	O	
9	were	O	
10	found	O	
11	,	O	
12	but	O	
13	rapid	O	
14	responders	O	
15	had	O	
16	a	O	
17	smaller	O	
18	mean	O	
19	initial	O	
20	platelet	B	
21	-	I	
22	associated	I	
23	IgG	I	
24	index	O	
25	which	O	
26	returned	O	
27	more	O	
28	rapidly	O	
29	and	O	
30	more	O	
31	permanently	O	
32	to	O	
33	normal	O	
34	than	O	
35	that	O	
36	of	O	
37	slow	O	
38	responders	O	
39	.	O	

1	A	O	
2	strong	O	
3	correlation	O	
4	exists	O	
5	between	O	
6	the	O	
7	numbers	O	
8	of	O	
9	CFU	O	
10	-	O	
11	GM	O	
12	transfused	O	
13	and	O	
14	the	O	
15	rate	O	
16	of	O	
17	granulocytes	O	
18	and	O	
19	platelets	O	
20	recovery	O	
21	.	O	

1	A	O	
2	high	O	
3	-	O	
4	frequency	O	
5	restriction	O	
6	fragment	O	
7	length	O	
8	polymorphism	O	
9	was	O	
10	evident	O	
11	in	O	
12	the	O	
13	DNA	O	
14	from	O	
15	29	O	
16	unrelated	O	
17	individuals	O	
18	using	O	
19	the	O	
20	enzyme	O	
21	BglII	B	
22	.	O	

1	Visual	O	
2	averaged	O	
3	evoked	O	
4	responses	O	
5	and	O	
6	platelet	B	
7	monoamine	I	
8	oxidase	I	
9	in	O	
10	patients	O	
11	suffering	O	
12	from	O	
13	alcoholism	O	
14	.	O	

1	Thus	O	
2	,	O	
3	the	O	
4	bovine	B	
5	PEDF	I	
6	cDNA	I	
7	isolated	O	
8	here	O	
9	codes	O	
10	for	O	
11	a	O	
12	functional	O	
13	soluble	O	
14	secreted	B	
15	PEDF	I	
16	glycoprotein	I	
17	.	O	

1	Combined	O	
2	immunochemotherapy	O	
3	with	O	
4	cyclophosphamide	O	
5	plus	O	
6	BCG	O	
7	gave	O	
8	a	O	
9	better	O	
10	enhancement	O	
11	of	O	
12	the	O	
13	antitumor	O	
14	effect	O	
15	of	O	
16	the	O	
17	cytostatic	O	
18	than	O	
19	that	O	
20	of	O	
21	the	O	
22	combination	O	
23	of	O	
24	methotrexate	O	
25	plus	O	
26	BCG	O	
27	and	O	
28	cyclophosphamide	O	
29	plus	O	
30	levamisole	O	
31	.	O	

1	The	O	
2	authors	O	
3	report	O	
4	the	O	
5	clinicopathologic	O	
6	findings	O	
7	in	O	
8	four	O	
9	cases	O	
10	of	O	
11	adult	O	
12	women	O	
13	with	O	
14	rhabdomyosarcomas	O	
15	that	O	
16	originated	O	
17	in	O	
18	the	O	
19	endometrium	O	
20	or	O	
21	cervix	O	
22	,	O	
23	or	O	
24	both	O	
25	.	O	

1	Evaluation	O	
2	of	O	
3	automatic	O	
4	blood	O	
5	cell	O	
6	counters	O	
7	.	O	

1	There	O	
2	is	O	
3	no	O	
4	TATA	O	
5	box	O	
6	around	O	
7	the	O	
8	transcriptional	O	
9	start	O	
10	points	O	
11	(	O	
12	tsp	O	
13	),	O	
14	as	O	
15	determined	O	
16	by	O	
17	primer	O	
18	extension	O	
19	analysis	O	
20	.	O	

1	Laboratory	O	
2	aspects	O	
3	with	O	
4	particular	O	
5	reference	O	
6	to	O	
7	chemotherapy	O	
8	and	O	
9	control	O	
10	.	O	

1	However	O	
2	,	O	
3	expression	O	
4	of	O	
5	sigma	B	
6	3	I	
7	from	O	
8	S4	B	
9	(	O	
10	3	B	
11	'	I	
12	UTR	I	
13	/	I	
14	S1	I	
15	),	O	
16	which	O	
17	included	O	
18	the	O	
19	PKR	B	
20	activator	I	
21	sequence	I	
22	from	O	
23	S1	B	
24	within	O	
25	the	O	
26	3	B	
27	'-	I	
28	UTR	I	
29	of	I	
30	S4	I	
31	,	O	
32	was	O	
33	comparable	O	
34	to	O	
35	that	O	
36	from	O	
37	wild	B	
38	-	I	
39	type	I	
40	S4	I	
41	.	O	

1	There	O	
2	was	O	
3	a	O	
4	positive	O	
5	correlation	O	
6	between	O	
7	pyridinium	O	
8	cross	O	
9	-	O	
10	link	O	
11	excretion	O	
12	and	O	
13	thyroid	O	
14	hormone	O	
15	concentrations	O	
16	.	O	

1	The	O	
2	location	O	
3	of	O	
4	multiple	O	
5	GRK2	B	
6	and	O	
7	GRK5	B	
8	phosphoacceptor	I	
9	sites	I	
10	at	O	
11	the	O	
12	extreme	O	
13	carboxyl	O	
14	terminus	O	
15	of	O	
16	the	O	
17	beta2AR	B	
18	is	O	
19	highly	O	
20	reminiscent	O	
21	of	O	
22	GRK1	B	
23	-	O	
24	mediated	O	
25	phosphorylation	O	
26	of	O	
27	rhodopsin	B	
28	.	O	

1	Statement	O	
2	of	O	
3	the	O	
4	American	O	
5	Academy	O	
6	of	O	
7	Implant	O	
8	Dentistry	O	
9	.	O	

1	Finally	O	
2	,	O	
3	we	O	
4	present	O	
5	evidence	O	
6	that	O	
7	fimbrin	B	
8	is	O	
9	a	O	
10	third	O	
11	distinct	O	
12	plastin	B	
13	isoform	I	
14	which	O	
15	is	O	
16	specifically	O	
17	expressed	O	
18	at	O	
19	high	O	
20	levels	O	
21	in	O	
22	the	O	
23	small	O	
24	intestine	O	
25	.	O	

1	Their	O	
2	use	O	
3	resulted	O	
4	in	O	
5	a	O	
6	sensitivity	O	
7	of	O	
8	73	O	
9	%	O	
10	and	O	
11	a	O	
12	specificity	O	
13	of	O	
14	74	O	
15	%	O	
16	with	O	
17	regard	O	
18	to	O	
19	predictability	O	
20	of	O	
21	ALT	B	
22	levels	O	
23	increasing	O	
24	during	O	
25	the	O	
26	trial	O	
27	.	O	

1	The	O	
2	polyubiquitin	B	
3	gene	I	
4	was	O	
5	transcribed	O	
6	throughout	O	
7	the	O	
8	Volvox	O	
9	life	O	
10	cycle	O	
11	with	O	
12	peaks	O	
13	in	O	
14	the	O	
15	1	O	
16	.	O	
17	6	O	
18	-	O	
19	kb	O	
20	mRNA	O	
21	levels	O	
22	during	O	
23	pre	O	
24	-	O	
25	cleavage	O	
26	,	O	
27	cleavage	O	
28	,	O	
29	and	O	
30	post	O	
31	-	O	
32	inversion	O	
33	.	O	

1	The	O	
2	patient	O	
3	underwent	O	
4	two	O	
5	intracytoplasmic	O	
6	sperm	O	
7	injection	O	
8	cycles	O	
9	with	O	
10	thawed	O	
11	epididymal	O	
12	spermatozoa	O	
13	,	O	
14	in	O	
15	which	O	
16	,	O	
17	due	O	
18	to	O	
19	a	O	
20	pharmacist	O	
21	'	O	
22	s	O	
23	mistake	O	
24	,	O	
25	ovarian	O	
26	stimulation	O	
27	was	O	
28	carried	O	
29	out	O	
30	by	O	
31	a	O	
32	combination	O	
33	of	O	
34	long	O	
35	-	O	
36	acting	O	
37	gonadotrophin	B	
38	-	I	
39	releasing	I	
40	hormone	I	
41	agonist	O	
42	(	O	
43	leuprolide	O	
44	depot	O	
45	)	O	
46	and	O	
47	gonadotrophins	B	
48	.	O	

1	An	O	
2	extensive	O	
3	inverted	O	
4	repeat	O	
5	is	O	
6	present	O	
7	3	O	
8	'	O	
9	of	O	
10	rpeA	B	
11	;	O	
12	inverted	O	
13	repeats	O	
14	are	O	
15	found	O	
16	downstream	O	
17	of	O	
18	all	O	
19	PE	B	
20	operons	I	
21	sequenced	O	
22	to	O	
23	date	O	
24	,	O	
25	although	O	
26	the	O	
27	sequence	O	
28	is	O	
29	not	O	
30	conserved	O	
31	.	O	

1	Granisetron	O	
2	,	O	
3	but	O	
4	not	O	
5	saline	O	
6	,	O	
7	abolished	O	
8	vomiting	O	
9	and	O	
10	nausea	O	
11	when	O	
12	given	O	
13	as	O	
14	intervention	O	
15	after	O	
16	this	O	
17	combined	O	
18	emetic	O	
19	regimen	O	
20	.	O	

1	These	O	
2	six	O	
3	districts	O	
4	have	O	
5	an	O	
6	area	O	
7	of	O	
8	34	O	
9	,	O	
10	000	O	
11	km2	O	
12	and	O	
13	hold	O	
14	a	O	
15	population	O	
16	of	O	
17	30	O	
18	million	O	
19	.	O	

1	Northern	O	
2	blot	O	
3	and	O	
4	in	O	
5	situ	O	
6	hybridization	O	
7	analyses	O	
8	revealed	O	
9	GPR34	B	
10	mRNA	I	
11	transcripts	I	
12	in	O	
13	several	O	
14	human	O	
15	and	O	
16	rat	O	
17	brain	O	
18	regions	O	
19	.	O	

1	Mutations	O	
2	within	O	
3	conserved	O	
4	region	O	
5	2	O	
6	(	O	
7	CR2	O	
8	)	O	
9	of	O	
10	E1A	B	
11	that	O	
12	inhibit	O	
13	the	O	
14	binding	O	
15	of	O	
16	E1A	B	
17	to	O	
18	the	O	
19	retinoblastoma	B	
20	gene	I	
21	product	I	
22	(	O	
23	pRb	B	
24	)	O	
25	further	O	
26	enhanced	O	
27	the	O	
28	stimulation	O	
29	of	O	
30	transcription	O	
31	from	O	
32	the	O	
33	PEPCK	B	
34	promoter	I	
35	by	O	
36	2	O	
37	3	O	
38	-	O	
39	fold	O	
40	compared	O	
41	with	O	
42	wild	B	
43	type	I	
44	E1A	I	
45	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	the	O	
5	PPSF	O	
6	+	O	
7	DBP	O	
8	side	O	
9	showed	O	
10	large	O	
11	amounts	O	
12	of	O	
13	bone	O	
14	formation	O	
15	,	O	
16	and	O	
17	bone	O	
18	almost	O	
19	covered	O	
20	the	O	
21	implant	O	
22	.	O	

1	SRC	B	
2	-	I	
3	1	I	
4	can	O	
5	relieve	O	
6	the	O	
7	NF	B	
8	-	I	
9	kappaB	I	
10	-	O	
11	mediated	O	
12	repression	O	
13	of	O	
14	GR	B	
15	activity	O	
16	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	we	O	
5	find	O	
6	that	O	
7	E2F	B	
8	-	I	
9	1	I	
10	can	O	
11	cause	O	
12	apoptosis	O	
13	in	O	
14	p53	B	
15	-/-	I	
16	tumour	O	
17	cells	O	
18	and	O	
19	further	O	
20	p300	B	
21	,	O	
22	which	O	
23	also	O	
24	functions	O	
25	as	O	
26	a	O	
27	co	O	
28	-	O	
29	activator	O	
30	for	O	
31	the	O	
32	E2F	B	
33	/	O	
34	DP	B	
35	heterodimer	O	
36	,	O	
37	enhances	O	
38	the	O	
39	apoptotic	O	
40	activity	O	
41	of	O	
42	E2F	B	
43	-	I	
44	1	I	
45	.	O	

1	The	O	
2	cleavage	O	
3	of	O	
4	Fak	B	
5	by	O	
6	caspases	B	
7	may	O	
8	thus	O	
9	play	O	
10	an	O	
11	important	O	
12	role	O	
13	in	O	
14	the	O	
15	execution	O	
16	of	O	
17	the	O	
18	suicide	O	
19	program	O	
20	by	O	
21	disabling	O	
22	the	O	
23	anti	O	
24	-	O	
25	apoptotic	O	
26	function	O	
27	of	O	
28	Fak	B	
29	.	O	

1	Like	O	
2	the	O	
3	elicitors	O	
4	of	O	
5	the	O	
6	hypersensitive	O	
7	reaction	O	
8	(	O	
9	HR	O	
10	)	O	
11	produced	O	
12	by	O	
13	E	O	
14	.	O	
15	chrysanthemi	O	
16	(	O	
17	HarpinEch	O	
18	)	O	
19	and	O	
20	E	O	
21	.	O	
22	amylovora	O	
23	(	O	
24	HarpinEa	O	
25	),	O	
26	the	O	
27	deduced	O	
28	36	O	
29	-	O	
30	kDa	O	
31	protein	O	
32	does	O	
33	not	O	
34	possess	O	
35	a	O	
36	typical	O	
37	signal	O	
38	sequence	O	
39	,	O	
40	but	O	
41	it	O	
42	contains	O	
43	a	O	
44	putative	O	
45	membrane	O	
46	-	O	
47	spanning	O	
48	domain	O	
49	.	O	

1	Crosstalk	O	
2	among	O	
3	the	O	
4	pathways	O	
5	may	O	
6	explain	O	
7	how	O	
8	some	O	
9	forms	O	
10	of	O	
11	stress	O	
12	can	O	
13	contribute	O	
14	to	O	
15	the	O	
16	development	O	
17	of	O	
18	a	O	
19	malignancy	O	
20	.	O	

1	Laboratory	O	
2	evaluation	O	
3	was	O	
4	normal	O	
5	,	O	
6	and	O	
7	neuroimaging	O	
8	failed	O	
9	to	O	
10	confirm	O	
11	obstruction	O	
12	of	O	
13	venous	O	
14	or	O	
15	lymphatic	O	
16	drainage	O	
17	.	O	

1	At	O	
2	physiological	O	
3	doses	O	
4	,	O	
5	either	O	
6	insulin	B	
7	-	I	
8	like	I	
9	growth	I	
10	factor	I	
11	I	I	
12	(	O	
13	IGF	B	
14	-	I	
15	I	I	
16	)	O	
17	or	O	
18	insulin	B	
19	turned	O	
20	out	O	
21	to	O	
22	be	O	
23	as	O	
24	potent	O	
25	as	O	
26	dibutyryl	O	
27	cAMP	O	
28	(	O	
29	dbcAMP	O	
30	)	O	
31	in	O	
32	increasing	O	
33	UCP1	B	
34	gene	I	
35	transcription	O	
36	rate	O	
37	(	O	
38	1	O	
39	h	O	
40	)	O	
41	and	O	
42	also	O	
43	UCP1	B	
44	mRNA	I	
45	accumulation	O	
46	(	O	
47	3	O	
48	h	O	
49	),	O	
50	their	O	
51	maximal	O	
52	effect	O	
53	(	O	
54	15	O	
55	-	O	
56	fold	O	
57	increase	O	
58	)	O	
59	reached	O	
60	upon	O	
61	treatment	O	
62	for	O	
63	24	O	
64	h	O	
65	.	O	

1	The	O	
2	P	B	
3	mRNA	I	
4	also	O	
5	contains	O	
6	a	O	
7	third	O	
8	ORF	O	
9	for	O	
10	the	O	
11	V	B	
12	protein	I	
13	,	O	
14	although	O	
15	it	O	
16	is	O	
17	unclear	O	
18	how	O	
19	or	O	
20	whether	O	
21	this	O	
22	ORF	O	
23	is	O	
24	accessed	O	
25	.	O	

1	Unilateral	O	
2	naris	O	
3	occlusion	O	
4	and	O	
5	the	O	
6	rat	O	
7	accessory	O	
8	olfactory	O	
9	bulb	O	
10	.	O	

1	Groups	O	
2	of	O	
3	ten	O	
4	dependent	O	
5	and	O	
6	ten	O	
7	saline	O	
8	mice	O	
9	were	O	
10	singly	O	
11	tested	O	
12	in	O	
13	both	O	
14	light	O	
15	and	O	
16	dark	O	
17	conditions	O	
18	in	O	
19	each	O	
20	of	O	
21	five	O	
22	covered	O	
23	cylinders	O	
24	(	O	
25	2	O	
26	-	O	
27	23	O	
28	in	O	
29	high	O	
30	).	O	

1	Regulation	O	
2	of	O	
3	the	O	
4	human	O	
5	p21	B	
6	/	O	
7	WAF1	B	
8	/	O	
9	Cip1	B	
10	promoter	O	
11	in	O	
12	hepatic	O	
13	cells	O	
14	by	O	
15	functional	O	
16	interactions	O	
17	between	O	
18	Sp1	B	
19	and	O	
20	Smad	B	
21	family	I	
22	members	I	
23	.	O	

1	This	O	
2	fragment	O	
3	can	O	
4	bind	O	
5	several	O	
6	trans	O	
7	-	O	
8	acting	O	
9	factors	O	
10	in	O	
11	vitro	O	
12	,	O	
13	including	O	
14	GATA	B	
15	-	I	
16	1	I	
17	and	O	
18	members	O	
19	of	O	
20	the	O	
21	Ets	B	
22	family	I	
23	.	O	

1	Since	O	
2	RCC1p	B	
3	acts	O	
4	as	O	
5	GNRP	B	
6	for	O	
7	Ran	B	
8	,	O	
9	a	O	
10	small	B	
11	nuclear	I	
12	GTPase	I	
13	of	O	
14	the	O	
15	ras	B	
16	superfamily	I	
17	,	O	
18	we	O	
19	have	O	
20	identified	O	
21	two	O	
22	homologs	O	
23	of	O	
24	Ran	B	
25	in	O	
26	S	O	
27	.	O	
28	cerevisiae	O	
29	(	O	
30	CNR1	B	
31	and	O	
32	CNR2	B	
33	).	O	

1	In	O	
2	a	O	
3	prospective	O	
4	,	O	
5	randomized	O	
6	clinical	O	
7	trial	O	
8	we	O	
9	compared	O	
10	the	O	
11	efficacy	O	
12	of	O	
13	subcutaneously	O	
14	(	O	
15	SC	O	
16	)	O	
17	administered	O	
18	(	O	
19	every	O	
20	8	O	
21	h	O	
22	)	O	
23	calcium	O	
24	heparin	O	
25	to	O	
26	intravenous	O	
27	(	O	
28	IV	O	
29	)	O	
30	sodium	O	
31	heparin	O	
32	in	O	
33	the	O	
34	treatment	O	
35	of	O	
36	proximal	O	
37	deep	O	
38	-	O	
39	vein	O	
40	thrombosis	O	
41	(	O	
42	DVT	O	
43	).	O	

1	Western	O	
2	blotting	O	
3	(	O	
4	immunoblotting	O	
5	)	O	
6	with	O	
7	an	O	
8	antiserum	O	
9	to	O	
10	a	O	
11	partial	O	
12	SOD	B	
13	expressed	O	
14	in	O	
15	Escherichia	O	
16	coli	O	
17	revealed	O	
18	two	O	
19	proteins	O	
20	with	O	
21	estimated	O	
22	molecular	O	
23	masses	O	
24	of	O	
25	19	O	
26	and	O	
27	29	O	
28	kDa	O	
29	.	O	

1	It	O	
2	was	O	
3	concluded	O	
4	that	O	
5	patients	O	
6	with	O	
7	acute	O	
8	respiratory	O	
9	failure	O	
10	requiring	O	
11	artificial	O	
12	ventilation	O	
13	have	O	
14	two	O	
15	componenents	O	
16	of	O	
17	the	O	
18	pulmonary	O	
19	shunt	O	
20	,	O	
21	one	O	
22	parallel	O	
23	with	O	
24	and	O	
25	the	O	
26	other	O	
27	inversely	O	
28	related	O	
29	with	O	
30	the	O	
31	PAO2	O	
32	.	O	

1	A	O	
2	consensus	O	
3	sequence	O	
4	indicates	O	
5	a	O	
6	highly	O	
7	conserved	O	
8	lysine	O	
9	residue	O	
10	,	O	
11	K120	O	
12	of	O	
13	endonuclease	B	
14	III	I	
15	or	O	
16	K241	O	
17	of	O	
18	Ogg1	B	
19	,	O	
20	respectively	O	
21	.	O	

1	Delayed	O	
2	mortality	O	
3	of	O	
4	mice	O	
5	following	O	
6	inhalation	O	
7	of	O	
8	acute	O	
9	doses	O	
10	of	O	
11	CH2O	O	
12	,	O	
13	SO2Cl2	O	
14	,	O	
15	and	O	
16	Br2	O	
17	.	O	

1	This	O	
2	organization	O	
3	suggests	O	
4	that	O	
5	duplication	O	
6	events	O	
7	that	O	
8	have	O	
9	generated	O	
10	the	O	
11	primate	O	
12	FUT3	B	
13	-	O	
14	FUT5	B	
15	-	O	
16	FUT6	B	
17	cluster	O	
18	might	O	
19	have	O	
20	occurred	O	
21	through	O	
22	a	O	
23	long	O	
24	-	O	
25	interspersed	O	
26	-	O	
27	nuclear	O	
28	-	O	
29	element	O	
30	-	O	
31	based	O	
32	mechanism	O	
33	of	O	
34	unequal	O	
35	crossing	O	
36	over	O	
37	,	O	
38	as	O	
39	described	O	
40	for	O	
41	the	O	
42	globin	B	
43	cluster	I	
44	.	O	

1	This	O	
2	experimental	O	
3	design	O	
4	was	O	
5	used	O	
6	to	O	
7	determine	O	
8	the	O	
9	effect	O	
10	of	O	
11	displacement	O	
12	of	O	
13	the	O	
14	alpha	B	
15	4	I	
16	-	I	
17	2	I	
18	binding	I	
19	site	I	
20	on	O	
21	the	O	
22	repression	O	
23	of	O	
24	alpha	B	
25	4	I	
26	gene	I	
27	transcription	O	
28	by	O	
29	ICP4	B	
30	.	O	

1	The	O	
2	coating	O	
3	materials	O	
4	were	O	
5	poloxamine	O	
6	904	O	
7	,	O	
8	poloxamine	O	
9	908	O	
10	,	O	
11	poloxamine	O	
12	1508	O	
13	,	O	
14	poloxamer	O	
15	338	O	
16	,	O	
17	and	O	
18	Brij	O	
19	35	O	
20	.	O	

1	Enhanced	O	
2	period	O	
3	-	O	
4	peak	O	
5	analysis	O	
6	of	O	
7	electro	O	
8	-	O	
9	encephalograms	O	
10	using	O	
11	a	O	
12	fast	O	
13	sinc	O	
14	function	O	
15	.	O	

1	Stable	O	
2	patients	O	
3	have	O	
4	mucous	O	
5	hypersecretion	O	
6	and	O	
7	little	O	
8	evidence	O	
9	of	O	
10	acute	O	
11	inflammation	O	
12	.	O	

1	Isolated	O	
2	calcaneal	O	
3	tuberculous	O	
4	osteomyelitis	O	
5	.	O	

1	The	O	
2	thrombolytic	O	
3	effects	O	
4	of	O	
5	native	O	
6	tissue	B	
7	-	I	
8	type	I	
9	plasminogen	I	
10	activator	I	
11	(	O	
12	AK	B	
13	-	I	
14	124	I	
15	)	O	
16	on	O	
17	experimental	O	
18	canine	O	
19	coronary	O	
20	thrombosis	O	
21	.	O	

1	METHODS	O	
2	:	O	
3	Millipore	O	
4	ultrafiltration	O	
5	membranes	O	
6	of	O	
7	three	O	
8	different	O	
9	pore	O	
10	sizes	O	
11	were	O	
12	used	O	
13	as	O	
14	model	O	
15	lenticule	O	
16	materials	O	
17	.	O	
18	The	O	
19	nominal	O	
20	membrane	O	
21	pore	O	
22	sizes	O	
23	were	O	
24	0	O	
25	.	O	
26	1	O	
27	microm	O	
28	,	O	
29	0	O	
30	.	O	
31	45	O	
32	microm	O	
33	,	O	
34	and	O	
35	3	O	
36	microm	O	
37	;	O	
38	the	O	
39	surface	O	
40	roughness	O	
41	increased	O	
42	in	O	
43	the	O	
44	same	O	
45	order	O	
46	The	O	
47	membranes	O	
48	were	O	
49	coated	O	
50	with	O	
51	a	O	
52	thin	O	
53	layer	O	
54	of	O	
55	collagen	B	
56	I	I	
57	and	O	
58	implanted	O	
59	in	O	
60	a	O	
61	circular	O	
62	pocket	O	
63	of	O	
64	the	O	
65	anterior	O	
66	cornea	O	
67	of	O	
68	adult	O	
69	cats	O	
70	,	O	
71	and	O	
72	were	O	
73	clinically	O	
74	evaluated	O	
75	for	O	
76	the	O	
77	extent	O	
78	of	O	
79	epithelialization	O	
80	and	O	
81	the	O	
82	persistence	O	
83	of	O	
84	epithelial	O	
85	attachment	O	
86	.	O	

1	Children	O	
2	with	O	
3	defective	O	
4	vision	O	

1	Methysergide	O	
2	is	O	
3	a	O	
4	serotonin	O	
5	antagonist	O	
6	and	O	
7	has	O	
8	been	O	
9	demonstrated	O	
10	to	O	
11	reduce	O	
12	wound	O	
13	blood	O	
14	flow	O	
15	and	O	
16	edema	O	
17	formation	O	
18	.	O	

1	Magnetic	O	
2	resonance	O	
3	imaging	O	
4	(	O	
5	MRI	O	
6	)	O	
7	has	O	
8	enabled	O	
9	us	O	
10	to	O	
11	see	O	
12	the	O	
13	spinal	O	
14	intramedullary	O	
15	pathology	O	
16	as	O	
17	differences	O	
18	in	O	
19	signal	O	
20	intensity	O	
21	.	O	

1	Mutations	O	
2	in	O	
3	the	O	
4	yeast	B	
5	RNA14	I	
6	and	O	
7	RNA15	B	
8	genes	I	
9	result	O	
10	in	O	
11	an	O	
12	abnormal	O	
13	mRNA	O	
14	decay	O	
15	rate	O	
16	;	O	
17	sequence	O	
18	analysis	O	
19	reveals	O	
20	an	O	
21	RNA	O	
22	-	O	
23	binding	O	
24	domain	O	
25	in	O	
26	the	O	
27	RNA15	B	
28	protein	I	
29	.	O	

1	These	O	
2	results	O	
3	show	O	
4	that	O	
5	Ski	B	
6	is	O	
7	a	O	
8	component	O	
9	of	O	
10	the	O	
11	HDAC	B	
12	complex	I	
13	and	O	
14	that	O	
15	Ski	B	
16	is	O	
17	required	O	
18	for	O	
19	the	O	
20	transcriptional	O	
21	repression	O	
22	mediated	O	
23	by	O	
24	this	O	
25	complex	O	
26	.	O	

1	Lengthy	O	
2	and	O	
3	repeated	O	
4	hemodialyses	O	
5	were	O	
6	required	O	
7	to	O	
8	lower	O	
9	lithemia	O	
10	to	O	
11	nontoxic	O	
12	ranges	O	
13	.	O	

1	Magnetotherapy	O	
2	of	O	
3	hepatitis	O	
4	A	O	
5	and	O	
6	B	O	
7	in	O	
8	children	O	

1	Genetic	O	
2	experiments	O	
3	using	O	
4	mutants	O	
5	defective	O	
6	in	O	
7	apontic	B	
8	and	O	
9	bruno	B	
10	reveal	O	
11	a	O	
12	functional	O	
13	interaction	O	
14	between	O	
15	these	O	
16	genes	O	
17	.	O	

1	Normal	O	
2	rates	O	
3	of	O	
4	weight	O	
5	gain	O	
6	were	O	
7	seen	O	
8	once	O	
9	absorbed	O	
10	energy	O	
11	intakes	O	
12	reached	O	
13	100	O	
14	-	O	
15	110	O	
16	%	O	
17	of	O	
18	requirements	O	
19	.	O	

1	Nuclease	O	
2	probing	O	
3	and	O	
4	structure	O	
5	-	O	
6	directed	O	
7	mutagenesis	O	
8	revealed	O	
9	that	O	
10	the	O	
11	105	O	
12	-	O	
13	nt	O	
14	TE	O	
15	(	O	
16	TE105	O	
17	)	O	
18	forms	O	
19	a	O	
20	cruciform	O	
21	secondary	O	
22	structure	O	
23	containing	O	
24	four	O	
25	helices	O	
26	connected	O	
27	by	O	
28	single	O	
29	-	O	
30	stranded	O	
31	regions	O	
32	.	O	

1	The	O	
2	effect	O	
3	of	O	
4	ethanol	O	
5	on	O	
6	human	O	
7	sensorimotor	O	
8	reactivity	O	
9	was	O	
10	assessed	O	
11	by	O	
12	examining	O	
13	the	O	
14	acoustic	O	
15	startle	O	
16	response	O	
17	.	O	

1	This	O	
2	study	O	
3	tested	O	
4	the	O	
5	hypothesis	O	
6	that	O	
7	sodium	O	
8	channel	O	
9	blocking	O	
10	drugs	O	
11	selectively	O	
12	prolong	O	
13	the	O	
14	late	O	
15	potential	O	
16	,	O	
17	or	O	
18	terminal	O	
19	low	O	
20	amplitude	O	
21	signal	O	
22	,	O	
23	portion	O	
24	of	O	
25	the	O	
26	signal	O	
27	-	O	
28	averaged	O	
29	QRS	O	
30	complex	O	
31	and	O	
32	that	O	
33	prolongation	O	
34	of	O	
35	the	O	
36	late	O	
37	potential	O	
38	would	O	
39	correlate	O	
40	with	O	
41	slowing	O	
42	of	O	
43	ventricular	O	
44	tachycardia	O	
45	.	O	

1	Deletion	O	
2	of	O	
3	an	O	
4	intergenic	O	
5	DNA	O	
6	-	O	
7	binding	O	
8	site	O	
9	for	O	
10	this	O	
11	complex	O	
12	from	O	
13	a	O	
14	human	B	
15	beta	I	
16	-	I	
17	globin	I	
18	locus	I	
19	construct	I	
20	results	O	
21	in	O	
22	delayed	O	
23	human	B	
24	gamma	I	
25	-	I	
26	to	I	
27	beta	I	
28	-	I	
29	globin	I	
30	switching	O	
31	in	O	
32	transgenic	O	
33	mice	O	
34	,	O	
35	suggesting	O	
36	that	O	
37	the	O	
38	PYR	B	
39	complex	I	
40	acts	O	
41	to	O	
42	facilitate	O	
43	the	O	
44	switch	O	
45	.	O	

1	The	O	
2	preferences	O	
3	were	O	
4	for	O	
5	intact	O	
6	vis	O	
7	-	O	
8	a	O	
9	-	O	
10	vis	O	
11	castrated	O	
12	males	O	
13	,	O	
14	though	O	
15	injections	O	
16	of	O	
17	TP	O	
18	restored	O	
19	the	O	
20	castrates	O	
21	'	O	
22	attractiveness	O	
23	to	O	
24	the	O	
25	females	O	
26	.	O	

1	A	O	
2	total	O	
3	of	O	
4	26	O	
5	BCG	O	
6	strains	O	
7	,	O	
8	out	O	
9	of	O	
10	them	O	
11	10	O	
12	Czechoslovak	O	
13	strains	O	
14	(	O	
15	2	O	
16	lyophilized	O	
17	cultures	O	
18	of	O	
19	BCG	O	
20	of	O	
21	different	O	
22	batch	O	
23	,	O	
24	6	O	
25	strains	O	
26	isolated	O	
27	from	O	
28	abscesses	O	
29	of	O	
30	children	O	
31	after	O	
32	BCG	O	
33	-	O	
34	vaccination	O	
35	and	O	
36	2	O	
37	strains	O	
38	from	O	
39	fatal	O	
40	cases	O	
41	after	O	
42	BCG	O	
43	-	O	
44	vaccination	O	
45	)	O	
46	and	O	
47	16	O	
48	strains	O	
49	obtained	O	
50	from	O	
51	foreign	O	
52	laboratories	O	
53	,	O	
54	were	O	
55	used	O	
56	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	all	O	
5	three	O	
6	Opa	B	
7	proteins	I	
8	of	O	
9	C751	O	
10	bind	O	
11	equally	O	
12	well	O	
13	to	O	
14	HeLa	O	
15	cells	O	
16	transfected	O	
17	with	O	
18	cDNA	O	
19	encoding	O	
20	the	O	
21	carcinoembryonic	B	
22	antigen	I	
23	[	O	
24	CEA	B	
25	(	O	
26	CD66e	B	
27	)]	O	
28	subgroup	O	
29	of	O	
30	the	O	
31	CD66	B	
32	family	I	
33	,	O	
34	but	O	
35	show	O	
36	distinct	O	
37	tropism	O	
38	for	O	
39	CGM1	B	
40	-	O	
41	(	O	
42	CD66d	B	
43	)	O	
44	and	O	
45	NCA	B	
46	(	O	
47	CD66c	B	
48	)-	O	
49	expressing	O	
50	cells	O	
51	.	O	

1	Growth	O	
2	of	O	
3	tracheal	O	
4	anastomoses	O	
5	in	O	
6	growing	O	
7	animals	O	

1	Haplotype	O	
2	mapping	O	
3	and	O	
4	sequence	O	
5	analysis	O	
6	of	O	
7	the	O	
8	mouse	O	
9	Nramp	B	
10	gene	I	
11	predict	O	
12	susceptibility	O	
13	to	O	
14	infection	O	
15	with	O	
16	intracellular	O	
17	parasites	O	
18	.	O	

1	During	O	
2	the	O	
3	years	O	
4	1980	O	
5	-	O	
6	87	O	
7	a	O	
8	total	O	
9	of	O	
10	287	O	
11	persons	O	
12	received	O	
13	disability	O	
14	pensions	O	
15	in	O	
16	the	O	
17	municipality	O	
18	of	O	
19	Nordreisa	O	
20	in	O	
21	northern	O	
22	Norway	O	
23	.	O	

1	Number	O	
2	of	O	
3	patients	O	
4	infected	O	
5	with	O	
6	nontuberculous	O	
7	mycobacteria	O	
8	(	O	
9	NTM	O	
10	)	O	
11	is	O	
12	increasing	O	
13	world	O	
14	-	O	
15	wide	O	
16	in	O	
17	recent	O	
18	years	O	
19	.	O	

1	In	O	
2	Wnt	B	
3	signaling	O	
4	,	O	
5	beta	B	
6	-	I	
7	catenin	I	
8	and	O	
9	plakoglobin	B	
10	transduce	O	
11	signals	O	
12	to	O	
13	the	O	
14	nucleus	O	
15	through	O	
16	interactions	O	
17	with	O	
18	TCF	B	
19	-	I	
20	type	I	
21	transcription	I	
22	factors	I	
23	.	O	

1	Asymptomatic	O	
2	bacteriospermia	O	
3	and	O	
4	fertility	O	

1	An	O	
2	approach	O	
3	to	O	
4	a	O	
5	biomathematical	O	
6	model	O	
7	of	O	
8	lymphocytopoiesis	O	
9	.	O	

1	Following	O	
2	conditioning	O	
3	,	O	
4	a	O	
5	single	O	
6	coat	O	
7	of	O	
8	adhesive	O	
9	was	O	
10	applied	O	
11	and	O	
12	light	O	
13	-	O	
14	cured	O	
15	.	O	

1	The	O	
2	diagnosis	O	
3	of	O	
4	miliary	O	
5	tuberculosis	O	
6	should	O	
7	be	O	
8	systematically	O	
9	considered	O	
10	in	O	
11	ARDS	O	
12	of	O	
13	unknown	O	
14	origin	O	
15	.	O	

1	Agonist	O	
2	-	O	
3	induced	O	
4	receptor	O	
5	internalization	O	
6	,	O	
7	determined	O	
8	as	O	
9	the	O	
10	percent	O	
11	of	O	
12	total	O	
13	[	O	
14	125I	O	
15	]	O	
16	Tyr0	B	
17	-	I	
18	oCRF	I	
19	bound	O	
20	located	O	
21	in	O	
22	the	O	
23	acid	O	
24	-	O	
25	resistant	O	
26	fraction	O	
27	of	O	
28	transfected	O	
29	Cos	O	
30	7	O	
31	cells	O	
32	,	O	
33	increased	O	
34	with	O	
35	time	O	
36	(	O	
37	0	O	
38	-	O	
39	60	O	
40	min	O	
41	at	O	
42	37	O	
43	degrees	O	
44	C	O	
45	)	O	
46	for	O	
47	both	O	
48	wild	O	
49	-	O	
50	type	O	
51	and	O	
52	variant	O	
53	oCRF1	B	
54	.	O	

1	Accurate	O	
2	evaluation	O	
3	of	O	
4	the	O	
5	treatment	O	
6	results	O	
7	in	O	
8	unresectable	O	
9	lung	O	
10	cancer	O	
11	patients	O	
12	must	O	
13	take	O	
14	the	O	
15	strong	O	
16	prognostic	O	
17	factors	O	
18	into	O	
19	account	O	
20	.	O	

1	When	O	
2	ligated	O	
3	to	O	
4	the	O	
5	proIL	B	
6	-	I	
7	1	I	
8	beta	I	
9	cap	I	
10	site	I	
11	-	I	
12	proximal	I	
13	region	I	
14	(	O	
15	located	O	
16	between	O	
17	-	O	
18	131	O	
19	to	O	
20	+	O	
21	12	O	
22	),	O	
23	both	O	
24	the	O	
25	proIL	B	
26	-	I	
27	1	I	
28	beta	I	
29	and	O	
30	the	O	
31	simian	B	
32	virus	I	
33	40	I	
34	enhancer	I	
35	elements	I	
36	functioned	O	
37	more	O	
38	efficiently	O	
39	in	O	
40	monocytes	O	
41	than	O	
42	in	O	
43	HeLa	O	
44	cells	O	
45	,	O	
46	which	O	
47	are	O	
48	not	O	
49	normally	O	
50	competent	O	
51	for	O	
52	IL	B	
53	-	I	
54	1	I	
55	beta	I	
56	expression	O	
57	.	O	

1	These	O	
2	animals	O	
3	were	O	
4	viable	O	
5	and	O	
6	fertile	O	
7	.	O	

1	In	O	
2	visible	O	
3	tumours	O	
4	the	O	
5	best	O	
6	results	O	
7	were	O	
8	obtained	O	
9	with	O	
10	FB	O	
11	(	O	
12	85	O	
13	%)	O	
14	while	O	
15	TBN	O	
16	was	O	
17	positive	O	
18	in	O	
19	65	O	
20	%.	O	

1	For	O	
2	E2	O	
3	,	O	
4	each	O	
5	cat	O	
6	was	O	
7	given	O	
8	either	O	
9	5	O	
10	(	O	
11	group	O	
12	[	O	
13	G	O	
14	]	O	
15	1	O	
16	)	O	
17	or	O	
18	10	O	
19	(	O	
20	G2	O	
21	)	O	
22	mg	O	
23	of	O	
24	itraconazole	O	
25	/	O	
26	kg	O	
27	(	O	
28	capsules	O	
29	)	O	
30	twice	O	
31	daily	O	
32	for	O	
33	6	O	
34	weeks	O	
35	.	O	

1	The	O	
2	latter	O	
3	domain	O	
4	appears	O	
5	to	O	
6	be	O	
7	involved	O	
8	in	O	
9	targeting	O	
10	Num1p	B	
11	to	O	
12	the	O	
13	mother	O	
14	cell	O	
15	cortex	O	
16	.	O	

1	Finally	O	
2	,	O	
3	some	O	
4	point	O	
5	mutations	O	
6	in	O	
7	the	O	
8	Gag	B	
9	-	O	
10	Pol	B	
11	PR	O	
12	domain	O	
13	inhibited	O	
14	activation	O	
15	of	O	
16	RT	B	
17	in	O	
18	trans	O	
19	by	O	
20	a	O	
21	wild	O	
22	-	O	
23	type	O	
24	PR	B	
25	,	O	
26	suggesting	O	
27	that	O	
28	the	O	
29	correct	O	
30	conformation	O	
31	of	O	
32	the	O	
33	PR	B	
34	domain	O	
35	in	O	
36	Gag	B	
37	-	O	
38	Pol	B	
39	is	O	
40	prerequisite	O	
41	for	O	
42	activation	O	
43	of	O	
44	RT	B	
45	.	O	

1	The	O	
2	mortality	O	
3	rate	O	
4	and	O	
5	histopathological	O	
6	features	O	
7	of	O	
8	Nocardia	O	
9	asteroides	O	
10	and	O	
11	Nocardia	O	
12	brasiliensis	O	
13	infections	O	
14	in	O	
15	congenitally	O	
16	athymic	O	
17	(	O	
18	nude	O	
19	)	O	
20	mice	O	
21	of	O	
22	ICR	O	
23	and	O	
24	C3H	O	
25	/	O	
26	eB	O	
27	origins	O	
28	were	O	
29	quite	O	
30	different	O	
31	from	O	
32	what	O	
33	we	O	
34	found	O	
35	for	O	
36	Swiss	O	
37	white	O	
38	mice	O	
39	and	O	
40	other	O	
41	inbred	O	
42	mouse	O	
43	strains	O	
44	(	O	
45	namely	O	
46	,	O	
47	C57	O	
48	/	O	
49	BL	O	
50	/	O	
51	6J	O	
52	,	O	
53	New	O	
54	Zealand	O	
55	Black	O	
56	,	O	
57	BALB	O	
58	/	O	
59	c	O	
60	,	O	
61	CBA	O	
62	/	O	
63	LAC	O	
64	,	O	
65	and	O	
66	C3H	O	
67	/	O	
68	eB	O	
69	).	O	

1	Nonsynonymous	O	
2	substitution	O	
3	in	O	
4	abalone	O	
5	sperm	O	
6	fertilization	O	
7	genes	O	
8	exceeds	O	
9	substitution	O	
10	in	O	
11	introns	O	
12	and	O	
13	mitochondrial	O	
14	DNA	O	
15	.	O	

1	51	O	
2	.	O	
3	9	O	
4	%	O	
5	(	O	
6	P	O	
7	=	O	
8	0	O	
9	.	O	
10	0006	O	
11	)	O	
12	in	O	
13	the	O	
14	MMF	O	
15	versus	O	
16	the	O	
17	AZA	O	
18	groups	O	
19	,	O	
20	respectively	O	
21	.	O	

1	Rabbits	O	
2	developed	O	
3	profound	O	
4	hypocalcemia	O	
5	,	O	
6	with	O	
7	levels	O	
8	falling	O	
9	from	O	
10	15	O	
11	.	O	
12	5	O	
13	+/-	O	
14	0	O	
15	.	O	
16	2	O	
17	to	O	
18	7	O	
19	.	O	
20	6	O	
21	+/-	O	
22	0	O	
23	.	O	
24	4	O	
25	mg	O	
26	/	O	
27	dl	O	
28	under	O	
29	the	O	
30	influence	O	
31	of	O	
32	TSST	B	
33	-	I	
34	1	I	
35	.	O	

1	Histopathological	O	
2	features	O	
3	of	O	
4	relapsed	O	
5	leprosy	O	
6	.	O	

1	The	O	
2	c	B	
3	-	I	
4	myc	I	
5	gene	I	
6	is	O	
7	overexpressed	O	
8	in	O	
9	a	O	
10	variety	O	
11	of	O	
12	tumor	O	
13	types	O	
14	and	O	
15	appears	O	
16	to	O	
17	play	O	
18	an	O	
19	important	O	
20	role	O	
21	in	O	
22	the	O	
23	abnormal	O	
24	growth	O	
25	of	O	
26	a	O	
27	number	O	
28	of	O	
29	cell	O	
30	types	O	
31	.	O	

1	CONCLUSION	O	
2	:	O	
3	Our	O	
4	findings	O	
5	suggest	O	
6	that	O	
7	endometriosis	O	
8	increases	O	
9	soluble	O	
10	CD23	B	
11	levels	O	
12	,	O	
13	which	O	
14	can	O	
15	be	O	
16	suppressed	O	
17	with	O	
18	either	O	
19	danazol	O	
20	or	O	
21	leuprolide	O	
22	acetate	O	
23	injection	O	
24	.	O	

1	The	O	
2	data	O	
3	suggest	O	
4	that	O	
5	ICP10	B	
6	constitutively	O	
7	increases	O	
8	ras	B	
9	activity	O	
10	,	O	
11	and	O	
12	its	O	
13	TM	O	
14	segment	O	
15	plays	O	
16	a	O	
17	critical	O	
18	role	O	
19	in	O	
20	transformation	O	
21	-	O	
22	related	O	
23	signaling	O	
24	pathways	O	
25	.	O	

1	The	O	
2	obtained	O	
3	results	O	
4	were	O	
5	compared	O	
6	with	O	
7	control	O	
8	group	O	
9	(	O	
10	10	O	
11	female	O	
12	volunteers	O	
13	).	O	

1	Homologous	O	
2	recombination	O	
3	between	O	
4	the	O	
5	Autographa	O	
6	californica	O	
7	nuclear	O	
8	polyhedrosis	O	
9	virus	O	
10	(	O	
11	AcNPV	O	
12	)	O	
13	genome	O	
14	and	O	
15	a	O	
16	0	O	
17	.	O	
18	6	O	
19	-	O	
20	kbp	O	
21	-	O	
22	long	O	
23	DNA	O	
24	fragment	O	
25	derived	O	
26	from	O	
27	the	O	
28	putative	O	
29	DNA	B	
30	helicase	I	
31	gene	I	
32	of	I	
33	Bombyx	I	
34	mori	I	
35	nuclear	I	
36	polyhedrosis	I	
37	virus	I	
38	generates	O	
39	eh2	O	
40	-	O	
41	AcNPV	O	
42	,	O	
43	an	O	
44	expanded	O	
45	-	O	
46	host	O	
47	-	O	
48	range	O	
49	AcNPV	O	
50	mutant	O	
51	(	O	
52	S	O	
53	.	O	

1	The	O	
2	mei4	B	
3	+	I	
4	gene	I	
5	of	O	
6	the	O	
7	fission	O	
8	yeast	O	
9	Schizosaccharomyces	O	
10	pombe	O	
11	was	O	
12	cloned	O	
13	by	O	
14	functional	O	
15	complementation	O	
16	.	O	

1	Existence	O	
2	and	O	
3	uniqueness	O	
4	of	O	
5	solutions	O	
6	of	O	
7	the	O	
8	appropriate	O	
9	boundary	O	
10	value	O	
11	problems	O	
12	are	O	
13	established	O	
14	,	O	
15	in	O	
16	the	O	
17	case	O	
18	of	O	
19	small	O	
20	permeability	O	
21	coefficients	O	
22	and	O	
23	transport	O	
24	rates	O	
25	,	O	
26	or	O	
27	large	O	
28	diffusion	O	
29	coefficients	O	
30	and	O	
31	small	O	
32	resistance	O	
33	to	O	
34	flow	O	
35	constants	O	
36	.	O	

1	Furthermore	O	
2	,	O	
3	p150	B	
4	suppresses	O	
5	actin	B	
6	gelation	O	
7	,	O	
8	which	O	
9	is	O	
10	induced	O	
11	by	O	
12	smooth	B	
13	muscle	I	
14	alpha	I	
15	-	I	
16	actinin	I	
17	.	O	

1	The	O	
2	inhibition	O	
3	of	O	
4	StAR	B	
5	gene	I	
6	transcription	O	
7	by	O	
8	DAX	B	
9	-	I	
10	1	I	
11	was	O	
12	dose	O	
13	-	O	
14	dependent	O	
15	reducing	O	
16	transcription	O	
17	to	O	
18	6	O	
19	%	O	
20	of	O	
21	control	O	
22	levels	O	
23	.	O	

1	All	O	
2	13	O	
3	patients	O	
4	showed	O	
5	endoscopic	O	
6	evidence	O	
7	of	O	
8	oesophagitis	O	
9	,	O	
10	moderate	O	
11	in	O	
12	4	O	
13	and	O	
14	severe	O	
15	in	O	
16	9	O	
17	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	despite	O	
5	external	O	
6	radiation	O	
7	therapy	O	
8	,	O	
9	brain	O	
10	metastases	O	
11	proved	O	
12	fatal	O	
13	.	O	

1	Polyprotein	O	
2	processing	O	
3	in	O	
4	Southampton	O	
5	virus	O	
6	:	O	
7	identification	O	
8	of	O	
9	3C	B	
10	-	I	
11	like	I	
12	protease	I	
13	cleavage	O	
14	sites	O	
15	by	O	
16	in	O	
17	vitro	O	
18	mutagenesis	O	
19	.	O	

1	Acoust	O	
2	.	O	

1	Isolation	O	
2	and	O	
3	characterization	O	
4	of	O	
5	the	O	
6	rat	O	
7	chromosomal	O	
8	gene	O	
9	for	O	
10	a	O	
11	polypeptide	O	
12	(	O	
13	pS1	B	
14	)	O	
15	antigenically	O	
16	related	O	
17	to	O	
18	statin	B	
19	.	O	

1	In	O	
2	order	O	
3	to	O	
4	gain	O	
5	deeper	O	
6	insight	O	
7	into	O	
8	the	O	
9	role	O	
10	of	O	
11	the	O	
12	amino	O	
13	-	O	
14	terminal	O	
15	domain	O	
16	of	O	
17	the	O	
18	p24	B	
19	(	O	
20	CA	B	
21	)	O	
22	protein	O	
23	during	O	
24	viral	O	
25	replication	O	
26	,	O	
27	eight	O	
28	highly	O	
29	conserved	O	
30	proline	O	
31	residues	O	
32	known	O	
33	to	O	
34	promote	O	
35	turns	O	
36	and	O	
37	to	O	
38	terminate	O	
39	alpha	O	
40	-	O	
41	helices	O	
42	within	O	
43	the	O	
44	p24	B	
45	tertiary	O	
46	structure	O	
47	were	O	
48	replaced	O	
49	by	O	
50	a	O	
51	leucine	O	
52	residue	O	
53	(	O	
54	P	O	
55	-	O	
56	position	O	
57	-	O	
58	L	O	
59	).	O	

1	This	O	
2	suggests	O	
3	that	O	
4	alaproclate	O	
5	acutely	O	
6	increases	O	
7	the	O	
8	responsiveness	O	
9	of	O	
10	postsynaptic	O	
11	muscarinic	B	
12	and	I	
13	alpha	I	
14	1	I	
15	adrenoceptors	I	
16	.	O	

1	In	O	
2	addition	O	
3	to	O	
4	homologues	O	
5	of	O	
6	the	O	
7	human	B	
8	genes	I	
9	PSMB5	I	
10	through	O	
11	PSMB9	B	
12	,	O	
13	two	O	
14	new	O	
15	genes	O	
16	,	O	
17	PSMB11	B	
18	and	O	
19	PSMB12	B	
20	,	O	
21	have	O	
22	been	O	
23	found	O	
24	for	O	
25	which	O	
26	there	O	
27	are	O	
28	no	O	
29	known	O	
30	corresponding	O	
31	genes	O	
32	in	O	
33	humans	O	
34	.	O	

1	Our	O	
2	study	O	
3	reveals	O	
4	that	O	
5	the	O	
6	modular	O	
7	structure	O	
8	of	O	
9	the	O	
10	FSH	B	
11	receptor	I	
12	gene	O	
13	generates	O	
14	motifs	O	
15	that	O	
16	allows	O	
17	coupling	O	
18	to	O	
19	different	O	
20	effectors	O	
21	.	O	

1	We	O	
2	also	O	
3	observed	O	
4	that	O	
5	the	O	
6	predictive	O	
7	ability	O	
8	of	O	
9	the	O	
10	selected	O	
11	attitudes	O	
12	and	O	
13	orientations	O	
14	increased	O	
15	considerably	O	
16	from	O	
17	1975	O	
18	to	O	
19	1982	O	
20	.	O	

1	Cryopreservation	O	
2	straws	O	
3	filled	O	
4	with	O	
5	media	O	
6	plus	O	
7	additive	O	
8	are	O	
9	emersed	O	
10	below	O	
11	the	O	
12	surface	O	
13	of	O	
14	an	O	
15	unprocessed	O	
16	donor	O	
17	ejaculate	O	
18	.	O	

1	The	O	
2	ATR	O	
3	-	O	
4	X	O	
5	syndrome	O	
6	results	O	
7	from	O	
8	mutations	O	
9	of	O	
10	the	O	
11	XH2	B	
12	gene	I	
13	,	O	
14	located	O	
15	on	O	
16	the	O	
17	X	O	
18	chromosome	O	
19	(	O	
20	Xq13	O	
21	.	O	
22	3	O	
23	)	O	
24	and	O	
25	coding	O	
26	for	O	
27	a	O	
28	transacting	O	
29	factor	O	
30	which	O	
31	regulates	O	
32	gene	O	
33	expression	O	
34	.	O	

1	By	O	
2	analyzing	O	
3	the	O	
4	RanGAP	B	
5	activity	O	
6	of	O	
7	a	O	
8	series	O	
9	of	O	
10	recombinantly	O	
11	expressed	O	
12	rna1p	B	
13	mutant	I	
14	derivatives	O	
15	,	O	
16	we	O	
17	show	O	
18	that	O	
19	the	O	
20	highly	O	
21	acidic	O	
22	sequence	O	
23	in	O	
24	the	O	
25	C	O	
26	-	O	
27	terminal	O	
28	domain	O	
29	of	O	
30	both	O	
31	yeast	O	
32	proteins	O	
33	is	O	
34	indispensable	O	
35	for	O	
36	activating	O	
37	Ran	B	
38	-	O	
39	mediated	O	
40	GTP	O	
41	hydrolysis	O	
42	.	O	

1	Following	O	
2	the	O	
3	observation	O	
4	that	O	
5	non	O	
6	-	O	
7	organ	O	
8	-	O	
9	specific	O	
10	antibodies	O	
11	are	O	
12	related	O	
13	with	O	
14	pregnancy	O	
15	loss	O	
16	and	O	
17	preeclampsia	O	
18	,	O	
19	the	O	
20	role	O	
21	of	O	
22	organ	O	
23	-	O	
24	specific	O	
25	antibodies	O	
26	is	O	
27	currently	O	
28	being	O	
29	extensively	O	
30	investigated	O	
31	.	O	

1	Lack	O	
2	of	O	
3	cyclin	B	
4	D	I	
5	-	O	
6	Cdk	B	
7	complexes	O	
8	in	O	
9	Rb	B	
10	-	O	
11	negative	O	
12	cells	O	
13	correlates	O	
14	with	O	
15	high	O	
16	levels	O	
17	of	O	
18	p16INK4	B	
19	/	O	
20	MTS1	B	
21	tumour	O	
22	suppressor	O	
23	gene	O	
24	product	O	
25	.	O	

1	Calcitonin	B	
2	simultaneously	O	
3	regulates	O	
4	both	O	
5	periosteal	O	
6	hyperostosis	O	
7	and	O	
8	trabecular	O	
9	osteopenia	O	
10	in	O	
11	the	O	
12	spinal	O	
13	hyperostotic	O	
14	mouse	O	
15	(	O	
16	twy	B	
17	/	O	
18	twy	B	
19	)	O	
20	in	O	
21	vivo	O	
22	.	O	

1	Copper	O	
2	and	O	
3	ceruloplasmin	B	
4	content	O	
5	in	O	
6	pregnant	O	
7	women	O	
8	and	O	
9	in	O	
10	women	O	
11	with	O	
12	certain	O	
13	gynecological	O	
14	diseases	O	

1	The	O	
2	C5	B	
3	alpha	I	
4	-	I	
5	chain	I	
6	was	O	
7	encoded	O	
8	by	O	
9	49	O	
10	kilobases	O	
11	containing	O	
12	26	O	
13	exons	O	
14	;	O	
15	the	O	
16	beta	O	
17	-	O	
18	chain	O	
19	was	O	
20	encoded	O	
21	by	O	
22	29	O	
23	kilobases	O	
24	containing	O	
25	16	O	
26	exons	O	
27	.	O	

1	The	O	
2	model	O	
3	captures	O	
4	the	O	
5	essence	O	
6	of	O	
7	predator	O	
8	-	O	
9	prey	O	
10	dynamics	O	
11	to	O	
12	provide	O	
13	reasonable	O	
14	predictions	O	
15	of	O	
16	population	O	
17	patterns	O	
18	.	O	

1	End	O	
2	-	O	
3	tidal	O	
4	PO2	O	
5	and	O	
6	the	O	
7	ratio	O	
8	of	O	
9	minute	O	
10	ventilation	O	
11	to	O	
12	oxygen	O	
13	consumption	O	
14	(	O	
15	VE	O	
16	/	O	
17	VO2	O	
18	)	O	
19	were	O	
20	lower	O	
21	while	O	
22	PETCO2	O	
23	was	O	
24	higher	O	
25	for	O	
26	Hyp	O	
27	(	O	
28	P	O	
29	<	O	
30	or	O	
31	=	O	
32	0	O	
33	.	O	
34	01	O	
35	).	O	

1	After	O	
2	that	O	
3	report	O	
4	,	O	
5	carboxypeptidase	B	
6	D	I	
7	(	O	
8	CPD	B	
9	)	O	
10	was	O	
11	subsequently	O	
12	purified	O	
13	from	O	
14	bovine	O	
15	pituitary	O	
16	and	O	
17	characterized	O	
18	as	O	
19	a	O	
20	novel	O	
21	carboxypeptidase	B	
22	E	I	
23	(	O	
24	CPE	B	
25	)-	O	
26	like	O	
27	enzyme	O	
28	,	O	
29	with	O	
30	many	O	
31	characteristics	O	
32	in	O	
33	common	O	
34	with	O	
35	duck	O	
36	gp180	B	
37	(	O	
38	Song	O	
39	,	O	
40	L	O	
41	.,	O	
42	Fricker	O	
43	,	O	
44	L	O	
45	.	O	
46	D	O	
47	.,	O	
48	1995	O	
49	.	O	

1	Chronic	O	
2	hypophosphatemia	O	
3	is	O	
4	the	O	
5	most	O	
6	common	O	
7	type	O	
8	of	O	
9	"	O	
10	resistant	O	
11	"	O	
12	rickets	O	
13	.	O	

1	Clone	O	
2	pSRc200	O	
3	hybrid	O	
4	selected	O	
5	an	O	
6	mRNA	O	
7	that	O	
8	on	O	
9	cell	O	
10	-	O	
11	free	O	
12	translation	O	
13	produced	O	
14	a	O	
15	38	O	
16	-	O	
17	kDa	O	
18	polypeptide	O	
19	.	O	

1	The	O	
2	NF	B	
3	-	I	
4	kappaB	I	
5	responsive	O	
6	reporter	O	
7	construct	O	
8	,	O	
9	(	O	
10	PRDII	O	
11	)(	O	
12	4	O	
13	)-	O	
14	CAT	B	
15	,	O	
16	was	O	
17	used	O	
18	to	O	
19	explore	O	
20	transcription	O	
21	resulting	O	
22	from	O	
23	NF	B	
24	-	I	
25	kappaB	I	
26	activated	O	
27	by	O	
28	Tat	B	
29	.	O	

1	STP1	B	
2	is	O	
3	an	O	
4	unessential	O	
5	yeast	O	
6	gene	O	
7	involved	O	
8	in	O	
9	the	O	
10	removal	O	
11	of	O	
12	intervening	O	
13	sequences	O	
14	from	O	
15	some	O	
16	,	O	
17	but	O	
18	not	O	
19	all	O	
20	,	O	
21	families	O	
22	of	O	
23	intervening	O	
24	sequence	O	
25	-	O	
26	containing	O	
27	pre	O	
28	-	O	
29	tRNAs	O	
30	.	O	

1	The	O	
2	gene	O	
3	encoding	O	
4	the	O	
5	receptor	O	
6	for	O	
7	macrophage	B	
8	colony	I	
9	-	I	
10	stimulating	I	
11	factor	I	
12	1	I	
13	(	O	
14	CSF	B	
15	-	I	
16	1	I	
17	),	O	
18	the	O	
19	c	B	
20	-	I	
21	fms	I	
22	protooncogene	I	
23	,	O	
24	is	O	
25	selectively	O	
26	expressed	O	
27	in	O	
28	immature	O	
29	and	O	
30	mature	O	
31	mononuclear	O	
32	phagocytes	O	
33	and	O	
34	trophoblasts	O	
35	.	O	

1	Randomised	O	
2	comparison	O	
3	of	O	
4	addition	O	
5	of	O	
6	autologous	O	
7	bone	O	
8	-	O	
9	marrow	O	
10	transplantation	O	
11	to	O	
12	intensive	O	
13	chemotherapy	O	
14	for	O	
15	acute	O	
16	myeloid	O	
17	leukaemia	O	
18	in	O	
19	first	O	
20	remission	O	
21	:	O	
22	results	O	
23	of	O	
24	MRC	O	
25	AML	O	
26	10	O	
27	trial	O	
28	.	O	

1	A	O	
2	diagnosis	O	
3	of	O	
4	IgA	B	
5	lambda	I	
6	multiple	O	
7	myeloma	O	
8	with	O	
9	peritoneal	O	
10	involvement	O	
11	was	O	
12	made	O	
13	.	O	

1	Furthermore	O	
2	,	O	
3	no	O	
4	Shine	O	
5	-	O	
6	Dalgarno	O	
7	sequences	O	
8	are	O	
9	present	O	
10	upstream	O	
11	of	O	
12	the	O	
13	presumed	O	
14	translational	O	
15	start	O	
16	codons	O	
17	.	O	

1	The	O	
2	amplitude	O	
3	of	O	
4	detrusor	O	
5	contractions	O	
6	at	O	
7	6	O	
8	,	O	
9	12	O	
10	,	O	
11	and	O	
12	24	O	
13	hours	O	
14	showed	O	
15	no	O	
16	significant	O	
17	difference	O	
18	from	O	
19	that	O	
20	in	O	
21	the	O	
22	controls	O	
23	.	O	

1	Thromboplastin	B	
2	time	O	
3	,	O	
4	partial	O	
5	thromboplastin	B	
6	time	O	
7	,	O	
8	thrombin	B	
9	time	O	
10	,	O	
11	heat	O	
12	-	O	
13	dependent	O	
14	fibrin	B	
15	,	O	
16	clot	O	
17	retraction	O	
18	,	O	
19	and	O	
20	clotting	B	
21	factors	I	
22	II	I	
23	,	I	
24	V	I	
25	,	I	
26	VIII	I	
27	,	I	
28	IX	I	
29	,	I	
30	X	I	
31	,	O	
32	and	O	
33	the	O	
34	platelet	O	
35	count	O	
36	were	O	
37	determined	O	
38	.	O	

1	Histological	O	
2	evaluation	O	
3	revealed	O	
4	a	O	
5	more	O	
6	than	O	
7	twofold	O	
8	increase	O	
9	in	O	
10	the	O	
11	number	O	
12	of	O	
13	interepithelial	O	
14	mononuclear	O	
15	cells	O	
16	(	O	
17	p	O	
18	less	O	
19	than	O	
20	0	O	
21	.	O	
22	005	O	
23	),	O	
24	while	O	
25	the	O	
26	number	O	
27	of	O	
28	epithelial	O	
29	cells	O	
30	/	O	
31	100	O	
32	microns	O	
33	of	O	
34	villous	O	
35	mucosa	O	
36	and	O	
37	the	O	
38	mean	O	
39	height	O	
40	of	O	
41	the	O	
42	epithelial	O	
43	cells	O	
44	were	O	
45	comparable	O	
46	in	O	
47	both	O	
48	groups	O	
49	.	O	

1	Letter	O	
2	:	O	
3	Lactose	O	
4	tolerance	O	
5	tests	O	
6	as	O	
7	a	O	
8	predictor	O	
9	of	O	
10	milk	O	
11	tolerance	O	
12	.	O	

1	NF	B	
2	-	I	
3	HB	I	
4	(	O	
5	BSAP	B	
6	)	O	
7	is	O	
8	a	O	
9	repressor	O	
10	of	O	
11	the	O	
12	murine	B	
13	immunoglobulin	I	
14	heavy	I	
15	-	I	
16	chain	I	
17	3	I	
18	'	I	
19	alpha	I	
20	enhancer	I	
21	at	O	
22	early	O	
23	stages	O	
24	of	O	
25	B	O	
26	-	O	
27	cell	O	
28	differentiation	O	
29	.	O	

1	Adverse	O	
2	reaction	O	
3	of	O	
4	the	O	
5	apparently	O	
6	healthy	O	
7	partner	O	
8	in	O	
9	response	O	
10	to	O	
11	improvement	O	
12	in	O	
13	the	O	
14	overtly	O	
15	dysfunctional	O	
16	partner	O	
17	.	O	

1	We	O	
2	have	O	
3	found	O	
4	that	O	
5	mcs4	B	
6	-	O	
7	cells	O	
8	are	O	
9	defective	O	
10	at	O	
11	activation	O	
12	of	O	
13	Spc1	B	
14	in	O	
15	response	O	
16	to	O	
17	various	O	
18	forms	O	
19	of	O	
20	stress	O	
21	.	O	

1	Critical	O	
2	evaluation	O	
3	of	O	
4	various	O	
5	methods	O	
6	of	O	
7	determining	O	
8	markers	O	
9	of	O	
10	fetal	O	
11	maturity	O	
12	in	O	
13	amniotic	O	
14	fluid	O	

1	CONCLUSION	O	
2	:	O	
3	More	O	
4	than	O	
5	50	O	
6	%	O	
7	of	O	
8	patients	O	
9	with	O	
10	perennial	O	
11	rhinitis	O	
12	and	O	
13	CRS	O	
14	do	O	
15	not	O	
16	improve	O	
17	after	O	
18	surgery	O	
19	,	O	
20	a	O	
21	response	O	
22	that	O	
23	may	O	
24	be	O	
25	predicted	O	
26	by	O	
27	more	O	
28	cells	O	
29	expressing	O	
30	IL	B	
31	-	I	
32	5	I	
33	mRNA	I	
34	in	O	
35	the	O	
36	ethmoid	O	
37	sinuses	O	
38	.	O	

1	Clinical	O	
2	accuracy	O	
3	of	O	
4	updated	O	
5	version	O	
6	of	O	
7	the	O	
8	Phadebas	O	
9	RAST	O	
10	test	O	
11	.	O	

1	The	O	
2	position	O	
3	,	O	
4	transcription	O	
5	orientation	O	
6	,	O	
7	and	O	
8	imprinted	O	
9	status	O	
10	of	O	
11	the	O	
12	genes	O	
13	immediately	O	
14	flanking	O	
15	Igf2r	B	
16	have	O	
17	been	O	
18	assessed	O	
19	.	O	

1	Aviators	O	
2	from	O	
3	the	O	
4	Light	O	
5	Attack	O	
6	Wing	O	
7	,	O	
8	Pacific	O	
9	were	O	
10	surveyed	O	
11	and	O	
12	the	O	
13	results	O	
14	were	O	
15	categorized	O	
16	by	O	
17	aircraft	O	
18	type	O	
19	.	O	

1	In	O	
2	this	O	
3	study	O	
4	,	O	
5	we	O	
6	have	O	
7	cloned	O	
8	the	O	
9	human	B	
10	DSG3	I	
11	gene	I	
12	and	O	
13	examined	O	
14	the	O	
15	transcriptional	O	
16	regulation	O	
17	of	O	
18	its	O	
19	expression	O	
20	.	O	

1	A	O	
2	potential	O	
3	outcome	O	
4	of	O	
5	these	O	
6	biochemical	O	
7	effects	O	
8	may	O	
9	include	O	
10	the	O	
11	limited	O	
12	responsiveness	O	
13	of	O	
14	infected	O	
15	T	O	
16	cells	O	
17	to	O	
18	antigenic	O	
19	stimulation	O	
20	observed	O	
21	during	O	
22	HIV	O	
23	-	O	
24	1	O	
25	infection	O	
26	.	O	

1	In	O	
2	turn	O	
3	,	O	
4	assembly	O	
5	of	O	
6	this	O	
7	complex	O	
8	mediates	O	
9	the	O	
10	enzymatic	O	
11	activation	O	
12	of	O	
13	the	O	
14	p21	B	
15	-	I	
16	activated	I	
17	protein	I	
18	kinase	I	
19	1	I	
20	and	O	
21	facilitates	O	
22	actin	B	
23	polymerization	O	
24	.	O	

1	MOP5	B	
2	contained	O	
3	the	O	
4	characteristic	O	
5	PAS	B	
6	domain	O	
7	and	O	
8	a	O	
9	variable	O	
10	C	O	
11	terminus	O	
12	;	O	
13	it	O	
14	is	O	
15	possible	O	
16	that	O	
17	the	O	
18	cDNA	O	
19	contains	O	
20	a	O	
21	bHLH	O	
22	domain	O	
23	,	O	
24	but	O	
25	the	O	
26	entire	O	
27	open	O	
28	reading	O	
29	frame	O	
30	has	O	
31	yet	O	
32	to	O	
33	be	O	
34	completed	O	
35	.	O	

1	The	O	
2	IgA	B	
3	deficiency	O	
4	is	O	
5	combined	O	
6	with	O	
7	the	O	
8	IgE	B	
9	one	O	
10	.	O	

1	In	O	
2	a	O	
3	gel	O	
4	retardation	O	
5	assay	O	
6	using	O	
7	HepG2	O	
8	nuclear	O	
9	extracts	O	
10	,	O	
11	the	O	
12	5	O	
13	'	O	
14	flanking	O	
15	sequence	O	
16	from	O	
17	-	O	
18	74	O	
19	to	O	
20	-	O	
21	46	O	
22	showed	O	
23	a	O	
24	shifted	O	
25	band	O	
26	.	O	

1	Within	O	
2	the	O	
3	span	O	
4	of	O	
5	attenuator	O	
6	region	O	
7	encoding	O	
8	the	O	
9	three	O	
10	stem	O	
11	-	O	
12	loop	O	
13	structures	O	
14	of	O	
15	mRNA	O	
16	secondary	O	
17	configuration	O	
18	,	O	
19	hot	O	
20	spots	O	
21	of	O	
22	base	O	
23	-	O	
24	residue	O	
25	divergence	O	
26	were	O	
27	localized	O	
28	to	O	
29	looped	O	
30	-	O	
31	out	O	
32	regions	O	
33	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	extracts	O	
5	of	O	
6	the	O	
7	mutant	O	
8	virions	O	
9	catalyze	O	
10	the	O	
11	wild	O	
12	-	O	
13	type	O	
14	level	O	
15	of	O	
16	transcription	O	
17	from	O	
18	an	O	
19	exogenous	O	
20	template	O	
21	containing	O	
22	an	O	
23	early	O	
24	promoter	O	
25	.	O	

1	PURPOSE	O	
2	:	O	
3	To	O	
4	evaluate	O	
5	the	O	
6	disease	O	
7	-	O	
8	free	O	
9	survival	O	
10	(	O	
11	DFS	O	
12	)	O	
13	and	O	
14	overall	O	
15	survival	O	
16	(	O	
17	OS	O	
18	),	O	
19	prognostic	O	
20	factors	O	
21	,	O	
22	and	O	
23	treatment	O	
24	-	O	
25	related	O	
26	mortality	O	
27	of	O	
28	women	O	
29	with	O	
30	stage	O	
31	IIIB	O	
32	inflammatory	O	
33	breast	O	
34	cancer	O	
35	(	O	
36	IBC	O	
37	)	O	
38	treated	O	
39	with	O	
40	combined	O	
41	modality	O	
42	therapy	O	
43	(	O	
44	CMT	O	
45	)	O	
46	and	O	
47	high	O	
48	-	O	
49	dose	O	
50	chemotherapy	O	
51	(	O	
52	HDCT	O	
53	)	O	
54	with	O	
55	autologous	O	
56	stem	O	
57	-	O	
58	cell	O	
59	transplantation	O	
60	.	O	

1	The	O	
2	operation	O	
3	recommended	O	
4	is	O	
5	excision	O	
6	of	O	
7	3	O	
8	mm	O	
9	of	O	
10	central	O	
11	slip	O	
12	followed	O	
13	by	O	
14	end	O	
15	-	O	
16	to	O	
17	-	O	
18	end	O	
19	repair	O	
20	of	O	
21	the	O	
22	tendon	O	
23	.	O	

1	There	O	
2	were	O	
3	122	O	
4	cases	O	
5	of	O	
6	tuberculosis	O	
7	over	O	
8	an	O	
9	average	O	
10	10	O	
11	.	O	
12	3	O	
13	yr	O	
14	of	O	
15	follow	O	
16	-	O	
17	up	O	
18	(	O	
19	crude	O	
20	annual	O	
21	incidence	O	
22	,	O	
23	76	O	
24	.	O	
25	2	O	
26	/	O	
27	100	O	
28	,	O	
29	000	O	
30	).	O	

1	Studies	O	
2	were	O	
3	performed	O	
4	on	O	
5	several	O	
6	superficial	O	
7	veins	O	
8	from	O	
9	the	O	
10	rabbit	O	
11	face	O	
12	to	O	
13	examine	O	
14	the	O	
15	relationship	O	
16	between	O	
17	beta	B	
18	adrenoceptor	I	
19	subtype	I	
20	distribution	O	
21	,	O	
22	intrinsic	O	
23	myogenic	O	
24	tone	O	
25	and	O	
26	sympathetic	O	
27	nerve	O	
28	innervation	O	
29	.	O	

1	MATERIALS	O	
2	AND	O	
3	METHODS	O	
4	:	O	
5	Coronal	O	
6	3D	O	
7	GRE	O	
8	imaging	O	
9	was	O	
10	used	O	
11	to	O	
12	study	O	
13	the	O	
14	volar	O	
15	,	O	
16	middle	O	
17	,	O	
18	and	O	
19	dorsal	O	
20	portions	O	
21	of	O	
22	the	O	
23	SLL	O	
24	in	O	
25	14	O	
26	patients	O	
27	with	O	
28	an	O	
29	arthroscopically	O	
30	normal	O	
31	SLL	O	
32	and	O	
33	in	O	
34	five	O	
35	cadaveric	O	
36	wrists	O	
37	that	O	
38	had	O	
39	a	O	
40	normal	O	
41	SLL	O	
42	proved	O	
43	with	O	
44	dissection	O	
45	.	O	

1	During	O	
2	ISO	O	
3	+	O	
4	AT	O	
5	infusion	O	
6	,	O	
7	abdominal	O	
8	fat	O	
9	blood	O	
10	flow	O	
11	was	O	
12	still	O	
13	significantly	O	
14	increased	O	
15	as	O	
16	compared	O	
17	with	O	
18	control	O	
19	values	O	
20	in	O	
21	lean	O	
22	and	O	
23	obese	O	
24	subjects	O	
25	.	O	

1	The	O	
2	results	O	
3	suggest	O	
4	that	O	
5	the	O	
6	presence	O	
7	or	O	
8	absence	O	
9	per	O	
10	se	O	
11	of	O	
12	keratan	O	
13	sulfate	O	
14	on	O	
15	native	O	
16	G1	O	
17	-	O	
18	G2	O	
19	does	O	
20	not	O	
21	affect	O	
22	the	O	
23	activity	O	
24	of	O	
25	atrolysin	O	
26	C	O	
27	toward	O	
28	the	O	
29	two	O	
30	sites	O	
31	.	O	

1	After	O	
2	2	O	
3	min	O	
4	of	O	
5	dobutamine	O	
6	injection	O	
7	,	O	
8	or	O	
9	after	O	
10	20	O	
11	min	O	
12	of	O	
13	pimobendan	O	
14	injection	O	
15	,	O	
16	the	O	
17	myocardium	O	
18	was	O	
19	removed	O	
20	,	O	
21	and	O	
22	used	O	
23	for	O	
24	determination	O	
25	of	O	
26	the	O	
27	tissue	O	
28	levels	O	
29	of	O	
30	metabolites	O	
31	of	O	
32	energy	O	
33	and	O	
34	carbohydrate	O	
35	metabolism	O	
36	.	O	

1	188	O	
2	patients	O	
3	received	O	
4	cimetidine	O	
5	400	O	
6	mg	O	
7	q	O	
8	.	O	
9	i	O	
10	.	O	
11	d	O	
12	.	O	
13	intravenously	O	
14	and	O	
15	1	O	
16	,	O	
17	000	O	
18	mg	O	
19	daily	O	
20	orally	O	
21	in	O	
22	divided	O	
23	doses	O	
24	.	O	

1	A	O	
2	new	O	
3	hemagglutination	O	
4	test	O	
5	for	O	
6	the	O	
7	on	O	
8	-	O	
9	slide	O	
10	assay	O	
11	of	O	
12	rheumatoid	B	
13	factor	I	

1	Removal	O	
2	of	O	
3	thick	O	
4	,	O	
5	permanently	O	
6	altered	O	
7	mucoas	O	
8	is	O	
9	recommended	O	
10	even	O	
11	in	O	
12	the	O	
13	absence	O	
14	of	O	
15	squamous	O	
16	epithelium	O	
17	.	O	

1	The	O	
2	ORF3	O	
3	mutant	O	
4	produced	O	
5	reduced	O	
6	levels	O	
7	of	O	
8	tabtoxin	B	
9	,	O	
10	indicating	O	
11	that	O	
12	ORF3	O	
13	may	O	
14	have	O	
15	a	O	
16	role	O	
17	in	O	
18	T	B	
19	beta	I	
20	L	I	
21	biosynthesis	O	
22	.	O	

1	Defects	O	
2	in	O	
3	the	O	
4	Schizosaccharomyces	O	
5	pombe	O	
6	(	O	
7	Sp	O	
8	)	O	
9	cell	O	
10	cycle	O	
11	-	O	
12	controlling	O	
13	genes	O	
14	prevent	O	
15	the	O	
16	cell	O	
17	cycle	O	
18	progression	O	
19	.	O	

1	In	O	
2	this	O	
3	paper	O	
4	,	O	
5	the	O	
6	current	O	
7	status	O	
8	of	O	
9	the	O	
10	understanding	O	
11	of	O	
12	the	O	
13	interaction	O	
14	mechanisms	O	
15	of	O	
16	ultrasound	O	
17	with	O	
18	biological	O	
19	media	O	
20	and	O	
21	the	O	
22	factors	O	
23	that	O	
24	govern	O	
25	different	O	
26	biological	O	
27	effects	O	
28	are	O	
29	surveyed	O	
30	.	O	

1	The	O	
2	response	O	
3	of	O	
4	serum	B	
5	GH	I	
6	to	O	
7	arginine	O	
8	infusion	O	
9	was	O	
10	normal	O	
11	,	O	
12	while	O	
13	that	O	
14	to	O	
15	insulin	B	
16	-	O	
17	induced	O	
18	hypoglycemia	O	
19	was	O	
20	poor	O	
21	.	O	

1	The	O	
2	authors	O	
3	report	O	
4	the	O	
5	results	O	
6	of	O	
7	a	O	
8	series	O	
9	of	O	
10	toxicological	O	
11	tests	O	
12	conducted	O	
13	on	O	
14	plastic	O	
15	materials	O	
16	(	O	
17	polyethylene	O	
18	)	O	
19	activated	O	
20	with	O	
21	tetraphenylbutadiene	O	
22	(	O	
23	TPB	O	
24	)	O	
25	an	O	
26	additive	O	
27	recently	O	
28	proposed	O	
29	as	O	
30	a	O	
31	sensitizer	O	
32	capable	O	
33	of	O	
34	photodegrading	O	
35	plastic	O	
36	materials	O	
37	.	O	

1	Linear	O	
2	extrapolation	O	
3	is	O	
4	used	O	
5	below	O	
6	the	O	
7	experimental	O	
8	data	O	
9	range	O	
10	to	O	
11	establish	O	
12	an	O	
13	upper	O	
14	bound	O	
15	on	O	
16	carcinogenic	O	
17	risk	O	
18	at	O	
19	low	O	
20	doses	O	
21	.	O	

1	Conversely	O	
2	,	O	
3	activation	O	
4	of	O	
5	Oct	B	
6	-	I	
7	3	I	
8	/	I	
9	4	I	
10	promoter	I	
11	by	O	
12	RAR	B	
13	:	O	
14	RXR	B	
15	heterodimers	I	
16	was	O	
17	completely	O	
18	abolished	O	
19	by	O	
20	EAR	B	
21	-	I	
22	3	I	
23	/	O	
24	COUP	B	
25	-	I	
26	TFI	I	
27	and	O	
28	by	O	
29	ARP	B	
30	-	I	
31	1	I	
32	/	O	
33	COUP	B	
34	-	I	
35	TFII	I	
36	.	O	

1	The	O	
2	predicted	O	
3	amino	O	
4	acid	O	
5	sequence	O	
6	exhibited	O	
7	70	O	
8	%	O	
9	identity	O	
10	to	O	
11	that	O	
12	of	O	
13	Bacillus	B	
14	stearothermophilus	I	
15	TyrTS	I	
16	and	O	
17	55	O	
18	%	O	
19	identity	O	
20	to	O	
21	that	O	
22	of	O	
23	E	B	
24	.	I	
25	coli	I	
26	TyrTS	I	
27	,	O	
28	while	O	
29	identity	O	
30	to	O	
31	a	O	
32	second	O	
33	cryptic	O	
34	B	B	
35	.	I	
36	subtilis	I	
37	TyrTS	I	
38	gene	I	
39	,	O	
40	designated	O	
41	tyrZ	B	
42	,	O	
43	was	O	
44	only	O	
45	27	O	
46	%.	O	

1	In	O	
2	this	O	
3	study	O	
4	we	O	
5	have	O	
6	investigated	O	
7	the	O	
8	role	O	
9	of	O	
10	C	B	
11	/	I	
12	EBP	I	
13	beta	I	
14	in	O	
15	initiating	O	
16	the	O	
17	adipogenic	O	
18	program	O	
19	by	O	
20	overexpressing	O	
21	C	B	
22	/	I	
23	EBP	I	
24	beta	I	
25	in	O	
26	multipotential	O	
27	NIH	O	
28	-	O	
29	3T3	O	
30	fibroblasts	O	
31	.	O	

1	Clinical	O	
2	implication	O	
3	of	O	
4	protein	O	
5	levels	O	
6	of	O	
7	IL	B	
8	-	I	
9	5	I	
10	in	O	
11	induced	O	
12	sputum	O	
13	in	O	
14	asthmatic	O	
15	patients	O	
16	.	O	

1	The	O	
2	cases	O	
3	included	O	
4	35	O	
5	de	O	
6	novo	O	
7	diffuse	O	
8	aggressive	O	
9	lymphomas	O	
10	(	O	
11	DAL	O	
12	;	O	
13	19	O	
14	large	O	
15	-	O	
16	cell	O	
17	,	O	
18	4	O	
19	mixed	O	
20	-	O	
21	cell	O	
22	,	O	
23	and	O	
24	12	O	
25	large	O	
26	-	O	
27	cell	O	
28	immunoblastic	O	
29	),	O	
30	52	O	
31	transformed	O	
32	aggressive	O	
33	lymphomas	O	
34	derived	O	
35	from	O	
36	follicular	O	
37	lymphomas	O	
38	(	O	
39	TFL	O	
40	),	O	
41	42	O	
42	indolent	O	
43	follicular	O	
44	lymphomas	O	
45	(	O	
46	FL	O	
47	),	O	
48	14	O	
49	mantle	O	
50	cell	O	
51	lymphomas	O	
52	(	O	
53	MCL	O	
54	),	O	
55	and	O	
56	27	O	
57	small	O	
58	noncleaved	O	
59	cell	O	
60	lymphomas	O	
61	(	O	
62	SNCL	O	
63	).	O	

1	Family	O	
2	environment	O	
3	was	O	
4	an	O	
5	important	O	
6	influence	O	
7	on	O	
8	interpersonal	O	
9	relationships	O	
10	,	O	
11	substance	O	
12	use	O	
13	,	O	
14	and	O	
15	social	O	
16	support	O	
17	.	O	

1	Hence	O	
2	,	O	
3	the	O	
4	replacement	O	
5	of	O	
6	Phe	O	
7	-	O	
8	62	O	
9	with	O	
10	Ser	O	
11	specifically	O	
12	affects	O	
13	a	O	
14	determinant	O	
15	on	O	
16	the	O	
17	lambda	B	
18	I	I	
19	light	I	
20	chain	I	
21	that	O	
22	is	O	
23	necessary	O	
24	for	O	
25	the	O	
26	intracellular	O	
27	transport	O	
28	of	O	
29	this	O	
30	molecule	O	
31	.	O	

1	Induction	O	
2	of	O	
3	both	O	
4	potential	O	
5	transcripts	O	
6	follows	O	
7	heat	O	
8	shock	O	
9	in	O	
10	vivo	O	
11	.	O	

1	We	O	
2	have	O	
3	isolated	O	
4	a	O	
5	new	O	
6	,	O	
7	larger	O	
8	rat	B	
9	B	I	
10	-	I	
11	myc	I	
12	genomic	I	
13	clone	I	
14	.	O	

1	We	O	
2	also	O	
3	identified	O	
4	an	O	
5	alternative	O	
6	spliced	O	
7	form	O	
8	of	O	
9	Lyp	B	
10	RNA	I	
11	,	O	
12	Lyp2	B	
13	.	O	

1	Autoradiographic	O	
2	localisation	O	
3	of	O	
4	its	O	
5	cellular	O	
6	distribution	O	
7	in	O	
8	the	O	
9	kidney	O	
10	.	O	

1	In	O	
2	the	O	
3	course	O	
4	of	O	
5	investigating	O	
6	the	O	
7	mechanisms	O	
8	by	O	
9	which	O	
10	OF5	B	
11	and	O	
12	OF3	B	
13	regulated	O	
14	CYP11A1	B	
15	transcription	O	
16	,	O	
17	we	O	
18	found	O	
19	that	O	
20	OF5	B	
21	and	O	
22	OF3	B	
23	bound	O	
24	Sp1	B	
25	and	O	
26	Sp3	B	
27	in	O	
28	JEG	O	
29	-	O	
30	3	O	
31	cells	O	
32	.	O	

1	Overexpression	O	
2	of	O	
3	MDR1	B	
4	has	O	
5	been	O	
6	demonstrated	O	
7	in	O	
8	many	O	
9	cancers	O	
10	,	O	
11	both	O	
12	in	O	
13	patient	O	
14	tumors	O	
15	and	O	
16	in	O	
17	cell	O	
18	lines	O	
19	selected	O	
20	with	O	
21	a	O	
22	variety	O	
23	of	O	
24	chemotherapeutic	O	
25	agents	O	
26	.	O	

1	Significant	O	
2	GMBF	O	
3	reductions	O	
4	occurred	O	
5	in	O	
6	early	O	
7	shock	O	
8	in	O	
9	both	O	
10	treatment	O	
11	groups	O	
12	.	O	

1	During	O	
2	the	O	
3	last	O	
4	6	O	
5	months	O	
6	of	O	
7	the	O	
8	study	O	
9	a	O	
10	striking	O	
11	change	O	
12	in	O	
13	epidemiology	O	
14	concerning	O	
15	hepatitis	O	
16	A	O	
17	was	O	
18	seen	O	
19	,	O	
20	apparently	O	
21	caused	O	
22	by	O	
23	a	O	
24	steep	O	
25	increase	O	
26	in	O	
27	the	O	
28	incidence	O	
29	of	O	
30	this	O	
31	type	O	
32	of	O	
33	hepatitis	O	
34	among	O	
35	drug	O	
36	addicts	O	
37	.	O	

1	Since	O	
2	the	O	
3	stability	O	
4	of	O	
5	TF1	B	
6	resides	O	
7	in	O	
8	its	O	
9	primary	O	
10	structure	O	
11	,	O	
12	we	O	
13	cloned	O	
14	a	O	
15	gene	O	
16	coding	O	
17	for	O	
18	TF1	B	
19	,	O	
20	and	O	
21	the	O	
22	primary	O	
23	structure	O	
24	of	O	
25	the	O	
26	beta	O	
27	subunit	O	
28	was	O	
29	deduced	O	
30	from	O	
31	the	O	
32	nucleotide	O	
33	sequence	O	
34	of	O	
35	the	O	
36	gene	O	
37	to	O	
38	compare	O	
39	the	O	
40	sequence	O	
41	with	O	
42	those	O	
43	of	O	
44	beta	O	
45	'	O	
46	s	O	
47	of	O	
48	three	O	
49	major	O	
50	categories	O	
51	of	O	
52	F1	B	
53	'	O	
54	s	O	
55	;	O	
56	prokaryotic	O	
57	membranes	O	
58	,	O	
59	chloroplasts	O	
60	,	O	
61	and	O	
62	mitochondria	O	
63	.	O	

1	This	O	
2	study	O	
3	was	O	
4	undertaken	O	
5	to	O	
6	define	O	
7	the	O	
8	mechanism	O	
9	for	O	
10	the	O	
11	respiratory	O	
12	inhibition	O	
13	observed	O	
14	during	O	
15	high	O	
16	-	O	
17	frequency	O	
18	oscillatory	O	
19	ventilation	O	
20	(	O	
21	HFOV	O	
22	).	O	

1	We	O	
2	further	O	
3	demonstrate	O	
4	that	O	
5	RU486	O	
6	-	O	
7	PR	B	
8	-	I	
9	B	I	
10	interacts	O	
11	physically	O	
12	with	O	
13	NCoR	B	
14	in	O	
15	vitro	O	
16	.	O	

1	In	O	
2	order	O	
3	to	O	
4	investigate	O	
5	to	O	
6	what	O	
7	extent	O	
8	this	O	
9	interaction	O	
10	might	O	
11	contribute	O	
12	to	O	
13	tumor	O	
14	induction	O	
15	by	O	
16	the	O	
17	virus	O	
18	,	O	
19	we	O	
20	have	O	
21	introduced	O	
22	two	O	
23	different	O	
24	point	O	
25	mutations	O	
26	within	O	
27	the	O	
28	putative	O	
29	pRb	B	
30	-	I	
31	binding	I	
32	sequence	I	
33	of	O	
34	large	B	
35	T	I	
36	antigen	I	
37	,	O	
38	and	O	
39	as	O	
40	a	O	
41	preliminary	O	
42	to	O	
43	in	O	
44	vivo	O	
45	experiments	O	
46	we	O	
47	have	O	
48	studied	O	
49	their	O	
50	effects	O	
51	in	O	
52	vitro	O	
53	on	O	
54	some	O	
55	biological	O	
56	activities	O	
57	relevant	O	
58	to	O	
59	tumor	O	
60	induction	O	
61	.	O	

1	A	O	
2	comparison	O	
3	of	O	
4	the	O	
5	predicted	O	
6	amino	O	
7	acid	O	
8	sequences	O	
9	of	O	
10	the	O	
11	two	O	
12	human	B	
13	PKC	I	
14	-	I	
15	delta	I	
16	clones	O	
17	with	O	
18	the	O	
19	rat	O	
20	and	O	
21	mouse	O	
22	homologues	O	
23	indicated	O	
24	a	O	
25	greater	O	
26	degree	O	
27	of	O	
28	sequence	O	
29	divergence	O	
30	(	O	
31	89	O	
32	-	O	
33	90	O	
34	%	O	
35	homology	O	
36	)	O	
37	compared	O	
38	to	O	
39	the	O	
40	high	O	
41	degree	O	
42	of	O	
43	sequence	O	
44	conservation	O	
45	observed	O	
46	with	O	
47	other	O	
48	human	B	
49	PKC	I	
50	family	I	
51	members	I	
52	and	O	
53	their	O	
54	mammalian	O	
55	counterparts	O	
56	.	O	

1	Significant	O	
2	increases	O	
3	in	O	
4	mean	O	
5	serum	O	
6	E2	O	
7	concentration	O	
8	(	O	
9	100	O	
10	to	O	
11	150	O	
12	pg	O	
13	/	O	
14	ml	O	
15	)	O	
16	were	O	
17	noted	O	
18	at	O	
19	6	O	
20	and	O	
21	8	O	
22	hours	O	
23	after	O	
24	administration	O	
25	on	O	
26	day	O	
27	1	O	
28	and	O	
29	at	O	
30	8	O	
31	hours	O	
32	on	O	
33	day	O	
34	4	O	
35	.	O	

1	Promoter	O	
2	analysis	O	
3	demonstrated	O	
4	that	O	
5	the	O	
6	sequence	O	
7	identical	O	
8	to	O	
9	consensus	O	
10	cAMP	O	
11	-	O	
12	responsive	O	
13	element	O	
14	(	O	
15	CRE	O	
16	)	O	
17	located	O	
18	at	O	
19	-	O	
20	481	O	
21	of	O	
22	the	O	
23	SMemb	B	
24	promoter	I	
25	was	O	
26	critical	O	
27	for	O	
28	Hex	B	
29	responsiveness	O	
30	.	O	

1	Detection	O	
2	of	O	
3	anti	O	
4	-	O	
5	lymphocyte	O	
6	antibodies	O	
7	using	O	
8	the	O	
9	immunoperoxidase	B	
10	antiglobulin	I	
11	technic	O	
12	.	O	

1	Lck	B	
2	has	O	
3	been	O	
4	postulated	O	
5	to	O	
6	dimerize	O	
7	through	O	
8	the	O	
9	SH2	B	
10	and	O	
11	SH3	B	
12	domains	I	
13	.	O	

1	The	O	
2	previously	O	
3	described	O	
4	enhanced	O	
5	translation	O	
6	of	O	
7	spinach	O	
8	L12	B	
9	mRNA	I	
10	from	O	
11	its	O	
12	two	O	
13	tandem	O	
14	AUG	O	
15	codons	O	
16	and	O	
17	the	O	
18	two	O	
19	functional	O	
20	rpl12	B	
21	genes	I	
22	in	O	
23	Arabidopsis	O	
24	probably	O	
25	provide	O	
26	two	O	
27	mechanisms	O	
28	for	O	
29	generating	O	
30	the	O	
31	four	O	
32	copies	O	
33	of	O	
34	L12	B	
35	/	I	
36	chloroplast	I	
37	ribosome	I	
38	,	O	
39	qualitatively	O	
40	different	O	
41	from	O	
42	those	O	
43	attempted	O	
44	in	O	
45	eubacteria	O	
46	.	O	

1	Activation	O	
2	mediated	O	
3	by	O	
4	Cat8p	B	
5	was	O	
6	no	O	
7	longer	O	
8	detectable	O	
9	in	O	
10	a	O	
11	cat1	B	
12	mutant	I	
13	.	O	

1	Antithrombin	B	
2	III	I	
3	(	O	
4	AT	B	
5	III	I	
6	)	O	
7	is	O	
8	a	O	
9	plasma	O	
10	protein	O	
11	which	O	
12	acts	O	
13	as	O	
14	the	O	
15	principal	O	
16	inhibitor	O	
17	of	O	
18	thrombin	B	
19	and	O	
20	is	O	
21	a	O	
22	major	O	
23	modulator	O	
24	of	O	
25	intravascular	O	
26	coagulation	O	
27	.	O	

1	The	O	
2	former	O	
3	procedure	O	
4	is	O	
5	economical	O	
6	but	O	
7	complicated	O	
8	,	O	
9	whereas	O	
10	the	O	
11	latter	O	
12	is	O	
13	simple	O	
14	and	O	
15	labour	O	
16	-	O	
17	saving	O	
18	,	O	
19	but	O	
20	a	O	
21	special	O	
22	ultrafiltration	O	
23	tube	O	
24	is	O	
25	required	O	
26	.	O	

1	In	O	
2	fus3	B	
3	mutants	I	
4	,	O	
5	the	O	
6	levels	O	
7	of	O	
8	Ty1	B	
9	RNA	I	
10	,	O	
11	protein	O	
12	synthesis	O	
13	,	O	
14	and	O	
15	proteolytic	O	
16	processing	O	
17	were	O	
18	not	O	
19	altered	O	
20	relative	O	
21	to	O	
22	those	O	
23	in	O	
24	FUS3	B	
25	strains	O	
26	but	O	
27	steady	O	
28	-	O	
29	state	O	
30	levels	O	
31	of	O	
32	TyA	B	
33	,	O	
34	integrase	B	
35	,	O	
36	and	O	
37	reverse	B	
38	transcriptase	I	
39	proteins	O	
40	and	O	
41	Ty1	B	
42	cDNA	I	
43	were	O	
44	all	O	
45	increased	O	
46	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	IgM	B	
5	can	O	
6	be	O	
7	absent	O	
8	in	O	
9	children	O	
10	with	O	
11	congenital	O	
12	toxoplasmosis	O	
13	or	O	
14	subjects	O	
15	with	O	
16	secondary	O	
17	reactivation	O	
18	.	O	

1	The	O	
2	ESEG	O	
3	'	O	
4	s	O	
5	are	O	
6	a	O	
7	direct	O	
8	result	O	
9	of	O	
10	the	O	
11	NEXT	O	
12	study	O	
13	.	O	

1	Calcification	O	
2	of	O	
3	a	O	
4	cariogenic	O	
5	Streptococcus	O	
6	and	O	
7	of	O	
8	Corynebacterium	O	
9	(	O	
10	Bacterionema	O	
11	)	O	
12	matruchotii	O	
13	.	O	

1	Previous	O	
2	studies	O	
3	showed	O	
4	that	O	
5	mutations	O	
6	in	O	
7	the	O	
8	6K	O	
9	protein	O	
10	led	O	
11	to	O	
12	the	O	
13	slow	O	
14	release	O	
15	of	O	
16	aberrant	O	
17	,	O	
18	multi	O	
19	-	O	
20	cored	O	
21	infectious	O	
22	virions	O	
23	.	O	

1	The	O	
2	RAT3	B	
3	gene	I	
4	encodes	O	
5	an	O	
6	1157	O	
7	-	O	
8	amino	O	
9	acid	O	
10	protein	O	
11	without	O	
12	similarity	O	
13	to	O	
14	other	O	
15	known	O	
16	proteins	O	
17	.	O	

1	Analysis	O	
2	of	O	
3	glucocorticoid	O	
4	unresponsive	O	
5	cell	O	
6	variants	O	
7	using	O	
8	a	O	
9	mouse	B	
10	glucocorticoid	I	
11	receptor	I	
12	complementary	O	
13	DNA	O	
14	clone	O	
15	.	O	

1	Basal	O	
2	promoter	O	
3	activity	O	
4	is	O	
5	enhanced	O	
6	by	O	
7	a	O	
8	functional	O	
9	M1	O	
10	domain	O	
11	in	O	
12	LHR	B	
13	-	O	
14	expressing	O	
15	mouse	O	
16	Leydig	O	
17	tumor	O	
18	cells	O	
19	(	O	
20	MLTC	O	
21	)	O	
22	but	O	
23	not	O	
24	in	O	
25	non	O	
26	-	O	
27	expressing	O	
28	CHO	O	
29	cells	O	
30	.	O	

1	Transforming	B	
2	growth	I	
3	factor	I	
4	(	I	
5	TGF	I	
6	)-	I	
7	beta1	I	
8	induces	O	
9	extracellular	O	
10	matrix	O	
11	deposition	O	
12	and	O	
13	proliferation	O	
14	of	O	
15	mesenchymal	O	
16	cells	O	
17	.	O	

1	Neither	O	
2	class	O	
3	II	O	
4	nor	O	
5	IV	O	
6	infections	O	
7	precluded	O	
8	transplantation	O	
9	.	O	

1	Localization	O	
2	of	O	
3	the	O	
4	brachial	O	
5	plexus	O	
6	with	O	
7	the	O	
8	nerve	O	
9	stimulator	O	
10	is	O	
11	equally	O	
12	effective	O	
13	at	O	
14	the	O	
15	interscalene	O	
16	,	O	
17	supraclavicular	O	
18	,	O	
19	and	O	
20	axillary	O	
21	sites	O	
22	.	O	

1	Midge	O	
2	control	O	
3	in	O	
4	flood	O	
5	channels	O	
6	.	O	

1	Cloning	O	
2	,	O	
3	expression	O	
4	,	O	
5	and	O	
6	nucleotide	O	
7	sequence	O	
8	of	O	
9	rat	B	
10	liver	I	
11	sterol	I	
12	carrier	I	
13	protein	I	
14	2	I	
15	cDNAs	I	
16	.	O	

1	Six	O	
2	patients	O	
3	with	O	
4	glomerulonephritis	O	
5	in	O	
6	association	O	
7	with	O	
8	a	O	
9	ventriculovascular	O	
10	shunt	O	
11	were	O	
12	treated	O	
13	with	O	
14	three	O	
15	basic	O	
16	modes	O	
17	of	O	
18	therapy	O	
19	.	O	

1	The	O	
2	p73pct1	B	
3	/	O	
4	p85cdc10	B	
5	complex	O	
6	binds	O	
7	both	O	
8	in	O	
9	vitro	O	
10	and	O	
11	in	O	
12	vivo	O	
13	to	O	
14	MCB	B	
15	but	O	
16	not	O	
17	SCB	B	
18	or	O	
19	E2F	B	
20	sites	I	
21	.	O	

1	Urinary	O	
2	urate	O	
3	excretion	O	
4	,	O	
5	urate	O	
6	clearance	O	
7	,	O	
8	and	O	
9	fractional	O	
10	excretion	O	
11	of	O	
12	urate	O	
13	all	O	
14	increased	O	
15	significantly	O	
16	during	O	
17	water	O	
18	immersion	O	
19	,	O	
20	and	O	
21	decreased	O	
22	in	O	
23	the	O	
24	hour	O	
25	following	O	
26	water	O	
27	immersion	O	
28	.	O	

1	We	O	
2	purified	O	
3	both	O	
4	proteins	O	
5	from	O	
6	human	O	
7	platelet	O	
8	membranes	O	
9	using	O	
10	DEAE	O	
11	-	O	
12	Sepharose	O	
13	chromatography	O	
14	followed	O	
15	by	O	
16	mAb	B	
17	F11	I	
18	affinity	O	
19	chromatography	O	
20	.	O	

1	Phosphate	B	
2	glucose	I	
3	dehydrogenase	I	
4	deficiency	O	
5	causing	O	
6	hyperbilirubinemia	O	
7	in	O	
8	the	O	
9	newborn	O	

1	Structural	O	
2	changes	O	
3	in	O	
4	the	O	
5	kinetically	O	
6	more	O	
7	damaged	O	
8	E44D	O	
9	mutant	O	
10	detected	O	
11	in	O	
12	(	O	
13	1	O	
14	)	O	
15	H	O	
16	-(	O	
17	15	O	
18	)	O	
19	N	O	
20	HSQC	O	
21	spectra	O	
22	were	O	
23	largely	O	
24	limited	O	
25	to	O	
26	the	O	
27	loop	O	
28	I	O	
29	-	O	
30	helix	O	
31	I	O	
32	motif	O	
33	,	O	
34	suggesting	O	
35	that	O	
36	Glu	O	
37	-	O	
38	44	O	
39	stabilizes	O	
40	the	O	
41	active	O	
42	site	O	
43	region	O	
44	.	O	

1	Cyclin	B	
2	D1	I	
3	-	I	
4	associated	I	
5	kinase	I	
6	activity	O	
7	and	O	
8	protein	O	
9	levels	O	
10	were	O	
11	increased	O	
12	in	O	
13	mammary	O	
14	tumors	O	
15	from	O	
16	murine	O	
17	mammary	O	
18	tumor	O	
19	virus	O	
20	-	O	
21	pp60	B	
22	(	O	
23	c	B	
24	-	I	
25	src527F	I	
26	)	O	
27	transgenic	O	
28	mice	O	
29	.	O	

1	A	O	
2	transparent	O	
3	overlay	O	
4	for	O	
5	assessing	O	
6	amplitude	O	
7	of	O	
8	ECG	O	
9	wave	O	
10	forms	O	
11	.	O	

1	At	O	
2	1	O	
3	,	O	
4	5	O	
5	,	O	
6	and	O	
7	9	O	
8	months	O	
9	after	O	
10	initial	O	
11	isolation	O	
12	of	O	
13	C	O	
14	.	O	
15	kutscheri	O	
16	from	O	
17	the	O	
18	oral	O	
19	cavity	O	
20	,	O	
21	hamsters	O	
22	were	O	
23	euthanatized	O	
24	,	O	
25	and	O	
26	attempts	O	
27	were	O	
28	made	O	
29	to	O	
30	culture	O	
31	C	O	
32	.	O	
33	kutscheri	O	
34	from	O	
35	13	O	
36	additional	O	
37	sites	O	
38	.	O	

1	Two	O	
2	classes	O	
3	of	O	
4	Xanthomonas	O	
5	pathogens	O	
6	evading	O	
7	Bs2	O	
8	host	O	
9	resistance	O	
10	and	O	
11	displaying	O	
12	reduced	O	
13	fitness	O	
14	were	O	
15	found	O	
16	to	O	
17	be	O	
18	specifically	O	
19	mutated	O	
20	in	O	
21	avrBs2	B	
22	.	O	

1	Antibodies	O	
2	to	O	
3	the	O	
4	human	B	
5	PTS1R	I	
6	recognize	O	
7	this	O	
8	protein	O	
9	in	O	
10	human	O	
11	,	O	
12	monkey	O	
13	,	O	
14	rat	O	
15	,	O	
16	and	O	
17	hamster	O	
18	cells	O	
19	.	O	

1	The	O	
2	activity	O	
3	of	O	
4	the	O	
5	coat	B	
6	protein	I	
7	promoter	I	
8	of	O	
9	chloris	O	
10	striate	O	
11	mosaic	O	
12	virus	O	
13	is	O	
14	enhanced	O	
15	by	O	
16	its	O	
17	own	O	
18	and	O	
19	C1	B	
20	-	O	
21	C2	B	
22	gene	O	
23	products	O	
24	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	an	O	
5	amino	O	
6	-	O	
7	terminal	O	
8	fragment	O	
9	containing	O	
10	the	O	
11	C	O	
12	/	O	
13	H1	O	
14	domain	O	
15	was	O	
16	sufficient	O	
17	for	O	
18	coactivation	O	
19	of	O	
20	Zta	B	
21	transcription	O	
22	and	O	
23	viral	O	
24	reactivation	O	
25	function	O	
26	.	O	

1	The	O	
2	5	O	
3	'	O	
4	ends	O	
5	of	O	
6	F3R	B	
7	late	O	
8	transcripts	O	
9	were	O	
10	located	O	
11	to	O	
12	an	O	
13	A	O	
14	within	O	
15	the	O	
16	sequence	O	
17	5	O	
18	'-	O	
19	TAAAG	O	
20	,	O	
21	41	O	
22	nt	O	
23	downstream	O	
24	from	O	
25	the	O	
26	early	O	
27	promoter	O	
28	and	O	
29	17	O	
30	nt	O	
31	upstream	O	
32	from	O	
33	the	O	
34	initiation	O	
35	codon	O	
36	.	O	

1	Using	O	
2	a	O	
3	previously	O	
4	published	O	
5	two	O	
6	-	O	
7	frequency	O	
8	(	O	
9	AC	O	
10	excitation	O	
11	)	O	
12	three	O	
13	-	O	
14	electrode	O	
15	method	O	
16	,	O	
17	the	O	
18	admittance	O	
19	locus	O	
20	plot	O	
21	(	O	
22	ALP	O	
23	)	O	
24	in	O	
25	the	O	
26	low	O	
27	-	O	
28	frequency	O	
29	region	O	
30	(<	O	
31	1000	O	
32	Hz	O	
33	)	O	
34	has	O	
35	been	O	
36	shown	O	
37	to	O	
38	be	O	
39	very	O	
40	well	O	
41	approximated	O	
42	by	O	
43	a	O	
44	straight	O	
45	line	O	
46	and	O	
47	can	O	
48	be	O	
49	described	O	
50	with	O	
51	frequency	O	
52	-	O	
53	independent	O	
54	parameters	O	
55	;	O	
56	phase	O	
57	angle	O	
58	alpha	O	
59	pi	O	
60	/	O	
61	2	O	
62	,	O	
63	conductance	O	
64	at	O	
65	extrapolated	O	
66	zero	O	
67	frequency	O	
68	G0	O	
69	=	O	
70	1	O	
71	/	O	
72	R0	O	
73	,	O	
74	and	O	
75	ion	O	
76	relaxation	O	
77	time	O	
78	tau	O	
79	.	O	

1	Perilunar	O	
2	luxation	O	
3	--	O	
4	an	O	
5	unusual	O	
6	injury	O	
7	demanding	O	
8	immediate	O	
9	and	O	
10	correct	O	
11	treatment	O	

1	The	O	
2	other	O	
3	patients	O	
4	continued	O	
5	the	O	
6	trial	O	
7	with	O	
8	single	O	
9	daily	O	
10	doses	O	
11	of	O	
12	monotherapy	O	
13	.	O	

1	Prostate	B	
2	-	I	
3	specific	I	
4	antigen	I	
5	(	O	
6	PSA	B	
7	)	O	
8	promoter	O	
9	-	O	
10	driven	O	
11	androgen	O	
12	-	O	
13	inducible	O	
14	expression	O	
15	of	O	
16	sodium	B	
17	iodide	I	
18	symporter	I	
19	in	O	
20	prostate	O	
21	cancer	O	
22	cell	O	
23	lines	O	
24	.	O	

1	We	O	
2	have	O	
3	isolated	O	
4	and	O	
5	characterised	O	
6	a	O	
7	differentially	O	
8	-	O	
9	regulated	O	
10	gene	O	
11	family	O	
12	in	O	
13	the	O	
14	protozoan	O	
15	parasite	O	
16	Leishmania	O	
17	major	O	
18	.	O	

1	No	O	
2	differences	O	
3	in	O	
4	fixation	O	
5	quality	O	
6	were	O	
7	observed	O	
8	between	O	
9	cochleas	O	
10	fixed	O	
11	by	O	
12	intravascular	O	
13	perfusion	O	
14	and	O	
15	cochleas	O	
16	fixed	O	
17	by	O	
18	intralabyrinthine	O	
19	perfusion	O	
20	.	O	

1	This	O	
2	analysis	O	
3	revealed	O	
4	an	O	
5	intact	O	
6	gene	O	
7	(	O	
8	arg4	B	
9	)	O	
10	showing	O	
11	a	O	
12	high	O	
13	degree	O	
14	of	O	
15	homology	O	
16	with	O	
17	the	O	
18	Saccharomyces	B	
19	cerevisiae	I	
20	CPA2	I	
21	gene	I	
22	encoding	O	
23	the	O	
24	large	O	
25	subunit	O	
26	of	O	
27	carbamoyl	B	
28	-	I	
29	phosphate	I	
30	synthetase	I	
31	(	O	
32	CPS	B	
33	-	I	
34	A	I	
35	).	O	

1	Cells	O	
2	respond	O	
3	to	O	
4	the	O	
5	accumulation	O	
6	of	O	
7	unfolded	O	
8	proteins	O	
9	in	O	
10	the	O	
11	endoplasmic	O	
12	reticulum	O	
13	(	O	
14	ER	O	
15	)	O	
16	by	O	
17	increasing	O	
18	the	O	
19	transcription	O	
20	of	O	
21	the	O	
22	genes	O	
23	encoding	O	
24	ER	B	
25	-	I	
26	resident	I	
27	chaperone	I	
28	proteins	I	
29	.	O	

1	AMY	B	
2	-	I	
3	1	I	
4	was	O	
5	localized	O	
6	in	O	
7	the	O	
8	cytoplasm	O	
9	in	O	
10	cells	O	
11	expressing	O	
12	c	B	
13	-	I	
14	myc	I	
15	at	O	
16	low	O	
17	levels	O	
18	,	O	
19	but	O	
20	in	O	
21	the	O	
22	nucleus	O	
23	in	O	
24	the	O	
25	cells	O	
26	of	O	
27	a	O	
28	high	O	
29	c	B	
30	-	I	
31	myc	I	
32	expression	O	
33	in	O	
34	transiently	O	
35	transfected	O	
36	cells	O	
37	.	O	

1	Scapulae	O	
2	with	O	
3	a	O	
4	Type	O	
5	I	O	
6	configuration	O	
7	were	O	
8	found	O	
9	to	O	
10	have	O	
11	low	O	
12	values	O	
13	for	O	
14	the	O	
15	coraco	O	
16	-	O	
17	glenoid	O	
18	angle	O	
19	and	O	
20	coracoid	O	
21	overlap	O	
22	,	O	
23	which	O	
24	are	O	
25	known	O	
26	to	O	
27	be	O	
28	associated	O	
29	with	O	
30	a	O	
31	short	O	
32	coraco	O	
33	-	O	
34	humeral	O	
35	distance	O	
36	.	O	

1	Despite	O	
2	the	O	
3	reported	O	
4	detrimental	O	
5	effects	O	
6	on	O	
7	CNS	O	
8	development	O	
9	,	O	
10	a	O	
11	number	O	
12	of	O	
13	animal	O	
14	studies	O	
15	have	O	
16	shown	O	
17	that	O	
18	pretreatment	O	
19	with	O	
20	corticosteroids	O	
21	nevertheless	O	
22	protect	O	
23	the	O	
24	brain	O	
25	from	O	
26	hypoxia	O	
27	-	O	
28	ischemic	O	
29	injury	O	
30	;	O	
31	however	O	
32	,	O	
33	clinically	O	
34	such	O	
35	treatment	O	
36	is	O	
37	no	O	
38	longer	O	
39	favored	O	
40	.	O	

1	Pit	B	
2	-	I	
3	1	I	
4	is	O	
5	a	O	
6	tissue	O	
7	-	O	
8	specific	O	
9	POU	B	
10	domain	I	
11	factor	I	
12	obligatory	O	
13	for	O	
14	the	O	
15	appearance	O	
16	of	O	
17	three	O	
18	cell	O	
19	phenotypes	O	
20	in	O	
21	the	O	
22	anterior	O	
23	pituitary	O	
24	gland	O	
25	.	O	

1	To	O	
2	test	O	
3	the	O	
4	hypothesis	O	
5	that	O	
6	progestin	O	
7	-	O	
8	mediated	O	
9	increases	O	
10	in	O	
11	resting	O	
12	core	O	
13	temperature	O	
14	and	O	
15	the	O	
16	core	O	
17	temperature	O	
18	threshold	O	
19	for	O	
20	sweating	O	
21	onset	O	
22	are	O	
23	counteracted	O	
24	by	O	
25	estrogen	O	
26	,	O	
27	we	O	
28	studied	O	
29	eight	O	
30	women	O	
31	(	O	
32	24	O	
33	+/-	O	
34	2	O	
35	yr	O	
36	)	O	
37	at	O	
38	27	O	
39	degrees	O	
40	C	O	
41	rest	O	
42	,	O	
43	during	O	
44	20	O	
45	min	O	
46	of	O	
47	passive	O	
48	heating	O	
49	(	O	
50	35	O	
51	degrees	O	
52	C	O	
53	),	O	
54	and	O	
55	during	O	
56	40	O	
57	min	O	
58	of	O	
59	exercise	O	
60	at	O	
61	35	O	
62	degrees	O	
63	C	O	
64	.	O	

1	Hepatitis	O	
2	B	O	
3	vaccine	O	

1	Analysis	O	
2	of	O	
3	its	O	
4	genomic	O	
5	region	O	
6	revealed	O	
7	that	O	
8	the	O	
9	13	O	
10	-	O	
11	kb	O	
12	Cdc6	B	
13	gene	I	
14	is	O	
15	divided	O	
16	into	O	
17	12	O	
18	exons	O	
19	by	O	
20	11	O	
21	introns	O	
22	.	O	

1	Sequence	O	
2	divergence	O	
3	is	O	
4	observed	O	
5	in	O	
6	untranslated	O	
7	regions	O	
8	which	O	
9	allows	O	
10	the	O	
11	definition	O	
12	of	O	
13	gene	O	
14	-	O	
15	specific	O	
16	probes	O	
17	.	O	

1	Transient	O	
2	overexpression	O	
3	of	O	
4	mutant	B	
5	EphB1	I	
6	receptors	I	
7	(	O	
8	Y594F	O	
9	)	O	
10	blocked	O	
11	Nck	B	
12	recruitment	O	
13	to	O	
14	EphB1	B	
15	,	O	
16	attenuated	O	
17	downstream	O	
18	JNK	B	
19	activation	O	
20	,	O	
21	and	O	
22	blocked	O	
23	cell	O	
24	attachment	O	
25	responses	O	
26	.	O	

1	Reverse	B	
2	transcriptase	I	
3	and	O	
4	protease	O	
5	activities	O	
6	of	O	
7	avian	O	
8	leukosis	O	
9	virus	O	
10	Gag	B	
11	-	O	
12	Pol	B	
13	fusion	O	
14	proteins	O	
15	expressed	O	
16	in	O	
17	insect	O	
18	cells	O	
19	.	O	

1	Phase	O	
2	II	O	
3	study	O	
4	of	O	
5	VP	O	
6	-	O	
7	16	O	
8	(	O	
9	capsule	O	
10	)	O	
11	in	O	
12	solid	O	
13	tumors	O	
14	.	O	

1	The	O	
2	nucleotide	O	
3	sequence	O	
4	of	O	
5	the	O	
6	region	O	
7	upstream	O	
8	from	O	
9	M	B	
10	.	I	
11	voltae	I	
12	ORFtrpA	I	
13	was	O	
14	determined	O	
15	and	O	
16	revealed	O	
17	the	O	
18	presence	O	
19	of	O	
20	an	O	
21	ORF	O	
22	of	O	
23	1227	O	
24	nucleotides	O	
25	(	O	
26	ORFtrpB	B	
27	)	O	
28	encoding	O	
29	a	O	
30	409	O	
31	amino	O	
32	acid	O	
33	polypeptide	O	
34	of	O	
35	mol	O	
36	.	O	
37	wt	O	
38	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	both	O	
5	Sp1	B	
6	and	O	
7	ETS	B	
8	proteins	I	
9	are	O	
10	required	O	
11	to	O	
12	bring	O	
13	about	O	
14	full	O	
15	promoter	O	
16	activity	O	
17	in	O	
18	the	O	
19	Surf	B	
20	-	I	
21	1	I	
22	direction	O	
23	.	O	

1	GCD10	B	
2	binds	O	
3	RNA	O	
4	in	O	
5	vitro	O	
6	and	O	
7	we	O	
8	present	O	
9	strong	O	
10	biochemical	O	
11	evidence	O	
12	that	O	
13	it	O	
14	is	O	
15	identical	O	
16	to	O	
17	the	O	
18	RNA	O	
19	-	O	
20	binding	O	
21	subunit	O	
22	of	O	
23	yeast	B	
24	initiation	I	
25	factor	I	
26	-	I	
27	3	I	
28	(	O	
29	eIF	B	
30	-	I	
31	3	I	
32	).	O	
33	eIF	B	
34	-	I	
35	3	I	
36	is	O	
37	a	O	
38	multisubunit	O	
39	complex	O	
40	that	O	
41	stimulates	O	
42	translation	O	
43	initiation	O	
44	in	O	
45	vitro	O	
46	at	O	
47	several	O	
48	different	O	
49	steps	O	
50	.	O	

1	Ten	O	
2	days	O	
3	of	O	
4	cefadroxil	O	
5	therapy	O	
6	was	O	
7	used	O	
8	to	O	
9	treat	O	
10	44	O	
11	children	O	
12	with	O	
13	urinary	O	
14	tract	O	
15	infection	O	
16	and	O	
17	CRP	B	
18	values	O	
19	greater	O	
20	than	O	
21	or	O	
22	equal	O	
23	to	O	
24	28	O	
25	microgram	O	
26	/	O	
27	ml	O	
28	(	O	
29	CRP	B	
30	-	O	
31	positive	O	
32	group	O	
33	).	O	

1	The	O	
2	S229A	O	
3	variant	O	
4	can	O	
5	better	O	
6	flip	O	
7	modified	O	
8	bases	O	
9	but	O	
10	does	O	
11	not	O	
12	tightly	O	
13	lock	O	
14	the	O	
15	flipped	O	
16	base	O	
17	into	O	
18	the	O	
19	adenine	O	
20	-	O	
21	binding	O	
22	pocket	O	
23	,	O	
24	suggesting	O	
25	that	O	
26	Ser229	O	
27	could	O	
28	form	O	
29	a	O	
30	contact	O	
31	to	O	
32	the	O	
33	flipped	O	
34	adenine	O	
35	.	O	

1	Intraoperatively	O	
2	the	O	
3	complement	B	
4	factor	I	
5	C3c	I	
6	decreased	O	
7	by	O	
8	20	O	
9	%,	O	
10	while	O	
11	alpha	B	
12	1	I	
13	-	I	
14	antitrypsin	I	
15	showed	O	
16	postoperatively	O	
17	an	O	
18	increase	O	
19	by	O	
20	30	O	
21	%.	O	

1	An	O	
2	int6	B	
3	deletion	I	
4	(	O	
5	int6Delta	B	
6	)	O	
7	mutant	O	
8	was	O	
9	viable	O	
10	but	O	
11	grew	O	
12	slowly	O	
13	in	O	
14	minimal	O	
15	medium	O	
16	.	O	

1	An	O	
2	experiment	O	
3	on	O	
4	the	O	
5	return	O	
6	-	O	
7	of	O	
8	-	O	
9	fear	O	
10	(	O	
11	ROF	O	
12	)	O	
13	was	O	
14	carried	O	
15	out	O	
16	on	O	
17	40	O	
18	snake	O	
19	-	O	
20	or	O	
21	spider	O	
22	-	O	
23	phobic	O	
24	subjects	O	
25	in	O	
26	order	O	
27	to	O	
28	determine	O	
29	whether	O	
30	an	O	
31	arousing	O	
32	event	O	
33	that	O	
34	occurs	O	
35	shortly	O	
36	before	O	
37	retest	O	
38	influences	O	
39	the	O	
40	magnitude	O	
41	of	O	
42	the	O	
43	ROF	O	
44	.	O	

1	I	O	
2	.	O	

1	We	O	
2	suggest	O	
3	that	O	
4	MotA	B	
5	and	O	
6	AsiA	B	
7	may	O	
8	function	O	
9	like	O	
10	certain	O	
11	eukaryotic	B	
12	TAFs	I	
13	(	O	
14	TATA	B	
15	binding	I	
16	protein	I	
17	(	I	
18	TBP	I	
19	)	I	
20	associated	I	
21	factors	I	
22	)	O	
23	whose	O	
24	binding	O	
25	to	O	
26	TBP	B	
27	results	O	
28	in	O	
29	transcription	O	
30	from	O	
31	new	O	
32	core	O	
33	promoter	O	
34	sequences	O	
35	.	O	

1	These	O	
2	findings	O	
3	indicate	O	
4	that	O	
5	autophosphorylation	O	
6	of	O	
7	Thr286	O	
8	(	O	
9	alpha	O	
10	subunit	O	
11	)	O	
12	and	O	
13	Thr287	O	
14	(	O	
15	beta	O	
16	subunit	O	
17	)	O	
18	is	O	
19	responsible	O	
20	for	O	
21	transition	O	
22	of	O	
23	CaM	B	
24	-	I	
25	kinase	I	
26	II	I	
27	to	O	
28	the	O	
29	Ca2	O	
30	+-	O	
31	independent	O	
32	form	O	
33	.	O	

1	We	O	
2	have	O	
3	separated	O	
4	a	O	
5	dermatan	O	
6	sulfate	O	
7	proteoglycan	O	
8	,	O	
9	epiphycan	O	
10	,	O	
11	from	O	
12	decorin	B	
13	and	O	
14	biglycan	O	
15	by	O	
16	using	O	
17	dissociative	O	
18	extraction	O	
19	of	O	
20	bovine	O	
21	fetal	O	
22	epiphyseal	O	
23	cartilage	O	
24	,	O	
25	followed	O	
26	by	O	
27	sequential	O	
28	ion	O	
29	-	O	
30	exchange	O	
31	,	O	
32	gel	O	
33	permeation	O	
34	,	O	
35	hydrophobic	O	
36	,	O	
37	and	O	
38	Zn2	O	
39	+	O	
40	chelate	O	
41	chromatographic	O	
42	steps	O	
43	.	O	

1	Thus	O	
2	,	O	
3	an	O	
4	increase	O	
5	in	O	
6	plasma	B	
7	TBG	I	
8	and	O	
9	a	O	
10	shift	O	
11	from	O	
12	adrenal	O	
13	androgen	O	
14	and	O	
15	mineralocorticoid	O	
16	steroid	O	
17	secretion	O	
18	towards	O	
19	cortisol	O	
20	secretion	O	
21	may	O	
22	be	O	
23	endocrine	O	
24	markers	O	
25	for	O	
26	progression	O	
27	of	O	
28	the	O	
29	disease	O	
30	in	O	
31	patients	O	
32	with	O	
33	HIV	O	
34	-	O	
35	infection	O	
36	.	O	

1	A	O	
2	single	O	
3	five	O	
4	minute	O	
5	period	O	
6	of	O	
7	rapid	O	
8	atrial	O	
9	pacing	O	
10	fails	O	
11	to	O	
12	limit	O	
13	infarct	O	
14	size	O	
15	in	O	
16	the	O	
17	in	O	
18	situ	O	
19	rabbit	O	
20	heart	O	
21	.	O	

1	There	O	
2	was	O	
3	no	O	
4	apparent	O	
5	effect	O	
6	of	O	
7	growth	O	
8	temperature	O	
9	on	O	
10	the	O	
11	steady	O	
12	-	O	
13	state	O	
14	levels	O	
15	of	O	
16	fad7	B	
17	mRNA	I	
18	in	O	
19	wild	O	
20	type	O	
21	plants	O	
22	.	O	

1	Though	O	
2	hepatomegaly	O	
3	and	O	
4	mild	O	
5	elevation	O	
6	of	O	
7	enzymes	O	
8	can	O	
9	be	O	
10	observed	O	
11	in	O	
12	a	O	
13	significant	O	
14	proportion	O	
15	of	O	
16	patients	O	
17	,	O	
18	involvement	O	
19	of	O	
20	liver	O	
21	leading	O	
22	to	O	
23	acute	O	
24	hepatitis	O	
25	or	O	
26	liver	O	
27	cell	O	
28	necrosis	O	
29	is	O	
30	a	O	
31	relatively	O	
32	uncommon	O	
33	complication	O	
34	in	O	
35	P	O	
36	.	O	
37	falciparum	O	
38	malaria	O	
39	.	O	

1	A	O	
2	set	O	
3	of	O	
4	peptides	O	
5	corresponding	O	
6	to	O	
7	the	O	
8	individual	O	
9	elements	O	
10	of	O	
11	secondary	O	
12	structure	O	
13	derived	O	
14	from	O	
15	the	O	
16	N	O	
17	-	O	
18	terminal	O	
19	domain	O	
20	of	O	
21	the	O	
22	ribosomal	B	
23	protein	I	
24	L9	I	
25	have	O	
26	been	O	
27	synthesized	O	
28	.	O	

1	Functional	O	
2	disorders	O	
3	of	O	
4	the	O	
5	ureter	O	
6	following	O	
7	gynecologic	O	
8	surgery	O	

1	Our	O	
2	results	O	
3	suggest	O	
4	that	O	
5	proteasome	O	
6	inhibition	O	
7	leads	O	
8	to	O	
9	upregulation	O	
10	of	O	
11	specific	O	
12	members	O	
13	of	O	
14	transcription	O	
15	factor	O	
16	families	O	
17	controlling	O	
18	cellular	O	
19	stress	O	
20	response	O	
21	and	O	
22	proliferation	O	
23	.	O	

1	In	O	
2	the	O	
3	present	O	
4	study	O	
5	we	O	
6	have	O	
7	investigated	O	
8	the	O	
9	regulatory	O	
10	mechanism	O	
11	for	O	
12	CD95L	B	
13	expression	O	
14	.	O	

1	Members	O	
2	of	O	
3	the	O	
4	Ras	B	
5	subfamily	I	
6	of	O	
7	small	B	
8	GTP	I	
9	-	I	
10	binding	I	
11	proteins	I	
12	have	O	
13	been	O	
14	shown	O	
15	to	O	
16	be	O	
17	promiscuous	O	
18	towards	O	
19	a	O	
20	variety	O	
21	of	O	
22	putative	O	
23	effector	O	
24	molecules	O	
25	such	O	
26	as	O	
27	the	O	
28	protein	B	
29	kinase	I	
30	c	I	
31	-	I	
32	Raf	I	
33	and	O	
34	the	O	
35	Ral	B	
36	-	I	
37	specific	I	
38	guanine	I	
39	nucleotide	I	
40	exchange	I	
41	factor	I	
42	(	O	
43	Ral	B	
44	-	I	
45	GEF	I	
46	).	O	

1	The	O	
2	control	O	
3	group	O	
4	included	O	
5	8	O	
6	afterbirth	O	
7	samples	O	
8	from	O	
9	physiological	O	
10	full	O	
11	-	O	
12	term	O	
13	pregnancies	O	
14	.	O	

1	Transgenic	O	
2	mice	O	
3	harboring	O	
4	the	O	
5	rat	O	
6	TnI	B	
7	-	O	
8	CAT	B	
9	fusion	O	
10	gene	O	
11	expressed	O	
12	the	O	
13	reporter	O	
14	specifically	O	
15	in	O	
16	the	O	
17	skeletal	O	
18	muscle	O	
19	.	O	

1	The	O	
2	histologic	O	
3	grade	O	
4	for	O	
5	the	O	
6	same	O	
7	anatomic	O	
8	site	O	
9	varied	O	
10	among	O	
11	hearts	O	
12	and	O	
13	among	O	
14	different	O	
15	anatomic	O	
16	sites	O	
17	in	O	
18	the	O	
19	same	O	
20	heart	O	
21	.	O	

1	The	O	
2	negative	O	
3	predictive	O	
4	value	O	
5	is	O	
6	92	O	
7	%,	O	
8	vs	O	
9	80	O	
10	%	O	
11	for	O	
12	the	O	
13	NCEP	O	
14	I	O	
15	.	O	

1	In	O	
2	the	O	
3	absence	O	
4	of	O	
5	E1A243	B	
6	,	O	
7	YY1	B	
8	represses	O	
9	CRE	O	
10	-	O	
11	dependent	O	
12	transcription	O	
13	of	O	
14	c	B	
15	-	I	
16	fos	I	
17	by	O	
18	physically	O	
19	interacting	O	
20	with	O	
21	ATF	B	
22	/	O	
23	CREB	B	
24	proteins	O	
25	bound	O	
26	to	O	
27	the	O	
28	-	O	
29	67	O	
30	CRE	O	
31	.	O	

1	The	O	
2	plant	O	
3	hormone	O	
4	auxin	O	
5	transcriptionally	O	
6	activates	O	
7	early	B	
8	genes	I	
9	.	O	

1	Taken	O	
2	together	O	
3	,	O	
4	our	O	
5	results	O	
6	indicate	O	
7	that	O	
8	the	O	
9	FCR1	B	
10	gene	I	
11	behaves	O	
12	as	O	
13	a	O	
14	negative	O	
15	regulator	O	
16	of	O	
17	drug	O	
18	resistance	O	
19	in	O	
20	C	O	
21	.	O	
22	albicans	O	
23	and	O	
24	constitute	O	
25	the	O	
26	first	O	
27	evidence	O	
28	that	O	
29	FCZ	O	
30	resistance	O	
31	can	O	
32	result	O	
33	from	O	
34	the	O	
35	inactivation	O	
36	of	O	
37	a	O	
38	regulatory	O	
39	factor	O	
40	such	O	
41	as	O	
42	Fcr1p	B	
43	.	O	

1	Modification	O	
2	of	O	
3	enteral	O	
4	resorption	O	
5	by	O	
6	cytostatic	O	
7	therapy	O	

1	Connector	B	
2	enhancer	I	
3	of	I	
4	KSR	I	
5	(	O	
6	CNK	B	
7	)	O	
8	is	O	
9	a	O	
10	multidomain	O	
11	protein	O	
12	required	O	
13	for	O	
14	RAS	B	
15	signaling	O	
16	.	O	

1	The	O	
2	major	O	
3	transcription	O	
4	factors	O	
5	controlling	O	
6	arginine	O	
7	metabolism	O	
8	in	O	
9	Escherichia	O	
10	coli	O	
11	and	O	
12	Bacillus	O	
13	subtilis	O	
14	,	O	
15	ArgR	B	
16	and	O	
17	AhrC	B	
18	,	O	
19	respectively	O	
20	,	O	
21	are	O	
22	homologous	O	
23	multimeric	O	
24	proteins	O	
25	that	O	
26	form	O	
27	l	O	
28	-	O	
29	arginine	O	
30	-	O	
31	dependent	O	
32	DNA	O	
33	-	O	
34	binding	O	
35	complexes	O	
36	capable	O	
37	of	O	
38	repressing	O	
39	transcription	O	
40	of	O	
41	the	O	
42	biosynthetic	O	
43	genes	O	
44	(	O	
45	both	O	
46	),	O	
47	activating	O	
48	transcription	O	
49	of	O	
50	catabolic	O	
51	genes	O	
52	(	O	
53	AhrC	B	
54	only	O	
55	)	O	
56	or	O	
57	facilitating	O	
58	plasmid	O	
59	dimer	O	
60	resolution	O	
61	(	O	
62	both	O	
63	).	O	

1	Alpha	B	
2	-	I	
3	1	I	
4	antitrypsin	I	
5	and	O	
6	Indian	O	
7	childhood	O	
8	cirrhosis	O	
9	.	O	

1	The	O	
2	significance	O	
3	of	O	
4	structural	O	
5	integrity	O	
6	of	O	
7	lymphoid	O	
8	tissue	O	
9	for	O	
10	antibody	O	
11	production	O	
12	in	O	
13	culture	O	
14	in	O	
15	vivo	O	

1	The	O	
2	AL	O	
3	-	O	
4	R8	O	
5	SI	O	
6	:	O	
7	the	O	
8	next	O	
9	generation	O	
10	staging	O	
11	container	O	
12	for	O	
13	plutonium	O	
14	pits	O	
15	at	O	
16	the	O	
17	USDOE	O	
18	Pantex	O	
19	Plant	O	
20	.	O	

1	We	O	
2	now	O	
3	show	O	
4	that	O	
5	regulation	O	
6	of	O	
7	flaN	B	
8	transcription	O	
9	in	O	
10	vivo	O	
11	depends	O	
12	on	O	
13	a	O	
14	sigma	B	
15	54	I	
16	promoter	I	
17	and	O	
18	two	O	
19	ftr	O	
20	elements	O	
21	located	O	
22	downstream	O	
23	of	O	
24	the	O	
25	transcription	O	
26	start	O	
27	site	O	
28	at	O	
29	+	O	
30	86	O	
31	(	O	
32	ftr2	O	
33	)	O	
34	and	O	
35	+	O	
36	120	O	
37	(	O	
38	ftr3	O	
39	).	O	

1	These	O	
2	motifs	O	
3	include	O	
4	a	O	
5	Chi	O	
6	motif	O	
7	and	O	
8	a	O	
9	Chi	O	
10	-	O	
11	like	O	
12	element	O	
13	previously	O	
14	found	O	
15	in	O	
16	the	O	
17	recombination	O	
18	hotspot	O	
19	region	O	
20	of	O	
21	the	O	
22	Bcl	B	
23	-	I	
24	2	I	
25	proto	I	
26	-	I	
27	oncogene	I	
28	and	O	
29	close	O	
30	to	O	
31	chromosomal	O	
32	breakpoints	O	
33	in	O	
34	T	O	
35	-	O	
36	ALL	O	
37	lines	O	
38	.	O	

1	Mammalian	O	
2	sperm	O	
3	motility	O	
4	is	O	
5	regulated	O	
6	by	O	
7	a	O	
8	cascade	O	
9	of	O	
10	cAMP	O	
11	-	O	
12	dependent	O	
13	protein	O	
14	phosphorylation	O	
15	events	O	
16	mediated	O	
17	by	O	
18	protein	B	
19	kinase	I	
20	A	I	
21	.	O	

1	Can	O	
2	thyroglobulin	B	
3	assay	O	
4	really	O	
5	supplant	O	
6	radioiodine	O	
7	scans	O	
8	in	O	
9	patients	O	
10	with	O	
11	differentiated	O	
12	thyroid	O	
13	cancer	O	
14	?	O	

1	In	O	
2	this	O	
3	article	O	
4	,	O	
5	the	O	
6	clinical	O	
7	actions	O	
8	of	O	
9	the	O	
10	principal	O	
11	dopamine	B	
12	receptor	I	
13	stimulating	O	
14	agents	O	
15	(	O	
16	apomorphine	O	
17	and	O	
18	its	O	
19	derivatives	O	
20	;	O	
21	piribedil	O	
22	,	O	
23	rye	O	
24	-	O	
25	ergot	O	
26	derivatives	O	
27	)	O	
28	are	O	
29	discussed	O	
30	on	O	
31	the	O	
32	basis	O	
33	of	O	
34	their	O	
35	biochemical	O	
36	and	O	
37	pharmacological	O	
38	properties	O	
39	.	O	

1	Magnetic	O	
2	storm	O	
3	indicators	O	
4	could	O	
5	be	O	
6	used	O	
7	in	O	
8	medicine	O	
9	,	O	
10	in	O	
11	geophysics	O	
12	and	O	
13	for	O	
14	special	O	
15	purposes	O	
16	.	O	

1	The	O	
2	encoded	O	
3	amino	O	
4	acid	O	
5	sequences	O	
6	in	O	
7	the	O	
8	full	O	
9	-	O	
10	length	O	
11	bovine	O	
12	and	O	
13	porcine	O	
14	cDNAs	O	
15	were	O	
16	identical	O	
17	,	O	
18	consisting	O	
19	of	O	
20	209	O	
21	amino	O	
22	acid	O	
23	residues	O	
24	,	O	
25	and	O	
26	were	O	
27	nearly	O	
28	the	O	
29	same	O	
30	as	O	
31	the	O	
32	published	O	
33	sequence	O	
34	determined	O	
35	by	O	
36	Edman	O	
37	degradation	O	
38	.	O	

1	All	O	
2	patients	O	
3	diagnosed	O	
4	of	O	
5	H	O	
6	.	O	
7	influenza	O	
8	type	O	
9	b	O	
10	meningitis	O	
11	were	O	
12	less	O	
13	than	O	
14	3	O	
15	years	O	
16	old	O	
17	.	O	

1	We	O	
2	discuss	O	
3	these	O	
4	results	O	
5	with	O	
6	respect	O	
7	to	O	
8	the	O	
9	transcriptional	O	
10	induction	O	
11	of	O	
12	the	O	
13	HNF	B	
14	-	I	
15	3	I	
16	alpha	I	
17	gene	I	
18	in	O	
19	respiratory	O	
20	epithelium	O	
21	during	O	
22	embryogenesis	O	
23	.	O	

1	The	O	
2	two	O	
3	most	O	
4	recent	O	
5	patients	O	
6	(	O	
7	35	O	
8	and	O	
9	132	O	
10	days	O	
11	)	O	
12	received	O	
13	only	O	
14	oral	O	
15	dipyridamole	O	
16	(	O	
17	75	O	
18	mg	O	
19	X	O	
20	3	O	
21	/	O	
22	day	O	
23	)	O	
24	and	O	
25	aspirin	O	
26	(	O	
27	80	O	
28	mg	O	
29	/	O	
30	day	O	
31	)	O	
32	after	O	
33	the	O	
34	early	O	
35	recovery	O	
36	period	O	
37	(	O	
38	four	O	
39	-	O	
40	six	O	
41	days	O	
42	),	O	
43	resulting	O	
44	in	O	
45	normal	O	
46	prothrombin	B	
47	and	O	
48	partial	O	
49	thromboplastin	B	
50	times	O	
51	.	O	

1	Hybrid	O	
2	-	O	
3	selection	O	
4	experiments	O	
5	against	O	
6	total	O	
7	PB	O	
8	-	O	
9	inducible	O	
10	RNA	O	
11	were	O	
12	performed	O	
13	with	O	
14	plasmid	O	
15	DNA	O	
16	derived	O	
17	from	O	
18	clones	O	
19	enriched	O	
20	in	O	
21	PB	O	
22	-	O	
23	inducible	O	
24	information	O	
25	.	O	

1	In	O	
2	both	O	
3	groups	O	
4	there	O	
5	were	O	
6	5	O	
7	management	O	
8	failure	O	
9	of	O	
10	therapy	O	
11	,	O	
12	so	O	
13	that	O	
14	alternative	O	
15	medication	O	
16	or	O	
17	a	O	
18	cesarean	O	
19	section	O	
20	lead	O	
21	to	O	
22	delivery	O	
23	.	O	

1	We	O	
2	have	O	
3	identified	O	
4	and	O	
5	characterized	O	
6	a	O	
7	vitamin	O	
8	D	O	
9	response	O	
10	element	O	
11	(	O	
12	VDRE	O	
13	)	O	
14	in	O	
15	the	O	
16	promoter	O	
17	of	O	
18	c	B	
19	-	I	
20	fos	I	
21	.	O	

1	The	O	
2	C	O	
3	-	O	
4	terminal	O	
5	mature	O	
6	region	O	
7	is	O	
8	highly	O	
9	conserved	O	
10	in	O	
11	other	O	
12	serine	B	
13	carboxypeptidases	I	
14	.	O	

1	Overexpression	O	
2	of	O	
3	ICBP90	B	
4	in	O	
5	COS	O	
6	-	O	
7	1	O	
8	-	O	
9	transfected	O	
10	cells	O	
11	induced	O	
12	an	O	
13	enhanced	O	
14	expression	O	
15	of	O	
16	endogenous	B	
17	topoisomerase	I	
18	IIalpha	I	
19	.	O	

1	Eleven	O	
2	biopsy	O	
3	specimens	O	
4	(	O	
5	five	O	
6	papules	O	
7	and	O	
8	six	O	
9	dusky	O	
10	or	O	
11	crusted	O	
12	lesions	O	
13	)	O	
14	from	O	
15	four	O	
16	patients	O	
17	with	O	
18	pityriasis	O	
19	lichenoides	O	
20	et	O	
21	varioliformis	O	
22	acuta	O	
23	(	O	
24	PLEVA	O	
25	)	O	
26	were	O	
27	studied	O	
28	by	O	
29	direct	O	
30	immunofluorescence	O	
31	and	O	
32	immunoperoxidase	B	
33	technics	O	
34	.	O	

1	Hepatitis	O	
2	B	O	
3	virus	O	
4	and	O	
5	hepatoma	O	
6	.	O	

1	Here	O	
2	we	O	
3	report	O	
4	the	O	
5	complete	O	
6	6	O	
7	-	O	
8	kilobase	O	
9	cDNA	O	
10	sequence	O	
11	coding	O	
12	for	O	
13	a	O	
14	chain	O	
15	of	O	
16	1775	O	
17	amino	O	
18	acids	O	
19	,	O	
20	as	O	
21	well	O	
22	as	O	
23	the	O	
24	genomic	O	
25	structure	O	
26	.	O	

1	SPECT	O	
2	is	O	
3	an	O	
4	important	O	
5	aid	O	
6	in	O	
7	the	O	
8	diagnosis	O	
9	of	O	
10	AIDS	O	
11	dementia	O	
12	complex	O	
13	and	O	
14	contributes	O	
15	to	O	
16	the	O	
17	understanding	O	
18	of	O	
19	the	O	
20	pathophysiological	O	
21	mechanisms	O	
22	of	O	
23	this	O	
24	disorder	O	
25	.	O	

1	The	O	
2	dorsal	O	
3	nerves	O	
4	of	O	
5	the	O	
6	penis	O	
7	were	O	
8	anesthetized	O	
9	bilaterally	O	
10	with	O	
11	lidocaine	O	
12	.	O	

1	Simultaneous	O	
2	determination	O	
3	of	O	
4	theophylline	O	
5	and	O	
6	its	O	
7	metabolites	O	
8	by	O	
9	HPLC	O	
10	]	O	
11	A	O	
12	high	O	
13	performance	O	
14	liquid	O	
15	chromatography	O	
16	(	O	
17	HPLC	O	
18	)	O	
19	method	O	
20	has	O	
21	been	O	
22	developed	O	
23	for	O	
24	the	O	
25	simultaneous	O	
26	determination	O	
27	of	O	
28	theophylline	O	
29	and	O	
30	its	O	
31	metabolites	O	
32	,	O	
33	with	O	
34	caffeine	O	
35	and	O	
36	its	O	
37	metabolites	O	
38	.	O	

1	The	O	
2	Drosophila	B	
3	melanogaster	I	
4	suppressor	I	
5	of	I	
6	sable	I	
7	gene	I	
8	,	O	
9	su	O	
10	(	O	
11	s	O	
12	),	O	
13	encodes	O	
14	a	O	
15	novel	O	
16	,	O	
17	150	O	
18	-	O	
19	kDa	O	
20	nuclear	O	
21	RNA	O	
22	binding	O	
23	protein	O	
24	,	O	
25	SU	O	
26	(	O	
27	S	O	
28	),	O	
29	that	O	
30	negatively	O	
31	regulates	O	
32	RNA	O	
33	accumulation	O	
34	from	O	
35	mutant	O	
36	alleles	O	
37	of	O	
38	other	O	
39	genes	O	
40	that	O	
41	have	O	
42	transposon	O	
43	insertions	O	
44	in	O	
45	the	O	
46	5	O	
47	'	O	
48	transcribed	O	
49	region	O	
50	.	O	

1	Mutations	O	
2	that	O	
3	alter	O	
4	photoreceptor	O	
5	cell	O	
6	structure	O	
7	and	O	
8	development	O	
9	were	O	
10	isolated	O	
11	that	O	
12	fail	O	
13	to	O	
14	complement	O	
15	these	O	
16	deletions	O	
17	.	O	

1	Elevated	O	
2	IOP	O	
3	developed	O	
4	in	O	
5	35	O	
6	patients	O	
7	(	O	
8	44	O	
9	eyes	O	
10	)	O	
11	during	O	
12	the	O	
13	study	O	
14	.	O	

1	Cross	O	
2	-	O	
3	linking	O	
4	the	O	
5	B	B	
6	cell	I	
7	Ag	I	
8	receptor	I	
9	(	O	
10	BCR	B	
11	)	O	
12	to	O	
13	surface	B	
14	Fc	I	
15	receptors	I	
16	for	O	
17	IgG	B	
18	(	O	
19	Fc	B	
20	gamma	I	
21	R	I	
22	)	O	
23	inhibits	O	
24	G1	O	
25	-	O	
26	to	O	
27	-	O	
28	S	O	
29	progression	O	
30	;	O	
31	the	O	
32	mechanism	O	
33	by	O	
34	which	O	
35	this	O	
36	occurs	O	
37	is	O	
38	not	O	
39	completely	O	
40	known	O	
41	.	O	

1	Use	O	
2	of	O	
3	subcutaneous	O	
4	deferoxamine	O	
5	in	O	
6	a	O	
7	child	O	
8	with	O	
9	hemochromatosis	O	
10	associated	O	
11	with	O	
12	congenital	O	
13	dyserythropoietic	O	
14	anemia	O	
15	,	O	
16	type	O	
17	I	O	
18	.	O	

1	Chem	O	
2	.	O	

1	The	O	
2	immunophilin	B	
3	,	O	
4	which	O	
5	can	O	
6	be	O	
7	of	O	
8	the	O	
9	FK506	O	
10	-	O	
11	or	O	
12	cyclosporin	O	
13	A	O	
14	-	O	
15	binding	O	
16	class	O	
17	,	O	
18	binds	O	
19	to	O	
20	hsp90	B	
21	via	O	
22	its	O	
23	tetratricopeptide	O	
24	repeat	O	
25	(	O	
26	TPR	O	
27	)	O	
28	domain	O	
29	,	O	
30	and	O	
31	different	O	
32	receptor	O	
33	heterocomplexes	O	
34	exist	O	
35	depending	O	
36	upon	O	
37	which	O	
38	immunophilin	B	
39	occupies	O	
40	the	O	
41	TPR	O	
42	-	O	
43	binding	O	
44	region	O	
45	of	O	
46	hsp90	B	
47	.	O	

1	Thus	O	
2	adaptation	O	
3	to	O	
4	continuous	O	
5	mild	O	
6	stress	O	
7	has	O	
8	a	O	
9	potent	O	
10	antiarrhythmic	O	
11	effect	O	
12	which	O	
13	occurs	O	
14	due	O	
15	to	O	
16	the	O	
17	increased	O	
18	vagal	O	
19	tone	O	
20	.	O	

1	We	O	
2	show	O	
3	that	O	
4	these	O	
5	three	O	
6	gain	O	
7	-	O	
8	of	O	
9	-	O	
10	function	O	
11	mutants	O	
12	differ	O	
13	considerably	O	
14	in	O	
15	their	O	
16	ability	O	
17	to	O	
18	bypass	O	
19	the	O	
20	sex	O	
21	determination	O	
22	signal	O	
23	,	O	
24	with	O	
25	SxlM4	B	
26	being	O	
27	the	O	
28	strongest	O	
29	and	O	
30	SxlM1	B	
31	the	O	
32	weakest	O	
33	.	O	

1	Linearized	O	
2	overall	O	
3	infection	O	
4	rates	O	
5	(	O	
6	events	O	
7	/	O	
8	100	O	
9	patient	O	
10	-	O	
11	days	O	
12	)	O	
13	were	O	
14	2	O	
15	.	O	
16	05	O	
17	+/-	O	
18	0	O	
19	.	O	
20	33	O	
21	(	O	
22	heart	O	
23	-	O	
24	lung	O	
25	)	O	
26	and	O	
27	2	O	
28	.	O	
29	34	O	
30	+/-	O	
31	0	O	
32	.	O	
33	34	O	
34	(	O	
35	double	O	
36	-	O	
37	lung	O	
38	;	O	
39	P	O	
40	=	O	
41	NS	O	
42	)	O	
43	at	O	
44	3	O	
45	months	O	
46	.	O	

1	Paradoxically	O	
2	,	O	
3	however	O	
4	,	O	
5	the	O	
6	GH	B	
7	receptor	I	
8	cloned	O	
9	from	O	
10	liver	O	
11	exhibits	O	
12	no	O	
13	sequence	O	
14	similarity	O	
15	to	O	
16	receptors	O	
17	with	O	
18	known	O	
19	signal	O	
20	transduction	O	
21	mechanisms	O	
22	,	O	
23	including	O	
24	those	O	
25	exhibiting	O	
26	ligand	O	
27	-	O	
28	activated	O	
29	tyrosine	B	
30	kinase	I	
31	activity	O	
32	.	O	

1	Serum	O	
2	Fibrin	B	
3	Degradation	I	
4	Products	I	
5	(	O	
6	FDP	B	
7	)	O	
8	were	O	
9	determined	O	
10	in	O	
11	50	O	
12	oral	O	
13	cancer	O	
14	patients	O	
15	and	O	
16	50	O	
17	normal	O	
18	individuals	O	
19	prior	O	
20	to	O	
21	any	O	
22	kind	O	
23	of	O	
24	treatment	O	
25	.	O	

1	Previous	O	
2	experimental	O	
3	evidence	O	
4	had	O	
5	indicated	O	
6	that	O	
7	Reg1	B	
8	might	O	
9	target	O	
10	Glc7	B	
11	to	O	
12	nuclear	O	
13	substrates	O	
14	such	O	
15	as	O	
16	the	O	
17	Snf1	B	
18	kinase	I	
19	complex	I	
20	.	O	

1	While	O	
2	these	O	
3	findings	O	
4	may	O	
5	reflect	O	
6	the	O	
7	sensitivity	O	
8	of	O	
9	a	O	
10	thick	O	
11	myocardial	O	
12	wall	O	
13	to	O	
14	ischaemia	O	
15	during	O	
16	surgery	O	
17	,	O	
18	the	O	
19	postoperative	O	
20	recovery	O	
21	was	O	
22	not	O	
23	related	O	
24	to	O	
25	the	O	
26	serum	B	
27	CK	I	
28	-	I	
29	MB	I	
30	level	O	
31	.	O	

1	Cocaine	O	
2	-	O	
3	treated	O	
4	rats	O	
5	acquired	O	
6	a	O	
7	preference	O	
8	for	O	
9	cocaine	O	
10	-	O	
11	associated	O	
12	contextual	O	
13	stimuli	O	
14	(	O	
15	CS	O	
16	)	O	
17	relative	O	
18	to	O	
19	saline	O	
20	-	O	
21	injected	O	
22	control	O	
23	rats	O	
24	.	O	

1	However	O	
2	,	O	
3	there	O	
4	has	O	
5	not	O	
6	been	O	
7	any	O	
8	evidence	O	
9	of	O	
10	A	O	
11	.	O	
12	salmonicida	O	
13	infections	O	
14	,	O	
15	specifically	O	
16	furunculosis	O	
17	,	O	
18	associated	O	
19	with	O	
20	the	O	
21	fish	O	
22	in	O	
23	this	O	
24	loch	O	
25	.	O	

1	Because	O	
2	of	O	
3	its	O	
4	great	O	
5	reliability	O	
6	,	O	
7	conventional	O	
8	arteriography	O	
9	occupies	O	
10	a	O	
11	place	O	
12	of	O	
13	choice	O	
14	among	O	
15	the	O	
16	medical	O	
17	imaging	O	
18	techniques	O	
19	.	O	

1	DMI	O	
2	and	O	
3	2	O	
4	-	O	
5	OH	O	
6	-	O	
7	DMI	O	
8	concentrations	O	
9	were	O	
10	determined	O	
11	in	O	
12	a	O	
13	similar	O	
14	group	O	
15	of	O	
16	61	O	
17	DMI	O	
18	-	O	
19	treated	O	
20	patients	O	
21	.	O	

1	None	O	
2	had	O	
3	a	O	
4	past	O	
5	history	O	
6	of	O	
7	opportunistic	O	
8	infections	O	
9	;	O	
10	neither	O	
11	did	O	
12	any	O	
13	have	O	
14	lymphopenia	O	
15	.	O	

1	Platelet	B	
2	-	I	
3	derived	I	
4	growth	I	
5	factor	I	
6	-	O	
7	dependent	O	
8	activation	O	
9	of	O	
10	phosphatidylinositol	B	
11	3	I	
12	-	I	
13	kinase	I	
14	is	O	
15	regulated	O	
16	by	O	
17	receptor	O	
18	binding	O	
19	of	O	
20	SH2	B	
21	-	I	
22	domain	I	
23	-	I	
24	containing	I	
25	proteins	I	
26	which	O	
27	influence	O	
28	Ras	B	
29	activity	O	
30	.	O	

1	Our	O	
2	data	O	
3	show	O	
4	also	O	
5	that	O	
6	phagocytic	O	
7	killing	O	
8	of	O	
9	meningococci	O	
10	is	O	
11	probably	O	
12	a	O	
13	more	O	
14	consistent	O	
15	assay	O	
16	than	O	
17	antibody	O	
18	titer	O	
19	levels	O	
20	for	O	
21	antimeningococcal	O	
22	immunity	O	
23	,	O	
24	especially	O	
25	in	O	
26	LCC	O	
27	-	O	
28	deficient	O	
29	patients	O	
30	.	O	

1	Sustained	O	
2	activation	O	
3	of	O	
4	p21	B	
5	expression	O	
6	is	O	
7	proposed	O	
8	to	O	
9	be	O	
10	a	O	
11	distinguishing	O	
12	feature	O	
13	of	O	
14	the	O	
15	activity	O	
16	of	O	
17	NGF	B	
18	that	O	
19	contributes	O	
20	to	O	
21	PC12	O	
22	growth	O	
23	arrest	O	
24	during	O	
25	differentiation	O	

1	Overexpression	O	
2	of	O	
3	SCS1	B	
4	could	O	
5	not	O	
6	complement	O	
7	an	O	
8	HSP60	B	
9	-	I	
10	null	I	
11	allele	I	
12	,	O	
13	indicating	O	
14	that	O	
15	suppression	O	
16	was	O	
17	not	O	
18	due	O	
19	to	O	
20	the	O	
21	bypassing	O	
22	of	O	
23	Hsp60	B	
24	activity	O	
25	.	O	

1	Human	O	
2	SRF	B	
3	-	I	
4	related	I	
5	proteins	I	
6	:	O	
7	DNA	O	
8	-	O	
9	binding	O	
10	properties	O	
11	and	O	
12	potential	O	
13	regulatory	O	
14	targets	O	
15	.	O	

1	Acute	O	
2	idiopathic	O	
3	thrombocytopenic	O	
4	purpura	O	
5	presenting	O	
6	a	O	
7	high	O	
8	serum	O	
9	level	O	
10	of	O	
11	immunoglobulin	B	
12	E	I	
13	and	O	
14	eosinophilia	O	
15	in	O	
16	an	O	
17	elderly	O	
18	patient	O	
19	.	O	

1	The	O	
2	hepatocyte	B	
3	nuclear	I	
4	factor	I	
5	-	I	
6	3	I	
7	(	O	
8	HNF	B	
9	-	I	
10	3	I	
11	)/	O	
12	forkhead	B	
13	(	O	
14	fkh	B	
15	)	O	
16	proteins	O	
17	consist	O	
18	of	O	
19	an	O	
20	extensive	O	
21	family	O	
22	of	O	
23	tissue	O	
24	-	O	
25	specific	O	
26	and	O	
27	developmental	O	
28	gene	O	
29	regulators	O	
30	which	O	
31	share	O	
32	homology	O	
33	within	O	
34	the	O	
35	winged	O	
36	helix	O	
37	DNA	O	
38	binding	O	
39	motif	O	
40	.	O	

1	Diagnosis	O	
2	of	O	
3	prostatic	O	
4	carcinoma	O	
5	:	O	
6	the	O	
7	yield	O	
8	of	O	
9	serum	B	
10	prostate	I	
11	specific	I	
12	antigen	I	
13	,	O	
14	digital	O	
15	rectal	O	
16	examination	O	
17	and	O	
18	transrectal	O	
19	ultrasonography	O	
20	.	O	

1	In	O	
2	Arabidopsis	O	
3	,	O	
4	the	O	
5	induction	O	
6	of	O	
7	a	O	
8	dehydration	O	
9	-	O	
10	responsive	O	
11	gene	O	
12	,	O	
13	rd22	B	
14	,	O	
15	is	O	
16	mediated	O	
17	by	O	
18	abscisic	O	
19	acid	O	
20	(	O	
21	ABA	O	
22	)	O	
23	and	O	
24	requires	O	
25	protein	O	
26	biosynthesis	O	
27	for	O	
28	ABA	O	
29	-	O	
30	dependent	O	
31	gene	O	
32	expression	O	
33	.	O	

1	The	O	
2	HMG	B	
3	CoA	I	
4	reductase	I	
5	inhibitors	O	
6	are	O	
7	the	O	
8	most	O	
9	effective	O	
10	cholesterol	O	
11	-	O	
12	lowering	O	
13	agents	O	
14	currently	O	
15	available	O	
16	.	O	

1	In	O	
2	7	O	
3	of	O	
4	9	O	
5	cases	O	
6	,	O	
7	the	O	
8	enhancer	O	
9	is	O	
10	fused	O	
11	to	O	
12	the	O	
13	c	B	
14	-	I	
15	myc	I	
16	bearing	I	
17	sequences	I	
18	of	O	
19	chromosome	O	
20	8	O	
21	.	O	

1	Urological	O	
2	complications	O	
3	are	O	
4	frequent	O	
5	during	O	
6	and	O	
7	after	O	
8	the	O	
9	treatment	O	
10	of	O	
11	gynecological	O	
12	malignancy	O	
13	.	O	

1	A	O	
2	yeast	O	
3	DNA	O	
4	fragment	O	
5	carrying	O	
6	the	O	
7	gene	B	
8	CP	I	
9	A1	I	
10	encoding	O	
11	the	O	
12	small	O	
13	subunit	O	
14	of	O	
15	the	O	
16	arginine	O	
17	pathway	O	
18	carbamoyl	B	
19	-	I	
20	phosphate	I	
21	synthetase	I	
22	has	O	
23	been	O	
24	sequenced	O	
25	.	O	

1	The	O	
2	Escherichia	B	
3	coli	I	
4	tet	I	
5	-	I	
6	repressor	I	
7	(	O	
8	TetR	B	
9	)	O	
10	operator	O	
11	system	O	
12	was	O	
13	used	O	
14	to	O	
15	develop	O	
16	a	O	
17	variation	O	
18	of	O	
19	the	O	
20	yeast	O	
21	two	O	
22	-	O	
23	hybrid	O	
24	assay	O	
25	in	O	
26	which	O	
27	disruptions	O	
28	of	O	
29	protein	O	
30	-	O	
31	protein	O	
32	interactions	O	
33	can	O	
34	be	O	
35	identified	O	
36	by	O	
37	a	O	
38	positive	O	
39	selection	O	
40	.	O	

1	Perfusion	O	
2	washout	O	
3	:	O	
4	increasing	O	
5	a	O	
6	microvascular	O	
7	free	O	
8	flap	O	
9	tolerance	O	
10	to	O	
11	ischemia	O	
12	.	O	

1	Examination	O	
2	of	O	
3	the	O	
4	mitochondrial	B	
5	bc1	I	
6	complex	I	
7	crystal	I	
8	structure	I	
9	[	O	
10	Zhang	O	
11	,	O	
12	Z	O	
13	.,	O	
14	Huang	O	
15	,	O	
16	L	O	
17	.,	O	
18	Shulmeister	O	
19	,	O	
20	V	O	
21	.	O	

1	Genetic	O	
2	and	O	
3	biochemical	O	
4	evidence	O	
5	suggests	O	
6	that	O	
7	v	B	
8	-	I	
9	Crk	I	
10	can	O	
11	induce	O	
12	transformation	O	
13	of	O	
14	chicken	O	
15	embryo	O	
16	fibroblasts	O	
17	by	O	
18	influencing	O	
19	the	O	
20	activity	O	
21	of	O	
22	cellular	O	
23	proteins	O	
24	involved	O	
25	in	O	
26	growth	O	
27	regulation	O	
28	.	O	

1	The	O	
2	Prolactin	B	
3	levels	O	
4	were	O	
5	within	O	
6	the	O	
7	physiological	O	
8	norms	O	
9	;	O	
10	the	O	
11	responses	O	
12	to	O	
13	TRH	B	
14	were	O	
15	normal	O	
16	,	O	
17	and	O	
18	elevated	O	
19	only	O	
20	in	O	
21	a	O	
22	few	O	
23	cases	O	
24	.	O	

1	The	O	
2	synthetic	O	
3	DNA	O	
4	sequence	O	
5	was	O	
6	constructed	O	
7	to	O	
8	achieve	O	
9	efficient	O	
10	base	O	
11	pairing	O	
12	with	O	
13	Escherichia	B	
14	coli	I	
15	16S	I	
16	ribosomal	I	
17	RNA	I	
18	,	O	
19	avoidance	O	
20	of	O	
21	internal	O	
22	secondary	O	
23	structure	O	
24	,	O	
25	and	O	
26	optimal	O	
27	codon	O	
28	usage	O	
29	for	O	
30	high	O	
31	-	O	
32	level	O	
33	protein	O	
34	expression	O	
35	in	O	
36	accord	O	
37	with	O	
38	the	O	
39	known	O	
40	preferences	O	
41	in	O	
42	E	O	
43	.	O	
44	coli	O	
45	.	O	

1	This	O	
2	distribution	O	
3	parallels	O	
4	that	O	
5	of	O	
6	the	O	
7	neurotransmitters	O	
8	glutamate	O	
9	and	O	
10	aspartate	O	
11	;	O	
12	however	O	
13	,	O	
14	neither	O	
15	of	O	
16	these	O	
17	excitatory	O	
18	amino	O	
19	acids	O	
20	is	O	
21	a	O	
22	substrate	O	
23	for	O	
24	transport	O	
25	.	O	

1	This	O	
2	loss	O	
3	was	O	
4	independent	O	
5	of	O	
6	drug	O	
7	concentration	O	
8	and	O	
9	a	O	
10	correction	O	
11	factor	O	
12	was	O	
13	employed	O	
14	to	O	
15	calculate	O	
16	the	O	
17	true	O	
18	free	O	
19	diazepam	O	
20	concentration	O	
21	.	O	

1	Simple	O	
2	reaction	O	
3	time	O	
4	(	O	
5	RT	O	
6	)	O	
7	to	O	
8	a	O	
9	peripheral	O	
10	visual	O	
11	target	O	
12	(	O	
13	S2	O	
14	)	O	
15	is	O	
16	shortened	O	
17	when	O	
18	a	O	
19	non	O	
20	-	O	
21	informative	O	
22	cue	O	
23	(	O	
24	S1	O	
25	)	O	
26	is	O	
27	flashed	O	
28	at	O	
29	the	O	
30	S2	O	
31	location	O	
32	100	O	
33	-	O	
34	150	O	
35	ms	O	
36	before	O	
37	target	O	
38	onset	O	
39	(	O	
40	early	O	
41	facilitation	O	
42	).	O	

1	Qualitatively	O	
2	,	O	
3	the	O	
4	results	O	
5	are	O	
6	similar	O	
7	for	O	
8	the	O	
9	two	O	
10	species	O	
11	:	O	
12	Both	O	
13	rhesus	O	
14	monkey	O	
15	and	O	
16	man	O	
17	have	O	
18	photopic	O	
19	and	O	
20	scotopic	O	
21	branches	O	
22	,	O	
23	which	O	
24	cross	O	
25	at	O	
26	approximately	O	
27	the	O	
28	same	O	
29	time	O	
30	in	O	
31	the	O	
32	dark	O	
33	and	O	
34	at	O	
35	approximately	O	
36	the	O	
37	same	O	
38	background	O	
39	luminance	O	
40	.	O	

1	The	O	
2	5	O	
3	'	O	
4	region	O	
5	of	O	
6	ADH5	B	
7	contains	O	
8	consensus	O	
9	binding	O	
10	sites	O	
11	for	O	
12	the	O	
13	transcriptional	O	
14	regulatory	O	
15	proteins	O	
16	,	O	
17	Sp1	B	
18	,	O	
19	AP2	B	
20	,	O	
21	LF	B	
22	-	I	
23	A1	I	
24	,	O	
25	NF	B	
26	-	I	
27	1	I	
28	,	O	
29	NF	B	
30	-	I	
31	A2	I	
32	,	O	
33	and	O	
34	NF	B	
35	-	I	
36	E1	I	
37	.	O	

1	BACKGROUND	O	
2	:	O	
3	Fluoroquinolones	O	
4	(	O	
5	FQ	O	
6	)	O	
7	are	O	
8	contraindicated	O	
9	in	O	
10	children	O	
11	because	O	
12	of	O	
13	the	O	
14	risk	O	
15	of	O	
16	cartilage	O	
17	damage	O	
18	.	O	

1	In	O	
2	view	O	
3	of	O	
4	these	O	
5	results	O	
6	,	O	
7	simultaneous	O	
8	pancreas	O	
9	-	O	
10	kidney	O	
11	transplantation	O	
12	appears	O	
13	to	O	
14	be	O	
15	the	O	
16	treatment	O	
17	of	O	
18	choice	O	
19	for	O	
20	Type	O	
21	I	O	
22	diabetic	O	
23	patients	O	
24	.	O	

1	Both	O	
2	mutations	O	
3	confer	O	
4	amino	O	
5	acid	O	
6	substitutions	O	
7	in	O	
8	the	O	
9	viral	B	
10	coat	I	
11	protein	I	
12	but	O	
13	differ	O	
14	in	O	
15	their	O	
16	relative	O	
17	abilities	O	
18	to	O	
19	utilize	O	
20	the	O	
21	foreign	O	
22	scaffolding	B	
23	protein	I	
24	.	O	

1	In	O	
2	transient	O	
3	assays	O	
4	,	O	
5	using	O	
6	rice	O	
7	suspension	O	
8	-	O	
9	cultured	O	
10	cells	O	
11	transformed	O	
12	by	O	
13	particle	O	
14	bombardment	O	
15	,	O	
16	we	O	
17	showed	O	
18	previously	O	
19	that	O	
20	Oshox1	B	
21	can	O	
22	transcriptionally	O	
23	repress	O	
24	the	O	
25	activity	O	
26	of	O	
27	reporter	O	
28	gene	O	
29	constructs	O	
30	with	O	
31	upstream	O	
32	HD	B	
33	-	I	
34	Zip	I	
35	binding	O	
36	sites	O	
37	.	O	

1	The	O	
2	mechanism	O	
3	involves	O	
4	Gbetagamma	B	
5	subunit	O	
6	-	O	
7	mediated	O	
8	increases	O	
9	in	O	
10	tyrosine	O	
11	phosphorylation	O	
12	of	O	
13	the	O	
14	Shc	B	
15	adapter	I	
16	protein	I	
17	,	O	
18	Shc	B	
19	*	O	
20	Grb2	B	
21	complex	O	
22	formation	O	
23	,	O	
24	and	O	
25	recruitment	O	
26	of	O	
27	Ras	B	
28	guanine	I	
29	nucleotide	I	
30	exchange	I	
31	factor	I	
32	activity	O	
33	.	O	

1	Derepression	O	
2	of	O	
3	gene	O	
4	expression	O	
5	mediated	O	
6	by	O	
7	the	O	
8	5	O	
9	'	O	
10	upstream	O	
11	region	O	
12	of	O	
13	the	O	
14	isocitrate	B	
15	lyase	I	
16	gene	I	
17	of	I	
18	Candida	I	
19	tropicalis	I	
20	is	O	
21	controlled	O	
22	by	O	
23	two	O	
24	distinct	O	
25	regulatory	O	
26	pathways	O	
27	in	O	
28	Saccharomyces	O	
29	cerevisiae	O	
30	.	O	

1	The	O	
2	concept	O	
3	of	O	
4	"	O	
5	structural	O	
6	identifiability	O	
7	"	O	
8	is	O	
9	employed	O	
10	in	O	
11	this	O	
12	analysis	O	
13	to	O	
14	determine	O	
15	which	O	
16	model	O	
17	parameters	O	
18	can	O	
19	be	O	
20	and	O	
21	which	O	
22	cannot	O	
23	be	O	
24	determined	O	
25	"	O	
26	uniquely	O	
27	"	O	
28	from	O	
29	given	O	
30	input	O	
31	-	O	
32	output	O	
33	data	O	
34	;	O	
35	a	O	
36	step	O	
37	-	O	
38	by	O	
39	-	O	
40	step	O	
41	procedure	O	
42	based	O	
43	on	O	
44	an	O	
45	extension	O	
46	of	O	
47	this	O	
48	concept	O	
49	is	O	
50	presented	O	
51	for	O	
52	adapting	O	
53	the	O	
54	overall	O	
55	approach	O	
56	to	O	
57	the	O	
58	experimental	O	
59	design	O	
60	problem	O	
61	.	O	

1	For	O	
2	the	O	
3	first	O	
4	time	O	
5	we	O	
6	describe	O	
7	deletion	O	
8	and	O	
9	point	O	
10	mutations	O	
11	within	O	
12	the	O	
13	plasma	B	
14	membrane	I	
15	family	I	
16	of	I	
17	guanylyl	I	
18	cyclase	I	
19	receptors	I	
20	that	O	
21	result	O	
22	in	O	
23	the	O	
24	formation	O	
25	of	O	
26	effective	O	
27	dominant	O	
28	negative	O	
29	proteins	O	
30	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	a	O	
5	Maf	B	
6	-	I	
7	related	I	
8	protein	I	
9	,	O	
10	Nrl	B	
11	,	O	
12	completely	O	
13	mimicked	O	
14	c	B	
15	-	I	
16	Maf	I	
17	actions	O	
18	.	O	

1	Coenzyme	O	
2	Q10	O	
3	:	O	
4	blood	O	
5	levels	O	
6	and	O	
7	metabolic	O	
8	demand	O	
9	.	O	

1	I	O	
2	.	O	

1	Thus	O	
2	,	O	
3	we	O	
4	have	O	
5	identified	O	
6	an	O	
7	activation	O	
8	target	O	
9	of	O	
10	a	O	
11	human	O	
12	activator	O	
13	,	O	
14	Oct	B	
15	-	I	
16	1	I	
17	,	O	
18	within	O	
19	its	O	
20	cognate	O	
21	basal	O	
22	transcription	O	
23	complex	O	
24	.	O	

1	Serum	O	
2	leptin	B	
3	concentrations	O	
4	in	O	
5	women	O	
6	during	O	
7	gonadotropin	B	
8	stimulation	O	
9	cycles	O	
10	.	O	

1	The	O	
2	promoter	O	
3	was	O	
4	stimulated	O	
5	8	O	
6	-	O	
7	20	O	
8	-	O	
9	fold	O	
10	by	O	
11	phorbol	O	
12	esters	O	
13	accounting	O	
14	for	O	
15	the	O	
16	previously	O	
17	observed	O	
18	transcriptional	O	
19	activation	O	
20	of	O	
21	protein	B	
22	kinase	I	
23	C	I	
24	beta	I	
25	.	O	

1	Gene	O	
2	constructs	O	
3	possessing	O	
4	the	O	
5	complete	B	
6	tat	I	
7	,	O	
8	rev	B	
9	(	O	
10	tat	B	
11	+	I	
12	rev	O	
13	+)	O	
14	and	O	
15	env	B	
16	genes	I	
17	were	O	
18	transiently	O	
19	expressed	O	
20	in	O	
21	COS	O	
22	-	O	
23	1	O	
24	cells	O	
25	as	O	
26	precursor	B	
27	SU	I	
28	-	I	
29	TM	I	
30	(	O	
31	gp160	B	
32	),	O	
33	SU	B	
34	.	I	
35	TM	I	
36	(	O	
37	gp120	B	
38	x	I	
39	41	I	
40	),	O	
41	and	O	
42	nucleolar	B	
43	rev	I	
44	protein	I	
45	.	O	

1	Cytoprotection	O	
2	with	O	
3	amifostine	O	
4	in	O	
5	radiotherapy	O	
6	or	O	
7	radio	O	
8	-	O	
9	chemotherapy	O	
10	of	O	
11	head	O	
12	and	O	
13	neck	O	
14	tumors	O	

1	MEASUREMENTS	O	
2	AND	O	
3	MAIN	O	
4	RESULTS	O	
5	:	O	
6	Lung	O	
7	elastance	O	
8	(	O	
9	EL	O	
10	)	O	
11	and	O	
12	resistance	O	
13	(	O	
14	RL	O	
15	)	O	
16	were	O	
17	calculated	O	
18	from	O	
19	measurements	O	
20	of	O	
21	airway	O	
22	pressure	O	
23	,	O	
24	esophageal	O	
25	pressure	O	
26	,	O	
27	and	O	
28	airway	O	
29	flow	O	
30	in	O	
31	five	O	
32	anesthetized	O	
33	,	O	
34	paralyzed	O	
35	dogs	O	
36	during	O	
37	sinusoidal	O	
38	forcing	O	
39	at	O	
40	a	O	
41	constant	O	
42	mean	O	
43	airway	O	
44	pressure	O	
45	of	O	
46	10	O	
47	cmH2O	O	
48	in	O	
49	a	O	
50	wide	O	
51	range	O	
52	of	O	
53	breathing	O	
54	frequencies	O	
55	(	O	
56	0	O	
57	.	O	
58	2	O	
59	to	O	
60	1	O	
61	.	O	
62	0	O	
63	Hz	O	
64	in	O	
65	intervals	O	
66	of	O	
67	0	O	
68	.	O	
69	2	O	
70	)	O	
71	and	O	
72	tidal	O	
73	volumes	O	
74	(	O	
75	50	O	
76	,	O	
77	100	O	
78	,	O	
79	200	O	
80	,	O	
81	and	O	
82	to	O	
83	300	O	
84	mL	O	
85	).	O	

1	Human	B	
2	PDK1	I	
3	is	O	
4	homologous	O	
5	to	O	
6	the	O	
7	Drosophila	B	
8	protein	I	
9	kinase	I	
10	DSTPK61	I	
11	,	O	
12	which	O	
13	has	O	
14	been	O	
15	implicated	O	
16	in	O	
17	the	O	
18	regulation	O	
19	of	O	
20	sex	O	
21	differentiation	O	
22	,	O	
23	oogenesis	O	
24	and	O	
25	spermatogenesis	O	
26	.	O	

1	Ruddell	O	
2	,	O	
3	M	O	
4	.	O	

1	In	O	
2	2	O	
3	subjects	O	
4	the	O	
5	phytomitogen	O	
6	reactivity	O	
7	of	O	
8	the	O	
9	lymphocytes	O	
10	was	O	
11	improved	O	
12	after	O	
13	treatment	O	
14	.	O	

1	In	O	
2	agreement	O	
3	with	O	
4	these	O	
5	data	O	
6	,	O	
7	western	O	
8	blot	O	
9	experiments	O	
10	using	O	
11	an	O	
12	antibody	O	
13	directed	O	
14	against	O	
15	the	O	
16	carboxy	O	
17	-	O	
18	terminal	O	
19	portion	O	
20	of	O	
21	the	O	
22	mouse	O	
23	c	B	
24	-	I	
25	kit	I	
26	protein	I	
27	showed	O	
28	that	O	
29	a	O	
30	polypeptide	O	
31	,	O	
32	of	O	
33	the	O	
34	size	O	
35	predicted	O	
36	by	O	
37	the	O	
38	open	O	
39	reading	O	
40	frame	O	
41	of	O	
42	the	O	
43	spermatid	B	
44	-	I	
45	specific	I	
46	c	I	
47	-	I	
48	kit	I	
49	cDNA	I	
50	,	O	
51	accumulates	O	
52	in	O	
53	the	O	
54	latest	O	
55	stages	O	
56	of	O	
57	spermatogenesis	O	
58	and	O	
59	in	O	
60	epididymal	O	
61	spermatozoa	O	
62	.	O	

1	The	O	
2	monoclonal	O	
3	immunoglobulin	B	
4	products	O	
5	of	O	
6	plasma	O	
7	cell	O	
8	neoplasm	O	
9	can	O	
10	give	O	
11	rise	O	
12	to	O	
13	a	O	
14	variety	O	
15	of	O	
16	manifestations	O	
17	including	O	
18	hyperviscosity	O	
19	,	O	
20	amyloidosis	O	
21	,	O	
22	cryoglobulinemia	O	
23	,	O	
24	neuropathy	O	
25	,	O	
26	and	O	
27	renal	O	
28	failure	O	
29	.	O	

1	The	O	
2	N	O	
3	-	O	
4	terminal	O	
5	small	O	
6	segment	O	
7	of	O	
8	yeast	B	
9	TAF145	I	
10	(	O	
11	yTAF145	B	
12	)	O	
13	binds	O	
14	to	O	
15	TBP	B	
16	and	O	
17	thereby	O	
18	inhibits	O	
19	TBP	B	
20	function	O	
21	.	O	

1	We	O	
2	were	O	
3	able	O	
4	to	O	
5	detect	O	
6	significant	O	
7	differences	O	
8	in	O	
9	functional	O	
10	residual	O	
11	capacity	O	
12	adjusted	O	
13	for	O	
14	weight	O	
15	or	O	
16	height	O	
17	,	O	
18	and	O	
19	compliance	O	
20	of	O	
21	the	O	
22	respiratory	O	
23	system	O	
24	adjusted	O	
25	for	O	
26	weight	O	
27	or	O	
28	lung	O	
29	volume	O	
30	in	O	
31	the	O	
32	ILD	O	
33	infants	O	
34	compared	O	
35	to	O	
36	the	O	
37	healthy	O	
38	controls	O	
39	or	O	
40	infants	O	
41	who	O	
42	had	O	
43	PPHN	O	
44	,	O	
45	indicating	O	
46	that	O	
47	these	O	
48	PFTs	O	
49	were	O	
50	sensitive	O	
51	enough	O	
52	to	O	
53	determine	O	
54	abnormal	O	
55	lung	O	
56	function	O	
57	in	O	
58	this	O	
59	age	O	
60	group	O	
61	.	O	

1	This	O	
2	study	O	
3	was	O	
4	undertaken	O	
5	to	O	
6	evaluate	O	
7	how	O	
8	couplers	O	
9	and	O	
10	their	O	
11	placement	O	
12	affect	O	
13	the	O	
14	ALGO2	O	
15	click	O	
16	spectral	O	
17	properties	O	
18	.	O	

1	Dominant	O	
2	negative	O	
3	Sos	B	
4	did	O	
5	not	O	
6	affect	O	
7	carbachol	O	
8	stimulation	O	
9	of	O	
10	HA	B	
11	-	O	
12	ERK2	B	
13	but	O	
14	inhibited	O	
15	the	O	
16	stimulatory	O	
17	effect	O	
18	of	O	
19	EGF	B	
20	by	O	
21	60	O	
22	%.	O	

1	A	O	
2	2	O	
3	.	O	
4	3	O	
5	-	O	
6	kb	O	
7	full	O	
8	-	O	
9	length	O	
10	cDNA	O	
11	clone	O	
12	of	O	
13	an	O	
14	Atlantic	B	
15	halibut	I	
16	Mx	I	
17	gene	I	
18	was	O	
19	isolated	O	
20	from	O	
21	a	O	
22	liver	O	
23	cDNA	O	
24	library	O	
25	.	O	

1	HBB	O	
2	concentration	O	
3	in	O	
4	the	O	
5	fetuses	O	
6	indicated	O	
7	little	O	
8	,	O	
9	if	O	
10	any	O	
11	accumulation	O	
12	.	O	

1	These	O	
2	regions	O	
3	overlap	O	
4	with	O	
5	the	O	
6	HIT	B	
7	protein	I	
8	similarity	I	
9	regions	I	
10	.	O	

1	Our	O	
2	results	O	
3	show	O	
4	that	O	
5	the	O	
6	temperature	B	
7	-	I	
8	sensitive	I	
9	rad54	I	
10	-	I	
11	3	I	
12	allele	I	
13	blocks	O	
14	mitotic	O	
15	recombination	O	
16	between	O	
17	tandemly	O	
18	repeated	O	
19	DYZ3	B	
20	satellite	I	
21	sequences	I	
22	and	O	
23	significantly	O	
24	stabilizes	O	
25	a	O	
26	human	B	
27	DYZ5	I	
28	satellite	O	
29	-	O	
30	containing	O	
31	YAC	O	
32	clone	O	
33	.	O	

1	We	O	
2	detected	O	
3	no	O	
4	effect	O	
5	of	O	
6	deleting	O	
7	YCL024W	B	
8	,	O	
9	either	O	
10	alone	O	
11	or	O	
12	in	O	
13	combination	O	
14	with	O	
15	deletion	O	
16	of	O	
17	GIN4	B	
18	.	O	

1	The	O	
2	study	O	
3	made	O	
4	to	O	
5	define	O	
6	the	O	
7	ability	O	
8	of	O	
9	lipid	B	
10	A	I	
11	monoclonal	I	
12	antibodies	I	
13	to	O	
14	correct	O	
15	hemodynamic	O	
16	disturbances	O	
17	due	O	
18	to	O	
19	endotoxemia	O	
20	in	O	
21	dog	O	
22	experiments	O	
23	showed	O	
24	the	O	
25	efficacy	O	
26	of	O	
27	the	O	
28	antibodies	O	
29	administration	O	
30	.	O	

1	Hence	O	
2	,	O	
3	scs32	B	
4	only	O	
5	partially	O	
6	suppressed	O	
7	the	O	
8	ts	O	
9	phenotype	O	
10	and	O	
11	was	O	
12	unable	O	
13	to	O	
14	suppress	O	
15	the	O	
16	Ino	O	
17	-	O	
18	phenotype	O	
19	of	O	
20	rpo26	B	
21	-	I	
22	31	I	
23	.	O	

1	BACKGROUND	O	
2	:	O	
3	Checkpoint	O	
4	pathways	O	
5	prevent	O	
6	cell	O	
7	-	O	
8	cycle	O	
9	progression	O	
10	in	O	
11	the	O	
12	event	O	
13	of	O	
14	DNA	O	
15	lesions	O	
16	.	O	

1	The	O	
2	distribution	O	
3	phase	O	
4	is	O	
5	followed	O	
6	by	O	
7	an	O	
8	elimination	O	
9	phase	O	
10	with	O	
11	a	O	
12	much	O	
13	longer	O	
14	half	O	
15	-	O	
16	life	O	
17	(	O	
18	mean	O	
19	value	O	
20	375	O	
21	min	O	
22	)	O	
23	and	O	
24	a	O	
25	volume	O	
26	of	O	
27	distribution	O	
28	of	O	
29	approximately	O	
30	200	O	
31	-	O	
32	400	O	
33	l	O	
34	.	O	

1	We	O	
2	here	O	
3	demonstrate	O	
4	that	O	
5	a	O	
6	temperature	O	
7	-	O	
8	sensitive	O	
9	fission	O	
10	yeast	O	
11	mutant	O	
12	which	O	
13	has	O	
14	a	O	
15	mutation	O	
16	in	O	
17	a	O	
18	homologous	O	
19	gene	O	
20	,	O	
21	and	O	
22	two	O	
23	of	O	
24	three	O	
25	additional	O	
26	(	O	
27	mtr1	B	
28	/	O	
29	prp20	B	
30	/	O	
31	srm1	B	
32	)	O	
33	mutants	O	
34	accumulate	O	
35	nuclear	O	
36	poly	O	
37	(	O	
38	A	O	
39	)+	O	
40	RNA	O	
41	at	O	
42	37	O	
43	degrees	O	
44	C	O	
45	.	O	

1	The	O	
2	5	O	
3	-	O	
4	year	O	
5	OS	O	
6	for	O	
7	stage	O	
8	IIIB	O	
9	was	O	
10	30	O	
11	.	O	
12	9	O	
13	%,	O	
14	compared	O	
15	to	O	
16	7	O	
17	.	O	
18	8	O	
19	%	O	
20	for	O	
21	stage	O	
22	IV	O	
23	.	O	

1	The	O	
2	SEB1	B	
3	homologue	O	
4	thus	O	
5	isolated	O	
6	,	O	
7	SEB2	B	
8	,	O	
9	encodes	O	
10	a	O	
11	protein	O	
12	53	O	
13	%	O	
14	identical	O	
15	to	O	
16	Seb1p	B	
17	.	O	

1	A	O	
2	single	O	
3	rectal	O	
4	dose	O	
5	of	O	
6	25	O	
7	mg	O	
8	/	O	
9	kg	O	
10	will	O	
11	obtain	O	
12	this	O	
13	lower	O	
14	concentration	O	
15	within	O	
16	1	O	
17	h	O	
18	of	O	
19	administration	O	
20	and	O	
21	maintain	O	
22	it	O	
23	for	O	
24	up	O	
25	to	O	
26	6	O	
27	h	O	
28	.	O	

1	Here	O	
2	,	O	
3	we	O	
4	show	O	
5	that	O	
6	aortic	O	
7	explants	O	
8	isolated	O	
9	from	O	
10	PPARalpha	B	
11	-	O	
12	null	O	
13	mice	O	
14	display	O	
15	an	O	
16	exacerbated	O	
17	response	O	
18	to	O	
19	inflammatory	O	
20	stimuli	O	
21	,	O	
22	such	O	
23	as	O	
24	lipopolysaccharide	O	
25	(	O	
26	LPS	O	
27	),	O	
28	as	O	
29	demonstrated	O	
30	by	O	
31	increased	O	
32	IL	B	
33	-	I	
34	6	I	
35	secretion	O	
36	.	O	

1	BCL	B	
2	-	I	
3	2	I	
4	,	O	
5	an	O	
6	inhibitor	O	
7	of	O	
8	apoptosis	O	
9	in	O	
10	a	O	
11	wide	O	
12	variety	O	
13	of	O	
14	cell	O	
15	types	O	
16	,	O	
17	has	O	
18	been	O	
19	reported	O	
20	to	O	
21	prevent	O	
22	oxidative	O	
23	stress	O	
24	-	O	
25	induced	O	
26	cell	O	
27	death	O	
28	.	O	

1	Different	O	
2	cortical	O	
3	malformations	O	
4	were	O	
5	produced	O	
6	in	O	
7	rats	O	
8	by	O	
9	a	O	
10	single	O	
11	dose	O	
12	of	O	
13	X	O	
14	-	O	
15	rays	O	
16	(	O	
17	200	O	
18	cGy	O	
19	)	O	
20	given	O	
21	on	O	
22	different	O	
23	days	O	
24	during	O	
25	gestation	O	
26	.	O	

1	The	O	
2	feed	O	
3	consumed	O	
4	which	O	
5	was	O	
6	lowered	O	
7	by	O	
8	25	O	
9	%	O	
10	initially	O	
11	,	O	
12	did	O	
13	not	O	
14	alter	O	
15	later	O	
16	.	O	

1	Retinoblastoma	O	
2	:	O	
3	a	O	
4	study	O	
5	of	O	
6	natural	O	
7	history	O	
8	and	O	
9	prognosis	O	
10	of	O	
11	268	O	
12	cases	O	
13	.	O	

1	Groups	O	
2	of	O	
3	male	O	
4	and	O	
5	female	O	
6	Fischer	O	
7	344	O	
8	rats	O	
9	,	O	
10	B6C3F1	O	
11	mice	O	
12	,	O	
13	and	O	
14	Hartley	O	
15	guinea	O	
16	pigs	O	
17	were	O	
18	exposed	O	
19	once	O	
20	for	O	
21	6	O	
22	hr	O	
23	to	O	
24	mean	O	
25	concentrations	O	
26	of	O	
27	10	O	
28	.	O	
29	5	O	
30	,	O	
31	5	O	
32	.	O	
33	4	O	
34	,	O	
35	2	O	
36	.	O	
37	4	O	
38	,	O	
39	1	O	
40	.	O	
41	0	O	
42	,	O	
43	or	O	
44	0	O	
45	(	O	
46	control	O	
47	)	O	
48	ppm	O	
49	of	O	
50	methyl	O	
51	isocyanate	O	
52	(	O	
53	MIC	O	
54	)	O	
55	vapor	O	
56	.	O	

1	Investigated	O	
2	the	O	
3	reliability	O	
4	,	O	
5	validity	O	
6	and	O	
7	dimensionality	O	
8	of	O	
9	scores	O	
10	obtained	O	
11	by	O	
12	acute	O	
13	psychiatric	O	
14	inpatients	O	
15	(	O	
16	N	O	
17	=	O	
18	120	O	
19	)	O	
20	on	O	
21	the	O	
22	Michigan	O	
23	Alcoholism	O	
24	Screening	O	
25	Test	O	
26	adapted	O	
27	to	O	
28	assess	O	
29	lifetime	O	
30	and	O	
31	current	O	
32	symptomatology	O	
33	.	O	

1	The	O	
2	corresponding	O	
3	inhibition	O	
4	of	O	
5	acid	B	
6	phosphatase	I	
7	activity	O	
8	in	O	
9	control	O	
10	male	O	
11	and	O	
12	female	O	
13	guinea	O	
14	pigs	O	
15	was	O	
16	15	O	
17	.	O	
18	91	O	
19	%	O	
20	and	O	
21	20	O	
22	.	O	
23	33	O	
24	%	O	
25	respectively	O	
26	.	O	

1	We	O	
2	analyzed	O	
3	the	O	
4	P	O	
5	-	O	
6	SAECG	O	
7	in	O	
8	the	O	
9	time	O	
10	and	O	
11	frequency	O	
12	domain	O	
13	in	O	
14	23	O	
15	patients	O	
16	with	O	
17	Paf	O	
18	and	O	
19	19	O	
20	controls	O	
21	.	O	

1	Max	B	
2	:	O	
3	functional	O	
4	domains	O	
5	and	O	
6	interaction	O	
7	with	O	
8	c	B	
9	-	I	
10	Myc	I	
11	.	O	

1	Taste	O	
2	reactivity	O	
3	tests	O	
4	were	O	
5	used	O	
6	to	O	
7	examine	O	
8	the	O	
9	orofacial	O	
10	responses	O	
11	of	O	
12	alcohol	O	
13	preferring	O	
14	(	O	
15	P	O	
16	)	O	
17	rats	O	
18	and	O	
19	alcohol	O	
20	nonpreferring	O	
21	(	O	
22	NP	O	
23	)	O	
24	rats	O	
25	to	O	
26	the	O	
27	taste	O	
28	of	O	
29	alcohol	O	
30	.	O	

1	Similar	O	
2	observations	O	
3	were	O	
4	made	O	
5	with	O	
6	unilateral	O	
7	pneumothorax	O	
8	of	O	
9	15	O	
10	cmH2O	O	
11	for	O	
12	30	O	
13	min	O	
14	.	O	

1	Letter	O	
2	:	O	
3	Is	O	
4	actinic	O	
5	(	O	
6	solar	O	
7	)	O	
8	damage	O	
9	the	O	
10	provoking	O	
11	cause	O	
12	of	O	
13	'	O	
14	post	O	
15	-	O	
16	inflammatory	O	
17	elastolysis	O	
18	and	O	
19	cutis	O	
20	laxa	O	
21	(	O	
22	PECL	O	
23	)'?	O	

1	At	O	
2	some	O	
3	sites	O	
4	,	O	
5	%	O	
6	T	O	
7	is	O	
8	greatly	O	
9	increased	O	
10	by	O	
11	Cl	O	
12	-	O	
13	concentrations	O	
14	up	O	
15	to	O	
16	1	O	
17	M	O	
18	,	O	
19	while	O	
20	at	O	
21	other	O	
22	sites	O	
23	%	O	
24	T	O	
25	is	O	
26	reduced	O	
27	or	O	
28	unaffected	O	
29	by	O	
30	these	O	
31	conditions	O	
32	.	O	

1	Various	O	
2	transcripts	O	
3	are	O	
4	generated	O	
5	from	O	
6	the	O	
7	VCSA1	B	
8	gene	I	
9	by	O	
10	alternative	O	
11	splicing	O	
12	and	O	
13	poly	O	
14	(	O	
15	A	O	
16	)	O	
17	processing	O	
18	in	O	
19	the	O	
20	rat	O	
21	submandibular	O	
22	gland	O	
23	.	O	

1	Stimulation	O	
2	of	O	
3	[	O	
4	3H	O	
5	]	O	
6	PA	O	
7	production	O	
8	upon	O	
9	CD3	B	
10	cross	O	
11	-	O	
12	linking	O	
13	was	O	
14	77	O	
15	%	O	
16	lower	O	
17	in	O	
18	permeabilized	O	
19	CD45	B	
20	-	I	
21	cells	O	
22	than	O	
23	in	O	
24	CD45	B	
25	+	I	
26	cells	O	
27	,	O	
28	consistent	O	
29	with	O	
30	the	O	
31	reduced	O	
32	activity	O	
33	of	O	
34	p59fyn	B	
35	in	O	
36	CD45	B	
37	-	I	
38	cells	O	
39	.	O	

1	In	O	
2	two	O	
3	-	O	
4	field	O	
5	nodal	O	
6	dissection	O	
7	,	O	
8	two	O	
9	components	O	
10	are	O	
11	included	O	
12	with	O	
13	(	O	
14	modern	O	
15	two	O	
16	-	O	
17	field	O	
18	)	O	
19	or	O	
20	without	O	
21	(	O	
22	traditional	O	
23	two	O	
24	-	O	
25	field	O	
26	)	O	
27	nodal	O	
28	dissection	O	
29	around	O	
30	both	O	
31	recurrent	O	
32	laryngeal	O	
33	nerve	O	
34	chains	O	
35	in	O	
36	the	O	
37	upper	O	
38	mediastinum	O	
39	.	O	

1	Range	O	
2	,	O	
3	variations	O	
4	and	O	
5	neoplastic	O	
6	potential	O	
7	.	O	

1	The	O	
2	induction	O	
3	of	O	
4	seizures	O	
5	in	O	
6	"	O	
7	Papio	O	
8	papio	O	
9	"	O	
10	following	O	
11	allylglycine	O	
12	alone	O	
13	or	O	
14	in	O	
15	combination	O	
16	with	O	
17	intermittent	O	
18	photic	O	
19	stimulation	O	

1	Structure	O	
2	and	O	
3	localization	O	
4	of	O	
5	the	O	
6	human	O	
7	gene	O	
8	encoding	O	
9	SR	B	
10	-	I	
11	BI	I	
12	/	O	
13	CLA	B	
14	-	I	
15	1	I	
16	.	O	

1	This	O	
2	action	O	
3	is	O	
4	dependent	O	
5	on	O	
6	helix	B	
7	-	I	
8	loop	I	
9	-	I	
10	helix	I	
11	factors	I	
12	bound	O	
13	to	O	
14	the	O	
15	E1	B	
16	element	O	
17	.	O	

1	Blocked	O	
2	shift	O	
3	/	O	
4	supershift	O	
5	analysis	O	
6	indicates	O	
7	that	O	
8	Fos	B	
9	family	I	
10	member	O	
11	proteins	O	
12	especially	O	
13	Fra	B	
14	-	I	
15	1	I	
16	and	O	
17	Fra	B	
18	-	I	
19	2	I	
20	are	O	
21	related	O	
22	to	O	
23	progression	O	
24	and	O	
25	no	O	
26	changes	O	
27	found	O	
28	in	O	
29	the	O	
30	Jun	B	
31	family	I	
32	member	O	
33	proteins	O	
34	although	O	
35	they	O	
36	are	O	
37	present	O	
38	in	O	
39	the	O	
40	AP	B	
41	-	I	
42	1	I	
43	/	I	
44	DNA	I	
45	binding	I	
46	complex	I	
47	.	O	

1	We	O	
2	demonstrate	O	
3	that	O	
4	a	O	
5	VT	O	
6	+	O	
7	peptide	O	
8	was	O	
9	specifically	O	
10	phosphorylated	O	
11	by	O	
12	protein	B	
13	kinase	I	
14	C	I	
15	(	O	
16	PKC	B	
17	)	O	
18	in	O	
19	vitro	O	
20	,	O	
21	but	O	
22	not	O	
23	by	O	
24	protein	B	
25	kinase	I	
26	A	I	
27	(	O	
28	PKA	B	
29	).	O	

1	A	O	
2	thermal	O	
3	Kubo	O	
4	-	O	
5	Martin	O	
6	-	O	
7	Schwinger	O	
8	condition	O	
9	arises	O	
10	due	O	
11	to	O	
12	the	O	
13	coupling	O	
14	of	O	
15	a	O	
16	computer	O	
17	to	O	
18	a	O	
19	strong	O	
20	periodic	O	
21	source	O	
22	,	O	
23	namely	O	
24	,	O	
25	the	O	
26	daily	O	
27	and	O	
28	weekly	O	
29	usage	O	
30	patterns	O	
31	of	O	
32	the	O	
33	system	O	
34	.	O	

1	BCL6	B	
2	encodes	O	
3	a	O	
4	POZ	B	
5	/	I	
6	Zn	I	
7	finger	I	
8	protein	I	
9	,	O	
10	a	O	
11	structure	O	
12	similar	O	
13	to	O	
14	that	O	
15	of	O	
16	many	O	
17	Drosophila	O	
18	developmental	O	
19	regulators	O	
20	and	O	
21	to	O	
22	another	O	
23	protein	O	
24	involved	O	
25	in	O	
26	a	O	
27	human	O	
28	hematopoietic	O	
29	malignancy	O	
30	,	O	
31	PLZF	B	
32	.	O	

1	4	O	
2	.	O	

1	The	O	
2	mean	O	
3	blood	O	
4	flow	O	
5	in	O	
6	the	O	
7	penile	O	
8	foreskin	O	
9	was	O	
10	estimated	O	
11	to	O	
12	be	O	
13	15	O	
14	ml	O	
15	/	O	
16	min	O	
17	/	O	
18	100	O	
19	g	O	
20	and	O	
21	it	O	
22	increased	O	
23	to	O	
24	150	O	
25	-	O	
26	200	O	
27	%	O	
28	after	O	
29	the	O	
30	induction	O	
31	of	O	
32	anesthesia	O	
33	,	O	
34	and	O	
35	then	O	
36	decreased	O	
37	to	O	
38	72	O	
39	%	O	
40	at	O	
41	the	O	
42	tip	O	
43	of	O	
44	the	O	
45	created	O	
46	parameatal	O	
47	foreskin	O	
48	flap	O	
49	.	O	

1	Certain	O	
2	transcript	O	
3	patterns	O	
4	in	O	
5	Epifagus	O	
6	plastids	O	
7	are	O	
8	highly	O	
9	complex	O	
10	and	O	
11	similar	O	
12	to	O	
13	those	O	
14	of	O	
15	tobacco	O	
16	operons	O	
17	.	O	

1	Complete	O	
2	recovery	O	
3	of	O	
4	liver	O	
5	function	O	
6	after	O	
7	this	O	
8	surgery	O	
9	tended	O	
10	to	O	
11	be	O	
12	slow	O	
13	.	O	

1	The	O	
2	effects	O	
3	of	O	
4	cardioselective	O	
5	beta	O	
6	-	O	
7	1	O	
8	adrenergic	O	
9	agonist	O	
10	,	O	
11	1	O	
12	-(	O	
13	4	O	
14	-	O	
15	hydroxyphenoxy	O	
16	)-	O	
17	isopropylamino	O	
18	-	O	
19	2	O	
20	-	O	
21	propanol	O	
22	),	O	
23	i	O	
24	.	O	
25	e	O	
26	.,	O	
27	prenalterol	O	
28	,	O	
29	were	O	
30	examined	O	
31	on	O	
32	direct	O	
33	and	O	
34	continuous	O	
35	measurements	O	
36	of	O	
37	left	O	
38	ventricular	O	
39	(	O	
40	LV	O	
41	)	O	
42	pressure	O	
43	,	O	
44	diameter	O	
45	,	O	
46	dP	O	
47	/	O	
48	dt	O	
49	,	O	
50	velocity	O	
51	of	O	
52	shortening	O	
53	,	O	
54	arterial	O	
55	pressure	O	
56	,	O	
57	iliac	O	
58	blood	O	
59	flow	O	
60	and	O	
61	heart	O	
62	rate	O	
63	in	O	
64	10	O	
65	conscious	O	
66	dogs	O	
67	.	O	

1	These	O	
2	risk	O	
3	factors	O	
4	can	O	
5	be	O	
6	divided	O	
7	into	O	
8	2	O	
9	groups	O	
10	:	O	
11	local	O	
12	vessel	O	
13	wall	O	
14	-	O	
15	related	O	
16	factors	O	
17	,	O	
18	and	O	
19	local	O	
20	(	O	
21	focal	O	
22	action	O	
23	)	O	
24	systemic	O	
25	factors	O	
26	.	O	

1	Natural	O	
2	and	O	
3	induced	O	
4	malarias	O	
5	in	O	
6	western	O	
7	hemisphere	O	
8	monkeys	O	
9	.	O	

1	Lead	O	
2	fixation	O	
3	in	O	
4	dogs	O	
5	achieved	O	
6	with	O	
7	RF	O	
8	energy	O	
9	.	O	

1	Double	O	
2	-	O	
3	staining	O	
4	confirmed	O	
5	that	O	
6	there	O	
7	were	O	
8	separate	O	
9	populations	O	
10	of	O	
11	CD68	B	
12	-	O	
13	positive	O	
14	macrophages	O	
15	and	O	
16	XIIIa	B	
17	-	O	
18	positive	O	
19	dendrocytes	O	
20	.	O	

1	Conditions	O	
2	influencing	O	
3	inhibitors	O	
4	of	O	
5	the	O	
6	colony	B	
7	-	I	
8	stimulating	I	
9	factor	I	
10	(	O	
11	CSF	B	
12	).	O	

1	Cell	O	
2	.	O	

1	Observations	O	
2	on	O	
3	saccules	O	
4	of	O	
5	rats	O	
6	exposed	O	
7	to	O	
8	long	O	
9	-	O	
10	term	O	
11	hypergravity	O	
12	.	O	

1	A	O	
2	second	O	
3	aim	O	
4	was	O	
5	to	O	
6	determine	O	
7	whether	O	
8	the	O	
9	decrease	O	
10	in	O	
11	muscle	O	
12	-	O	
13	tendon	O	
14	unit	O	
15	rest	O	
16	length	O	
17	produced	O	
18	by	O	
19	prolonged	O	
20	immobilisation	O	
21	in	O	
22	a	O	
23	shortened	O	
24	position	O	
25	is	O	
26	mediated	O	
27	primarily	O	
28	by	O	
29	adaptations	O	
30	of	O	
31	the	O	
32	muscle	O	
33	or	O	
34	tendon	O	
35	.	O	

1	Stems	O	
2	contain	O	
3	distinctly	O	
4	less	O	
5	P	B	
6	protein	I	
7	mRNA	I	
8	and	O	
9	the	O	
10	relative	O	
11	level	O	
12	in	O	
13	roots	O	
14	is	O	
15	very	O	
16	low	O	
17	but	O	
18	still	O	
19	clearly	O	
20	detectable	O	
21	.	O	

1	A	O	
2	38	O	
3	-	O	
4	bp	O	
5	poly	O	
6	(	O	
7	dA	O	
8	-	O	
9	dT	O	
10	)	O	
11	region	O	
12	was	O	
13	found	O	
14	to	O	
15	be	O	
16	a	O	
17	positive	O	
18	regulator	O	
19	of	O	
20	Act1	B	
21	promoter	I	
22	activity	O	
23	.	O	

1	Whereas	O	
2	creatine	B	
3	kinase	I	
4	activity	O	
5	declined	O	
6	exponentially	O	
7	from	O	
8	a	O	
9	single	O	
10	peak	O	
11	,	O	
12	myoglobin	B	
13	appeared	O	
14	in	O	
15	multiple	O	
16	episodes	O	
17	inadequately	O	
18	represented	O	
19	by	O	
20	a	O	
21	single	O	
22	peak	O	
23	value	O	
24	and	O	
25	having	O	
26	no	O	
27	clear	O	
28	clinical	O	
29	correlation	O	
30	.	O	

1	The	O	
2	existence	O	
3	of	O	
4	threshold	O	
5	concentrations	O	
6	,	O	
7	above	O	
8	which	O	
9	certain	O	
10	phenomena	O	
11	may	O	
12	occur	O	
13	,	O	
14	strengthens	O	
15	the	O	
16	role	O	
17	of	O	
18	sentinels	O	
19	.	O	

1	Primary	O	
2	and	O	
3	secondary	O	
4	structural	O	
5	elements	O	
6	required	O	
7	for	O	
8	synthesis	O	
9	of	O	
10	barley	O	
11	yellow	O	
12	dwarf	O	
13	virus	O	
14	subgenomic	O	
15	RNA1	O	
16	.	O	

1	Catheter	O	
2	transit	O	
3	slows	O	
4	the	O	
5	response	O	
6	to	O	
7	a	O	
8	step	O	
9	increase	O	
10	in	O	
11	concentration	O	
12	by	O	
13	about	O	
14	0	O	
15	.	O	
16	13	O	
17	s	O	
18	(	O	
19	from	O	
20	10	O	
21	per	O	
22	cent	O	
23	-	O	
24	90	O	
25	per	O	
26	cent	O	
27	)	O	
28	and	O	
29	prolongs	O	
30	the	O	
31	transit	O	
32	time	O	
33	through	O	
34	the	O	
35	catheter	O	
36	for	O	
37	a	O	
38	volatile	O	
39	anesthetic	O	
40	by	O	
41	about	O	
42	0	O	
43	.	O	
44	04	O	
45	s	O	
46	more	O	
47	than	O	
48	N2	O	
49	.	O	

1	In	O	
2	this	O	
3	article	O	
4	we	O	
5	propose	O	
6	to	O	
7	find	O	
8	out	O	
9	the	O	
10	percentage	O	
11	of	O	
12	normal	O	
13	occlusion	O	
14	and	O	
15	the	O	
16	distribution	O	
17	of	O	
18	maloclusions	O	
19	,	O	
20	according	O	
21	to	O	
22	the	O	
23	anteroposterior	O	
24	relationship	O	
25	between	O	
26	the	O	
27	dental	O	
28	archs	O	
29	(	O	
30	following	O	
31	the	O	
32	ANGLE3	O	
33	classification	O	
34	).	O	

1	Volunteers	O	
2	were	O	
3	irradiated	O	
4	on	O	
5	their	O	
6	backs	O	
7	with	O	
8	suberythemal	O	
9	UV	O	
10	daily	O	
11	for	O	
12	5	O	
13	d	O	
14	after	O	
15	application	O	
16	of	O	
17	the	O	
18	sunscreens	O	
19	and	O	
20	their	O	
21	base	O	
22	lotion	O	
23	to	O	
24	different	O	
25	sites	O	
26	.	O	

1	It	O	
2	is	O	
3	transparent	O	
4	,	O	
5	cheap	O	
6	to	O	
7	be	O	
8	made	O	
9	,	O	
10	and	O	
11	easy	O	
12	to	O	
13	empty	O	
14	and	O	
15	was	O	
16	tested	O	
17	in	O	
18	118	O	
19	animals	O	
20	for	O	
21	two	O	
22	and	O	
23	four	O	
24	weeks	O	
25	.	O	

1	C	O	
2	.,	O	
3	Sun	O	
4	,	O	
5	J	O	
6	.,	O	
7	Hsu	O	
8	,	O	
9	M	O	
10	.-	O	
11	Y	O	
12	.,	O	
13	Vallejo	O	
14	-	O	
15	Ramirez	O	
16	,	O	
17	J	O	
18	.,	O	
19	Inouye	O	
20	,	O	
21	S	O	
22	.,	O	
23	and	O	
24	Inouye	O	
25	,	O	
26	M	O	
27	.	O	

1	Incorporation	O	
2	of	O	
3	0	O	
4	.	O	
5	1	O	
6	or	O	
7	0	O	
8	.	O	
9	2	O	
10	M	O	
11	sodium	O	
12	dihydrogen	O	
13	phosphate	O	
14	in	O	
15	the	O	
16	sugar	O	
17	solutions	O	
18	resulted	O	
19	in	O	
20	a	O	
21	decrease	O	
22	in	O	
23	the	O	
24	shelf	O	
25	-	O	
26	life	O	
27	of	O	
28	diltiazem	O	
29	.	O	

1	Value	O	
2	of	O	
3	Normotest	O	
4	and	O	
5	antithrombin	B	
6	3	I	
7	in	O	
8	the	O	
9	assessment	O	
10	of	O	
11	liver	O	
12	function	O	
13	.	O	

1	TbRAB31	B	
2	behaviour	O	
3	was	O	
4	also	O	
5	studied	O	
6	during	O	
7	the	O	
8	cell	O	
9	cycle	O	
10	;	O	
11	TbRAB31	B	
12	always	O	
13	localised	O	
14	to	O	
15	a	O	
16	discrete	O	
17	structure	O	
18	that	O	
19	duplicated	O	
20	very	O	
21	early	O	
22	in	O	
23	mitosis	O	
24	and	O	
25	relocated	O	
26	to	O	
27	daughter	O	
28	cells	O	
29	in	O	
30	a	O	
31	coordinate	O	
32	manner	O	
33	with	O	
34	the	O	
35	basal	O	
36	body	O	
37	and	O	
38	kinetoplast	O	
39	,	O	
40	suggesting	O	
41	the	O	
42	involvement	O	
43	of	O	
44	microtubules	O	
45	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	in	O	
5	vitro	O	
6	mutagenesis	O	
7	of	O	
8	both	O	
9	Engrailed	B	
10	and	O	
11	Pbx1	B	
12	sites	I	
13	indicated	O	
14	that	O	
15	other	O	
16	unidentified	O	
17	sites	O	
18	are	O	
19	responsible	O	
20	for	O	
21	the	O	
22	transcriptional	O	
23	enhancement	O	
24	observed	O	
25	with	O	
26	the	O	
27	intronic	O	
28	fragment	O	
29	.	O	

1	Gene	O	
2	and	O	
3	pseudogene	O	
4	of	O	
5	the	O	
6	mouse	O	
7	cation	O	
8	-	O	
9	dependent	O	
10	mannose	B	
11	6	I	
12	-	I	
13	phosphate	I	
14	receptor	I	
15	.	O	

1	Regressing	O	
2	microaneurysms	O	
3	in	O	
4	5	O	
5	cases	O	
6	of	O	
7	hepatitis	O	
8	B	O	
9	virus	O	
10	related	O	
11	polyarteritis	O	
12	nodosa	O	
13	.	O	

1	The	O	
2	cardiac	B	
3	myosin	I	
4	light	I	
5	chain	I	
6	-	I	
7	2	I	
8	(	O	
9	MLC	B	
10	-	I	
11	2	I	
12	)	O	
13	gene	O	
14	promoter	O	
15	contains	O	
16	several	O	
17	positive	O	
18	and	O	
19	negative	O	
20	cis	O	
21	-	O	
22	acting	O	
23	sequences	O	
24	that	O	
25	are	O	
26	involved	O	
27	in	O	
28	the	O	
29	regulation	O	
30	of	O	
31	its	O	
32	expression	O	
33	.	O	

1	Here	O	
2	we	O	
3	describe	O	
4	the	O	
5	optimization	O	
6	and	O	
7	characterization	O	
8	of	O	
9	a	O	
10	140	O	
11	-	O	
12	residue	O	
13	fragment	O	
14	,	O	
15	containing	O	
16	the	O	
17	Runt	B	
18	domain	I	
19	of	O	
20	AML1	B	
21	,	O	
22	which	O	
23	is	O	
24	suitable	O	
25	for	O	
26	structural	O	
27	studies	O	
28	.	O	

1	Unexpectedly	O	
2	,	O	
3	ALK7	B	
4	signaling	O	
5	produced	O	
6	a	O	
7	remarkable	O	
8	change	O	
9	in	O	
10	cell	O	
11	morphology	O	
12	characterized	O	
13	by	O	
14	cell	O	
15	flattening	O	
16	and	O	
17	elaboration	O	
18	of	O	
19	blunt	O	
20	,	O	
21	short	O	
22	cell	O	
23	processes	O	
24	.	O	

1	Habituation	O	
2	of	O	
3	completely	O	
4	isolated	O	
5	neurons	O	
6	of	O	
7	the	O	
8	edible	O	
9	snail	O	
10	to	O	
11	electrical	O	
12	stimulation	O	
13	.	O	

1	Several	O	
2	lines	O	
3	of	O	
4	evidence	O	
5	presented	O	
6	here	O	
7	suggest	O	
8	that	O	
9	PKC	B	
10	-	I	
11	zeta	I	
12	plays	O	
13	a	O	
14	role	O	
15	in	O	
16	alpha	B	
17	2	I	
18	integrin	I	
19	gene	I	
20	expression	O	
21	.	O	

1	A	O	
2	group	O	
3	of	O	
4	66	O	
5	DSM	O	
6	-	O	
7	IV	O	
8	paranoid	O	
9	schizophrenic	O	
10	in	O	
11	-	O	
12	patients	O	
13	were	O	
14	assessed	O	
15	three	O	
16	times	O	
17	using	O	
18	the	O	
19	SAPS	O	
20	,	O	
21	SANS	O	
22	,	O	
23	BPRS	O	
24	and	O	
25	PAS	O	
26	.	O	

1	The	O	
2	LAMMER	B	
3	protein	O	
4	kinase	O	
5	encoded	O	
6	by	O	
7	the	O	
8	Doa	B	
9	locus	I	
10	of	O	
11	Drosophila	O	
12	is	O	
13	required	O	
14	in	O	
15	both	O	
16	somatic	O	
17	and	O	
18	germline	O	
19	cells	O	
20	and	O	
21	is	O	
22	expressed	O	
23	as	O	
24	both	O	
25	nuclear	O	
26	and	O	
27	cytoplasmic	O	
28	isoforms	O	
29	throughout	O	
30	development	O	
31	.	O	

1	The	O	
2	3	O	
3	-	O	
4	hour	O	
5	test	O	
6	iodine	O	
7	(	O	
8	I	O	
9	-	O	
10	132	O	
11	)	O	
12	uptake	O	
13	by	O	
14	the	O	
15	thyroid	O	
16	in	O	
17	children	O	
18	with	O	
19	growth	O	
20	deficiency	O	

1	The	O	
2	primary	O	
3	pancreatic	O	
4	insult	O	
5	seemed	O	
6	to	O	
7	be	O	
8	unaffected	O	
9	by	O	
10	the	O	
11	treatment	O	
12	,	O	
13	because	O	
14	neither	O	
15	the	O	
16	rise	O	
17	in	O	
18	plasma	B	
19	lipase	I	
20	nor	O	
21	the	O	
22	development	O	
23	of	O	
24	ascites	O	
25	or	O	
26	the	O	
27	extension	O	
28	of	O	
29	the	O	
30	pancreatic	O	
31	necrosis	O	
32	were	O	
33	diminished	O	
34	.	O	

1	OBJECTIVE	O	
2	:	O	
3	To	O	
4	determine	O	
5	the	O	
6	impact	O	
7	of	O	
8	the	O	
9	introduction	O	
10	of	O	
11	clarithromycin	O	
12	and	O	
13	azithromycin	O	
14	on	O	
15	the	O	
16	treatment	O	
17	and	O	
18	survival	O	
19	of	O	
20	patients	O	
21	with	O	
22	AIDS	O	
23	and	O	
24	disseminated	O	
25	Mycobacterium	O	
26	avium	O	
27	complex	O	
28	(	O	
29	DMAC	O	
30	).	O	

1	On	O	
2	physical	O	
3	examination	O	
4	a	O	
5	mild	O	
6	symmetrical	O	
7	polyarthritis	O	
8	of	O	
9	small	O	
10	and	O	
11	large	O	
12	joints	O	
13	was	O	
14	seen	O	
15	.	O	

1	By	O	
2	using	O	
3	total	O	
4	-	O	
5	protein	O	
6	extracts	O	
7	from	O	
8	mycelia	O	
9	grown	O	
10	under	O	
11	penicillin	O	
12	producing	O	
13	conditions	O	
14	we	O	
15	have	O	
16	detected	O	
17	a	O	
18	DNA	O	
19	-	O	
20	binding	O	
21	activity	O	
22	that	O	
23	specifically	O	
24	shifts	O	
25	a	O	
26	promoter	O	
27	fragment	O	
28	located	O	
29	between	O	
30	-	O	
31	654	O	
32	and	O	
33	-	O	
34	455	O	
35	(	O	
36	relative	O	
37	to	O	
38	IPNS	B	
39	tsp	I	
40	).	O	

1	GRFI	B	
2	bound	O	
3	to	O	
4	sequences	O	
5	at	O	
6	the	O	
7	negative	O	
8	regulatory	O	
9	elements	O	
10	(	O	
11	silencers	O	
12	)	O	
13	of	O	
14	the	O	
15	silent	B	
16	mating	I	
17	type	I	
18	loci	I	
19	HML	I	
20	E	I	
21	and	O	
22	HMR	B	
23	E	I	
24	and	O	
25	to	O	
26	the	O	
27	upstream	O	
28	activating	O	
29	sequence	O	
30	(	O	
31	UAS	O	
32	)	O	
33	required	O	
34	for	O	
35	transcription	O	
36	of	O	
37	the	O	
38	MAT	B	
39	alpha	I	
40	genes	I	
41	.	O	

1	Other	O	
2	assays	O	
3	also	O	
4	distinguished	O	
5	the	O	
6	processive	O	
7	replication	O	
8	of	O	
9	pNeo	O	
10	.	O	
11	Myc	O	
12	-	O	
13	2	O	
14	.	O	
15	4	O	
16	from	O	
17	the	O	
18	dispersive	O	
19	labeling	O	
20	of	O	
21	control	O	
22	plasmids	O	
23	.	O	

1	Deletion	O	
2	or	O	
3	inactivation	O	
4	of	O	
5	CRY1	B	
6	leads	O	
7	to	O	
8	5	O	
9	-	O	
10	to	O	
11	10	O	
12	-	O	
13	fold	O	
14	-	O	
15	increased	O	
16	levels	O	
17	of	O	
18	CRY2	B	
19	mRNA	I	
20	.	O	

1	Solving	O	
2	an	O	
3	age	O	
4	old	O	
5	problem	O	
6	.	O	

1	This	O	
2	stimulatory	O	
3	effect	O	
4	could	O	
5	also	O	
6	be	O	
7	elicited	O	
8	by	O	
9	c	B	
10	-	I	
11	Jun	I	
12	,	O	
13	which	O	
14	interacts	O	
15	with	O	
16	topo	B	
17	II	I	
18	,	O	
19	but	O	
20	not	O	
21	by	O	
22	c	B	
23	-	I	
24	Fos	I	
25	,	O	
26	which	O	
27	does	O	
28	not	O	
29	bind	O	
30	topo	B	
31	II	I	
32	in	O	
33	our	O	
34	in	O	
35	vitro	O	
36	assay	O	
37	.	O	

1	DNase	B	
2	I	I	
3	footprinting	O	
4	and	O	
5	electrophoretic	O	
6	mobility	O	
7	shift	O	
8	analyses	O	
9	revealed	O	
10	two	O	
11	hepatocyte	B	
12	nuclear	I	
13	factor	I	
14	-	I	
15	1	I	
16	(	O	
17	HNF1	B	
18	),	O	
19	three	O	
20	CCAAT	B	
21	/	I	
22	enhancer	I	
23	-	I	
24	binding	I	
25	protein	I	
26	(	O	
27	C	B	
28	/	I	
29	EBP	I	
30	),	O	
31	and	O	
32	one	O	
33	consensus	O	
34	palindromic	O	
35	thyroid	O	
36	hormone	O	
37	response	O	
38	elements	O	
39	within	O	
40	the	O	
41	first	O	
42	215	O	
43	base	O	
44	pairs	O	
45	(	O	
46	bp	O	
47	)	O	
48	of	O	
49	the	O	
50	promoter	O	
51	sequence	O	
52	of	O	
53	rat	B	
54	Std	I	
55	.	O	

1	Alveolar	O	
2	lymphocytes	O	
3	were	O	
4	surprisingly	O	
5	increased	O	
6	in	O	
7	most	O	
8	patients	O	
9	with	O	
10	AIDS	O	
11	(	O	
12	mean	O	
13	26	O	
14	.	O	
15	1	O	
16	+/-	O	
17	21	O	
18	.	O	
19	9	O	
20	%;	O	
21	range	O	
22	1	O	
23	-	O	
24	76	O	
25	%)	O	
26	and	O	
27	CGL	O	
28	(	O	
29	mean	O	
30	26	O	
31	.	O	
32	6	O	
33	+/-	O	
34	22	O	
35	.	O	
36	6	O	
37	%;	O	
38	range	O	
39	3	O	
40	-	O	
41	76	O	
42	%)	O	
43	with	O	
44	criteria	O	
45	of	O	
46	activation	O	
47	contrasting	O	
48	with	O	
49	the	O	
50	blood	O	
51	lymphopenia	O	
52	.	O	

1	Study	O	
2	on	O	
3	micromelias	O	
4	in	O	
5	the	O	
6	mouse	O	
7	fetus	O	
8	caused	O	
9	by	O	
10	x	O	
11	-	O	
12	radiation	O	
13	,	O	
14	hypoxia	O	
15	,	O	
16	trypan	O	
17	blue	O	
18	injection	O	
19	of	O	
20	hypervitaminosis	O	
21	-	O	
22	A	O	
23	upon	O	
24	mother	O	
25	animals	O	
26	during	O	
27	pregnancy	O	
28	.	O	

1	Based	O	
2	on	O	
3	peptide	O	
4	map	O	
5	similarities	O	
6	,	O	
7	partial	O	
8	amino	O	
9	-	O	
10	terminal	O	
11	sequence	O	
12	data	O	
13	,	O	
14	and	O	
15	common	O	
16	genetic	O	
17	origin	O	
18	,	O	
19	it	O	
20	is	O	
21	suggested	O	
22	that	O	
23	p60	B	
24	and	O	
25	p62	B	
26	have	O	
27	identical	O	
28	amino	O	
29	acid	O	
30	sequences	O	
31	carboxy	O	
32	-	O	
33	terminal	O	
34	to	O	
35	the	O	
36	p60	B	
37	initiator	O	
38	methionine	O	
39	(	O	
40	residue	O	
41	21	O	
42	of	O	
43	p62	B	
44	).	O	

1	Study	O	
2	on	O	
3	distribution	O	
4	of	O	
5	metal	O	
6	in	O	
7	the	O	
8	teeth	O	
9	treated	O	
10	by	O	
11	iontophoresis	O	
12	with	O	
13	transparent	O	
14	specimens	O	

1	Solution	O	
2	structure	O	
3	and	O	
4	mechanism	O	
5	of	O	
6	the	O	
7	MutT	B	
8	pyrophosphohydrolase	I	
9	.	O	

1	Both	O	
2	mutations	O	
3	completely	O	
4	abolished	O	
5	binding	O	
6	of	O	
7	the	O	
8	Abl	B	
9	SH3	I	
10	domain	O	
11	to	O	
12	proline	O	
13	-	O	
14	rich	O	
15	target	O	
16	proteins	O	
17	in	O	
18	a	O	
19	filter	O	
20	-	O	
21	binding	O	
22	assay	O	
23	.	O	

1	The	O	
2	examinations	O	
3	were	O	
4	performed	O	
5	on	O	
6	two	O	
7	groups	O	
8	of	O	
9	20	O	
10	(	O	
11	using	O	
12	AmF	O	
13	/	O	
14	SnF2	O	
15	)-,	O	
16	resp	O	
17	.	O	

1	The	O	
2	histidine	O	
3	-	O	
4	tagged	O	
5	gene	O	
6	,	O	
7	rpoCHIS	B	
8	,	O	
9	was	O	
10	used	O	
11	to	O	
12	replace	O	
13	the	O	
14	wild	O	
15	-	O	
16	type	O	
17	allele	O	
18	in	O	
19	the	O	
20	chromosome	O	
21	of	O	
22	S	O	
23	.	O	
24	coelicolor	O	
25	and	O	
26	S	O	
27	.	O	
28	lividans	O	
29	.	O	

1	Signaling	O	
2	from	O	
3	the	O	
4	small	B	
5	GTP	I	
6	-	I	
7	binding	I	
8	proteins	I	
9	Rac1	I	
10	and	O	
11	Cdc42	B	
12	to	O	
13	the	O	
14	c	B	
15	-	I	
16	Jun	I	
17	N	I	
18	-	I	
19	terminal	I	
20	kinase	I	
21	/	O	
22	stress	B	
23	-	I	
24	activated	I	
25	protein	I	
26	kinase	I	
27	pathway	O	
28	.	O	

1	Furthermore	O	
2	,	O	
3	early	O	
4	-	O	
5	and	O	
6	late	O	
7	-	O	
8	firing	O	
9	origins	O	
10	differ	O	
11	not	O	
12	in	O	
13	the	O	
14	timing	O	
15	of	O	
16	their	O	
17	recruitment	O	
18	of	O	
19	an	O	
20	Mcm	B	
21	protein	I	
22	,	O	
23	but	O	
24	in	O	
25	the	O	
26	timing	O	
27	of	O	
28	RPA	B	
29	'	I	
30	s	I	
31	recruitment	O	
32	.	O	

1	Association	O	
2	of	O	
3	human	B	
4	Pur	I	
5	alpha	I	
6	with	O	
7	the	O	
8	retinoblastoma	B	
9	protein	I	
10	,	O	
11	Rb	B	
12	,	O	
13	regulates	O	
14	binding	O	
15	to	O	
16	the	O	
17	single	O	
18	-	O	
19	stranded	O	
20	DNA	O	
21	Pur	B	
22	alpha	I	
23	recognition	I	
24	element	I	
25	.	O	

1	Following	O	
2	treatment	O	
3	,	O	
4	serum	O	
5	estradiol	O	
6	levels	O	
7	were	O	
8	higher	O	
9	in	O	
10	groups	O	
11	E	O	
12	+	O	
13	T	O	
14	and	O	
15	E	O	
16	than	O	
17	in	O	
18	group	O	
19	C	O	
20	.	O	

1	Both	O	
2	fusion	O	
3	proteins	O	
4	form	O	
5	stable	O	
6	specific	O	
7	complexes	O	
8	with	O	
9	a	O	
10	short	O	
11	DNA	O	
12	duplex	O	
13	harboring	O	
14	the	O	
15	CTGT	O	
16	(	O	
17	at	O	
18	)	O	
19	4ACAG	O	
20	consensus	O	
21	sequence	O	
22	of	O	
23	the	O	
24	LexA	B	
25	repressor	I	
26	.	O	

1	Mutations	O	
2	in	O	
3	genes	O	
4	encoding	O	
5	PR65	B	
6	/	I	
7	A	I	
8	subunits	I	
9	have	O	
10	been	O	
11	identified	O	
12	in	O	
13	several	O	
14	different	O	
15	human	O	
16	cancers	O	
17	and	O	
18	the	O	
19	PP2A	B	
20	inhibitor	O	
21	,	O	
22	termed	O	
23	fostriecin	O	
24	,	O	
25	is	O	
26	being	O	
27	tested	O	
28	as	O	
29	an	O	
30	anticancer	O	
31	drug	O	
32	.	O	

1	Responses	O	
2	to	O	
3	brainstem	O	
4	of	O	
5	nuclei	O	
6	medialis	O	
7	dorsalis	O	
8	,	O	
9	lateralis	O	
10	posterior	O	
11	were	O	
12	of	O	
13	considerably	O	
14	longer	O	
15	latency	O	
16	.	O	

1	One	O	
2	of	O	
3	these	O	
4	is	O	
5	located	O	
6	in	O	
7	the	O	
8	5	O	
9	'-	O	
10	untranslated	O	
11	region	O	
12	,	O	
13	and	O	
14	may	O	
15	encode	O	
16	regulatory	O	
17	sequences	O	
18	.	O	

1	Among	O	
2	known	O	
3	flea	O	
4	larvae	O	
5	,	O	
6	the	O	
7	genus	O	
8	Anomiopsyllus	O	
9	(	O	
10	Anomiopsyllinae	O	
11	,	O	
12	Anomiopsyllini	O	
13	)	O	
14	is	O	
15	as	O	
16	distinctive	O	
17	in	O	
18	larval	O	
19	form	O	
20	as	O	
21	are	O	
22	the	O	
23	adults	O	
24	.	O	

1	Histone	B	
2	acetylation	O	
3	levels	O	
4	in	O	
5	cells	O	
6	result	O	
7	from	O	
8	a	O	
9	dynamic	O	
10	equilibrium	O	
11	between	O	
12	competing	O	
13	histone	B	
14	acetylases	I	
15	and	I	
16	deacetylases	I	
17	.	O	

1	BACKGROUND	O	
2	:	O	
3	Hepatic	O	
4	encephalopathy	O	
5	is	O	
6	a	O	
7	neuropsychiatric	O	
8	syndrome	O	
9	associated	O	
10	with	O	
11	acute	O	
12	liver	O	
13	failure	O	
14	,	O	
15	chronic	O	
16	parenchymal	O	
17	liver	O	
18	disease	O	
19	or	O	
20	portal	O	
21	systemic	O	
22	anastomosis	O	
23	.	O	

1	The	O	
2	circadian	O	
3	rhythmicity	O	
4	of	O	
5	sleep	O	
6	was	O	
7	pronounced	O	
8	.	O	

1	The	O	
2	efficacy	O	
3	of	O	
4	these	O	
5	immunosuppressive	O	
6	drugs	O	
7	is	O	
8	clinical	O	
9	proven	O	
10	.	O	

1	Recent	O	
2	studies	O	
3	have	O	
4	demonstrated	O	
5	that	O	
6	the	O	
7	activated	O	
8	GH	B	
9	receptor	I	
10	can	O	
11	stimulate	O	
12	Stat1	B	
13	,	O	
14	a	O	
15	cytoplasmic	O	
16	transcription	O	
17	factor	O	
18	that	O	
19	becomes	O	
20	tyrosine	O	
21	phosphorylated	O	
22	and	O	
23	translocates	O	
24	to	O	
25	the	O	
26	nucleus	O	
27	,	O	
28	where	O	
29	it	O	
30	can	O	
31	interact	O	
32	with	O	
33	specific	O	
34	DNA	O	
35	sequences	O	
36	to	O	
37	modulate	O	
38	gene	O	
39	expression	O	
40	.	O	

1	A	O	
2	note	O	
3	on	O	
4	some	O	
5	consequences	O	
6	of	O	
7	UV	O	
8	vision	O	
9	in	O	
10	birds	O	
11	.	O	

1	A	O	
2	coiled	B	
3	-	I	
4	coil	I	
5	related	I	
6	protein	I	
7	specific	O	
8	for	O	
9	synapsed	O	
10	regions	O	
11	of	O	
12	meiotic	O	
13	prophase	O	
14	chromosomes	O	
15	.	O	

1	39	O	
2	-	O	
3	47	O	
4	.	O	

1	The	O	
2	results	O	
3	confirm	O	
4	that	O	
5	a	O	
6	single	O	
7	base	O	
8	change	O	
9	in	O	
10	the	O	
11	branchpoint	O	
12	consensus	O	
13	sequence	O	
14	of	O	
15	an	O	
16	intron	O	
17	can	O	
18	cause	O	
19	human	O	
20	disease	O	
21	although	O	
22	this	O	
23	sequence	O	
24	is	O	
25	poorly	O	
26	conserved	O	
27	in	O	
28	mammals	O	
29	.	O	

1	Transvenous	O	
2	serial	O	
3	xeroradiography	O	
4	.	O	

1	Vbeta	B	
2	segments	O	
3	are	O	
4	appended	O	
5	to	O	
6	DJbeta	B	
7	rearrangements	O	
8	,	O	
9	with	O	
10	little	O	
11	or	O	
12	no	O	
13	direct	O	
14	Vbeta	B	
15	to	O	
16	Jbeta	B	
17	joining	O	
18	,	O	
19	despite	O	
20	12	O	
21	/	O	
22	23	O	
23	compatibility	O	
24	of	O	
25	Vbeta	B	
26	23	I	
27	-	I	
28	RSSs	I	
29	and	O	
30	Jbeta12	B	
31	-	I	
32	RSSs	I	
33	.	O	

1	The	O	
2	antibody	O	
3	titer	O	
4	of	O	
5	202	O	
6	chickens	O	
7	to	O	
8	SA	O	
9	-	O	
10	11	O	
11	rotavirus	O	
12	was	O	
13	determined	O	
14	by	O	
15	enzyme	O	
16	-	O	
17	linked	O	
18	immunosorbent	O	
19	blocking	O	
20	assay	O	
21	.	O	

1	The	O	
2	pseudolymphoma	O	
3	syndrome	O	
4	is	O	
5	a	O	
6	reversible	O	
7	reactive	O	
8	condition	O	
9	consisting	O	
10	of	O	
11	fever	O	
12	,	O	
13	lymphadenopathy	O	
14	and	O	
15	generalized	O	
16	rash	O	
17	.	O	

1	Another	O	
2	stem	O	
3	-	O	
4	loop	O	
5	called	O	
6	structure	O	
7	III	O	
8	near	O	
9	the	O	
10	3	O	
11	'-	O	
12	end	O	
13	of	O	
14	repY	B	
15	sequesters	O	
16	both	O	
17	the	O	
18	5	O	
19	'-	O	
20	rCGCC	O	
21	-	O	
22	3	O	
23	'	O	
24	sequence	O	
25	and	O	
26	the	O	
27	repZ	B	
28	ribosome	I	
29	-	I	
30	binding	I	
31	site	I	
32	.	O	

1	The	O	
2	authors	O	
3	conclude	O	
4	that	O	
5	nonspecificity	O	
6	of	O	
7	low	O	
8	platelet	B	
9	MAO	I	
10	as	O	
11	a	O	
12	possible	O	
13	correlate	O	
14	of	O	
15	bipolar	O	
16	affective	O	
17	disorder	O	
18	,	O	
19	as	O	
20	well	O	
21	as	O	
22	schizophrenia	O	
23	,	O	
24	increases	O	
25	the	O	
26	burden	O	
27	of	O	
28	proof	O	
29	necessary	O	
30	before	O	
31	findings	O	
32	of	O	
33	low	O	
34	platelet	B	
35	MAO	I	
36	can	O	
37	be	O	
38	accepted	O	
39	as	O	
40	primary	O	
41	.	O	

1	Expression	O	
2	of	O	
3	activated	O	
4	Cdc42	B	
5	results	O	
6	in	O	
7	the	O	
8	translocation	O	
9	of	O	
10	PKClambda	B	
11	from	O	
12	the	O	
13	nucleus	O	
14	into	O	
15	the	O	
16	cytosol	O	
17	,	O	
18	and	O	
19	Cdc42	B	
20	and	O	
21	PKClambda	B	
22	colocalize	O	
23	at	O	
24	the	O	
25	plasma	O	
26	membrane	O	
27	and	O	
28	in	O	
29	the	O	
30	cytoplasm	O	
31	.	O	

1	Together	O	
2	,	O	
3	these	O	
4	data	O	
5	support	O	
6	a	O	
7	model	O	
8	in	O	
9	which	O	
10	Tax	B	
11	anchors	O	
12	CBP	B	
13	to	O	
14	the	O	
15	HTLV	B	
16	-	I	
17	1	I	
18	promoter	I	
19	,	O	
20	with	O	
21	strong	O	
22	transcriptional	O	
23	activation	O	
24	resulting	O	
25	from	O	
26	the	O	
27	CBP	B	
28	-	O	
29	associated	O	
30	activities	O	
31	of	O	
32	nucleosome	O	
33	remodeling	O	
34	and	O	
35	recruitment	O	
36	of	O	
37	the	O	
38	general	O	
39	transcription	O	
40	machinery	O	
41	.	O	

1	We	O	
2	previously	O	
3	described	O	
4	the	O	
5	purification	O	
6	of	O	
7	an	O	
8	83	B	
9	-	I	
10	kDa	I	
11	phosphatidic	I	
12	acid	I	
13	phosphatase	I	
14	(	O	
15	PAP	B	
16	)	O	
17	from	O	
18	the	O	
19	porcine	O	
20	thymus	O	
21	membranes	O	
22	(	O	
23	Kanoh	O	
24	,	O	
25	H	O	
26	.,	O	
27	Imai	O	
28	,	O	
29	S	O	
30	.-	O	
31	i	O	
32	.,	O	
33	Yamada	O	
34	,	O	
35	K	O	
36	.	O	
37	and	O	
38	Sakane	O	
39	,	O	
40	F	O	
41	.(	O	
42	1992	O	
43	)	O	
44	J	O	
45	.	O	

1	Both	O	
2	HEF1	B	
3	and	O	
4	Cas	B	
5	were	O	
6	found	O	
7	to	O	
8	complex	O	
9	with	O	
10	the	O	
11	related	B	
12	adhesion	I	
13	focal	I	
14	tyrosine	I	
15	kinase	I	
16	(	O	
17	RAFTK	B	
18	),	O	
19	and	O	
20	when	O	
21	tyrosine	O	
22	phosphorylated	O	
23	,	O	
24	with	O	
25	the	O	
26	adapter	O	
27	molecule	O	
28	CrkL	B	
29	.	O	

1	The	O	
2	highest	O	
3	prevalence	O	
4	of	O	
5	reported	O	
6	pet	O	
7	allergy	O	
8	,	O	
9	chronic	O	
10	cough	O	
11	,	O	
12	wheeze	O	
13	,	O	
14	attacks	O	
15	of	O	
16	shortness	O	
17	of	O	
18	breath	O	
19	with	O	
20	wheezing	O	
21	,	O	
22	and	O	
23	doctor	O	
24	-	O	
25	diagnosed	O	
26	asthma	O	
27	was	O	
28	found	O	
29	in	O	
30	children	O	
31	who	O	
32	had	O	
33	pets	O	
34	in	O	
35	the	O	
36	past	O	
37	but	O	
38	not	O	
39	anymore	O	
40	.	O	

1	Ras	B	
2	-	I	
3	and	I	
4	ultra	I	
5	-	I	
6	violet	I	
7	-	I	
8	responsive	I	
9	protein	I	
10	kinases	I	
11	that	O	
12	phosphorylate	O	
13	c	B	
14	-	I	
15	Jun	I	
16	on	O	
17	serine	O	
18	residues	O	
19	at	O	
20	positions	O	
21	63	O	
22	and	O	
23	73	O	
24	and	O	
25	stimulate	O	
26	its	O	
27	transcriptional	O	
28	activity	O	
29	have	O	
30	been	O	
31	identified	O	
32	.	O	

1	Importance	O	
2	of	O	
3	determining	O	
4	the	O	
5	blood	O	
6	sulfhydryl	O	
7	groups	O	
8	in	O	
9	fractures	O	
10	of	O	
11	the	O	
12	long	O	
13	tubular	O	
14	bones	O	
15	complicated	O	
16	by	O	
17	infection	O	

1	Analysis	O	
2	of	O	
3	functional	O	
4	domains	O	
5	of	O	
6	Arix	B	
7	reveals	O	
8	an	O	
9	N	O	
10	-	O	
11	terminal	O	
12	activation	O	
13	domain	O	
14	and	O	
15	a	O	
16	C	O	
17	-	O	
18	terminal	O	
19	repression	O	
20	domain	O	
21	.	O	

1	We	O	
2	also	O	
3	observed	O	
4	that	O	
5	cell	O	
6	surface	O	
7	CD4	B	
8	(-)	O	
9	CD8	B	
10	(-)	O	
11	CD3	B	
12	(-)	O	
13	cells	O	
14	with	O	
15	rearranged	B	
16	TCR	I	
17	genes	I	
18	developed	O	
19	from	O	
20	Id3	B	
21	-	O	
22	transduced	O	
23	but	O	
24	not	O	
25	from	O	
26	control	O	
27	-	O	
28	transduced	O	
29	pre	O	
30	-	O	
31	T	O	
32	cells	O	
33	in	O	
34	an	O	
35	FTOC	O	
36	.	O	

1	The	O	
2	biochemical	O	
3	and	O	
4	molecular	O	
5	spectrum	O	
6	of	O	
7	ornithine	B	
8	transcarbamylase	I	
9	deficiency	O	
10	.	O	

1	We	O	
2	cloned	O	
3	and	O	
4	sequenced	O	
5	the	O	
6	cDNAs	O	
7	against	O	
8	genomic	O	
9	RNA	O	
10	and	O	
11	mRNA	O	
12	for	O	
13	phosphoprotein	B	
14	(	I	
15	P	I	
16	)	I	
17	of	O	
18	human	O	
19	parainfluenza	O	
20	type	O	
21	2	O	
22	virus	O	
23	(	O	
24	PIV	O	
25	-	O	
26	2	O	
27	).	O	
28	cDNA	O	
29	clone	O	
30	from	O	
31	genomic	O	
32	RNA	O	
33	was	O	
34	1439	O	
35	nucleotides	O	
36	in	O	
37	length	O	
38	excluding	O	
39	poly	O	
40	(	O	
41	A	O	
42	)	O	
43	and	O	
44	was	O	
45	found	O	
46	to	O	
47	have	O	
48	two	O	
49	small	O	
50	open	O	
51	reading	O	
52	frames	O	
53	encoding	O	
54	proteins	O	
55	of	O	
56	233	O	
57	and	O	
58	249	O	
59	amino	O	
60	acids	O	
61	.	O	

1	Epstein	B	
2	-	I	
3	Barr	I	
4	virus	I	
5	-	I	
6	encoded	I	
7	latent	I	
8	membrane	I	
9	protein	I	
10	1	I	
11	activates	O	
12	the	O	
13	JNK	B	
14	pathway	O	
15	through	O	
16	its	O	
17	extreme	O	
18	C	O	
19	terminus	O	
20	via	O	
21	a	O	
22	mechanism	O	
23	involving	O	
24	TRADD	B	
25	and	O	
26	TRAF2	B	
27	.	O	

1	We	O	
2	previously	O	
3	described	O	
4	two	O	
5	alanine	O	
6	cluster	O	
7	mutations	O	
8	,	O	
9	R77	O	
10	to	O	
11	A	O	
12	(	O	
13	R77A	O	
14	)-	O	
15	K79A	O	
16	and	O	
17	E192A	O	
18	-	O	
19	E194A	O	
20	,	O	
21	which	O	
22	selectively	O	
23	inactivated	O	
24	the	O	
25	triphosphatase	O	
26	component	O	
27	.	O	

1	Subunit	O	
2	composition	O	
3	and	O	
4	domain	O	
5	structure	O	
6	of	O	
7	the	O	
8	Spo0A	B	
9	sporulation	I	
10	transcription	I	
11	factor	I	
12	of	I	
13	Bacillus	I	
14	subtilis	I	
15	.	O	

1	Two	O	
2	major	O	
3	and	O	
4	one	O	
5	minor	O	
6	transcription	O	
7	initiation	O	
8	sites	O	
9	were	O	
10	assigned	O	
11	to	O	
12	positions	O	
13	+	O	
14	1	O	
15	and	O	
16	+	O	
17	24	O	
18	and	O	
19	position	O	
20	+	O	
21	14	O	
22	,	O	
23	respectively	O	
24	,	O	
25	by	O	
26	a	O	
27	combination	O	
28	of	O	
29	ribonuclease	O	
30	protection	O	
31	,	O	
32	primer	O	
33	extension	O	
34	,	O	
35	and	O	
36	5	O	
37	'	O	
38	RACE	O	
39	analyses	O	
40	.	O	

1	Pentachlorophenol	O	
2	accelerates	O	
3	the	O	
4	onset	O	
5	of	O	
6	HCB	O	
7	porphyria	O	
8	,	O	
9	in	O	
10	other	O	
11	words	O	
12	it	O	
13	increases	O	
14	the	O	
15	total	O	
16	urinary	O	
17	porphyrin	O	
18	excretion	O	
19	and	O	
20	causes	O	
21	an	O	
22	earlier	O	
23	disturbance	O	
24	of	O	
25	the	O	
26	porphyrin	O	
27	pattern	O	
28	.	O	

1	This	O	
2	may	O	
3	account	O	
4	,	O	
5	at	O	
6	least	O	
7	in	O	
8	part	O	
9	,	O	
10	for	O	
11	the	O	
12	ability	O	
13	of	O	
14	excess	O	
15	wt	B	
16	p53	I	
17	to	O	
18	inhibit	O	
19	cell	O	
20	proliferation	O	
21	and	O	
22	to	O	
23	interfere	O	
24	with	O	
25	neoplastic	O	
26	processes	O	
27	.	O	

1	Intravenous	O	
2	administration	O	
3	(	O	
4	25	O	
5	mg	O	
6	/	O	
7	kg	O	
8	)	O	
9	of	O	
10	carbonic	B	
11	anhydrase	I	
12	inhibitors	O	
13	(	O	
14	acetazolamide	O	
15	,	O	
16	methazolamide	O	
17	,	O	
18	dichlorphenamide	O	
19	,	O	
20	sulthiame	O	
21	)	O	
22	induced	O	
23	an	O	
24	early	O	
25	important	O	
26	rise	O	
27	of	O	
28	cortical	O	
29	p	O	
30	O2	O	
31	,	O	
32	which	O	
33	is	O	
34	not	O	
35	dependent	O	
36	on	O	
37	increase	O	
38	of	O	
39	p	O	
40	O2	O	
41	and	O	
42	p	O	
43	CO2	O	
44	and	O	
45	decrease	O	
46	of	O	
47	pH	O	
48	in	O	
49	arterial	O	
50	blood	O	
51	.	O	

1	Under	O	
2	the	O	
3	same	O	
4	hematocrit	O	
5	and	O	
6	flow	O	
7	conditions	O	
8	,	O	
9	the	O	
10	rate	O	
11	of	O	
12	oxygen	O	
13	saturation	O	
14	decrease	O	
15	was	O	
16	significantly	O	
17	higher	O	
18	for	O	
19	the	O	
20	sickle	O	
21	cells	O	
22	than	O	
23	for	O	
24	normal	O	
25	cells	O	
26	.	O	

1	Effect	O	
2	of	O	
3	bromazepam	O	
4	on	O	
5	growth	B	
6	hormone	I	
7	and	O	
8	prolactin	B	
9	secretion	O	
10	in	O	
11	normal	O	
12	subjects	O	
13	.	O	

1	The	O	
2	basal	O	
3	promoter	O	
4	strength	O	
5	of	O	
6	constructs	O	
7	that	O	
8	contained	O	
9	deletions	O	
10	in	O	
11	the	O	
12	U5	B	
13	region	I	
14	of	O	
15	the	O	
16	LTR	O	
17	was	O	
18	analyzed	O	
19	by	O	
20	chloramphenicol	B	
21	acetyltransferase	I	
22	(	O	
23	CAT	B	
24	)	O	
25	assays	O	
26	following	O	
27	transfection	O	
28	of	O	
29	HeLa	O	
30	cells	O	
31	or	O	
32	Jurkat	O	
33	T	O	
34	-	O	
35	cells	O	
36	in	O	
37	the	O	
38	presence	O	
39	or	O	
40	absence	O	
41	of	O	
42	viral	O	
43	transactivator	O	
44	tax	B	
45	protein	O	
46	.	O	

1	Ozagrel	O	
2	,	O	
3	ifenprodil	O	
4	,	O	
5	cinnarizine	O	
6	and	O	
7	dilazep	O	
8	were	O	
9	more	O	
10	effective	O	
11	than	O	
12	pentoxifylline	O	
13	in	O	
14	increasing	O	
15	rCBF	O	
16	at	O	
17	the	O	
18	HPC	O	
19	.	O	

1	Two	O	
2	classes	O	
3	of	O	
4	mutations	O	
5	were	O	
6	obtained	O	
7	:	O	
8	(	O	
9	i	O	
10	)	O	
11	those	O	
12	that	O	
13	altered	O	
14	the	O	
15	coding	O	
16	region	O	
17	of	O	
18	HOL1	B	
19	,	O	
20	conferring	O	
21	the	O	
22	ability	O	
23	to	O	
24	take	O	
25	up	O	
26	histidinol	O	
27	;	O	
28	and	O	
29	(	O	
30	ii	O	
31	)	O	
32	cis	O	
33	-	O	
34	acting	O	
35	mutations	O	
36	(	O	
37	selected	O	
38	in	O	
39	a	O	
40	mutant	O	
41	HOL1	B	
42	-	I	
43	1	I	
44	background	O	
45	)	O	
46	that	O	
47	increased	O	
48	expression	O	
49	of	O	
50	the	O	
51	Hol1	B	
52	protein	I	
53	.	O	

1	The	O	
2	inhibition	O	
3	of	O	
4	focus	O	
5	formation	O	
6	observed	O	
7	in	O	
8	the	O	
9	presence	O	
10	of	O	
11	C3G	B	
12	was	O	
13	not	O	
14	due	O	
15	to	O	
16	toxic	O	
17	effects	O	
18	on	O	
19	cell	O	
20	viability	O	
21	,	O	
22	since	O	
23	transfected	O	
24	C3G	B	
25	cells	O	
26	exhibited	O	
27	the	O	
28	same	O	
29	survival	O	
30	and	O	
31	growth	O	
32	rates	O	
33	as	O	
34	untransfected	O	
35	NIH3T3	O	
36	cells	O	
37	or	O	
38	cells	O	
39	transfected	O	
40	with	O	
41	plasmid	O	
42	vector	O	
43	alone	O	
44	.	O	

1	Although	O	
2	increased	O	
3	expression	O	
4	of	O	
5	the	O	
6	HMG	B	
7	-	I	
8	I	I	
9	/	I	
10	Y	I	
11	proteins	I	
12	is	O	
13	associated	O	
14	with	O	
15	cellular	O	
16	proliferation	O	
17	,	O	
18	neoplastic	O	
19	transformation	O	
20	,	O	
21	and	O	
22	several	O	
23	human	O	
24	cancers	O	
25	,	O	
26	the	O	
27	role	O	
28	of	O	
29	these	O	
30	proteins	O	
31	in	O	
32	the	O	
33	pathogenesis	O	
34	of	O	
35	malignancy	O	
36	remains	O	
37	unclear	O	
38	.	O	

1	Fifty	O	
2	-	O	
3	eight	O	
4	RMI	O	
5	'	O	
6	s	O	
7	occurred	O	
8	in	O	
9	the	O	
10	placebo	O	
11	group	O	
12	as	O	
13	compared	O	
14	to	O	
15	only	O	
16	twenty	O	
17	in	O	
18	the	O	
19	AC	O	
20	group	O	
21	(	O	
22	p	O	
23	less	O	
24	than	O	
25	0	O	
26	.	O	
27	01	O	
28	).	O	

1	The	O	
2	highly	O	
3	restrained	O	
4	girls	O	
5	had	O	
6	a	O	
7	significantly	O	
8	higher	O	
9	EAT	O	
10	score	O	
11	than	O	
12	the	O	
13	low	O	
14	-	O	
15	restrained	O	
16	girls	O	
17	,	O	
18	and	O	
19	shared	O	
20	with	O	
21	their	O	
22	mothers	O	
23	a	O	
24	susceptibility	O	
25	to	O	
26	the	O	
27	disinhibitory	O	
28	effects	O	
29	of	O	
30	negative	O	
31	mood	O	
32	states	O	
33	on	O	
34	their	O	
35	eating	O	
36	behaviour	O	
37	.	O	

1	The	O	
2	Siglecs	B	
3	are	O	
4	a	O	
5	subfamily	O	
6	of	O	
7	I	B	
8	-	I	
9	type	I	
10	lectins	I	
11	(	O	
12	immunoglobulin	B	
13	superfamily	I	
14	proteins	I	
15	that	O	
16	bind	O	
17	sugars	O	
18	)	O	
19	that	O	
20	specifically	O	
21	recognize	O	
22	sialic	O	
23	acids	O	
24	.	O	

1	Serum	B	
2	beta	I	
3	2	I	
4	-	I	
5	microglobulin	I	
6	levels	O	
7	(	O	
8	beta	B	
9	-	I	
10	2	I	
11	-	I	
12	M	I	
13	)	O	
14	were	O	
15	studied	O	
16	in	O	
17	150	O	
18	drug	O	
19	addicts	O	
20	,	O	
21	50	O	
22	of	O	
23	them	O	
24	asymptomatic	O	
25	carriers	O	
26	of	O	
27	anti	B	
28	HIV	I	
29	-	I	
30	1	I	
31	antibodies	I	
32	,	O	
33	50	O	
34	symptomatic	O	
35	carriers	O	
36	with	O	
37	persistent	O	
38	generalized	O	
39	lymphadenopathy	O	
40	(	O	
41	P	O	
42	.	O	
43	G	O	
44	.	O	
45	L	O	
46	.)	O	
47	and	O	
48	50	O	
49	serum	O	
50	negative	O	
51	patients	O	
52	who	O	
53	had	O	
54	been	O	
55	living	O	
56	in	O	
57	a	O	
58	closed	O	
59	community	O	
60	for	O	
61	at	O	
62	least	O	
63	2	O	
64	years	O	
65	.	O	

1	The	O	
2	coding	O	
3	sequence	O	
4	for	O	
5	a	O	
6	260	O	
7	-	O	
8	amino	O	
9	-	O	
10	acid	O	
11	residue	O	
12	polypeptide	O	
13	was	O	
14	interrupted	O	
15	by	O	
16	a	O	
17	single	O	
18	short	O	
19	intron	O	
20	of	O	
21	60	O	
22	base	O	
23	pairs	O	
24	(	O	
25	bp	O	
26	),	O	
27	and	O	
28	about	O	
29	70	O	
30	%	O	
31	of	O	
32	the	O	
33	deduced	O	
34	amino	O	
35	acid	O	
36	sequence	O	
37	of	O	
38	the	O	
39	Drosophila	B	
40	PCNA	I	
41	was	O	
42	identical	O	
43	to	O	
44	the	O	
45	rat	O	
46	and	O	
47	human	B	
48	PCNA	I	
49	polypeptides	I	
50	,	O	
51	with	O	
52	conserved	O	
53	unique	O	
54	repeats	O	
55	of	O	
56	leucine	O	
57	in	O	
58	the	O	
59	C	O	
60	-	O	
61	terminal	O	
62	region	O	
63	.	O	

1	Diltiazem	O	
2	caused	O	
3	significant	O	
4	decrease	O	
5	in	O	
6	the	O	
7	ventricular	O	
8	response	O	
9	without	O	
10	conversion	O	
11	to	O	
12	sinus	O	
13	rhythm	O	
14	.	O	

1	Autopsy	O	
2	demonstrated	O	
3	good	O	
4	survival	O	
5	of	O	
6	the	O	
7	transplanted	O	
8	cells	O	
9	with	O	
10	good	O	
11	integration	O	
12	with	O	
13	the	O	
14	brain	O	
15	of	O	
16	the	O	
17	recipient	O	
18	and	O	
19	traces	O	
20	of	O	
21	positive	O	
22	immunocytochemical	O	
23	reaction	O	
24	for	O	
25	tyrosine	B	
26	hydroxylase	I	
27	.	O	

1	Homozygous	O	
2	mutation	O	
3	in	O	
4	two	O	
5	children	O	
6	led	O	
7	to	O	
8	amputation	O	
9	of	O	
10	legs	O	
11	due	O	
12	to	O	
13	purpura	O	
14	fulminans	O	
15	.	O	

1	Improving	O	
2	the	O	
3	evidence	O	
4	base	O	
5	for	O	
6	anaesthesia	O	
7	.	O	

1	Only	O	
2	two	O	
3	of	O	
4	27	O	
5	participants	O	
6	(	O	
7	7	O	
8	.	O	
9	4	O	
10	%)	O	
11	with	O	
12	definite	O	
13	POAG	O	
14	had	O	
15	been	O	
16	previously	O	
17	diagnosed	O	
18	and	O	
19	treated	O	
20	,	O	
21	and	O	
22	66	O	
23	.	O	
24	7	O	
25	%	O	
26	of	O	
27	the	O	
28	previously	O	
29	undiagnosed	O	
30	had	O	
31	IOP	O	
32	less	O	
33	than	O	
34	22	O	
35	mmHg	O	
36	.	O	

1	Retroviral	B	
2	nucleocapsid	I	
3	proteins	I	
4	(	O	
5	NCPs	B	
6	)	O	
7	are	O	
8	CCHC	B	
9	-	I	
10	type	I	
11	zinc	I	
12	finger	I	
13	proteins	I	
14	that	O	
15	mediate	O	
16	virion	O	
17	RNA	O	
18	binding	O	
19	activities	O	
20	associated	O	
21	with	O	
22	retrovirus	O	
23	assembly	O	
24	and	O	
25	genomic	O	
26	RNA	O	
27	encapsidation	O	
28	.	O	

1	Both	O	
2	quantitative	O	
3	and	O	
4	qualitative	O	
5	analysis	O	
6	of	O	
7	individual	O	
8	cytoarchitectonic	O	
9	peculiarities	O	
10	of	O	
11	Meynart	O	
12	'	O	
13	s	O	
14	nucleus	O	
15	as	O	
16	well	O	
17	as	O	
18	of	O	
19	external	O	
20	part	O	
21	of	O	
22	dorsomedial	O	
23	nucleus	O	
24	of	O	
25	thalamus	O	
26	was	O	
27	performed	O	
28	in	O	
29	mentally	O	
30	normal	O	
31	individuals	O	
32	.	O	

1	MVR	O	
2	typing	O	
3	of	O	
4	rare	O	
5	-	O	
6	length	O	
7	alleles	O	
8	indicates	O	
9	that	O	
10	they	O	
11	are	O	
12	comprised	O	
13	of	O	
14	disorganized	O	
15	sequences	O	
16	,	O	
17	although	O	
18	they	O	
19	usually	O	
20	bear	O	
21	a	O	
22	resemblance	O	
23	to	O	
24	one	O	
25	of	O	
26	the	O	
27	common	O	
28	alleles	O	
29	at	O	
30	the	O	
31	5	O	
32	'-	O	
33	most	O	
34	end	O	
35	.	O	

1	This	O	
2	study	O	
3	was	O	
4	carried	O	
5	out	O	
6	to	O	
7	analyze	O	
8	PRL	B	
9	secretion	O	
10	in	O	
11	metastatic	O	
12	prostate	O	
13	cancer	O	
14	patients	O	
15	both	O	
16	at	O	
17	basal	O	
18	conditions	O	
19	and	O	
20	in	O	
21	response	O	
22	to	O	
23	L	O	
24	-	O	
25	Dopa	O	
26	and	O	
27	metoclopramide	O	
28	,	O	
29	which	O	
30	represents	O	
31	the	O	
32	most	O	
33	classical	O	
34	inhibitory	O	
35	and	O	
36	stimulatory	O	
37	tests	O	
38	for	O	
39	PRL	B	
40	secretion	O	
41	,	O	
42	respectively	O	
43	.	O	

1	To	O	
2	address	O	
3	the	O	
4	biological	O	
5	effect	O	
6	of	O	
7	specific	O	
8	isoform	O	
9	expression	O	
10	,	O	
11	NIH3T3	O	
12	cells	O	
13	were	O	
14	transfected	O	
15	with	O	
16	a	O	
17	eukaryotic	O	
18	expression	O	
19	vector	O	
20	containing	O	
21	cDNA	O	
22	for	O	
23	FGF8a	B	
24	,	O	
25	FGF8b	B	
26	,	O	
27	or	O	
28	FGF8e	B	
29	.	O	

1	SNAC	O	
2	or	O	
3	PBS	O	
4	was	O	
5	infused	O	
6	for	O	
7	6	O	
8	.	O	
9	5	O	
10	h	O	
11	,	O	
12	beginning	O	
13	30	O	
14	min	O	
15	before	O	
16	ischemia	O	
17	and	O	
18	continuing	O	
19	throughout	O	
20	the	O	
21	duration	O	
22	of	O	
23	reperfusion	O	
24	.	O	

1	SCFFWD1	B	
2	may	O	
3	be	O	
4	critical	O	
5	for	O	
6	tumor	O	
7	development	O	
8	and	O	
9	suppression	O	
10	through	O	
11	regulation	O	
12	of	O	
13	beta	B	
14	-	I	
15	catenin	I	
16	protein	I	
17	stability	O	
18	.	O	

1	We	O	
2	observed	O	
3	abundant	O	
4	levels	O	
5	of	O	
6	Rev	B	
7	-	O	
8	erbA	B	
9	alpha	I	
10	mRNA	O	
11	in	O	
12	dividing	O	
13	C2C12	O	
14	myoblasts	O	
15	,	O	
16	which	O	
17	were	O	
18	suppressed	O	
19	when	O	
20	the	O	
21	cells	O	
22	differentiated	O	
23	into	O	
24	postmitotic	O	
25	multinucleated	O	
26	myotubes	O	
27	.	O	

1	Nine	O	
2	DNA	O	
3	fragments	O	
4	that	O	
5	were	O	
6	specifically	O	
7	recognized	O	
8	and	O	
9	bound	O	
10	by	O	
11	histidine	O	
12	-	O	
13	tagged	O	
14	AdpA	B	
15	were	O	
16	isolated	O	
17	by	O	
18	cycles	O	
19	of	O	
20	a	O	
21	gel	O	
22	mobility	O	
23	shift	O	
24	-	O	
25	PCR	O	
26	method	O	
27	.	O	

1	The	O	
2	transcriptional	O	
3	activities	O	
4	of	O	
5	the	O	
6	full	O	
7	-	O	
8	length	O	
9	promoter	O	
10	(-	O	
11	295	O	
12	to	O	
13	+	O	
14	85	O	
15	)	O	
16	and	O	
17	of	O	
18	three	O	
19	deletion	O	
20	constructs	O	
21	(-	O	
22	197	O	
23	,	O	
24	-	O	
25	154	O	
26	and	O	
27	-	O	
28	74	O	
29	to	O	
30	+	O	
31	85	O	
32	)	O	
33	were	O	
34	significantly	O	
35	down	O	
36	-	O	
37	regulated	O	
38	in	O	
39	resistant	O	
40	cells	O	
41	.	O	

1	The	O	
2	class	B	
3	II	I	
4	Escherichia	I	
5	coli	I	
6	alanine	I	
7	tRNA	I	
8	synthetase	I	
9	aminoacylates	I	
10	RNA	I	
11	miniduplexes	I	
12	,	O	
13	which	O	
14	reconstruct	O	
15	the	O	
16	acceptor	O	
17	end	O	
18	of	O	
19	alanine	B	
20	tRNA	I	
21	with	O	
22	the	O	
23	critical	O	
24	G3	O	
25	:	O	
26	U70	O	
27	base	O	
28	pair	O	
29	.	O	

1	Mutations	O	
2	in	O	
3	UPF1	B	
4	lead	O	
5	to	O	
6	the	O	
7	selective	O	
8	stabilization	O	
9	of	O	
10	mRNAs	O	
11	containing	O	
12	early	O	
13	nonsense	O	
14	mutations	O	
15	without	O	
16	affecting	O	
17	the	O	
18	decay	O	
19	rates	O	
20	of	O	
21	most	O	
22	other	O	
23	mRNAs	O	
24	.	O	

1	Judge	O	
2	OKs	O	
3	docs	O	
4	'	O	
5	bid	O	
6	for	O	
7	Chicago	O	
8	hospital	O	
9	.	O	

1	Among	O	
2	blood	O	
3	donors	O	
4	in	O	
5	the	O	
6	Republic	O	
7	of	O	
8	Serbia	O	
9	,	O	
10	regardless	O	
11	the	O	
12	number	O	
13	of	O	
14	blood	O	
15	donations	O	
16	,	O	
17	the	O	
18	percentage	O	
19	of	O	
20	female	O	
21	donors	O	
22	is	O	
23	significantly	O	
24	lower	O	
25	compared	O	
26	to	O	
27	the	O	
28	percentage	O	
29	of	O	
30	male	O	
31	blood	O	
32	donors	O	
33	.	O	

1	Mean	O	
2	+/-	O	
3	SD	O	
4	serum	B	
5	VEGF	I	
6	concentrations	O	
7	were	O	
8	significantly	O	
9	higher	O	
10	(	O	
11	P	O	
12	<	O	
13	0	O	
14	.	O	
15	001	O	
16	)	O	
17	in	O	
18	women	O	
19	with	O	
20	PCO	O	
21	and	O	
22	PCOS	O	
23	(	O	
24	3	O	
25	.	O	
26	4	O	
27	+/-	O	
28	0	O	
29	.	O	
30	7	O	
31	and	O	
32	3	O	
33	.	O	
34	2	O	
35	+/-	O	
36	0	O	
37	.	O	
38	66	O	
39	ng	O	
40	/	O	
41	ml	O	
42	respectively	O	
43	)	O	
44	compared	O	
45	with	O	
46	women	O	
47	with	O	
48	normal	O	
49	ovaries	O	
50	(	O	
51	2	O	
52	.	O	
53	3	O	
54	+/-	O	
55	0	O	
56	.	O	
57	5	O	
58	ng	O	
59	/	O	
60	ml	O	
61	).	O	

1	Acad	O	
2	.	O	

1	Only	O	
2	two	O	
3	of	O	
4	the	O	
5	isoforms	O	
6	possess	O	
7	the	O	
8	N	O	
9	-	O	
10	terminal	O	
11	zinc	O	
12	finger	O	
13	domain	O	
14	that	O	
15	is	O	
16	necessary	O	
17	and	O	
18	sufficient	O	
19	for	O	
20	TdT	B	
21	promoter	I	
22	binding	O	
23	.	O	

1	Ischemic	O	
2	stroke	O	
3	due	O	
4	to	O	
5	protein	B	
6	C	I	
7	deficiency	O	
8	.	O	

1	Cell	O	
2	49	O	
3	,	O	
4	753	O	
5	-	O	
6	761	O	
7	].	O	

1	Studies	O	
2	using	O	
3	the	O	
4	yeast	O	
5	two	O	
6	-	O	
7	hybrid	O	
8	system	O	
9	also	O	
10	did	O	
11	not	O	
12	provide	O	
13	evidence	O	
14	for	O	
15	the	O	
16	formation	O	
17	of	O	
18	a	O	
19	VDR	B	
20	-	O	
21	TR	B	
22	protein	O	
23	-	O	
24	protein	O	
25	interaction	O	
26	.	O	

1	Transfection	O	
2	analyses	O	
3	indicate	O	
4	that	O	
5	mutation	O	
6	of	O	
7	any	O	
8	one	O	
9	of	O	
10	these	O	
11	TGACCT	O	
12	motifs	O	
13	or	O	
14	truncation	O	
15	of	O	
16	the	O	
17	entire	O	
18	HD	B	
19	PPRE	O	
20	into	O	
21	a	O	
22	separate	O	
23	DR1	O	
24	and	O	
25	DR2	O	
26	element	O	
27	significantly	O	
28	reduced	O	
29	the	O	
30	transcriptional	O	
31	response	O	
32	of	O	
33	HD	B	
34	PPRE	O	
35	to	O	
36	peroxisome	O	
37	proliferators	O	
38	.	O	

1	Envelope	O	
2	-	O	
3	function	O	
4	matching	O	
5	conditions	O	
6	for	O	
7	GaAs	O	
8	/(	O	
9	Al	O	
10	,	O	
11	Ga	O	
12	)	O	
13	As	O	
14	heterojunctions	O	
15	.	O	

1	The	O	
2	concomitant	O	
3	interaction	O	
4	of	O	
5	mSTI1	B	
6	with	O	
7	hsp70	B	
8	and	O	
9	hsp90	B	
10	at	O	
11	its	O	
12	N	O	
13	-	O	
14	and	O	
15	C	O	
16	-	O	
17	termini	O	
18	respectively	O	
19	is	O	
20	mediated	O	
21	by	O	
22	the	O	
23	tetratricopeptide	O	
24	repeat	O	
25	(	O	
26	TPR	O	
27	)	O	
28	motifs	O	
29	in	O	
30	these	O	
31	regions	O	
32	.	O	

1	"	O	
2	Let	O	
3	the	O	
4	hundred	O	
5	flowers	O	
6	bloom	O	
7	".	O	

1	Laboratory	O	
2	studies	O	
3	using	O	
4	Ca45	O	
5	labeled	O	
6	teeth	O	
7	and	O	
8	biologically	O	
9	stained	O	
10	teeth	O	
11	confirmed	O	
12	that	O	
13	the	O	
14	dentifrice	O	
15	did	O	
16	not	O	
17	decalcify	O	
18	enamel	O	
19	or	O	
20	bleach	O	
21	teeth	O	
22	.	O	

1	The	O	
2	double	O	
3	-	O	
4	stranded	O	
5	RNA	O	
6	binding	O	
7	domain	O	
8	(	O	
9	dsRBD	O	
10	)	O	
11	is	O	
12	an	O	
13	approximately	O	
14	65	O	
15	amino	O	
16	acid	O	
17	motif	O	
18	that	O	
19	is	O	
20	found	O	
21	in	O	
22	a	O	
23	variety	O	
24	of	O	
25	proteins	O	
26	that	O	
27	interact	O	
28	with	O	
29	double	O	
30	-	O	
31	stranded	O	
32	(	O	
33	ds	O	
34	)	O	
35	RNA	O	
36	,	O	
37	such	O	
38	as	O	
39	Escherichia	O	
40	coli	O	
41	RNase	B	
42	III	I	
43	and	O	
44	the	O	
45	dsRNA	B	
46	-	I	
47	dependent	I	
48	kinase	I	
49	,	O	
50	PKR	B	
51	.	O	

1	No	O	
2	anisotropism	O	
3	was	O	
4	recorded	O	
5	in	O	
6	a	O	
7	tetrahydrofuran	O	
8	solution	O	
9	.	O	

1	Reporter	O	
2	gene	O	
3	expression	O	
4	analyses	O	
5	indicate	O	
6	that	O	
7	both	O	
8	WASP	B	
9	promoters	I	
10	show	O	
11	high	O	
12	levels	O	
13	of	O	
14	expression	O	
15	in	O	
16	different	O	
17	hematopoietic	O	
18	cell	O	
19	lines	O	
20	.	O	

1	Three	O	
2	separate	O	
3	activation	O	
4	subdomains	O	
5	,	O	
6	and	O	
7	one	O	
8	negative	O	
9	-	O	
10	acting	O	
11	region	O	
12	,	O	
13	which	O	
14	function	O	
15	in	O	
16	yeast	O	
17	were	O	
18	located	O	
19	in	O	
20	the	O	
21	carboxyl	O	
22	-	O	
23	terminal	O	
24	region	O	
25	of	O	
26	NIT4	B	
27	.	O	

1	Antibiotic	O	
2	effect	O	
3	of	O	
4	the	O	
5	mud	O	
6	from	O	
7	heviz	O	

1	Radiogallium	O	
2	imaging	O	
3	is	O	
4	thus	O	
5	of	O	
6	limited	O	
7	use	O	
8	in	O	
9	evaluation	O	
10	of	O	
11	suspected	O	
12	giant	O	
13	cell	O	
14	tumors	O	
15	of	O	
16	bone	O	
17	.	O	

1	It	O	
2	was	O	
3	found	O	
4	that	O	
5	the	O	
6	primary	O	
7	visual	O	
8	cortex	O	
9	of	O	
10	the	O	
11	rat	O	
12	is	O	
13	asymmetrical	O	
14	in	O	
15	volume	O	
16	,	O	
17	and	O	
18	that	O	
19	the	O	
20	asymmetry	O	
21	reflects	O	
22	side	O	
23	differences	O	
24	in	O	
25	the	O	
26	number	O	
27	of	O	
28	neurons	O	
29	.	O	

1	These	O	
2	data	O	
3	do	O	
4	not	O	
5	support	O	
6	the	O	
7	use	O	
8	of	O	
9	LDD	O	
10	to	O	
11	reduce	O	
12	risk	O	
13	of	O	
14	progression	O	
15	to	O	
16	MSOF	O	
17	in	O	
18	sepsis	O	
19	.	O	

1	NH2	O	
2	-	O	
3	and	O	
4	COOH	O	
5	-	O	
6	terminal	O	
7	deletion	O	
8	analysis	O	
9	revealed	O	
10	that	O	
11	both	O	
12	the	O	
13	PH	B	
14	and	O	
15	putative	O	
16	guanine	B	
17	nucleotide	I	
18	exchange	I	
19	factor	I	
20	domains	I	
21	are	O	
22	required	O	
23	,	O	
24	but	O	
25	the	O	
26	zinc	O	
27	butterfly	O	
28	is	O	
29	dispensable	O	
30	,	O	
31	for	O	
32	transformation	O	
33	.	O	

1	Evolutive	O	
2	morphology	O	
3	of	O	
4	the	O	
5	olfactory	O	
6	bulb	O	
7	in	O	
8	man	O	
9	and	O	
10	certain	O	
11	non	O	
12	-	O	
13	human	O	
14	mammals	O	

1	Twelve	O	
2	out	O	
3	of	O	
4	43	O	
5	renal	O	
6	failure	O	
7	patients	O	
8	had	O	
9	troponin	B	
10	I	I	
11	0	O	
12	.	O	
13	13	O	
14	-	O	
15	0	O	
16	.	O	
17	9	O	
18	microg	O	
19	/	O	
20	l	O	
21	using	O	
22	Axsym	O	
23	method	O	
24	and	O	
25	4	O	
26	had	O	
27	levels	O	
28	of	O	
29	0	O	
30	.	O	
31	07	O	
32	-	O	
33	0	O	
34	.	O	
35	13	O	
36	microg	O	
37	/	O	
38	l	O	
39	using	O	
40	Immuno	O	
41	1	O	
42	.	O	

1	In	O	
2	patients	O	
3	with	O	
4	type	O	
5	IA	O	
6	maple	O	
7	syrup	O	
8	urine	O	
9	disease	O	
10	,	O	
11	the	O	
12	E1alpha	B	
13	subunit	I	
14	is	O	
15	affected	O	
16	,	O	
17	resulting	O	
18	in	O	
19	the	O	
20	loss	O	
21	of	O	
22	E1	B	
23	and	O	
24	branched	B	
25	-	I	
26	chain	I	
27	ketoacid	I	
28	dehydrogenase	I	
29	catalytic	O	
30	activities	O	
31	.	O	

1	Downstream	O	
2	of	O	
3	the	O	
4	G	O	
5	-	O	
6	A	O	
7	anastomosis	O	
8	,	O	
9	the	O	
10	RD	O	
11	,	O	
12	CC	O	
13	,	O	
14	E	O	
15	(	O	
16	p	O	
17	)	O	
18	and	O	
19	loop	O	
20	areas	O	
21	were	O	
22	significantly	O	
23	different	O	
24	from	O	
25	REF	O	
26	,	O	
27	but	O	
28	significantly	O	
29	different	O	
30	from	O	
31	A	O	
32	-	O	
33	A	O	
34	.	O	

1	The	O	
2	monoexponential	O	
3	rate	O	
4	of	O	
5	clearance	O	
6	of	O	
7	tracer	O	
8	--	O	
9	obtained	O	
10	from	O	
11	the	O	
12	portion	O	
13	of	O	
14	the	O	
15	residue	O	
16	-	O	
17	detection	O	
18	curve	O	
19	reflecting	O	
20	metabolism	O	
21	of	O	
22	fatty	O	
23	acid	O	
24	incorporated	O	
25	into	O	
26	neutral	O	
27	lipids	O	
28	--	O	
29	correlated	O	
30	directly	O	
31	with	O	
32	induced	O	
33	changes	O	
34	in	O	
35	tension	O	
36	-	O	
37	time	O	
38	index	O	
39	after	O	
40	injections	O	
41	into	O	
42	the	O	
43	left	O	
44	atrium	O	
45	(	O	
46	r	O	
47	=	O	
48	0	O	
49	.	O	
50	96	O	
51	,	O	
52	n	O	
53	=	O	
54	12	O	
55	),	O	
56	right	O	
57	atrium	O	
58	(	O	
59	r	O	
60	=	O	
61	0	O	
62	.	O	
63	86	O	
64	,	O	
65	n	O	
66	=	O	
67	14	O	
68	),	O	
69	and	O	
70	ear	O	
71	vein	O	
72	(	O	
73	r	O	
74	=	O	
75	0	O	
76	.	O	
77	93	O	
78	,	O	
79	n	O	
80	=	O	
81	14	O	
82	).	O	

1	The	O	
2	primary	O	
3	CT	O	
4	findings	O	
5	were	O	
6	misinterpreted	O	
7	as	O	
8	a	O	
9	brain	O	
10	infarct	O	
11	or	O	
12	possibly	O	
13	a	O	
14	tumour	O	
15	.	O	

1	In	O	
2	contrast	O	
3	to	O	
4	the	O	
5	wild	O	
6	-	O	
7	type	O	
8	protein	O	
9	,	O	
10	expression	O	
11	of	O	
12	p45	B	
13	NF	I	
14	-	I	
15	E2	I	
16	lacking	O	
17	this	O	
18	activation	O	
19	domain	O	
20	in	O	
21	an	O	
22	NF	B	
23	-	I	
24	E2	I	
25	null	O	
26	cell	O	
27	line	O	
28	fails	O	
29	to	O	
30	support	O	
31	enhancer	O	
32	-	O	
33	dependent	O	
34	transcription	O	
35	in	O	
36	transient	O	
37	assays	O	
38	.	O	

1	Blood	O	
2	flow	O	
3	velocity	O	
4	waveforms	O	
5	were	O	
6	recorded	O	
7	by	O	
8	pulsed	O	
9	Doppler	O	
10	examination	O	
11	of	O	
12	the	O	
13	fetal	O	
14	internal	O	
15	carotid	O	
16	and	O	
17	middle	O	
18	cerebral	O	
19	arteries	O	
20	using	O	
21	the	O	
22	established	O	
23	transabdominal	O	
24	route	O	
25	as	O	
26	well	O	
27	as	O	
28	a	O	
29	new	O	
30	transvaginal	O	
31	approach	O	
32	.	O	

1	The	O	
2	expression	O	
3	pattern	O	
4	of	O	
5	GL2	B	
6	,	O	
7	as	O	
8	demonstrated	O	
9	by	O	
10	in	O	
11	situ	O	
12	hybridization	O	
13	,	O	
14	indicated	O	
15	that	O	
16	the	O	
17	gene	O	
18	is	O	
19	expressed	O	
20	in	O	
21	trichome	O	
22	progenitor	O	
23	cells	O	
24	and	O	
25	at	O	
26	stages	O	
27	associated	O	
28	with	O	
29	trichome	O	
30	development	O	
31	.	O	

1	RESULTS	O	
2	:	O	
3	Surprisingly	O	
4	,	O	
5	PAF	B	
6	blockade	O	
7	increased	O	
8	mortality	O	
9	after	O	
10	trauma	O	
11	(	O	
12	5	O	
13	of	O	
14	11	O	
15	WEB	O	
16	-	O	
17	2086	O	
18	animals	O	
19	versus	O	
20	1	O	
21	of	O	
22	9	O	
23	vehicle	O	
24	animals	O	
25	;	O	
26	p	O	
27	=	O	
28	0	O	
29	.	O	
30	15	O	
31	)	O	
32	and	O	
33	depressed	O	
34	cardiac	O	
35	index	O	
36	and	O	
37	O2	O	
38	delivery	O	
39	at	O	
40	72	O	
41	hours	O	
42	(	O	
43	p	O	
44	<	O	
45	0	O	
46	.	O	
47	05	O	
48	).	O	

1	I	O	
2	.	O	

1	In	O	
2	this	O	
3	study	O	
4	,	O	
5	the	O	
6	general	O	
7	clinical	O	
8	criteria	O	
9	for	O	
10	inhalation	O	
11	injury	O	
12	--	O	
13	presence	O	
14	of	O	
15	facial	O	
16	or	O	
17	oropharyngeal	O	
18	burns	O	
19	,	O	
20	carboxyhemoglobin	B	
21	levels	O	
22	,	O	
23	carbonaceous	O	
24	sputum	O	
25	,	O	
26	or	O	
27	closed	O	
28	space	O	
29	injury	O	
30	--	O	
31	did	O	
32	not	O	
33	differentiate	O	
34	patients	O	
35	with	O	
36	airway	O	
37	injury	O	
38	only	O	
39	from	O	
40	those	O	
41	with	O	
42	parenchymal	O	
43	injury	O	
44	.	O	

1	The	O	
2	predicted	O	
3	L	B	
4	mRNA	I	
5	was	O	
6	6398	O	
7	nucleotides	O	
8	long	O	
9	and	O	
10	contained	O	
11	a	O	
12	single	O	
13	open	O	
14	reading	O	
15	frame	O	
16	corresponding	O	
17	to	O	
18	an	O	
19	L	B	
20	protein	I	
21	encompassing	I	
22	2109	I	
23	amino	I	
24	acids	I	
25	with	O	
26	a	O	
27	MW	O	
28	of	O	
29	241	O	
30	,	O	
31	546	O	
32	.	O	

1	It	O	
2	was	O	
3	found	O	
4	that	O	
5	the	O	
6	ROSP	O	
7	undergoes	O	
8	a	O	
9	number	O	
10	of	O	
11	fluctuations	O	
12	in	O	
13	the	O	
14	negative	O	
15	and	O	
16	positive	O	
17	directions	O	
18	with	O	
19	a	O	
20	gradually	O	
21	decreasing	O	
22	amplitude	O	
23	in	O	
24	the	O	
25	course	O	
26	of	O	
27	5	O	
28	-	O	
29	25	O	
30	days	O	
31	following	O	
32	the	O	
33	operation	O	
34	,	O	
35	after	O	
36	which	O	
37	relatively	O	
38	stable	O	
39	negative	O	
40	values	O	
41	of	O	
42	the	O	
43	ROSP	O	
44	are	O	
45	established	O	
46	on	O	
47	the	O	
48	average	O	
49	in	O	
50	electrodes	O	
51	implanted	O	
52	to	O	
53	the	O	
54	level	O	
55	of	O	
56	the	O	
57	dura	O	
58	mater	O	
59	,	O	
60	and	O	
61	positive	O	
62	values	O	
63	in	O	
64	electrodes	O	
65	implanted	O	
66	to	O	
67	the	O	
68	level	O	
69	of	O	
70	the	O	
71	pia	O	
72	mater	O	
73	.	O	

1	Angiography	O	
2	was	O	
3	performed	O	
4	following	O	
5	the	O	
6	rCBF	O	
7	study	O	
8	and	O	
9	the	O	
10	degree	O	
11	of	O	
12	vasospasm	O	
13	was	O	
14	measured	O	
15	on	O	
16	the	O	
17	angiograms	O	
18	.	O	

1	Workplace	O	
2	violence	O	
3	--	O	
4	nurses	O	
5	at	O	
6	risk	O	
7	.	O	

1	It	O	
2	is	O	
3	mainly	O	
4	transcribed	O	
5	in	O	
6	neural	O	
7	structures	O	
8	and	O	
9	in	O	
10	developing	O	
11	organs	O	
12	characterized	O	
13	by	O	
14	epithelial	O	
15	-	O	
16	mesenchymal	O	
17	interactions	O	
18	.	O	

1	The	O	
2	beta	O	
3	chain	O	
4	contains	O	
5	five	O	
6	potential	O	
7	N	O	
8	-	O	
9	linked	O	
10	glycosylation	O	
11	sites	O	
12	,	O	
13	and	O	
14	endoglycosidase	B	
15	digestion	O	
16	suggested	O	
17	that	O	
18	the	O	
19	beta	O	
20	chain	O	
21	contained	O	
22	multiple	O	
23	complex	O	
24	carbohydrate	O	
25	side	O	
26	chains	O	
27	.	O	

1	A	O	
2	novel	O	
3	pleckstrin	B	
4	homology	I	
5	-	I	
6	related	I	
7	gene	I	
8	family	I	
9	defined	O	
10	by	O	
11	Ipl	B	
12	/	O	
13	Tssc3	B	
14	,	O	
15	TDAG51	B	
16	,	O	
17	and	O	
18	Tih1	B	
19	:	O	
20	tissue	O	
21	-	O	
22	specific	O	
23	expression	O	
24	,	O	
25	chromosomal	O	
26	location	O	
27	,	O	
28	and	O	
29	parental	O	
30	imprinting	O	
31	.	O	

1	ACTH	B	
2	release	O	
3	is	O	
4	transiently	O	
5	suppressed	O	
6	in	O	
7	some	O	
8	children	O	
9	after	O	
10	exogenous	O	
11	ACTH	B	
12	treatment	O	
13	.	O	

1	We	O	
2	found	O	
3	that	O	
4	total	O	
5	PSA	B	
6	can	O	
7	be	O	
8	detected	O	
9	in	O	
10	all	O	
11	cyst	O	
12	fluids	O	
13	and	O	
14	in	O	
15	about	O	
16	75	O	
17	%	O	
18	of	O	
19	female	O	
20	sera	O	
21	.	O	

1	Also	O	
2	discussed	O	
3	is	O	
4	the	O	
5	possibility	O	
6	of	O	
7	a	O	
8	combined	O	
9	genetic	O	
10	and	O	
11	environmental	O	
12	etiology	O	
13	.	O	

1	Immunostaining	O	
2	of	O	
3	cells	O	
4	transfected	O	
5	with	O	
6	these	O	
7	constructs	O	
8	revealed	O	
9	that	O	
10	both	O	
11	the	O	
12	myristoylated	O	
13	and	O	
14	nonmyristoylated	O	
15	mutants	O	
16	were	O	
17	localized	O	
18	in	O	
19	nuclei	O	
20	,	O	
21	whereas	O	
22	wild	B	
23	-	I	
24	type	I	
25	PKC	I	
26	alpha	I	
27	was	O	
28	primarily	O	
29	cytoplasmic	O	
30	and	O	
31	perinuclear	O	
32	.	O	

1	Members	O	
2	of	O	
3	the	O	
4	meis1	B	
5	and	O	
6	pbx	B	
7	homeodomain	I	
8	protein	I	
9	families	I	
10	cooperatively	O	
11	bind	O	
12	a	O	
13	cAMP	O	
14	-	O	
15	responsive	O	
16	sequence	O	
17	(	O	
18	CRS1	O	
19	)	O	
20	from	O	
21	bovine	B	
22	CYP17	I	
23	.	O	

1	9	O	
2	,	O	
3	1498	O	
4	-	O	
5	1506	O	
6	).	O	

1	The	O	
2	5	O	
3	'-	O	
4	flanking	O	
5	region	O	
6	,	O	
7	from	O	
8	nucleotide	O	
9	-	O	
10	837	O	
11	to	O	
12	-	O	
13	336	O	
14	,	O	
15	contains	O	
16	TATA	O	
17	and	O	
18	inverted	O	
19	CAAT	O	
20	boxes	O	
21	as	O	
22	well	O	
23	as	O	
24	GATA	B	
25	-	I	
26	1	I	
27	/	O	
28	SP1	B	
29	erythroid	O	
30	-	O	
31	specific	O	
32	cis	O	
33	-	O	
34	acting	O	
35	regulatory	O	
36	elements	O	
37	.	O	

1	A	O	
2	canonical	O	
3	TATA	O	
4	box	O	
5	was	O	
6	not	O	
7	detected	O	
8	.	O	

1	The	O	
2	adeno	B	
3	-	I	
4	associated	I	
5	virus	I	
6	(	I	
7	AAV	I	
8	)	I	
9	rep	I	
10	gene	I	
11	encodes	O	
12	four	O	
13	proteins	O	
14	(	O	
15	Rep78	B	
16	,	O	
17	Rep68	B	
18	,	O	
19	Rep52	B	
20	,	O	
21	and	O	
22	Rep40	B	
23	)	O	
24	required	O	
25	for	O	
26	AAV	O	
27	DNA	O	
28	replication	O	
29	and	O	
30	AAV	O	
31	gene	O	
32	regulation	O	
33	.	O	

1	Ischemic	O	
2	heart	O	
3	disease	O	
4	,	O	
5	age	O	
6	of	O	
7	more	O	
8	than	O	
9	75	O	
10	years	O	
11	,	O	
12	and	O	
13	the	O	
14	fact	O	
15	that	O	
16	the	O	
17	patient	O	
18	was	O	
19	a	O	
20	woman	O	
21	were	O	
22	independent	O	
23	predictors	O	
24	of	O	
25	poor	O	
26	cardiac	O	
27	function	O	
28	.	O	

1	The	O	
2	kappa	O	
3	coefficient	O	
4	of	O	
5	agreement	O	
6	between	O	
7	the	O	
8	Patho	O	
9	Dx	O	
10	Kit	O	
11	and	O	
12	the	O	
13	standard	O	
14	method	O	
15	was	O	
16	0	O	
17	.	O	
18	958	O	
19	.	O	

1	Radiolabelled	O	
2	palmitate	O	
3	was	O	
4	not	O	
5	incorporated	O	
6	into	O	
7	the	O	
8	mutated	O	
9	protein	O	
10	,	O	
11	showing	O	
12	that	O	
13	lipid	O	
14	modification	O	
15	occurs	O	
16	at	O	
17	the	O	
18	Cys	O	
19	-	O	
20	22	O	
21	residue	O	
22	.	O	

1	One	O	
2	hundred	O	
3	and	O	
4	four	O	
5	(	O	
6	14	O	
7	per	O	
8	cent	O	
9	)	O	
10	second	O	
11	primary	O	
12	tumours	O	
13	were	O	
14	reported	O	
15	.	O	

1	The	O	
2	interferon	B	
3	(	O	
4	IFN	B	
5	)-	O	
6	induced	O	
7	double	B	
8	-	I	
9	stranded	I	
10	RNA	I	
11	(	I	
12	dsRNA	I	
13	)-	I	
14	activated	I	
15	Ser	I	
16	/	I	
17	Thr	I	
18	protein	I	
19	kinase	I	
20	(	O	
21	PKR	B	
22	)	O	
23	plays	O	
24	a	O	
25	role	O	
26	in	O	
27	the	O	
28	antiviral	O	
29	and	O	
30	antiproliferative	O	
31	effects	O	
32	of	O	
33	IFN	B	
34	.	O	

1	Prolonged	O	
2	heavy	O	
3	work	O	
4	effected	O	
5	an	O	
6	increase	O	
7	of	O	
8	10	O	
9	.	O	
10	3	O	
11	plus	O	
12	or	O	
13	minus	O	
14	0	O	
15	.	O	
16	9	O	
17	mmHg	O	
18	in	O	
19	in	O	
20	vivo	O	
21	P50	O	
22	(	O	
23	7	O	
24	.	O	
25	30	O	
26	PH	O	
27	-	O	
28	v	O	
29	,	O	
30	41	O	
31	degrees	O	
32	C	O	
33	-	O	
34	v	O	
35	,	O	
36	and	O	
37	45	O	
38	Pv	O	
39	-	O	
40	CO2	O	
41	);	O	
42	due	O	
43	entirely	O	
44	to	O	
45	the	O	
46	additive	O	
47	effects	O	
48	of	O	
49	increased	O	
50	venous	O	
51	temperature	O	
52	and	O	
53	[	O	
54	H	O	
55	+].	O	

1	However	O	
2	,	O	
3	in	O	
4	the	O	
5	subgroup	O	
6	with	O	
7	normal	O	
8	Ht	O	
9	(<	O	
10	0	O	
11	.	O	
12	45	O	
13	l	O	
14	/	O	
15	l	O	
16	;	O	
17	n	O	
18	=	O	
19	201	O	
20	)	O	
21	there	O	
22	was	O	
23	a	O	
24	significant	O	
25	reduction	O	
26	(	O	
27	p	O	
28	<	O	
29	0	O	
30	.	O	
31	05	O	
32	)	O	
33	of	O	
34	the	O	
35	mortality	O	
36	after	O	
37	3	O	
38	months	O	
39	(	O	
40	27	O	
41	%	O	
42	and	O	
43	16	O	
44	%,	O	
45	respectively	O	
46	)	O	
47	and	O	
48	an	O	
49	increase	O	
50	of	O	
51	independence	O	
52	at	O	
53	home	O	
54	(	O	
55	35	O	
56	%	O	
57	and	O	
58	48	O	
59	%,	O	
60	respectively	O	
61	)	O	
62	due	O	
63	to	O	
64	a	O	
65	reduction	O	
66	of	O	
67	the	O	
68	viscosity	O	
69	by	O	
70	means	O	
71	of	O	
72	haemodilution	O	
73	with	O	
74	albumin	B	
75	(	O	
76	a	O	
77	specific	O	
78	viscosity	O	
79	effect	O	
80	in	O	
81	the	O	
82	normovolaemic	O	
83	group	O	
84	).	O	

1	Two	O	
2	specific	O	
3	DNA	O	
4	-	O	
5	protein	O	
6	complexes	O	
7	were	O	
8	identified	O	
9	in	O	
10	gel	O	
11	retardation	O	
12	assays	O	
13	using	O	
14	HeLa	O	
15	cell	O	
16	nuclear	O	
17	extracts	O	
18	and	O	
19	an	O	
20	oligonucleotide	O	
21	probe	O	
22	spanning	O	
23	the	O	
24	footprinted	O	
25	region	O	
26	.	O	

1	The	O	
2	prescription	O	
3	for	O	
4	apoplexy	O	
5	includes	O	
6	C1	O	
7	-	O	
8	7	O	
9	,	O	
10	T1	O	
11	-	O	
12	9	O	
13	and	O	
14	L2	O	
15	-	O	
16	4	O	
17	.	O	

1	While	O	
2	the	O	
3	latter	O	
4	corresponded	O	
5	to	O	
6	a	O	
7	protein	O	
8	of	O	
9	824	O	
10	amino	O	
11	acids	O	
12	,	O	
13	an	O	
14	upstream	O	
15	open	O	
16	reading	O	
17	frame	O	
18	(	O	
19	uORF	O	
20	)	O	
21	within	O	
22	the	O	
23	5	O	
24	'	O	
25	leader	O	
26	could	O	
27	potentially	O	
28	encode	O	
29	a	O	
30	54	O	
31	amino	O	
32	acid	O	
33	peptide	O	
34	.	O	

1	The	O	
2	5	O	
3	'	O	
4	flanking	O	
5	region	O	
6	of	O	
7	the	O	
8	CD1	B	
9	gene	I	
10	contained	O	
11	the	O	
12	binding	O	
13	motifs	O	
14	for	O	
15	two	O	
16	cytokine	O	
17	-	O	
18	inducible	O	
19	transcription	O	
20	factors	O	
21	,	O	
22	NF	B	
23	-	I	
24	IL2	I	
25	-	I	
26	A	I	
27	and	O	
28	NF	B	
29	-	I	
30	IL6	I	
31	.	O	

1	Thus	O	
2	,	O	
3	a	O	
4	negative	O	
5	test	O	
6	is	O	
7	compatible	O	
8	with	O	
9	low	O	
10	disease	O	
11	activity	O	
12	and	O	
13	/	O	
14	or	O	
15	efficacy	O	
16	of	O	
17	calcium	O	
18	antagonist	O	
19	treatment	O	
20	.	O	

1	In	O	
2	the	O	
3	present	O	
4	study	O	
5	,	O	
6	we	O	
7	sought	O	
8	to	O	
9	investigate	O	
10	whether	O	
11	constitutive	O	
12	NF	B	
13	-	I	
14	kappaB	I	
15	activity	O	
16	in	O	
17	chronically	O	
18	HIV	O	
19	-	O	
20	1	O	
21	-	O	
22	infected	O	
23	promonocytic	O	
24	U937	O	
25	(	O	
26	U9	O	
27	-	O	
28	IIIB	O	
29	)	O	
30	and	O	
31	myeloblastic	O	
32	PLB	O	
33	-	O	
34	985	O	
35	(	O	
36	PLB	O	
37	-	O	
38	IIIB	O	
39	)	O	
40	cells	O	
41	affects	O	
42	apoptotic	O	
43	signaling	O	
44	.	O	

1	The	O	
2	gene	O	
3	is	O	
4	contained	O	
5	within	O	
6	a	O	
7	1	O	
8	.	O	
9	8	O	
10	-	O	
11	kilobase	O	
12	AccI	B	
13	-	O	
14	EcoRI	B	
15	restriction	O	
16	fragment	O	
17	mapping	O	
18	at	O	
19	map	O	
20	coordinates	O	
21	0	O	
22	.	O	
23	136	O	
24	to	O	
25	0	O	
26	.	O	
27	148	O	
28	in	O	
29	the	O	
30	UL	O	
31	region	O	
32	of	O	
33	the	O	
34	EHV	O	
35	-	O	
36	1	O	
37	genome	O	
38	and	O	
39	is	O	
40	transcribed	O	
41	from	O	
42	right	O	
43	to	O	
44	left	O	
45	.	O	

1	Gaucher	O	
2	'	O	
3	s	O	
4	disease	O	
5	is	O	
6	a	O	
7	rare	O	
8	metabolic	O	
9	disorder	O	
10	characterized	O	
11	by	O	
12	the	O	
13	lack	O	
14	of	O	
15	beta	B	
16	-	I	
17	glucocerebrosidase	I	
18	enzyme	I	
19	.	O	

1	Radiolabeled	O	
2	recombinant	B	
3	TARC	I	
4	specifically	O	
5	bound	O	
6	to	O	
7	T	O	
8	cell	O	
9	lines	O	
10	and	O	
11	peripheral	O	
12	T	O	
13	cells	O	
14	but	O	
15	not	O	
16	to	O	
17	monocytes	O	
18	or	O	
19	granulocytes	O	
20	.	O	

1	Rat	B	
2	kidney	I	
3	carboxylesterase	I	
4	.	O	

1	The	O	
2	number	O	
3	of	O	
4	polymerases	O	
5	active	O	
6	in	O	
7	vitro	O	
8	at	O	
9	the	O	
10	E	O	
11	strand	O	
12	promoter	O	
13	was	O	
14	similar	O	
15	to	O	
16	the	O	
17	number	O	
18	of	O	
19	polymerases	O	
20	at	O	
21	the	O	
22	L	O	
23	strand	O	
24	promoter	O	
25	.	O	

1	Quantitative	O	
2	analysis	O	
3	of	O	
4	the	O	
5	coronary	O	
6	stenosis	O	
7	was	O	
8	assessed	O	
9	before	O	
10	and	O	
11	after	O	
12	PTCA	O	
13	,	O	
14	and	O	
15	the	O	
16	dilatation	O	
17	resulted	O	
18	in	O	
19	an	O	
20	increase	O	
21	in	O	
22	minimal	O	
23	luminal	O	
24	cross	O	
25	-	O	
26	sectional	O	
27	area	O	
28	from	O	
29	1	O	
30	.	O	
31	1	O	
32	+/-	O	
33	0	O	
34	.	O	
35	8	O	
36	to	O	
37	2	O	
38	.	O	
39	7	O	
40	+/-	O	
41	1	O	
42	.	O	
43	2	O	
44	mm2	O	
45	.	O	

1	The	O	
2	elevations	O	
3	achieved	O	
4	by	O	
5	LDEE	O	
6	given	O	
7	s	O	
8	.	O	
9	c	O	
10	.	O	
11	were	O	
12	higher	O	
13	than	O	
14	those	O	
15	achieved	O	
16	after	O	
17	i	O	
18	.	O	
19	p	O	
20	.	O	
21	administration	O	
22	and	O	
23	lasted	O	
24	for	O	
25	longer	O	
26	periods	O	
27	.	O	

1	GlcNAc	O	
2	-	O	
3	and	O	
4	GlcNAc2	O	
5	-	O	
6	PP	O	
7	-	O	
8	Dolichol	O	
9	biosynthesis	O	
10	could	O	
11	be	O	
12	shown	O	
13	with	O	
14	isolated	O	
15	S	O	
16	.	O	
17	cerevisiae	O	
18	membranes	O	
19	from	O	
20	cells	O	
21	harboring	O	
22	the	O	
23	recombinant	O	
24	plasmid	O	
25	and	O	
26	grown	O	
27	on	O	
28	glucose	O	
29	thus	O	
30	suppressing	O	
31	transcription	O	
32	of	O	
33	the	O	
34	endogenous	O	
35	gene	O	
36	.	O	

1	The	O	
2	addition	O	
3	of	O	
4	a	O	
5	Paf	B	
6	-	O	
7	containing	O	
8	extract	O	
9	does	O	
10	not	O	
11	lead	O	
12	to	O	
13	significant	O	
14	protein	O	
15	binding	O	
16	to	O	
17	these	O	
18	two	O	
19	hly	B	
20	target	I	
21	sequences	I	
22	in	O	
23	the	O	
24	absence	O	
25	of	O	
26	PrfA	B	
27	but	O	
28	converts	O	
29	the	O	
30	complex	O	
31	(	O	
32	CIII	O	
33	)	O	
34	consisting	O	
35	of	O	
36	PrfA	B	
37	and	O	
38	the	O	
39	109	B	
40	bp	I	
41	hly	I	
42	DNA	I	
43	fragment	I	
44	to	O	
45	a	O	
46	slower	O	
47	migrating	O	
48	PrfA	B	
49	-	O	
50	Paf	B	
51	-	O	
52	DNA	O	
53	complex	O	
54	(	O	
55	CI	O	
56	).	O	

1	Selection	O	
2	of	O	
3	the	O	
4	22	O	
5	items	O	
6	of	O	
7	the	O	
8	Clinical	O	
9	Institute	O	
10	Withdrawal	O	
11	Assessment	O	
12	-	O	
13	Benzodiazepines	O	
14	(	O	
15	CIWA	O	
16	-	O	
17	B	O	
18	)	O	
19	was	O	
20	based	O	
21	on	O	
22	statistically	O	
23	significant	O	
24	differences	O	
25	between	O	
26	baseline	O	
27	and	O	
28	critical	O	
29	withdrawal	O	
30	periods	O	
31	in	O	
32	high	O	
33	-	O	
34	dose	O	
35	subjects	O	
36	and	O	
37	between	O	
38	symptoms	O	
39	associated	O	
40	with	O	
41	placebo	O	
42	and	O	
43	diazepam	O	
44	in	O	
45	low	O	
46	-	O	
47	dose	O	
48	subjects	O	
49	,	O	
50	using	O	
51	contingency	O	
52	tables	O	
53	and	O	
54	logistic	O	
55	regression	O	
56	analysis	O	
57	.	O	

1	Fenoldopam	O	
2	,	O	
3	a	O	
4	dopamine	B	
5	receptor	I	
6	agonist	O	
7	,	O	
8	has	O	
9	been	O	
10	shown	O	
11	,	O	
12	in	O	
13	animal	O	
14	experiments	O	
15	,	O	
16	to	O	
17	improve	O	
18	renal	O	
19	perfusion	O	
20	.	O	

1	Induction	O	
2	of	O	
3	the	O	
4	urokinase	B	
5	promoter	I	
6	by	O	
7	HGF	B	
8	/	O	
9	SF	B	
10	via	O	
11	the	O	
12	Met	B	
13	receptor	I	
14	was	O	
15	blocked	O	
16	by	O	
17	co	O	
18	-	O	
19	expression	O	
20	of	O	
21	a	O	
22	dominant	O	
23	-	O	
24	negative	O	
25	Grb2	B	
26	and	O	
27	Sos1	B	
28	expression	O	
29	construct	O	
30	.	O	

1	This	O	
2	makes	O	
3	these	O	
4	compounds	O	
5	attractive	O	
6	as	O	
7	vehicles	O	
8	for	O	
9	these	O	
10	and	O	
11	other	O	
12	gases	O	
13	in	O	
14	-	O	
15	vivo	O	
16	and	O	
17	in	O	
18	-	O	
19	vitro	O	
20	.	O	

1	The	O	
2	mitochondrial	B	
3	regulatory	I	
4	region	I	
5	(	O	
6	mrr	B	
7	)	O	
8	located	O	
9	between	O	
10	the	O	
11	tRNAPhe	B	
12	and	O	
13	tRNAPro	B	
14	genes	I	
15	of	O	
16	mitochondrial	O	
17	DNA	O	
18	(	O	
19	mtDNA	O	
20	)	O	
21	is	O	
22	essential	O	
23	for	O	
24	regulation	O	
25	of	O	
26	replication	O	
27	and	O	
28	transcription	O	
29	of	O	
30	the	O	
31	mitochondrial	O	
32	genome	O	
33	.	O	

1	Histopathological	O	
2	examination	O	
3	revealed	O	
4	dose	O	
5	-	O	
6	related	O	
7	proliferation	O	
8	of	O	
9	type	O	
10	II	O	
11	pneumocytes	O	
12	in	O	
13	dams	O	
14	and	O	
15	proliferation	O	
16	of	O	
17	interstitial	O	
18	cells	O	
19	and	O	
20	delayed	O	
21	septal	O	
22	/	O	
23	capillary	O	
24	development	O	
25	in	O	
26	neonates	O	
27	.(	O	
28	ABSTRACT	O	
29	TRUNCATED	O	
30	AT	O	
31	250	O	
32	WORDS	O	
33	)	O	

1	Phosphorylation	O	
2	and	O	
3	spindle	O	
4	pole	O	
5	body	O	
6	localization	O	
7	of	O	
8	the	O	
9	Cdc15p	B	
10	mitotic	I	
11	regulatory	I	
12	protein	I	
13	kinase	I	
14	in	I	
15	budding	I	
16	yeast	I	
17	.	O	

1	These	O	
2	results	O	
3	suggest	O	
4	that	O	
5	HAPE	O	
6	-	O	
7	S	O	
8	-	O	
9	S	O	
10	are	O	
11	prone	O	
12	to	O	
13	irregular	O	
14	nocturnal	O	
15	breathing	O	
16	patterns	O	
17	at	O	
18	high	O	
19	altitude	O	
20	,	O	
21	which	O	
22	is	O	
23	associated	O	
24	with	O	
25	the	O	
26	development	O	
27	of	O	
28	AMS	O	
29	,	O	
30	but	O	
31	it	O	
32	was	O	
33	not	O	
34	possible	O	
35	to	O	
36	determine	O	
37	whether	O	
38	these	O	
39	abnormal	O	
40	breathing	O	
41	patterns	O	
42	are	O	
43	a	O	
44	cause	O	
45	or	O	
46	an	O	
47	effect	O	
48	of	O	
49	AMS	O	
50	.	O	

1	The	O	
2	micromethod	O	
3	uses	O	
4	microcuvettes	O	
5	and	O	
6	substitutes	O	
7	ferrozine	O	
8	for	O	
9	the	O	
10	bathophenanthroline	O	
11	chromogen	O	
12	of	O	
13	the	O	
14	ICSH	O	
15	.	O	

1	Specifically	O	
2	,	O	
3	the	O	
4	deduced	O	
5	FR	B	
6	-	I	
7	19	I	
8	amino	I	
9	acid	I	
10	sequence	I	
11	has	O	
12	approximately89	O	
13	,	O	
14	77	O	
15	,	O	
16	and	O	
17	68	O	
18	%	O	
19	overall	O	
20	identity	O	
21	to	O	
22	chicken	B	
23	TEF	I	
24	-	I	
25	1A	I	
26	,	O	
27	mouse	B	
28	TEF	I	
29	-	I	
30	1	I	
31	,	O	
32	and	O	
33	mouse	B	
34	embryonic	I	
35	TEA	I	
36	domain	I	
37	-	I	
38	containing	I	
39	factor	I	
40	,	O	
41	respectively	O	
42	.	O	

1	Elledge	O	
2	,	O	
3	P	O	
4	.	O	

1	In	O	
2	a	O	
3	112	O	
4	-	O	
5	d	O	
6	feedlot	O	
7	trial	O	
8	,	O	
9	105	O	
10	heifers	O	
11	were	O	
12	assigned	O	
13	to	O	
14	light	O	
15	,	O	
16	medium	O	
17	and	O	
18	heavy	O	
19	weight	O	
20	blocks	O	
21	on	O	
22	five	O	
23	treatments	O	
24	:	O	
25	dietary	O	
26	MGA	O	
27	(.	O	
28	5	O	
29	mg	O	
30	.	O	
31	hd	O	
32	-	O	
33	1	O	
34	.	O	
35	d	O	
36	-	O	
37	1	O	
38	),	O	
39	control	O	
40	(	O	
41	no	O	
42	MGA	O	
43	)	O	
44	or	O	
45	DEPO	O	
46	-	O	
47	MGA	O	
48	on	O	
49	d	O	
50	1	O	
51	at	O	
52	.	O	
53	5	O	
54	,	O	
55	1	O	
56	.	O	
57	0	O	
58	or	O	
59	1	O	
60	.	O	
61	5	O	
62	ml	O	
63	/	O	
64	hd	O	
65	(	O	
66	30	O	
67	,	O	
68	60	O	
69	or	O	
70	90	O	
71	mg	O	
72	MGA	O	
73	/	O	
74	hd	O	
75	,	O	
76	respectively	O	
77	).	O	

1	The	O	
2	first	O	
3	symptoms	O	
4	of	O	
5	enzootic	O	
6	calcinosis	O	
7	were	O	
8	noted	O	
9	in	O	
10	March	O	
11	1998	O	
12	,	O	
13	when	O	
14	some	O	
15	of	O	
16	the	O	
17	cows	O	
18	developed	O	
19	locomotor	O	
20	abnormalities	O	
21	.	O	

1	These	O	
2	results	O	
3	suggest	O	
4	that	O	
5	leader	O	
6	-	O	
7	mRNA	O	
8	fusion	O	
9	in	O	
10	coronavirus	O	
11	transcription	O	
12	does	O	
13	not	O	
14	require	O	
15	direct	O	
16	RNA	O	
17	-	O	
18	RNA	O	
19	interaction	O	
20	between	O	
21	complementary	O	
22	sequences	O	
23	.	O	

1	GAP	O	
2	JUNCTIONS	O	
3	IN	O	
4	THE	O	
5	BRAIN	O	
6	:	O	
7	PREFACE	O	
8	.	O	

1	At	O	
2	Cabras	O	
3	(	O	
4	Oristano	O	
5	),	O	
6	a	O	
7	town	O	
8	characterized	O	
9	by	O	
10	a	O	
11	high	O	
12	incidence	O	
13	of	O	
14	thalassaemia	O	
15	and	O	
16	G6PD	B	
17	deficiency	O	
18	less	O	
19	than	O	
20	half	O	
21	the	O	
22	people	O	
23	between	O	
24	18	O	
25	and	O	
26	35	O	
27	have	O	
28	a	O	
29	fair	O	
30	knowledge	O	
31	of	O	
32	genetic	O	
33	diseases	O	
34	and	O	
35	of	O	
36	their	O	
37	prevention	O	
38	.	O	

1	Ketamine	O	
2	in	O	
3	the	O	
4	treatment	O	
5	of	O	
6	bronchospasm	O	
7	during	O	
8	mechanical	O	
9	ventilation	O	
10	.	O	

1	Foreign	O	
2	profiles	O	
3	in	O	
4	air	O	
5	pollution	O	
6	control	O	
7	activities	O	
8	.	O	

1	When	O	
2	the	O	
3	E1A	B	
4	N	I	
5	-	I	
6	terminus	I	
7	is	O	
8	used	O	
9	as	O	
10	a	O	
11	competitor	O	
12	in	O	
13	squelshing	O	
14	experiments	O	
15	it	O	
16	abolishes	O	
17	CBP	B	
18	-	O	
19	induced	O	
20	activation	O	
21	of	O	
22	E2F1	B	
23	/	O	
24	DP1	B	
25	,	O	
26	whereas	O	
27	an	O	
28	E1A	B	
29	mutant	I	
30	lacking	O	
31	CBP	B	
32	binding	O	
33	ability	O	
34	fails	O	
35	to	O	
36	do	O	
37	so	O	
38	.	O	

1	Effect	O	
2	of	O	
3	thrombotic	O	
4	and	O	
5	antithrombotic	O	
6	drugs	O	
7	on	O	
8	the	O	
9	surface	O	
10	charge	O	
11	characteristics	O	
12	of	O	
13	canine	O	
14	blood	O	
15	vessels	O	
16	:	O	
17	in	O	
18	vivo	O	
19	and	O	
20	in	O	
21	vitro	O	
22	studies	O	
23	.	O	

1	These	O	
2	CTD	B	
3	kinases	I	
4	,	O	
5	designated	O	
6	CTDK1	B	
7	and	O	
8	CTDK2	B	
9	,	O	
10	are	O	
11	fractionated	O	
12	by	O	
13	chromatography	O	
14	on	O	
15	Mono	O	
16	Q	O	
17	.	O	

1	Thus	O	
2	,	O	
3	this	O	
4	study	O	
5	provides	O	
6	evidence	O	
7	that	O	
8	a	O	
9	novel	O	
10	,	O	
11	ubiquitous	O	
12	factor	O	
13	(	O	
14	HF	B	
15	-	I	
16	1a	I	
17	)	O	
18	and	O	
19	a	O	
20	muscle	O	
21	factor	O	
22	(	O	
23	HF	B	
24	-	I	
25	1b	I	
26	/	O	
27	MEF	B	
28	-	I	
29	2	I	
30	)	O	
31	can	O	
32	form	O	
33	a	O	
34	novel	O	
35	,	O	
36	E	O	
37	-	O	
38	box	O	
39	-	O	
40	independent	O	
41	pathway	O	
42	for	O	
43	muscle	O	
44	-	O	
45	specific	O	
46	expression	O	
47	in	O	
48	ventricular	O	
49	cardiac	O	
50	muscle	O	
51	cells	O	
52	.	O	

1	All	O	
2	patients	O	
3	had	O	
4	abnormal	O	
5	von	B	
6	Willebrand	I	
7	factor	I	
8	(	O	
9	vWF	B	
10	)	O	
11	fragmentation	O	
12	as	O	
13	reflected	O	
14	by	O	
15	decreased	O	
16	high	O	
17	molecular	O	
18	weight	O	
19	and	O	
20	increased	O	
21	low	O	
22	molecular	O	
23	weight	O	
24	vWF	B	
25	multimers	I	
26	in	O	
27	the	O	
28	circulation	O	
29	.	O	

1	During	O	
2	V	O	
3	-	O	
4	A	O	
5	bypass	O	
6	,	O	
7	hemodynamics	O	
8	were	O	
9	stable	O	
10	.	O	

1	On	O	
2	parents	O	

1	Truncated	O	
2	forms	O	
3	of	O	
4	a	O	
5	novel	O	
6	yeast	O	
7	protein	O	
8	suppress	O	
9	the	O	
10	lethality	O	
11	of	O	
12	a	O	
13	G	B	
14	protein	I	
15	alpha	I	
16	subunit	I	
17	deficiency	O	
18	by	O	
19	interacting	O	
20	with	O	
21	the	O	
22	beta	O	
23	subunit	O	
24	.	O	

1	Cellular	B	
2	Csk	I	
3	was	O	
4	associated	O	
5	with	O	
6	several	O	
7	phosphoproteins	O	
8	,	O	
9	some	O	
10	of	O	
11	which	O	
12	were	O	
13	interacting	O	
14	with	O	
15	the	O	
16	Csk	B	
17	SH2	I	
18	domain	I	
19	.	O	

1	The	O	
2	P131	O	
3	ORF	O	
4	is	O	
5	followed	O	
6	in	O	
7	-	O	
8	frame	O	
9	by	O	
10	a	O	
11	second	O	
12	ORF	O	
13	which	O	
14	is	O	
15	probably	O	
16	expressed	O	
17	by	O	
18	partial	O	
19	readthrough	O	
20	of	O	
21	the	O	
22	UGA	O	
23	termination	O	
24	codon	O	
25	of	O	
26	the	O	
27	P131	O	
28	ORF	O	
29	to	O	
30	produce	O	
31	a	O	
32	polypeptide	O	
33	of	O	
34	M	O	
35	(	O	
36	r	O	
37	)	O	
38	191044	O	
39	(	O	
40	P191	O	
41	).	O	

1	We	O	
2	conclude	O	
3	that	O	
4	at	O	
5	these	O	
6	low	O	
7	levels	O	
8	studied	O	
9	,	O	
10	aluminum	O	
11	accumulates	O	
12	in	O	
13	intestinal	O	
14	tissue	O	
15	,	O	
16	and	O	
17	that	O	
18	this	O	
19	accumulation	O	
20	is	O	
21	enhanced	O	
22	by	O	
23	citrate	O	
24	ligand	O	
25	.	O	

1	Acute	O	
2	pancreatitis	O	
3	:	O	
4	a	O	
5	multisystem	O	
6	disease	O	
7	.	O	

1	After	O	
2	the	O	
3	application	O	
4	of	O	
5	RS	O	
6	86	O	
7	,	O	
8	REM	O	
9	latency	O	
10	was	O	
11	shortened	O	
12	in	O	
13	all	O	
14	groups	O	
15	under	O	
16	investigation	O	
17	.	O	

1	The	O	
2	hyperacute	O	
3	phase	O	
4	of	O	
5	posterolateral	O	
6	myocardial	O	
7	infarction	O	
8	.	O	

1	Hepatitis	O	
2	C	O	
3	virus	O	
4	infection	O	
5	is	O	
6	a	O	
7	risk	O	
8	factor	O	
9	for	O	
10	liver	O	
11	failure	O	
12	from	O	
13	veno	O	
14	-	O	
15	occlusive	O	
16	disease	O	
17	after	O	
18	bone	O	
19	marrow	O	
20	transplantation	O	
21	.	O	

1	Linking	O	
2	continuous	O	
3	community	O	
4	-	O	
5	based	O	
6	morbidity	O	
7	recording	O	
8	of	O	
9	influenza	O	
10	-	O	
11	like	O	
12	illness	O	
13	(	O	
14	ILI	O	
15	)	O	
16	with	O	
17	virological	O	
18	sampling	O	
19	has	O	
20	consistently	O	
21	proved	O	
22	its	O	
23	value	O	
24	as	O	
25	one	O	
26	of	O	
27	the	O	
28	earliest	O	
29	indicators	O	
30	of	O	
31	circulating	O	
32	influenza	O	
33	activity	O	
34	.	O	

1	Increased	O	
2	plasma	O	
3	IgE	B	
4	was	O	
5	also	O	
6	confirmed	O	
7	in	O	
8	the	O	
9	NC	O	
10	mice	O	
11	,	O	
12	and	O	
13	treatment	O	
14	with	O	
15	FK506	O	
16	ointment	O	
17	reduced	O	
18	the	O	
19	plasma	O	
20	IgE	B	
21	level	O	
22	.	O	

1	Somatostatin	B	
2	-	O	
3	producing	O	
4	endocrine	O	
5	pancreatic	O	
6	tumor	O	
7	in	O	
8	Recklinghausen	O	
9	'	O	
10	s	O	
11	neurofibromatosis	O	
12	.	O	

1	We	O	
2	propose	O	
3	that	O	
4	Mnt	B	
5	:	O	
6	Max	B	
7	:	O	
8	Sin3	B	
9	complexes	O	
10	normally	O	
11	function	O	
12	to	O	
13	restrict	O	
14	Myc	B	
15	:	O	
16	Max	B	
17	activities	O	
18	associated	O	
19	with	O	
20	cell	O	
21	proliferation	O	
22	.	O	

1	Note	O	
2	on	O	
3	Slot	O	
4	'	O	
5	s	O	
6	method	O	
7	for	O	
8	the	O	
9	specific	O	
10	determination	O	
11	of	O	
12	creatinine	O	
13	.	O	

1	Moreover	O	
2	,	O	
3	exons	O	
4	2a	O	
5	and	O	
6	2b	O	
7	share	O	
8	the	O	
9	same	O	
10	5	O	
11	'	O	
12	sequence	O	
13	but	O	
14	differ	O	
15	from	O	
16	each	O	
17	other	O	
18	by	O	
19	the	O	
20	use	O	
21	of	O	
22	two	O	
23	distinct	O	
24	donor	O	
25	splice	O	
26	sites	O	
27	171	O	
28	bp	O	
29	apart	O	
30	in	O	
31	the	O	
32	gene	O	
33	.	O	

1	CONCLUSION	O	
2	:	O	
3	Vitrectomy	O	
4	for	O	
5	vitreous	O	
6	hemorrhage	O	
7	in	O	
8	Terson	O	
9	syndrome	O	
10	is	O	
11	a	O	
12	safe	O	
13	and	O	
14	effective	O	
15	procedure	O	
16	,	O	
17	offering	O	
18	a	O	
19	rapid	O	
20	and	O	
21	prolonged	O	
22	improvement	O	
23	in	O	
24	vision	O	
25	.	O	

1	An	O	
2	activation	O	
3	-	O	
4	responsive	O	
5	element	O	
6	in	O	
7	single	B	
8	C	I	
9	motif	I	
10	-	I	
11	1	I	
12	/	O	
13	lymphotactin	B	
14	promoter	O	
15	is	O	
16	a	O	
17	site	O	
18	of	O	
19	constitutive	O	
20	and	O	
21	inducible	O	
22	DNA	O	
23	-	O	
24	protein	O	
25	interactions	O	
26	involving	O	
27	nuclear	O	
28	factor	O	
29	of	O	
30	activated	O	
31	T	O	
32	cell	O	
33	.	O	

1	The	O	
2	ability	O	
3	of	O	
4	U6	B	
5	-	O	
6	U57	B	
7	mutants	O	
8	to	O	
9	influence	O	
10	the	O	
11	fidelity	O	
12	of	O	
13	both	O	
14	branch	O	
15	site	O	
16	and	O	
17	3	O	
18	'	O	
19	splice	O	
20	site	O	
21	recognition	O	
22	suggests	O	
23	that	O	
24	this	O	
25	nucleotide	O	
26	may	O	
27	participate	O	
28	in	O	
29	the	O	
30	formation	O	
31	of	O	
32	the	O	
33	active	O	
34	site	O	
35	(	O	
36	s	O	
37	)	O	
38	of	O	
39	the	O	
40	spliceosome	O	
41	.	O	

1	Our	O	
2	results	O	
3	,	O	
4	when	O	
5	combined	O	
6	with	O	
7	previously	O	
8	published	O	
9	in	O	
10	vitro	O	
11	results	O	
12	,	O	
13	support	O	
14	a	O	
15	direct	O	
16	role	O	
17	for	O	
18	Prp44p	B	
19	in	O	
20	unwinding	O	
21	of	O	
22	the	O	
23	U4	B	
24	/	O	
25	U6	B	
26	helix	O	
27	.	O	

1	There	O	
2	was	O	
3	a	O	
4	close	O	
5	correlation	O	
6	between	O	
7	plasma	O	
8	clearance	O	
9	of	O	
10	NT	O	
11	by	O	
12	10	O	
13	-	O	
14	hydroxylation	O	
15	and	O	
16	the	O	
17	D	O	
18	metabolic	O	
19	ratio	O	
20	(	O	
21	D	O	
22	/	O	
23	4	O	
24	-	O	
25	OH	O	
26	-	O	
27	D	O	
28	in	O	
29	urine	O	
30	)	O	
31	in	O	
32	the	O	
33	Ghanaians	O	
34	(	O	
35	rs	O	
36	=	O	
37	-	O	
38	0	O	
39	.	O	
40	95	O	
41	;	O	
42	P	O	
43	less	O	
44	than	O	
45	0	O	
46	.	O	
47	01	O	
48	)	O	
49	and	O	
50	Swedes	O	
51	(	O	
52	rs	O	
53	=	O	
54	-	O	
55	0	O	
56	.	O	
57	84	O	
58	;	O	
59	P	O	
60	less	O	
61	than	O	
62	0	O	
63	.	O	
64	01	O	
65	).	O	

1	The	O	
2	mean	O	
3	values	O	
4	of	O	
5	the	O	
6	concentrations	O	
7	of	O	
8	the	O	
9	components	O	
10	due	O	
11	to	O	
12	tobacco	O	
13	smoke	O	
14	are	O	
15	:	O	
16	CO	O	
17	=	O	
18	1	O	
19	.	O	
20	1	O	
21	ppm	O	
22	,	O	
23	NO	O	
24	=	O	
25	32	O	
26	ppb	O	
27	,	O	
28	NO2	O	
29	=	O	
30	24	O	
31	ppb	O	
32	,	O	
33	nicotine	O	
34	=	O	
35	0	O	
36	.	O	
37	9	O	
38	micrograms	O	
39	/	O	
40	m3	O	
41	,	O	
42	particulate	O	
43	matter	O	
44	=	O	
45	133	O	
46	micrograms	O	
47	/	O	
48	m3	O	
49	.	O	

1	Phosphocreatine	O	
2	hydrolysis	O	
3	during	O	
4	submaximal	O	
5	exercise	O	
6	:	O	
7	the	O	
8	effect	O	
9	of	O	
10	FIO2	O	
11	.	O	

1	Little	O	
2	is	O	
3	known	O	
4	about	O	
5	the	O	
6	mechanism	O	
7	,	O	
8	but	O	
9	the	O	
10	availability	O	
11	of	O	
12	rapid	O	
13	facile	O	
14	assays	O	
15	for	O	
16	monitoring	O	
17	immunoglobulin	B	
18	hypermutation	O	
19	would	O	
20	greatly	O	
21	aid	O	
22	the	O	
23	development	O	
24	of	O	
25	culture	O	
26	systems	O	
27	for	O	
28	hypermutating	O	
29	B	O	
30	cells	O	
31	as	O	
32	well	O	
33	as	O	
34	the	O	
35	screening	O	
36	for	O	
37	individuals	O	
38	deficient	O	
39	in	O	
40	the	O	
41	process	O	
42	.	O	

1	The	O	
2	results	O	
3	indicate	O	
4	that	O	
5	the	O	
6	relationship	O	
7	between	O	
8	comprehension	O	
9	and	O	
10	production	O	
11	is	O	
12	different	O	
13	at	O	
14	different	O	
15	stages	O	
16	in	O	
17	development	O	
18	.	O	

1	These	O	
2	data	O	
3	showed	O	
4	:	O	
5	that	O	
6	progesterone	O	
7	secretion	O	
8	is	O	
9	pulsatile	O	
10	throughout	O	
11	the	O	
12	human	O	
13	luteal	O	
14	phase	O	
15	,	O	
16	with	O	
17	maximum	O	
18	frequency	O	
19	in	O	
20	the	O	
21	mid	O	
22	-	O	
23	luteal	O	
24	phase	O	
25	;	O	
26	that	O	
27	during	O	
28	the	O	
29	mid	O	
30	-	O	
31	luteal	O	
32	phase	O	
33	most	O	
34	subjects	O	
35	had	O	
36	progesterone	O	
37	levels	O	
38	both	O	
39	above	O	
40	and	O	
41	below	O	
42	currently	O	
43	accepted	O	
44	ovulatory	O	
45	thresholds	O	
46	;	O	
47	the	O	
48	use	O	
49	of	O	
50	a	O	
51	single	O	
52	measurement	O	
53	of	O	
54	progesterone	O	
55	in	O	
56	the	O	
57	mid	O	
58	-	O	
59	luteal	O	
60	phase	O	
61	is	O	
62	not	O	
63	always	O	
64	a	O	
65	reliable	O	
66	indicator	O	
67	of	O	
68	ovulation	O	
69	;	O	
70	a	O	
71	threshold	O	
72	greater	O	
73	than	O	
74	20	O	
75	nmol	O	
76	/	O	
77	l	O	
78	may	O	
79	yield	O	
80	an	O	
81	unacceptable	O	
82	number	O	
83	of	O	
84	false	O	
85	negative	O	
86	results	O	
87	.	O	

1	The	O	
2	Oct	B	
3	-	I	
4	3	I	
5	/	I	
6	4	I	
7	gene	I	
8	product	I	
9	,	O	
10	which	O	
11	belongs	O	
12	to	O	
13	the	O	
14	POU	B	
15	family	I	
16	of	I	
17	transcription	I	
18	factors	I	
19	,	O	
20	is	O	
21	a	O	
22	good	O	
23	candidate	O	
24	for	O	
25	regulating	O	
26	initial	O	
27	differentiation	O	
28	decisions	O	
29	.	O	

1	Shc	B	
2	stimulates	O	
3	Ras	B	
4	/	O	
5	mitogen	B	
6	-	I	
7	activated	I	
8	protein	I	
9	kinase	I	
10	(	O	
11	MAPK	B	
12	)	O	
13	through	O	
14	forming	O	
15	a	O	
16	complex	O	
17	with	O	
18	Grb2	B	
19	at	O	
20	the	O	
21	phosphorylated	O	
22	tyrosine	O	
23	(	O	
24	Y	O	
25	)	O	
26	residue	O	
27	317	O	
28	.	O	

1	However	O	
2	,	O	
3	the	O	
4	element	O	
5	proximal	O	
6	to	O	
7	the	O	
8	transcription	O	
9	start	O	
10	site	O	
11	is	O	
12	dependent	O	
13	on	O	
14	the	O	
15	SRE	O	
16	-	O	
17	1	O	
18	.	O	

1	H	O	
2	-	O	
3	7	O	
4	,	O	
5	which	O	
6	specifically	O	
7	,	O	
8	although	O	
9	weakly	O	
10	,	O	
11	inhibited	O	
12	PKC	B	
13	activation	O	
14	,	O	
15	had	O	
16	no	O	
17	effect	O	
18	on	O	
19	tyrosine	O	
20	phosphorylation	O	
21	and	O	
22	PtdIns	O	
23	(	O	
24	3	O	
25	,	O	
26	4	O	
27	)	O	
28	P2	O	
29	production	O	
30	.	O	

1	The	O	
2	genomic	O	
3	fragments	O	
4	were	O	
5	fused	O	
6	upstream	O	
7	of	O	
8	the	O	
9	luciferase	B	
10	reporter	I	
11	gene	I	
12	.	O	

1	Stable	O	
2	association	O	
3	of	O	
4	U2	B	
5	snRNP	I	
6	with	O	
7	the	O	
8	branchpoint	O	
9	sequence	O	
10	of	O	
11	mammalian	O	
12	pre	O	
13	-	O	
14	mRNAs	O	
15	requires	O	
16	binding	O	
17	of	O	
18	a	O	
19	non	O	
20	-	O	
21	snRNP	O	
22	protein	O	
23	to	O	
24	the	O	
25	polypyrimidine	O	
26	tract	O	
27	.	O	

1	SETTING	O	
2	--	O	
3	Women	O	
4	,	O	
5	Infants	O	
6	,	O	
7	and	O	
8	Children	O	
9	clinics	O	
10	in	O	
11	Minneapolis	O	
12	,	O	
13	Minn	O	
14	.	O	

1	A	O	
2	candidate	O	
3	gene	O	
4	for	O	
5	Bcg	B	
6	,	O	
7	designated	O	
8	natural	B	
9	resistance	I	
10	-	I	
11	associated	I	
12	macrophage	I	
13	protein	I	
14	(	O	
15	Nramp	B	
16	),	O	
17	has	O	
18	been	O	
19	isolated	O	
20	and	O	
21	shown	O	
22	to	O	
23	encode	O	
24	a	O	
25	novel	O	
26	macrophage	O	
27	-	O	
28	specific	O	
29	membrane	O	
30	protein	O	
31	,	O	
32	which	O	
33	is	O	
34	altered	O	
35	in	O	
36	susceptible	O	
37	animals	O	
38	.	O	

1	Cluster	O	
2	formation	O	
3	of	O	
4	E	B	
5	-	I	
6	cadherin	I	
7	on	O	
8	the	O	
9	cell	O	
10	surface	O	
11	is	O	
12	believed	O	
13	to	O	
14	be	O	
15	of	O	
16	major	O	
17	importance	O	
18	for	O	
19	cell	O	
20	-	O	
21	cell	O	
22	adhesion	O	
23	.	O	

1	To	O	
2	further	O	
3	our	O	
4	knowledge	O	
5	about	O	
6	the	O	
7	systemic	O	
8	humoral	O	
9	immune	O	
10	system	O	
11	response	O	
12	to	O	
13	weak	O	
14	hapten	O	
15	-	O	
16	syngeneic	O	
17	or	O	
18	allogeneic	O	
19	protein	O	
20	conjugates	O	
21	(	O	
22	corrosion	O	
23	and	O	
24	wear	O	
25	products	O	
26	of	O	
27	metallic	O	
28	orthopedic	O	
29	devices	O	
30	),	O	
31	a	O	
32	sensitive	O	
33	enzyme	O	
34	-	O	
35	linked	O	
36	immunosorbent	O	
37	assay	O	
38	(	O	
39	ELISA	O	
40	)	O	
41	method	O	
42	for	O	
43	testing	O	
44	for	O	
45	antibody	O	
46	(	O	
47	humoral	O	
48	immunity	O	
49	)	O	
50	to	O	
51	metals	O	
52	was	O	
53	developed	O	
54	.	O	

1	Members	O	
2	of	O	
3	the	O	
4	MAPK	B	
5	family	I	
6	include	O	
7	the	O	
8	extracellular	B	
9	response	I	
10	kinases	I	
11	(	O	
12	ERKs	B	
13	or	O	
14	p42	B	
15	/	I	
16	44	I	
17	(	O	
18	MAPK	B	
19	)),	O	
20	the	O	
21	c	B	
22	-	I	
23	Jun	I	
24	amino	I	
25	-	I	
26	terminal	I	
27	kinases	I	
28	(	O	
29	JNKs	B	
30	),	O	
31	and	O	
32	the	O	
33	p38	B	
34	/	O	
35	Hog	B	
36	1	I	
37	protein	O	
38	kinases	O	
39	.	O	

1	These	O	
2	data	O	
3	suggest	O	
4	that	O	
5	the	O	
6	G	B	
7	-	I	
8	protein	I	
9	gene	I	
10	family	I	
11	may	O	
12	be	O	
13	distributed	O	
14	over	O	
15	at	O	
16	least	O	
17	two	O	
18	human	O	
19	chromosomes	O	
20	.	O	

1	Two	O	
2	basic	O	
3	patterns	O	
4	of	O	
5	locomotor	O	
6	behavior	O	
7	and	O	
8	corresponding	O	
9	torso	O	
10	morphology	O	
11	exist	O	
12	among	O	
13	extant	O	
14	anthropoids	O	
15	.	O	

1	The	O	
2	imprinted	O	
3	expression	O	
4	of	O	
5	the	O	
6	endogenous	O	
7	gene	O	
8	can	O	
9	be	O	
10	recapitulated	O	
11	in	O	
12	mice	O	
13	by	O	
14	using	O	
15	a	O	
16	14	O	
17	-	O	
18	kb	O	
19	transgene	O	
20	encompassing	O	
21	4	O	
22	kb	O	
23	of	O	
24	5	O	
25	'-	O	
26	flanking	O	
27	sequence	O	
28	,	O	
29	8	O	
30	kb	O	
31	of	O	
32	3	O	
33	'-	O	
34	flanking	O	
35	sequence	O	
36	,	O	
37	which	O	
38	includes	O	
39	the	O	
40	two	O	
41	endoderm	O	
42	-	O	
43	specific	O	
44	enhancers	O	
45	,	O	
46	and	O	
47	an	O	
48	internally	O	
49	deleted	O	
50	structural	O	
51	gene	O	
52	.	O	

1	Trinipatch	O	
2	is	O	
3	a	O	
4	small	O	
5	,	O	
6	transparent	O	
7	,	O	
8	matricial	O	
9	,	O	
10	monolayer	O	
11	patch	O	
12	with	O	
13	an	O	
14	absorption	O	
15	promoter	O	
16	,	O	
17	marketed	O	
18	in	O	
19	two	O	
20	dose	O	
21	-	O	
22	strengths	O	
23	(	O	
24	5	O	
25	mg	O	
26	/	O	
27	24	O	
28	h	O	
29	and	O	
30	10	O	
31	mg	O	
32	/	O	
33	24	O	
34	h	O	
35	)	O	
36	by	O	
37	Laboratoires	O	
38	Synthelabo	O	
39	.	O	

1	Primer	O	
2	extension	O	
3	experiments	O	
4	indicated	O	
5	that	O	
6	the	O	
7	transcription	O	
8	initiation	O	
9	site	O	
10	mapped	O	
11	to	O	
12	a	O	
13	position	O	
14	on	O	
15	gene	B	
16	IV	I	
17	that	O	
18	was	O	
19	analogous	O	
20	to	O	
21	that	O	
22	reported	O	
23	for	O	
24	the	O	
25	structurally	O	
26	similar	O	
27	P	B	
28	-	I	
29	450e	I	
30	gene	I	
31	.	O	

1	Thus	O	
2	,	O	
3	Fis	B	
4	acts	O	
5	as	O	
6	an	O	
7	accessory	O	
8	transcriptional	O	
9	activator	O	
10	at	O	
11	the	O	
12	mar	B	
13	promoter	I	
14	.	O	

1	This	O	
2	gene	O	
3	spans	O	
4	23	O	
5	kb	O	
6	and	O	
7	is	O	
8	composed	O	
9	of	O	
10	five	O	
11	exons	O	
12	and	O	
13	four	O	
14	introns	O	
15	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	capsid	B	
5	proteins	I	
6	derived	O	
7	from	O	
8	the	O	
9	P1	B	
10	precursor	I	
11	with	O	
12	a	O	
13	valine	O	
14	substitution	O	
15	at	O	
16	the	O	
17	amino	O	
18	terminus	O	
19	of	O	
20	VP1	B	
21	(	O	
22	VP1	B	
23	-	I	
24	G001V	I	
25	)	O	
26	assembled	O	
27	empty	O	
28	capsid	O	
29	particles	O	
30	but	O	
31	were	O	
32	deficient	O	
33	in	O	
34	assembling	O	
35	RNA	O	
36	-	O	
37	containing	O	
38	virions	O	
39	.	O	

1	Transcriptional	O	
2	analysis	O	
3	of	O	
4	a	O	
5	series	O	
6	of	O	
7	deletion	O	
8	mutants	O	
9	of	O	
10	the	O	
11	gene	O	
12	in	O	
13	the	O	
14	nuclear	O	
15	extracts	O	
16	prepared	O	
17	from	O	
18	the	O	
19	middle	O	
20	silk	O	
21	gland	O	
22	of	O	
23	2	O	
24	-	O	
25	day	O	
26	-	O	
27	old	O	
28	fifth	O	
29	instar	O	
30	larvae	O	
31	revealed	O	
32	the	O	
33	presence	O	
34	of	O	
35	multiple	O	
36	cis	O	
37	-	O	
38	regulatory	O	
39	elements	O	
40	located	O	
41	both	O	
42	upstream	O	
43	and	O	
44	downstream	O	
45	of	O	
46	the	O	
47	initiation	O	
48	site	O	
49	.	O	

1	The	O	
2	protein	O	
3	folds	O	
4	correctly	O	
5	with	O	
6	two	O	
7	disulfide	O	
8	bonds	O	
9	and	O	
10	a	O	
11	free	O	
12	thiol	O	
13	group	O	
14	at	O	
15	Cys25	O	
16	.	O	

1	The	O	
2	clinico	O	
3	-	O	
4	pathological	O	
5	data	O	
6	from	O	
7	a	O	
8	patient	O	
9	with	O	
10	irreversible	O	
11	post	O	
12	-	O	
13	partum	O	
14	renal	O	
15	failure	O	
16	(	O	
17	IPRF	O	
18	)	O	
19	are	O	
20	presented	O	
21	.	O	

1	Immobilization	O	
2	of	O	
3	the	O	
4	fracture	O	
5	in	O	
6	a	O	
7	collar	O	
8	and	O	
9	cuff	O	
10	sling	O	
11	was	O	
12	as	O	
13	effective	O	
14	as	O	
15	more	O	
16	elaborate	O	
17	methods	O	
18	.	O	

1	When	O	
2	multiple	O	
3	copies	O	
4	of	O	
5	the	O	
6	IL	B	
7	-	I	
8	1	I	
9	beta	I	
10	NF	I	
11	-	I	
12	kappa	I	
13	B	I	
14	site	I	
15	were	O	
16	linked	O	
17	to	O	
18	an	O	
19	enhancerless	O	
20	simian	B	
21	virus	I	
22	40	I	
23	promoter	I	
24	,	O	
25	this	O	
26	element	O	
27	was	O	
28	able	O	
29	to	O	
30	mediate	O	
31	phorbol	O	
32	ester	O	
33	-	O	
34	or	O	
35	lipopolysaccharide	O	
36	-	O	
37	inducible	O	
38	gene	O	
39	expression	O	
40	.	O	

1	Mutational	O	
2	analysis	O	
3	of	O	
4	the	O	
5	L1	B	
6	binding	I	
7	site	I	
8	of	O	
9	23S	B	
10	rRNA	I	
11	in	I	
12	Escherichia	I	
13	coli	I	
14	.	O	

1	The	O	
2	possibility	O	
3	of	O	
4	selective	O	
5	chemotherapy	O	
6	of	O	
7	progressive	O	
8	recurring	O	
9	ovarian	O	
10	carcinoma	O	
11	with	O	
12	the	O	
13	aid	O	
14	of	O	
15	cytodiagnosis	O	
16	and	O	
17	incorporation	O	
18	of	O	
19	tagged	O	
20	idoxuridine	O	

1	However	O	
2	,	O	
3	study	O	
4	of	O	
5	the	O	
6	productive	O	
7	gamma	O	
8	gene	O	
9	showed	O	
10	that	O	
11	the	O	
12	skipped	O	
13	variable	O	
14	exon	O	
15	was	O	
16	bounded	O	
17	by	O	
18	normal	O	
19	splicing	O	
20	signals	O	
21	and	O	
22	that	O	
23	the	O	
24	adjacent	O	
25	intron	O	
26	organization	O	
27	was	O	
28	not	O	
29	altered	O	
30	.	O	

1	It	O	
2	has	O	
3	been	O	
4	calculated	O	
5	that	O	
6	600	O	
7	,	O	
8	000	O	
9	new	O	
10	cases	O	
11	of	O	
12	lung	O	
13	cancer	O	
14	occur	O	
15	worldwide	O	
16	every	O	
17	year	O	
18	,	O	
19	most	O	
20	of	O	
21	them	O	
22	due	O	
23	to	O	
24	smoking	O	
25	.	O	

1	BACKGROUND	O	
2	:	O	
3	We	O	
4	conducted	O	
5	a	O	
6	phase	O	
7	I	O	
8	study	O	
9	with	O	
10	MDL	O	
11	73	O	
12	,	O	
13	147EF	O	
14	,	O	
15	a	O	
16	new	O	
17	5	B	
18	hydroxytryptamine	I	
19	3	I	
20	(	I	
21	5	I	
22	-	I	
23	HT3	I	
24	)	I	
25	receptor	I	
26	antagonist	O	
27	,	O	
28	in	O	
29	25	O	
30	patients	O	
31	requiring	O	
32	emetogenic	O	
33	chemotherapy	O	
34	.	O	

1	The	O	
2	protein	O	
3	was	O	
4	associated	O	
5	with	O	
6	purified	O	
7	vaccinia	O	
8	virus	O	
9	particles	O	
10	and	O	
11	with	O	
12	membranes	O	
13	of	O	
14	immature	O	
15	and	O	
16	mature	O	
17	virions	O	
18	that	O	
19	were	O	
20	visualized	O	
21	by	O	
22	electron	O	
23	microscopy	O	
24	of	O	
25	infected	O	
26	cells	O	
27	.	O	

1	Comparisons	O	
2	with	O	
3	other	O	
4	known	O	
5	germins	B	
6	and	O	
7	germin	B	
8	-	I	
9	like	I	
10	proteins	I	
11	indicate	O	
12	that	O	
13	these	O	
14	Arabidopsis	O	
15	GLP	B	
16	subfamilies	O	
17	are	O	
18	unique	O	
19	from	O	
20	wheat	O	
21	germin	B	
22	.	O	

1	The	O	
2	MCA	O	
3	and	O	
4	UA	O	
5	PI	O	
6	values	O	
7	showed	O	
8	the	O	
9	greatest	O	
10	deviation	O	
11	for	O	
12	any	O	
13	single	O	
14	-	O	
15	vessel	O	
16	parameter	O	
17	.	O	

1	Selection	O	
2	using	O	
3	SC	O	
4	EPD	O	
5	was	O	
6	more	O	
7	effective	O	
8	than	O	
9	phenotypic	O	
10	selection	O	
11	in	O	
12	reducing	O	
13	age	O	
14	at	O	
15	puberty	O	
16	in	O	
17	daughters	O	
18	.	O	

1	No	O	
2	significant	O	
3	differences	O	
4	were	O	
5	identified	O	
6	between	O	
7	groups	O	
8	for	O	
9	pH	O	
10	,	O	
11	PaCO2	O	
12	,	O	
13	intracranial	O	
14	pressure	O	
15	,	O	
16	heart	O	
17	rate	O	
18	,	O	
19	brain	O	
20	temperature	O	
21	,	O	
22	or	O	
23	glucose	O	
24	levels	O	
25	.	O	

1	Among	O	
2	9	O	
3	group	O	
4	I	O	
5	patients	O	
6	with	O	
7	a	O	
8	positive	O	
9	result	O	
10	on	O	
11	head	O	
12	-	O	
13	up	O	
14	tilt	O	
15	-	O	
16	table	O	
17	testing	O	
18	and	O	
19	no	O	
20	evidence	O	
21	of	O	
22	structural	O	
23	heart	O	
24	disease	O	
25	(	O	
26	mean	O	
27	follow	O	
28	-	O	
29	up	O	
30	4	O	
31	.	O	
32	3	O	
33	years	O	
34	),	O	
35	7	O	
36	are	O	
37	without	O	
38	further	O	
39	episodes	O	
40	of	O	
41	syncope	O	
42	;	O	
43	3	O	
44	have	O	
45	discontinued	O	
46	medication	O	
47	and	O	
48	5	O	
49	have	O	
50	resumed	O	
51	at	O	
52	least	O	
53	limited	O	
54	exercise	O	
55	.	O	

1	The	O	
2	general	O	
3	transcription	B	
4	factor	I	
5	IIA	I	
6	(	O	
7	TFIIA	B	
8	)	O	
9	interacts	O	
10	with	O	
11	the	O	
12	TATA	B	
13	binding	I	
14	protein	I	
15	(	O	
16	TBP	B	
17	)	O	
18	and	O	
19	promoter	O	
20	DNA	O	
21	to	O	
22	mediate	O	
23	transcription	O	
24	activation	O	
25	in	O	
26	vitro	O	
27	.	O	

1	Syndromes	O	
2	of	O	
3	abnormal	O	
4	fat	O	
5	redistribution	O	
6	and	O	
7	metabolic	O	
8	complications	O	
9	in	O	
10	HIV	O	
11	-	O	
12	infected	O	
13	patients	O	
14	.	O	

1	Results	O	
2	showed	O	
3	that	O	
4	the	O	
5	mean	O	
6	bond	O	
7	strength	O	
8	of	O	
9	H	O	
10	.	O	
11	T	O	
12	.	O	
13	V	O	
14	.	O	
15	specimens	O	
16	ranged	O	
17	from	O	
18	9	O	
19	.	O	
20	6	O	
21	to	O	
22	13	O	
23	.	O	
24	12	O	
25	kg	O	
26	/	O	
27	cm2	O	
28	,	O	
29	while	O	
30	the	O	
31	mean	O	
32	bond	O	
33	strength	O	
34	of	O	
35	R	O	
36	.	O	
37	T	O	
38	.	O	
39	V	O	
40	.	O	
41	specimens	O	
42	ranged	O	
43	from	O	
44	0	O	
45	.	O	
46	36	O	
47	to	O	
48	1	O	
49	.	O	
50	75	O	
51	kg	O	
52	/	O	
53	cm2	O	
54	.	O	

1	We	O	
2	thus	O	
3	conclude	O	
4	that	O	
5	the	O	
6	NFAT	B	
7	RIR	I	
8	plays	O	
9	an	O	
10	essential	O	
11	dual	O	
12	role	O	
13	in	O	
14	DNA	O	
15	recognition	O	
16	and	O	
17	cooperative	O	
18	binding	O	
19	to	O	
20	AP	B	
21	-	I	
22	1	I	
23	family	I	
24	transcription	I	
25	factors	I	
26	.	O	

1	Besides	O	
2	,	O	
3	we	O	
4	found	O	
5	in	O	
6	3	O	
7	patients	O	
8	increased	O	
9	serum	B	
10	immunoglobulins	I	
11	,	O	
12	chiefly	O	
13	IgG	B	
14	,	O	
15	as	O	
16	first	O	
17	Russe	O	
18	,	O	
19	Busey	O	
20	and	O	
21	Barbeau	O	
22	demonstrated	O	
23	in	O	
24	a	O	
25	large	O	
26	French	O	
27	-	O	
28	Canadian	O	
29	family	O	
30	.	O	

1	Armed	O	
2	with	O	
3	a	O	
4	clear	O	
5	understanding	O	
6	of	O	
7	the	O	
8	pathophysiologic	O	
9	pathways	O	
10	that	O	
11	may	O	
12	cause	O	
13	and	O	
14	/	O	
15	or	O	
16	contribute	O	
17	to	O	
18	the	O	
19	development	O	
20	of	O	
21	unconjugated	O	
22	hyperbilirubinemia	O	
23	and	O	
24	the	O	
25	associated	O	
26	jaundice	O	
27	,	O	
28	the	O	
29	practitioner	O	
30	will	O	
31	be	O	
32	successful	O	
33	in	O	
34	helping	O	
35	the	O	
36	family	O	
37	understand	O	
38	their	O	
39	child	O	
40	'	O	
41	s	O	
42	illness	O	
43	.	O	

1	These	O	
2	results	O	
3	suggest	O	
4	that	O	
5	5	O	
6	KE	O	
7	X	O	
8	3	O	
9	/	O	
10	W	O	
11	may	O	
12	be	O	
13	the	O	
14	optimal	O	
15	regimen	O	
16	to	O	
17	augment	O	
18	the	O	
19	antitumor	O	
20	immunity	O	
21	of	O	
22	RNL	O	
23	.	O	

1	However	O	
2	,	O	
3	the	O	
4	published	O	
5	reports	O	
6	consist	O	
7	of	O	
8	a	O	
9	small	O	
10	number	O	
11	of	O	
12	patients	O	
13	and	O	
14	limited	O	
15	data	O	
16	.	O	

1	METHODS	O	
2	AND	O	
3	RESULTS	O	
4	:	O	
5	We	O	
6	prospectively	O	
7	compared	O	
8	the	O	
9	automated	O	
10	measurements	O	
11	of	O	
12	left	O	
13	ventricular	O	
14	ejection	O	
15	fraction	O	
16	(	O	
17	LVEF	O	
18	)	O	
19	and	O	
20	volumes	O	
21	from	O	
22	rest	O	
23	-	O	
24	injected	O	
25	gated	O	
26	Technetium	O	
27	99m	O	
28	(	O	
29	Tc99m	O	
30	)	O	
31	perfusion	O	
32	SPECT	O	
33	with	O	
34	equilibrium	O	
35	radionuclide	O	
36	angiocardiography	O	
37	(	O	
38	ERNA	O	
39	)	O	
40	in	O	
41	62	O	
42	patients	O	
43	and	O	
44	the	O	
45	assessment	O	
46	of	O	
47	regional	O	
48	function	O	
49	with	O	
50	echocardiography	O	
51	in	O	
52	22	O	
53	patients	O	
54	.	O	

1	In	O	
2	an	O	
3	earlier	O	
4	study	O	
5	(	O	
6	Kimura	O	
7	,	O	
8	Y	O	
9	.,	O	
10	Kurzydlowski	O	
11	,	O	
12	K	O	
13	.,	O	
14	Tada	O	
15	,	O	
16	M	O	
17	.,	O	
18	and	O	
19	MacLennan	O	
20	,	O	
21	D	O	
22	.	O	

1	It	O	
2	has	O	
3	repeatedly	O	
4	been	O	
5	shown	O	
6	that	O	
7	HCMV	O	
8	IE1	B	
9	/	O	
10	IE2	B	
11	can	O	
12	independently	O	
13	transactivate	O	
14	HIV	B	
15	-	I	
16	1	I	
17	LTR	I	
18	.	O	

1	These	O	
2	results	O	
3	are	O	
4	very	O	
5	useful	O	
6	for	O	
7	deciding	O	
8	on	O	
9	the	O	
10	doses	O	
11	of	O	
12	hormones	O	
13	and	O	
14	the	O	
15	expected	O	
16	serum	O	
17	estradiol	O	
18	level	O	
19	in	O	
20	HRT	O	
21	for	O	
22	Japanese	O	
23	women	O	
24	.	O	

1	Plastic	O	
2	solution	O	
3	of	O	
4	elbow	O	
5	joint	O	
6	ankylosis	O	
7	with	O	
8	a	O	
9	decorticated	O	
10	cylindrical	O	
11	flap	O	

1	Influence	O	
2	of	O	
3	neural	O	
4	regulation	O	
5	on	O	
6	anti	O	
7	-	O	
8	arrhythmic	O	
9	effects	O	
10	of	O	
11	GABA	O	
12	in	O	
13	rats	O	

1	We	O	
2	have	O	
3	previously	O	
4	identified	O	
5	,	O	
6	by	O	
7	screening	O	
8	a	O	
9	lambda	O	
10	gt11	O	
11	expression	O	
12	library	O	
13	,	O	
14	murine	B	
15	protein	I	
16	mXBP	I	
17	,	O	
18	which	O	
19	binds	O	
20	to	O	
21	a	O	
22	sequence	O	
23	which	O	
24	overlaps	O	
25	the	O	
26	3	O	
27	'	O	
28	end	O	
29	of	O	
30	the	O	
31	murine	B	
32	class	I	
33	II	I	
34	major	I	
35	histocompatibility	I	
36	complex	I	
37	A	I	
38	alpha	I	
39	gene	I	
40	X	I	
41	box	I	
42	,	O	
43	a	O	
44	conserved	O	
45	transcription	O	
46	element	O	
47	found	O	
48	upstream	O	
49	of	O	
50	all	O	
51	class	O	
52	II	O	
53	genes	O	
54	.	O	

1	Trichloroethylene	O	
2	,	O	
3	in	O	
4	turn	O	
5	,	O	
6	increased	O	
7	the	O	
8	AUC	O	
9	5	O	
10	.	O	
11	0	O	
12	(	O	
13	1	O	
14	.	O	
15	9	O	
16	-	O	
17	13	O	
18	.	O	
19	4	O	
20	),	O	
21	25	O	
22	.	O	
23	8	O	
24	(	O	
25	8	O	
26	.	O	
27	2	O	
28	-	O	
29	80	O	
30	.	O	
31	8	O	
32	)	O	
33	and	O	
34	2	O	
35	.	O	
36	9	O	
37	(	O	
38	1	O	
39	.	O	
40	6	O	
41	-	O	
42	5	O	
43	.	O	
44	4	O	
45	),	O	
46	respectively	O	
47	,	O	
48	whereas	O	
49	the	O	
50	corresponding	O	
51	values	O	
52	for	O	
53	n	O	
54	-	O	
55	hexane	O	
56	were	O	
57	1	O	
58	.	O	
59	9	O	
60	(	O	
61	0	O	
62	.	O	
63	7	O	
64	-	O	
65	5	O	
66	.	O	
67	1	O	
68	),	O	
69	1	O	
70	.	O	
71	5	O	
72	(	O	
73	0	O	
74	.	O	
75	5	O	
76	-	O	
77	4	O	
78	.	O	
79	6	O	
80	),	O	
81	and	O	
82	3	O	
83	.	O	
84	2	O	
85	(	O	
86	1	O	
87	.	O	
88	8	O	
89	-	O	
90	5	O	
91	.	O	
92	9	O	
93	).	O	

1	These	O	
2	early	O	
3	structural	O	
4	processes	O	
5	are	O	
6	assumed	O	
7	to	O	
8	be	O	
9	subserved	O	
10	by	O	
11	the	O	
12	anterior	O	
13	parts	O	
14	of	O	
15	the	O	
16	left	O	
17	hemisphere	O	
18	,	O	
19	as	O	
20	event	O	
21	-	O	
22	related	O	
23	brain	O	
24	potentials	O	
25	show	O	
26	this	O	
27	area	O	
28	to	O	
29	be	O	
30	maximally	O	
31	activated	O	
32	when	O	
33	phrase	O	
34	structure	O	
35	violations	O	
36	are	O	
37	processed	O	
38	and	O	
39	as	O	
40	circumscribed	O	
41	lesions	O	
42	in	O	
43	this	O	
44	area	O	
45	lead	O	
46	to	O	
47	an	O	
48	impairment	O	
49	of	O	
50	the	O	
51	on	O	
52	-	O	
53	line	O	
54	structural	O	
55	assignment	O	
56	.	O	

1	Human	B	
2	thymine	I	
3	-	I	
4	DNA	I	
5	glycosylase	I	
6	maps	O	
7	at	O	
8	chromosome	O	
9	12q22	O	
10	-	O	
11	q24	O	
12	.	O	
13	1	O	
14	:	O	
15	a	O	
16	region	O	
17	of	O	
18	high	O	
19	loss	O	
20	of	O	
21	heterozygosity	O	
22	in	O	
23	gastric	O	
24	cancer	O	
25	.	O	

1	Simian	O	
2	parainfluenza	O	
3	virus	O	
4	5	O	
5	(	O	
6	SV5	O	
7	)	O	
8	is	O	
9	a	O	
10	prototype	O	
11	of	O	
12	the	O	
13	Paramyxoviridae	O	
14	family	O	
15	of	O	
16	nonsegmented	O	
17	negative	O	
18	-	O	
19	sense	O	
20	RNA	O	
21	viruses	O	
22	.	O	

1	The	O	
2	medium	O	
3	chains	O	
4	of	O	
5	these	O	
6	complexes	O	
7	,	O	
8	mu1	B	
9	and	O	
10	mu2	B	
11	,	O	
12	have	O	
13	been	O	
14	implicated	O	
15	in	O	
16	two	O	
17	types	O	
18	of	O	
19	interaction	O	
20	:	O	
21	assembly	O	
22	with	O	
23	the	O	
24	beta1	B	
25	and	I	
26	beta2	I	
27	chains	I	
28	of	O	
29	the	O	
30	corresponding	O	
31	complexes	O	
32	and	O	
33	recognition	O	
34	of	O	
35	tyrosine	O	
36	-	O	
37	based	O	
38	sorting	O	
39	signals	O	
40	.	O	

1	Doppler	O	
2	ultrasound	O	
3	studies	O	
4	of	O	
5	long	O	
6	-	O	
7	term	O	
8	follow	O	
9	-	O	
10	up	O	
11	of	O	
12	children	O	
13	with	O	
14	hemolytic	O	
15	-	O	
16	uremic	O	
17	syndrome	O	

1	Abstracts	O	
2	.	O	

1	The	O	
2	use	O	
3	of	O	
4	primary	O	
5	GE	O	
6	cells	O	
7	thus	O	
8	provides	O	
9	a	O	
10	convenient	O	
11	in	O	
12	vitro	O	
13	system	O	
14	for	O	
15	further	O	
16	study	O	
17	of	O	
18	the	O	
19	endocrine	O	
20	,	O	
21	paracrine	O	
22	,	O	
23	and	O	
24	autocrine	O	
25	factors	O	
26	regulating	O	
27	endometrial	O	
28	gene	O	
29	expression	O	
30	during	O	
31	pregnancy	O	
32	.	O	

1	These	O	
2	effects	O	
3	were	O	
4	abrogated	O	
5	by	O	
6	co	O	
7	-	O	
8	expression	O	
9	of	O	
10	kinase	B	
11	-	I	
12	deficient	I	
13	PKC	I	
14	zeta	I	
15	and	O	
16	inhibition	O	
17	of	O	
18	phosphatidylinositol	B	
19	3	I	
20	-	I	
21	kinase	I	
22	p85alpha	I	
23	-	O	
24	p110	B	
25	by	O	
26	wortmannin	O	
27	,	O	
28	LY294002	O	
29	and	O	
30	a	O	
31	dominant	O	
32	-	O	
33	negative	O	
34	mutant	O	
35	of	O	
36	p85alpha	B	
37	.	O	

1	The	O	
2	roxithromycin	O	
3	doses	O	
4	that	O	
5	were	O	
6	chosen	O	
7	for	O	
8	these	O	
9	studies	O	
10	were	O	
11	less	O	
12	than	O	
13	achievable	O	
14	blood	O	
15	levels	O	
16	.	O	

1	Radiosensitive	O	
2	nature	O	
3	of	O	
4	paravascular	O	
5	infiltrate	O	
6	-	O	
7	producing	O	
8	potential	O	
9	of	O	
10	parental	O	
11	spleen	O	
12	cells	O	
13	.	O	

1	In	O	
2	contrast	O	
3	to	O	
4	T	O	
5	cells	O	
6	,	O	
7	in	O	
8	fibroblasts	O	
9	PILOT	B	
10	gene	I	
11	expression	O	
12	requires	O	
13	only	O	
14	one	O	
15	signal	O	
16	(	O	
17	PMA	O	
18	)	O	
19	and	O	
20	is	O	
21	not	O	
22	affected	O	
23	by	O	
24	CyA	O	
25	.	O	

1	The	O	
2	minimal	O	
3	region	O	
4	of	O	
5	overlap	O	
6	of	O	
7	Langer	O	
8	-	O	
9	Giedion	O	
10	syndrome	O	
11	deletions	O	
12	,	O	
13	previously	O	
14	identified	O	
15	by	O	
16	analysis	O	
17	of	O	
18	15	O	
19	patients	O	
20	,	O	
21	was	O	
22	placed	O	
23	on	O	
24	the	O	
25	map	O	
26	by	O	
27	analysis	O	
28	of	O	
29	2	O	
30	patients	O	
31	whose	O	
32	deletions	O	
33	define	O	
34	the	O	
35	endpoints	O	
36	.	O	

1	In	O	
2	EEG	O	
3	only	O	
4	single	O	
5	slow	O	
6	waves	O	
7	above	O	
8	left	O	
9	temporal	O	
10	region	O	
11	were	O	
12	revealed	O	
13	.	O	

1	Clinical	O	
2	use	O	
3	of	O	
4	absorbable	O	
5	polyglycolic	O	
6	acid	O	
7	suture	O	
8	in	O	
9	Blalock	O	
10	-	O	
11	Taussig	O	
12	'	O	
13	s	O	
14	operation	O	

1	A	O	
2	semiautomatic	O	
3	digital	O	
4	system	O	
5	(	O	
6	Videoplan	O	
7	2	O	
8	)	O	
9	was	O	
10	used	O	
11	.	O	

1	To	O	
2	investigate	O	
3	the	O	
4	requirements	O	
5	for	O	
6	CBF2	B	
7	binding	O	
8	,	O	
9	we	O	
10	synthesized	O	
11	a	O	
12	series	O	
13	of	O	
14	oligonucleotides	O	
15	carrying	O	
16	double	O	
17	transversion	O	
18	mutations	O	
19	spanning	O	
20	both	O	
21	the	O	
22	conserved	O	
23	core	O	
24	sequence	O	
25	and	O	
26	outside	O	
27	flanking	O	
28	sequences	O	
29	.	O	

1	We	O	
2	have	O	
3	identified	O	
4	in	O	
5	the	O	
6	5	O	
7	'	O	
8	untranslated	O	
9	region	O	
10	of	O	
11	the	O	
12	Drosophila	B	
13	copia	I	
14	retrotransposon	I	
15	,	O	
16	3	O	
17	'	O	
18	to	O	
19	the	O	
20	left	O	
21	LTR	O	
22	,	O	
23	a	O	
24	sequence	O	
25	for	O	
26	transcriptional	O	
27	regulation	O	
28	by	O	
29	homeoproteins	O	
30	.	O	

1	Nucleotide	O	
2	sequence	O	
3	analysis	O	
4	of	O	
5	R	O	
6	has	O	
7	revealed	O	
8	similarities	O	
9	to	O	
10	the	O	
11	R1	O	
12	plasmid	O	
13	found	O	
14	in	O	
15	some	O	
16	South	O	
17	American	O	
18	maize	O	
19	races	O	
20	with	O	
21	RU	O	
22	cytoplasm	O	
23	,	O	
24	to	O	
25	the	O	
26	M1	O	
27	plasmid	O	
28	found	O	
29	in	O	
30	one	O	
31	source	O	
32	of	O	
33	Zea	O	
34	luxurians	O	
35	teosinte	O	
36	,	O	
37	to	O	
38	the	O	
39	atp9	B	
40	mitochondrial	I	
41	gene	I	
42	and	O	
43	its	O	
44	3	O	
45	'	O	
46	flanking	O	
47	sequence	O	
48	,	O	
49	and	O	
50	also	O	
51	to	O	
52	a	O	
53	region	O	
54	3	O	
55	'	O	
56	to	O	
57	the	O	
58	orf221	B	
59	gene	I	
60	.	O	

1	Moreover	O	
2	,	O	
3	in	O	
4	transient	O	
5	transfection	O	
6	assays	O	
7	,	O	
8	PU	B	
9	.	I	
10	1	I	
11	alone	O	
12	activated	O	
13	reporter	O	
14	constructs	O	
15	containing	O	
16	the	O	
17	JB	O	
18	cis	O	
19	-	O	
20	element	O	
21	,	O	
22	and	O	
23	the	O	
24	activation	O	
25	was	O	
26	shown	O	
27	to	O	
28	be	O	
29	dependent	O	
30	on	O	
31	a	O	
32	glutamine	O	
33	-	O	
34	rich	O	
35	sequence	O	
36	in	O	
37	the	O	
38	amino	O	
39	-	O	
40	terminal	O	
41	portion	O	
42	of	O	
43	PU	B	
44	.	I	
45	1	I	
46	.	O	

1	INTERVENTIONS	O	
2	:	O	
3	Study	O	
4	patients	O	
5	were	O	
6	randomly	O	
7	divided	O	
8	into	O	
9	four	O	
10	parallel	O	
11	groups	O	
12	to	O	
13	receive	O	
14	either	O	
15	terbinafine	O	
16	250	O	
17	mg	O	
18	a	O	
19	day	O	
20	for	O	
21	12	O	
22	or	O	
23	16	O	
24	weeks	O	
25	(	O	
26	groups	O	
27	T12	O	
28	and	O	
29	T16	O	
30	)	O	
31	or	O	
32	itraconazole	O	
33	400	O	
34	mg	O	
35	a	O	
36	day	O	
37	for	O	
38	1	O	
39	week	O	
40	in	O	
41	every	O	
42	4	O	
43	weeks	O	
44	for	O	
45	12	O	
46	or	O	
47	16	O	
48	weeks	O	
49	(	O	
50	groups	O	
51	I3	O	
52	and	O	
53	I4	O	
54	).	O	

1	Interestingly	O	
2	,	O	
3	the	O	
4	positions	O	
5	of	O	
6	these	O	
7	introns	O	
8	have	O	
9	been	O	
10	conserved	O	
11	in	O	
12	comparison	O	
13	with	O	
14	the	O	
15	genes	O	
16	of	O	
17	two	O	
18	other	O	
19	transglutaminase	O	
20	-	O	
21	like	O	
22	activities	O	
23	described	O	
24	in	O	
25	the	O	
26	literature	O	
27	,	O	
28	but	O	
29	the	O	
30	TGM1	B	
31	gene	I	
32	is	O	
33	by	O	
34	far	O	
35	the	O	
36	smallest	O	
37	characterized	O	
38	to	O	
39	date	O	
40	because	O	
41	its	O	
42	introns	O	
43	are	O	
44	relatively	O	
45	smaller	O	
46	.	O	

1	Using	O	
2	a	O	
3	polymerase	O	
4	chain	O	
5	reaction	O	
6	-	O	
7	based	O	
8	approach	O	
9	,	O	
10	we	O	
11	cloned	O	
12	a	O	
13	150	O	
14	-	O	
15	base	O	
16	pair	O	
17	fragment	O	
18	of	O	
19	a	O	
20	new	O	
21	sialymotif	O	
22	from	O	
23	human	O	
24	placenta	O	
25	mRNA	O	
26	,	O	
27	which	O	
28	was	O	
29	then	O	
30	used	O	
31	as	O	
32	a	O	
33	probe	O	
34	to	O	
35	clone	O	
36	the	O	
37	complete	O	
38	coding	O	
39	sequence	O	
40	of	O	
41	the	O	
42	corresponding	O	
43	gene	O	
44	from	O	
45	a	O	
46	cDNA	O	
47	library	O	
48	.	O	

1	Risk	O	
2	of	O	
3	HTLV	O	
4	infection	O	
5	in	O	
6	patients	O	
7	on	O	
8	haemodialysis	O	
9	.	O	

1	The	O	
2	Abbreviated	O	
3	Injury	O	
4	Scale	O	
5	(	O	
6	AIS	O	
7	),	O	
8	Injury	O	
9	Severity	O	
10	Scale	O	
11	and	O	
12	TRISS	O	
13	methodology	O	
14	comprise	O	
15	a	O	
16	mathematically	O	
17	sound	O	
18	system	O	
19	for	O	
20	the	O	
21	analysis	O	
22	of	O	
23	injuries	O	
24	and	O	
25	injured	O	
26	patients	O	
27	.	O	

1	Althoug	O	
2	RBF	O	
3	tended	O	
4	to	O	
5	increase	O	
6	after	O	
7	the	O	
8	therapy	O	
9	,	O	
10	there	O	
11	was	O	
12	no	O	
13	statistically	O	
14	significant	O	
15	change	O	
16	in	O	
17	RBF	O	
18	,	O	
19	GFR	O	
20	and	O	
21	cardiac	O	
22	output	O	
23	.	O	

1	JNK	B	
2	and	O	
3	p38	B	
4	are	O	
5	constitutively	O	
6	present	O	
7	in	O	
8	the	O	
9	nucleus	O	
10	,	O	
11	and	O	
12	DNA	O	
13	-	O	
14	bound	O	
15	c	B	
16	-	I	
17	JUN	I	
18	and	O	
19	ATF	B	
20	-	I	
21	2	I	
22	are	O	
23	stably	O	
24	contacted	O	
25	by	O	
26	JNK	B	
27	and	O	
28	p38	B	
29	,	O	
30	respectively	O	
31	.	O	

1	This	O	
2	region	O	
3	is	O	
4	required	O	
5	for	O	
6	activation	O	
7	of	O	
8	DNA	O	
9	binding	O	
10	of	O	
11	MyoD	B	
12	and	O	
13	E12	B	
14	homodimers	I	
15	and	O	
16	E12	B	
17	/	O	
18	MyoD	B	
19	heterodimers	O	
20	.	O	

1	The	O	
2	M	O	
3	-	O	
4	3	O	
5	subtype	O	
6	was	O	
7	an	O	
8	adverse	O	
9	prognostic	O	
10	factor	O	
11	.	O	

1	Second	O	
2	,	O	
3	the	O	
4	membrane	O	
5	expression	O	
6	of	O	
7	alpha	O	
8	and	O	
9	beta	O	
10	subunits	O	
11	was	O	
12	mimicked	O	
13	by	O	
14	cholesterol	O	
15	and	O	
16	17	O	
17	-	O	
18	ketocholesterol	O	
19	,	O	
20	both	O	
21	of	O	
22	which	O	
23	inhibit	O	
24	HMG	B	
25	-	I	
26	CoA	I	
27	reductase	I	
28	.	O	

1	Intracavitary	O	
2	irradiation	O	
3	was	O	
4	carried	O	
5	out	O	
6	with	O	
7	a	O	
8	microSelectron	O	
9	HDR	O	
10	afterloading	O	
11	device	O	
12	and	O	
13	usually	O	
14	22	O	
15	.	O	
16	5	O	
17	Gy	O	
18	was	O	
19	given	O	
20	in	O	
21	three	O	
22	fractions	O	
23	repeated	O	
24	weekly	O	
25	.	O	

1	Chlorambucil	O	
2	and	O	
3	interferon	B	
4	for	O	
5	low	O	
6	grade	O	
7	non	O	
8	-	O	
9	Hodgkin	O	
10	'	O	
11	s	O	
12	lymphoma	O	
13	.	O	

1	Treatment	O	
2	of	O	
3	recurrent	O	
4	FSGS	O	
5	has	O	
6	included	O	
7	high	O	
8	-	O	
9	dose	O	
10	steroids	O	
11	,	O	
12	high	O	
13	-	O	
14	dose	O	
15	cyclosporine	O	
16	(	O	
17	CSA	O	
18	),	O	
19	plasmapheresis	O	
20	,	O	
21	and	O	
22	ACE	B	
23	inhibitors	O	
24	with	O	
25	mixed	O	
26	results	O	
27	.	O	

1	Characteristics	O	
2	of	O	
3	lipase	B	
4	activity	O	
5	.	O	

1	In	O	
2	this	O	
3	animal	O	
4	,	O	
5	infected	O	
6	with	O	
7	what	O	
8	was	O	
9	judged	O	
10	previously	O	
11	to	O	
12	be	O	
13	the	O	
14	less	O	
15	virulent	O	
16	of	O	
17	the	O	
18	two	O	
19	T	O	
20	.	O	
21	cruzi	O	
22	stocks	O	
23	used	O	
24	('	O	
25	strain	O	
26	7	O	
27	'),	O	
28	there	O	
29	was	O	
30	severe	O	
31	myocarditis	O	
32	,	O	
33	with	O	
34	myofibre	O	
35	degeneration	O	
36	,	O	
37	and	O	
38	lesions	O	
39	of	O	
40	the	O	
41	oesophagus	O	
42	.	O	

1	RESULTS	O	
2	:	O	
3	In	O	
4	an	O	
5	18	O	
6	moth	O	
7	period	O	
8	and	O	
9	out	O	
10	of	O	
11	a	O	
12	total	O	
13	of	O	
14	284	O	
15	positive	O	
16	blood	O	
17	cultures	O	
18	(	O	
19	154	O	
20	significant	O	
21	isolations	O	
22	)	O	
23	14	O	
24	episodes	O	
25	of	O	
26	bacteremia	O	
27	by	O	
28	M	O	
29	.	O	
30	tuberculosis	O	
31	were	O	
32	studied	O	
33	in	O	
34	12	O	
35	prison	O	
36	patients	O	
37	coinfected	O	
38	by	O	
39	the	O	
40	human	O	
41	immunodeficiency	O	
42	virus	O	
43	with	O	
44	associated	O	
45	severe	O	
46	immunosuppression	O	
47	(	O	
48	mean	O	
49	of	O	
50	CD4	B	
51	=	O	
52	0	O	
53	.	O	
54	068	O	
55	x	O	
56	10	O	
57	(	O	
58	9	O	
59	)/	O	
60	l	O	
61	).	O	

1	Several	O	
2	PTPases	B	
3	were	O	
4	expressed	O	
5	abundantly	O	
6	in	O	
7	the	O	
8	5	O	
9	-	O	
10	FU	O	
11	-	O	
12	treated	O	
13	bone	O	
14	marrow	O	
15	stem	O	
16	cells	O	
17	.	O	

1	In	O	
2	previous	O	
3	work	O	
4	(	O	
5	E	O	
6	.	O	

1	A	O	
2	total	O	
3	of	O	
4	125	O	
5	acute	O	
6	leukemia	O	
7	adult	O	
8	patients	O	
9	were	O	
10	autografted	O	
11	with	O	
12	bone	O	
13	marrow	O	
14	(	O	
15	BM	O	
16	)	O	
17	purged	O	
18	by	O	
19	mafosfamide	O	
20	(	O	
21	ASTA	O	
22	Z	O	
23	)	O	
24	during	O	
25	the	O	
26	period	O	
27	of	O	
28	January	O	
29	1983	O	
30	to	O	
31	January	O	
32	1993	O	
33	.	O	

1	Dilutions	O	
2	of	O	
3	H	B	
4	-	I	
5	2b	I	
6	or	I	
7	H	I	
8	-	I	
9	2d	I	
10	NP	I	
11	peptides	I	
12	indicated	O	
13	that	O	
14	3	O	
15	-	O	
16	4	O	
17	logs	O	
18	less	O	
19	H	B	
20	-	I	
21	2b	I	
22	NP	I	
23	peptide	I	
24	was	O	
25	required	O	
26	to	O	
27	sensitize	O	
28	syngeneic	O	
29	target	O	
30	cells	O	
31	for	O	
32	CTL	O	
33	-	O	
34	specific	O	
35	lysis	O	
36	,	O	
37	suggesting	O	
38	that	O	
39	the	O	
40	differing	O	
41	affinities	O	
42	of	O	
43	H	O	
44	-	O	
45	2b	O	
46	and	O	
47	H	O	
48	-	O	
49	2d	O	
50	major	B	
51	histocompatibility	I	
52	complex	I	
53	molecules	I	
54	for	O	
55	their	O	
56	peptides	O	
57	likely	O	
58	account	O	
59	for	O	
60	the	O	
61	total	O	
62	removal	O	
63	of	O	
64	NP	O	
65	CTL	O	
66	in	O	
67	the	O	
68	H	O	
69	-	O	
70	2b	O	
71	mice	O	
72	but	O	
73	only	O	
74	partial	O	
75	removal	O	
76	in	O	
77	H	O	
78	-	O	
79	2d	O	
80	mice	O	
81	made	O	
82	to	O	
83	express	O	
84	thymic	O	
85	NP	O	
86	.	O	

1	Secretion	O	
2	in	O	
3	milk	O	
4	and	O	
5	transplacental	O	
6	transfer	O	
7	of	O	
8	two	O	
9	iodized	O	
10	oils	O	
11	,	O	
12	Lipiodol	O	
13	UF	O	
14	and	O	
15	Oriodol	O	
16	,	O	
17	in	O	
18	rabbits	O	
19	.	O	

1	The	O	
2	1	O	
3	.	O	
4	9	O	
5	-	O	
6	kb	O	
7	C	B	
8	mu	I	
9	RNA	O	
10	contains	O	
11	the	O	
12	3	O	
13	'	O	
14	sequence	O	
15	characteristic	O	
16	of	O	
17	secreted	O	
18	mu	B	
19	chain	I	
20	,	O	
21	whereas	O	
22	the	O	
23	longer	O	
24	species	O	
25	bear	O	
26	that	O	
27	of	O	
28	membrane	O	
29	-	O	
30	bound	O	
31	mu	B	
32	chin	O	
33	.	O	

1	Computer	O	
2	assisted	O	
3	mapping	O	
4	in	O	
5	quantitative	O	
6	analysis	O	
7	of	O	
8	cerebral	O	
9	positron	O	
10	emission	O	
11	tomograms	O	
12	.	O	

1	2	O	
2	)	O	
3	The	O	
4	time	O	
5	-	O	
6	sharing	O	
7	principle	O	
8	was	O	
9	applied	O	
10	to	O	
11	gain	O	
12	high	O	
13	stability	O	
14	.	O	

1	Histological	O	
2	examination	O	
3	revealed	O	
4	a	O	
5	small	O	
6	simple	O	
7	renal	O	
8	cyst	O	
9	associated	O	
10	with	O	
11	renal	O	
12	cell	O	
13	carcinoma	O	
14	.	O	

1	Two	O	
2	experiments	O	
3	investigating	O	
4	the	O	
5	effects	O	
6	of	O	
7	short	O	
8	-	O	
9	term	O	
10	spaceflight	O	
11	on	O	
12	cancellous	O	
13	bone	O	
14	turnover	O	
15	were	O	
16	carried	O	
17	out	O	
18	:	O	
19	Physiological	O	
20	Systems	O	
21	Experiment	O	
22	-	O	
23	1	O	
24	(	O	
25	PSE	O	
26	-	O	
27	1	O	
28	)	O	
29	(	O	
30	a	O	
31	4	O	
32	-	O	
33	d	O	
34	orbital	O	
35	spaceflight	O	
36	)	O	
37	and	O	
38	PSE	O	
39	-	O	
40	2	O	
41	(	O	
42	a	O	
43	10	O	
44	-	O	
45	d	O	
46	flight	O	
47	).	O	

1	This	O	
2	study	O	
3	provides	O	
4	direct	O	
5	evidence	O	
6	that	O	
7	USF	B	
8	,	O	
9	a	O	
10	member	O	
11	of	O	
12	the	O	
13	basic	B	
14	helix	I	
15	-	I	
16	loop	I	
17	-	I	
18	helix	I	
19	leucine	I	
20	zipper	I	
21	family	I	
22	,	O	
23	binds	O	
24	to	O	
25	MLE1	B	
26	,	O	
27	HF	B	
28	-	I	
29	1a	I	
30	,	O	
31	and	O	
32	PRE	B	
33	B	I	
34	sites	I	
35	and	O	
36	suggests	O	
37	that	O	
38	it	O	
39	is	O	
40	a	O	
41	component	O	
42	of	O	
43	protein	O	
44	complexes	O	
45	that	O	
46	may	O	
47	coordinately	O	
48	control	O	
49	the	O	
50	expression	O	
51	of	O	
52	MLC	B	
53	-	I	
54	2v	I	
55	and	O	
56	alpha	B	
57	-	I	
58	myosin	I	
59	heavy	I	
60	-	I	
61	chain	I	
62	genes	I	
63	.	O	

1	These	O	
2	fusions	O	
3	are	O	
4	contained	O	
5	on	O	
6	plasmids	O	
7	which	O	
8	have	O	
9	both	O	
10	yeast	O	
11	and	O	
12	E	O	
13	.	O	
14	coli	O	
15	replication	O	
16	origins	O	
17	and	O	
18	selectable	O	
19	markers	O	
20	and	O	
21	,	O	
22	therefore	O	
23	,	O	
24	can	O	
25	be	O	
26	used	O	
27	to	O	
28	transform	O	
29	either	O	
30	yeast	O	
31	or	O	
32	E	O	
33	.	O	
34	coli	O	
35	cells	O	
36	.	O	

1	These	O	
2	data	O	
3	provide	O	
4	evidence	O	
5	that	O	
6	the	O	
7	2	B	
8	.	I	
9	0	I	
10	-	I	
11	kb	I	
12	LAT	I	
13	is	O	
14	an	O	
15	intron	O	
16	of	O	
17	the	O	
18	mLAT	B	
19	pre	I	
20	-	I	
21	mRNA	I	
22	with	O	
23	a	O	
24	unique	O	
25	branch	O	
26	point	O	
27	.	O	

1	Female	O	
2	Wistar	O	
3	rats	O	
4	were	O	
5	fed	O	
6	a	O	
7	liquid	O	
8	diet	O	
9	,	O	
10	Sustacal	O	
11	,	O	
12	which	O	
13	contained	O	
14	ethanol	O	
15	(	O	
16	40	O	
17	%	O	
18	of	O	
19	calories	O	
20	)	O	
21	or	O	
22	isocaloric	O	
23	sucrose	O	
24	.	O	

1	CKbeta4GT	B	
2	-	I	
3	II	I	
4	is	O	
5	predicted	O	
6	to	O	
7	encode	O	
8	a	O	
9	type	B	
10	II	I	
11	transmembrane	I	
12	glycoprotein	I	
13	of	O	
14	43	O	
15	kDa	O	
16	with	O	
17	five	O	
18	potential	O	
19	N	O	
20	-	O	
21	linked	O	
22	glycosylation	O	
23	sites	O	
24	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	mutations	O	
5	affecting	O	
6	the	O	
7	other	O	
8	two	O	
9	Nim1p	B	
10	-	I	
11	related	I	
12	kinases	I	
13	in	O	
14	S	O	
15	.	O	
16	cerevisiae	O	
17	,	O	
18	Hsl1p	B	
19	and	O	
20	Kcc4p	B	
21	,	O	
22	produce	O	
23	no	O	
24	detectable	O	
25	effect	O	
26	on	O	
27	septin	B	
28	organization	O	
29	.	O	

1	However	O	
2	,	O	
3	cotransfection	O	
4	studies	O	
5	indicate	O	
6	that	O	
7	RVR	B	
8	does	O	
9	not	O	
10	activate	O	
11	transcription	O	
12	when	O	
13	this	O	
14	hormone	O	
15	response	O	
16	element	O	
17	is	O	
18	linked	O	
19	to	O	
20	a	O	
21	reporter	O	
22	gene	O	
23	but	O	
24	rather	O	
25	acts	O	
26	as	O	
27	a	O	
28	potent	O	
29	competitive	O	
30	repressor	O	
31	of	O	
32	ROR	B	
33	alpha	I	
34	function	O	
35	.	O	

1	Interpersonal	O	
2	style	O	
3	differences	O	
4	among	O	
5	drug	O	
6	abusers	O	
7	were	O	
8	explored	O	
9	using	O	
10	Ryan	O	
11	'	O	
12	s	O	
13	(	O	
14	1977	O	
15	)	O	
16	typological	O	
17	system	O	
18	of	O	
19	FIRO	O	
20	-	O	
21	B	O	
22	interpretation	O	
23	.	O	

1	Several	O	
2	new	O	
3	techniques	O	
4	are	O	
5	available	O	
6	for	O	
7	monitoring	O	
8	control	O	
9	of	O	
10	diabetes	O	
11	.	O	

1	Radioimmunoassays	O	
2	of	O	
3	pregnenolone	O	
4	,	O	
5	progesterone	O	
6	,	O	
7	dehydroepiandrosterone	O	
8	(	O	
9	DHA	O	
10	)	O	
11	16	O	
12	alpha	O	
13	-	O	
14	hydroxy	O	
15	-	O	
16	DHA	O	
17	,	O	
18	estriol	O	
19	,	O	
20	and	O	
21	cortisol	O	
22	were	O	
23	performed	O	
24	on	O	
25	a	O	
26	total	O	
27	of	O	
28	0	O	
29	;	O	
30	1	O	
31	ml	O	
32	;	O	
33	of	O	
34	fetal	O	
35	plasma	O	
36	,	O	
37	collected	O	
38	during	O	
39	the	O	
40	course	O	
41	of	O	
42	normal	O	
43	vaginal	O	
44	delivery	O	
45	.	O	

1	Cephradine	O	
2	250	O	
3	mg	O	
4	at	O	
5	night	O	
6	for	O	
7	12	O	
8	months	O	
9	was	O	
10	given	O	
11	as	O	
12	a	O	
13	prophylactic	O	
14	measure	O	
15	to	O	
16	33	O	
17	female	O	
18	patients	O	
19	of	O	
20	mean	O	
21	age	O	
22	41	O	
23	.	O	
24	6	O	
25	years	O	
26	,	O	
27	who	O	
28	had	O	
29	a	O	
30	history	O	
31	in	O	
32	the	O	
33	preceding	O	
34	12	O	
35	months	O	
36	of	O	
37	between	O	
38	three	O	
39	and	O	
40	24	O	
41	(	O	
42	median	O	
43	=	O	
44	7	O	
45	)	O	
46	episodes	O	
47	of	O	
48	frequency	O	
49	and	O	
50	/	O	
51	or	O	
52	dysuria	O	
53	.	O	

1	SIM1	B	
2	and	O	
3	SIM2	B	
4	do	O	
5	not	O	
6	form	O	
7	homodimers	O	
8	,	O	
9	and	O	
10	they	O	
11	do	O	
12	not	O	
13	interact	O	
14	with	O	
15	AHR	B	
16	.	O	

1	Recent	O	
2	investigations	O	
3	have	O	
4	shown	O	
5	that	O	
6	Grenz	O	
7	rays	O	
8	can	O	
9	suppress	O	
10	the	O	
11	allergic	O	
12	contact	O	
13	dermatitis	O	
14	reaction	O	
15	completely	O	
16	and	O	
17	that	O	
18	Langerhans	O	
19	cells	O	
20	,	O	
21	identified	O	
22	by	O	
23	OKT6	B	
24	antibodies	I	
25	and	O	
26	electron	O	
27	microscopy	O	
28	,	O	
29	disappear	O	
30	from	O	
31	the	O	
32	epidermis	O	
33	at	O	
34	the	O	
35	same	O	
36	time	O	
37	.	O	

1	The	O	
2	effect	O	
3	of	O	
4	osmotic	O	
5	flow	O	
6	on	O	
7	the	O	
8	distribution	O	
9	of	O	
10	horseradish	B	
11	peroxidase	I	
12	within	O	
13	the	O	
14	intercellular	O	
15	spaces	O	
16	of	O	
17	toad	O	
18	bladder	O	
19	epithelium	O	
20	.	O	

1	Our	O	
2	mapping	O	
3	results	O	
4	did	O	
5	not	O	
6	suggest	O	
7	involvement	O	
8	of	O	
9	this	O	
10	gene	O	
11	in	O	
12	previously	O	
13	mapped	O	
14	genetic	O	
15	disorders	O	
16	or	O	
17	in	O	
18	known	O	
19	neoplasia	O	
20	-	O	
21	associated	O	
22	translocation	O	
23	breakpoints	O	
24	.	O	

1	Phorbol	O	
2	esters	O	
3	stimulated	O	
4	phosphorylation	O	
5	of	O	
6	CSK	B	
7	35H	I	
8	proteins	I	
9	,	O	
10	thus	O	
11	emphasizing	O	
12	that	O	
13	sequences	O	
14	isolated	O	
15	according	O	
16	to	O	
17	PKC	B	
18	binding	O	
19	activity	O	
20	in	O	
21	vitro	O	
22	are	O	
23	also	O	
24	PKC	B	
25	substrates	O	
26	in	O	
27	vivo	O	
28	.	O	

1	Yeast	B	
2	Gal11	I	
3	protein	I	
4	mediates	O	
5	the	O	
6	transcriptional	O	
7	activation	O	
8	signal	O	
9	of	O	
10	two	O	
11	different	O	
12	transacting	O	
13	factors	O	
14	,	O	
15	Gal4	B	
16	and	O	
17	general	B	
18	regulatory	I	
19	factor	I	
20	I	I	
21	/	O	
22	repressor	B	
23	/	I	
24	activator	I	
25	site	I	
26	binding	I	
27	protein	I	
28	1	I	
29	/	I	
30	translation	I	
31	upstream	I	
32	factor	I	
33	.	O	

1	Twenty	O	
2	food	O	
3	products	O	
4	were	O	
5	contaminated	O	
6	with	O	
7	V	O	
8	.	O	
9	cholerae	O	
10	O1	O	
11	,	O	
12	Ogawa	O	
13	,	O	
14	toxigenic	O	
15	and	O	
16	not	O	
17	toxigenic	O	
18	strains	O	
19	:	O	
20	yoghurt	O	
21	,	O	
22	cream	O	
23	cheese	O	
24	,	O	
25	apricot	O	
26	marmelade	O	
27	,	O	
28	hip	O	
29	rose	O	
30	marmelade	O	
31	,	O	
32	mayonnaise	O	
33	,	O	
34	italian	O	
35	pasta	O	
36	for	O	
37	"	O	
38	empanadas	O	
39	",	O	
40	"	O	
41	dulce	O	
42	de	O	
43	leche	O	
44	",	O	
45	meat	O	
46	sausage	O	
47	,	O	
48	meat	O	
49	and	O	
50	spinach	O	
51	ravioli	O	
52	,	O	
53	margarine	O	
54	,	O	
55	milk	O	
56	dessert	O	
57	(	O	
58	made	O	
59	with	O	
60	cocoa	O	
61	,	O	
62	milk	O	
63	confiture	O	
64	,	O	
65	starch	O	
66	and	O	
67	additives	O	
68	),	O	
69	lettuce	O	
70	,	O	
71	tuna	O	
72	fish	O	
73	,	O	
74	ricotta	O	
75	and	O	
76	sterilized	O	
77	milk	O	
78	.	O	

1	Monitoring	O	
2	of	O	
3	rheumatoid	O	
4	arthritis	O	
5	.	O	

1	Analysis	O	
2	of	O	
3	a	O	
4	set	O	
5	of	O	
6	deletion	O	
7	constructs	O	
8	in	O	
9	transient	O	
10	transfection	O	
11	assays	O	
12	measuring	O	
13	heterologous	O	
14	reporter	O	
15	gene	O	
16	(	O	
17	luciferase	B	
18	)	O	
19	activity	O	
20	demonstrated	O	
21	that	O	
22	the	O	
23	182	O	
24	-	O	
25	bp	O	
26	5	O	
27	'-	O	
28	flanking	O	
29	region	O	
30	provides	O	
31	full	O	
32	promoter	O	
33	activity	O	
34	in	O	
35	IL	B	
36	-	I	
37	2	I	
38	-	O	
39	stimulated	O	
40	L2	O	
41	cells	O	
42	.	O	

1	Increasing	O	
2	the	O	
3	phosphorus	O	
4	content	O	
5	of	O	
6	the	O	
7	diet	O	
8	improved	O	
9	the	O	
10	reabsorption	O	
11	of	O	
12	calcium	O	
13	and	O	
14	magnesium	O	
15	.	O	

1	We	O	
2	conclude	O	
3	that	O	
4	the	O	
5	'	O	
6	morning	O	
7	dip	O	
8	'	O	
9	observed	O	
10	in	O	
11	asthmatic	O	
12	patients	O	
13	cannot	O	
14	simply	O	
15	be	O	
16	explained	O	
17	by	O	
18	changes	O	
19	in	O	
20	cell	O	
21	receptor	O	
22	number	O	
23	or	O	
24	affinity	O	
25	,	O	
26	as	O	
27	our	O	
28	results	O	
29	suggest	O	
30	that	O	
31	both	O	
32	groups	O	
33	have	O	
34	intact	O	
35	beta	B	
36	-	I	
37	adrenoceptor	I	
38	function	O	
39	.	O	

1	However	O	
2	,	O	
3	if	O	
4	EMPD	O	
5	involves	O	
6	the	O	
7	glans	O	
8	penis	O	
9	or	O	
10	perianal	O	
11	area	O	
12	,	O	
13	a	O	
14	search	O	
15	for	O	
16	internal	O	
17	malignancy	O	
18	is	O	
19	still	O	
20	warranted	O	
21	.	O	

1	One	O	
2	extract	O	
3	with	O	
4	the	O	
5	lowest	O	
6	PCA	O	
7	content	O	
8	was	O	
9	non	O	
10	-	O	
11	carcinogenic	O	
12	.	O	

1	The	O	
2	solitary	O	
3	kidney	O	
4	:	O	
5	a	O	
6	model	O	
7	of	O	
8	chronic	O	
9	hyperfiltration	O	
10	in	O	
11	humans	O	
12	.	O	

1	Trypanosoma	O	
2	cruzi	O	
3	.	O	

1	All	O	
2	of	O	
3	the	O	
4	elements	O	
5	exhibited	O	
6	a	O	
7	uniform	O	
8	structure	O	
9	.	O	

1	Four	O	
2	of	O	
3	these	O	
4	five	O	
5	subjects	O	
6	also	O	
7	performed	O	
8	mixed	O	
9	sequences	O	
10	under	O	
11	conditional	O	
12	control	O	
13	of	O	
14	the	O	
15	words	O	
16	(	O	
17	e	O	
18	.	O	
19	g	O	
20	.,	O	
21	A1	O	
22	----	O	
23	B2	O	
24	----	O	
25	A3	O	
26	----	O	
27	B4	O	
28	----	O	
29	A5	O	
30	and	O	
31	its	O	
32	reversal	O	
33	),	O	
34	verifying	O	
35	that	O	
36	the	O	
37	stimuli	O	
38	which	O	
39	occupied	O	
40	the	O	
41	same	O	
42	position	O	
43	in	O	
44	each	O	
45	sequence	O	
46	were	O	
47	members	O	
48	of	O	
49	the	O	
50	same	O	
51	class	O	
52	.	O	

1	Ultrasonography	O	
2	provides	O	
3	excellent	O	
4	intraoperative	O	
5	evaluation	O	
6	of	O	
7	spinal	O	
8	cord	O	
9	injury	O	
10	.	O	

1	Interferon	B	
2	type	I	
3	I	I	
4	in	O	
5	protective	O	
6	body	O	
7	reactions	O	
8	in	O	
9	an	O	
10	experimental	O	
11	Klebsiella	O	
12	infection	O	

1	Transcription	O	
2	of	O	
3	the	O	
4	gene	O	
5	for	O	
6	ivanolysin	B	
7	O	I	
8	and	O	
9	expression	O	
10	of	O	
11	other	O	
12	genes	O	
13	of	O	
14	the	O	
15	virulence	B	
16	gene	I	
17	cluster	I	
18	in	I	
19	L	I	
20	.	I	
21	ivanovii	I	
22	were	O	
23	dependent	O	
24	on	O	
25	PrfA	B	
26	.	O	

1	However	O	
2	,	O	
3	for	O	
4	the	O	
5	evaluable	O	
6	cases	O	
7	,	O	
8	the	O	
9	performances	O	
10	of	O	
11	the	O	
12	CD3500	O	
13	and	O	
14	the	O	
15	STKS	O	
16	were	O	
17	broadly	O	
18	similar	O	
19	and	O	
20	generally	O	
21	correlated	O	
22	well	O	
23	with	O	
24	the	O	
25	manual	O	
26	reference	O	
27	procedure	O	
28	.	O	

1	Inhibition	O	
2	of	O	
3	Fusarium	O	
4	moniliforme	O	
5	var	O	
6	.	O	
7	subglutinans	O	
8	,	O	
9	the	O	
10	causal	O	
11	agent	O	
12	of	O	
13	pine	O	
14	pitch	O	
15	canker	O	
16	,	O	
17	by	O	
18	the	O	
19	soil	O	
20	bacterium	O	
21	Arthrobacter	O	
22	sp	O	
23	.	O	

1	In	O	
2	the	O	
3	ePTFE	O	
4	specimens	O	
5	,	O	
6	tissue	O	
7	coverage	O	
8	had	O	
9	increased	O	
10	.	O	

1	5	O	
2	'-	O	
3	RACE	O	
4	analysis	O	
5	suggested	O	
6	a	O	
7	single	O	
8	transcription	O	
9	initiation	O	
10	site	O	
11	187	O	
12	bp	O	
13	upstream	O	
14	from	O	
15	the	O	
16	translational	O	
17	start	O	
18	site	O	
19	.	O	

1	Most	O	
2	importantly	O	
3	,	O	
4	the	O	
5	addition	O	
6	of	O	
7	purified	O	
8	17S	B	
9	U2	I	
10	snRNPs	I	
11	,	O	
12	but	O	
13	not	O	
14	of	O	
15	12S	B	
16	U2	I	
17	snRNPs	I	
18	,	O	
19	to	O	
20	HeLa	O	
21	splicing	O	
22	extracts	O	
23	in	O	
24	which	O	
25	the	O	
26	endogeneous	B	
27	U2	I	
28	snRNPs	I	
29	have	O	
30	been	O	
31	functionally	O	
32	neutralized	O	
33	with	O	
34	anti	B	
35	-	I	
36	PRP9	I	
37	antibodies	I	
38	fully	O	
39	restores	O	
40	the	O	
41	mRNA	O	
42	-	O	
43	splicing	O	
44	activity	O	
45	of	O	
46	the	O	
47	extracts	O	
48	.	O	

1	Replacement	O	
2	of	O	
3	the	O	
4	CRE	O	
5	with	O	
6	a	O	
7	second	O	
8	copy	O	
9	of	O	
10	the	O	
11	AP	B	
12	-	I	
13	1	I	
14	site	I	
15	results	O	
16	in	O	
17	a	O	
18	level	O	
19	of	O	
20	transcriptional	O	
21	activity	O	
22	comparable	O	
23	with	O	
24	that	O	
25	of	O	
26	the	O	
27	wild	O	
28	-	O	
29	type	O	
30	sequence	O	
31	,	O	
32	but	O	
33	replacement	O	
34	of	O	
35	the	O	
36	AP	B	
37	-	I	
38	1	I	
39	site	I	
40	with	O	
41	a	O	
42	CRE	O	
43	abolishes	O	
44	activity	O	
45	.	O	

1	Both	O	
2	antidepressants	O	
3	elevated	O	
4	the	O	
5	pain	O	
6	threshold	O	
7	acutely	O	
8	,	O	
9	while	O	
10	pretreatment	O	
11	with	O	
12	pCPA	O	
13	largely	O	
14	blocked	O	
15	the	O	
16	analgesia	O	
17	.	O	

1	Heterogeneous	B	
2	nuclear	I	
3	ribonucleoprotein	I	
4	(	I	
5	hnRNP	I	
6	)	I	
7	core	I	
8	protein	I	
9	A1	I	
10	is	O	
11	a	O	
12	major	O	
13	component	O	
14	of	O	
15	mammalian	B	
16	hnRNP	I	
17	40	I	
18	S	I	
19	particles	I	
20	.	O	

1	The	O	
2	por	B	
3	gene	I	
4	has	O	
5	been	O	
6	expressed	O	
7	,	O	
8	for	O	
9	the	O	
10	first	O	
11	time	O	
12	,	O	
13	in	O	
14	anaerobically	O	
15	grown	O	
16	Escherichia	O	
17	coli	O	
18	behind	O	
19	the	O	
20	isopropyl	O	
21	-	O	
22	beta	O	
23	-	O	
24	D	O	
25	-	O	
26	thiogalactopyranoside	O	
27	-	O	
28	inducible	O	
29	tac	B	
30	promoter	I	
31	,	O	
32	resulting	O	
33	in	O	
34	the	O	
35	production	O	
36	of	O	
37	POR	B	
38	in	O	
39	its	O	
40	active	O	
41	form	O	
42	.	O	

1	Changes	O	
2	in	O	
3	immunologic	O	
4	reactivity	O	
5	in	O	
6	subjects	O	
7	receiving	O	
8	transfer	B	
9	factor	I	
10	could	O	
11	not	O	
12	be	O	
13	distinguished	O	
14	from	O	
15	those	O	
16	in	O	
17	subjects	O	
18	receiving	O	
19	placebo	O	
20	.	O	

1	DNase	B	
2	I	I	
3	footprinting	O	
4	of	O	
5	the	O	
6	proximal	O	
7	promoter	O	
8	revealed	O	
9	four	O	
10	regions	O	
11	of	O	
12	protection	O	
13	.	O	

1	Epstein	B	
2	-	I	
3	Barr	I	
4	virus	I	
5	(	I	
6	EBV	I	
7	)	I	
8	latent	I	
9	membrane	I	
10	protein	I	
11	1	I	
12	(	O	
13	LMP1	B	
14	)	O	
15	is	O	
16	essential	O	
17	for	O	
18	EBV	O	
19	-	O	
20	mediated	O	
21	transformation	O	
22	of	O	
23	primary	O	
24	B	O	
25	lymphocytes	O	
26	.	O	

1	Rare	O	
2	neurogenic	O	
3	tumor	O	
4	with	O	
5	metastasis	O	
6	to	O	
7	mouth	O	
8	,	O	
9	jaw	O	
10	and	O	
11	face	O	
12	regions	O	

1	The	O	
2	retrovesical	O	
3	hydatid	O	
4	cyst	O	
5	is	O	
6	a	O	
7	very	O	
8	rare	O	
9	site	O	
10	.	O	

1	The	O	
2	terminator	O	
3	region	O	
4	supported	O	
5	termination	O	
6	of	O	
7	transcripts	O	
8	initiated	O	
9	by	O	
10	RNA	B	
11	polymerase	I	
12	I	I	
13	in	O	
14	vivo	O	
15	.	O	

1	Transfection	O	
2	of	O	
3	increasing	O	
4	amounts	O	
5	of	O	
6	delta5ERalpha	B	
7	expression	O	
8	vector	O	
9	into	O	
10	[	O	
11	ERalpha	B	
12	+]	O	
13	OS	O	
14	cells	O	
15	resulted	O	
16	in	O	
17	potentiation	O	
18	of	O	
19	E2	O	
20	-	O	
21	stimulated	O	
22	ERELuc	B	
23	activity	O	
24	in	O	
25	a	O	
26	synergistic	O	
27	,	O	
28	dose	O	
29	-	O	
30	dependent	O	
31	manner	O	
32	.	O	

1	Effect	O	
2	of	O	
3	proteolytic	O	
4	enzymes	O	
5	and	O	
6	polypeptides	O	
7	on	O	
8	the	O	
9	antacid	O	
10	activity	O	
11	of	O	
12	almagate	O	
13	and	O	
14	other	O	
15	antacids	O	
16	.	O	

1	Expression	O	
2	of	O	
3	this	O	
4	cDNA	O	
5	in	O	
6	vitro	O	
7	yields	O	
8	a	O	
9	peptide	O	
10	which	O	
11	comigrates	O	
12	with	O	
13	natural	B	
14	eIF	I	
15	-	I	
16	2B	I	
17	alpha	I	
18	in	O	
19	SDS	O	
20	/	O	
21	polyacrylamide	O	
22	gels	O	
23	.	O	

1	The	O	
2	Ras	B	
3	-	I	
4	related	I	
5	GTPases	I	
6	are	O	
7	small	O	
8	,	O	
9	20	O	
10	-	O	
11	to	O	
12	25	O	
13	-	O	
14	kDa	O	
15	proteins	O	
16	which	O	
17	cycle	O	
18	between	O	
19	an	O	
20	inactive	O	
21	GDP	O	
22	-	O	
23	bound	O	
24	form	O	
25	and	O	
26	an	O	
27	active	O	
28	GTP	O	
29	-	O	
30	bound	O	
31	state	O	
32	.	O	

1	Derivatives	O	
2	of	O	
3	boswellic	O	
4	acids	O	
5	.	O	

1	DESIGN	O	
2	:	O	
3	Comparison	O	
4	of	O	
5	number	O	
6	of	O	
7	women	O	
8	with	O	
9	PKU	O	
10	aged	O	
11	15	O	
12	-	O	
13	44	O	
14	years	O	
15	on	O	
16	the	O	
17	NSW	O	
18	PKU	O	
19	database	O	
20	(	O	
21	observed	O	
22	number	O	
23	)	O	
24	with	O	
25	expected	O	
26	number	O	
27	derived	O	
28	from	O	
29	population	O	
30	data	O	
31	.	O	

1	Whether	O	
2	or	O	
3	not	O	
4	there	O	
5	are	O	
6	sequences	O	
7	conferring	O	
8	cAMP	O	
9	responsiveness	O	
10	which	O	
11	are	O	
12	common	O	
13	both	O	
14	to	O	
15	P	B	
16	-	I	
17	450scc	I	
18	and	O	
19	the	O	
20	other	O	
21	steroidogenic	O	
22	P	B	
23	-	I	
24	450	I	
25	genes	I	
26	remains	O	
27	to	O	
28	be	O	
29	established	O	
30	.	O	

1	Clones	O	
2	that	O	
3	expressed	O	
4	DBD	O	
5	exhibited	O	
6	a	O	
7	dominant	O	
8	negative	O	
9	phenotype	O	
10	and	O	
11	did	O	
12	not	O	
13	elicit	O	
14	antiviral	O	
15	activity	O	
16	against	O	
17	vesicular	O	
18	stomatitis	O	
19	virus	O	
20	(	O	
21	VSV	O	
22	)	O	
23	infection	O	
24	upon	O	
25	IFN	B	
26	treatment	O	
27	.	O	

1	Localization	O	
2	of	O	
3	the	O	
4	cytokine	O	
5	response	O	
6	element	O	
7	by	O	
8	5	O	
9	'-	O	
10	deletion	O	
11	analysis	O	
12	and	O	
13	site	O	
14	-	O	
15	directed	O	
16	mutagenesis	O	
17	revealed	O	
18	a	O	
19	cis	O	
20	-	O	
21	acting	O	
22	binding	O	
23	site	O	
24	for	O	
25	activated	O	
26	STAT	B	
27	complexes	O	
28	.	O	

1	N	O	
2	.,	O	
3	and	O	
4	Fanning	O	
5	,	O	
6	E	O	
7	.	O	

1	Mutations	O	
2	in	O	
3	the	O	
4	small	O	
5	subunit	O	
6	of	O	
7	ribulosebisphosphate	B	
8	carboxylase	I	
9	affect	O	
10	subunit	O	
11	binding	O	
12	and	O	
13	catalysis	O	
14	.	O	

1	Thus	O	
2	,	O	
3	dpp	B	
4	and	O	
5	omb	B	
6	promote	O	
7	both	O	
8	dorsal	O	
9	leg	O	
10	cell	O	
11	fate	O	
12	as	O	
13	well	O	
14	as	O	
15	transdetermination	O	
16	-	O	
17	competent	O	
18	leg	O	
19	disc	O	
20	cells	O	
21	.	O	

1	Disruption	O	
2	mutations	O	
3	have	O	
4	been	O	
5	constructed	O	
6	in	O	
7	the	O	
8	SLK1	B	
9	gene	I	
10	.	O	
11	slk1	B	
12	null	I	
13	mutants	I	
14	cannot	O	
15	grow	O	
16	at	O	
17	37	O	
18	degrees	O	
19	C	O	
20	,	O	
21	but	O	
22	many	O	
23	cells	O	
24	can	O	
25	grow	O	
26	at	O	
27	30	O	
28	,	O	
29	24	O	
30	,	O	
31	and	O	
32	17	O	
33	degrees	O	
34	C	O	
35	.	O	

1	This	O	
2	hypothesis	O	
3	is	O	
4	consistent	O	
5	with	O	
6	the	O	
7	occurrence	O	
8	of	O	
9	PEA3	B	
10	binding	I	
11	sites	I	
12	in	O	
13	the	O	
14	PEA3	B	
15	promoter	I	
16	and	O	
17	with	O	
18	the	O	
19	ability	O	
20	of	O	
21	PEA3	B	
22	to	O	
23	transactivate	O	
24	this	O	
25	promoter	O	
26	.	O	

1	This	O	
2	review	O	
3	summarizes	O	
4	the	O	
5	clinical	O	
6	evidence	O	
7	to	O	
8	support	O	
9	current	O	
10	therapies	O	
11	in	O	
12	irritable	O	
13	bowel	O	
14	syndrome	O	
15	(	O	
16	IBS	O	
17	).	O	

1	Using	O	
2	the	O	
3	yeast	O	
4	two	O	
5	-	O	
6	hybrid	O	
7	system	O	
8	to	O	
9	screen	O	
10	for	O	
11	proteins	O	
12	which	O	
13	interact	O	
14	with	O	
15	Tax1	B	
16	,	O	
17	we	O	
18	isolated	O	
19	the	O	
20	B	O	
21	subunit	O	
22	of	O	
23	the	O	
24	CCAAT	O	
25	binding	O	
26	protein	O	
27	NF	B	
28	-	I	
29	Y	I	
30	from	O	
31	a	O	
32	HeLa	O	
33	cDNA	O	
34	library	O	
35	.	O	

1	No	O	
2	significant	O	
3	differences	O	
4	existed	O	
5	between	O	
6	the	O	
7	two	O	
8	age	O	
9	groups	O	
10	in	O	
11	baseline	O	
12	characteristics	O	
13	,	O	
14	including	O	
15	treatment	O	
16	protocol	O	
17	,	O	
18	performance	O	
19	status	O	
20	,	O	
21	and	O	
22	serum	B	
23	lactate	I	
24	dehydrogenase	I	
25	(	O	
26	LDH	B	
27	)	O	
28	level	O	
29	.	O	

1	Genomic	O	
2	Southern	O	
3	blot	O	
4	analysis	O	
5	of	O	
6	rat	B	
7	EFIA	I	
8	(	O	
9	gene	O	
10	encoding	O	
11	enhancer	B	
12	factor	I	
13	I	I	
14	subunit	I	
15	A	I	
16	)	O	
17	reveals	O	
18	a	O	
19	complex	O	
20	band	O	
21	pattern	O	
22	when	O	
23	cDNA	O	
24	subfragment	O	
25	probes	O	
26	are	O	
27	used	O	
28	.	O	

1	Previously	O	
2	,	O	
3	we	O	
4	reported	O	
5	the	O	
6	sequence	O	
7	of	O	
8	the	O	
9	gene	B	
10	encoding	I	
11	human	I	
12	K14	I	
13	(	O	
14	D	O	
15	.	O	

1	Fibromuscular	O	
2	intimal	O	
3	thickening	O	
4	was	O	
5	seen	O	
6	in	O	
7	the	O	
8	ascending	O	
9	and	O	
10	thoracic	O	
11	aorta	O	
12	of	O	
13	the	O	
14	swine	O	
15	fed	O	
16	62	O	
17	,	O	
18	500	O	
19	IU	O	
20	of	O	
21	vitamin	O	
22	D3	O	
23	/	O	
24	kg	O	
25	of	O	
26	diet	O	
27	for	O	
28	three	O	
29	months	O	
30	duration	O	
31	;	O	
32	and	O	
33	after	O	
34	3	O	
35	months	O	
36	of	O	
37	vitamin	O	
38	D3	O	
39	withdrawal	O	
40	,	O	
41	atherosclerotic	O	
42	lesions	O	
43	were	O	
44	found	O	
45	.	O	

1	Analysis	O	
2	of	O	
3	Standard	O	
4	Reference	O	
5	Material	O	
6	1846	O	
7	,	O	
8	Infant	O	
9	Formula	O	
10	,	O	
11	gave	O	
12	a	O	
13	mean	O	
14	value	O	
15	of	O	
16	0	O	
17	.	O	
18	95	O	
19	+/-	O	
20	0	O	
21	.	O	
22	088	O	
23	mg	O	
24	vitamin	O	
25	K	O	
26	/	O	
27	kg	O	
28	(	O	
29	K	O	
30	or	O	
31	K1	O	
32	?)	O	
33	(	O	
34	n	O	
35	=	O	
36	31	O	
37	)	O	
38	with	O	
39	a	O	
40	coefficient	O	
41	of	O	
42	variation	O	
43	of	O	
44	9	O	
45	.	O	
46	26	O	
47	.	O	

1	It	O	
2	is	O	
3	now	O	
4	recognized	O	
5	that	O	
6	essentially	O	
7	all	O	
8	eukaryotic	O	
9	and	O	
10	prokaryotic	O	
11	genes	O	
12	whose	O	
13	5	O	
14	'-	O	
15	flanking	O	
16	regions	O	
17	are	O	
18	known	O	
19	and	O	
20	that	O	
21	encode	O	
22	barbiturate	O	
23	-	O	
24	inducible	O	
25	proteins	O	
26	contain	O	
27	the	O	
28	Barbie	O	
29	box	O	
30	element	O	
31	.	O	

1	Resistance	O	
2	ratios	O	
3	for	O	
4	the	O	
5	other	O	
6	field	O	
7	strains	O	
8	obtained	O	
9	by	O	
10	comparison	O	
11	with	O	
12	the	O	
13	R5	O	
14	strain	O	
15	ranged	O	
16	from	O	
17	24	O	
18	.	O	
19	5	O	
20	to	O	
21	239	O	
22	for	O	
23	topical	O	
24	application	O	
25	and	O	
26	from	O	
27	1	O	
28	.	O	
29	2	O	
30	to	O	
31	9	O	
32	.	O	
33	8	O	
34	for	O	
35	the	O	
36	glass	O	
37	jar	O	
38	method	O	
39	.	O	

1	We	O	
2	conducted	O	
3	a	O	
4	prospective	O	
5	,	O	
6	randomized	O	
7	controlled	O	
8	trial	O	
9	of	O	
10	metoprolol	O	
11	,	O	
12	a	O	
13	selective	O	
14	beta	O	
15	-	O	
16	blocker	O	
17	for	O	
18	prevention	O	
19	of	O	
20	gastrointestinal	O	
21	bleeding	O	
22	from	O	
23	portal	O	
24	hypertension	O	
25	in	O	
26	29	O	
27	non	O	
28	-	O	
29	selected	O	
30	patients	O	
31	with	O	
32	liver	O	
33	disease	O	
34	and	O	
35	previous	O	
36	gastrointestinal	O	
37	bleeding	O	
38	.	O	

1	After	O	
2	description	O	
3	of	O	
4	his	O	
5	short	O	
6	life	O	
7	and	O	
8	an	O	
9	explanation	O	
10	of	O	
11	the	O	
12	light	O	
13	conductor	O	
14	Bozzini	O	
15	'	O	
16	s	O	
17	merit	O	
18	is	O	
19	emphasized	O	
20	,	O	
21	by	O	
22	his	O	
23	invention	O	
24	as	O	
25	first	O	
26	physician	O	
27	to	O	
28	have	O	
29	made	O	
30	accessible	O	
31	to	O	
32	medicine	O	
33	endoscopic	O	
34	diagnostic	O	
35	possibilities	O	
36	.	O	

1	Intrathecal	O	
2	acetyl	B	
3	cholinesterase	I	
4	inhibitors	O	
5	produce	O	
6	analgesia	O	
7	that	O	
8	is	O	
9	synergistic	O	
10	with	O	
11	morphine	O	
12	and	O	
13	clonidine	O	
14	in	O	
15	rats	O	
16	.	O	

1	A	O	
2	brief	O	
3	discussion	O	
4	of	O	
5	color	O	
6	deficiencies	O	
7	.	O	

1	A	O	
2	3	O	
3	-	O	
4	yr	O	
5	retrospective	O	
6	review	O	
7	is	O	
8	effective	O	
9	and	O	
10	detects	O	
11	94	O	
12	%	O	
13	of	O	
14	the	O	
15	undercalls	O	
16	.	O	

1	The	O	
2	second	O	
3	primary	O	
4	mutant	O	
5	contained	O	
6	a	O	
7	proline	O	
8	-	O	
9	to	O	
10	-	O	
11	leucine	O	
12	change	O	
13	at	O	
14	position	O	
15	243	O	
16	(	O	
17	P243L	O	
18	).	O	

1	Thus	O	
2	,	O	
3	these	O	
4	studies	O	
5	indicate	O	
6	that	O	
7	the	O	
8	104	O	
9	-	O	
10	kDa	O	
11	isoform	O	
12	is	O	
13	required	O	
14	for	O	
15	normal	O	
16	proliferation	O	
17	of	O	
18	female	O	
19	germline	O	
20	cells	O	
21	and	O	
22	perhaps	O	
23	for	O	
24	oocyte	O	
25	differentiation	O	
26	.	O	

1	In	O	
2	the	O	
3	first	O	
4	group	O	
5	,	O	
6	0	O	
7	.	O	
8	02	O	
9	%	O	
10	Prazosin	O	
11	(	O	
12	0	O	
13	.	O	
14	5	O	
15	mg	O	
16	/	O	
17	kg	O	
18	)	O	
19	was	O	
20	administered	O	
21	intravenously	O	
22	for	O	
23	1	O	
24	.	O	
25	5	O	
26	hours	O	
27	before	O	
28	the	O	
29	application	O	
30	of	O	
31	Oxy	O	
32	-	O	
33	Hb	O	
34	or	O	
35	PGF2	O	
36	alpha	O	
37	.	O	

1	In	O	
2	conclusion	O	
3	,	O	
4	these	O	
5	observations	O	
6	demonstrated	O	
7	that	O	
8	stratification	O	
9	of	O	
10	acute	O	
11	MI	O	
12	patients	O	
13	by	O	
14	plasma	O	
15	ANF	B	
16	level	O	
17	is	O	
18	a	O	
19	useful	O	
20	non	O	
21	-	O	
22	invasive	O	
23	method	O	
24	for	O	
25	predicting	O	
26	prognosis	O	
27	and	O	
28	for	O	
29	identifying	O	
30	individuals	O	
31	at	O	
32	high	O	
33	risk	O	
34	of	O	
35	cardiac	O	
36	death	O	
37	.	O	

1	Among	O	
2	six	O	
3	different	O	
4	library	O	
5	isolates	O	
6	containing	O	
7	6	B	
8	.	I	
9	5	I	
10	-	I	
11	to	I	
12	7	I	
13	-	I	
14	kb	I	
15	IAP	I	
16	units	I	
17	,	O	
18	some	O	
19	restriction	O	
20	sites	O	
21	were	O	
22	highly	O	
23	conserved	O	
24	whereas	O	
25	others	O	
26	varied	O	
27	in	O	
28	both	O	
29	occurrence	O	
30	and	O	
31	position	O	
32	.	O	

1	In	O	
2	controls	O	
3	,	O	
4	only	O	
5	modest	O	
6	differences	O	
7	were	O	
8	observed	O	
9	.	O	

1	The	O	
2	decline	O	
3	in	O	
4	the	O	
5	activity	O	
6	of	O	
7	cytochrome	B	
8	oxidase	I	
9	,	O	
10	peroxidase	B	
11	and	O	
12	in	O	
13	the	O	
14	lipid	O	
15	content	O	
16	of	O	
17	peripheral	O	
18	neutrophils	O	
19	was	O	
20	followed	O	
21	by	O	
22	a	O	
23	decrease	O	
24	in	O	
25	the	O	
26	phagocytic	O	
27	activity	O	
28	.	O	

1	Surprisingly	O	
2	,	O	
3	the	O	
4	RXR	B	
5	-	O	
6	specific	O	
7	ligand	O	
8	9	O	
9	-	O	
10	cis	O	
11	-	O	
12	retinoic	O	
13	acid	O	
14	induced	O	
15	binding	O	
16	of	O	
17	SRC	B	
18	-	I	
19	1	I	
20	to	O	
21	the	O	
22	RXR	B	
23	component	I	
24	of	O	
25	the	O	
26	TRE	O	
27	-	O	
28	bound	O	
29	heterodimer	O	
30	.	O	

1	FTF	B	
2	is	O	
3	also	O	
4	abundantly	O	
5	expressed	O	
6	in	O	
7	the	O	
8	pancreas	O	
9	and	O	
10	may	O	
11	exert	O	
12	differentiation	O	
13	functions	O	
14	in	O	
15	endodermal	O	
16	sublineages	O	
17	,	O	
18	similar	O	
19	to	O	
20	SF	B	
21	-	I	
22	1	I	
23	in	O	
24	steroidogenic	O	
25	tissues	O	
26	.	O	

1	4	O	
2	Five	O	
3	patients	O	
4	died	O	
5	within	O	
6	one	O	
7	month	O	
8	of	O	
9	captopril	O	
10	and	O	
11	five	O	
12	between	O	
13	four	O	
14	and	O	
15	seven	O	
16	months	O	
17	,	O	
18	three	O	
19	of	O	
20	whom	O	
21	had	O	
22	improved	O	
23	to	O	
24	class	O	
25	IIM	O	
26	and	O	
27	one	O	
28	to	O	
29	IIS	O	
30	before	O	
31	death	O	
32	.	O	

1	The	O	
2	downstream	O	
3	,	O	
4	TATA	O	
5	-	O	
6	less	O	
7	promoter	O	
8	has	O	
9	high	O	
10	G	O	
11	+	O	
12	C	O	
13	content	O	
14	,	O	
15	and	O	
16	exon	O	
17	1b	O	
18	predominates	O	
19	among	O	
20	abundantly	O	
21	expressed	O	
22	mRNA	O	
23	species	O	
24	.	O	

1	Interestingly	O	
2	,	O	
3	although	O	
4	E	O	
5	domains	O	
6	of	O	
7	these	O	
8	two	O	
9	receptors	O	
10	are	O	
11	much	O	
12	less	O	
13	conserved	O	
14	,	O	
15	replacement	O	
16	of	O	
17	this	O	
18	domain	O	
19	in	O	
20	rtER	B	
21	by	O	
22	its	O	
23	human	O	
24	counterpart	O	
25	resulted	O	
26	in	O	
27	higher	O	
28	estradiol	O	
29	sensitivity	O	
30	but	O	
31	no	O	
32	increase	O	
33	in	O	
34	the	O	
35	magnitude	O	
36	of	O	
37	transactivation	O	
38	.	O	

1	All	O	
2	the	O	
3	women	O	
4	received	O	
5	13	O	
6	.	O	
7	5	O	
8	mg	O	
9	plain	O	
10	bupivacaine	O	
11	via	O	
12	subarachnoid	O	
13	injection	O	
14	at	O	
15	the	O	
16	L2	O	
17	-	O	
18	3	O	
19	interspace	O	
20	.	O	

1	The	O	
2	interaction	O	
3	does	O	
4	not	O	
5	depend	O	
6	on	O	
7	the	O	
8	presence	O	
9	of	O	
10	the	O	
11	correct	O	
12	amino	O	
13	-	O	
14	terminal	O	
15	DNA	O	
16	binding	O	
17	domain	O	
18	or	O	
19	the	O	
20	amino	O	
21	acid	O	
22	sequences	O	
23	between	O	
24	the	O	
25	DNA	O	
26	binding	O	
27	domain	O	
28	and	O	
29	the	O	
30	last	O	
31	ten	O	
32	amino	O	
33	acids	O	
34	.	O	

1	This	O	
2	observation	O	
3	calls	O	
4	for	O	
5	careful	O	
6	monitoring	O	
7	of	O	
8	calcium	O	
9	and	O	
10	alkaline	B	
11	phosphatase	I	
12	values	O	
13	and	O	
14	possible	O	
15	adjustments	O	
16	of	O	
17	vitamin	O	
18	D	O	
19	intake	O	
20	when	O	
21	fortifiers	O	
22	are	O	
23	used	O	
24	for	O	
25	extended	O	
26	periods	O	
27	.	O	

1	Some	O	
2	research	O	
3	studies	O	
4	have	O	
5	related	O	
6	this	O	
7	kind	O	
8	of	O	
9	tumors	O	
10	with	O	
11	prolonged	O	
12	ingestion	O	
13	of	O	
14	H2	O	
15	inhibitors	O	
16	and	O	
17	others	O	
18	antacid	O	
19	.	O	

1	Calcium	O	
2	and	O	
3	phosphorus	O	
4	metabolism	O	
5	in	O	
6	chronic	O	
7	uremia	O	
8	.	O	

1	These	O	
2	include	O	
3	NPF	O	
4	repeats	O	
5	,	O	
6	a	O	
7	leucine	O	
8	heptad	O	
9	repeat	O	
10	enriched	O	
11	in	O	
12	charged	O	
13	residues	O	
14	,	O	
15	and	O	
16	a	O	
17	proline	O	
18	-	O	
19	rich	O	
20	SH3	B	
21	-	I	
22	like	I	
23	and	O	
24	/	O	
25	or	O	
26	WW	O	
27	domain	O	
28	-	O	
29	binding	O	
30	site	O	
31	in	O	
32	the	O	
33	N	O	
34	-	O	
35	terminal	O	
36	domain	O	
37	,	O	
38	which	O	
39	is	O	
40	followed	O	
41	by	O	
42	a	O	
43	membrane	O	
44	core	O	
45	containing	O	
46	four	O	
47	putative	O	
48	transmembrane	O	
49	spans	O	
50	and	O	
51	three	O	
52	amphiphilic	O	
53	segments	O	
54	that	O	
55	are	O	
56	the	O	
57	most	O	
58	highly	O	
59	conserved	O	
60	structural	O	
61	elements	O	
62	.	O	

1	Chimeric	O	
2	phage	O	
3	-	O	
4	plasmid	O	
5	expression	O	
6	vectors	O	
7	were	O	
8	constructed	O	
9	from	O	
10	pUC18	O	
11	/	O	
12	19	O	
13	plasmids	O	
14	by	O	
15	cloning	O	
16	a	O	
17	single	O	
18	-	O	
19	stranded	O	
20	DNA	O	
21	(	O	
22	ssDNA	O	
23	)	O	
24	origin	O	
25	of	O	
26	replication	O	
27	from	O	
28	bacteriophage	O	
29	f1	O	
30	and	O	
31	inserting	O	
32	a	O	
33	bacteriophage	O	
34	T7	O	
35	promoter	O	
36	within	O	
37	the	O	
38	beta	B	
39	-	I	
40	galactosidase	I	
41	gene	I	
42	.	O	

1	We	O	
2	now	O	
3	describe	O	
4	a	O	
5	second	O	
6	RIM	B	
7	protein	I	
8	,	O	
9	called	O	
10	RIM2	B	
11	,	O	
12	that	O	
13	is	O	
14	highly	O	
15	homologous	O	
16	to	O	
17	RIM1	B	
18	and	O	
19	also	O	
20	expressed	O	
21	primarily	O	
22	in	O	
23	brain	O	
24	.	O	

1	The	O	
2	aim	O	
3	of	O	
4	the	O	
5	present	O	
6	study	O	
7	was	O	
8	to	O	
9	examine	O	
10	the	O	
11	antimicrobial	O	
12	susceptibility	O	
13	to	O	
14	10	O	
15	currently	O	
16	used	O	
17	antimicrobial	O	
18	agents	O	
19	of	O	
20	50	O	
21	strains	O	
22	of	O	
23	P	O	
24	.	O	
25	acnes	O	
26	isolated	O	
27	from	O	
28	acne	O	
29	lesions	O	
30	and	O	
31	identified	O	
32	using	O	
33	a	O	
34	Rap	O	
35	ID	O	
36	ANA	O	
37	II	O	
38	panel	O	
39	.	O	

1	Using	O	
2	the	O	
3	balloon	O	
4	-	O	
5	gas	O	
6	procedure	O	
7	with	O	
8	a	O	
9	single	O	
10	gas	O	
11	injection	O	
12	,	O	
13	a	O	
14	bubble	O	
15	was	O	
16	obtained	O	
17	that	O	
18	was	O	
19	large	O	
20	enough	O	
21	to	O	
22	tamponade	O	
23	a	O	
24	giant	O	
25	tear	O	
26	without	O	
27	prior	O	
28	drainage	O	
29	of	O	
30	subretinal	O	
31	fluid	O	
32	or	O	
33	vitrectomy	O	
34	.	O	

1	The	O	
2	mean	O	
3	times	O	
4	to	O	
5	detection	O	
6	of	O	
7	all	O	
8	mycobacteria	O	
9	with	O	
10	BACTEC	O	
11	9000	O	
12	MB	O	
13	and	O	
14	BACTEC	O	
15	460	O	
16	TB	O	
17	were	O	
18	similar	O	
19	(	O	
20	10	O	
21	.	O	
22	3	O	
23	and	O	
24	10	O	
25	.	O	
26	0	O	
27	days	O	
28	,	O	
29	respectively	O	
30	).	O	

1	Re	O	
2	:	O	
3	A	O	
4	modified	O	
5	method	O	
6	for	O	
7	the	O	
8	in	O	
9	vivo	O	
10	labeling	O	
11	of	O	
12	red	O	
13	blood	O	
14	cells	O	
15	with	O	
16	Tc	O	
17	-	O	
18	99m	O	
19	.	O	

1	The	O	
2	identity	O	
3	between	O	
4	hnRNPs	B	
5	H	I	
6	and	O	
7	H	B	
8	'	I	
9	is	O	
10	96	O	
11	%,	O	
12	between	O	
13	H	B	
14	and	O	
15	F	B	
16	78	O	
17	%,	O	
18	and	O	
19	between	O	
20	H	B	
21	'	I	
22	and	O	
23	F	B	
24	75	O	
25	%,	O	
26	respectively	O	
27	.	O	

1	A	O	
2	recombinant	O	
3	derivative	O	
4	harboring	O	
5	the	O	
6	pMJ101	O	
7	replication	O	
8	region	O	
9	proved	O	
10	to	O	
11	be	O	
12	compatible	O	
13	with	O	
14	pJM1	O	
15	,	O	
16	a	O	
17	plasmid	O	
18	containing	O	
19	the	O	
20	iron	O	
21	acquisition	O	
22	system	O	
23	required	O	
24	for	O	
25	the	O	
26	virulence	O	
27	of	O	
28	V	O	
29	.	O	
30	anguillarum	O	
31	775	O	
32	,	O	
33	another	O	
34	important	O	
35	pathogen	O	
36	that	O	
37	causes	O	
38	vibriosis	O	
39	.	O	

1	We	O	
2	suggest	O	
3	that	O	
4	CT	O	
5	scan	O	
6	be	O	
7	preferable	O	
8	in	O	
9	diagnosis	O	
10	of	O	
11	tumors	O	
12	in	O	
13	that	O	
14	area	O	
15	.	O	

1	The	O	
2	present	O	
3	study	O	
4	investigates	O	
5	whether	O	
6	prostaglandins	O	
7	"	O	
8	cytoprotect	O	
9	"	O	
10	the	O	
11	gastric	O	
12	mucosa	O	
13	against	O	
14	hemorrhage	O	
15	-	O	
16	induced	O	
17	stress	O	
18	ulceration	O	
19	by	O	
20	assessing	O	
21	the	O	
22	influence	O	
23	of	O	
24	16	O	
25	,	O	
26	16	O	
27	-	O	
28	dimethyl	O	
29	prostaglandin	O	
30	E2	O	
31	(	O	
32	16	O	
33	,	O	
34	16	O	
35	-	O	
36	dm	O	
37	PGE2	O	
38	)	O	
39	on	O	
40	gross	O	
41	and	O	
42	microscopic	O	
43	lesion	O	
44	formation	O	
45	,	O	
46	intramucosal	O	
47	tissue	O	
48	pH	O	
49	,	O	
50	H	O	
51	+	O	
52	back	O	
53	-	O	
54	diffusion	O	
55	,	O	
56	and	O	
57	mucosal	O	
58	blood	O	
59	flow	O	
60	in	O	
61	rat	O	
62	gastric	O	
63	mucosa	O	
64	exposed	O	
65	to	O	
66	luminal	O	
67	acid	O	
68	(	O	
69	100	O	
70	mM	O	
71	HCl	O	
72	)	O	
73	during	O	
74	hemorrhagic	O	
75	shock	O	
76	(	O	
77	13	O	
78	ml	O	
79	/	O	
80	kg	O	
81	for	O	
82	20	O	
83	min	O	
84	).	O	

1	Drugs	O	
2	suppressed	O	
3	>	O	
4	or	O	
5	=	O	
6	75	O	
7	%	O	
8	of	O	
9	the	O	
10	total	O	
11	premature	O	
12	ventricular	O	
13	contractions	O	
14	in	O	
15	all	O	
16	patients	O	
17	who	O	
18	had	O	
19	both	O	
20	use	O	
21	-	O	
22	dependent	O	
23	QRS	O	
24	prolongation	O	
25	and	O	
26	reverse	O	
27	use	O	
28	-	O	
29	dependent	O	
30	QT	O	
31	prolongation	O	
32	,	O	
33	in	O	
34	79	O	
35	%	O	
36	of	O	
37	patients	O	
38	with	O	
39	use	O	
40	-	O	
41	dependent	O	
42	QRS	O	
43	prolongation	O	
44	alone	O	
45	,	O	
46	in	O	
47	70	O	
48	%	O	
49	with	O	
50	reverse	O	
51	use	O	
52	-	O	
53	dependent	O	
54	QT	O	
55	prolongation	O	
56	alone	O	
57	,	O	
58	and	O	
59	in	O	
60	11	O	
61	%	O	
62	with	O	
63	neither	O	
64	use	O	
65	-	O	
66	dependent	O	
67	QRS	O	
68	prolongation	O	
69	nor	O	
70	reverse	O	
71	use	O	
72	-	O	
73	dependent	O	
74	QT	O	
75	prolongation	O	
76	.	O	

1	Review	O	
2	of	O	
3	the	O	
4	literature	O	
5	and	O	
6	report	O	
7	of	O	
8	a	O	
9	case	O	
10	of	O	
11	a	O	
12	dermoid	O	
13	cyst	O	
14	.	O	

1	These	O	
2	data	O	
3	show	O	
4	that	O	
5	heterologous	O	
6	virus	O	
7	RNAs	O	
8	(	O	
9	BSMV	O	
10	)	O	
11	can	O	
12	serve	O	
13	as	O	
14	primer	O	
15	donors	O	
16	for	O	
17	MStV	O	
18	mRNA	O	
19	capped	O	
20	RNA	O	
21	-	O	
22	primed	O	
23	transcription	O	
24	in	O	
25	doubly	O	
26	infected	O	
27	plants	O	
28	.	O	

1	In	O	
2	the	O	
3	present	O	
4	study	O	
5	,	O	
6	we	O	
7	demonstrate	O	
8	that	O	
9	expression	O	
10	of	O	
11	TD	B	
12	-	I	
13	IkappaBalpha	I	
14	blocked	O	
15	phorbol	O	
16	myristate	O	
17	acetate	B	
18	-	I	
19	phytohemagglutinin	I	
20	or	O	
21	tumor	B	
22	necrosis	I	
23	factor	I	
24	alpha	I	
25	-	O	
26	induced	O	
27	IkappaBalpha	B	
28	gene	I	
29	transcription	O	
30	and	O	
31	abolished	O	
32	NF	B	
33	-	I	
34	kappaB	I	
35	DNA	O	
36	binding	O	
37	activity	O	
38	,	O	
39	due	O	
40	to	O	
41	the	O	
42	continued	O	
43	cytoplasmic	O	
44	sequestration	O	
45	of	O	
46	RelA	B	
47	(	O	
48	p65	B	
49	)	O	
50	by	O	
51	TD	B	
52	-	I	
53	IkappaBalpha	I	
54	.	O	

1	The	O	
2	nucleotide	O	
3	sequences	O	
4	at	O	
5	the	O	
6	5	O	
7	'	O	
8	and	O	
9	3	O	
10	'	O	
11	ends	O	
12	of	O	
13	these	O	
14	introns	O	
15	are	O	
16	characteristic	O	
17	of	O	
18	spliced	O	
19	transcripts	O	
20	from	O	
21	eukaryotic	O	
22	protein	O	
23	-	O	
24	encoding	O	
25	genes	O	
26	,	O	
27	with	O	
28	one	O	
29	significant	O	
30	difference	O	
31	;	O	
32	i	O	
33	.	O	
34	e	O	
35	.,	O	
36	the	O	
37	5	O	
38	'	O	
39	end	O	
40	of	O	
41	the	O	
42	LAT	B	
43	intron	I	
44	is	O	
45	GC	O	
46	instead	O	
47	of	O	
48	the	O	
49	consensus	O	
50	sequence	O	
51	GT	O	
52	.	O	

1	The	O	
2	time	O	
3	course	O	
4	of	O	
5	RNA1	B	
6	replication	O	
7	and	O	
8	RNA3	B	
9	synthesis	O	
10	in	O	
11	induced	O	
12	yeast	O	
13	paralleled	O	
14	that	O	
15	in	O	
16	yeast	O	
17	transfected	O	
18	with	O	
19	natural	O	
20	FHV	O	
21	virion	O	
22	RNA	O	
23	.	O	

1	Thus	O	
2	,	O	
3	CHOP	B	
4	not	O	
5	only	O	
6	is	O	
7	a	O	
8	negative	O	
9	or	O	
10	a	O	
11	positive	O	
12	regulator	O	
13	of	O	
14	C	B	
15	/	I	
16	EBP	I	
17	target	O	
18	genes	O	
19	but	O	
20	also	O	
21	,	O	
22	when	O	
23	tethered	O	
24	to	O	
25	AP	B	
26	-	I	
27	1	I	
28	factors	I	
29	,	O	
30	can	O	
31	activate	O	
32	AP	B	
33	-	I	
34	1	I	
35	target	O	
36	genes	O	
37	.	O	

1	The	O	
2	results	O	
3	presented	O	
4	in	O	
5	this	O	
6	report	O	
7	suggest	O	
8	that	O	
9	the	O	
10	SV40	O	
11	G	O	
12	-	O	
13	C	O	
14	-	O	
15	rich	O	
16	sequences	O	
17	can	O	
18	function	O	
19	as	O	
20	independent	O	
21	RNA	B	
22	polymerase	I	
23	II	I	
24	transcriptional	O	
25	-	O	
26	control	O	
27	elements	O	
28	.	O	

1	Synthetic	O	
2	oligonucleotides	O	
3	representing	O	
4	the	O	
5	19	O	
6	bp	O	
7	repeat	O	
8	unit	O	
9	strongly	O	
10	reduced	O	
11	the	O	
12	activity	O	
13	of	O	
14	the	O	
15	IE1	B	
16	/	I	
17	2	I	
18	enhancer	I	
19	/	I	
20	promoter	I	
21	in	O	
22	cotransfection	O	
23	assays	O	
24	after	O	
25	transient	O	
26	expression	O	
27	.	O	

1	We	O	
2	recently	O	
3	characterized	O	
4	a	O	
5	single	O	
6	yeast	B	
7	hnRNP	I	
8	methyltransferase	I	
9	(	O	
10	HMT1	B	
11	).	O	

1	A	O	
2	platelet	B	
3	-	I	
4	derived	I	
5	growth	I	
6	factor	I	
7	receptor	I	
8	(	O	
9	PDGF	B	
10	-	I	
11	R	I	
12	)	O	
13	phosphopeptide	O	
14	containing	O	
15	Tyr	O	
16	-	O	
17	857	O	
18	does	O	
19	not	O	
20	bind	O	
21	appreciably	O	
22	to	O	
23	the	O	
24	Src	B	
25	SH2	I	
26	domain	I	
27	,	O	
28	suggesting	O	
29	it	O	
30	is	O	
31	not	O	
32	the	O	
33	PDGF	B	
34	-	I	
35	R	I	
36	binding	O	
37	site	O	
38	for	O	
39	Src	B	
40	as	O	
41	previously	O	
42	reported	O	
43	.	O	

1	Orientation	O	
2	of	O	
3	the	O	
4	nuclear	O	
5	spin	O	
6	system	O	
7	by	O	
8	optical	O	
9	pumping	O	
10	causes	O	
11	an	O	
12	Overhauser	O	
13	shift	O	
14	of	O	
15	the	O	
16	excitonic	O	
17	energy	O	
18	levels	O	
19	proportional	O	
20	to	O	
21	the	O	
22	degree	O	
23	of	O	
24	nuclear	O	
25	orientation	O	
26	.	O	

1	Cytoplasmic	B	
2	dynein	I	
3	is	O	
4	a	O	
5	multisubunit	O	
6	,	O	
7	microtubule	O	
8	-	O	
9	dependent	O	
10	mechanochemical	O	
11	enzyme	O	
12	that	O	
13	has	O	
14	been	O	
15	proposed	O	
16	to	O	
17	function	O	
18	in	O	
19	a	O	
20	variety	O	
21	of	O	
22	intracellular	O	
23	movements	O	
24	,	O	
25	including	O	
26	minus	O	
27	-	O	
28	end	O	
29	-	O	
30	directed	O	
31	transport	O	
32	of	O	
33	organelles	O	
34	.	O	

1	Most	O	
2	of	O	
3	the	O	
4	expressed	O	
5	human	B	
6	E3	I	
7	polypeptides	I	
8	(	O	
9	five	O	
10	bands	O	
11	)	O	
12	were	O	
13	found	O	
14	in	O	
15	the	O	
16	insoluble	O	
17	pellet	O	
18	while	O	
19	primarily	O	
20	full	B	
21	-	I	
22	length	I	
23	mature	I	
24	E3	I	
25	was	O	
26	found	O	
27	in	O	
28	the	O	
29	soluble	O	
30	fraction	O	
31	.	O	

1	Male	O	
2	contraception	O	
3	:	O	
4	ideas	O	
5	for	O	
6	the	O	
7	future	O	
8	.	O	

1	The	O	
2	eukaryotic	O	
3	cell	O	
4	cycle	O	
5	is	O	
6	governed	O	
7	in	O	
8	part	O	
9	by	O	
10	the	O	
11	periodic	O	
12	transcription	O	
13	of	O	
14	cyclin	B	
15	genes	I	
16	,	O	
17	whose	O	
18	protein	O	
19	products	O	
20	associate	O	
21	with	O	
22	and	O	
23	positively	O	
24	regulate	O	
25	the	O	
26	cyclin	B	
27	-	I	
28	dependent	I	
29	kinases	I	
30	.	O	

1	Using	O	
2	in	O	
3	organello	O	
4	footprint	O	
5	analysis	O	
6	,	O	
7	we	O	
8	demonstrate	O	
9	that	O	
10	within	O	
11	human	O	
12	placental	O	
13	mitochondria	O	
14	there	O	
15	is	O	
16	a	O	
17	high	O	
18	level	O	
19	of	O	
20	protein	O	
21	-	O	
22	DNA	O	
23	binding	O	
24	at	O	
25	regularly	O	
26	phased	O	
27	intervals	O	
28	throughout	O	
29	a	O	
30	500	O	
31	-	O	
32	bp	O	
33	region	O	
34	encompassing	O	
35	the	O	
36	D	O	
37	-	O	
38	loop	O	
39	DNA	O	
40	origins	O	
41	and	O	
42	two	O	
43	promoter	O	
44	regions	O	
45	.	O	

1	Hepatitis	B	
2	B	I	
3	surface	I	
4	antigen	I	
5	was	O	
6	detected	O	
7	in	O	
8	2	O	
9	patients	O	
10	,	O	
11	with	O	
12	negative	O	
13	hepatitis	B	
14	C	I	
15	virus	I	
16	antibody	I	
17	.	O	

1	These	O	
2	findings	O	
3	suggest	O	
4	that	O	
5	late	O	
6	MYO	O	
7	/	O	
8	M	O	
9	is	O	
10	more	O	
11	useful	O	
12	than	O	
13	washout	O	
14	rate	O	
15	to	O	
16	assess	O	
17	the	O	
18	effect	O	
19	of	O	
20	treatment	O	
21	on	O	
22	heart	O	
23	failure	O	
24	due	O	
25	to	O	
26	DCM	O	
27	.	O	

1	In	O	
2	patients	O	
3	with	O	
4	osteomyelitis	O	
5	and	O	
6	joint	O	
7	empyema	O	
8	(	O	
9	n	O	
10	=	O	
11	48	O	
12	)	O	
13	PMN	B	
14	elastase	I	
15	had	O	
16	a	O	
17	sensitivity	O	
18	of	O	
19	77	O	
20	%,	O	
21	which	O	
22	was	O	
23	only	O	
24	exceeded	O	
25	by	O	
26	that	O	
27	of	O	
28	the	O	
29	unspecific	O	
30	erythrocyte	O	
31	sedimentation	O	
32	rate	O	
33	(	O	
34	sensitivity	O	
35	89	O	
36	%).	O	

1	As	O	
2	a	O	
3	result	O	
4	,	O	
5	beta	O	
6	-	O	
7	apo	O	
8	-	O	
9	8	O	
10	'-	O	
11	carotenoic	O	
12	acid	O	
13	ethyl	O	
14	ester	O	
15	(	O	
16	apo	O	
17	-	O	
18	EE	O	
19	)	O	
20	was	O	
21	used	O	
22	as	O	
23	a	O	
24	reference	O	
25	standard	O	
26	in	O	
27	Experiments	O	
28	4	O	
29	to	O	
30	6	O	
31	.	O	

1	Escherichia	O	
2	of	O	
3	a	O	
4	single	O	
5	sero	O	
6	-	O	
7	anzymatic	O	
8	type	O	
9	(	O	
10	06a6b	O	
11	:	O	
12	K13	O	
13	:	O	
14	H1	O	
15	)	O	
16	were	O	
17	isolated	O	
18	in	O	
19	a	O	
20	group	O	
21	affection	O	
22	.	O	

1	To	O	
2	elucidate	O	
3	whether	O	
4	potential	O	
5	endocrine	O	
6	changes	O	
7	resulted	O	
8	from	O	
9	acute	O	
10	hypoxaemia	O	
11	alone	O	
12	,	O	
13	the	O	
14	underlying	O	
15	disease	O	
16	,	O	
17	or	O	
18	unspecific	O	
19	influences	O	
20	connected	O	
21	with	O	
22	the	O	
23	ICU	O	
24	setting	O	
25	,	O	
26	all	O	
27	measurements	O	
28	were	O	
29	compared	O	
30	to	O	
31	those	O	
32	of	O	
33	a	O	
34	completely	O	
35	healthy	O	
36	reference	O	
37	group	O	
38	(	O	
39	REF	O	
40	)	O	
41	with	O	
42	comparable	O	
43	acute	O	
44	experimental	O	
45	hypoxaemia	O	
46	.	O	

1	Transformed	O	
2	cell	O	
3	lines	O	
4	expressing	O	
5	solely	O	
6	E1a	B	
7	or	O	
8	E1a	B	
9	and	O	
10	E1b	B	
11	gene	I	
12	products	I	
13	derived	O	
14	from	O	
15	these	O	
16	viruses	O	
17	display	O	
18	enhanced	O	
19	anchorage	O	
20	-	O	
21	independent	O	
22	growth	O	
23	at	O	
24	37	O	
25	degrees	O	
26	C	O	
27	versus	O	
28	32	O	
29	degrees	O	
30	C	O	
31	and	O	
32	display	O	
33	a	O	
34	cytoskeletal	O	
35	architecture	O	
36	resembling	O	
37	untransformed	O	
38	fibroblastic	O	
39	CREF	O	
40	cells	O	
41	.	O	

1	The	O	
2	extraction	O	
3	recovery	O	
4	of	O	
5	Amphotericin	O	
6	B	O	
7	from	O	
8	the	O	
9	cerebrospinal	O	
10	fluid	O	
11	is	O	
12	higher	O	
13	than	O	
14	90	O	
15	%	O	
16	over	O	
17	the	O	
18	entire	O	
19	linear	O	
20	range	O	
21	.	O	

1	Weak	O	
2	promoter	O	
3	activity	O	
4	was	O	
5	observed	O	
6	for	O	
7	the	O	
8	promoter	O	
9	of	O	
10	the	O	
11	C1	B	
12	and	O	
13	C2	B	
14	ORFs	O	
15	(	O	
16	C1	B	
17	-	O	
18	C2	B	
19	gene	O	
20	)	O	
21	and	O	
22	for	O	
23	the	O	
24	promoter	O	
25	of	O	
26	the	O	
27	V1	B	
28	ORF	I	
29	.	O	

1	Six	O	
2	tandem	O	
3	repeats	O	
4	of	O	
5	the	O	
6	P	B	
7	element	I	
8	linked	O	
9	to	O	
10	the	O	
11	SV40	B	
12	promoter	I	
13	responded	O	
14	to	O	
15	phorbol	O	
16	12	O	
17	-	O	
18	myristate	O	
19	13	O	
20	-	O	
21	acetate	O	
22	,	O	
23	while	O	
24	that	O	
25	of	O	
26	other	O	
27	elements	O	
28	did	O	
29	not	O	
30	.	O	

1	Gamma	B	
2	glutamyl	I	
3	transpeptidase	I	
4	(	O	
5	GGTP	B	
6	)	O	
7	activity	O	
8	in	O	
9	the	O	
10	seminal	O	
11	fluid	O	

1	HeLa	O	
2	and	O	
3	Jurkat	O	
4	cell	O	
5	lines	O	
6	carrying	O	
7	the	O	
8	nef	B	
9	gene	I	
10	linked	O	
11	to	O	
12	the	O	
13	CMV	O	
14	promoter	O	
15	or	O	
16	the	O	
17	HIV	B	
18	-	I	
19	1	I	
20	LTR	I	
21	were	O	
22	isolated	O	
23	by	O	
24	coselection	O	
25	for	O	
26	neomycin	O	
27	resistance	O	
28	.	O	

1	A	O	
2	series	O	
3	of	O	
4	5	O	
5	'-	O	
6	deletions	O	
7	revealed	O	
8	that	O	
9	the	O	
10	fragment	O	
11	-	O	
12	218	O	
13	to	O	
14	+	O	
15	4	O	
16	from	O	
17	the	O	
18	TSS	O	
19	had	O	
20	the	O	
21	highest	O	
22	promoter	O	
23	activity	O	
24	,	O	
25	nearly	O	
26	1000	O	
27	-	O	
28	fold	O	
29	greater	O	
30	than	O	
31	the	O	
32	promoterless	O	
33	chloramphenicol	B	
34	acetyltransferase	I	
35	construct	I	
36	.	O	

1	The	O	
2	inner	O	
3	ears	O	
4	were	O	
5	exposed	O	
6	by	O	
7	microdissection	O	
8	,	O	
9	and	O	
10	the	O	
11	vestibular	O	
12	sensory	O	
13	regions	O	
14	were	O	
15	either	O	
16	sectioned	O	
17	and	O	
18	studied	O	
19	with	O	
20	light	O	
21	or	O	
22	electron	O	
23	microscopy	O	
24	,	O	
25	or	O	
26	prepared	O	
27	and	O	
28	studied	O	
29	with	O	
30	the	O	
31	surface	O	
32	specimen	O	
33	technique	O	
34	.	O	

1	Effects	O	
2	of	O	
3	cortisone	O	
4	,	O	
5	starvation	O	
6	,	O	
7	and	O	
8	rickets	O	
9	on	O	
10	oxidative	O	
11	enzyme	O	
12	activities	O	
13	of	O	
14	epiphyseal	O	
15	cartilage	O	
16	from	O	
17	rats	O	
18	.	O	

1	Serum	O	
2	antibodies	O	
3	were	O	
4	detected	O	
5	in	O	
6	at	O	
7	least	O	
8	95	O	
9	%	O	
10	of	O	
11	the	O	
12	infected	O	
13	guinea	O	
14	pigs	O	
15	between	O	
16	4	O	
17	-	O	
18	30	O	
19	WPI	O	
20	and	O	
21	rats	O	
22	between	O	
23	3	O	
24	-	O	
25	16	O	
26	WPI	O	
27	.	O	

1	Susceptibilities	O	
2	of	O	
3	540	O	
4	anaerobic	O	
5	gram	O	
6	-	O	
7	negative	O	
8	bacilli	O	
9	to	O	
10	amoxicillin	O	
11	,	O	
12	amoxicillin	O	
13	-	O	
14	BRL	O	
15	42715	O	
16	,	O	
17	amoxicillin	O	
18	-	O	
19	clavulanate	O	
20	,	O	
21	temafloxacin	O	
22	,	O	
23	and	O	
24	clindamycin	O	
25	.	O	

1	SCOB	O	
2	testing	O	
3	of	O	
4	food	O	
5	-	O	
6	restricted	O	
7	animals	O	
8	,	O	
9	using	O	
10	a	O	
11	multiple	O	
12	fixed	O	
13	ratio	O	
14	(	O	
15	FR	O	
16	)/	O	
17	fixed	O	
18	interval	O	
19	(	O	
20	FI	O	
21	)	O	
22	schedule	O	
23	(	O	
24	FR20	O	
25	:	O	
26	FI120	O	
27	),	O	
28	was	O	
29	conducted	O	
30	prior	O	
31	to	O	
32	each	O	
33	exposure	O	
34	to	O	
35	maintain	O	
36	the	O	
37	operant	O	
38	behavior	O	
39	;	O	
40	the	O	
41	data	O	
42	from	O	
43	Weeks	O	
44	-	O	
45	1	O	
46	,	O	
47	4	O	
48	,	O	
49	8	O	
50	,	O	
51	and	O	
52	13	O	
53	were	O	
54	evaluated	O	
55	for	O	
56	evidence	O	
57	of	O	
58	neurotoxicity	O	
59	.	O	

1	The	O	
2	history	O	
3	of	O	
4	exposure	O	
5	and	O	
6	carboxyhemoglobin	B	
7	levels	O	
8	should	O	
9	alert	O	
10	the	O	
11	physician	O	
12	to	O	
13	this	O	
14	diagnosis	O	
15	.	O	

1	The	O	
2	C	O	
3	-	O	
4	terminal	O	
5	peptide	O	
6	sequences	O	
7	of	O	
8	the	O	
9	human	B	
10	lymphocyte	I	
11	-	I	
12	specific	I	
13	high	I	
14	mobility	I	
15	group	I	
16	(	I	
17	HMG	I	
18	)-	I	
19	box	I	
20	transcription	I	
21	factor	I	
22	TCF	I	
23	-	I	
24	1	I	
25	are	O	
26	determined	O	
27	by	O	
28	alternative	O	
29	splice	O	
30	mechanisms	O	
31	affecting	O	
32	the	O	
33	exons	O	
34	VIII	O	
35	to	O	
36	X	O	
37	.	O	

1	Small	O	
2	-	O	
3	molecule	O	
4	control	O	
5	of	O	
6	insulin	B	
7	and	O	
8	PDGF	B	
9	receptor	I	
10	signaling	O	
11	and	O	
12	the	O	
13	role	O	
14	of	O	
15	membrane	O	
16	attachment	O	
17	.	O	

1	After	O	
2	determining	O	
3	isoflurane	O	
4	MAC	O	
5	in	O	
6	triplicate	O	
7	,	O	
8	birds	O	
9	were	O	
10	given	O	
11	a	O	
12	mu	O	
13	-	O	
14	opioid	O	
15	agonist	O	
16	(	O	
17	morphine	O	
18	,	O	
19	n	O	
20	=	O	
21	9	O	
22	)	O	
23	or	O	
24	a	O	
25	kappa	O	
26	-	O	
27	opioid	O	
28	agonist	O	
29	(	O	
30	U50488H	O	
31	,	O	
32	n	O	
33	=	O	
34	9	O	
35	).	O	

1	Controlled	O	
2	versus	O	
3	uncontrolled	O	
4	reperfusion	O	
5	of	O	
6	ischemic	O	
7	myocardium	O	
8	after	O	
9	experimental	O	
10	coronary	O	
11	artery	O	
12	occlusion	O	
13	was	O	
14	studied	O	
15	to	O	
16	determine	O	
17	the	O	
18	effect	O	
19	on	O	
20	regional	O	
21	ventricular	O	
22	wall	O	
23	motion	O	
24	and	O	
25	associated	O	
26	biochemical	O	
27	alterations	O	
28	.	O	

1	In	O	
2	electromobility	O	
3	shift	O	
4	assays	O	
5	,	O	
6	EWS	B	
7	-	O	
8	FLI	B	
9	-	I	
10	1	I	
11	binding	O	
12	to	O	
13	the	O	
14	SRE	O	
15	is	O	
16	detectable	O	
17	in	O	
18	the	O	
19	absence	O	
20	of	O	
21	SRF	B	
22	whereas	O	
23	the	O	
24	binding	O	
25	of	O	
26	FLI	B	
27	-	I	
28	1	I	
29	is	O	
30	not	O	
31	,	O	
32	suggesting	O	
33	that	O	
34	the	O	
35	interaction	O	
36	with	O	
37	DNA	O	
38	is	O	
39	the	O	
40	step	O	
41	which	O	
42	limits	O	
43	ternary	O	
44	complex	O	
45	formation	O	
46	by	O	
47	FLI	B	
48	-	I	
49	1	I	
50	.	O	

1	This	O	
2	study	O	
3	provides	O	
4	a	O	
5	direct	O	
6	demonstration	O	
7	of	O	
8	a	O	
9	role	O	
10	for	O	
11	G	B	
12	betagamma	I	
13	in	O	
14	mediating	O	
15	the	O	
16	agonist	O	
17	-	O	
18	stimulated	O	
19	translocation	O	
20	of	O	
21	GRK2	B	
22	and	O	
23	GRK3	B	
24	in	O	
25	an	O	
26	intact	O	
27	cellular	O	
28	system	O	
29	and	O	
30	demonstrates	O	
31	isoform	O	
32	specificity	O	
33	in	O	
34	the	O	
35	interaction	O	
36	of	O	
37	these	O	
38	components	O	
39	.	O	

1	As	O	
2	shown	O	
3	previously	O	
4	,	O	
5	EBNA2	B	
6	transactivates	O	
7	the	O	
8	promoters	O	
9	of	O	
10	the	O	
11	viral	B	
12	latent	I	
13	membrane	I	
14	proteins	I	
15	.	O	

1	Estimated	O	
2	nucleic	O	
3	acid	O	
4	N	O	
5	absorption	O	
6	is	O	
7	7	O	
8	-	O	
9	8	O	
10	%	O	
11	of	O	
12	N	O	
13	intake	O	
14	.	O	

1	By	O	
2	contrast	O	
3	,	O	
4	their	O	
5	basal	O	
6	adrenal	O	
7	androgen	O	
8	levels	O	
9	were	O	
10	significantly	O	
11	decreased	O	
12	compared	O	
13	to	O	
14	those	O	
15	in	O	
16	normal	O	
17	subjects	O	
18	on	O	
19	both	O	
20	the	O	
21	day	O	
22	on	O	
23	and	O	
24	the	O	
25	day	O	
26	off	O	
27	prednisone	O	
28	(	O	
29	P	O	
30	less	O	
31	than	O	
32	0	O	
33	.	O	
34	05	O	
35	).	O	

1	The	O	
2	antilog	O	
3	transformation	O	
4	of	O	
5	pH	O	
6	did	O	
7	not	O	
8	improve	O	
9	the	O	
10	results	O	
11	.	O	

1	SCID	O	
2	V	B	
3	(	O	
4	D	B	
5	)	O	
6	J	B	
7	recombination	O	
8	can	O	
9	be	O	
10	partly	O	
11	rescued	O	
12	in	O	
13	T	O	
14	-	O	
15	lymphocytes	O	
16	by	O	
17	either	O	
18	DNA	O	
19	-	O	
20	damaging	O	
21	agents	O	
22	(	O	
23	gamma	O	
24	-	O	
25	irradiation	O	
26	and	O	
27	bieomycin	O	
28	)	O	
29	or	O	
30	a	O	
31	null	O	
32	mutation	O	
33	of	O	
34	the	O	
35	p53	B	
36	gene	I	
37	,	O	
38	possibly	O	
39	because	O	
40	of	O	
41	transiently	O	
42	elevated	O	
43	DNA	O	
44	repair	O	
45	activity	O	
46	in	O	
47	response	O	
48	to	O	
49	DNA	O	
50	damage	O	
51	or	O	
52	to	O	
53	delayed	O	
54	apoptosis	O	
55	in	O	
56	the	O	
57	absence	O	
58	of	O	
59	p53	B	
60	.	O	

1	Ras	B	
2	is	O	
3	not	O	
4	associated	O	
5	with	O	
6	the	O	
7	tegument	O	
8	.	O	

1	Analysis	O	
2	of	O	
3	proteins	O	
4	synthesized	O	
5	by	O	
6	plasmids	O	
7	containing	O	
8	deleted	O	
9	forms	O	
10	of	O	
11	the	O	
12	trfA	B	
13	region	I	
14	indicates	O	
15	that	O	
16	the	O	
17	A2	B	
18	protein	I	
19	is	O	
20	the	O	
21	essential	O	
22	trfA	B	
23	-	I	
24	encoded	I	
25	replication	I	
26	protein	I	
27	of	O	
28	plasmid	O	
29	RK2	O	
30	.	O	

1	PAI	B	
2	-	I	
3	1	I	
4	levels	O	
5	increased	O	
6	significantly	O	
7	in	O	
8	patients	O	
9	who	O	
10	received	O	
11	iohexol	O	
12	but	O	
13	not	O	
14	in	O	
15	those	O	
16	who	O	
17	received	O	
18	ioxaglate	O	
19	.	O	

1	Nucleotide	O	
2	sequence	O	
3	analysis	O	
4	of	O	
5	the	O	
6	Pseudomonas	B	
7	putida	I	
8	PpG7	I	
9	salicylate	I	
10	hydroxylase	I	
11	gene	I	
12	(	O	
13	nahG	B	
14	)	O	
15	and	O	
16	its	O	
17	3	O	
18	'-	O	
19	flanking	O	
20	region	O	
21	.	O	

1	Products	O	
2	of	O	
3	immune	O	
4	cells	O	
5	such	O	
6	as	O	
7	transfer	B	
8	factor	I	
9	and	O	
10	lymphokines	O	
11	form	O	
12	the	O	
13	third	O	
14	and	O	
15	possibly	O	
16	most	O	
17	important	O	
18	group	O	
19	of	O	
20	immune	O	
21	-	O	
22	stimulating	O	
23	agents	O	
24	.	O	

1	Transcription	O	
2	of	O	
3	the	O	
4	six	O	
5	EBNA	B	
6	genes	I	
7	,	O	
8	which	O	
9	are	O	
10	expressed	O	
11	in	O	
12	EBV	O	
13	-	O	
14	immortalized	O	
15	primary	O	
16	B	O	
17	cells	O	
18	,	O	
19	arises	O	
20	from	O	
21	one	O	
22	of	O	
23	two	O	
24	promoters	O	
25	,	O	
26	Cp	B	
27	and	O	
28	Wp	B	
29	,	O	
30	located	O	
31	near	O	
32	the	O	
33	left	O	
34	end	O	
35	of	O	
36	the	O	
37	viral	O	
38	genome	O	
39	.	O	

1	Twenty	O	
2	-	O	
3	five	O	
4	patients	O	
5	(	O	
6	80	O	
7	,	O	
8	6	O	
9	%)	O	
10	with	O	
11	mixed	O	
12	neoplasms	O	
13	were	O	
14	operated	O	
15	on	O	
16	by	O	
17	total	O	
18	conservative	O	
19	parotidectomy	O	
20	(	O	
21	T	O	
22	.	O	
23	C	O	
24	.	O	
25	P	O	
26	.),	O	
27	3	O	
28	(	O	
29	9	O	
30	,	O	
31	7	O	
32	%)	O	
33	by	O	
34	S	O	
35	.	O	
36	P	O	
37	.	O	
38	and	O	
39	3	O	
40	(	O	
41	9	O	
42	,	O	
43	7	O	
44	%)	O	
45	by	O	
46	En	O	
47	.	O	

1	The	O	
2	statistical	O	
3	significance	O	
4	of	O	
5	the	O	
6	prognosis	O	
7	factors	O	
8	was	O	
9	studied	O	
10	by	O	
11	uni	O	
12	-	O	
13	and	O	
14	multivariative	O	
15	methods	O	
16	,	O	
17	according	O	
18	to	O	
19	the	O	
20	model	O	
21	of	O	
22	Cox	O	
23	,	O	
24	with	O	
25	the	O	
26	help	O	
27	of	O	
28	an	O	
29	IMB	O	
30	computer	O	
31	.	O	

1	Third	O	
2	-	O	
3	and	O	
4	later	O	
5	-	O	
6	parity	O	
7	cows	O	
8	were	O	
9	randomly	O	
10	assigned	O	
11	after	O	
12	each	O	
13	parturition	O	
14	to	O	
15	Charolais	O	
16	and	O	
17	Red	O	
18	Poll	O	
19	bulls	O	
20	in	O	
21	multiple	O	
22	-	O	
23	sire	O	
24	pastures	O	
25	.	O	

1	After	O	
2	a	O	
3	baseline	O	
4	study	O	
5	,	O	
6	WPW	O	
7	syndrome	O	
8	was	O	
9	simulated	O	
10	by	O	
11	stimulation	O	
12	at	O	
13	seven	O	
14	different	O	
15	sites	O	
16	around	O	
17	the	O	
18	base	O	
19	of	O	
20	the	O	
21	ventricles	O	
22	,	O	
23	and	O	
24	RNV	O	
25	'	O	
26	s	O	
27	were	O	
28	obtained	O	
29	.	O	

1	Using	O	
2	Southern	O	
3	blot	O	
4	analysis	O	
5	and	O	
6	restriction	O	
7	mapping	O	
8	of	O	
9	genomic	O	
10	YAC	O	
11	(	O	
12	yeast	O	
13	artificial	O	
14	chromosome	O	
15	)	O	
16	and	O	
17	cosmid	O	
18	clones	O	
19	,	O	
20	we	O	
21	located	O	
22	the	O	
23	human	B	
24	RIL	I	
25	gene	I	
26	240	O	
27	-	O	
28	260	O	
29	kb	O	
30	telomeric	O	
31	to	O	
32	the	O	
33	IRF1	B	
34	gene	I	
35	and	O	
36	characterized	O	
37	its	O	
38	genomic	O	
39	structure	O	
40	.	O	

1	Preliminary	O	
2	report	O	
3	.	O	

1	A	O	
2	high	O	
3	mean	O	
4	intensity	O	
5	of	O	
6	CLTPA	O	
7	(	O	
8	standardized	O	
9	multivariate	O	
10	regression	O	
11	coefficient	O	
12	beta	O	
13	-	O	
14	0	O	
15	.	O	
16	059	O	
17	,	O	
18	p	O	
19	=	O	
20	0	O	
21	.	O	
22	020	O	
23	)	O	
24	and	O	
25	a	O	
26	high	O	
27	maximal	O	
28	oxygen	O	
29	uptake	O	
30	(	O	
31	beta	O	
32	-	O	
33	0	O	
34	.	O	
35	163	O	
36	,	O	
37	p	O	
38	<	O	
39	0	O	
40	.	O	
41	001	O	
42	)	O	
43	were	O	
44	associated	O	
45	with	O	
46	reduced	O	
47	plasma	B	
48	fibrinogen	I	
49	when	O	
50	adjusting	O	
51	for	O	
52	the	O	
53	strongest	O	
54	covariates	O	
55	.	O	

1	For	O	
2	85Sr	O	
3	,	O	
4	larger	O	
5	-	O	
6	than	O	
7	-	O	
8	expected	O	
9	distribution	O	
10	coefficients	O	
11	were	O	
12	obtained	O	
13	in	O	
14	the	O	
15	desorption	O	
16	experiments	O	
17	,	O	
18	an	O	
19	indication	O	
20	of	O	
21	the	O	
22	irreversible	O	
23	formation	O	
24	of	O	
25	metal	O	
26	-	O	
27	oxyhydroxides	O	
28	during	O	
29	a	O	
30	slow	O	
31	reaction	O	
32	.	O	

1	High	O	
2	levels	O	
3	of	O	
4	C	B	
5	subunits	I	
6	are	O	
7	observed	O	
8	in	O	
9	several	O	
10	subsequent	O	
11	larval	O	
12	and	O	
13	adult	O	
14	stages	O	
15	of	O	
16	development	O	
17	.	O	

1	We	O	
2	have	O	
3	shown	O	
4	previously	O	
5	that	O	
6	GH3	O	
7	cells	O	
8	transfected	O	
9	with	O	
10	the	O	
11	rat	B	
12	GnRH	I	
13	receptor	I	
14	cDNA	I	
15	(	O	
16	GGH3	O	
17	-	O	
18	1	O	
19	'	O	
20	cells	O	
21	)	O	
22	support	O	
23	the	O	
24	expression	O	
25	of	O	
26	a	O	
27	cotransfected	O	
28	fusion	O	
29	gene	O	
30	composed	O	
31	of	O	
32	797	O	
33	base	O	
34	pairs	O	
35	of	O	
36	rat	B	
37	LHbeta	I	
38	gene	I	
39	5	I	
40	'-	I	
41	flanking	I	
42	sequence	I	
43	and	O	
44	the	O	
45	first	O	
46	5	O	
47	base	O	
48	pairs	O	
49	of	O	
50	the	O	
51	5	O	
52	'-	O	
53	untranslated	O	
54	region	O	
55	fused	O	
56	to	O	
57	a	O	
58	luciferase	B	
59	reporter	I	
60	(-	I	
61	797	I	
62	/+	I	
63	5LHbetaLUC	I	
64	)	I	
65	and	O	
66	respond	O	
67	to	O	
68	a	O	
69	GnRH	B	
70	agonist	O	
71	with	O	
72	a	O	
73	10	O	
74	-	O	
75	fold	O	
76	stimulation	O	
77	of	O	
78	activity	O	
79	.	O	

1	Change	O	
2	in	O	
3	the	O	
4	makeup	O	
5	of	O	
6	the	O	
7	blood	O	
8	following	O	
9	a	O	
10	short	O	
11	-	O	
12	term	O	
13	local	O	
14	action	O	
15	of	O	
16	a	O	
17	permanent	O	
18	magnetic	O	
19	field	O	
20	on	O	
21	the	O	
22	human	O	
23	body	O	

1	Most	O	
2	likely	O	
3	they	O	
4	might	O	
5	represent	O	
6	regulatory	O	
7	RNAs	O	
8	or	O	
9	transcribed	O	
10	transposable	O	
11	elements	O	
12	.	O	

1	Comparisons	O	
2	of	O	
3	rrnB	B	
4	P1	I	
5	-	O	
6	lacZ	B	
7	expression	O	
8	at	O	
9	different	O	
10	ppGpp	O	
11	levels	O	
12	is	O	
13	interpreted	O	
14	for	O	
15	the	O	
16	rpoD	B	
17	(	I	
18	P504L	I	
19	)	I	
20	mutant	I	
21	as	O	
22	resulting	O	
23	from	O	
24	a	O	
25	hypersensitivity	O	
26	to	O	
27	ppGpp	O	
28	.	O	

1	Because	O	
2	of	O	
3	the	O	
4	functional	O	
5	conservation	O	
6	of	O	
7	cell	O	
8	cycle	O	
9	control	O	
10	elements	O	
11	,	O	
12	the	O	
13	expression	O	
14	of	O	
15	a	O	
16	vertebrate	B	
17	wee1	I	
18	or	O	
19	mik1	B	
20	homolog	I	
21	would	O	
22	be	O	
23	expected	O	
24	to	O	
25	rescue	O	
26	such	O	
27	lethal	O	
28	mutations	O	
29	in	O	
30	yeast	O	
31	.	O	

1	Experimental	O	
2	studies	O	
3	on	O	
4	virus	O	
5	excretion	O	
6	and	O	
7	non	O	
8	-	O	
9	arthropod	O	
10	transmission	O	
11	.	O	

1	The	O	
2	gene	O	
3	was	O	
4	uniquely	O	
5	mapped	O	
6	with	O	
7	odds	O	
8	>	O	
9	1	O	
10	,	O	
11	000	O	
12	:	O	
13	1	O	
14	on	O	
15	chromosome	O	
16	3p	O	
17	in	O	
18	Centre	O	
19	d	O	
20	'	O	
21	Etude	O	
22	du	O	
23	Polymorphisme	O	
24	Humain	O	
25	pedigrees	O	
26	.	O	

1	The	O	
2	promoter	O	
3	for	O	
4	HMG	B	
5	-	I	
6	CoA	I	
7	synthase	I	
8	contains	O	
9	two	O	
10	binding	O	
11	sites	O	
12	for	O	
13	the	O	
14	sterol	B	
15	regulatory	I	
16	element	I	
17	-	I	
18	binding	I	
19	proteins	I	
20	(	O	
21	SREBPs	B	
22	).	O	

1	Based	O	
2	on	O	
3	16S	B	
4	rRNA	I	
5	gene	I	
6	sequence	I	
7	analysis	O	
8	,	O	
9	the	O	
10	11	O	
11	species	O	
12	having	O	
13	two	O	
14	tuf	B	
15	genes	I	
16	all	O	
17	have	O	
18	a	O	
19	common	O	
20	ancestor	O	
21	,	O	
22	while	O	
23	the	O	
24	six	O	
25	species	O	
26	having	O	
27	only	O	
28	one	O	
29	copy	O	
30	diverged	O	
31	from	O	
32	the	O	
33	enterococcal	O	
34	lineage	O	
35	before	O	
36	that	O	
37	common	O	
38	ancestor	O	
39	.	O	

1	Retrograde	O	
2	filling	O	
3	consists	O	
4	in	O	
5	sealing	O	
6	endodontics	O	
7	system	O	
8	directly	O	
9	at	O	
10	the	O	
11	apical	O	
12	zone	O	
13	after	O	
14	surgical	O	
15	approach	O	
16	.	O	

1	Urinary	B	
2	N	I	
3	-	I	
4	acetylglucosaminidase	I	
5	activity	O	
6	per	O	
7	mg	O	
8	creatinine	O	
9	did	O	
10	not	O	
11	differ	O	
12	significantly	O	
13	between	O	
14	groups	O	
15	.	O	

1	The	O	
2	nonconsensus	O	
3	TATA	O	
4	box	O	
5	in	O	
6	promoter	O	
7	B	O	
8	plays	O	
9	a	O	
10	more	O	
11	important	O	
12	role	O	
13	in	O	
14	promoter	O	
15	activity	O	
16	than	O	
17	the	O	
18	TATA	O	
19	box	O	
20	in	O	
21	promoter	O	
22	A	O	
23	.	O	

1	Five	O	
2	different	O	
3	subtypes	O	
4	of	O	
5	spondyloarthropathy	O	
6	(	O	
7	SpA	O	
8	)	O	
9	are	O	
10	now	O	
11	recognized	O	
12	.	O	

1	Sequence	O	
2	conservation	O	
3	is	O	
4	greatest	O	
5	for	O	
6	residues	O	
7	located	O	
8	near	O	
9	the	O	
10	active	O	
11	centers	O	
12	of	O	
13	the	O	
14	exo	B	
15	and	O	
16	pol	B	
17	domains	I	
18	of	O	
19	the	O	
20	E	B	
21	.	I	
22	coli	I	
23	DNA	I	
24	polymerase	I	
25	I	I	
26	structure	O	
27	.	O	

1	Who	O	
2	says	O	
3	'	O	
4	National	O	
5	Health	O	
6	Dis	O	
7	-	O	
8	service	O	
9	'.	O	

1	Surprisingly	O	
2	,	O	
3	the	O	
4	CSF1R	B	
5	/	O	
6	IRDelta960	B	
7	was	O	
8	as	O	
9	effective	O	
10	as	O	
11	the	O	
12	CSF1R	B	
13	/	O	
14	IR	B	
15	in	O	
16	mediating	O	
17	CSF	B	
18	-	I	
19	1	I	
20	protection	O	
21	of	O	
22	cells	O	
23	from	O	
24	staurosporine	O	
25	-	O	
26	induced	O	
27	apoptosis	O	
28	.	O	

1	It	O	
2	was	O	
3	concluded	O	
4	that	O	
5	both	O	
6	of	O	
7	these	O	
8	surgical	O	
9	procedures	O	
10	were	O	
11	as	O	
12	effective	O	
13	as	O	
14	pinealectomy	O	
15	in	O	
16	reversing	O	
17	the	O	
18	pineal	O	
19	-	O	
20	induced	O	
21	alterations	O	
22	in	O	
23	the	O	
24	reproductive	O	
25	physiology	O	
26	of	O	
27	the	O	
28	blind	O	
29	-	O	
30	anosmic	O	
31	female	O	
32	rat	O	
33	.	O	

1	Pathways	O	
2	linking	O	
3	the	O	
4	olfactory	O	
5	bulbs	O	
6	with	O	
7	the	O	
8	medial	O	
9	preoptic	O	
10	anterior	O	
11	hypothalamus	O	
12	are	O	
13	important	O	
14	for	O	
15	intermale	O	
16	aggression	O	
17	in	O	
18	mice	O	
19	.	O	

1	Cat	B	
2	-	I	
3	1	I	
4	is	O	
5	identical	O	
6	to	O	
7	the	O	
8	recently	O	
9	identified	O	
10	binding	O	
11	partner	O	
12	for	O	
13	the	O	
14	beta	B	
15	-	I	
16	adrenergic	I	
17	receptor	I	
18	kinase	I	
19	(	O	
20	betaARK	B	
21	or	O	
22	GRK	B	
23	-	I	
24	2	I	
25	),	O	
26	which	O	
27	was	O	
28	shown	O	
29	to	O	
30	have	O	
31	Arf	B	
32	-	O	
33	GAP	B	
34	activity	O	
35	.	O	

1	In	O	
2	a	O	
3	series	O	
4	of	O	
5	402	O	
6	consecutive	O	
7	autopsies	O	
8	,	O	
9	parietal	O	
10	pleural	O	
11	plaques	O	
12	(	O	
13	PP	O	
14	)	O	
15	were	O	
16	found	O	
17	in	O	
18	68	O	
19	individuals	O	
20	above	O	
21	40	O	
22	years	O	
23	of	O	
24	age	O	
25	.	O	

1	Our	O	
2	findings	O	
3	support	O	
4	the	O	
5	view	O	
6	of	O	
7	a	O	
8	multifactorial	O	
9	genesis	O	
10	of	O	
11	the	O	
12	cardiac	O	
13	involvement	O	
14	in	O	
15	uremic	O	
16	patients	O	
17	.	O	

1	Similarly	O	
2	,	O	
3	a	O	
4	human	O	
5	but	O	
6	not	O	
7	a	O	
8	bovine	B	
9	alpha	I	
10	transgene	I	
11	was	O	
12	expressed	O	
13	in	O	
14	placenta	O	
15	in	O	
16	transgenic	O	
17	mice	O	
18	.	O	

1	Vasopressin	B	
2	(	O	
3	AVP	B	
4	),	O	
5	the	O	
6	antidiuretic	O	
7	hormone	O	
8	,	O	
9	is	O	
10	a	O	
11	cyclic	O	
12	nonapeptide	O	
13	that	O	
14	acts	O	
15	through	O	
16	binding	O	
17	to	O	
18	G	B	
19	protein	I	
20	-	I	
21	coupled	I	
22	specific	I	
23	membrane	I	
24	receptors	I	
25	pharmacologically	O	
26	divided	O	
27	into	O	
28	three	O	
29	subtypes	O	
30	(	O	
31	V1a	B	
32	,	O	
33	V1b	B	
34	,	O	
35	and	O	
36	V2	B	
37	)	O	
38	linked	O	
39	to	O	
40	distinct	O	
41	second	O	
42	messengers	O	
43	.	O	

1	Furthermore	O	
2	,	O	
3	rhoA	B	
4	-	O	
5	mediated	O	
6	SRE	O	
7	activation	O	
8	was	O	
9	blocked	O	
10	by	O	
11	dominant	O	
12	negative	O	
13	mutants	O	
14	of	O	
15	PKC	B	
16	-	I	
17	alpha	I	
18	or	O	
19	PKC	B	
20	-	I	
21	epsilon	I	
22	.	O	

1	In	O	
2	both	O	
3	settings	O	
4	,	O	
5	it	O	
6	can	O	
7	be	O	
8	phosphorylated	O	
9	by	O	
10	cyclin	B	
11	D	I	
12	-	I	
13	dependent	I	
14	kinases	I	
15	,	O	
16	suggesting	O	
17	that	O	
18	its	O	
19	transcriptional	O	
20	activity	O	
21	may	O	
22	normally	O	
23	be	O	
24	regulated	O	
25	through	O	
26	such	O	
27	mechanisms	O	
28	.	O	

1	Partial	O	
2	N	O	
3	-	O	
4	terminal	O	
5	amino	O	
6	acid	O	
7	sequence	O	
8	analysis	O	
9	showed	O	
10	that	O	
11	the	O	
12	43K	B	
13	and	I	
14	42K	I	
15	T	I	
16	antigens	I	
17	contain	O	
18	methionine	O	
19	at	O	
20	residues	O	
21	1	O	
22	and	O	
23	5	O	
24	,	O	
25	as	O	
26	predicted	O	
27	from	O	
28	the	O	
29	DNA	O	
30	sequence	O	
31	,	O	
32	whereas	O	
33	no	O	
34	methionine	O	
35	was	O	
36	released	O	
37	from	O	
38	the	O	
39	39K	B	
40	T	I	
41	antigen	I	
42	during	O	
43	the	O	
44	first	O	
45	six	O	
46	cycles	O	
47	of	O	
48	Edman	O	
49	degradation	O	
50	.	O	

1	During	O	
2	1985	O	
3	,	O	
4	1990	O	
5	,	O	
6	and	O	
7	1995	O	
8	,	O	
9	respectively	O	
10	,	O	
11	11	O	
12	.	O	
13	7	O	
14	,	O	
15	11	O	
16	.	O	
17	3	O	
18	,	O	
19	and	O	
20	11	O	
21	.	O	
22	4	O	
23	infants	O	
24	per	O	
25	100	O	
26	,	O	
27	000	O	
28	live	O	
29	births	O	
30	had	O	
31	a	O	
32	diagnosis	O	
33	of	O	
34	HSV	O	
35	(	O	
36	P	O	
37	=.	O	
38	98	O	
39	).	O	

1	The	O	
2	nucleotide	O	
3	sequences	O	
4	of	O	
5	these	O	
6	genes	O	
7	differ	O	
8	at	O	
9	only	O	
10	nine	O	
11	positions	O	
12	,	O	
13	resulting	O	
14	in	O	
15	three	O	
16	amino	O	
17	acid	O	
18	differences	O	
19	.	O	

1	Discrepant	O	
2	results	O	
3	with	O	
4	a	O	
5	latex	O	
6	agglutination	O	
7	test	O	
8	in	O	
9	the	O	
10	assessment	O	
11	of	O	
12	cytomegalovirus	O	
13	antibody	O	
14	status	O	
15	of	O	
16	cardiac	O	
17	transplant	O	
18	donors	O	
19	.	O	

1	Brain	O	
2	scan	O	
3	with	O	
4	99mTc	O	
5	-	O	
6	labelled	O	
7	macroaggregated	B	
8	albumin	I	
9	(	O	
10	MAA	B	
11	brain	O	
12	scan	O	
13	)	O	
14	and	O	
15	computed	O	
16	tomography	O	
17	studies	O	
18	(	O	
19	CT	O	
20	)	O	
21	were	O	
22	performed	O	
23	on	O	
24	78	O	
25	patients	O	
26	with	O	
27	intracranial	O	
28	diseases	O	
29	.	O	

1	A	O	
2	new	O	
3	Onchocerca	O	
4	species	O	
5	,	O	
6	a	O	
7	parasite	O	
8	of	O	
9	domestic	O	
10	cattle	O	
11	,	O	
12	in	O	
13	Senegal	O	

1	In	O	
2	conclusion	O	
3	,	O	
4	our	O	
5	data	O	
6	do	O	
7	not	O	
8	support	O	
9	a	O	
10	role	O	
11	for	O	
12	IVIg	B	
13	in	O	
14	the	O	
15	remyelination	O	
16	of	O	
17	stable	O	
18	multiple	O	
19	sclerosis	O	
20	lesions	O	
21	as	O	
22	measured	O	
23	by	O	
24	central	O	
25	conduction	O	
26	time	O	
27	.	O	

1	Evaluation	O	
2	of	O	
3	the	O	
4	new	O	
5	Gravigard	O	
6	IUCD	O	
7	inserter	O	
8	.	O	

1	This	O	
2	effect	O	
3	and	O	
4	the	O	
5	fact	O	
6	that	O	
7	all	O	
8	three	O	
9	doses	O	
10	were	O	
11	toxic	O	
12	to	O	
13	the	O	
14	dams	O	
15	dictated	O	
16	that	O	
17	a	O	
18	second	O	
19	experiment	O	
20	be	O	
21	carried	O	
22	out	O	
23	at	O	
24	lower	O	
25	doses	O	
26	.	O	

1	The	O	
2	same	O	
3	IL	B	
4	-	I	
5	4	I	
6	-	O	
7	inducible	O	
8	reporter	O	
9	gene	O	
10	is	O	
11	also	O	
12	synergistically	O	
13	activated	O	
14	by	O	
15	the	O	
16	endogenous	B	
17	Stat6	I	
18	and	O	
19	NF	B	
20	-	I	
21	kappaB	I	
22	proteins	I	
23	in	O	
24	IL	B	
25	-	I	
26	4	I	
27	-	O	
28	stimulated	O	
29	I	O	
30	.	O	
31	29mu	O	
32	B	O	
33	lymphoma	O	
34	cells	O	
35	.	O	

1	Besides	O	
2	the	O	
3	characterization	O	
4	and	O	
5	discussion	O	
6	of	O	
7	the	O	
8	experimental	O	
9	setup	O	
10	used	O	
11	,	O	
12	the	O	
13	rate	O	
14	constants	O	
15	obtained	O	
16	are	O	
17	discussed	O	
18	and	O	
19	compared	O	
20	with	O	
21	estimated	O	
22	values	O	
23	.	O	

1	We	O	
2	have	O	
3	reviewed	O	
4	the	O	
5	experience	O	
6	of	O	
7	a	O	
8	major	O	
9	MMT	O	
10	general	O	
11	practice	O	
12	with	O	
13	hepatitis	O	
14	C	O	
15	virus	O	
16	(	O	
17	HCV	O	
18	)	O	
19	infection	O	
20	from	O	
21	1991	O	
22	to	O	
23	1995	O	
24	.	O	

1	Commutative	O	
2	saccadic	O	
3	generator	O	
4	is	O	
5	sufficient	O	
6	to	O	
7	control	O	
8	a	O	
9	3	O	
10	-	O	
11	D	O	
12	ocular	O	
13	plant	O	
14	with	O	
15	pulleys	O	
16	.	O	

1	The	O	
2	extended	O	
3	rat	B	
4	SP	I	
5	-	I	
6	A	I	
7	isoforms	I	
8	were	O	
9	enriched	O	
10	in	O	
11	the	O	
12	more	O	
13	fully	O	
14	glycosylated	O	
15	and	O	
16	multimeric	O	
17	SP	B	
18	-	I	
19	A	I	
20	species	O	
21	separated	O	
22	on	O	
23	SDS	O	
24	-	O	
25	PAGE	O	
26	gels	O	
27	.	O	

1	Interestingly	O	
2	,	O	
3	the	O	
4	avirulent	O	
5	strain	O	
6	H37Ra	O	
7	showed	O	
8	weak	O	
9	hybridization	O	
10	with	O	
11	these	O	
12	two	O	
13	probes	O	
14	,	O	
15	suggesting	O	
16	that	O	
17	these	O	
18	genes	O	
19	might	O	
20	have	O	
21	been	O	
22	deleted	O	
23	in	O	
24	the	O	
25	avirulent	O	
26	strain	O	
27	or	O	
28	are	O	
29	present	O	
30	in	O	
31	limited	O	
32	copy	O	
33	numbers	O	
34	as	O	
35	opposed	O	
36	to	O	
37	those	O	
38	in	O	
39	the	O	
40	virulent	O	
41	strain	O	
42	H37Rv	O	
43	.	O	

1	Two	O	
2	new	O	
3	artifacts	O	
4	in	O	
5	automated	O	
6	coagulation	O	
7	testing	O	
8	.	O	

1	Two	O	
2	hundred	O	
3	forty	O	
4	-	O	
5	three	O	
6	patients	O	
7	have	O	
8	received	O	
9	WR	O	
10	-	O	
11	2721	O	
12	in	O	
13	Phase	O	
14	I	O	
15	-	O	
16	II	O	
17	studies	O	
18	.	O	

1	Furthermore	O	
2	,	O	
3	the	O	
4	wide	O	
5	distribution	O	
6	of	O	
7	the	O	
8	GFP	B	
9	-	O	
10	POLO	B	
11	protein	O	
12	to	O	
13	all	O	
14	compartments	O	
15	of	O	
16	the	O	
17	mitotic	O	
18	apparatus	O	
19	provides	O	
20	a	O	
21	valuable	O	
22	tool	O	
23	for	O	
24	future	O	
25	studies	O	
26	on	O	
27	cell	O	
28	cycle	O	
29	during	O	
30	development	O	
31	.	O	

1	S6K2	B	
2	is	O	
3	highly	O	
4	homologous	O	
5	to	O	
6	S6K1	B	
7	in	O	
8	the	O	
9	core	O	
10	kinase	O	
11	and	O	
12	linker	O	
13	regulatory	O	
14	domains	O	
15	but	O	
16	differs	O	
17	from	O	
18	S6K1	B	
19	in	O	
20	the	O	
21	N	O	
22	-	O	
23	and	O	
24	C	O	
25	-	O	
26	terminal	O	
27	regions	O	
28	and	O	
29	is	O	
30	differently	O	
31	localized	O	
32	primarily	O	
33	to	O	
34	the	O	
35	nucleus	O	
36	because	O	
37	of	O	
38	a	O	
39	C	O	
40	-	O	
41	terminal	O	
42	nuclear	O	
43	localization	O	
44	signal	O	
45	unique	O	
46	to	O	
47	S6K2	B	
48	.	O	

1	Sp1	B	
2	can	O	
3	activate	O	
4	transcription	O	
5	through	O	
6	immunoglobulin	B	
7	kappa	I	
8	-	I	
9	chain	I	
10	enhancer	I	
11	or	O	
12	P	B	
13	-	I	
14	selectin	I	
15	promoter	I	
16	NF	I	
17	-	I	
18	kappaB	I	
19	sites	I	
20	.	O	
21	p50	B	
22	homodimers	I	
23	replace	O	
24	Sp1	B	
25	from	O	
26	the	O	
27	P	B	
28	-	I	
29	selectin	I	
30	promoter	I	
31	by	O	
32	binding	O	
33	site	O	
34	competition	O	
35	and	O	
36	thereby	O	
37	either	O	
38	inhibit	O	
39	basal	O	
40	Sp1	B	
41	-	O	
42	driven	O	
43	expression	O	
44	or	O	
45	,	O	
46	in	O	
47	concert	O	
48	with	O	
49	Bcl	B	
50	-	I	
51	3	I	
52	,	O	
53	stimulate	O	
54	expression	O	
55	.	O	

1	The	O	
2	injection	O	
3	of	O	
4	XDRP1	B	
5	protein	I	
6	into	O	
7	fertilized	O	
8	Xenopus	O	
9	eggs	O	
10	blocked	O	
11	embryonic	O	
12	cell	O	
13	division	O	
14	.	O	

1	Serum	B	
2	ACTH	I	
3	did	O	
4	not	O	
5	respond	O	
6	to	O	
7	insulin	B	
8	and	O	
9	metyrapone	O	
10	.	O	

1	To	O	
2	examine	O	
3	the	O	
4	basis	O	
5	for	O	
6	the	O	
7	apparent	O	
8	differences	O	
9	in	O	
10	postsegregational	O	
11	killing	O	
12	between	O	
13	the	O	
14	two	O	
15	E	O	
16	.	O	
17	coli	O	
18	strains	O	
19	,	O	
20	transformation	O	
21	assays	O	
22	were	O	
23	carried	O	
24	out	O	
25	to	O	
26	determine	O	
27	the	O	
28	relative	O	
29	sensitivities	O	
30	of	O	
31	the	O	
32	strains	O	
33	to	O	
34	the	O	
35	ParE	B	
36	toxin	I	
37	protein	I	
38	.	O	

1	Correlation	O	
2	between	O	
3	intraocular	O	
4	involvement	O	
5	and	O	
6	systemic	O	
7	outcome	O	
8	was	O	
9	poor	O	
10	.	O	

1	An	O	
2	immunologically	O	
3	related	O	
4	protein	O	
5	was	O	
6	detected	O	
7	in	O	
8	ribosome	O	
9	and	O	
10	membrane	O	
11	fractions	O	
12	of	O	
13	mitochondria	O	
14	from	O	
15	Saccharomyces	O	
16	cerevisiae	O	
17	.	O	

1	High	O	
2	fibrinogen	B	
3	levels	O	
4	could	O	
5	thus	O	
6	be	O	
7	a	O	
8	risk	O	
9	for	O	
10	perioperative	O	
11	thrombosis	O	
12	.	O	

1	Two	O	
2	mammalian	O	
3	enzymes	O	
4	,	O	
5	the	O	
6	haem	B	
7	-	I	
8	controlled	I	
9	repressor	I	
10	(	O	
11	HCR	B	
12	)	O	
13	and	O	
14	the	O	
15	double	B	
16	-	I	
17	stranded	I	
18	RNA	I	
19	-	I	
20	activated	I	
21	inhibitor	I	
22	(	O	
23	dsI	B	
24	),	O	
25	phosphorylate	O	
26	Ser	O	
27	-	O	
28	51	O	
29	of	O	
30	the	O	
31	alpha	O	
32	subunit	O	
33	,	O	
34	thereby	O	
35	inhibiting	O	
36	the	O	
37	exchange	O	
38	of	O	
39	bound	O	
40	nucleotides	O	
41	on	O	
42	,	O	
43	and	O	
44	thus	O	
45	the	O	
46	recycling	O	
47	of	O	
48	,	O	
49	eIF	B	
50	-	I	
51	2	I	
52	.	O	

1	Three	O	
2	radiologists	O	
3	without	O	
4	knowledge	O	
5	of	O	
6	patients	O	
7	'	O	
8	data	O	
9	and	O	
10	treatment	O	
11	analyzed	O	
12	30	O	
13	angiograms	O	
14	with	O	
15	and	O	
16	30	O	
17	examinations	O	
18	without	O	
19	PGF	O	
20	.	O	

1	Moreover	O	
2	,	O	
3	in	O	
4	one	O	
5	patient	O	
6	with	O	
7	a	O	
8	sarcoma	O	
9	who	O	
10	underwent	O	
11	a	O	
12	leg	O	
13	-	O	
14	sparing	O	
15	procedure	O	
16	,	O	
17	no	O	
18	sciatic	O	
19	nerve	O	
20	enlargement	O	
21	was	O	
22	seen	O	
23	postoperatively	O	
24	.	O	

1	Human	B	
2	acid	I	
3	ceramidase	I	
4	((	O	
5	AC	O	
6	)	O	
7	N	O	
8	-	O	
9	acylsphingosine	O	
10	amidohydrolase	O	
11	,	O	
12	EC	B	
13	3	I	
14	.	I	
15	5	I	
16	.	O	

1	The	O	
2	experimental	O	
3	design	O	
4	represents	O	
5	a	O	
6	2	O	
7	x	O	
8	3	O	
9	factorial	O	
10	arrangement	O	
11	of	O	
12	treatments	O	
13	with	O	
14	three	O	
15	dietary	O	
16	levels	O	
17	of	O	
18	incorporation	O	
19	of	O	
20	RSB	O	
21	(	O	
22	0	O	
23	,	O	
24	50	O	
25	,	O	
26	and	O	
27	100	O	
28	%),	O	
29	and	O	
30	chickens	O	
31	either	O	
32	infected	O	
33	or	O	
34	uninfected	O	
35	.	O	

1	An	O	
2	11	O	
3	-	O	
4	month	O	
5	-	O	
6	old	O	
7	girl	O	
8	suffering	O	
9	from	O	
10	Dandy	O	
11	-	O	
12	Walker	O	
13	malformation	O	
14	(	O	
15	DWM	O	
16	)	O	
17	associated	O	
18	with	O	
19	tetralogy	O	
20	of	O	
21	Fallot	O	
22	(	O	
23	TOF	O	
24	)	O	
25	is	O	
26	presented	O	
27	.	O	

1	272	O	
2	,	O	
3	1904	O	
4	].	O	

1	In	O	
2	the	O	
3	absence	O	
4	of	O	
5	other	O	
6	stabilizers	O	
7	,	O	
8	increased	O	
9	sucrose	O	
10	can	O	
11	provide	O	
12	increased	O	
13	thermoresistance	O	
14	to	O	
15	the	O	
16	virus	O	
17	in	O	
18	2	O	
19	.	O	
20	5	O	
21	%	O	
22	albumin	B	
23	.	O	

1	The	O	
2	sequence	O	
3	up	O	
4	to	O	
5	-	O	
6	267	O	
7	bp	O	
8	relative	O	
9	to	O	
10	the	O	
11	transcription	O	
12	start	O	
13	site	O	
14	was	O	
15	sufficient	O	
16	to	O	
17	enhance	O	
18	reporter	O	
19	gene	O	
20	expression	O	
21	depending	O	
22	on	O	
23	the	O	
24	mesodermal	O	
25	differentiation	O	
26	of	O	
27	P19	O	
28	cells	O	
29	.	O	

1	Previous	O	
2	studies	O	
3	have	O	
4	indicated	O	
5	that	O	
6	a	O	
7	hamster	O	
8	cell	O	
9	line	O	
10	(	O	
11	ts13	O	
12	)	O	
13	with	O	
14	a	O	
15	point	O	
16	mutation	O	
17	in	O	
18	the	O	
19	TAF	B	
20	(	I	
21	II	I	
22	)	I	
23	250	I	
24	/	O	
25	CCG1	B	
26	(	O	
27	TAF	B	
28	(	I	
29	II	I	
30	)	I	
31	250	I	
32	)	O	
33	gene	O	
34	shows	O	
35	temperature	O	
36	-	O	
37	sensitive	O	
38	expression	O	
39	of	O	
40	a	O	
41	subset	O	
42	of	O	
43	genes	O	
44	and	O	
45	arrests	O	
46	in	O	
47	late	O	
48	G1	O	
49	at	O	
50	39	O	
51	.	O	
52	5	O	
53	degrees	O	
54	C	O	
55	.	O	

1	Interestingly	O	
2	,	O	
3	we	O	
4	find	O	
5	that	O	
6	the	O	
7	interaction	O	
8	between	O	
9	Tat	B	
10	and	O	
11	hCycT1	B	
12	requires	O	
13	zinc	O	
14	as	O	
15	well	O	
16	as	O	
17	essential	O	
18	cysteine	O	
19	residues	O	
20	in	O	
21	both	O	
22	proteins	O	
23	.	O	

1	The	O	
2	combination	O	
3	of	O	
4	F1	O	
5	and	O	
6	F2	O	
7	which	O	
8	was	O	
9	the	O	
10	best	O	
11	predictor	O	
12	of	O	
13	CHD	O	
14	in	O	
15	this	O	
16	population	O	
17	(	O	
18	G1	O	
19	)	O	
20	might	O	
21	be	O	
22	interpreted	O	
23	as	O	
24	reflecting	O	
25	trunk	O	
26	adiposity	O	
27	mainly	O	
28	abdominal	O	
29	.	O	

1	A	O	
2	poor	O	
3	correlation	O	
4	was	O	
5	also	O	
6	observed	O	
7	between	O	
8	PbB	O	
9	and	O	
10	ALAD	B	
11	activity	O	
12	of	O	
13	the	O	
14	stearate	O	
15	workers	O	
16	.	O	

1	IL	B	
2	-	I	
3	12	I	
4	production	O	
5	was	O	
6	correlated	O	
7	with	O	
8	C3a	O	
9	concentration	O	
10	measured	O	
11	at	O	
12	the	O	
13	outlet	O	
14	of	O	
15	hemodialyzer	O	
16	after	O	
17	15	O	
18	min	O	
19	of	O	
20	dialysis	O	
21	(	O	
22	r	O	
23	=	O	
24	0	O	
25	.	O	
26	69	O	
27	,	O	
28	P	O	
29	<	O	
30	0	O	
31	.	O	
32	01	O	
33	).	O	

1	In	O	
2	two	O	
3	experiments	O	
4	,	O	
5	neonatal	O	
6	female	O	
7	BALB	O	
8	/	O	
9	cCrgl	O	
10	or	O	
11	BALB	O	
12	/	O	
13	cfC3HCrgl	O	
14	mice	O	
15	were	O	
16	given	O	
17	subcutaneous	O	
18	injections	O	
19	of	O	
20	5	O	
21	micrograms	O	
22	17	O	
23	beta	O	
24	-	O	
25	estradiol	O	
26	or	O	
27	sesame	O	
28	oil	O	
29	for	O	
30	the	O	
31	first	O	
32	3	O	
33	days	O	
34	of	O	
35	life	O	
36	and	O	
37	were	O	
38	ovariectomized	O	
39	at	O	
40	60	O	
41	days	O	
42	of	O	
43	age	O	
44	,	O	
45	at	O	
46	which	O	
47	time	O	
48	vaginal	O	
49	concretions	O	
50	(	O	
51	Experiments	O	
52	I	O	
53	and	O	
54	II	O	
55	)	O	
56	or	O	
57	silica	O	
58	(	O	
59	Experiment	O	
60	II	O	
61	)	O	
62	were	O	
63	implanted	O	
64	intravaginally	O	
65	.	O	

1	In	O	
2	particular	O	
3	,	O	
4	the	O	
5	potential	O	
6	for	O	
7	prostate	O	
8	cancer	O	
9	chemoprevention	O	
10	using	O	
11	nonsteroidal	O	
12	anti	O	
13	-	O	
14	inflammatory	O	
15	drugs	O	
16	(	O	
17	cyclo	B	
18	-	I	
19	oxygenase	I	
20	inhibitors	O	
21	;	O	
22	NSAIDs	O	
23	)	O	
24	has	O	
25	received	O	
26	little	O	
27	attention	O	
28	.	O	

1	Visidex	O	
2	I	O	
3	is	O	
4	unsuitable	O	
5	for	O	
6	storage	O	
7	and	O	
8	re	O	
9	-	O	
10	reading	O	
11	.	O	

1	Occupational	O	
2	exposure	O	
3	to	O	
4	hepatitis	O	
5	B	O	
6	virus	O	
7	and	O	
8	human	O	
9	immunodeficiency	O	
10	virus	O	
11	:	O	
12	a	O	
13	comparative	O	
14	risk	O	
15	analysis	O	
16	.	O	

1	This	O	
2	region	O	
3	,	O	
4	however	O	
5	,	O	
6	contains	O	
7	a	O	
8	CCAATC	O	
9	box	O	
10	in	O	
11	the	O	
12	reverse	O	
13	complement	O	
14	and	O	
15	several	O	
16	GC	O	
17	boxes	O	
18	that	O	
19	are	O	
20	recognition	O	
21	sites	O	
22	for	O	
23	SP1	B	
24	.	O	

1	The	O	
2	human	B	
3	p100	I	
4	protein	I	
5	was	O	
6	recently	O	
7	identified	O	
8	as	O	
9	a	O	
10	coactivator	O	
11	of	O	
12	the	O	
13	Epstein	B	
14	-	I	
15	Barr	I	
16	virus	I	
17	nuclear	I	
18	antigen	I	
19	2	I	
20	.	O	

1	Decreased	O	
2	cardiac	O	
3	glycogen	O	
4	following	O	
5	phenformin	O	
6	injection	O	
7	in	O	
8	hyperglycemic	O	
9	,	O	
10	hyperinsulinemic	O	
11	anaesthetized	O	
12	rats	O	
13	.	O	

1	In	O	
2	subjects	O	
3	(	O	
4	n	O	
5	=	O	
6	5	O	
7	)	O	
8	with	O	
9	quadriplegia	O	
10	and	O	
11	reduced	O	
12	sympathetic	O	
13	tone	O	
14	secondary	O	
15	to	O	
16	cervical	O	
17	cord	O	
18	trauma	O	
19	,	O	
20	TcpO2	O	
21	at	O	
22	42	O	
23	degrees	O	
24	C	O	
25	and	O	
26	vasodilation	O	
27	index	O	
28	were	O	
29	increased	O	
30	(	O	
31	45	O	
32	.	O	
33	0	O	
34	mmHg	O	
35	and	O	
36	0	O	
37	.	O	
38	61	O	
39	);	O	
40	TcpO2	O	
41	at	O	
42	45	O	
43	degrees	O	
44	C	O	
45	did	O	
46	not	O	
47	change	O	
48	.	O	

1	Atorvastatin	O	
2	was	O	
3	the	O	
4	most	O	
5	cost	O	
6	-	O	
7	effective	O	
8	HMG	B	
9	-	I	
10	CoA	I	
11	reductase	I	
12	inhibitor	O	
13	.	O	

1	Information	O	
2	about	O	
3	immunologic	O	
4	drug	O	
5	interactions	O	
6	is	O	
7	needed	O	
8	by	O	
9	pharmacists	O	
10	to	O	
11	make	O	
12	rational	O	
13	drug	O	
14	-	O	
15	use	O	
16	decisions	O	
17	.	O	

1	APOE	B	
2	-	O	
3	epsilon4	O	
4	count	O	
5	predicts	O	
6	age	O	
7	when	O	
8	prevalence	O	
9	of	O	
10	AD	O	
11	increases	O	
12	,	O	
13	then	O	
14	declines	O	
15	:	O	
16	the	O	
17	Cache	O	
18	County	O	
19	Study	O	
20	.	O	

1	RESULTS	O	
2	:	O	
3	In	O	
4	the	O	
5	AGA	O	
6	group	O	
7	,	O	
8	both	O	
9	fetal	O	
10	and	O	
11	maternal	O	
12	serum	O	
13	prolactin	B	
14	concentration	O	
15	increased	O	
16	significantly	O	
17	with	O	
18	gestation	O	
19	(	O	
20	P	O	
21	<	O	
22	0	O	
23	.	O	
24	001	O	
25	and	O	
26	P	O	
27	<	O	
28	0	O	
29	.	O	
30	01	O	
31	,	O	
32	respectively	O	
33	).	O	

1	CyIIa	B	
2	transcription	O	
3	follows	O	
4	,	O	
5	and	O	
6	is	O	
7	therefore	O	
8	downstream	O	
9	of	O	
10	,	O	
11	the	O	
12	initial	O	
13	specification	O	
14	of	O	
15	these	O	
16	embryonic	O	
17	domains	O	
18	.	O	

1	Expression	O	
2	of	O	
3	h6	O	
4	.	O	
5	1	O	
6	in	O	
7	COS	O	
8	-	O	
9	1	O	
10	cells	O	
11	led	O	
12	to	O	
13	the	O	
14	production	O	
15	of	O	
16	a	O	
17	typical	O	
18	type	B	
19	IV	I	
20	PDE	I	
21	activity	O	
22	in	O	
23	that	O	
24	cAMP	O	
25	,	O	
26	but	O	
27	not	O	
28	cGMP	O	
29	,	O	
30	served	O	
31	as	O	
32	substrate	O	
33	and	O	
34	its	O	
35	activity	O	
36	was	O	
37	insensitive	O	
38	to	O	
39	either	O	
40	Ca2	O	
41	+/	O	
42	CaM	B	
43	or	O	
44	cGMP	O	
45	but	O	
46	was	O	
47	inhibited	O	
48	by	O	
49	low	O	
50	concentrations	O	
51	of	O	
52	rolipram	O	
53	.(	O	
54	ABSTRACT	O	
55	TRUNCATED	O	
56	AT	O	
57	400	O	
58	WORDS	O	
59	)	O	

1	A	O	
2	method	O	
3	for	O	
4	establishing	O	
5	stimulus	O	
6	control	O	
7	of	O	
8	ethanol	O	
9	responding	O	
10	was	O	
11	developed	O	
12	.	O	

1	Taken	O	
2	together	O	
3	,	O	
4	the	O	
5	results	O	
6	suggest	O	
7	that	O	
8	chlorphentermine	O	
9	may	O	
10	be	O	
11	capable	O	
12	of	O	
13	producing	O	
14	dual	O	
15	stimulus	O	
16	effects	O	
17	in	O	
18	animals	O	
19	.	O	

1	The	O	
2	expression	O	
3	of	O	
4	the	O	
5	first	O	
6	two	O	
7	genes	O	
8	located	O	
9	in	O	
10	this	O	
11	unit	O	
12	(	O	
13	c	B	
14	-	I	
15	gvpD	I	
16	and	O	
17	c	B	
18	-	I	
19	gvpE	I	
20	)	O	
21	was	O	
22	also	O	
23	monitored	O	
24	by	O	
25	Western	O	
26	blot	O	
27	(	O	
28	immunoblot	O	
29	)	O	
30	analyses	O	
31	using	O	
32	antisera	O	
33	raised	O	
34	against	O	
35	these	O	
36	proteins	O	
37	synthesized	O	
38	in	O	
39	Escherichia	O	
40	coli	O	
41	.	O	

1	Eight	O	
2	highly	O	
3	trained	O	
4	male	O	
5	kayakers	O	
6	were	O	
7	studied	O	
8	to	O	
9	determine	O	
10	the	O	
11	relationship	O	
12	between	O	
13	critical	O	
14	power	O	
15	(	O	
16	CP	O	
17	)	O	
18	and	O	
19	the	O	
20	onset	O	
21	of	O	
22	blood	O	
23	lactate	O	
24	accumulation	O	
25	(	O	
26	OBLA	O	
27	).	O	

1	Removal	O	
2	of	O	
3	each	O	
4	of	O	
5	three	O	
6	contiguous	O	
7	segments	O	
8	from	O	
9	the	O	
10	N	O	
11	-	O	
12	terminal	O	
13	half	O	
14	specifically	O	
15	inhibits	O	
16	the	O	
17	formation	O	
18	of	O	
19	5	B	
20	.	I	
21	8Ss	I	
22	rRNA	I	
23	,	O	
24	whereas	O	
25	deleting	O	
26	part	O	
27	of	O	
28	the	O	
29	C	O	
30	-	O	
31	terminal	O	
32	region	O	
33	of	O	
34	the	O	
35	protein	O	
36	only	O	
37	blocks	O	
38	the	O	
39	production	O	
40	of	O	
41	18S	B	
42	rRNA	I	
43	.	O	

1	We	O	
2	also	O	
3	show	O	
4	that	O	
5	zygotically	O	
6	activated	O	
7	Xretpos	O	
8	transcripts	O	
9	are	O	
10	restricted	O	
11	to	O	
12	ventro	O	
13	-	O	
14	posterior	O	
15	specific	O	
16	regions	O	
17	and	O	
18	induced	O	
19	by	O	
20	UV	O	
21	-	O	
22	irradiation	O	
23	and	O	
24	BMP	B	
25	-	I	
26	4	I	
27	overexpression	O	
28	in	O	
29	cycloheximide	O	
30	-	O	
31	dependent	O	
32	way	O	
33	.	O	
34	genesis	O	
35	26	O	
36	:	O	
37	198	O	
38	-	O	
39	207	O	
40	,	O	
41	2000	O	
42	.	O	

1	It	O	
2	has	O	
3	also	O	
4	been	O	
5	shown	O	
6	that	O	
7	a	O	
8	variety	O	
9	of	O	
10	extracellular	O	
11	factors	O	
12	stimulate	O	
13	a	O	
14	pair	O	
15	of	O	
16	MAPK	O	
17	p44	B	
18	and	O	
19	MAPK	O	
20	p42	B	
21	of	O	
22	MAPK	B	
23	family	I	
24	members	I	
25	.	O	

1	It	O	
2	contained	O	
3	seven	O	
4	extra	O	
5	amino	O	
6	acids	O	
7	of	O	
8	FVVLNLQ	O	
9	;	O	
10	this	O	
11	short	O	
12	stretch	O	
13	of	O	
14	extra	O	
15	sequence	O	
16	was	O	
17	found	O	
18	between	O	
19	Gln	O	
20	(	O	
21	421	O	
22	)	O	
23	and	O	
24	Phe	O	
25	(	O	
26	422	O	
27	)	O	
28	within	O	
29	the	O	
30	SET	B	
31	(	O	
32	Suvar3	B	
33	-	I	
34	9	I	
35	,	O	
36	Enhancer	B	
37	-	I	
38	of	I	
39	-	I	
40	zeste	I	
41	,	O	
42	Trithorax	B	
43	)	O	
44	interacting	O	
45	domain	O	
46	(	O	
47	SID	O	
48	)	O	
49	of	O	
50	rMTM	B	
51	.	O	

1	Mitogen	B	
2	-	I	
3	activated	I	
4	protein	I	
5	(	I	
6	MAP	I	
7	)	I	
8	kinase	I	
9	phosphatase	I	
10	-	I	
11	3	I	
12	(	O	
13	MKP	B	
14	-	I	
15	3	I	
16	)	O	
17	is	O	
18	a	O	
19	dual	O	
20	specificity	O	
21	phosphatase	O	
22	that	O	
23	inactivates	O	
24	extracellular	B	
25	signal	I	
26	-	I	
27	regulated	I	
28	kinase	I	
29	(	O	
30	ERK	B	
31	)	O	
32	MAP	B	
33	kinases	I	
34	.	O	

1	In	O	
2	vitro	O	
3	binding	O	
4	studies	O	
5	using	O	
6	GST	B	
7	fusion	O	
8	proteins	O	
9	and	O	
10	yeast	O	
11	extracts	O	
12	defined	O	
13	distinct	O	
14	binding	O	
15	sites	O	
16	on	O	
17	yAP180A	B	
18	for	O	
19	Pan1p	B	
20	and	O	
21	clathrin	B	
22	.	O	
23	yAP180	B	
24	proteins	I	
25	and	O	
26	Pan1p	B	
27	,	O	
28	like	O	
29	actin	B	
30	,	O	
31	localize	O	
32	to	O	
33	peripheral	O	
34	patches	O	
35	along	O	
36	the	O	
37	plasma	O	
38	membrane	O	
39	.	O	

1	Positive	O	
2	shifts	O	
3	of	O	
4	basal	O	
5	skin	O	
6	potentials	O	
7	during	O	
8	human	O	
9	sleep	O	
10	.	O	

1	Technetium	O	
2	-	O	
3	99m	O	
4	methylene	O	
5	diphosphonate	O	
6	scintimammography	O	
7	for	O	
8	evaluation	O	
9	of	O	
10	palpable	O	
11	breast	O	
12	masses	O	
13	.	O	

1	The	O	
2	marker	O	
3	orders	O	
4	from	O	
5	the	O	
6	genetic	O	
7	and	O	
8	RH	O	
9	maps	O	
10	were	O	
11	consistent	O	
12	.	O	

1	Multiple	O	
2	mitogen	B	
3	-	I	
4	activated	I	
5	protein	I	
6	kinase	I	
7	signaling	O	
8	pathways	O	
9	connect	O	
10	the	O	
11	cot	B	
12	oncoprotein	I	
13	to	O	
14	the	O	
15	c	B	
16	-	I	
17	jun	I	
18	promoter	I	
19	and	O	
20	to	O	
21	cellular	O	
22	transformation	O	
23	.	O	

1	Microstructure	O	
2	and	O	
3	conductivity	O	
4	of	O	
5	hierarchical	O	
6	laminate	O	
7	composites	O	
8	.	O	

1	Patients	O	
2	had	O	
3	to	O	
4	have	O	
5	adequate	O	
6	liver	O	
7	,	O	
8	renal	O	
9	,	O	
10	and	O	
11	marrow	O	
12	functions	O	
13	.	O	

1	Ariga	O	
2	,	O	
3	Biochem	O	
4	.	O	

1	Rhizobium	O	
2	meliloti	O	
3	large	O	
4	plasmid	O	
5	pRmeGR4b	O	
6	carries	O	
7	the	O	
8	nodulation	O	
9	competitiveness	O	
10	locus	O	
11	nfe	B	
12	responsible	O	
13	for	O	
14	the	O	
15	nodulation	O	
16	efficiency	O	
17	and	O	
18	competitive	O	
19	ability	O	
20	of	O	
21	strain	O	
22	GR4	O	
23	on	O	
24	alfalfa	O	
25	roots	O	
26	.	O	

1	However	O	
2	,	O	
3	division	O	
4	of	O	
5	the	O	
6	chest	O	
7	wall	O	
8	muscles	O	
9	,	O	
10	usually	O	
11	with	O	
12	diathermy	O	
13	,	O	
14	contributes	O	
15	to	O	
16	prolonged	O	
17	pain	O	
18	and	O	
19	morbidity	O	
20	.	O	

1	The	O	
2	"	O	
3	tobacco	O	
4	issue	O	
5	".	O	

1	Thyroid	O	
2	disease	O	
3	and	O	
4	pregnancy	O	
5	.	O	

1	Two	O	
2	patients	O	
3	with	O	
4	recurrent	O	
5	tumors	O	
6	had	O	
7	high	O	
8	S	O	
9	-	O	
10	phase	O	
11	fractions	O	
12	both	O	
13	on	O	
14	the	O	
15	first	O	
16	resected	O	
17	specimens	O	
18	and	O	
19	at	O	
20	the	O	
21	time	O	
22	of	O	
23	the	O	
24	second	O	
25	operation	O	
26	.	O	

1	The	O	
2	C	O	
3	terminus	O	
4	of	O	
5	TRBP	B	
6	binds	O	
7	to	O	
8	CBP	B	
9	/	O	
10	p300	B	
11	and	O	
12	DRIP130	B	
13	,	O	
14	a	O	
15	component	O	
16	of	O	
17	the	O	
18	DRIP	B	
19	/	O	
20	TRAP	B	
21	/	O	
22	ARC	B	
23	complex	O	
24	,	O	
25	which	O	
26	suggests	O	
27	that	O	
28	TRBP	B	
29	may	O	
30	activate	O	
31	transcription	O	
32	by	O	
33	means	O	
34	of	O	
35	such	O	
36	interactions	O	
37	.	O	

1	A	O	
2	recombinant	O	
3	with	O	
4	a	O	
5	5	O	
6	'	O	
7	end	O	
8	from	O	
9	src	B	
10	and	O	
11	a	O	
12	3	O	
13	'	O	
14	end	O	
15	from	O	
16	ros	B	
17	,	O	
18	called	O	
19	SRC	B	
20	x	O	
21	ROS	B	
22	,	O	
23	transformed	O	
24	chicken	O	
25	embryo	O	
26	fibroblasts	O	
27	(	O	
28	CEF	O	
29	)	O	
30	to	O	
31	a	O	
32	spindle	O	
33	shape	O	
34	morphology	O	
35	,	O	
36	mimicking	O	
37	that	O	
38	of	O	
39	UR2	B	
40	.	O	

1	Unlike	O	
2	p59v	B	
3	-	O	
4	rel	B	
5	,	O	
6	which	O	
7	is	O	
8	a	O	
9	nuclear	O	
10	protein	O	
11	in	O	
12	CEF	O	
13	,	O	
14	indirect	O	
15	immunofluorescence	O	
16	showed	O	
17	that	O	
18	p68c	B	
19	-	O	
20	rel	B	
21	in	O	
22	JD214c	O	
23	-	O	
24	rel	O	
25	infected	O	
26	CEF	O	
27	is	O	
28	located	O	
29	exclusively	O	
30	in	O	
31	the	O	
32	cytoplasm	O	
33	of	O	
34	these	O	
35	cells	O	
36	,	O	
37	even	O	
38	though	O	
39	the	O	
40	sequence	O	
41	of	O	
42	p68c	B	
43	-	O	
44	rel	B	
45	showed	O	
46	that	O	
47	it	O	
48	contains	O	
49	a	O	
50	nuclear	O	
51	localizing	O	
52	sequence	O	
53	identical	O	
54	to	O	
55	the	O	
56	one	O	
57	previously	O	
58	identified	O	
59	in	O	
60	p59v	B	
61	-	O	
62	rel	B	
63	.	O	

1	She	O	
2	had	O	
3	been	O	
4	receiving	O	
5	MTX	O	
6	7	O	
7	.	O	
8	5	O	
9	mg	O	
10	/	O	
11	week	O	
12	for	O	
13	2	O	
14	.	O	
15	5	O	
16	months	O	
17	because	O	
18	of	O	
19	her	O	
20	vasculitis	O	
21	symptoms	O	
22	.	O	

1	NF	B	
2	-	I	
3	kappa	I	
4	B	I	
5	/	O	
6	Rel	B	
7	transcription	O	
8	factors	O	
9	participate	O	
10	in	O	
11	the	O	
12	activation	O	
13	of	O	
14	numerous	O	
15	genes	O	
16	involved	O	
17	in	O	
18	immune	O	
19	regulation	O	
20	/	O	
21	inflammation	O	
22	including	O	
23	cytokines	O	
24	,	O	
25	cell	O	
26	surface	O	
27	receptors	O	
28	,	O	
29	adhesion	O	
30	molecules	O	
31	,	O	
32	and	O	
33	acute	O	
34	phase	O	
35	proteins	O	
36	.	O	

1	In	O	
2	gel	O	
3	retardation	O	
4	assays	O	
5	,	O	
6	an	O	
7	RCS	O	
8	cell	O	
9	-	O	
10	specific	O	
11	protein	O	
12	and	O	
13	another	O	
14	closely	O	
15	related	O	
16	protein	O	
17	expressed	O	
18	only	O	
19	in	O	
20	RCS	O	
21	cells	O	
22	and	O	
23	primary	O	
24	chondrocytes	O	
25	bound	O	
26	to	O	
27	a	O	
28	10	O	
29	-	O	
30	bp	O	
31	sequence	O	
32	within	O	
33	the	O	
34	18	O	
35	-	O	
36	mer	O	
37	.	O	

1	Immunoprecipitation	O	
2	experiments	O	
3	using	O	
4	DokR	B	
5	-	I	
6	specific	I	
7	antibodies	I	
8	revealed	O	
9	an	O	
10	interaction	O	
11	between	O	
12	endogenous	B	
13	DokR	I	
14	and	O	
15	a	O	
16	150	O	
17	-	O	
18	kDa	O	
19	protein	O	
20	that	O	
21	is	O	
22	tyrosine	O	
23	-	O	
24	phosphorylated	O	
25	in	O	
26	EGF	B	
27	-	O	
28	stimulated	O	
29	BaF	O	
30	/	O	
31	3	O	
32	cells	O	
33	.	O	

1	Coexpression	O	
2	studies	O	
3	indicate	O	
4	that	O	
5	insulin	B	
6	and	O	
7	PKB	B	
8	suppress	O	
9	transactivation	O	
10	by	O	
11	C	B	
12	/	I	
13	EBPbeta	I	
14	,	O	
15	but	O	
16	not	O	
17	C	B	
18	/	I	
19	EBPalpha	I	
20	,	O	
21	and	O	
22	that	O	
23	N	O	
24	-	O	
25	terminal	O	
26	transactivation	O	
27	domains	O	
28	in	O	
29	C	B	
30	/	I	
31	EBPbeta	I	
32	are	O	
33	required	O	
34	.	O	

1	The	O	
2	requirement	O	
3	of	O	
4	PilE	B	
5	in	O	
6	pilus	O	
7	biogenesis	O	
8	was	O	
9	confirmed	O	
10	by	O	
11	demonstrating	O	
12	that	O	
13	chromosomal	B	
14	pilE	I	
15	insertion	I	
16	mutants	I	
17	were	O	
18	pilus	O	
19	-	O	
20	and	O	
21	twitching	O	
22	-	O	
23	motility	O	
24	deficient	O	
25	.	O	

1	Phylogenetic	O	
2	position	O	
3	of	O	
4	the	O	
5	Phacotaceae	O	
6	within	O	
7	the	O	
8	Chlamydophyceaeas	O	
9	revealed	O	
10	by	O	
11	analysis	O	
12	of	O	
13	18S	B	
14	rDNA	I	
15	and	O	
16	rbcL	B	
17	sequences	I	
18	.	O	

1	We	O	
2	suggest	O	
3	that	O	
4	sensitivity	O	
5	to	O	
6	photoperiod	O	
7	in	O	
8	pallid	O	
9	bats	O	
10	,	O	
11	as	O	
12	in	O	
13	several	O	
14	other	O	
15	mammals	O	
16	,	O	
17	is	O	
18	mediated	O	
19	by	O	
20	the	O	
21	pineal	O	
22	gland	O	
23	.	O	

1	Thrombophlebitis	O	
2	and	O	
3	pulmonary	O	
4	embolism	O	
5	in	O	
6	congenital	O	
7	factor	B	
8	XII	I	
9	deficiency	O	

1	(	O	
2	5	O	
3	)	O	
4	No	O	
5	changes	O	
6	were	O	
7	observed	O	
8	in	O	
9	the	O	
10	gastric	O	
11	venous	O	
12	blood	O	
13	flow	O	
14	by	O	
15	continuous	O	
16	intravenous	O	
17	injection	O	
18	of	O	
19	cimetidine	O	
20	,	O	
21	but	O	
22	by	O	
23	rapid	O	
24	injection	O	
25	both	O	
26	the	O	
27	flow	O	
28	was	O	
29	augmented	O	
30	and	O	
31	the	O	
32	systemic	O	
33	blood	O	
34	pressure	O	
35	decreased	O	
36	transiently	O	
37	.	O	

1	The	O	
2	second	O	
3	class	O	
4	of	O	
5	cDNA	O	
6	hybridized	O	
7	to	O	
8	a	O	
9	13	O	
10	kb	O	
11	transcript	O	
12	,	O	
13	which	O	
14	was	O	
15	approximately	O	
16	twice	O	
17	as	O	
18	large	O	
19	as	O	
20	the	O	
21	mammalian	B	
22	lactase	I	
23	mRNA	I	
24	.	O	

1	2	O	
2	.	O	

1	As	O	
2	PP2A	B	
3	exerts	O	
4	a	O	
5	range	O	
6	of	O	
7	cellular	O	
8	functions	O	
9	including	O	
10	cell	O	
11	cycle	O	
12	regulation	O	
13	and	O	
14	cell	O	
15	fate	O	
16	determination	O	
17	,	O	
18	we	O	
19	were	O	
20	surprised	O	
21	to	O	
22	find	O	
23	that	O	
24	these	O	
25	embryos	O	
26	develop	O	
27	normally	O	
28	until	O	
29	postimplantation	O	
30	,	O	
31	around	O	
32	embryonic	O	
33	day	O	
34	5	O	
35	.	O	
36	5	O	
37	/	O	
38	6	O	
39	.	O	
40	0	O	
41	.	O	

1	Very	O	
2	good	O	
3	accuracy	O	
4	(	O	
5	r	O	
6	greater	O	
7	than	O	
8	0	O	
9	.	O	
10	9	O	
11	)	O	
12	was	O	
13	found	O	
14	when	O	
15	except	O	
16	comparing	O	
17	H	O	
18	*	O	
19	2	O	
20	with	O	
21	the	O	
22	other	O	
23	machine	O	
24	and	O	
25	the	O	
26	reference	O	
27	methods	O	
28	,	O	
29	except	O	
30	for	O	
31	MCHCH	O	
32	and	O	
33	basophil	O	
34	count	O	
35	.	O	

1	If	O	
2	hnRNP	B	
3	K	I	
4	is	O	
5	a	O	
6	transcription	O	
7	factor	O	
8	,	O	
9	then	O	
10	interactions	O	
11	with	O	
12	the	O	
13	RNA	B	
14	polymerase	I	
15	II	I	
16	transcription	O	
17	apparatus	O	
18	are	O	
19	predicted	O	
20	.	O	

1	By	O	
2	Felix	O	
3	Lagrange	O	
4	,	O	
5	1918	O	
6	.	O	

1	Two	O	
2	experiments	O	
3	(	O	
4	N	O	
5	=	O	
6	20	O	
7	each	O	
8	)	O	
9	were	O	
10	carried	O	
11	out	O	
12	to	O	
13	explore	O	
14	the	O	
15	nature	O	
16	of	O	
17	ERP	O	
18	negativities	O	
19	in	O	
20	a	O	
21	visuospatial	O	
22	memory	O	
23	task	O	
24	and	O	
25	in	O	
26	an	O	
27	auditory	O	
28	spatial	O	
29	memory	O	
30	task	O	
31	,	O	
32	respectively	O	
33	.	O	

1	Using	O	
2	an	O	
3	audiotape	O	
4	cassette	O	
5	and	O	
6	headphones	O	
7	the	O	
8	duration	O	
9	of	O	
10	the	O	
11	hallucinations	O	
12	decreased	O	
13	significantly	O	
14	.	O	

1	Underestimations	O	
2	by	O	
3	as	O	
4	much	O	
5	as	O	
6	35	O	
7	%	O	
8	may	O	
9	occur	O	
10	due	O	
11	to	O	
12	the	O	
13	problems	O	
14	in	O	
15	the	O	
16	existing	O	
17	methodologies	O	
18	.	O	

1	To	O	
2	test	O	
3	the	O	
4	role	O	
5	of	O	
6	ML	O	
7	in	O	
8	human	O	
9	reproductive	O	
10	axis	O	
11	,	O	
12	128	O	
13	healthy	O	
14	children	O	
15	,	O	
16	68	O	
17	boys	O	
18	and	O	
19	60	O	
20	girls	O	
21	,	O	
22	were	O	
23	studied	O	
24	.	O	

1	Further	O	
2	,	O	
3	we	O	
4	show	O	
5	that	O	
6	this	O	
7	EIA	B	
8	-	O	
9	inducible	O	
10	CBF	O	
11	/	O	
12	cdc2	B	
13	is	O	
14	related	O	
15	to	O	
16	the	O	
17	CBF	B	
18	which	O	
19	was	O	
20	shown	O	
21	to	O	
22	activate	O	
23	the	O	
24	heat	B	
25	shock	I	
26	protein	I	
27	70	I	
28	promoter	I	
29	.	O	

1	The	O	
2	domains	O	
3	involved	O	
4	in	O	
5	superactivation	O	
6	appear	O	
7	to	O	
8	be	O	
9	a	O	
10	subset	O	
11	of	O	
12	those	O	
13	necessary	O	
14	to	O	
15	achieve	O	
16	synergistic	O	
17	activation	O	
18	.	O	

1	The	O	
2	RNA	O	
3	genome	O	
4	of	O	
5	rabbit	O	
6	hemorrhagic	O	
7	disease	O	
8	virus	O	
9	(	O	
10	RHDV	O	
11	)	O	
12	was	O	
13	molecularly	O	
14	cloned	O	
15	.	O	

1	The	O	
2	sub	O	
3	-	O	
4	acute	O	
5	inhalation	O	
6	toxicity	O	
7	of	O	
8	furfural	O	
9	was	O	
10	studied	O	
11	in	O	
12	Syrian	O	
13	golden	O	
14	hamsters	O	
15	.	O	

1	Lac	B	
2	operators	O	
3	were	O	
4	introduced	O	
5	into	O	
6	several	O	
7	positions	O	
8	within	O	
9	the	O	
10	CAB	B	
11	promoter	I	
12	and	O	
13	operator	O	
14	-	O	
15	free	O	
16	plasmid	O	
17	was	O	
18	used	O	
19	as	O	
20	control	O	
21	.	O	

1	However	O	
2	,	O	
3	the	O	
4	requirement	O	
5	of	O	
6	rev3	B	
7	for	O	
8	the	O	
9	production	O	
10	of	O	
11	G	O	
12	.	O	
13	C	O	
14	-->	O	
15	T	O	
16	.	O	
17	A	O	
18	transversions	O	
19	by	O	
20	the	O	
21	rad18	B	
22	mutator	I	
23	,	O	
24	which	O	
25	induces	O	
26	only	O	
27	these	O	
28	substitutions	O	
29	,	O	
30	was	O	
31	similar	O	
32	to	O	
33	that	O	
34	for	O	
35	rad6	B	
36	-	O	
37	mediated	O	
38	G	O	
39	.	O	
40	C	O	
41	-->	O	
42	T	O	
43	.	O	
44	A	O	
45	transversion	O	
46	.	O	

1	Phosphatidylinositol	B	
2	3	I	
3	-	I	
4	kinase	I	
5	requirement	O	
6	in	O	
7	activation	O	
8	of	O	
9	the	O	
10	ras	B	
11	/	O	
12	C	B	
13	-	I	
14	raf	I	
15	-	I	
16	1	I	
17	/	O	
18	MEK	B	
19	/	O	
20	ERK	B	
21	and	O	
22	p70	B	
23	(	O	
24	s6k	B	
25	)	O	
26	signaling	O	
27	cascade	O	
28	by	O	
29	the	O	
30	insulinomimetic	O	
31	agent	O	
32	vanadyl	O	
33	sulfate	O	
34	.	O	

1	The	O	
2	most	O	
3	common	O	
4	characteristics	O	
5	of	O	
6	VRE	O	
7	patients	O	
8	were	O	
9	recent	O	
10	prior	O	
11	vancomycin	O	
12	use	O	
13	,	O	
14	recent	O	
15	prior	O	
16	susceptible	O	
17	enterococcal	O	
18	infection	O	
19	,	O	
20	coinfection	O	
21	with	O	
22	other	O	
23	microbial	O	
24	pathogens	O	
25	,	O	
26	and	O	
27	concurrent	O	
28	fungal	O	
29	infection	O	
30	.	O	

1	If	O	
2	,	O	
3	however	O	
4	,	O	
5	the	O	
6	mean	O	
7	temperature	O	
8	rise	O	
9	was	O	
10	higher	O	
11	(	O	
12	0	O	
13	.	O	
14	57	O	
15	degrees	O	
16	C	O	
17	or	O	
18	0	O	
19	.	O	
20	69	O	
21	degrees	O	
22	C	O	
23	),	O	
24	such	O	
25	a	O	
26	selection	O	
27	practically	O	
28	resulted	O	
29	in	O	
30	the	O	
31	disappearance	O	
32	of	O	
33	'	O	
34	passable	O	
35	'	O	
36	qualifications	O	
37	in	O	
38	the	O	
39	triplet	O	
40	groups	O	
41	and	O	
42	a	O	
43	great	O	
44	predominance	O	
45	of	O	
46	'	O	
47	to	O	
48	be	O	
49	rejected	O	
50	'	O	
51	qualifications	O	
52	in	O	
53	the	O	
54	large	O	
55	groups	O	
56	.	O	

1	The	O	
2	GEF	B	
3	and	O	
4	GAP	B	
5	activities	O	
6	for	O	
7	Ypt1p	B	
8	localize	O	
9	to	O	
10	particulate	O	
11	cellular	O	
12	fractions	O	
13	.	O	

1	Both	O	
2	inserts	O	
3	are	O	
4	larger	O	
5	than	O	
6	their	O	
7	homologues	O	
8	in	O	
9	eIF	B	
10	-	I	
11	2alpha	I	
12	kinases	I	
13	.	O	

1	Subsequently	O	
2	,	O	
3	HD	O	
4	inhibited	O	
5	healing	O	
6	because	O	
7	it	O	
8	significantly	O	
9	delayed	O	
10	epithelialization	O	
11	and	O	
12	caused	O	
13	protracted	O	
14	inflammation	O	
15	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	media	O	
5	containing	O	
6	F	B	
7	beta	I	
8	alpha	I	
9	/	O	
10	CG	B	
11	beta	I	
12	displayed	O	
13	high	O	
14	-	O	
15	affinity	O	
16	binding	O	
17	to	O	
18	both	O	
19	CG	B	
20	and	I	
21	FSH	I	
22	receptors	I	
23	.	O	

1	The	O	
2	mucosal	O	
3	defence	O	
4	capacity	O	
5	against	O	
6	proteolytic	O	
7	leukocyte	O	
8	enzymes	O	
9	.	O	

1	66	O	
2	:	O	
3	469	O	
4	-	O	
5	479	O	
6	,	O	
7	1992	O	
8	).	O	

1	The	O	
2	Asian	O	
3	mouse	O	
4	Mus	O	
5	castaneus	O	
6	is	O	
7	resistant	O	
8	to	O	
9	infection	O	
10	by	O	
11	the	O	
12	polytropic	O	
13	mink	O	
14	cell	O	
15	focus	O	
16	-	O	
17	inducing	O	
18	(	O	
19	MCF	O	
20	)	O	
21	subgroup	O	
22	of	O	
23	murine	O	
24	leukemia	O	
25	viruses	O	
26	(	O	
27	MuLVs	O	
28	).	O	

1	Fifty	O	
2	-	O	
3	one	O	
4	patients	O	
5	with	O	
6	primary	O	
7	refractory	O	
8	or	O	
9	relapsed	O	
10	malignant	O	
11	lymphoma	O	
12	(	O	
13	47	O	
14	non	O	
15	-	O	
16	Hodgkin	O	
17	'	O	
18	s	O	
19	lymphoma	O	
20	and	O	
21	four	O	
22	Hodgkin	O	
23	'	O	
24	s	O	
25	disease	O	
26	)	O	
27	were	O	
28	treated	O	
29	with	O	
30	a	O	
31	new	O	
32	chemotherapeutic	O	
33	regimen	O	
34	(	O	
35	cisplatinum	O	
36	,	O	
37	methyl	O	
38	GAG	O	
39	,	O	
40	bleomocyin	O	
41	,	O	
42	methyl	O	
43	prednisolon	O	
44	).	O	

1	The	O	
2	results	O	
3	suggest	O	
4	that	O	
5	the	O	
6	greater	O	
7	estrogenic	O	
8	influence	O	
9	associated	O	
10	with	O	
11	the	O	
12	ethinyl	O	
13	estradiol	O	
14	-	O	
15	containing	O	
16	OC	O	
17	resulted	O	
18	in	O	
19	inhibition	O	
20	of	O	
21	coronary	O	
22	artery	O	
23	atherosclerosis	O	
24	despite	O	
25	a	O	
26	pronounced	O	
27	progestin	O	
28	-	O	
29	induced	O	
30	lowering	O	
31	of	O	
32	plasma	O	
33	HDL	B	
34	cholesterol	I	
35	concentration	O	
36	and	O	
37	,	O	
38	further	O	
39	,	O	
40	that	O	
41	hormonal	O	
42	balance	O	
43	may	O	
44	have	O	
45	a	O	
46	marked	O	
47	influence	O	
48	on	O	
49	the	O	
50	relationship	O	
51	between	O	
52	plasma	O	
53	lipids	O	
54	and	O	
55	atherogenesis	O	
56	.	O	

1	The	O	
2	paper	O	
3	is	O	
4	concerned	O	
5	with	O	
6	the	O	
7	data	O	
8	on	O	
9	change	O	
10	in	O	
11	the	O	
12	blood	O	
13	level	O	
14	of	O	
15	ACTH	B	
16	,	O	
17	STH	B	
18	,	O	
19	TSH	B	
20	,	O	
21	cortisol	O	
22	,	O	
23	T3	O	
24	,	O	
25	insulin	B	
26	,	O	
27	C	B	
28	-	I	
29	peptide	I	
30	during	O	
31	a	O	
32	25	O	
33	-	O	
34	minute	O	
35	session	O	
36	of	O	
37	respiration	O	
38	using	O	
39	a	O	
40	gaseous	O	
41	hypoxic	O	
42	mixture	O	
43	with	O	
44	10	O	
45	%	O	
46	oxygen	O	
47	(	O	
48	GHM	O	
49	-	O	
50	10	O	
51	).	O	

1	A	O	
2	given	O	
3	standard	O	
4	input	O	
5	function	O	
6	and	O	
7	a	O	
8	given	O	
9	value	O	
10	of	O	
11	distribution	O	
12	volume	O	
13	(	O	
14	Vd	O	
15	)	O	
16	used	O	
17	for	O	
18	the	O	
19	rCBF	O	
20	measurement	O	
21	of	O	
22	this	O	
23	method	O	
24	were	O	
25	calculated	O	
26	from	O	
27	the	O	
28	dynamic	O	
29	study	O	
30	by	O	
31	six	O	
32	normal	O	
33	volunteers	O	
34	.	O	

1	The	O	
2	"	O	
3	28	O	
4	percent	O	
5	"	O	
6	Venturi	O	
7	mask	O	
8	in	O	
9	obstructive	O	
10	airway	O	
11	disease	O	
12	.	O	

1	Automatic	O	
2	view	O	
3	box	O	
4	.	O	

1	Brainstem	O	
2	auditory	O	
3	evoked	O	
4	responses	O	
5	(	O	
6	BAERs	O	
7	)	O	
8	and	O	
9	quantitative	O	
10	saccadic	O	
11	eye	O	
12	movement	O	
13	studies	O	
14	provide	O	
15	information	O	
16	on	O	
17	the	O	
18	integrity	O	
19	of	O	
20	pathways	O	
21	traversing	O	
22	the	O	
23	brainstem	O	
24	.	O	

1	AMDA	O	
2	white	O	
3	paper	O	
4	identifies	O	
5	ways	O	
6	to	O	
7	improve	O	
8	pharmaceutical	O	
9	care	O	
10	in	O	
11	SNFs	O	
12	.	O	

1	Hex	B	
2	is	O	
3	expressed	O	
4	in	O	
5	the	O	
6	developing	O	
7	liver	O	
8	coincident	O	
9	with	O	
10	the	O	
11	forkhead	B	
12	/	O	
13	winged	B	
14	helix	I	
15	transcription	O	
16	factor	O	
17	,	O	
18	Hepatocyte	B	
19	Nuclear	I	
20	Factor	I	
21	3beta	I	
22	(	O	
23	HNF3beta	B	
24	).	O	

1	These	O	
2	mutations	O	
3	are	O	
4	localized	O	
5	in	O	
6	the	O	
7	same	O	
8	region	O	
9	where	O	
10	the	O	
11	HSV	B	
12	transactivator	I	
13	VP16	I	
14	binds	O	
15	,	O	
16	but	O	
17	did	O	
18	not	O	
19	coincide	O	
20	with	O	
21	the	O	
22	VP16	B	
23	contacts	O	
24	.	O	

1	The	O	
2	intensity	O	
3	of	O	
4	myocardial	O	
5	uptake	O	
6	of	O	
7	Tc	O	
8	-	O	
9	99m	O	
10	-	O	
11	PYP	O	
12	in	O	
13	patients	O	
14	with	O	
15	echocardiographic	O	
16	left	O	
17	ventricular	O	
18	hypertrophy	O	
19	and	O	
20	/	O	
21	or	O	
22	highly	O	
23	refractile	O	
24	myocardial	O	
25	echoes	O	
26	,	O	
27	so	O	
28	-	O	
29	called	O	
30	granular	O	
31	sparkling	O	
32	appearance	O	
33	(	O	
34	GS	O	
35	)	O	
36	was	O	
37	slightly	O	
38	greater	O	
39	than	O	
40	that	O	
41	in	O	
42	patients	O	
43	with	O	
44	neither	O	
45	myocardial	O	
46	hypertrophy	O	
47	nor	O	
48	GS	O	
49	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	the	O	
5	deduced	O	
6	amino	O	
7	acid	O	
8	sequence	O	
9	of	O	
10	a	O	
11	second	O	
12	family	O	
13	(	O	
14	ART5	B	
15	)	O	
16	of	O	
17	transferases	O	
18	,	O	
19	cloned	O	
20	from	O	
21	murine	O	
22	lymphoma	O	
23	cells	O	
24	and	O	
25	expressed	O	
26	in	O	
27	high	O	
28	abundance	O	
29	in	O	
30	testis	O	
31	,	O	
32	displays	O	
33	a	O	
34	hydrophobic	O	
35	amino	O	
36	terminus	O	
37	,	O	
38	consistent	O	
39	with	O	
40	a	O	
41	signal	O	
42	sequence	O	
43	,	O	
44	but	O	
45	lacks	O	
46	a	O	
47	hydrophobic	O	
48	signal	O	
49	sequence	O	
50	at	O	
51	its	O	
52	carboxyl	O	
53	terminus	O	
54	,	O	
55	suggesting	O	
56	that	O	
57	the	O	
58	protein	O	
59	is	O	
60	destined	O	
61	for	O	
62	export	O	
63	.	O	

1	We	O	
2	show	O	
3	here	O	
4	that	O	
5	these	O	
6	Jun	B	
7	/	O	
8	eb1	B	
9	chimeras	O	
10	are	O	
11	potent	O	
12	transactivators	O	
13	of	O	
14	AP1	B	
15	sites	I	
16	and	O	
17	that	O	
18	they	O	
19	can	O	
20	cooperate	O	
21	with	O	
22	c	B	
23	-	I	
24	Ha	I	
25	-	I	
26	Ras	I	
27	to	O	
28	induce	O	
29	foci	O	
30	.	O	

1	This	O	
2	alternatively	O	
3	spliced	O	
4	transcript	O	
5	contained	O	
6	an	O	
7	open	O	
8	reading	O	
9	frame	O	
10	extending	O	
11	from	O	
12	the	O	
13	upstream	O	
14	J	O	
15	alpha	O	
16	11	O	
17	-	O	
18	2	O	
19	region	O	
20	to	O	
21	82	O	
22	nucleotides	O	
23	downstream	O	
24	of	O	
25	the	O	
26	beginning	O	
27	of	O	
28	the	O	
29	TCR	B	
30	C	I	
31	alpha	I	
32	region	I	
33	,	O	
34	and	O	
35	potentially	O	
36	encoded	O	
37	a	O	
38	36	O	
39	amino	O	
40	acid	O	
41	polypeptide	O	
42	.	O	

1	She	O	
2	improved	O	
3	with	O	
4	a	O	
5	combination	O	
6	of	O	
7	benzodiazepines	O	
8	and	O	
9	the	O	
10	acetylcholinesterase	B	
11	inhibitor	O	
12	physostigmine	O	
13	.	O	

1	Transfer	O	
2	also	O	
3	correlated	O	
4	inversely	O	
5	with	O	
6	gastric	O	
7	juice	O	
8	pH	O	
9	(	O	
10	r	O	
11	=	O	
12	-	O	
13	0	O	
14	.	O	
15	619	O	
16	,	O	
17	P	O	
18	<	O	
19	0	O	
20	.	O	
21	02	O	
22	).	O	

1	Dangers	O	
2	in	O	
3	use	O	
4	of	O	
5	live	O	
6	-	O	
7	virus	O	
8	vaccines	O	
9	.	O	

1	METHODS	O	
2	AND	O	
3	RESULTS	O	
4	:	O	
5	In	O	
6	25	O	
7	open	O	
8	-	O	
9	chest	O	
10	,	O	
11	anesthetized	O	
12	dogs	O	
13	,	O	
14	progressive	O	
15	circumflex	O	
16	artery	O	
17	stenosis	O	
18	led	O	
19	to	O	
20	a	O	
21	concordant	O	
22	decrease	O	
23	of	O	
24	circumflex	O	
25	artery	O	
26	resting	O	
27	and	O	
28	hyperemic	O	
29	flow	O	
30	,	O	
31	coronary	O	
32	flow	O	
33	reserve	O	
34	,	O	
35	and	O	
36	inverse	O	
37	angiographic	O	
38	mean	O	
39	transit	O	
40	time	O	
41	Tmicro	O	
42	-	O	
43	1	O	
44	(	O	
45	P	O	
46	<	O	
47	.	O	
48	01	O	
49	).	O	

1	A	O	
2	prospective	O	
3	trial	O	
4	was	O	
5	carried	O	
6	out	O	
7	in	O	
8	156	O	
9	unselected	O	
10	patients	O	
11	(	O	
12	41	O	
13	men	O	
14	,	O	
15	mean	O	
16	age	O	
17	67	O	
18	.	O	
19	5	O	
20	years	O	
21	,	O	
22	115	O	
23	women	O	
24	,	O	
25	mean	O	
26	age	O	
27	71	O	
28	.	O	
29	4	O	
30	years	O	
31	)	O	
32	who	O	
33	had	O	
34	undergone	O	
35	total	O	
36	hip	O	
37	joint	O	
38	replacement	O	
39	because	O	
40	of	O	
41	degenerative	O	
42	or	O	
43	inflammatory	O	
44	arthritis	O	
45	or	O	
46	fracture	O	
47	of	O	
48	the	O	
49	neck	O	
50	of	O	
51	the	O	
52	femur	O	
53	.	O	

1	Relations	O	
2	between	O	
3	adrenergic	O	
4	mechanisms	O	
5	and	O	
6	analgesic	O	
7	effects	O	

1	Mitochondrial	B	
2	Mas70p	I	
3	signal	I	
4	anchor	I	
5	sequence	I	
6	.	O	

1	Unique	O	
2	to	O	
3	this	O	
4	system	O	
5	,	O	
6	the	O	
7	activity	O	
8	of	O	
9	TraR	B	
10	is	O	
11	negatively	O	
12	modulated	O	
13	by	O	
14	an	O	
15	antiactivator	O	
16	called	O	
17	TraM	B	
18	.	O	

1	The	O	
2	substrates	O	
3	for	O	
4	glycan	O	
5	synthesis	O	
6	in	O	
7	the	O	
8	lumen	O	
9	of	O	
10	the	O	
11	Golgi	O	
12	are	O	
13	nucleotide	O	
14	sugars	O	
15	that	O	
16	must	O	
17	be	O	
18	transported	O	
19	from	O	
20	the	O	
21	cytosol	O	
22	by	O	
23	specific	O	
24	membrane	O	
25	-	O	
26	bound	O	
27	transporters	O	
28	.	O	

1	CASE	O	
2	REPORT	O	
3	:	O	
4	We	O	
5	observed	O	
6	a	O	
7	congenital	O	
8	skin	O	
9	defect	O	
10	located	O	
11	exclusively	O	
12	on	O	
13	the	O	
14	trunk	O	
15	.	O	

1	Electrophoretic	O	
2	mobility	O	
3	shift	O	
4	assays	O	
5	using	O	
6	crude	O	
7	extracts	O	
8	from	O	
9	FREJ4	O	
10	cells	O	
11	revealed	O	
12	the	O	
13	binding	O	
14	of	O	
15	a	O	
16	member	O	
17	(	O	
18	s	O	
19	)	O	
20	of	O	
21	the	O	
22	Ets	B	
23	family	I	
24	of	I	
25	transcription	I	
26	factors	I	
27	to	O	
28	the	O	
29	P4	B	
30	EBS	I	
31	,	O	
32	as	O	
33	well	O	
34	as	O	
35	the	O	
36	interaction	O	
37	of	O	
38	two	O	
39	members	O	
40	of	O	
41	the	O	
42	Sp1	B	
43	family	I	
44	,	O	
45	Sp1	B	
46	and	O	
47	Sp3	B	
48	,	O	
49	with	O	
50	the	O	
51	adjacent	O	
52	GC	O	
53	box	O	
54	.	O	

1	Surprisingly	O	
2	,	O	
3	double	O	
4	mutants	O	
5	of	O	
6	the	O	
7	shy2	B	
8	-	I	
9	1D	I	
10	mutant	I	
11	with	O	
12	the	O	
13	phytochrome	B	
14	-	O	
15	deficient	O	
16	mutants	O	
17	hy2	B	
18	,	O	
19	hy3	B	
20	(	O	
21	phyB	B	
22	-	I	
23	1	I	
24	)	O	
25	and	O	
26	fre1	B	
27	-	I	
28	1	I	
29	(	O	
30	phyA	B	
31	-	I	
32	201	I	
33	)	O	
34	showed	O	
35	reduced	O	
36	photomorphogenic	O	
37	response	O	
38	in	O	
39	darkness	O	
40	with	O	
41	a	O	
42	longer	O	
43	hypocotyl	O	
44	,	O	
45	a	O	
46	longer	O	
47	inflorescence	O	
48	stem	O	
49	,	O	
50	and	O	
51	a	O	
52	lower	O	
53	level	O	
54	expression	O	
55	of	O	
56	the	O	
57	CAB	B	
58	gene	I	
59	than	O	
60	the	O	
61	shy2	B	
62	-	I	
63	1D	I	
64	single	I	
65	mutant	I	
66	.	O	

1	By	O	
2	150	O	
3	minutes	O	
4	after	O	
5	Cr2O3	O	
6	inhalation	O	
7	,	O	
8	FEV1	O	
9	.	O	
10	0	O	
11	had	O	
12	decreased	O	
13	by	O	
14	32	O	
15	%.	O	

1	The	O	
2	method	O	
3	is	O	
4	applied	O	
5	to	O	
6	determine	O	
7	aberration	O	
8	constants	O	
9	of	O	
10	a	O	
11	CM300	O	
12	FEG	O	
13	/	O	
14	UT	O	
15	microscope	O	
16	with	O	
17	correction	O	
18	of	O	
19	the	O	
20	three	O	
21	-	O	
22	fold	O	
23	astigmatism	O	
24	.	O	

1	The	O	
2	7	O	
3	-	O	
4	kb	O	
5	mRNA	O	
6	differs	O	
7	by	O	
8	alternative	O	
9	splicing	O	
10	such	O	
11	that	O	
12	it	O	
13	encodes	O	
14	a	O	
15	protein	O	
16	with	O	
17	a	O	
18	distinct	O	
19	amino	O	
20	terminus	O	
21	.	O	

1	The	O	
2	cis	O	
3	-	O	
4	acting	O	
5	element	O	
6	mediating	O	
7	glucocorticoid	O	
8	inducibility	O	
9	of	O	
10	the	O	
11	chicken	B	
12	glutamine	I	
13	synthetase	I	
14	gene	I	
15	has	O	
16	been	O	
17	identified	O	
18	.	O	

1	Since	O	
2	1990	O	
3	the	O	
4	University	O	
5	Hospital	O	
6	of	O	
7	Tromso	O	
8	has	O	
9	provided	O	
10	local	O	
11	hospitals	O	
12	in	O	
13	northern	O	
14	Norway	O	
15	with	O	
16	a	O	
17	remote	O	
18	frozen	O	
19	section	O	
20	service	O	
21	and	O	
22	with	O	
23	access	O	
24	to	O	
25	video	O	
26	conferences	O	
27	for	O	
28	the	O	
29	review	O	
30	of	O	
31	microscopic	O	
32	findings	O	
33	and	O	
34	for	O	
35	the	O	
36	discussion	O	
37	of	O	
38	major	O	
39	diagnostic	O	
40	issues	O	
41	.	O	

1	Vibrio	O	
2	fluvialis	O	
3	(	O	
4	group	O	
5	F	O	
6	vibrio	O	
7	)	O	
8	in	O	
9	Maharashtra	O	
10	.	O	

1	The	O	
2	addition	O	
3	of	O	
4	zidovudine	O	
5	did	O	
6	not	O	
7	influence	O	
8	this	O	
9	transfer	O	
10	.	O	

1	On	O	
2	cessation	O	
3	of	O	
4	steroid	O	
5	therapy	O	
6	the	O	
7	patient	O	
8	was	O	
9	noted	O	
10	to	O	
11	have	O	
12	radiologic	O	
13	manifestations	O	
14	of	O	
15	hypertrophic	O	
16	osteoarthropathy	O	
17	(	O	
18	HOA	O	
19	)	O	
20	as	O	
21	well	O	
22	as	O	
23	clinical	O	
24	and	O	
25	laboratory	O	
26	features	O	
27	of	O	
28	rheumatoid	O	
29	arthritis	O	
30	(	O	
31	RA	O	
32	).	O	

1	Among	O	
2	the	O	
3	total	O	
4	CDSs	O	
5	,	O	
6	8	O	
7	.	O	
8	8	O	
9	%	O	
10	match	O	
11	sequences	O	
12	of	O	
13	proteins	O	
14	found	O	
15	only	O	
16	in	O	
17	Bacillus	O	
18	subtilis	O	
19	and	O	
20	66	O	
21	.	O	
22	7	O	
23	%	O	
24	are	O	
25	widely	O	
26	conserved	O	
27	in	O	
28	comparison	O	
29	with	O	
30	the	O	
31	proteins	O	
32	of	O	
33	various	O	
34	organisms	O	
35	,	O	
36	including	O	
37	B	O	
38	.	O	
39	subtilis	O	
40	.	O	

1	The	O	
2	present	O	
3	paper	O	
4	elucidates	O	
5	the	O	
6	existing	O	
7	discrepancies	O	
8	,	O	
9	and	O	
10	offers	O	
11	a	O	
12	consistent	O	
13	terminology	O	
14	incorporating	O	
15	also	O	
16	such	O	
17	terms	O	
18	as	O	
19	"	O	
20	additivity	O	
21	",	O	
22	"	O	
23	potentiation	O	
24	",	O	
25	and	O	
26	"	O	
27	simple	O	
28	similarity	O	
29	".	O	

1	All	O	
2	numbers	O	
3	refer	O	
4	to	O	
5	nucleotide	O	
6	positions	O	
7	on	O	
8	the	O	
9	wild	O	
10	-	O	
11	type	O	
12	HIV	O	
13	-	O	
14	1	O	
15	transcript	O	
16	.	O	

1	Mesial	O	
2	temporal	O	
3	sclerosis	O	
4	.	O	

1	MZF	B	
2	-	I	
3	1	I	
4	represses	O	
5	CAT	B	
6	reporter	I	
7	gene	I	
8	expression	O	
9	via	O	
10	GAL4	B	
11	binding	I	
12	sites	I	
13	in	O	
14	the	O	
15	nonhematopoietic	O	
16	cell	O	
17	lines	O	
18	NIH	O	
19	3T3	O	
20	and	O	
21	293	O	
22	.	O	

1	These	O	
2	studies	O	
3	identify	O	
4	several	O	
5	of	O	
6	the	O	
7	signal	O	
8	-	O	
9	transduction	O	
10	events	O	
11	involved	O	
12	in	O	
13	the	O	
14	apoptosis	O	
15	of	O	
16	malignant	O	
17	B	O	
18	cells	O	
19	that	O	
20	transpire	O	
21	following	O	
22	ligation	O	
23	of	O	
24	CD20	B	
25	by	O	
26	anti	B	
27	-	I	
28	CD20	I	
29	antibodies	I	
30	in	O	
31	the	O	
32	presence	O	
33	of	O	
34	Fc	B	
35	-	I	
36	receptor	I	
37	-	O	
38	expressing	O	
39	cells	O	
40	or	O	
41	secondary	O	
42	goat	O	
43	anti	B	
44	-(	I	
45	mouse	I	
46	Ig	I	
47	)	I	
48	antibodies	I	
49	and	O	
50	which	O	
51	may	O	
52	contribute	O	
53	to	O	
54	the	O	
55	tumor	O	
56	regressions	O	
57	observed	O	
58	in	O	
59	mouse	O	
60	models	O	
61	and	O	
62	clinical	O	
63	trials	O	
64	.	O	

1	We	O	
2	have	O	
3	now	O	
4	located	O	
5	the	O	
6	5	O	
7	'	O	
8	ends	O	
9	of	O	
10	the	O	
11	two	O	
12	remaining	O	
13	late	O	
14	mRNAs	O	
15	.	O	

1	A	O	
2	total	O	
3	of	O	
4	7	O	
5	(	O	
6	4	O	
7	males	O	
8	and	O	
9	3	O	
10	females	O	
11	)	O	
12	patients	O	
13	were	O	
14	included	O	
15	in	O	
16	this	O	
17	retrospective	O	
18	study	O	
19	to	O	
20	determine	O	
21	the	O	
22	sensitivity	O	
23	of	O	
24	radioimmunoscintigraphy	O	
25	with	O	
26	I	O	
27	-	O	
28	131	O	
29	labeled	O	
30	anti	B	
31	CEA	I	
32	/	O	
33	CA	B	
34	19	I	
35	-	I	
36	9	I	
37	monoclonal	O	
38	antibodies	O	
39	.	O	

1	Poliomyelitis	O	
2	from	O	
3	a	O	
4	vaccine	O	
5	.	O	

1	There	O	
2	were	O	
3	18	O	
4	patients	O	
5	with	O	
6	Group	O	
7	II	O	
8	(	O	
9	a	O	
10	)	O	
11	tumors	O	
12	;	O	
13	although	O	
14	tumor	O	
15	biopsy	O	
16	was	O	
17	attempted	O	
18	on	O	
19	eight	O	
20	of	O	
21	these	O	
22	,	O	
23	pathological	O	
24	diagnosis	O	
25	at	O	
26	the	O	
27	time	O	
28	of	O	
29	surgery	O	
30	was	O	
31	made	O	
32	in	O	
33	only	O	
34	one	O	
35	case	O	
36	.	O	

1	Over	O	
2	-	O	
3	expression	O	
4	of	O	
5	the	O	
6	cofactor	O	
7	p300	B	
8	,	O	
9	which	O	
10	functions	O	
11	as	O	
12	a	O	
13	coactivator	O	
14	of	O	
15	myoD	B	
16	-	O	
17	mediated	O	
18	transcription	O	
19	,	O	
20	alleviated	O	
21	repression	O	
22	by	O	
23	COUP	B	
24	-	I	
25	TF	I	
26	II	I	
27	.	O	

1	Our	O	
2	results	O	
3	suggest	O	
4	that	O	
5	the	O	
6	crucial	O	
7	role	O	
8	of	O	
9	the	O	
10	mutations	O	
11	activating	O	
12	v	B	
13	-	I	
14	erbA	I	
15	as	O	
16	an	O	
17	oncogene	O	
18	is	O	
19	to	O	
20	'	O	
21	freeze	O	
22	'	O	
23	c	B	
24	-	I	
25	ErbA	I	
26	/	O	
27	TRalpha	B	
28	in	O	
29	its	O	
30	non	O	
31	-	O	
32	liganded	O	
33	,	O	
34	repressive	O	
35	conformation	O	
36	and	O	
37	to	O	
38	facilitate	O	
39	its	O	
40	overexpression	O	
41	.	O	

1	In	O	
2	three	O	
3	of	O	
4	the	O	
5	seven	O	
6	,	O	
7	inhalation	O	
8	of	O	
9	2	O	
10	ml	O	
11	normal	O	
12	saline	O	
13	produced	O	
14	FEV1	O	
15	falls	O	
16	of	O	
17	25	O	
18	%	O	
19	to	O	
20	30	O	
21	%,	O	
22	but	O	
23	these	O	
24	falls	O	
25	were	O	
26	not	O	
27	as	O	
28	great	O	
29	as	O	
30	each	O	
31	subject	O	
32	'	O	
33	s	O	
34	reactions	O	
35	to	O	
36	the	O	
37	test	O	
38	solutions	O	
39	.	O	

1	The	O	
2	mRNA	O	
3	identified	O	
4	in	O	
5	both	O	
6	human	O	
7	and	O	
8	rat	O	
9	cells	O	
10	with	O	
11	the	O	
12	human	B	
13	clathrin	I	
14	clone	O	
15	revealed	O	
16	transcripts	O	
17	of	O	
18	approximately	O	
19	6	O	
20	.	O	
21	5	O	
22	kb	O	
23	,	O	
24	which	O	
25	is	O	
26	consistent	O	
27	with	O	
28	the	O	
29	predicted	O	
30	180	O	
31	kDa	O	
32	molecular	O	
33	weight	O	
34	of	O	
35	the	O	
36	clathrin	B	
37	heavy	I	
38	chain	I	
39	.	O	

1	Relation	O	
2	between	O	
3	mixing	O	
4	ratio	O	
5	of	O	
6	raw	O	
7	materials	O	
8	and	O	
9	composition	O	
10	of	O	
11	products	O	
12	in	O	
13	the	O	
14	synthesis	O	
15	of	O	
16	aluminosilicates	O	

1	The	O	
2	construct	O	
3	was	O	
4	introduced	O	
5	into	O	
6	BW2001	O	
7	(	O	
8	xth	O	
9	-	O	
10	11	O	
11	,	O	
12	nfo	O	
13	-	O	
14	2	O	
15	)	O	
16	strain	O	
17	cells	O	
18	of	O	
19	Escherichia	O	
20	coli	O	
21	.	O	

1	Acute	O	
2	appearance	O	
3	of	O	
4	hemiparesis	O	
5	or	O	
6	hemiplegia	O	
7	with	O	
8	initial	O	
9	marked	O	
10	spasticity	O	
11	was	O	
12	observed	O	
13	in	O	
14	8	O	
15	stroke	O	
16	patients	O	
17	.	O	

1	Three	O	
2	sequence	O	
3	elements	O	
4	are	O	
5	shown	O	
6	to	O	
7	be	O	
8	required	O	
9	for	O	
10	accurate	O	
11	and	O	
12	efficient	O	
13	transcription	O	
14	termination	O	
15	by	O	
16	RNA	B	
17	polymerase	I	
18	I	I	
19	(	O	
20	pol	B	
21	I	I	
22	)	O	
23	assayed	O	
24	both	O	
25	in	O	
26	a	O	
27	cell	O	
28	-	O	
29	free	O	
30	transcription	O	
31	system	O	
32	and	O	
33	in	O	
34	vivo	O	
35	after	O	
36	transfection	O	
37	of	O	
38	rDNA	O	
39	minigene	O	
40	constructs	O	
41	into	O	
42	3T6	O	
43	cells	O	
44	.	O	

1	We	O	
2	are	O	
3	reporting	O	
4	an	O	
5	autopsy	O	
6	case	O	
7	of	O	
8	so	O	
9	-	O	
10	called	O	
11	"	O	
12	acute	O	
13	multiple	O	
14	sclerosis	O	
15	"	O	
16	that	O	
17	was	O	
18	difficult	O	
19	to	O	
20	differentiate	O	
21	from	O	
22	a	O	
23	brain	O	
24	tumor	O	
25	on	O	
26	MRI	O	
27	findings	O	
28	.	O	

1	New	O	
2	diagnostic	O	
3	strategies	O	
4	for	O	
5	lupus	O	
6	anticoagulants	O	
7	and	O	
8	antiphospholipid	O	
9	antibodies	O	
10	.	O	

1	Inhibition	O	
2	appears	O	
3	to	O	
4	result	O	
5	from	O	
6	titration	O	
7	of	O	
8	general	O	
9	transcription	O	
10	factors	O	
11	because	O	
12	MDM2	B	
13	overexpression	O	
14	inhibits	O	
15	c	B	
16	-	I	
17	fos	I	
18	as	O	
19	well	O	
20	as	O	
21	other	O	
22	promoters	O	
23	in	O	
24	vivo	O	
25	and	O	
26	basal	O	
27	transcription	O	
28	in	O	
29	vitro	O	
30	.	O	

1	The	O	
2	healing	O	
3	rate	O	
4	in	O	
5	HIV	O	
6	-	O	
7	positive	O	
8	patients	O	
9	was	O	
10	66	O	
11	percent	O	
12	after	O	
13	14	O	
14	weeks	O	
15	and	O	
16	100	O	
17	percent	O	
18	after	O	
19	32	O	
20	weeks	O	
21	;	O	
22	the	O	
23	corresponding	O	
24	figures	O	
25	for	O	
26	patients	O	
27	with	O	
28	acquired	O	
29	immunodeficiency	O	
30	syndrome	O	
31	were	O	
32	0	O	
33	and	O	
34	50	O	
35	percent	O	
36	.	O	

1	I	O	
2	.	O	

1	The	O	
2	results	O	
3	show	O	
4	that	O	
5	the	O	
6	structure	O	
7	of	O	
8	the	O	
9	decorin	B	
10	gene	I	
11	promoter	I	
12	is	O	
13	different	O	
14	from	O	
15	that	O	
16	of	O	
17	any	O	
18	other	O	
19	proteoglycan	O	
20	promoter	O	
21	characterized	O	
22	so	O	
23	far	O	
24	and	O	
25	indicate	O	
26	that	O	
27	the	O	
28	pur	O	
29	/	O	
30	pyr	O	
31	segment	O	
32	plays	O	
33	a	O	
34	role	O	
35	in	O	
36	the	O	
37	regulation	O	
38	of	O	
39	gene	O	
40	transcription	O	
41	.	O	

1	Transcript	O	
2	analysis	O	
3	reveals	O	
4	that	O	
5	lethal	O	
6	B	B	
7	block	I	
8	substitutions	O	
9	reduce	O	
10	U6	B	
11	RNA	I	
12	synthesis	O	
13	at	O	
14	least	O	
15	10	O	
16	-	O	
17	fold	O	
18	in	O	
19	vivo	O	
20	and	O	
21	20	O	
22	-	O	
23	fold	O	
24	in	O	
25	vitro	O	
26	.	O	

1	Elevated	O	
2	expression	O	
3	of	O	
4	a	O	
5	previously	O	
6	uncharacterized	O	
7	gene	O	
8	,	O	
9	SPP381	B	
10	,	O	
11	efficiently	O	
12	suppresses	O	
13	the	O	
14	growth	O	
15	and	O	
16	splicing	O	
17	defects	O	
18	of	O	
19	a	O	
20	temperature	O	
21	-	O	
22	sensitive	O	
23	(	O	
24	Ts	O	
25	)	O	
26	mutant	B	
27	prp38	I	
28	-	I	
29	1	I	
30	.	O	

1	Analysis	O	
2	of	O	
3	clearance	O	
4	curve	O	
5	of	O	
6	rose	O	
7	bengal	O	
8	-	O	
9	I	O	
10	-	O	
11	131	O	

1	Multifunctional	B	
2	protein	I	
3	kinase	I	
4	(	O	
5	MFPK	B	
6	)	O	
7	phosphorylates	O	
8	ATP	B	
9	-	I	
10	citrate	I	
11	lyase	I	
12	on	O	
13	peptide	B	
14	B	I	
15	on	O	
16	two	O	
17	sites	O	
18	,	O	
19	BT	O	
20	and	O	
21	BS	O	
22	,	O	
23	on	O	
24	threonine	O	
25	and	O	
26	serine	O	
27	,	O	
28	respectively	O	
29	,	O	
30	inhibitor	B	
31	2	I	
32	on	O	
33	a	O	
34	threonyl	O	
35	residue	O	
36	,	O	
37	and	O	
38	glycogen	B	
39	synthase	I	
40	at	O	
41	sites	O	
42	2	O	
43	and	O	
44	3	O	
45	.	O	

1	Protein	B	
2	tyrosine	I	
3	kinases	I	
4	(	O	
5	PTKs	B	
6	)	O	
7	are	O	
8	implicated	O	
9	in	O	
10	the	O	
11	control	O	
12	of	O	
13	cell	O	
14	growth	O	
15	by	O	
16	virtue	O	
17	of	O	
18	their	O	
19	frequent	O	
20	appearance	O	
21	as	O	
22	products	O	
23	of	O	
24	retroviral	O	
25	oncogenes	O	
26	,	O	
27	as	O	
28	intracellular	O	
29	signal	O	
30	transducers	O	
31	,	O	
32	and	O	
33	as	O	
34	growth	B	
35	factor	I	
36	receptors	I	
37	or	O	
38	components	O	
39	thereof	O	
40	.	O	

1	Our	O	
2	observations	O	
3	suggest	O	
4	that	O	
5	members	O	
6	of	O	
7	the	O	
8	HMG	B	
9	-	I	
10	I	I	
11	family	I	
12	play	O	
13	an	O	
14	important	O	
15	role	O	
16	in	O	
17	SRF	B	
18	-	O	
19	dependent	O	
20	transcription	O	
21	and	O	
22	that	O	
23	their	O	
24	effect	O	
25	is	O	
26	mediated	O	
27	primarily	O	
28	by	O	
29	a	O	
30	protein	O	
31	-	O	
32	protein	O	
33	interaction	O	
34	.	O	

1	Additionally	O	
2	,	O	
3	although	O	
4	c	B	
5	-	I	
6	fos	I	
7	and	O	
8	egr	B	
9	-	I	
10	1	I	
11	mRNAs	I	
12	are	O	
13	expressed	O	
14	at	O	
15	elevated	O	
16	levels	O	
17	in	O	
18	stimulated	O	
19	liver	O	
20	cells	O	
21	,	O	
22	fos	B	
23	-	I	
24	B	I	
25	,	O	
26	fra	B	
27	-	I	
28	1	I	
29	,	O	
30	and	O	
31	egr	B	
32	-	I	
33	2	I	
34	are	O	
35	not	O	
36	,	O	
37	which	O	
38	suggests	O	
39	that	O	
40	factors	O	
41	in	O	
42	addition	O	
43	to	O	
44	the	O	
45	serum	B	
46	response	I	
47	factor	I	
48	participate	O	
49	in	O	
50	the	O	
51	regulation	O	
52	of	O	
53	immediate	B	
54	-	I	
55	early	I	
56	gene	I	
57	induction	O	
58	.	O	

1	The	O	
2	origins	O	
3	of	O	
4	reflected	O	
5	light	O	
6	changes	O	
7	associated	O	
8	with	O	
9	neuronal	O	
10	activity	O	
11	(	O	
12	optical	O	
13	signals	O	
14	)	O	
15	were	O	
16	investigated	O	
17	in	O	
18	rat	O	
19	somatosensory	O	
20	cortex	O	
21	with	O	
22	optical	O	
23	imaging	O	
24	,	O	
25	microspectrophotometry	O	
26	,	O	
27	and	O	
28	laser	O	
29	-	O	
30	Doppler	O	
31	flowmetry	O	
32	,	O	
33	and	O	
34	dynamic	O	
35	changes	O	
36	in	O	
37	local	O	
38	hemoglobin	B	
39	concentration	O	
40	and	O	
41	oxygenation	O	
42	were	O	
43	focused	O	
44	on	O	
45	.	O	

1	Here	O	
2	we	O	
3	report	O	
4	that	O	
5	Dbp5p	B	
6	and	O	
7	Rat7p	B	
8	interact	O	
9	through	O	
10	their	O	
11	Nterminal	O	
12	domains	O	
13	.	O	

1	These	O	
2	results	O	
3	suggest	O	
4	that	O	
5	Thr115	O	
6	may	O	
7	play	O	
8	an	O	
9	important	O	
10	role	O	
11	in	O	
12	the	O	
13	regulation	O	
14	of	O	
15	MyoD	B	
16	function	O	
17	under	O	
18	conditions	O	
19	of	O	
20	high	O	
21	mitogenesis	O	
22	.	O	

1	In	O	
2	fact	O	
3	,	O	
4	SPT	B	
5	activity	O	
6	in	O	
7	the	O	
8	fly	O	
9	expressing	O	
10	epitope	O	
11	-	O	
12	tagged	O	
13	Lace	B	
14	was	O	
15	absorbed	O	
16	by	O	
17	epitope	O	
18	-	O	
19	specific	O	
20	antibody	O	
21	.	O	

1	Copyright	O	
2	2000	O	
3	Academic	O	
4	Press	O	
5	.	O	

1	TPA	O	
2	and	O	
3	TGF	B	
4	-	I	
5	beta	I	
6	1	I	
7	did	O	
8	not	O	
9	markedly	O	
10	affect	O	
11	the	O	
12	activities	O	
13	of	O	
14	the	O	
15	72	O	
16	-	O	
17	kDa	O	
18	enzyme	O	
19	.	O	

1	5	O	
2	)	O	
3	We	O	
4	'	O	
5	ve	O	
6	noticed	O	
7	that	O	
8	the	O	
9	mean	O	
10	value	O	
11	of	O	
12	the	O	
13	cost	O	
14	for	O	
15	episode	O	
16	of	O	
17	pnx	O	
18	s	O	
19	.	O	
20	in	O	
21	class	O	
22	A	O	
23	was	O	
24	more	O	
25	than	O	
26	15	O	
27	%	O	
28	compared	O	
29	to	O	
30	class	O	
31	B	O	
32	and	O	
33	the	O	
34	cost	O	
35	for	O	
36	patient	O	
37	in	O	
38	class	O	
39	A	O	
40	was	O	
41	nearly	O	
42	double	O	
43	than	O	
44	in	O	
45	class	O	
46	B	O	
47	.	O	

1	The	O	
2	titer	O	
3	of	O	
4	anti	B	
5	HSV	I	
6	type	I	
7	1	I	
8	and	O	
9	anti	B	
10	HSV	I	
11	type	I	
12	2	I	
13	antibodies	I	
14	in	O	
15	the	O	
16	mothers	O	
17	'	O	
18	and	O	
19	cord	O	
20	blood	O	
21	was	O	
22	determined	O	
23	and	O	
24	compared	O	
25	.	O	

1	Sequencing	O	
2	analysis	O	
3	revealed	O	
4	that	O	
5	the	O	
6	0	O	
7	.	O	
8	54	O	
9	-	O	
10	and	O	
11	0	O	
12	.	O	
13	4	O	
14	-	O	
15	kb	O	
16	fragments	O	
17	are	O	
18	identical	O	
19	except	O	
20	for	O	
21	150	O	
22	nucleotides	O	
23	missing	O	
24	at	O	
25	the	O	
26	5	O	
27	'	O	
28	region	O	
29	of	O	
30	the	O	
31	0	O	
32	.	O	
33	4	O	
34	-	O	
35	kb	O	
36	fragment	O	
37	.	O	

1	The	O	
2	results	O	
3	show	O	
4	that	O	
5	ROS	O	
6	production	O	
7	by	O	
8	viable	O	
9	spermatozoa	O	
10	is	O	
11	highly	O	
12	correlated	O	
13	with	O	
14	the	O	
15	concentration	O	
16	of	O	
17	PMN	B	
18	elastase	I	
19	and	O	
20	the	O	
21	number	O	
22	of	O	
23	both	O	
24	peroxidase	B	
25	-	O	
26	positive	O	
27	and	O	
28	round	O	
29	cells	O	
30	.	O	

1	For	O	
2	each	O	
3	night	O	
4	,	O	
5	the	O	
6	diary	O	
7	allowed	O	
8	the	O	
9	subjective	O	
10	measurement	O	
11	of	O	
12	bedtime	O	
13	,	O	
14	wake	O	
15	time	O	
16	,	O	
17	time	O	
18	in	O	
19	bed	O	
20	(	O	
21	TIB	O	
22	),	O	
23	sleep	O	
24	efficiency	O	
25	,	O	
26	number	O	
27	of	O	
28	minutes	O	
29	of	O	
30	wake	O	
31	after	O	
32	sleep	O	
33	onset	O	
34	(	O	
35	WASO	O	
36	),	O	
37	alertness	O	
38	on	O	
39	awakening	O	
40	,	O	
41	and	O	
42	percentage	O	
43	of	O	
44	morning	O	
45	needing	O	
46	an	O	
47	alarm	O	
48	(	O	
49	or	O	
50	a	O	
51	person	O	
52	functioning	O	
53	as	O	
54	one	O	
55	).	O	

1	The	O	
2	p55	B	
3	mRNA	I	
4	is	O	
5	undetectable	O	
6	in	O	
7	non	O	
8	-	O	
9	EBV	O	
10	-	O	
11	infected	O	
12	B	O	
13	-	O	
14	and	O	
15	T	O	
16	-	O	
17	cell	O	
18	lines	O	
19	or	O	
20	in	O	
21	a	O	
22	myelomonocytic	O	
23	cell	O	
24	line	O	
25	(	O	
26	U937	O	
27	).	O	

1	The	O	
2	cis	O	
3	-	O	
4	acting	O	
5	element	O	
6	,	O	
7	identified	O	
8	as	O	
9	CACGTGACCCG	O	
10	,	O	
11	is	O	
12	located	O	
13	34	O	
14	bp	O	
15	upstream	O	
16	from	O	
17	the	O	
18	transcription	O	
19	initiation	O	
20	site	O	
21	,	O	
22	and	O	
23	contains	O	
24	the	O	
25	core	O	
26	sequence	O	
27	of	O	
28	the	O	
29	upstream	O	
30	promoter	O	
31	sequence	O	
32	of	O	
33	Ad2MLP	B	
34	.	O	

1	Macroscopic	O	
2	researches	O	
3	on	O	
4	heart	O	
5	vascularization	O	
6	have	O	
7	indicated	O	
8	that	O	
9	the	O	
10	angioarchitecture	O	
11	of	O	
12	the	O	
13	conducting	O	
14	system	O	
15	differs	O	
16	from	O	
17	that	O	
18	of	O	
19	the	O	
20	normal	O	
21	myocardium	O	
22	.	O	

1	Pharmacologic	O	
2	aspects	O	
3	of	O	
4	neonatal	O	
5	hyperbilirubinemia	O	
6	.	O	

1	Administration	O	
2	of	O	
3	the	O	
4	dopamine	O	
5	agonist	O	
6	bromocriptine	O	
7	(	O	
8	2	O	
9	.	O	
10	5	O	
11	mg	O	
12	three	O	
13	times	O	
14	a	O	
15	day	O	
16	for	O	
17	4	O	
18	days	O	
19	)	O	
20	suppressed	O	
21	(	O	
22	P	O	
23	less	O	
24	than	O	
25	0	O	
26	.	O	
27	01	O	
28	)	O	
29	mean	O	
30	24	O	
31	-	O	
32	h	O	
33	plasma	O	
34	18	O	
35	-	O	
36	OHB	O	
37	levels	O	
38	from	O	
39	21	O	
40	.	O	
41	9	O	
42	+/-	O	
43	2	O	
44	.	O	
45	0	O	
46	to	O	
47	14	O	
48	.	O	
49	8	O	
50	+/-	O	
51	1	O	
52	.	O	
53	4	O	
54	ng	O	
55	/	O	
56	dl	O	
57	.	O	

1	The	O	
2	carcinogen	O	
3	bioassay	O	
4	therefore	O	
5	is	O	
6	a	O	
7	very	O	
8	important	O	
9	component	O	
10	of	O	
11	the	O	
12	battery	O	
13	of	O	
14	toxicological	O	
15	tests	O	
16	used	O	
17	in	O	
18	hazard	O	
19	evaluation	O	
20	.	O	

1	A	O	
2	segment	O	
3	of	O	
4	mRNA	O	
5	encoding	O	
6	the	O	
7	leader	O	
8	peptide	O	
9	of	O	
10	the	O	
11	CPA1	B	
12	gene	I	
13	confers	O	
14	repression	O	
15	by	O	
16	arginine	O	
17	on	O	
18	a	O	
19	heterologous	O	
20	yeast	O	
21	gene	O	
22	transcript	O	
23	.	O	

1	Plasma	B	
2	secretin	I	
3	,	O	
4	pancreozymin	B	
5	,	O	
6	and	O	
7	somatostatin	B	
8	-	I	
9	like	I	
10	hormone	I	
11	in	O	
12	chronic	O	
13	renal	O	
14	failure	O	
15	patients	O	
16	.	O	

1	Recent	O	
2	studies	O	
3	have	O	
4	demonstrated	O	
5	that	O	
6	Cbl	B	
7	,	O	
8	the	O	
9	120	O	
10	-	O	
11	kDa	O	
12	protein	O	
13	product	O	
14	of	O	
15	the	O	
16	c	B	
17	-	I	
18	cbl	I	
19	proto	I	
20	-	I	
21	oncogene	I	
22	,	O	
23	serves	O	
24	as	O	
25	a	O	
26	substrate	O	
27	of	O	
28	a	O	
29	number	O	
30	of	O	
31	receptor	B	
32	-	I	
33	coupled	I	
34	tyrosine	I	
35	kinases	I	
36	and	O	
37	forms	O	
38	complexes	O	
39	with	O	
40	SH3	B	
41	and	O	
42	SH2	B	
43	domain	O	
44	-	O	
45	containing	O	
46	proteins	O	
47	,	O	
48	pointing	O	
49	to	O	
50	its	O	
51	role	O	
52	in	O	
53	signal	O	
54	transduction	O	
55	.	O	

1	Moreover	O	
2	,	O	
3	LD50	O	
4	in	O	
5	mice	O	
6	of	O	
7	RP	O	
8	-	O	
9	170	O	
10	(	O	
11	4	O	
12	.	O	
13	3	O	
14	g	O	
15	/	O	
16	kg	O	
17	on	O	
18	i	O	
19	.	O	
20	v	O	
21	.)	O	
22	was	O	
23	increased	O	
24	to	O	
25	5	O	
26	.	O	
27	2	O	
28	g	O	
29	/	O	
30	kg	O	
31	by	O	
32	oral	O	
33	administration	O	
34	.	O	

1	Reverse	O	
2	transcription	O	
3	(	O	
4	RT	O	
5	)-	O	
6	PCR	O	
7	products	O	
8	were	O	
9	synthesized	O	
10	with	O	
11	two	O	
12	degenerate	O	
13	primers	O	
14	derived	O	
15	from	O	
16	the	O	
17	conserved	O	
18	motifs	O	
19	of	O	
20	various	O	
21	tyrosine	B	
22	kinases	I	
23	.	O	

1	Their	O	
2	hydropathic	O	
3	plots	O	
4	are	O	
5	very	O	
6	similar	O	
7	and	O	
8	both	O	
9	possess	O	
10	three	O	
11	hydrophobic	O	
12	segments	O	
13	that	O	
14	are	O	
15	likely	O	
16	alpha	O	
17	-	O	
18	helical	O	
19	transmembrane	O	
20	segments	O	
21	.	O	

1	Full	B	
2	-	I	
3	length	I	
4	AT	I	
5	-	I	
6	PHH1	I	
7	,	O	
8	and	O	
9	both	O	
10	AT	B	
11	-	I	
12	PHH1	I	
13	and	O	
14	AT	B	
15	-	I	
16	PHH1	I	
17	delta	I	
18	C	I	
19	-	I	
20	513	I	
21	(	O	
22	truncated	O	
23	to	O	
24	be	O	
25	approximately	O	
26	the	O	
27	size	O	
28	of	O	
29	microbial	B	
30	photolyase	I	
31	genes	I	
32	)	O	
33	cDNAs	O	
34	,	O	
35	were	O	
36	overexpressed	O	
37	,	O	
38	respectively	O	
39	,	O	
40	in	O	
41	yeast	O	
42	and	O	
43	Escherichia	O	
44	coli	O	
45	mutants	O	
46	hypersensitive	O	
47	to	O	
48	ultraviolet	O	
49	light	O	
50	.	O	

1	Over	O	
2	-	O	
3	expression	O	
4	of	O	
5	Azf1p	B	
6	in	O	
7	the	O	
8	yeast	O	
9	cell	O	
10	does	O	
11	not	O	
12	influence	O	
13	the	O	
14	expression	O	
15	level	O	
16	of	O	
17	the	O	
18	mitochondrial	B	
19	transcription	I	
20	factor	I	
21	Mtf1p	I	
22	,	O	
23	indicating	O	
24	that	O	
25	the	O	
26	influence	O	
27	of	O	
28	Azf1p	B	
29	on	O	
30	the	O	
31	suppression	O	
32	of	O	
33	the	O	
34	special	O	
35	mitochondrial	B	
36	RNA	I	
37	polymerase	I	
38	mutant	I	
39	is	O	
40	an	O	
41	indirect	O	
42	one	O	
43	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	overproduction	O	
5	of	O	
6	Der3p	B	
7	is	O	
8	lethal	O	
9	in	O	
10	a	O	
11	sec61	B	
12	-	I	
13	2	I	
14	strain	O	
15	at	O	
16	the	O	
17	permissive	O	
18	temperature	O	
19	of	O	
20	25	O	
21	degrees	O	
22	C	O	
23	.	O	

1	The	O	
2	minimum	O	
3	and	O	
4	essential	O	
5	subunits	O	
6	for	O	
7	RNA	O	
8	synthesis	O	
9	have	O	
10	not	O	
11	yet	O	
12	been	O	
13	identified	O	
14	.	O	

1	Ent	B	
2	-	I	
3	kaurene	I	
4	synthase	I	
5	from	I	
6	the	I	
7	fungus	I	
8	Phaeosphaeria	I	
9	sp	O	
10	.	O	

1	Furthermore	O	
2	,	O	
3	a	O	
4	p21X	B	
5	protein	I	
6	lacking	O	
7	the	O	
8	N	O	
9	-	O	
10	terminus	O	
11	of	O	
12	Rex1	B	
13	was	O	
14	expressed	O	
15	at	O	
16	high	O	
17	levels	O	
18	;	O	
19	our	O	
20	data	O	
21	indicate	O	
22	that	O	
23	p21X	B	
24	is	O	
25	translated	O	
26	from	O	
27	the	O	
28	1	O	
29	.	O	
30	6	O	
31	-	O	
32	kb	O	
33	mRNA	O	
34	which	O	
35	is	O	
36	derived	O	
37	primarily	O	
38	from	O	
39	deleted	O	
40	proviruses	O	
41	.	O	

1	Diagnosis	O	
2	and	O	
3	differential	O	
4	diagnosis	O	

1	CCAAT	B	
2	displacement	I	
3	protein	I	
4	binds	O	
5	to	O	
6	and	O	
7	negatively	O	
8	regulates	O	
9	human	O	
10	papillomavirus	O	
11	type	O	
12	6	O	
13	E6	B	
14	,	O	
15	E7	B	
16	,	O	
17	and	O	
18	E1	B	
19	promoters	O	
20	.	O	

1	The	O	
2	husband	O	
3	in	O	
4	one	O	
5	of	O	
6	the	O	
7	married	O	
8	couples	O	
9	was	O	
10	treated	O	
11	for	O	
12	hepatitis	O	
13	of	O	
14	unidentified	O	
15	etiology	O	
16	in	O	
17	an	O	
18	Infectology	O	
19	Department	O	
20	four	O	
21	years	O	
22	ago	O	
23	.	O	

1	Two	O	
2	other	O	
3	patients	O	
4	underwent	O	
5	PRFR	O	
6	.	O	

1	Unfolding	O	
2	can	O	
3	be	O	
4	described	O	
5	by	O	
6	a	O	
7	two	O	
8	-	O	
9	state	O	
10	process	O	
11	since	O	
12	a	O	
13	ratio	O	
14	of	O	
15	delta	O	
16	Hcalorimetric	O	
17	to	O	
18	delta	O	
19	Hvan	O	
20	'	O	
21	t	O	
22	Hoff	O	
23	equals	O	
24	0	O	
25	.	O	
26	96	O	
27	.	O	

1	BiP670	B	
2	retains	O	
3	basal	O	
4	and	O	
5	Ca2	O	
6	+	O	
7	ionophore	O	
8	A23187	O	
9	-	O	
10	inducible	O	
11	activities	O	
12	.	O	

1	The	O	
2	same	O	
3	ligands	O	
4	also	O	
5	exhibit	O	
6	a	O	
7	similar	O	
8	inhibitory	O	
9	effect	O	
10	on	O	
11	PDGF	B	
12	-	I	
13	BB	I	
14	-	O	
15	dependent	O	
16	[	O	
17	3H	O	
18	]	O	
19	thymidine	O	
20	incorporation	O	
21	in	O	
22	PAE	O	
23	cells	O	
24	expressing	O	
25	the	O	
26	PDGF	B	
27	beta	I	
28	-	I	
29	receptors	I	
30	.	O	

1	The	O	
2	fragments	O	
3	are	O	
4	separated	O	
5	and	O	
6	directly	O	
7	sized	O	
8	by	O	
9	agarose	O	
10	gel	O	
11	electrophoresis	O	
12	.	O	

1	The	O	
2	similar	O	
3	phenotypes	O	
4	of	O	
5	bur6	B	
6	and	O	
7	bur3	B	
8	(	O	
9	mot1	B	
10	)	O	
11	mutations	O	
12	suggest	O	
13	that	O	
14	Bur6p	B	
15	and	O	
16	Mot1p	B	
17	have	O	
18	related	O	
19	,	O	
20	but	O	
21	not	O	
22	identical	O	
23	,	O	
24	functions	O	
25	in	O	
26	modulating	O	
27	the	O	
28	activity	O	
29	of	O	
30	the	O	
31	general	O	
32	transcription	O	
33	machinery	O	
34	in	O	
35	vivo	O	
36	.	O	

1	The	O	
2	structural	O	
3	changes	O	
4	in	O	
5	intra	O	
6	-	O	
7	acinar	O	
8	artery	O	
9	manifested	O	
10	mainly	O	
11	by	O	
12	an	O	
13	increase	O	
14	in	O	
15	number	O	
16	of	O	
17	muscular	O	
18	artery	O	
19	resulting	O	
20	from	O	
21	muscularization	O	
22	of	O	
23	precursor	O	
24	cells	O	
25	(	O	
26	pericytes	O	
27	and	O	
28	intermediate	O	
29	cells	O	
30	)	O	
31	located	O	
32	within	O	
33	partially	O	
34	muscular	O	
35	and	O	
36	nonmuscular	O	
37	arterial	O	
38	wall	O	
39	to	O	
40	smooth	O	
41	muscle	O	
42	cell	O	
43	,	O	
44	and	O	
45	by	O	
46	the	O	
47	medial	O	
48	wall	O	
49	thickened	O	
50	due	O	
51	to	O	
52	hypertrophy	O	
53	and	O	
54	hyperplasia	O	
55	of	O	
56	smooth	O	
57	muscle	O	
58	cells	O	
59	as	O	
60	well	O	
61	as	O	
62	accumulation	O	
63	of	O	
64	a	O	
65	large	O	
66	amount	O	
67	of	O	
68	collagen	B	
69	,	O	
70	especially	O	
71	the	O	
72	type	B	
73	1	I	
74	collagen	I	
75	.	O	

1	This	O	
2	coat	B	
3	protein	I	
4	consists	O	
5	of	O	
6	Sar1p	B	
7	,	O	
8	the	O	
9	Sec23p	B	
10	protein	I	
11	complex	I	
12	containing	O	
13	Sec23p	B	
14	and	O	
15	Sec24p	B	
16	,	O	
17	and	O	
18	the	O	
19	Sec13p	B	
20	protein	I	
21	complex	I	
22	containing	O	
23	Sec13p	B	
24	and	O	
25	a	O	
26	novel	O	
27	150	B	
28	-	I	
29	kDa	I	
30	protein	I	
31	,	I	
32	p150	I	
33	.	O	

1	The	O	
2	requirement	O	
3	of	O	
4	3	O	
5	'	O	
6	complementarity	O	
7	for	O	
8	a	O	
9	ligation	O	
10	reaction	O	
11	is	O	
12	reaffirmed	O	
13	by	O	
14	results	O	
15	from	O	
16	1	O	
17	nt	O	
18	insertions	O	
19	on	O	
20	either	O	
21	the	O	
22	3	O	
23	'-	O	
24	or	O	
25	5	O	
26	'-	O	
27	side	O	
28	of	O	
29	the	O	
30	nick	O	
31	.	O	

1	An	O	
2	examination	O	
3	of	O	
4	the	O	
5	properties	O	
6	of	O	
7	sequences	O	
8	surrounding	O	
9	ARS1	O	
10	left	O	
11	open	O	
12	the	O	
13	possibility	O	
14	that	O	
15	ABFI	B	
16	enhances	O	
17	the	O	
18	initiation	O	
19	of	O	
20	DNA	O	
21	replication	O	
22	at	O	
23	ARS1	O	
24	by	O	
25	transcriptional	O	
26	activation	O	
27	.	O	

1	All	O	
2	lambs	O	
3	with	O	
4	B	O	
5	breeding	O	
6	had	O	
7	significantly	O	
8	higher	O	
9	Hb	B	
10	levels	O	
11	at	O	
12	the	O	
13	end	O	
14	of	O	
15	the	O	
16	experiment	O	
17	than	O	
18	did	O	
19	NB	O	
20	lambs	O	
21	.	O	
22	b	O	
23	and	O	
24	S	O	
25	x	O	
26	B	O	
27	lambs	O	
28	had	O	
29	higher	O	
30	(	O	
31	P	O	
32	<	O	
33	.	O	
34	05	O	
35	)	O	
36	Hb	B	
37	levels	O	
38	than	O	
39	the	O	
40	D	O	
41	x	O	
42	B	O	
43	lambs	O	
44	,	O	
45	and	O	
46	B	O	
47	lambs	O	
48	had	O	
49	the	O	
50	highest	O	
51	(	O	
52	P	O	
53	<	O	
54	.	O	
55	05	O	
56	)	O	
57	mean	O	
58	corpuscular	O	
59	hemoglobin	B	
60	concentrations	O	
61	.	O	

1	Recombinant	B	
2	I	I	
3	-	I	
4	kappa	I	
5	B	I	
6	alpha	I	
7	inhibited	O	
8	kappa	B	
9	B	I	
10	motif	I	
11	binding	O	
12	by	O	
13	nuclear	B	
14	factor	I	
15	-	I	
16	kappa	I	
17	B1	I	
18	,	O	
19	RelA	B	
20	,	O	
21	and	O	
22	c	B	
23	-	I	
24	Rel	I	
25	as	O	
26	indicated	O	
27	by	O	
28	studies	O	
29	using	O	
30	UV	O	
31	radiation	O	
32	-	O	
33	induced	O	
34	covalent	O	
35	cross	O	
36	-	O	
37	linking	O	
38	to	O	
39	a	O	
40	bromodeoxyuridine	O	
41	-	O	
42	substituted	O	
43	kappa	B	
44	B	I	
45	oligonucleotide	I	
46	.	O	

1	CONCLUSION	O	
2	:	O	
3	These	O	
4	findings	O	
5	imply	O	
6	that	O	
7	eotaxin	O	
8	either	O	
9	is	O	
10	mechanistically	O	
11	involved	O	
12	in	O	
13	acute	O	
14	asthma	O	
15	or	O	
16	serves	O	
17	as	O	
18	a	O	
19	biomarker	O	
20	for	O	
21	activity	O	
22	of	O	
23	the	O	
24	CCR3	B	
25	receptor	I	
26	ligand	I	
27	system	O	
28	,	O	
29	which	O	
30	is	O	
31	functionally	O	
32	linked	O	
33	to	O	
34	asthma	O	
35	.	O	

1	To	O	
2	assess	O	
3	the	O	
4	health	O	
5	significance	O	
6	of	O	
7	the	O	
8	early	O	
9	renal	O	
10	changes	O	
11	after	O	
12	chronic	O	
13	exposure	O	
14	to	O	
15	cadmium	O	
16	,	O	
17	23	O	
18	workers	O	
19	removed	O	
20	from	O	
21	exposure	O	
22	because	O	
23	of	O	
24	the	O	
25	discovery	O	
26	of	O	
27	an	O	
28	increased	O	
29	urinary	O	
30	excretion	O	
31	of	O	
32	beta	B	
33	2	I	
34	-	I	
35	microglobulin	I	
36	or	O	
37	retinol	B	
38	binding	I	
39	protein	I	
40	,	O	
41	or	O	
42	both	O	
43	,	O	
44	have	O	
45	been	O	
46	examined	O	
47	once	O	
48	a	O	
49	year	O	
50	for	O	
51	five	O	
52	years	O	
53	.	O	

1	A	O	
2	third	O	
3	ORF	O	
4	,	O	
5	ORF5	O	
6	,	O	
7	shows	O	
8	homology	O	
9	with	O	
10	gene	B	
11	agrB	I	
12	from	O	
13	Staphylococcus	O	
14	aureus	O	
15	,	O	
16	which	O	
17	is	O	
18	involved	O	
19	in	O	
20	the	O	
21	mechanism	O	
22	of	O	
23	regulation	O	
24	of	O	
25	the	O	
26	virulence	O	
27	phenotype	O	
28	in	O	
29	this	O	
30	species	O	
31	.	O	

1	This	O	
2	article	O	
3	will	O	
4	briefly	O	
5	review	O	
6	the	O	
7	published	O	
8	data	O	
9	on	O	
10	the	O	
11	morphology	O	
12	,	O	
13	function	O	
14	,	O	
15	and	O	
16	biochemistry	O	
17	of	O	
18	the	O	
19	normal	O	
20	renal	O	
21	medulla	O	
22	and	O	
23	the	O	
24	pathology	O	
25	associated	O	
26	with	O	
27	RPN	O	
28	,	O	
29	together	O	
30	with	O	
31	the	O	
32	secondary	O	
33	changes	O	
34	which	O	
35	give	O	
36	rise	O	
37	to	O	
38	cortical	O	
39	degeneration	O	
40	or	O	
41	epithelial	O	
42	carcinoma	O	
43	.	O	

1	Oleate	O	
2	induced	O	
3	steady	O	
4	-	O	
5	state	O	
6	levels	O	
7	of	O	
8	M	B	
9	-	I	
10	CPT	I	
11	I	I	
12	mRNA	I	
13	4	O	
14	.	O	
15	5	O	
16	-	O	
17	fold	O	
18	.	O	

1	Angiotensin	B	
2	II	I	
3	induces	O	
4	nuclear	B	
5	factor	I	
6	(	I	
7	NF	I	
8	)-	I	
9	kappaB1	I	
10	isoforms	I	
11	to	O	
12	bind	O	
13	the	O	
14	angiotensinogen	B	
15	gene	I	
16	acute	O	
17	-	O	
18	phase	O	
19	response	O	
20	element	O	
21	:	O	
22	a	O	
23	stimulus	O	
24	-	O	
25	specific	O	
26	pathway	O	
27	for	O	
28	NF	B	
29	-	I	
30	kappaB	I	
31	activation	O	
32	.	O	

1	A	O	
2	control	O	
3	group	O	
4	of	O	
5	nine	O	
6	women	O	
7	(	O	
8	age	O	
9	23	O	
10	-	O	
11	40	O	
12	years	O	
13	)	O	
14	on	O	
15	oral	O	
16	contraceptives	O	
17	(	O	
18	Nordette	O	
19	-	O	
20	28	O	
21	)	O	
22	was	O	
23	also	O	
24	studied	O	
25	four	O	
26	times	O	
27	during	O	
28	a	O	
29	pill	O	
30	cycle	O	
31	.	O	

1	In	O	
2	a	O	
3	reconstituted	O	
4	human	O	
5	DNA	O	
6	repair	O	
7	system	O	
8	containing	O	
9	DNA	B	
10	polymerase	I	
11	beta	I	
12	and	O	
13	DNA	B	
14	ligase	I	
15	III	I	
16	-	O	
17	XRCC1	B	
18	,	O	
19	accurate	O	
20	rejoining	O	
21	of	O	
22	a	O	
23	3	O	
24	'	O	
25	mismatched	O	
26	base	O	
27	residue	O	
28	at	O	
29	a	O	
30	single	O	
31	-	O	
32	strand	O	
33	break	O	
34	is	O	
35	dependent	O	
36	on	O	
37	addition	O	
38	of	O	
39	the	O	
40	exonuclease	O	
41	.	O	

1	Femoral	O	
2	strain	O	
3	adaptation	O	
4	after	O	
5	total	O	
6	hip	O	
7	replacement	O	
8	:	O	
9	a	O	
10	comparison	O	
11	of	O	
12	cemented	O	
13	and	O	
14	porous	O	
15	ingrowth	O	
16	components	O	
17	in	O	
18	canines	O	
19	.	O	

1	The	O	
2	equivalent	O	
3	of	O	
4	the	O	
5	third	O	
6	ligand	O	
7	,	O	
8	H	O	
9	-	O	
10	87	O	
11	,	O	
12	is	O	
13	T	O	
14	-	O	
15	47	O	
16	in	O	
17	the	O	
18	PSTAIRE	O	
19	sequence	O	
20	motif	O	
21	.	O	

1	Two	O	
2	such	O	
3	genes	O	
4	,	O	
5	designated	O	
6	hsiggll150	B	
7	and	O	
8	hsiggll295	B	
9	,	O	
10	were	O	
11	cloned	O	
12	and	O	
13	sequenced	O	
14	from	O	
15	genomic	O	
16	DNA	O	
17	.	O	

1	RNase	B	
2	MRP	I	
3	is	O	
4	a	O	
5	ribonucleoprotein	O	
6	endoribonuclease	O	
7	that	O	
8	has	O	
9	been	O	
10	shown	O	
11	to	O	
12	have	O	
13	roles	O	
14	in	O	
15	both	O	
16	mitochondrial	O	
17	DNA	O	
18	replication	O	
19	and	O	
20	nuclear	B	
21	5	I	
22	.	I	
23	8S	I	
24	rRNA	I	
25	processing	O	
26	.	O	

1	This	O	
2	structure	O	
3	interconnects	O	
4	specific	O	
5	triplets	O	
6	of	O	
7	the	O	
8	basal	O	
9	bodies	O	
10	with	O	
11	the	O	
12	microtubular	O	
13	bundles	O	
14	that	O	
15	emerge	O	
16	from	O	
17	the	O	
18	basal	O	
19	apparatus	O	
20	.	O	

1	Specific	O	
2	class	B	
3	I	I	
4	and	I	
5	II	I	
6	histone	I	
7	deacetylases	I	
8	(	O	
9	HDACs	B	
10	)	O	
11	interact	O	
12	in	O	
13	vivo	O	
14	with	O	
15	BCoR	B	
16	,	O	
17	suggesting	O	
18	that	O	
19	BCoR	B	
20	may	O	
21	functionally	O	
22	link	O	
23	these	O	
24	two	O	
25	classes	O	
26	of	O	
27	HDACs	B	
28	.	O	

1	These	O	
2	results	O	
3	support	O	
4	the	O	
5	view	O	
6	that	O	
7	clonidine	O	
8	and	O	
9	6	O	
10	-	O	
11	OHDA	O	
12	,	O	
13	but	O	
14	not	O	
15	alpha	O	
16	-	O	
17	MD	O	
18	,	O	
19	have	O	
20	central	O	
21	pressor	O	
22	actions	O	
23	in	O	
24	the	O	
25	rat	O	
26	that	O	
27	oppose	O	
28	their	O	
29	antihypertensive	O	
30	action	O	
31	.	O	

1	This	O	
2	result	O	
3	indicates	O	
4	that	O	
5	separate	O	
6	complexes	O	
7	exist	O	
8	containing	O	
9	ankyrin	B	
10	and	O	
11	fodrin	B	
12	with	O	
13	either	O	
14	uvomorulin	B	
15	or	O	
16	Na	B	
17	+,	I	
18	K	I	
19	+-	I	
20	ATPase	I	
21	.	O	

1	UF	O	
2	-	O	
3	021	O	
4	ophthalmic	O	
5	solution	O	
6	(	O	
7	0	O	
8	.	O	
9	03	O	
10	to	O	
11	0	O	
12	.	O	
13	24	O	
14	%),	O	
15	when	O	
16	topically	O	
17	applied	O	
18	to	O	
19	the	O	
20	eyes	O	
21	of	O	
22	rabbits	O	
23	,	O	
24	caused	O	
25	dose	O	
26	-	O	
27	dependent	O	
28	IOP	O	
29	reduction	O	
30	(	O	
31	2	O	
32	.	O	
33	8	O	
34	to	O	
35	5	O	
36	.	O	
37	2	O	
38	mmHg	O	
39	),	O	
40	without	O	
41	transient	O	
42	IOP	O	
43	rise	O	
44	.	O	

1	XII	O	
2	.	O	

1	The	O	
2	DHEAS	O	
3	levels	O	
4	in	O	
5	all	O	
6	stages	O	
7	of	O	
8	decreased	O	
9	BMD	O	
10	were	O	
11	significantly	O	
12	lower	O	
13	than	O	
14	those	O	
15	in	O	
16	the	O	
17	group	O	
18	with	O	
19	normal	O	
20	BMD	O	
21	.	O	

1	Results	O	
2	of	O	
3	this	O	
4	study	O	
5	indicate	O	
6	that	O	
7	GLC	O	
8	of	O	
9	short	O	
10	chain	O	
11	fatty	O	
12	acids	O	
13	produced	O	
14	on	O	
15	agar	O	
16	medium	O	
17	by	O	
18	anaerobes	O	
19	,	O	
20	combined	O	
21	with	O	
22	simple	O	
23	tests	O	
24	such	O	
25	as	O	
26	Gram	O	
27	'	O	
28	s	O	
29	stain	O	
30	and	O	
31	colonial	O	
32	morphology	O	
33	,	O	
34	may	O	
35	allow	O	
36	fir	O	
37	direct	O	
38	presumptive	O	
39	genus	O	
40	identification	O	
41	from	O	
42	an	O	
43	initial	O	
44	pure	O	
45	agar	O	
46	culture	O	
47	.	O	

1	RNase	B	
2	protection	O	
3	experiments	O	
4	confirmed	O	
5	the	O	
6	presence	O	
7	of	O	
8	the	O	
9	GHR1	B	
10	-	I	
11	279	I	
12	variant	I	
13	in	O	
14	IM	O	
15	-	O	
16	9	O	
17	cells	O	
18	and	O	
19	human	O	
20	liver	O	
21	.	O	

1	Transcription	O	
2	factors	O	
3	containing	O	
4	a	O	
5	basic	O	
6	helix	O	
7	-	O	
8	loop	O	
9	-	O	
10	helix	O	
11	(	O	
12	bHLH	O	
13	)	O	
14	motif	O	
15	regulate	O	
16	the	O	
17	expression	O	
18	of	O	
19	tissue	O	
20	-	O	
21	specific	O	
22	genes	O	
23	in	O	
24	a	O	
25	number	O	
26	of	O	
27	mammalian	O	
28	and	O	
29	insect	O	
30	systems	O	
31	.	O	

1	The	O	
2	survival	O	
3	in	O	
4	the	O	
5	case	O	
6	of	O	
7	these	O	
8	patients	O	
9	was	O	
10	studied	O	
11	five	O	
12	years	O	
13	later	O	
14	.	O	

1	Double	O	
2	-	O	
3	blind	O	
4	,	O	
5	placebo	O	
6	-	O	
7	controlled	O	
8	trial	O	
9	.	O	

1	The	O	
2	method	O	
3	has	O	
4	been	O	
5	satisfactorily	O	
6	applied	O	
7	to	O	
8	the	O	
9	determination	O	
10	of	O	
11	paracetamol	O	
12	in	O	
13	pharmaceutical	O	
14	formulations	O	
15	and	O	
16	biological	O	
17	fluids	O	
18	.	O	

1	This	O	
2	study	O	
3	was	O	
4	performed	O	
5	to	O	
6	assess	O	
7	the	O	
8	role	O	
9	of	O	
10	additional	O	
11	diagnostic	O	
12	laparoscopy	O	
13	in	O	
14	the	O	
15	preoperative	O	
16	staging	O	
17	of	O	
18	patients	O	
19	with	O	
20	adenocarcinoma	O	
21	of	O	
22	the	O	
23	esophagus	O	
24	,	O	
25	gastric	O	
26	cancer	O	
27	and	O	
28	pancreatic	O	
29	cancer	O	
30	prior	O	
31	to	O	
32	intended	O	
33	curative	O	
34	surgery	O	
35	.	O	

1	Typical	O	
2	configurations	O	
3	of	O	
4	psychosocial	O	
5	stress	O	
6	factors	O	
7	of	O	
8	psychiatrically	O	
9	conspicuous	O	
10	children	O	
11	and	O	
12	adolescents	O	

1	MEF	B	
2	and	O	
3	AML1B	B	
4	synergistically	O	
5	transactivated	O	
6	an	O	
7	interleukin	B	
8	3	I	
9	promoter	I	
10	reporter	I	
11	gene	I	
12	construct	I	
13	,	O	
14	yet	O	
15	the	O	
16	activating	O	
17	activity	O	
18	of	O	
19	MEF	B	
20	was	O	
21	abolished	O	
22	when	O	
23	MEF	B	
24	was	O	
25	coexpressed	O	
26	with	O	
27	AML1	B	
28	/	O	
29	ETO	B	
30	.	O	

1	The	O	
2	nucleotide	O	
3	sequence	O	
4	of	O	
5	the	O	
6	chloroplast	O	
7	(	O	
8	cp	O	
9	)	O	
10	DNA	O	
11	from	O	
12	maize	O	
13	(	O	
14	Zea	O	
15	mays	O	
16	)	O	
17	has	O	
18	been	O	
19	completed	O	
20	.	O	

1	A	O	
2	suspected	O	
3	hypothalamic	O	
4	dysfunction	O	
5	and	O	
6	a	O	
7	slightly	O	
8	impaired	O	
9	pituitary	O	
10	function	O	
11	manifested	O	
12	as	O	
13	GH	B	
14	deficiency	O	
15	were	O	
16	their	O	
17	common	O	
18	endocrinological	O	
19	features	O	
20	.	O	

1	Gtx	B	
2	mRNA	I	
3	accumulates	O	
4	in	O	
5	parallel	O	
6	with	O	
7	the	O	
8	RNAs	O	
9	encoding	O	
10	the	O	
11	major	O	
12	structural	O	
13	proteins	O	
14	of	O	
15	myelin	O	
16	,	O	
17	myelin	B	
18	basic	I	
19	protein	I	
20	(	O	
21	MBP	B	
22	),	O	
23	and	O	
24	proteolipid	B	
25	protein	I	
26	(	O	
27	PLP	B	
28	)	O	
29	during	O	
30	postnatal	O	
31	brain	O	
32	development	O	
33	;	O	
34	Gtx	B	
35	mRNA	I	
36	decreases	O	
37	in	O	
38	parallel	O	
39	with	O	
40	MBP	B	
41	and	O	
42	PLP	B	
43	mRNAs	I	
44	in	O	
45	the	O	
46	brains	O	
47	of	O	
48	myelin	O	
49	-	O	
50	deficient	O	
51	rats	O	
52	,	O	
53	which	O	
54	have	O	
55	a	O	
56	point	O	
57	mutation	O	
58	in	O	
59	the	O	
60	PLP	B	
61	gene	I	
62	.	O	

1	To	O	
2	determine	O	
3	whether	O	
4	mononuclear	O	
5	cell	O	
6	secretory	O	
7	products	O	
8	contribute	O	
9	to	O	
10	the	O	
11	changes	O	
12	in	O	
13	bone	O	
14	turnover	O	
15	that	O	
16	characterize	O	
17	the	O	
18	development	O	
19	of	O	
20	postmenopausal	O	
21	osteoporosis	O	
22	,	O	
23	we	O	
24	evaluated	O	
25	the	O	
26	effects	O	
27	of	O	
28	oophorectomy	O	
29	and	O	
30	subsequent	O	
31	estrogen	O	
32	replacement	O	
33	on	O	
34	the	O	
35	spontaneous	O	
36	secretion	O	
37	of	O	
38	interleukin	B	
39	1	I	
40	(	O	
41	IL	B	
42	-	I	
43	1	I	
44	)	O	
45	and	O	
46	tumor	B	
47	necrosis	I	
48	factor	I	
49	alpha	I	
50	(	O	
51	TNF	B	
52	-	I	
53	alpha	I	
54	)	O	
55	and	O	
56	on	O	
57	the	O	
58	phytohemagglutinin	B	
59	A	I	
60	-	O	
61	induced	O	
62	secretion	O	
63	of	O	
64	granulocyte	B	
65	-	I	
66	macrophage	I	
67	colony	I	
68	-	I	
69	stimulating	I	
70	factor	I	
71	(	O	
72	GM	B	
73	-	I	
74	CSF	I	
75	)	O	
76	from	O	
77	peripheral	O	
78	blood	O	
79	mononuclear	O	
80	cells	O	
81	.	O	

1	The	O	
2	effects	O	
3	of	O	
4	taloximine	O	
5	and	O	
6	aminophylline	O	
7	on	O	
8	isolated	O	
9	human	O	
10	smooth	O	
11	muscle	O	
12	.	O	

1	Oestrogen	O	
2	implant	O	
3	overdose	O	
4	.	O	

1	METHODS	O	
2	:	O	
3	Twenty	O	
4	-	O	
5	two	O	
6	patients	O	
7	were	O	
8	grouped	O	
9	according	O	
10	to	O	
11	their	O	
12	etiology	O	
13	based	O	
14	on	O	
15	the	O	
16	study	O	
17	of	O	
18	antiadrenal	O	
19	antibodies	O	
20	at	O	
21	diagnosis	O	
22	of	O	
23	the	O	
24	disease	O	
25	:	O	
26	7	O	
27	were	O	
28	positive	O	
29	(	O	
30	autoimmune	O	
31	etiology	O	
32	or	O	
33	EAA	O	
34	),	O	
35	11	O	
36	were	O	
37	negative	O	
38	(	O	
39	tuberculous	O	
40	etiology	O	
41	or	O	
42	EAT	O	
43	)	O	
44	and	O	
45	in	O	
46	four	O	
47	serologic	O	
48	study	O	
49	was	O	
50	not	O	
51	available	O	
52	(	O	
53	undetermined	O	
54	etiology	O	
55	or	O	
56	EAI	O	
57	).	O	

1	Processing	O	
2	of	O	
3	the	O	
4	polycistronic	O	
5	precursor	O	
6	requires	O	
7	nucleases	O	
8	also	O	
9	involved	O	
10	in	O	
11	rRNA	O	
12	processing	O	
13	,	O	
14	i	O	
15	.	O	
16	e	O	
17	.,	O	
18	Rnt1p	B	
19	and	O	
20	Rat1p	B	
21	.	O	

1	Angionephroscintigraphy	O	
2	in	O	
3	the	O	
4	diagnosis	O	
5	of	O	
6	diseases	O	
7	of	O	
8	the	O	
9	kidney	O	

1	Calves	O	
2	fed	O	
3	MCT	O	
4	-	O	
5	milk	O	
6	had	O	
7	significantly	O	
8	lower	O	
9	blood	O	
10	cholesterol	O	
11	than	O	
12	calves	O	
13	fed	O	
14	T	O	
15	-	O	
16	or	O	
17	SBO	O	
18	-	O	
19	milk	O	
20	.	O	

1	The	O	
2	HOI	O	
3	induced	O	
4	a	O	
5	nearly	O	
6	fourfold	O	
7	increase	O	
8	in	O	
9	ANF	B	
10	in	O	
11	the	O	
12	elderly	O	
13	,	O	
14	whereas	O	
15	that	O	
16	for	O	
17	the	O	
18	young	O	
19	was	O	
20	threefold	O	
21	.	O	

1	Resistance	O	
2	training	O	
3	shifts	O	
4	the	O	
5	power	O	
6	curve	O	
7	in	O	
8	a	O	
9	positive	O	
10	direction	O	
11	when	O	
12	the	O	
13	measurements	O	
14	are	O	
15	determined	O	
16	with	O	
17	absolute	O	
18	loads	O	
19	,	O	
20	but	O	
21	the	O	
22	increased	O	
23	power	O	
24	may	O	
25	not	O	
26	be	O	
27	transferred	O	
28	to	O	
29	an	O	
30	absolute	O	
31	performance	O	
32	task	O	
33	like	O	
34	the	O	
35	SSP	O	
36	.	O	

1	At	O	
2	cuticular	O	
3	positions	O	
4	exhibiting	O	
5	the	O	
6	Brd	B	
7	bristle	I	
8	loss	I	
9	phenotype	I	
10	,	O	
11	we	O	
12	have	O	
13	found	O	
14	that	O	
15	the	O	
16	progeny	O	
17	of	O	
18	the	O	
19	multiplied	O	
20	SOPs	O	
21	develop	O	
22	aberrantly	O	
23	,	O	
24	in	O	
25	that	O	
26	neurons	O	
27	and	O	
28	thecogen	O	
29	(	O	
30	sheath	O	
31	)	O	
32	cells	O	
33	appear	O	
34	but	O	
35	not	O	
36	trichogen	O	
37	(	O	
38	shaft	O	
39	)	O	
40	and	O	
41	tormogen	O	
42	(	O	
43	socket	O	
44	)	O	
45	cells	O	
46	.	O	

1	Likewise	O	
2	,	O	
3	at	O	
4	150	O	
5	degrees	O	
6	C	O	
7	with	O	
8	2	O	
9	%	O	
10	APS	O	
11	the	O	
12	surface	O	
13	density	O	
14	of	O	
15	NH2	O	
16	groups	O	
17	reached	O	
18	a	O	
19	maximum	O	
20	at	O	
21	24	O	
22	hr	O	
23	and	O	
24	remained	O	
25	relatively	O	
26	constant	O	
27	up	O	
28	to	O	
29	96	O	
30	hr	O	
31	.	O	

1	None	O	
2	of	O	
3	the	O	
4	cystometrograms	O	
5	showed	O	
6	uninhibited	O	
7	detrusor	O	
8	contractions	O	
9	.	O	

1	Factors	O	
2	influencing	O	
3	in	O	
4	vitro	O	
5	skin	B	
6	permeability	I	
7	factor	I	
8	production	O	
9	by	O	
10	Vibrio	O	
11	cholerae	O	
12	.	O	

1	It	O	
2	is	O	
3	largely	O	
4	predicted	O	
5	by	O	
6	lupus	O	
7	anticoagulant	O	
8	(	O	
9	estimated	O	
10	by	O	
11	activated	O	
12	partial	O	
13	thromboplastin	B	
14	time	O	
15	)	O	
16	and	O	
17	/	O	
18	or	O	
19	antibody	O	
20	to	O	
21	cardiolipin	O	
22	.	O	

1	Management	O	
2	often	O	
3	involves	O	
4	beta	O	
5	-	O	
6	and	O	
7	calcium	O	
8	channel	O	
9	blocking	O	
10	drugs	O	
11	or	O	
12	type	O	
13	IC	O	
14	antiarrhythmic	O	
15	drugs	O	
16	.	O	

1	Deadenylation	O	
2	and	O	
3	decay	O	
4	of	O	
5	beta	B	
6	-	I	
7	globin	I	
8	mRNA	I	
9	in	O	
10	K562	O	
11	cells	O	
12	is	O	
13	extraordinarily	O	
14	slow	O	
15	compared	O	
16	with	O	
17	NIH	O	
18	3T3	O	
19	cells	O	
20	,	O	
21	suggesting	O	
22	that	O	
23	the	O	
24	increased	O	
25	stability	O	
26	gained	O	
27	by	O	
28	beta	B	
29	-	I	
30	globin	I	
31	mRNA	I	
32	in	O	
33	K562	O	
34	cells	O	
35	is	O	
36	mainly	O	
37	controlled	O	
38	at	O	
39	the	O	
40	deadenylation	O	
41	step	O	
42	.	O	

1	Is	O	
2	criticism	O	
3	of	O	
4	patient	O	
5	care	O	
6	justified	O	
7	and	O	
8	does	O	
9	it	O	
10	have	O	
11	educational	O	
12	value	O	
13	?	O	
14	Patients	O	
15	'	O	
16	criticism	O	
17	contributes	O	
18	to	O	
19	improved	O	
20	patient	O	
21	care	O	

1	Responses	O	
2	to	O	
3	the	O	
4	Plowright	O	
5	Rinderpest	O	
6	vaccine	O	
7	by	O	
8	43	O	
9	calves	O	
10	and	O	
11	70	O	
12	adult	O	
13	cattle	O	
14	in	O	
15	Uganda	O	
16	in	O	
17	1990	O	
18	,	O	
19	through	O	
20	the	O	
21	production	O	
22	of	O	
23	IgG	B	
24	antibodies	I	
25	,	O	
26	were	O	
27	monitored	O	
28	for	O	
29	4	O	
30	weeks	O	
31	using	O	
32	the	O	
33	ELISA	O	
34	assay	O	
35	.	O	

1	Interferon	B	
2	-	I	
3	alpha	I	
4	may	O	
5	exacerbate	O	
6	cryoblobulinemia	O	
7	-	O	
8	related	O	
9	ischemic	O	
10	manifestations	O	
11	:	O	
12	an	O	
13	adverse	O	
14	effect	O	
15	potentially	O	
16	related	O	
17	to	O	
18	its	O	
19	anti	O	
20	-	O	
21	angiogenic	O	
22	activity	O	
23	.	O	

1	Composites	O	
2	as	O	
3	restoration	O	
4	materials	O	

1	Northern	O	
2	blot	O	
3	analysis	O	
4	of	O	
5	LeMT	B	
6	(	I	
7	A	I	
8	)	I	
9	and	O	
10	LeMT	B	
11	(	I	
12	B	I	
13	)	I	
14	showed	O	
15	that	O	
16	transcripts	O	
17	of	O	
18	both	O	
19	MT	B	
20	-	I	
21	like	I	
22	genes	I	
23	were	O	
24	more	O	
25	abundant	O	
26	in	O	
27	leaves	O	
28	than	O	
29	roots	O	
30	in	O	
31	tomato	O	
32	plants	O	
33	grown	O	
34	without	O	
35	addition	O	
36	of	O	
37	extra	O	
38	metal	O	
39	ions	O	
40	,	O	
41	a	O	
42	characteristic	O	
43	of	O	
44	type	B	
45	II	I	
46	MTs	I	
47	.	O	

1	The	O	
2	maximum	O	
3	induction	O	
4	of	O	
5	ACC	B	
6	-	I	
7	oxidase	I	
8	transcripts	I	
9	occurred	O	
10	at	O	
11	about	O	
12	6	O	
13	h	O	
14	after	O	
15	excision	O	
16	,	O	
17	while	O	
18	the	O	
19	maximum	O	
20	enzyme	O	
21	activity	O	
22	was	O	
23	observed	O	
24	at	O	
25	24	O	
26	h	O	
27	.	O	

1	Method	O	
2	of	O	
3	synthesis	O	
4	of	O	
5	the	O	
6	rheumatoid	B	
7	factor	I	
8	in	O	
9	clinico	O	
10	-	O	
11	immunological	O	
12	studies	O	

1	We	O	
2	have	O	
3	now	O	
4	shown	O	
5	that	O	
6	in	O	
7	vivo	O	
8	phosphorylation	O	
9	of	O	
10	14	B	
11	-	I	
12	3	I	
13	-	I	
14	3	I	
15	zeta	I	
16	at	O	
17	the	O	
18	CKIalpha	B	
19	site	I	
20	(	I	
21	Thr	I	
22	-	I	
23	233	I	
24	)	I	
25	negatively	O	
26	regulates	O	
27	its	O	
28	binding	O	
29	to	O	
30	c	B	
31	-	I	
32	Raf	I	
33	,	O	
34	and	O	
35	may	O	
36	be	O	
37	important	O	
38	in	O	
39	Raf	B	
40	-	O	
41	mediated	O	
42	signal	O	
43	transduction	O	
44	.	O	

1	Amplification	O	
2	and	O	
3	overexpression	O	
4	of	O	
5	the	O	
6	c	B	
7	-	I	
8	erbB	I	
9	-	I	
10	2	I	
11	gene	I	
12	in	O	
13	21MT	O	
14	-	O	
15	2	O	
16	and	O	
17	21MT	O	
18	-	O	
19	1	O	
20	human	O	
21	breast	O	
22	carcinoma	O	
23	cells	O	
24	results	O	
25	in	O	
26	progressively	O	
27	elevated	O	
28	levels	O	
29	of	O	
30	constitutively	O	
31	tyrosine	B	
32	-	I	
33	phosphorylated	I	
34	p185erbB	I	
35	-	I	
36	2	I	
37	and	O	
38	is	O	
39	associated	O	
40	with	O	
41	progressive	O	
42	insulin	B	
43	-	I	
44	like	I	
45	growth	I	
46	factor	I	
47	(	O	
48	IGF	B	
49	)	O	
50	and	O	
51	combined	O	
52	IGF	B	
53	/	O	
54	epidermal	B	
55	growth	I	
56	factor	I	
57	(	O	
58	EGF	B	
59	)	O	
60	independence	O	
61	in	O	
62	culture	O	
63	.	O	

1	Botulinum	B	
2	toxin	I	
3	A	I	
4	in	O	
5	the	O	
6	treatment	O	
7	of	O	
8	hemiplegic	O	
9	spastic	O	
10	foot	O	
11	drop	O	
12	--	O	
13	clinical	O	
14	and	O	
15	functional	O	
16	outcomes	O	
17	.	O	

1	Efficacy	O	
2	and	O	
3	field	O	
4	evaluation	O	
5	of	O	
6	Bacillus	O	
7	thuringiensis	O	
8	(	O	
9	H	O	
10	-	O	
11	14	O	
12	)	O	
13	and	O	
14	B	O	
15	.	O	
16	sphaericus	O	
17	against	O	
18	floodwater	O	
19	mosquitoes	O	
20	in	O	
21	California	O	
22	.	O	

1	Its	O	
2	clinical	O	
3	and	O	
4	histopathologic	O	
5	characteristics	O	
6	.	O	

1	When	O	
2	comparing	O	
3	the	O	
4	barley	B	
5	PSI	I	
6	-	I	
7	K	I	
8	and	O	
9	PSI	B	
10	-	I	
11	G	I	
12	with	O	
13	the	O	
14	reported	O	
15	PSI	B	
16	-	I	
17	K	I	
18	sequence	I	
19	from	I	
20	Synechococcus	I	
21	vulcanus	I	
22	,	O	
23	the	O	
24	degree	O	
25	of	O	
26	similarity	O	
27	is	O	
28	equal	O	
29	,	O	
30	suggesting	O	
31	that	O	
32	an	O	
33	ancestral	O	
34	gene	O	
35	has	O	
36	been	O	
37	duplicated	O	
38	in	O	
39	a	O	
40	chloroplast	O	
41	progenitor	O	
42	but	O	
43	not	O	
44	in	O	
45	a	O	
46	cyanobacterial	O	
47	.	O	

1	In	O	
2	TNF	B	
3	-	O	
4	resistant	O	
5	T24	O	
6	bladder	O	
7	carcinoma	O	
8	cells	O	
9	,	O	
10	TNF	B	
11	failed	O	
12	to	O	
13	alter	O	
14	EGF	B	
15	-	I	
16	R	I	
17	tyrosine	I	
18	protein	I	
19	kinase	I	
20	activity	O	
21	although	O	
22	both	O	
23	EGF	B	
24	and	O	
25	phorbol	O	
26	ester	O	
27	were	O	
28	shown	O	
29	to	O	
30	modulate	O	
31	the	O	
32	enzymatic	O	
33	activity	O	
34	of	O	
35	the	O	
36	receptor	O	
37	in	O	
38	these	O	
39	cells	O	
40	.	O	

1	Consistent	O	
2	with	O	
3	this	O	
4	finding	O	
5	,	O	
6	wild	B	
7	-	I	
8	type	I	
9	SAGA	I	
10	inhibits	O	
11	TBP	B	
12	binding	O	
13	to	O	
14	the	O	
15	HIS3	B	
16	promoter	I	
17	in	O	
18	vitro	O	
19	,	O	
20	while	O	
21	SAGA	B	
22	lacking	O	
23	Spt3	B	
24	or	O	
25	Spt8	B	
26	is	O	
27	not	O	
28	inhibitory	O	
29	.	O	

1	Expression	O	
2	of	O	
3	six	O	
4	genes	O	
5	,	O	
6	ipaB	B	
7	,	O	
8	ipaC	B	
9	,	O	
10	invE	B	
11	,	O	
12	invG	B	
13	,	O	
14	invJ	B	
15	,	O	
16	and	O	
17	invK	B	
18	,	O	
19	was	O	
20	apparently	O	
21	regulated	O	
22	by	O	
23	the	O	
24	positive	O	
25	regulator	O	
26	virF	B	
27	.	O	

1	The	O	
2	elm1	B	
3	kinase	I	
4	functions	O	
5	in	O	
6	a	O	
7	mitotic	O	
8	signaling	O	
9	network	O	
10	in	O	
11	budding	O	
12	yeast	O	
13	.	O	

1	Regulation	O	
2	of	O	
3	Gax	B	
4	homeobox	I	
5	gene	I	
6	transcription	O	
7	by	O	
8	a	O	
9	combination	O	
10	of	O	
11	positive	O	
12	factors	O	
13	including	O	
14	myocyte	B	
15	-	I	
16	specific	I	
17	enhancer	I	
18	factor	I	
19	2	I	
20	.	O	

1	The	O	
2	C	O	
3	-	O	
4	terminal	O	
5	domains	O	
6	(	O	
7	CTDs	O	
8	)	O	
9	of	O	
10	the	O	
11	RPase	B	
12	beta	I	
13	subunit	I	
14	and	O	
15	DNA	B	
16	primase	I	
17	(	O	
18	dnaG	B	
19	protein	I	
20	)	O	
21	were	O	
22	not	O	
23	only	O	
24	strongly	O	
25	homologous	O	
26	to	O	
27	each	O	
28	other	O	
29	but	O	
30	also	O	
31	considerably	O	
32	homologous	O	
33	to	O	
34	the	O	
35	RPase	B	
36	alpha	I	
37	,	O	
38	suggesting	O	
39	that	O	
40	an	O	
41	alpha	O	
42	subunit	O	
43	-	O	
44	like	O	
45	enzyme	O	
46	must	O	
47	have	O	
48	been	O	
49	commonly	O	
50	ancestral	O	
51	to	O	
52	core	B	
53	enzyme	I	
54	subunits	I	
55	and	O	
56	primase	B	
57	.	O	

1	Although	O	
2	the	O	
3	effects	O	
4	of	O	
5	the	O	
6	calcium	O	
7	supplement	O	
8	or	O	
9	calcium	O	
10	antagonist	O	
11	alone	O	
12	were	O	
13	significant	O	
14	,	O	
15	such	O	
16	hypotensive	O	
17	responses	O	
18	were	O	
19	not	O	
20	optimal	O	
21	or	O	
22	predictable	O	
23	or	O	
24	clearly	O	
25	dose	O	
26	-	O	
27	dependent	O	
28	.	O	

1	Within	O	
2	12	O	
3	hours	O	
4	after	O	
5	MR	O	
6	tomography	O	
7	the	O	
8	patients	O	
9	were	O	
10	surgically	O	
11	explored	O	
12	,	O	
13	biopsied	O	
14	and	O	
15	if	O	
16	necessary	O	
17	orchiectomised	O	
18	.	O	

1	The	O	
2	mRNA	O	
3	expression	O	
4	of	O	
5	RFX1	B	
6	,	O	
7	RFX2	B	
8	,	O	
9	and	O	
10	RFX3	B	
11	was	O	
12	detected	O	
13	ubiquitously	O	
14	,	O	
15	but	O	
16	in	O	
17	transient	O	
18	-	O	
19	transfection	O	
20	assays	O	
21	,	O	
22	multimerized	B	
23	RFX	I	
24	binding	I	
25	sites	I	
26	in	O	
27	front	O	
28	of	O	
29	a	O	
30	basal	O	
31	promoter	O	
32	efficiently	O	
33	functioned	O	
34	in	O	
35	a	O	
36	tissue	O	
37	-	O	
38	and	O	
39	lineage	O	
40	-	O	
41	specific	O	
42	manner	O	
43	.	O	

1	Goodpasture	O	
2	'	O	
3	s	O	
4	-	O	
5	like	O	
6	syndrome	O	
7	and	O	
8	effect	O	
9	of	O	
10	extracorporeal	O	
11	membrane	O	
12	oxygenator	O	
13	support	O	
14	.	O	

1	6	O	
2	.	O	

1	Sensitivity	O	
2	and	O	
3	specificity	O	
4	was	O	
5	established	O	
6	for	O	
7	the	O	
8	Pharmacia	O	
9	CAP	O	
10	System	O	
11	and	O	
12	the	O	
13	DPC	O	
14	AlaSTAT	O	
15	System	O	
16	by	O	
17	comparison	O	
18	with	O	
19	results	O	
20	of	O	
21	the	O	
22	skin	O	
23	prick	O	
24	test	O	
25	.	O	

1	100	O	
2	years	O	
3	of	O	
4	dentistry	O	
5	at	O	
6	the	O	
7	Friedrich	O	
8	Schiller	O	
9	University	O	
10	in	O	
11	Jena	O	

1	In	O	
2	vivo	O	
3	,	O	
4	MyoD	B	
5	requires	O	
6	this	O	
7	tryptophan	O	
8	motif	O	
9	to	O	
10	evoke	O	
11	chromatin	O	
12	remodeling	O	
13	in	O	
14	the	O	
15	Myogenin	B	
16	promoter	I	
17	and	O	
18	to	O	
19	activate	O	
20	Myogenin	B	
21	transcription	O	
22	.	O	

1	The	O	
2	gene	O	
3	contains	O	
4	six	O	
5	exons	O	
6	separated	O	
7	by	O	
8	1	O	
9	.	O	
10	1	O	
11	-	O	
12	5	O	
13	.	O	
14	8	O	
15	kb	O	
16	introns	O	
17	and	O	
18	has	O	
19	been	O	
20	localized	O	
21	to	O	
22	the	O	
23	murine	O	
24	chromosome	O	
25	2	O	
26	by	O	
27	linkage	O	
28	analysis	O	
29	.	O	

1	Similarly	O	
2	,	O	
3	expression	O	
4	of	O	
5	a	O	
6	transiently	O	
7	transfected	O	
8	wild	B	
9	-	I	
10	type	I	
11	prothymosin	I	
12	alpha	I	
13	gene	I	
14	as	O	
15	the	O	
16	reporter	O	
17	was	O	
18	not	O	
19	affected	O	
20	by	O	
21	a	O	
22	repertoire	O	
23	of	O	
24	myc	B	
25	-	I	
26	derived	I	
27	genes	I	
28	,	O	
29	including	O	
30	myc	B	
31	itself	O	
32	and	O	
33	dominant	O	
34	or	O	
35	recessive	O	
36	negative	O	
37	myc	B	
38	mutants	I	
39	.	O	

1	During	O	
2	both	O	
3	encephalopathy	O	
4	episodes	O	
5	,	O	
6	CSF	O	
7	protein	O	
8	and	O	
9	immunoglobulin	B	
10	G	I	
11	(	O	
12	IgG	B	
13	)	O	
14	levels	O	
15	were	O	
16	elevated	O	
17	without	O	
18	an	O	
19	increased	O	
20	IgG	B	
21	index	O	
22	or	O	
23	IgG	B	
24	synthesis	O	
25	rate	O	
26	.	O	

1	This	O	
2	study	O	
3	describes	O	
4	a	O	
5	new	O	
6	MADS	B	
7	box	I	
8	gene	I	
9	,	O	
10	nmhC5	B	
11	,	O	
12	which	O	
13	along	O	
14	with	O	
15	nmh7	B	
16	(	O	
17	J	O	
18	.	O	

1	5	O	
2	.	O	

1	Mapping	O	
2	of	O	
3	the	O	
4	human	B	
5	Voltage	I	
6	-	I	
7	Dependent	I	
8	Anion	I	
9	Channel	I	
10	isoforms	I	
11	1	I	
12	and	I	
13	2	I	
14	reconsidered	O	
15	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	the	O	
5	acetyltransferase	O	
6	activity	O	
7	of	O	
8	p300	B	
9	was	O	
10	observed	O	
11	to	O	
12	be	O	
13	distinct	O	
14	from	O	
15	the	O	
16	broadly	O	
17	essential	O	
18	activation	O	
19	function	O	
20	of	O	
21	the	O	
22	CH3	B	
23	domain	I	
24	/	O	
25	E1A	B	
26	-	O	
27	binding	O	
28	region	O	
29	.	O	

1	After	O	
2	overtraining	O	
3	on	O	
4	the	O	
5	original	O	
6	discrimination	O	
7	,	O	
8	the	O	
9	controls	O	
10	showed	O	
11	the	O	
12	normal	O	
13	difficulty	O	
14	in	O	
15	learning	O	
16	the	O	
17	first	O	
18	reversal	O	
19	.	O	

1	In	O	
2	this	O	
3	study	O	
4	,	O	
5	we	O	
6	identified	O	
7	four	O	
8	distinct	O	
9	E2F	B	
10	complexes	I	
11	present	O	
12	in	O	
13	aged	O	
14	and	O	
15	senescent	O	
16	normal	O	
17	,	O	
18	human	O	
19	diploid	O	
20	fibroblasts	O	
21	.	O	

1	We	O	
2	have	O	
3	tested	O	
4	this	O	
5	proposal	O	
6	by	O	
7	carrying	O	
8	out	O	
9	circular	O	
10	dichroism	O	
11	(	O	
12	CD	O	
13	)	O	
14	and	O	
15	NMR	O	
16	experiments	O	
17	on	O	
18	the	O	
19	Skn	B	
20	domain	I	
21	and	O	
22	five	O	
23	truncated	O	
24	proteins	O	
25	.	O	

1	These	O	
2	discoloration	O	
3	'	O	
4	s	O	
5	can	O	
6	be	O	
7	treated	O	
8	in	O	
9	several	O	
10	ways	O	
11	but	O	
12	up	O	
13	to	O	
14	lately	O	
15	tooth	O	
16	structure	O	
17	had	O	
18	to	O	
19	be	O	
20	removed	O	
21	in	O	
22	an	O	
23	irreversible	O	
24	manner	O	
25	in	O	
26	order	O	
27	to	O	
28	provide	O	
29	sufficient	O	
30	bulk	O	
31	for	O	
32	the	O	
33	new	O	
34	restorative	O	
35	material	O	
36	.	O	

1	Effects	O	
2	of	O	
3	a	O	
4	selective	O	
5	monoamine	B	
6	oxidase	I	
7	(	I	
8	MAO	I	
9	)--	I	
10	A	I	
11	inhibitor	O	
12	,	O	
13	clorgyline	O	
14	,	O	
15	a	O	
16	selective	O	
17	MAO	B	
18	-	I	
19	B	I	
20	inhibitor	O	
21	,	O	
22	deprenyl	O	
23	,	O	
24	and	O	
25	a	O	
26	non	O	
27	-	O	
28	selective	O	
29	MAO	B	
30	inhibitor	O	
31	,	O	
32	nialamide	O	
33	,	O	
34	were	O	
35	investigated	O	
36	on	O	
37	footshock	O	
38	-	O	
39	induced	O	
40	aggression	O	
41	(	O	
42	FIA	O	
43	)	O	
44	in	O	
45	paired	O	
46	rats	O	
47	.	O	

1	The	O	
2	Mauriceville	O	
3	and	O	
4	Varkud	O	
5	mitochondrial	O	
6	plasmids	O	
7	are	O	
8	closely	O	
9	related	O	
10	,	O	
11	closed	O	
12	-	O	
13	circular	O	
14	DNAs	O	
15	(	O	
16	3	O	
17	.	O	
18	6	O	
19	and	O	
20	3	O	
21	.	O	
22	7	O	
23	kb	O	
24	,	O	
25	respectively	O	
26	)	O	
27	that	O	
28	have	O	
29	characteristics	O	
30	of	O	
31	mtDNA	O	
32	introns	O	
33	and	O	
34	retroid	O	
35	elements	O	
36	.	O	

1	The	O	
2	mean	O	
3	marginal	O	
4	discrepancy	O	
5	of	O	
6	provisional	O	
7	restorations	O	
8	was	O	
9	compared	O	
10	for	O	
11	restorations	O	
12	fabricated	O	
13	from	O	
14	stone	O	
15	,	O	
16	low	O	
17	-	O	
18	viscosity	O	
19	poly	O	
20	(	O	
21	vinyl	O	
22	siloxane	O	
23	),	O	
24	and	O	
25	medium	O	
26	-	O	
27	viscosity	O	
28	poly	O	
29	(	O	
30	vinyl	O	
31	siloxane	O	
32	).	O	

1	Consistent	O	
2	with	O	
3	the	O	
4	hypothesis	O	
5	that	O	
6	it	O	
7	acts	O	
8	as	O	
9	transcriptional	O	
10	regulator	O	
11	,	O	
12	wild	B	
13	-	I	
14	type	I	
15	p53	I	
16	protein	I	
17	binds	O	
18	DNA	O	
19	and	O	
20	activates	O	
21	transcription	O	
22	of	O	
23	several	O	
24	promoters	O	
25	.	O	

1	The	O	
2	transcription	O	
3	factor	O	
4	CHOP	B	
5	/	O	
6	GADD153	B	
7	gene	O	
8	is	O	
9	induced	O	
10	by	O	
11	cellular	O	
12	stress	O	
13	and	O	
14	is	O	
15	involved	O	
16	in	O	
17	mediating	O	
18	apoptosis	O	
19	.	O	

1	The	O	
2	catenins	B	
3	bind	O	
4	to	O	
5	APC	B	
6	and	O	
7	E	B	
8	-	I	
9	cadherin	I	
10	in	O	
11	a	O	
12	similar	O	
13	fashion	O	
14	,	O	
15	but	O	
16	APC	B	
17	and	O	
18	E	B	
19	-	I	
20	cadherin	I	
21	do	O	
22	not	O	
23	associate	O	
24	with	O	
25	each	O	
26	other	O	
27	either	O	
28	in	O	
29	the	O	
30	presence	O	
31	or	O	
32	absence	O	
33	of	O	
34	catenins	B	
35	.	O	

1	The	O	
2	concentration	O	
3	of	O	
4	mite	O	
5	allergen	O	
6	was	O	
7	very	O	
8	low	O	
9	(	O	
10	mean	O	
11	0	O	
12	.	O	
13	18	O	
14	micrograms	O	
15	Der	O	
16	p	O	
17	milligrams	O	
18	sieved	O	
19	house	O	
20	dust	O	
21	),	O	
22	whereas	O	
23	that	O	
24	of	O	
25	cat	O	
26	allergen	O	
27	was	O	
28	high	O	
29	in	O	
30	homes	O	
31	with	O	
32	a	O	
33	cat	O	
34	(	O	
35	80	O	
36	.	O	
37	8	O	
38	micrograms	O	
39	Fel	O	
40	d	O	
41	milligrams	O	
42	)	O	
43	but	O	
44	also	O	
45	in	O	
46	homes	O	
47	with	O	
48	no	O	
49	cat	O	
50	(	O	
51	3	O	
52	.	O	
53	2	O	
54	micrograms	O	
55	Fel	O	
56	d	O	
57	milligrams	O	
58	).	O	

1	Significance	O	
2	of	O	
3	cytokine	O	
4	production	O	
5	and	O	
6	adhesion	O	
7	molecules	O	
8	in	O	
9	malarial	O	
10	immunopathology	O	
11	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	depletion	O	
5	of	O	
6	Oct	B	
7	-	I	
8	1	I	
9	from	O	
10	the	O	
11	nuclear	O	
12	extract	O	
13	by	O	
14	using	O	
15	Oct	B	
16	-	I	
17	1	I	
18	-	O	
19	specific	O	
20	antiserum	O	
21	or	O	
22	a	O	
23	sequence	O	
24	-	O	
25	specific	O	
26	DNA	O	
27	affinity	O	
28	resin	O	
29	decreased	O	
30	in	O	
31	vitro	O	
32	transcription	O	
33	from	O	
34	the	O	
35	wild	O	
36	-	O	
37	type	O	
38	MMTV	O	
39	promoter	O	
40	to	O	
41	a	O	
42	level	O	
43	identical	O	
44	to	O	
45	that	O	
46	obtained	O	
47	from	O	
48	a	O	
49	promoter	O	
50	in	O	
51	which	O	
52	all	O	
53	three	O	
54	octamer	O	
55	-	O	
56	related	O	
57	sequences	O	
58	were	O	
59	mutated	O	
60	.	O	

1	We	O	
2	also	O	
3	examined	O	
4	the	O	
5	effect	O	
6	of	O	
7	proteolytic	O	
8	processing	O	
9	in	O	
10	the	O	
11	MVE	O	
12	nonstructural	O	
13	polyprotein	O	
14	segment	O	
15	mediated	O	
16	by	O	
17	the	O	
18	viral	B	
19	proteinase	I	
20	NS3	I	
21	on	O	
22	antigen	O	
23	processing	O	
24	and	O	
25	presentation	O	
26	of	O	
27	the	O	
28	MVE	O	
29	H	O	
30	-	O	
31	2Kk	O	
32	-	O	
33	restricted	O	
34	T	O	
35	cell	O	
36	determinant	O	
37	.	O	

1	Upstream	O	
2	activating	O	
3	sequences	O	
4	(	O	
5	UASs	O	
6	)	O	
7	derived	O	
8	from	O	
9	known	O	
10	Ste12p	B	
11	-	O	
12	dependent	O	
13	genes	O	
14	have	O	
15	previously	O	
16	been	O	
17	characterized	O	
18	to	O	
19	require	O	
20	either	O	
21	multiple	O	
22	PREs	O	
23	or	O	
24	a	O	
25	single	O	
26	PRE	O	
27	coupled	O	
28	to	O	
29	a	O	
30	binding	O	
31	site	O	
32	for	O	
33	a	O	
34	second	O	
35	protein	O	
36	.	O	

1	Most	O	
2	eukaryotic	O	
3	mRNAs	O	
4	are	O	
5	translated	O	
6	by	O	
7	a	O	
8	"	O	
9	scanning	O	
10	ribosome	O	
11	"	O	
12	mechanism	O	
13	.	O	

1	Reaction	O	
2	time	O	
3	(	O	
4	RT	O	
5	)	O	
6	and	O	
7	P300	O	
8	were	O	
9	collected	O	
10	simultaneously	O	
11	.	O	

1	The	O	
2	IPL1	B	
3	gene	I	
4	is	O	
5	required	O	
6	for	O	
7	high	O	
8	-	O	
9	fidelity	O	
10	chromosome	O	
11	segregation	O	
12	in	O	
13	the	O	
14	budding	O	
15	yeast	O	
16	Saccharomyces	O	
17	cerevisiae	O	
18	.	O	

1	Many	O	
2	of	O	
3	these	O	
4	landfill	O	
5	operations	O	
6	were	O	
7	undertaken	O	
8	in	O	
9	the	O	
10	early	O	
11	1950s	O	
12	and	O	
13	1960s	O	
14	,	O	
15	when	O	
16	knowledge	O	
17	regarding	O	
18	the	O	
19	safe	O	
20	and	O	
21	prolonged	O	
22	containment	O	
23	of	O	
24	the	O	
25	waste	O	
26	buried	O	
27	was	O	
28	nonexistent	O	
29	or	O	
30	minimal	O	
31	at	O	
32	best	O	
33	.	O	

1	Liver	O	
2	injuries	O	

1	Seventy	O	
2	-	O	
3	one	O	
4	percent	O	
5	of	O	
6	patients	O	
7	treated	O	
8	with	O	
9	ticarcillin	O	
10	alone	O	
11	responded	O	
12	favorably	O	
13	.	O	

1	In	O	
2	PC	O	
3	,	O	
4	rare	O	
5	MNGCs	O	
6	had	O	
7	intranuclear	O	
8	inclusions	O	
9	and	O	
10	grooves	O	
11	.	O	

1	Pharmacokinetics	O	
2	of	O	
3	FK	O	
4	506	O	
5	in	O	
6	transplant	O	
7	patients	O	
8	.	O	

1	Vascular	O	
2	responses	O	
3	to	O	
4	reactive	O	
5	hyperemia	O	
6	(	O	
7	with	O	
8	flow	O	
9	increase	O	
10	leading	O	
11	to	O	
12	endothelium	O	
13	-	O	
14	dependent	O	
15	dilation	O	
16	)	O	
17	and	O	
18	to	O	
19	sublingual	O	
20	glyceryl	O	
21	trinitrate	O	
22	(	O	
23	GTN	O	
24	;	O	
25	endothelium	O	
26	-	O	
27	independent	O	
28	dilation	O	
29	)	O	
30	were	O	
31	recorded	O	
32	.	O	

1	Air	O	
2	lead	O	
3	was	O	
4	not	O	
5	a	O	
6	significant	O	
7	explanatory	O	
8	variable	O	
9	.	O	

1	Analysis	O	
2	of	O	
3	viral	O	
4	mutants	O	
5	in	O	
6	vivo	O	
7	demonstrated	O	
8	that	O	
9	the	O	
10	NFIII	B	
11	/	O	
12	OCT	B	
13	-	I	
14	1	I	
15	binding	O	
16	site	O	
17	and	O	
18	a	O	
19	conserved	O	
20	ATF	B	
21	motif	I	
22	were	O	
23	important	O	
24	for	O	
25	efficient	O	
26	viral	O	
27	growth	O	
28	.	O	

1	At	O	
2	necropsy	O	
3	28	O	
4	days	O	
5	post	O	
6	-	O	
7	inoculation	O	
8	,	O	
9	F344	O	
10	rats	O	
11	had	O	
12	no	O	
13	gross	O	
14	lung	O	
15	lesions	O	
16	,	O	
17	even	O	
18	those	O	
19	given	O	
20	the	O	
21	maximum	O	
22	dose	O	
23	of	O	
24	1	O	
25	.	O	
26	4	O	
27	X	O	
28	10	O	
29	(	O	
30	9	O	
31	)	O	
32	colony	O	
33	-	O	
34	forming	O	
35	units	O	
36	of	O	
37	M	O	
38	.	O	
39	pulmonis	O	
40	.	O	

1	The	O	
2	sites	O	
3	targeted	O	
4	for	O	
5	mutagenesis	O	
6	,	O	
7	residues	O	
8	60	O	
9	,	O	
10	61	O	
11	,	O	
12	and	O	
13	66	O	
14	,	O	
15	are	O	
16	located	O	
17	within	O	
18	a	O	
19	putative	O	
20	helical	O	
21	loop	O	
22	structure	O	
23	which	O	
24	may	O	
25	be	O	
26	involved	O	
27	in	O	
28	substrate	O	
29	recognition	O	
30	by	O	
31	the	O	
32	enzyme	O	
33	.	O	

1	Analysis	O	
2	of	O	
3	one	O	
4	cDNA	O	
5	revealed	O	
6	an	O	
7	unusual	O	
8	splicing	O	
9	event	O	
10	involving	O	
11	EZH1	B	
12	and	O	
13	a	O	
14	tandemly	O	
15	linked	O	
16	gene	O	
17	GPR2	B	
18	and	O	
19	suggests	O	
20	a	O	
21	potential	O	
22	mechanism	O	
23	for	O	
24	modifying	O	
25	the	O	
26	EZH1	B	
27	protein	I	
28	in	O	
29	the	O	
30	conserved	O	
31	C	O	
32	-	O	
33	terminal	O	
34	domain	O	
35	.	O	

1	The	O	
2	effects	O	
3	of	O	
4	a	O	
5	1	O	
6	-	O	
7	or	O	
8	24	O	
9	-	O	
10	hour	O	
11	pretreatment	O	
12	regimen	O	
13	with	O	
14	monophosphoryl	O	
15	lipid	O	
16	A	O	
17	(	O	
18	MLA	O	
19	,	O	
20	35	O	
21	micrograms	O	
22	/	O	
23	kg	O	
24	i	O	
25	.	O	
26	v	O	
27	.)	O	
28	on	O	
29	myocardial	O	
30	stunning	O	
31	produced	O	
32	by	O	
33	repetitive	O	
34	coronary	O	
35	occlusions	O	
36	were	O	
37	studied	O	
38	in	O	
39	barbital	O	
40	-	O	
41	anesthetized	O	
42	dogs	O	
43	.	O	

1	Ninety	O	
2	-	O	
3	four	O	
4	percent	O	
5	of	O	
6	the	O	
7	EPs	O	
8	were	O	
9	tubal	O	
10	,	O	
11	and	O	
12	90	O	
13	%	O	
14	of	O	
15	the	O	
16	tubes	O	
17	exhibited	O	
18	some	O	
19	pathologic	O	
20	changes	O	
21	,	O	
22	including	O	
23	chronic	O	
24	salpingitis	O	
25	(	O	
26	49	O	
27	.	O	
28	5	O	
29	%)	O	
30	and	O	
31	follicular	O	
32	salpingitis	O	
33	(	O	
34	10	O	
35	%),	O	
36	among	O	
37	others	O	
38	.	O	

1	These	O	
2	probable	O	
3	border	O	
4	sequences	O	
5	are	O	
6	closely	O	
7	related	O	
8	to	O	
9	those	O	
10	of	O	
11	other	O	
12	known	O	
13	T	O	
14	-	O	
15	regions	O	
16	and	O	
17	define	O	
18	a	O	
19	second	O	
20	T	O	
21	-	O	
22	region	O	
23	of	O	
24	pTiChry5	O	
25	,	O	
26	called	O	
27	T	O	
28	-	O	
29	right	O	
30	(	O	
31	TR	O	
32	),	O	
33	that	O	
34	confers	O	
35	production	O	
36	of	O	
37	the	O	
38	Amadoriopines	O	
39	.	O	

1	Comparison	O	
2	of	O	
3	cDNA	O	
4	and	O	
5	genomic	O	
6	sequences	O	
7	shows	O	
8	that	O	
9	the	O	
10	ZNF189	B	
11	gene	I	
12	spans	O	
13	approximately	O	
14	11	O	
15	kb	O	
16	and	O	
17	is	O	
18	organized	O	
19	into	O	
20	at	O	
21	least	O	
22	four	O	
23	exons	O	
24	,	O	
25	the	O	
26	large	O	
27	3	O	
28	'-	O	
29	end	O	
30	exon	O	
31	coding	O	
32	for	O	
33	the	O	
34	complete	O	
35	zinc	O	
36	finger	O	
37	domain	O	
38	and	O	
39	the	O	
40	3	O	
41	'	O	
42	untranslated	O	
43	region	O	
44	.	O	

1	Specifically	O	
2	,	O	
3	by	O	
4	oligonucleotide	O	
5	-	O	
6	directed	O	
7	site	O	
8	-	O	
9	specific	O	
10	mutagenesis	O	
11	,	O	
12	we	O	
13	demonstrate	O	
14	that	O	
15	of	O	
16	10	O	
17	cysteine	O	
18	residues	O	
19	in	O	
20	the	O	
21	ORF4	O	
22	polypeptide	O	
23	,	O	
24	only	O	
25	C	O	
26	-	O	
27	421	O	
28	and	O	
29	C	O	
30	-	O	
31	426	O	
32	are	O	
33	essential	O	
34	for	O	
35	transactivator	O	
36	function	O	
37	and	O	
38	suggest	O	
39	that	O	
40	these	O	
41	cysteine	O	
42	residues	O	
43	may	O	
44	participate	O	
45	in	O	
46	critical	O	
47	protein	O	
48	-	O	
49	protein	O	
50	interactions	O	
51	rather	O	
52	than	O	
53	protein	O	
54	-	O	
55	nucleic	O	
56	acid	O	
57	interactions	O	
58	to	O	
59	mediate	O	
60	ORF4	O	
61	inducibility	O	
62	.	O	

1	The	O	
2	maximum	O	
3	amplitude	O	
4	of	O	
5	evoked	O	
6	responses	O	
7	in	O	
8	the	O	
9	cervical	O	
10	sympathetic	O	
11	trunk	O	
12	was	O	
13	obtained	O	
14	when	O	
15	the	O	
16	T2	O	
17	white	O	
18	ramus	O	
19	was	O	
20	stimulated	O	
21	and	O	
22	decreased	O	
23	gradually	O	
24	when	O	
25	followed	O	
26	by	O	
27	the	O	
28	stimulation	O	
29	of	O	
30	T1	O	
31	,	O	
32	T3	O	
33	,	O	
34	T4	O	
35	and	O	
36	T5	O	
37	white	O	
38	rami	O	
39	.	O	

1	An	O	
2	endogenous	O	
3	mammalian	O	
4	regulator	O	
5	of	O	
6	this	O	
7	process	O	
8	,	O	
9	named	O	
10	Usurpin	B	
11	,	O	
12	has	O	
13	been	O	
14	identified	O	
15	(	O	
16	aliases	O	
17	for	O	
18	Usurpin	B	
19	include	O	
20	CASH	B	
21	,	O	
22	Casper	B	
23	,	O	
24	CLARP	B	
25	,	O	
26	FLAME	B	
27	-	I	
28	1	I	
29	,	O	
30	FLIP	B	
31	,	O	
32	I	B	
33	-	I	
34	FLICE	I	
35	and	O	
36	MRIT	B	
37	).	O	

1	To	O	
2	identify	O	
3	some	O	
4	of	O	
5	the	O	
6	genes	O	
7	expressed	O	
8	in	O	
9	LPS	O	
10	-	O	
11	activated	O	
12	coelomocytes	O	
13	,	O	
14	we	O	
15	sequenced	O	
16	randomly	O	
17	chosen	O	
18	clones	O	
19	from	O	
20	a	O	
21	directionally	O	
22	constructed	O	
23	cDNA	O	
24	library	O	
25	to	O	
26	produce	O	
27	a	O	
28	set	O	
29	of	O	
30	expressed	O	
31	sequence	O	
32	tags	O	
33	(	O	
34	ESTs	O	
35	).	O	

1	TNF	B	
2	Treatment	O	
3	of	O	
4	cell	O	
5	activated	O	
6	the	O	
7	p38	B	
8	MAP	I	
9	kinase	I	
10	pathway	O	
11	,	O	
12	as	O	
13	revealed	O	
14	by	O	
15	increased	O	
16	phosphorylation	O	
17	of	O	
18	p38	B	
19	MAP	I	
20	kinase	I	
21	itself	O	
22	,	O	
23	activation	O	
24	of	O	
25	the	O	
26	substrate	O	
27	protein	O	
28	MAPKAP	B	
29	kinase	I	
30	-	I	
31	2	I	
32	,	O	
33	and	O	
34	culminating	O	
35	in	O	
36	the	O	
37	phosphorylation	O	
38	of	O	
39	the	O	
40	heat	B	
41	shock	I	
42	protein	I	
43	27	I	
44	(	O	
45	hsp27	B	
46	).	O	

1	The	O	
2	Mif1	B	
3	5	I	
4	'	I	
5	flanking	I	
6	region	I	
7	contains	O	
8	a	O	
9	functional	O	
10	ER	O	
11	stress	O	
12	-	O	
13	responsive	O	
14	element	O	
15	which	O	
16	is	O	
17	sufficient	O	
18	for	O	
19	induction	O	
20	by	O	
21	tunicamycin	O	
22	.	O	

1	The	O	
2	routine	O	
3	administration	O	
4	of	O	
5	fat	O	
6	-	O	
7	soluble	O	
8	vitamins	O	
9	appears	O	
10	unnecessary	O	
11	but	O	
12	it	O	
13	is	O	
14	prudent	O	
15	to	O	
16	measure	O	
17	prothrombin	B	
18	time	O	
19	and	O	
20	serum	O	
21	vitamins	O	
22	A	O	
23	and	O	
24	E	O	
25	at	O	
26	intervals	O	
27	.	O	

1	The	O	
2	TA	O	
3	muscle	O	
4	was	O	
5	fatigued	O	
6	by	O	
7	four	O	
8	forms	O	
9	of	O	
10	repeated	O	
11	isometric	O	
12	contractions	O	
13	:	O	
14	(	O	
15	1	O	
16	)	O	
17	maximal	O	
18	voluntary	O	
19	contractions	O	
20	(	O	
21	MVC	O	
22	),	O	
23	(	O	
24	2	O	
25	)	O	
26	MVC	O	
27	with	O	
28	circulation	O	
29	occluded	O	
30	,	O	
31	(	O	
32	3	O	
33	)	O	
34	electrically	O	
35	evoked	O	
36	contractions	O	
37	with	O	
38	20	O	
39	Hz	O	
40	supramaximal	O	
41	voltage	O	
42	stimulation	O	
43	and	O	
44	(	O	
45	4	O	
46	)	O	
47	electrically	O	
48	evoked	O	
49	contractions	O	
50	with	O	
51	circulation	O	
52	occluded	O	
53	.	O	

1	Leukocyte	O	
2	cultures	O	
3	,	O	
4	prepared	O	
5	from	O	
6	blood	O	
7	drawn	O	
8	from	O	
9	these	O	
10	18	O	
11	children	O	
12	at	O	
13	6	O	
14	months	O	
15	of	O	
16	age	O	
17	,	O	
18	produced	O	
19	lower	O	
20	yields	O	
21	of	O	
22	IFN	B	
23	than	O	
24	those	O	
25	of	O	
26	the	O	
27	remaining	O	
28	53	O	
29	children	O	
30	,	O	
31	when	O	
32	stimulated	O	
33	with	O	
34	adenovirus	O	
35	(	O	
36	P	O	
37	<	O	
38	0	O	
39	.	O	
40	001	O	
41	),	O	
42	coronavirus	O	
43	(	O	
44	P	O	
45	<	O	
46	0	O	
47	.	O	
48	001	O	
49	)	O	
50	or	O	
51	rhinovirus	O	
52	(	O	
53	P	O	
54	=	O	
55	0	O	
56	.	O	
57	002	O	
58	).	O	

1	Efficacy	O	
2	was	O	
3	determined	O	
4	by	O	
5	responses	O	
6	to	O	
7	question	O	
8	3	O	
9	(	O	
10	ability	O	
11	to	O	
12	achieve	O	
13	an	O	
14	erection	O	
15	)	O	
16	and	O	
17	question	O	
18	4	O	
19	(	O	
20	ability	O	
21	to	O	
22	maintain	O	
23	an	O	
24	erection	O	
25	)	O	
26	of	O	
27	the	O	
28	15	O	
29	-	O	
30	item	O	
31	International	O	
32	Index	O	
33	of	O	
34	Erectile	O	
35	Function	O	
36	(	O	
37	IIEF	O	
38	).	O	

1	In	O	
2	the	O	
3	icosahaedral	O	
4	MVMi	O	
5	capsid	O	
6	,	O	
7	this	O	
8	sequence	O	
9	forms	O	
10	the	O	
11	carboxy	O	
12	end	O	
13	of	O	
14	the	O	
15	amphipathic	O	
16	beta	O	
17	-	O	
18	strand	O	
19	I	O	
20	(	O	
21	betaI	O	
22	),	O	
23	and	O	
24	all	O	
25	its	O	
26	basic	O	
27	residues	O	
28	are	O	
29	contiguously	O	
30	positioned	O	
31	at	O	
32	the	O	
33	face	O	
34	that	O	
35	in	O	
36	the	O	
37	unassembled	O	
38	subunit	O	
39	would	O	
40	be	O	
41	exposed	O	
42	to	O	
43	solvent	O	
44	.	O	

1	BRCA1	B	
2	protein	I	
3	contains	O	
4	an	O	
5	amino	O	
6	-	O	
7	terminal	O	
8	zinc	O	
9	finger	O	
10	motif	O	
11	and	O	
12	a	O	
13	carboxy	O	
14	-	O	
15	terminal	O	
16	acidic	O	
17	region	O	
18	.	O	

1	BCR	B	
2	-	O	
3	ABL	B	
4	and	O	
5	v	B	
6	-	I	
7	abl	I	
8	oncogenes	I	
9	induce	O	
10	distinct	O	
11	patterns	O	
12	of	O	
13	thymic	O	
14	lymphoma	O	
15	involving	O	
16	different	O	
17	lymphocyte	O	
18	subsets	O	
19	.	O	

1	Inspection	O	
2	of	O	
3	enhancer	O	
4	mutants	O	
5	suggests	O	
6	that	O	
7	trans	O	
8	-	O	
9	activation	O	
10	by	O	
11	hLEF	B	
12	/	O	
13	GAL4	B	
14	is	O	
15	especially	O	
16	dependent	O	
17	on	O	
18	TCF	B	
19	-	I	
20	2	I	
21	,	O	
22	a	O	
23	distinct	O	
24	T	O	
25	-	O	
26	cell	O	
27	-	O	
28	enriched	O	
29	protein	O	
30	that	O	
31	binds	O	
32	to	O	
33	sequences	O	
34	flanking	O	
35	the	O	
36	hLEF	B	
37	-	I	
38	binding	I	
39	site	I	
40	in	O	
41	the	O	
42	enhancer	O	
43	.	O	

1	INTERVENTION	O	
2	(	O	
3	S	O	
4	):	O	
5	Twenty	O	
6	-	O	
7	six	O	
8	hemostasis	O	
9	parameters	O	
10	evaluated	O	
11	repeatedly	O	
12	in	O	
13	patients	O	
14	undergoing	O	
15	IVF	O	
16	-	O	
17	ET	O	
18	.	O	

1	The	O	
2	abscess	O	
3	was	O	
4	debrided	O	
5	and	O	
6	the	O	
7	septum	O	
8	was	O	
9	patched	O	
10	with	O	
11	a	O	
12	single	O	
13	layer	O	
14	of	O	
15	autologous	O	
16	pericardium	O	
17	.	O	

1	Findings	O	
2	of	O	
3	positive	O	
4	potentials	O	
5	showed	O	
6	that	O	
7	N1	O	
8	originated	O	
9	in	O	
10	the	O	
11	area	O	
12	of	O	
13	ventral	O	
14	gray	O	
15	matter	O	
16	through	O	
17	the	O	
18	ventro	O	
19	-	O	
20	lateral	O	
21	column	O	
22	and	O	
23	N2	O	
24	through	O	
25	the	O	
26	dorsal	O	
27	column	O	
28	.	O	

1	The	O	
2	structural	O	
3	analysis	O	
4	also	O	
5	demonstrated	O	
6	that	O	
7	the	O	
8	heterogeneity	O	
9	of	O	
10	the	O	
11	HDC	B	
12	mRNA	I	
13	is	O	
14	caused	O	
15	by	O	
16	an	O	
17	insertion	O	
18	of	O	
19	the	O	
20	seventh	O	
21	intron	O	
22	sequence	O	
23	and	O	
24	alternative	O	
25	use	O	
26	of	O	
27	the	O	
28	splicing	O	
29	acceptor	O	
30	site	O	
31	at	O	
32	the	O	
33	12th	O	
34	exon	O	
35	.	O	

1	However	O	
2	,	O	
3	a	O	
4	surprisingly	O	
5	high	O	
6	degree	O	
7	of	O	
8	conservation	O	
9	of	O	
10	intron	O	
11	sequences	O	
12	was	O	
13	observed	O	
14	between	O	
15	both	O	
16	species	O	
17	.	O	

1	CONCLUSIONS	O	
2	:	O	
3	These	O	
4	routinely	O	
5	collected	O	
6	data	O	
7	provided	O	
8	quantitative	O	
9	estimates	O	
10	of	O	
11	changes	O	
12	in	O	
13	CBZ	O	
14	Cl	O	
15	/	O	
16	F	O	
17	due	O	
18	to	O	
19	comedication	O	
20	and	O	
21	an	O	
22	age	O	
23	-	O	
24	related	O	
25	decrease	O	
26	in	O	
27	Cl	O	
28	/	O	
29	F	O	
30	The	O	
31	derived	O	
32	regression	O	
33	equations	O	
34	reasonably	O	
35	predicted	O	
36	concentrations	O	
37	in	O	
38	a	O	
39	separate	O	
40	validation	O	
41	set	O	
42	.	O	

1	By	O	
2	stepwise	O	
3	linear	O	
4	multiple	O	
5	regression	O	
6	analysis	O	
7	,	O	
8	ionized	O	
9	magnesium	O	
10	was	O	
11	significantly	O	
12	related	O	
13	to	O	
14	cyclosporin	O	
15	trough	O	
16	level	O	
17	and	O	
18	total	O	
19	cholesterol	O	
20	but	O	
21	not	O	
22	to	O	
23	serum	O	
24	creatinine	O	
25	,	O	
26	time	O	
27	after	O	
28	transplant	O	
29	or	O	
30	the	O	
31	dose	O	
32	of	O	
33	cyclosporin	O	
34	.	O	

1	The	O	
2	coefficient	O	
3	of	O	
4	determination	O	
5	,	O	
6	r2	O	
7	,	O	
8	of	O	
9	the	O	
10	other	O	
11	scores	O	
12	ranged	O	
13	from	O	
14	0	O	
15	.	O	
16	56	O	
17	to	O	
18	0	O	
19	.	O	
20	61	O	
21	.	O	

1	Fortunately	O	
2	DDT	O	
3	-,	O	
4	HCH	O	
5	-	O	
6	and	O	
7	HCB	O	
8	-	O	
9	levels	O	
10	decreased	O	
11	in	O	
12	breast	O	
13	milk	O	
14	during	O	
15	the	O	
16	last	O	
17	years	O	
18	.	O	

1	Ca2	O	
2	+	O	
3	decreased	O	
4	Zn2	O	
5	+	O	
6	binding	O	
7	in	O	
8	S100	B	
9	beta	I	
10	but	O	
11	it	O	
12	did	O	
13	not	O	
14	influence	O	
15	binding	O	
16	to	O	
17	MRP14	B	
18	,	O	
19	suggesting	O	
20	that	O	
21	the	O	
22	Zn2	O	
23	+	O	
24	binding	O	
25	site	O	
26	was	O	
27	distinct	O	
28	from	O	
29	and	O	
30	independent	O	
31	of	O	
32	the	O	
33	two	O	
34	Ca2	O	
35	+	O	
36	binding	O	
37	domains	O	
38	.	O	

1	Commun	O	
2	.	O	

1	Although	O	
2	the	O	
3	molecular	O	
4	mechanisms	O	
5	involved	O	
6	in	O	
7	this	O	
8	regulation	O	
9	are	O	
10	currently	O	
11	being	O	
12	elucidated	O	
13	,	O	
14	very	O	
15	little	O	
16	is	O	
17	known	O	
18	about	O	
19	the	O	
20	trans	O	
21	-	O	
22	acting	O	
23	factors	O	
24	that	O	
25	allow	O	
26	expression	O	
27	of	O	
28	the	O	
29	nitrate	B	
30	and	I	
31	nitrite	I	
32	reductase	I	
33	genes	I	
34	which	O	
35	code	O	
36	for	O	
37	the	O	
38	first	O	
39	enzymes	O	
40	in	O	
41	the	O	
42	pathway	O	
43	.	O	

1	Stable	O	
2	expression	O	
3	of	O	
4	the	O	
5	chimeric	O	
6	alpha	B	
7	i	I	
8	(	I	
9	54	I	
10	)/	I	
11	s	I	
12	polypeptide	O	
13	in	O	
14	Chinese	O	
15	hamster	O	
16	ovary	O	
17	(	O	
18	CHO	O	
19	)	O	
20	cells	O	
21	constitutively	O	
22	increased	O	
23	both	O	
24	cAMP	O	
25	synthesis	O	
26	and	O	
27	cAMP	B	
28	-	I	
29	dependent	I	
30	protein	I	
31	kinase	I	
32	activity	O	
33	.	O	

1	A	O	
2	stable	O	
3	heterologous	O	
4	cell	O	
5	line	O	
6	containing	O	
7	the	O	
8	mouse	B	
9	TRH	I	
10	receptor	I	
11	was	O	
12	constructed	O	
13	by	O	
14	transfection	O	
15	of	O	
16	nonexcitable	O	
17	293	O	
18	cells	O	
19	,	O	
20	which	O	
21	lack	O	
22	L	O	
23	channel	O	
24	activity	O	
25	.	O	

1	The	O	
2	skp1	B	
3	+	I	
4	gene	I	
5	is	O	
6	not	O	
7	essential	O	
8	.	O	

1	The	O	
2	mapping	O	
3	was	O	
4	completed	O	
5	with	O	
6	Southern	O	
7	blotting	O	
8	and	O	
9	restriction	O	
10	analysis	O	
11	.	O	

1	We	O	
2	have	O	
3	found	O	
4	that	O	
5	the	O	
6	expression	O	
7	of	O	
8	GTPase	B	
9	-	O	
10	deficient	O	
11	mutants	O	
12	of	O	
13	alpha	B	
14	12	I	
15	(	O	
16	alpha	B	
17	12Q229L	I	
18	)	O	
19	or	O	
20	alpha	B	
21	13	I	
22	(	O	
23	alpha	B	
24	13Q226L	I	
25	)	O	
26	leads	O	
27	to	O	
28	robust	O	
29	activation	O	
30	of	O	
31	the	O	
32	Jun	B	
33	kinase	I	
34	/	O	
35	stress	B	
36	-	I	
37	activated	I	
38	protein	I	
39	kinase	I	
40	(	O	
41	JNK	B	
42	/	O	
43	SAPK	B	
44	)	O	
45	pathway	O	
46	.	O	

1	A	O	
2	phylogenetic	O	
3	analysis	O	
4	of	O	
5	the	O	
6	reverse	B	
7	transcriptase	I	
8	domain	I	
9	confirms	O	
10	our	O	
11	differential	O	
12	genetic	O	
13	assessment	O	
14	that	O	
15	Cyclops	B	
16	from	O	
17	pea	O	
18	is	O	
19	a	O	
20	novel	O	
21	element	O	
22	with	O	
23	no	O	
24	specific	O	
25	relationship	O	
26	to	O	
27	the	O	
28	previously	O	
29	described	O	
30	Gypsy	B	
31	-	I	
32	like	I	
33	elements	I	
34	from	O	
35	plants	O	
36	.	O	

1	Repair	O	
2	of	O	
3	double	O	
4	-	O	
5	strand	O	
6	breaks	O	
7	(	O	
8	DSBs	O	
9	)	O	
10	in	O	
11	chromosomal	O	
12	DNA	O	
13	by	O	
14	nonhomologous	O	
15	end	O	
16	-	O	
17	joining	O	
18	(	O	
19	NHEJ	O	
20	)	O	
21	is	O	
22	not	O	
23	well	O	
24	characterized	O	
25	in	O	
26	the	O	
27	yeast	O	
28	Saccharomyces	O	
29	cerevisiae	O	
30	.	O	

1	Identification	O	
2	of	O	
3	Ste4	B	
4	as	O	
5	a	O	
6	potential	O	
7	regulator	O	
8	of	O	
9	Byr2	B	
10	in	O	
11	the	O	
12	sexual	O	
13	response	O	
14	pathway	O	
15	of	O	
16	Schizosaccharomyces	O	
17	pombe	O	
18	.	O	

1	When	O	
2	Hy	O	
3	-	O	
4	Vac	O	
5	SPF	O	
6	type	O	
7	V	O	
8	embryos	O	
9	were	O	
10	exposed	O	
11	to	O	
12	either	O	
13	0	O	
14	.	O	
15	20	O	
16	ml	O	
17	50	O	
18	%	O	
19	ethanol	O	
20	in	O	
21	CRS	O	
22	or	O	
23	to	O	
24	0	O	
25	.	O	
26	20	O	
27	ml	O	
28	CRS	O	
29	(	O	
30	controls	O	
31	),	O	
32	ethanol	O	
33	-	O	
34	treated	O	
35	embryos	O	
36	showed	O	
37	a	O	
38	VSD	O	
39	incidence	O	
40	of	O	
41	34	O	
42	.	O	
43	1	O	
44	%	O	
45	compared	O	
46	with	O	
47	a	O	
48	3	O	
49	.	O	
50	6	O	
51	%	O	
52	incidence	O	
53	in	O	
54	the	O	
55	controls	O	
56	(	O	
57	P	O	
58	=	O	
59	0	O	
60	.	O	
61	0017	O	
62	).	O	

1	The	O	
2	5	O	
3	'	O	
4	regions	O	
5	of	O	
6	these	O	
7	two	O	
8	soybean	B	
9	actin	I	
10	genes	I	
11	contain	O	
12	many	O	
13	unusual	O	
14	features	O	
15	including	O	
16	(	O	
17	CT	O	
18	)	O	
19	repeats	O	
20	and	O	
21	long	O	
22	stretches	O	
23	of	O	
24	pyrimidine	O	
25	-	O	
26	rich	O	
27	DNA	O	
28	.	O	

1	Based	O	
2	on	O	
3	213	O	
4	determinations	O	
5	,	O	
6	the	O	
7	control	O	
8	mean	O	
9	serum	B	
10	CPK	I	
11	activity	O	
12	was	O	
13	262	O	
14	+/-	O	
15	113	O	
16	I	O	
17	.	O	
18	U	O	
19	./	O	
20	liter	O	
21	.	O	

1	The	O	
2	NR2	O	
3	hybrid	O	
4	is	O	
5	a	O	
6	powerful	O	
7	tool	O	
8	for	O	
9	the	O	
10	mapping	O	
11	of	O	
12	new	O	
13	probes	O	
14	of	O	
15	this	O	
16	region	O	
17	,	O	
18	as	O	
19	well	O	
20	as	O	
21	for	O	
22	obtaining	O	
23	new	O	
24	informative	O	
25	probes	O	
26	specific	O	
27	for	O	
28	the	O	
29	deletion	O	
30	by	O	
31	subtractive	O	
32	cloning	O	
33	of	O	
34	the	O	
35	region	O	
36	.	O	

1	In	O	
2	addition	O	
3	,	O	
4	mutation	O	
5	of	O	
6	the	O	
7	Sp1	B	
8	site	I	
9	also	O	
10	significantly	O	
11	reduced	O	
12	promoter	O	
13	activity	O	
14	.	O	

1	The	O	
2	aim	O	
3	of	O	
4	our	O	
5	study	O	
6	was	O	
7	to	O	
8	evaluate	O	
9	the	O	
10	level	O	
11	of	O	
12	oxidative	O	
13	stress	O	
14	in	O	
15	healthy	O	
16	controls	O	
17	(	O	
18	CTL	O	
19	)	O	
20	compared	O	
21	with	O	
22	CRF	O	
23	and	O	
24	HD	O	
25	patients	O	
26	before	O	
27	(	O	
28	pre	O	
29	-	O	
30	HD	O	
31	)	O	
32	and	O	
33	after	O	
34	(	O	
35	post	O	
36	-	O	
37	HD	O	
38	)	O	
39	the	O	
40	dialysis	O	
41	session	O	
42	,	O	
43	carried	O	
44	out	O	
45	on	O	
46	a	O	
47	high	O	
48	biocompatible	O	
49	polyacrylonitrile	O	
50	membrane	O	
51	AN69	O	
52	.	O	

1	The	O	
2	p36	B	
3	gene	I	
4	is	O	
5	at	O	
6	least	O	
7	22	O	
8	kb	O	
9	in	O	
10	length	O	
11	and	O	
12	has	O	
13	a	O	
14	coding	O	
15	sequence	O	
16	of	O	
17	approximately	O	
18	1	O	
19	kb	O	
20	,	O	
21	representing	O	
22	only	O	
23	4	O	
24	.	O	
25	5	O	
26	%	O	
27	of	O	
28	the	O	
29	gene	O	
30	.(	O	
31	ABSTRACT	O	
32	TRUNCATED	O	
33	AT	O	
34	250	O	
35	WORDS	O	
36	)	O	

1	A	O	
2	catalytic	O	
3	domain	O	
4	of	O	
5	eukaryotic	B	
6	DNA	I	
7	topoisomerase	I	
8	I	I	
9	.	O	

1	Detection	O	
2	of	O	
3	exercise	O	
4	-	O	
5	induced	O	
6	asynergy	O	
7	by	O	
8	M	O	
9	-	O	
10	mode	O	
11	echocardiography	O	
12	.	O	

1	Tumor	B	
2	necrosis	I	
3	factor	I	
4	-	I	
5	alpha	I	
6	(	O	
7	TNF	B	
8	alpha	I	
9	),	O	
10	a	O	
11	proinflammatory	O	
12	cytokine	O	
13	,	O	
14	inhibits	O	
15	cAMP	O	
16	-	O	
17	stimulated	O	
18	testosterone	O	
19	production	O	
20	in	O	
21	mouse	O	
22	Leydig	O	
23	cells	O	
24	.	O	

1	A	O	
2	correlation	O	
3	coefficient	O	
4	was	O	
5	used	O	
6	for	O	
7	assessing	O	
8	the	O	
9	similarity	O	
10	of	O	
11	each	O	
12	map	O	
13	pattern	O	
14	with	O	
15	the	O	
16	normal	O	
17	mean	O	
18	IQRST	O	
19	map	O	
20	.	O	

1	In	O	
2	the	O	
3	studies	O	
4	reported	O	
5	here	O	
6	,	O	
7	the	O	
8	5	O	
9	'-	O	
10	flanking	O	
11	region	O	
12	of	O	
13	the	O	
14	human	B	
15	gp130	I	
16	gene	I	
17	was	O	
18	isolated	O	
19	and	O	
20	the	O	
21	transcription	O	
22	initiation	O	
23	sites	O	
24	were	O	
25	mapped	O	
26	.	O	

1	Derivatives	O	
2	of	O	
3	fluorene	O	
4	.	O	

1	Coronary	O	
2	vasoconstriction	O	
3	caused	O	
4	by	O	
5	endothelin	B	
6	-	I	
7	1	I	
8	is	O	
9	enhanced	O	
10	by	O	
11	ischemia	O	
12	-	O	
13	reperfusion	O	
14	and	O	
15	by	O	
16	norepinephrine	O	
17	present	O	
18	in	O	
19	concentrations	O	
20	typically	O	
21	observed	O	
22	after	O	
23	neonatal	O	
24	cardiopulmonary	O	
25	bypass	O	
26	.	O	

1	Erythema	O	
2	exsudativum	O	
3	multiforme	O	
4	induced	O	
5	by	O	
6	granulocyte	B	
7	colony	I	
8	-	I	
9	stimulating	I	
10	factor	I	
11	in	O	
12	an	O	
13	allogeneic	O	
14	peripheral	O	
15	blood	O	
16	stem	O	
17	cell	O	
18	donor	O	
19	.	O	

1	The	O	
2	cDNAs	O	
3	cross	O	
4	-	O	
5	hybridize	O	
6	with	O	
7	genomic	O	
8	sequences	O	
9	in	O	
10	rat	O	
11	,	O	
12	human	O	
13	,	O	
14	and	O	
15	chicken	O	
16	DNA	O	
17	,	O	
18	but	O	
19	not	O	
20	with	O	
21	DNA	O	
22	from	O	
23	frog	O	
24	,	O	
25	Drosophila	O	
26	,	O	
27	or	O	
28	sea	O	
29	urchin	O	
30	.	O	

1	Neural	O	
2	blockade	O	
3	in	O	
4	chronic	O	
5	and	O	
6	cancer	O	
7	pain	O	
8	.	O	

1	Immunofluoresence	O	
2	data	O	
3	indicated	O	
4	that	O	
5	once	O	
6	bound	O	
7	to	O	
8	the	O	
9	mutant	O	
10	receptor	O	
11	,	O	
12	fluorescent	O	
13	-	O	
14	labeled	O	
15	RAP	B	
16	co	O	
17	-	O	
18	localized	O	
19	with	O	
20	markers	O	
21	of	O	
22	the	O	
23	endosomal	O	
24	pathway	O	
25	,	O	
26	whereas	O	
27	,	O	
28	in	O	
29	cells	O	
30	expressing	O	
31	the	O	
32	wild	O	
33	-	O	
34	type	O	
35	receptor	O	
36	,	O	
37	RAP	B	
38	fluorescence	O	
39	co	O	
40	-	O	
41	localized	O	
42	with	O	
43	lysosomal	O	
44	markers	O	
45	.	O	

1	A	O	
2	case	O	
3	observed	O	
4	in	O	
5	Saigon	O	

1	In	O	
2	the	O	
3	first	O	
4	series	O	
5	of	O	
6	experiments	O	
7	,	O	
8	Sprague	O	
9	-	O	
10	Dawley	O	
11	male	O	
12	rats	O	
13	were	O	
14	implanted	O	
15	unilaterally	O	
16	with	O	
17	guide	O	
18	cannulas	O	
19	aimed	O	
20	at	O	
21	the	O	
22	lateral	O	
23	ventricle	O	
24	.	O	

1	The	O	
2	authors	O	
3	proposed	O	
4	that	O	
5	the	O	
6	highly	O	
7	convergent	O	
8	inputs	O	
9	to	O	
10	the	O	
11	entorhinal	O	
12	cortex	O	
13	indicate	O	
14	this	O	
15	region	O	
16	may	O	
17	be	O	
18	particularly	O	
19	important	O	
20	for	O	
21	selecting	O	
22	or	O	
23	compressing	O	
24	information	O	
25	.	O	

1	This	O	
2	article	O	
3	reviews	O	
4	recent	O	
5	information	O	
6	on	O	
7	the	O	
8	frequency	O	
9	,	O	
10	characteristics	O	
11	,	O	
12	and	O	
13	possible	O	
14	pathogenic	O	
15	mechanisms	O	
16	of	O	
17	the	O	
18	vasculitides	O	
19	occurring	O	
20	in	O	
21	patients	O	
22	with	O	
23	the	O	
24	main	O	
25	connective	O	
26	tissue	O	
27	diseases	O	
28	.	O	

1	Genomic	O	
2	organization	O	
3	of	O	
4	the	O	
5	human	O	
6	phosphodiesterase	B	
7	PDE11A	I	
8	gene	I	
9	.	O	

1	Cloning	O	
2	and	O	
3	expression	O	
4	of	O	
5	a	O	
6	specific	O	
7	human	B	
8	alpha	I	
9	1	I	
10	,	I	
11	2	I	
12	-	I	
13	mannosidase	I	
14	that	O	
15	trims	O	
16	Man9GlcNAc2	O	
17	to	O	
18	Man8GlcNAc2	O	
19	isomer	O	
20	B	O	
21	during	O	
22	N	O	
23	-	O	
24	glycan	O	
25	biosynthesis	O	
26	.	O	

1	It	O	
2	is	O	
3	concluded	O	
4	that	O	
5	stereotypy	O	
6	can	O	
7	be	O	
8	evoked	O	
9	also	O	
10	in	O	
11	the	O	
12	case	O	
13	when	O	
14	the	O	
15	striatal	O	
16	dopaminergic	O	
17	tone	O	
18	is	O	
19	normal	O	
20	or	O	
21	even	O	
22	below	O	
23	normal	O	
24	:	O	
25	it	O	
26	is	O	
27	the	O	
28	equilibrium	O	
29	of	O	
30	the	O	
31	striatal	O	
32	cholinergic	O	
33	-	O	
34	dopaminergic	O	
35	systems	O	
36	which	O	
37	must	O	
38	be	O	
39	shifted	O	
40	towards	O	
41	dopamine	O	
42	,	O	
43	which	O	
44	is	O	
45	necessary	O	
46	for	O	
47	the	O	
48	development	O	
49	of	O	
50	this	O	
51	behavioral	O	
52	manifestation	O	
53	.	O	

1	Cardiovascular	O	
2	risk	O	
3	factors	O	
4	were	O	
5	measured	O	
6	by	O	
7	standardized	O	
8	techniques	O	
9	.	O	

1	The	O	
2	enhancer	O	
3	region	O	
4	of	O	
5	Akv	O	
6	murine	O	
7	leukemia	O	
8	virus	O	
9	contains	O	
10	the	O	
11	sequence	O	
12	motif	O	
13	ACAGATGG	O	
14	.	O	

1	A	O	
2	2	B	
3	.	I	
4	4	I	
5	-	I	
6	kb	I	
7	MAPKAPK	I	
8	-	I	
9	2	I	
10	message	I	
11	is	O	
12	expressed	O	
13	throughout	O	
14	development	O	
15	,	O	
16	while	O	
17	two	O	
18	shorter	O	
19	transcripts	O	
20	of	O	
21	2	O	
22	.	O	
23	3	O	
24	and	O	
25	1	O	
26	.	O	
27	8	O	
28	kb	O	
29	appear	O	
30	to	O	
31	be	O	
32	specifically	O	
33	expressed	O	
34	in	O	
35	the	O	
36	germline	O	
37	.	O	

1	At	O	
2	rest	O	
3	AFF	O	
4	was	O	
5	significantly	O	
6	higher	O	
7	in	O	
8	UT	O	
9	(	O	
10	29	O	
11	%)	O	
12	as	O	
13	compared	O	
14	to	O	
15	AT	O	
16	(	O	
17	25	O	
18	%)	O	
19	and	O	
20	UEA	O	
21	(	O	
22	25	O	
23	%).	O	

1	The	O	
2	use	O	
3	of	O	
4	specific	O	
5	antibodies	O	
6	allowed	O	
7	the	O	
8	identification	O	
9	of	O	
10	at	O	
11	least	O	
12	RAR	B	
13	beta	I	
14	in	O	
15	some	O	
16	of	O	
17	the	O	
18	DNA	O	
19	-	O	
20	protein	O	
21	complexes	O	
22	,	O	
23	although	O	
24	the	O	
25	four	O	
26	sequences	O	
27	bind	O	
28	single	O	
29	RARs	B	
30	transfected	O	
31	in	O	
32	COS	O	
33	cells	O	
34	much	O	
35	less	O	
36	efficiently	O	
37	,	O	
38	or	O	
39	not	O	
40	at	O	
41	all	O	
42	,	O	
43	when	O	
44	compared	O	
45	to	O	
46	a	O	
47	canonical	O	
48	RAR	B	
49	responsive	I	
50	element	I	
51	.	O	

1	The	O	
2	patients	O	
3	were	O	
4	divided	O	
5	into	O	
6	ischaemia	O	
7	and	O	
8	non	O	
9	-	O	
10	ischaemia	O	
11	groups	O	
12	on	O	
13	the	O	
14	basis	O	
15	of	O	
16	the	O	
17	change	O	
18	in	O	
19	lactate	O	
20	extraction	O	
21	ratio	O	
22	during	O	
23	balloon	O	
24	inflation	O	
25	.	O	

1	Clinical	O	
2	applications	O	
3	of	O	
4	inhibition	O	
5	of	O	
6	beta	B	
7	-	I	
8	adrenergic	I	
9	receptors	I	
10	with	O	
11	propranolol	O	
12	.	O	

1	Spontaneous	O	
2	sensitization	O	
3	to	O	
4	cross	O	
5	-	O	
6	reacting	O	
7	chemicals	O	
8	in	O	
9	a	O	
10	proportion	O	
11	of	O	
12	control	O	
13	animals	O	
14	is	O	
15	strongly	O	
16	suggested	O	
17	,	O	
18	somewhat	O	
19	akin	O	
20	to	O	
21	spontaneous	O	
22	sensitization	O	
23	in	O	
24	patients	O	
25	with	O	
26	anaphylactoid	O	
27	reactions	O	
28	to	O	
29	neuromuscular	O	
30	blockers	O	
31	on	O	
32	first	O	
33	exposure	O	
34	,	O	
35	and	O	
36	in	O	
37	whom	O	
38	IgE	B	
39	antibodies	I	
40	are	O	
41	detected	O	
42	.	O	

1	In	O	
2	contrast	O	
3	,	O	
4	similar	O	
5	rates	O	
6	of	O	
7	B	O	
8	.	O	
9	sphaericus	O	
10	products	O	
11	,	O	
12	ABG	O	
13	-	O	
14	6184	O	
15	technical	O	
16	powder	O	
17	and	O	
18	BSP	O	
19	-	O	
20	2	O	
21	flowable	O	
22	concentrate	O	
23	,	O	
24	produced	O	
25	no	O	
26	significant	O	
27	reduction	O	
28	.	O	

1	OKA	O	
2	and	O	
3	calyculin	O	
4	A	O	
5	do	O	
6	not	O	
7	decrease	O	
8	OCFRE	B	
9	DNA	O	
10	-	O	
11	protein	O	
12	interactions	O	
13	,	O	
14	suggesting	O	
15	that	O	
16	important	O	
17	protein	O	
18	-	O	
19	protein	O	
20	interactions	O	
21	are	O	
22	phosphatase	O	
23	regulated	O	
24	.	O	

1	Interestingly	O	
2	,	O	
3	following	O	
4	induction	O	
5	of	O	
6	stress	O	
7	by	O	
8	heat	O	
9	shock	O	
10	,	O	
11	high	O	
12	salt	O	
13	,	O	
14	or	O	
15	ethanol	O	
16	,	O	
17	conditions	O	
18	under	O	
19	which	O	
20	most	O	
21	mRNA	O	
22	export	O	
23	is	O	
24	blocked	O	
25	,	O	
26	Npl3p	B	
27	is	O	
28	still	O	
29	exported	O	
30	from	O	
31	the	O	
32	nucleus	O	
33	.	O	

1	Two	O	
2	predominant	O	
3	effects	O	
4	were	O	
5	noted	O	
6	:	O	
7	(	O	
8	i	O	
9	)	O	
10	the	O	
11	Xaa	O	
12	residue	O	
13	in	O	
14	the	O	
15	dual	O	
16	phosphorylation	O	
17	motif	O	
18	Thr	O	
19	-	O	
20	Xaa	O	
21	-	O	
22	Tyr	O	
23	as	O	
24	well	O	
25	as	O	
26	the	O	
27	length	O	
28	of	O	
29	L12	O	
30	influence	O	
31	p38	B	
32	substrate	O	
33	specificity	O	
34	,	O	
35	and	O	
36	(	O	
37	ii	O	
38	)	O	
39	the	O	
40	length	O	
41	of	O	
42	L12	O	
43	plays	O	
44	a	O	
45	major	O	
46	role	O	
47	in	O	
48	controlling	O	
49	autophosphorylation	O	
50	.	O	

1	Therefore	O	
2	,	O	
3	we	O	
4	studied	O	
5	ninety	O	
6	coagulopathic	O	
7	patients	O	
8	with	O	
9	the	O	
10	aim	O	
11	of	O	
12	determining	O	
13	the	O	
14	prevalence	O	
15	of	O	
16	hepatitis	B	
17	C	I	
18	virus	I	
19	(	I	
20	HCV	I	
21	)	I	
22	antibodies	I	
23	using	O	
24	the	O	
25	ELISA	O	
26	and	O	
27	RIBA	O	
28	methods	O	
29	.	O	

1	Transfection	O	
2	with	O	
3	a	O	
4	CSF	B	
5	-	I	
6	1R	I	
7	expression	O	
8	plasmid	O	
9	permitted	O	
10	CSF	B	
11	-	I	
12	1	I	
13	-	O	
14	dependent	O	
15	activation	O	
16	of	O	
17	the	O	
18	signalling	O	
19	pathway	O	
20	targeting	O	
21	an	O	
22	Ets	B	
23	/	O	
24	AP1	B	
25	(	O	
26	activator	B	
27	protein	I	
28	1	I	
29	)	O	
30	element	O	
31	in	O	
32	the	O	
33	uPA	B	
34	promoter	I	
35	that	O	
36	has	O	
37	been	O	
38	shown	O	
39	previously	O	
40	to	O	
41	be	O	
42	a	O	
43	target	O	
44	of	O	
45	oncogenic	B	
46	ras	I	
47	and	O	
48	protein	O	
49	kinase	O	
50	C	O	
51	pathways	O	
52	.	O	

1	LON	O	
2	-	O	
3	72	O	
4	(	O	
5	34	O	
6	isolates	O	
7	),	O	
8	LON	O	
9	-	O	
10	73	O	
11	(	O	
12	1	O	
13	),	O	
14	LON	O	
15	-	O	
16	71	O	
17	(	O	
18	2	O	
19	)	O	
20	and	O	
21	LON	O	
22	-	O	
23	10	O	
24	(	O	
25	2	O	
26	)	O	
27	were	O	
28	found	O	
29	at	O	
30	altitudes	O	
31	around	O	
32	2000	O	
33	m	O	
34	,	O	
35	3	O	
36	of	O	
37	them	O	
38	in	O	
39	a	O	
40	single	O	
41	village	O	
42	.	O	

1	Forty	O	
2	-	O	
3	five	O	
4	cases	O	
5	were	O	
6	surgically	O	
7	by	O	
8	direct	O	
9	approach	O	
10	to	O	
11	the	O	
12	tumour	O	
13	,	O	
14	while	O	
15	two	O	
16	cases	O	
17	were	O	
18	treated	O	
19	only	O	
20	with	O	
21	a	O	
22	shunt	O	
23	.	O	

1	They	O	
2	also	O	
3	reported	O	
4	that	O	
5	E	B	
6	mu	I	
7	pim	I	
8	-	I	
9	1	I	
10	transgenic	O	
11	mice	O	
12	show	O	
13	greatly	O	
14	accelerated	O	
15	lymphoma	O	
16	development	O	
17	when	O	
18	infected	O	
19	with	O	
20	wild	O	
21	-	O	
22	type	O	
23	M	O	
24	-	O	
25	MuLV	O	
26	at	O	
27	birth	O	
28	.	O	

1	To	O	
2	study	O	
3	the	O	
4	structure	O	
5	-	O	
6	function	O	
7	of	O	
8	the	O	
9	gene	B	
10	5	I	
11	product	I	
12	,	O	
13	wild	O	
14	-	O	
15	type	O	
16	and	O	
17	mutant	O	
18	forms	O	
19	of	O	
20	NS53	B	
21	were	O	
22	produced	O	
23	by	O	
24	using	O	
25	a	O	
26	recombinant	O	
27	baculovirus	O	
28	expression	O	
29	system	O	
30	and	O	
31	a	O	
32	recombinant	O	
33	vaccinia	O	
34	virus	O	
35	/	O	
36	T7	O	
37	(	O	
38	vTF7	O	
39	-	O	
40	3	O	
41	)	O	
42	expression	O	
43	system	O	
44	.	O	

1	The	O	
2	N	O	
3	-	O	
4	syndecan	O	
5	-	O	
6	dependent	O	
7	neurite	O	
8	outgrowth	O	
9	is	O	
10	inhibited	O	
11	by	O	
12	the	O	
13	tyrosine	B	
14	kinase	I	
15	inhibitors	O	
16	herbimycin	O	
17	A	O	
18	and	O	
19	PP1	B	
20	.	O	

1	These	O	
2	data	O	
3	suggest	O	
4	that	O	
5	RPF	B	
6	-	I	
7	1	I	
8	is	O	
9	likely	O	
10	to	O	
11	be	O	
12	involved	O	
13	in	O	
14	early	O	
15	steps	O	
16	in	O	
17	the	O	
18	differentiation	O	
19	of	O	
20	amacrine	O	
21	and	O	
22	ganglion	O	
23	cells	O	
24	.	O	

1	Effects	O	
2	of	O	
3	a	O	
4	new	O	
5	antihypertensive	O	
6	agent	O	
7	,	O	
8	SGB	O	
9	-	O	
10	1534	O	
11	,	O	
12	on	O	
13	rat	O	
14	platelet	O	
15	aggregation	O	
16	.	O	

1	In	O	
2	this	O	
3	study	O	
4	,	O	
5	we	O	
6	investigated	O	
7	the	O	
8	molecular	O	
9	mechanisms	O	
10	underlying	O	
11	the	O	
12	inducible	O	
13	expression	O	
14	of	O	
15	the	O	
16	flt	B	
17	-	I	
18	1	I	
19	gene	I	
20	during	O	
21	the	O	
22	activation	O	
23	of	O	
24	THP	O	
25	-	O	
26	1	O	
27	cells	O	
28	.	O	

1	Allergy	O	
2	and	O	
3	Tourette	O	
4	'	O	
5	s	O	
6	syndrome	O	
7	.	O	

1	The	O	
2	limits	O	
3	of	O	
4	agreement	O	
5	between	O	
6	DBS	O	
7	and	O	
8	TOF	O	
9	responses	O	
10	were	O	
11	so	O	
12	wide	O	
13	that	O	
14	they	O	
15	cannot	O	
16	be	O	
17	used	O	
18	interchangeably	O	
19	.	O	

1	Arterial	O	
2	radioactivity	O	
3	content	O	
4	after	O	
5	the	O	
6	intravenous	O	
7	administration	O	
8	of	O	
9	HMPAO	O	
10	in	O	
11	seven	O	
12	human	O	
13	subjects	O	
14	was	O	
15	analyzed	O	
16	.	O	

1	The	O	
2	effect	O	
3	of	O	
4	emotional	O	
5	-	O	
6	painful	O	
7	stress	O	
8	(	O	
9	EPS	O	
10	)	O	
11	on	O	
12	myocardial	O	
13	extensibility	O	
14	and	O	
15	contractility	O	
16	was	O	
17	studied	O	
18	on	O	
19	an	O	
20	isolated	O	
21	rat	O	
22	atrium	O	
23	.	O	

1	For	O	
2	SMX	O	
3	at	O	
4	pH	O	
5	7	O	
6	.	O	
7	0	O	
8	,	O	
9	a	O	
10	1	O	
11	:	O	
12	1	O	
13	complex	O	
14	is	O	
15	formed	O	
16	,	O	
17	but	O	
18	at	O	
19	pH	O	
20	7	O	
21	.	O	
22	5	O	
23	HPCD	O	
24	has	O	
25	little	O	
26	effect	O	
27	on	O	
28	the	O	
29	solubility	O	
30	of	O	
31	the	O	
32	highly	O	
33	ionized	O	
34	SMX	O	
35	,	O	
36	presumably	O	
37	since	O	
38	only	O	
39	un	O	
40	-	O	
41	ionized	O	
42	molecules	O	
43	can	O	
44	form	O	
45	inclusion	O	
46	complexes	O	
47	with	O	
48	the	O	
49	HPCD	O	
50	.	O	

1	Testosterone	O	
2	,	O	
3	free	O	
4	testosterone	O	
5	,	O	
6	non	B	
7	-	I	
8	sex	I	
9	hormone	I	
10	-	I	
11	binding	I	
12	globulin	I	
13	-	O	
14	bound	O	
15	testosterone	O	
16	,	O	
17	and	O	
18	free	O	
19	androgen	O	
20	index	O	
21	:	O	
22	which	O	
23	testosterone	O	
24	measurement	O	
25	is	O	
26	most	O	
27	relevant	O	
28	to	O	
29	reproductive	O	
30	and	O	
31	sexual	O	
32	function	O	
33	in	O	
34	men	O	
35	with	O	
36	epilepsy	O	
37	?	O	

1	The	O	
2	C	O	
3	-	O	
4	terminal	O	
5	mutants	O	
6	were	O	
7	strongly	O	
8	dominant	O	
9	over	O	
10	TraR	B	
11	,	O	
12	suggesting	O	
13	that	O	
14	they	O	
15	can	O	
16	form	O	
17	heteromultimers	O	
18	with	O	
19	the	O	
20	wild	O	
21	-	O	
22	type	O	
23	activator	O	
24	.	O	

1	Large	B	
2	T	I	
3	antigen	I	
4	was	O	
5	coimmunoprecipitated	O	
6	by	O	
7	antibodies	O	
8	to	O	
9	epitope	O	
10	-	O	
11	tagged	O	
12	TBP	B	
13	,	O	
14	endogenous	O	
15	TBP	B	
16	,	O	
17	hTAF	B	
18	(	I	
19	II	I	
20	)	I	
21	100	I	
22	,	O	
23	hTAF	B	
24	(	I	
25	II	I	
26	)	I	
27	130	I	
28	,	O	
29	and	O	
30	hTAF	B	
31	(	I	
32	II	I	
33	)	I	
34	250	I	
35	,	O	
36	under	O	
37	conditions	O	
38	where	O	
39	holo	B	
40	-	I	
41	TFIID	I	
42	would	O	
43	be	O	
44	precipitated	O	
45	.	O	

1	Isolation	O	
2	of	O	
3	Aeromonas	O	
4	from	O	
5	faeces	O	
6	.	O	

1	Holger	O	
2	v	O	
3	.	O	

1	The	O	
2	combination	O	
3	PIP	O	
4	64	O	
5	micrograms	O	
6	-	O	
7	PEF	O	
8	4	O	
9	micrograms	O	
10	prevents	O	
11	the	O	
12	frequent	O	
13	secondary	O	
14	regrowth	O	
15	seen	O	
16	after	O	
17	6	O	
18	hours	O	
19	with	O	
20	the	O	
21	antibiotics	O	
22	used	O	
23	alone	O	
24	.	O	

1	Altogether	O	
2	,	O	
3	these	O	
4	data	O	
5	suggest	O	
6	that	O	
7	Ypt51p	B	
8	,	O	
9	Ypt52p	B	
10	,	O	
11	and	O	
12	Ypt53p	B	
13	are	O	
14	required	O	
15	for	O	
16	transport	O	
17	in	O	
18	the	O	
19	endocytic	O	
20	pathway	O	
21	and	O	
22	for	O	
23	correct	O	
24	sorting	O	
25	of	O	
26	vacuolar	B	
27	hydrolases	I	
28	suggesting	O	
29	a	O	
30	possible	O	
31	intersection	O	
32	of	O	
33	the	O	
34	endocytic	O	
35	with	O	
36	the	O	
37	vacuolar	O	
38	sorting	O	
39	pathway	O	
40	.	O	

1	Displacement	O	
2	thresholds	O	
3	of	O	
4	peripheral	O	
5	sites	O	
6	in	O	
7	monocular	O	
8	human	O	
9	vision	O	
10	were	O	
11	obtained	O	
12	.	O	

1	The	O	
2	COP	O	
3	-	O	
4	PAWP	O	
5	gradient	O	
6	was	O	
7	markedly	O	
8	decreased	O	
9	in	O	
10	both	O	
11	shock	O	
12	and	O	
13	non	O	
14	-	O	
15	shock	O	
16	patients	O	
17	with	O	
18	pulmonary	O	
19	edema	O	
20	.	O	

